S-1/A

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001193125-24-152294.txt : 20240603 0001193125-24-152294.hdr.sgml : 20240603 20240603060833 ACCESSION NUMBER: 0001193125-24-152294 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 29 FILED AS OF DATE: 20240603 DATE AS OF CHANGE: 20240603 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Rapport Therapeutics, Inc. CENTRAL INDEX KEY: 0002012593 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 880724208 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-279486 FILM NUMBER: 241011898 BUSINESS ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 BUSINESS PHONE: 857-321-8020 MAIL ADDRESS: STREET 1: 1325 BOYLSTON STREET STREET 2: SUITE 401 CITY: BOSTON STATE: MA ZIP: 02215 S-1/A 1 d803738ds1a.htm S-1/A S-1/A

As filed with the Securities and Exchange Commission on June 3, 2024.

Registration No. 333-279486

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

Amendment No. 1

FORM S-1

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

Rapport Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

2834

88-0724208

(State or other jurisdiction of

incorporation or organization)

(Primary Standard Industrial

Classification Code Number)

(I.R.S. Employer

Identification Number)

Rapport Therapeutics, Inc.

1325 Boylston Street, Suite 401

Boston, MA 02215

(857) 321-8020

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Abraham N. Ceesay, M.B.A.

Chief Executive Officer

1325 Boylston Street, Suite 401

Boston, MA 02215

(857) 321-8020

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Kingsley L. Taft

Stephanie A. Richards

Justin S. Platt

Goodwin Procter LLP

100 Northern Avenue

Boston, MA 02210

(617) 570-1000

Troy Ignelzi

Chief Financial Officer

1325 Boylston Street,
Suite 401

Boston, MA 02215

(857) 321-8020

Richard Segal

Divakar Gupta

Darah Protas

Ryan Sansom

Cooley LLP

55 Hudson Yards

New York, NY 10001

(212) 479-6000

Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement becomes effective.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☐

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until the Registration Statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

Subject to Completion, Dated June 3, 2024

8,000,000 Shares

LOGO

Common Stock

This is an initial public offering of shares of common stock of Rapport Therapeutics, Inc. We are offering 8,000,000 shares of our common stock.

Prior to this offering, there has been no public market for our common stock. It is currently estimated that the initial public offering price per share will be between $16.00 and $18.00. We have applied to list our common stock on the Nasdaq Global Market under the symbol “RAPP.” We believe that upon the completion of this offering, we will meet the standards for listing on Nasdaq, and the completion of this offering is contingent upon such listing.

We are an “emerging growth company” and “smaller reporting company” as defined under the U.S. federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements in this prospectus and future filings.

See the section titled “Risk Factors” beginning on page 17 to read about factors you should consider before deciding to invest in shares of our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.


	Per Share	Total
Initial public offering price	$	$
Underwriting discounts and commissions ⁽¹⁾	$	$
Proceeds, before expenses, to Rapport Therapeutics, Inc.	$	$

(1)	See the section titled “Underwriting” for additional information regarding compensation payable to the underwriters.

We have granted the underwriters the option to purchase up to an additional 1,200,000 shares of common stock from us, at the initial public offering price, less the underwriting discounts and commissions.

Sofinnova Venture Partners, XI, L.P. and affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC, each of which are existing stockholders, are expected to purchase approximately $8 million and $10 million, respectively, in shares of our common stock in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a per share price equal to the initial public offering price (or an aggregate of 1,058,824 shares based on the initial public offering price of $17.00 per share, which is the midpoint of the price range set forth above). The private placement would close concurrently with, and be contingent and conditioned upon consummation of, this offering. However, this offering is not contingent on the consummation of the concurrent private placement. Because we have not yet entered into a binding agreement with such existing stockholders, we could determine to sell more, fewer or no shares to each of these existing stockholders, and any of such existing stockholders could determine to purchase more, fewer or no shares in the concurrent private placement. The underwriters are acting as placement agents in connection with the concurrent private placement and will receive a placement agent fee equal to 7.0% of the total purchase price of the private placement shares.

The underwriters expect to deliver the shares against payment on or about , 2024.

Goldman Sachs & Co. LLC

Jefferies

TD Cowen

Stifel

Prospectus dated , 2024

TABLE OF CONTENTS


	Page
PROSPECTUS SUMMARY		3
RISK FACTORS		17
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS		83
USE OF PROCEEDS		85
DIVIDEND POLICY		87
CAPITALIZATION		88
DILUTION		90
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS		93
BUSINESS		119
MANAGEMENT		167
EXECUTIVE COMPENSATION		178
DIRECTOR COMPENSATION		192
CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS		194
PRINCIPAL STOCKHOLDERS		198
DESCRIPTION OF CAPITAL STOCK		202
SHARES ELIGIBLE FOR FUTURE SALE		208
MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS		210
UNDERWRITING		215
LEGAL MATTERS		223
EXPERTS		223
WHERE YOU CAN FIND ADDITIONAL INFORMATION		223
INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS		F-1

Through and including , 2024 (the 25^th day after the date of this prospectus), all dealers effecting transactions in our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to a dealer’s obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription.

Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date.

For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States.

We own, have applied for or have rights to use one or more registered and common law trademarks, service marks and/or trade names in connection with our business in the United States, which may be used throughout this prospectus. This prospectus also includes trademarks, tradenames, and service marks of third-parties which are the property of their respective owners. Our use or display of third-parties’ trademarks, service marks, tradenames or products in this prospectus and our other public filings is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks,

logos and trade names referred to in this prospectus and our other public filings may appear without the ^®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable owner of or licensor to these trademarks, service marks and trade names.

Market, Industry and Other Data

The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this prospectus, and we believe that these sources are reliable, however, we have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section titled “Risk Factors” and elsewhere in this prospectus. Some data are also based on our good faith estimates.

PROSPECTUS SUMMARY

This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, including the sections of this prospectus titled “Risk Factors,” “Special Note Regarding Forward-Looking Statements,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless otherwise indicated, all references in this prospectus to “Rapport,” the “company,” “we,” “our,” “us” or similar terms refer to Rapport Therapeutics, Inc. and its wholly owned subsidiary, or either or both of them as the context may require.

Company Overview

We are a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function. Our founders have made pioneering discoveries related to RAP function to form the basis of our RAP technology platform. We believe that our deep expertise in RAP biology provides an opportunity for us to interrogate previously inaccessible targets and develop CNS drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. RAP-219, our most advanced product candidate, is an AMPA receptor (“AMPAR”) negative allosteric modulator (“NAM”). RAP-219 is designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. Whereas AMPARs are distributed widely in the CNS, TARPg8 is expressed only in discrete regions, including the hippocampus, a key site involved in focal epilepsy. We completed our Phase 1 trials in healthy adults to assess the safety and tolerability of RAP-219, and we intend to initiate a Phase 2a proof-of-concept trial in adult patients with drug-resistant focal epilepsy in the second or third quarter of (“mid”) 2024, with topline results expected in mid 2025. We believe RAP-219 also has therapeutic potential in peripheral neuropathic pain and bipolar disorder, and we intend to initiate Phase 2a trials in these indications in the second half of 2024 and in 2025, respectively. We have also identified another TARPg8 targeted molecule with differentiated chemical and pharmacokinetic properties, RAP-199, for which we expect to initiate a Phase 1 trial in the first half of 2025.

Rapport was formed in February 2022, with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC. Our scientific founder and Chief Scientific Officer, David Bredt, M.D., Ph.D., pioneered the discovery of RAPs and their targeting by small molecules while serving as Global Head of Neuroscience Discovery at Janssen Pharmaceutica NV (“Janssen”) and prior to that as Vice President of Neuroscience at Eli Lilly and Company and as a Professor of Physiology at the University of California, San Francisco. Dr. Bredt was subsequently joined at Rapport by additional scientists who previously worked on the RAP platform at Janssen.

Janssen prior to the Janssen License. In many cases, these efforts were made by certain of the same personnel who have since joined Rapport.

Our Pipeline

Our current portfolio of programs from our RAP technology platform is summarized in the pipeline chart below:

LOGO

Introduction to RAP-219

RAP-219 is an investigational small molecule that is designed to inhibit TARPg8-containing AMPARs with picomolar (“pM”) affinity, which implies tight binding. Given RAP-219’s mechanism of action, neuroanatomical specificity and target potency observed to date in preclinical studies, we believe it has the potential to be a differentiated therapy for focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Epilepsy has profound negative impacts on a patient’s quality of life, including limitations on social engagement, physical activity and independence. Despite there being more than 20 antiseizure medications (“ASMs”) approved by the U.S. Food and Drug Administration (“FDA”), 30 to 40 percent of patients with epilepsy continue to experience recurring seizures despite taking two or more ASMs, termed “drug-resistant epilepsy.” In addition to providing sub-optimal efficacy, ASMs are commonly associated with risks of intolerable and debilitating adverse events (“AEs”). These AEs often lead to dosing adjustments and patient nonadherence, both of which can limit efficacy. We believe tolerability, adherence and clinical benefit can be improved with RAP-219, an investigational therapy that is designed to precisely modulate only diseased brain regions.

other forebrain structures, which are key sites associated with focal onset seizures. As brain regions with TAPRg8 expression closely overlay with the brain sites most often involved with the pathophysiology of focal epilepsy, we believe that RAP-219, which has been shown in preclinical studies to bind to TARPg8, has potential to provide a differentiated profile. Furthermore, preclinical studies have demonstrated that TARPg8 expression is enriched in the hippocampus, amygdala, cerebral cortex and striatum and has minimal or no expression in certain other areas that are critical for normal brain functions, including the cerebellum and brainstem. In contrast to the precision mechanism of RAP-219, the majority of ASMs, including perampanel, bind their target receptors throughout the brain, and we believe this lack of anatomical specificity may contribute to their side effect profiles. We believe that RAP-219, as compared to currently available ASMs, has the potential to have a greater therapeutic index, meaning a wider range of doses at which it is likely to be effective without causing unacceptable AEs. If RAP-219 is approved, this could have important clinical utility for the management of focal epilepsy.

We have completed two Phase 1 trials evaluating RAP-219 in healthy adult volunteers to assess its safety, tolerability and pharmacokinetics. We observed RAP-219 to be generally well tolerated in these trials. The plasma concentrations of RAP-219 measured during those trials suggested that once-daily oral administration with a simple dosing schedule could achieve our targeted therapeutic exposures (3 ng/mL to 7 ng/mL). For our Phase 2a proof-of-concept trial, we plan to enroll adult patients with drug-resistant focal epilepsy who have an implanted responsive neurostimulation (“RNS”) system, an FDA approved device for refractory focal onset epilepsy. The RNS system includes an electrode that continually monitors intracranial brain waves and detects the magnitude, duration and frequency of electrographic activity, which are recorded as intracranial electroencephalography (“iEEG”) data. We plan to use these iEEG data as the biomarker-based primary endpoint in our proof-of-concept trial. We believe these data could be translatable to a clinical seizure endpoint in future registrational trials. We intend to initiate this Phase 2a proof-of-concept trial in focal epilepsy in mid 2024, with topline results expected in mid 2025.

In addition to treating seizures, we believe RAP-219 has the potential to provide therapeutic benefit in additional CNS indications such as peripheral neuropathic pain and bipolar disorder. We intend to initiate Phase 2a trials of RAP-219 in peripheral neuropathic pain and bipolar disorder in the second half of 2024 and in 2025, respectively.

Introduction to Our Discovery-Stage Nicotinic Acetylcholine Receptor Programs

In addition to RAP-219, we have two discovery-stage programs stemming from our RAP technology platform. Our a6 nAChR and a9a10 nAChR programs were both enabled by our discovery of RAPs that drive the assembly of functional versions of these receptors in cell lines. Based on third-party genetic data, we believe the a6 and a9a10 nAChR subtypes could be attractive drug targets in the treatment of chronic pain and hearing disorders, respectively. However, it was not until our identification of these RAPs that it became possible to create cell lines for in vitro compound screening and optimization against these important targets.

We are optimizing molecules in our nAChR programs, in anticipation of selecting candidates to advance into the clinic.

Our RAP Technology Platform

Our founders are pioneers of RAP biology who have made key discoveries related to RAP function. Their findings form the basis of our RAP technology platform, which can potentially provide a differentiated approach to generate precision small molecule product candidates and to overcome many limitations of conventional neurology drug discovery. Using two distinct strategies, we are leveraging our expertise in RAP biology to develop a portfolio of precision neuroscience product candidates that we believe will transform the treatment of many CNS disorders. One strategy uses a RAP as a direct target, which can be more precise than drugging a

receptor itself. RAP-219 exemplifies this, as it has been shown in preclinical studies to bind to an AMPA RAP, TARPg8, which is enriched in brain regions that initiate or perpetuate seizures in focal epilepsy. A second strategy uses RAPs to “unlock” receptors for potentially first-in-class drug discovery programs. Many receptors cannot function without their RAPs, and such receptors have therefore been inaccessible to study in vitro. This second strategy enabled our discovery stage nAChR programs, which focus on a6 and a9a10. We continue to leverage our RAP technology platform to discover additional product candidates.

Our Strategy

Leveraging our RAP technology platform, we strive to become a leader in precision neuroscience through the discovery and development of transformational small molecule medicines for patients suffering from CNS disorders. As key elements of our strategy, we intend to:

•

Advance RAP-219 clinical development for the treatment of focal epilepsy;

•

Expand the potential of RAP-219 in additional neurological indications;

•

Extend the life cycle of RAP-219 and expand the TARPg8 franchise;

•

Advance development of our RAP-enabled nAChR programs;

•

Fortify our leadership position in RAP-enabled drug discovery to expand our pipeline of transformative precision neuroscience therapies for patients; and

•

Pursue strategic partnerships opportunistically.

Our Team

We have a seasoned leadership team with deep expertise in building novel therapeutic platforms, bringing therapeutics to market and supporting the growth of public biopharmaceutical companies. Abraham N. Ceesay, M.B.A., our Chief Executive Officer and a member of our board of directors, has extensive biopharmaceutical leadership experience, most recently as President of Cerevel Therapeutics Holdings, Inc. and prior to that as Chief Executive Officer of Tiburio Therapeutics, Inc. Bradley S. Galer, M.D., our Chief Medical Officer, has over twenty years of experience leading and building global drug development and medical affairs teams in epilepsy and pain, including as Executive Vice President and Chief Medical Officer at Zogenix, Inc. Dr. Galer was involved in the clinical development of fenfluramine (Fintepla), lidocaine patch (Lidoderm), gabapentin (Neurontin) and pregabalin (Lyrica) and previously acted as an academic key opinion leader in neuropathic pain. Troy Ignelzi, our Chief Financial Officer, has served in a similar role for several biopharmaceutical companies, most recently as Chief Financial Officer at Karuna Therapeutics, Inc. (“Karuna”). Cheryl Gault, our Chief Operating Officer, has over twenty years of biopharmaceutical experience, most recently serving as Chief Operating Officer at Cyclerion Therapeutics, Inc. Swamy Yeleswaram, Ph.D., our Chief Development Officer was a founding scientist at Incyte Corporation, most recently serving as Group Vice President of Drug Metabolism, Pharmacokinetics and Clinical Pharmacology. Kathy Wilkinson, our Chief People Officer, has previously served in similar roles at public companies, including 2seventy bio, Inc. and bluebird bio, Inc. Karina Chmielewski, our Chief Information Officer, previously served as Vice President, Platform Operations at Third Rock Ventures.

Our board of directors is composed of accomplished leaders in the life sciences industry, including board chair Steven M. Paul, M.D., former President and Chief Executive Officer of Karuna. We have also assembled a scientific advisory board, composed of leading experts in the fields of neuroscience, pain and pharmaceutical chemistry. Our scientific advisory board includes co-chairs David Julius, Ph.D., Chair of Physiology at the University of California San Francisco and 2021 Nobel Prize laureate in physiology or medicine, and Sir David MacMillan, Ph.D., Professor of Chemistry at Princeton University and 2021 Nobel Prize laureate in chemistry.

Risks Associated With Our Business

Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks include, but are not limited to, the following:

•

We are a clinical-stage biopharmaceutical company with a limited operating history, which may make it difficult to evaluate our current business and predict our future success and viability. We have incurred significant financial losses since our inception and anticipate that we will continue to incur significant financial losses for the foreseeable future.

•

Even if this offering and the concurrent private placement are successful, we will require additional funding in order to finance operations. If we are unable to raise capital when needed, or on acceptable terms, we could be forced to delay, reduce or eliminate our product development programs or commercialization efforts.

•

Our business is highly dependent on the success of our product candidates, particularly RAP-219 for focal epilepsy. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed.

•

The successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain.

•

Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a greater likelihood of success.

•

The regulatory approval processes of the FDA, European Medicines Agency (“EMA”), and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

•

We are dependent on a third party having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that were previously conducted for our product candidates. In addition, we rely on preclinical data using earlier generation TARPy8 NAMs and third-party published data with other TARPy8 NAMs for support of RAP-219. It is possible that similar studies with RAP-219 would not have generated entirely consistent results and, as such, the studies performed with other molecules of the same class may not be reflective of the therapeutic potential of RAP-219.

•

If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.

•

If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be harmed.

•

Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.

•

We have concentrated our research and development efforts on the treatment of disorders of the brain and nervous system, a field that faces certain challenges in drug development.

•

Even if any of our product candidates receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.

•

The number of patients with the diseases and disorders for which we are developing our product candidates has not been established with precision. If the actual number of patients with the diseases or disorders we elect to pursue with our product candidates is smaller than we anticipate, we may have difficulties in enrolling patients in our clinical trials, which may delay or prevent development of our product candidates. Even if such product candidates are successfully developed and approved, the markets for our product candidates may be smaller than we expect and our revenue potential and ability to achieve profitability may be materially adversely affected.

•

We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed.

•

We depend on in-licensed intellectual property. If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.

•

If we or our licensors are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our product candidates and our ability to successfully commercialize our product candidates may be adversely affected.

The summary risk factors described above should be read together with the text of the full risk factors in the section titled “Risk Factors” and the other information set forth in this prospectus, including our consolidated financial statements and the related notes, as well as in other documents that we file with the Securities and Exchange Commission (“SEC”). The risks summarized above or described in full elsewhere in this prospectus are not the only risks that we face. Additional risks and uncertainties not presently known to us, or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future, growth prospects.

Concurrent Private Placement

Sofinnova Venture Partners, XI, L.P. and affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC, each of which are existing stockholders, are expected to purchase approximately $8 million and $10 million, respectively, in shares of our common stock in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a per share price equal to the initial public offering price (or an aggregate of 1,058,824 shares based on the initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus). The private placement would close concurrently with, and be contingent and conditioned upon consummation of, this offering, as well as certain other customary closing conditions. However, this offering is not contingent on the consummation of the concurrent private placement. Because we have not yet entered into a binding agreement with such existing stockholders, we could determine to sell more, fewer or no shares to each of these existing stockholders, and any of such existing stockholders could determine to purchase more, fewer or no shares in the concurrent private placement. The underwriters are acting as placement agents in connection with the concurrent private placement and will receive a placement agent fee equal to 7.0% of the total purchase price of the private placement shares. In connection with the concurrent private placement, we will enter into a stock purchase agreement with each of such existing investors.

Corporate information

We were incorporated under the laws of the State of Delaware in February 2022 under the name Precision Neuroscience NewCo, Inc., and changed our name to Rapport Therapeutics, Inc. in October 2022. Our principal executive offices are located at 1325 Boylston Street, Suite 401, Boston, MA 02215, and our telephone number is (857) 321-8020. We have one subsidiary, Rapport Therapeutics Securities Corporation, formed in December 2022 under the laws of the Commonwealth of Massachusetts. Our website address is www.rapportrx.com. The information contained in or accessible from our website is not incorporated into this prospectus, and you should not consider it part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

Implications of being an emerging growth company and a smaller reporting company

We qualify as an “emerging growth company” as defined in the Jumpstart Our Business Startups Act of 2012, as amended (“JOBS Act”). As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These provisions include:

•

being permitted to present only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this prospectus;

•

reduced disclosure about our executive compensation arrangements;

•

not being required to hold advisory votes on executive compensation or to obtain stockholder approval of any golden parachute arrangements not previously approved;

•

an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes-Oxley Act”); and

•

an exemption from compliance with the requirements of the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor’s report on the financial statements.

We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company on the date that is the earliest of (i) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (ii) the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering; (iii) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not emerging growth companies. As a result of this election, our financial statements may not be comparable to those of other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We have in the past chosen and may in the future choose to early adopt any new or revised accounting standards whenever such early adoptions is permitted for private companies.

We are also a “smaller reporting company,” meaning that the market value of our shares held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i) the market value of our shares held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.

THE OFFERING

Common stock offered by us

8,000,000 shares

Option to purchase additional shares of common stock offered by us

1,200,000 shares

Concurrent private placement

Sofinnova Venture Partners, XI, L.P. and affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC, each of which are existing stockholders, are expected to purchase approximately $8 million and $10 million, respectively, in shares of our common stock in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a per share price equal to the initial public offering price (or an aggregate of 1,058,824 shares based on the initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus). The private placement would close concurrently with, and be contingent and conditioned upon consummation of, this offering, as well as certain other customary closing conditions. However, this offering is not contingent on the consummation of the concurrent private placement. Because we have not yet entered into a binding agreement with such existing stockholders, we could determine to sell more, fewer or no shares to each of these existing stockholders, and any of such existing stockholders could determine to purchase more, fewer or no shares in the concurrent private placement. The underwriters are acting as placement agents in connection with the concurrent private placement and will receive a placement agent fee equal to 7.0% of the total purchase price of the private placement shares. In connection with the concurrent private placement, we will enter into a stock purchase agreement with each of such existing investors.

Common stock to be outstanding immediately after this offering and the concurrent private placement

35,376,457 shares (or 36,576,457 shares if the underwriters exercise their option to purchase additional shares of common stock in full).

Use of proceeds

We estimate that the net proceeds from the sale of our common stock in this offering will be approximately $122.1 million (or approximately $141.1 million if the underwriters exercise their option to purchase additional shares of common stock in full), based on the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. In addition, we expect to receive an additional $16.7 million in net proceeds from the sale of shares of our common stock to certain of our existing stockholders in the concurrent private placement, after deducting placement agent fees and estimated private placement expenses payable by us.

We currently intend to use the net proceeds we receive from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments (i) to advance the Phase 2a development of our lead TARPg8 AMPAR program, RAP-219, including the completion of our proof-of-concept trials in focal epilepsy, peripheral neuropathic pain and bipolar disorder; (ii) to conduct our second MAD trial and PET trial, for the advancement of a long-acting injectable formulation of RAP-219, and to advance our second TARPg8 AMPAR program, RAP-199, through Phase 1 of development; and (iii) the remainder for other research and development activities, including the development of our nAChR discovery programs, costs associated with operating as a public company, and general corporate purposes. See the section titled “Use of Proceeds” for additional information.

Risk factors

See the section titled “Risk Factors” for a discussion of factors you should carefully consider before deciding whether to invest in our common stock.

Proposed Nasdaq Global Market trading symbol

“RAPP”

The number of shares of our common stock that will be outstanding after this offering and the concurrent private placement is based on 26,317,633 shares of common stock outstanding as of March 31, 2024 (which includes 2,030,242 shares of unvested restricted common stock outstanding as of March 31, 2024), after giving effect to the automatic conversion of all 189,613,384 shares of our convertible preferred stock outstanding as of March 31, 2024 into 22,146,816 shares of common stock immediately prior to the completion of this offering, and excludes:

•

2,677,487 shares of common stock issuable upon exercise of outstanding stock options as of March 31, 2024 under our 2022 Stock Option and Grant Plan, as amended (“2022 Plan”), with a weighted average exercise price of $5.23 per share;

•

92,234 shares of common stock issuable upon exercise of outstanding stock options granted after March 31, 2024 pursuant to our 2022 Plan, with a weighted average exercise price of $11.57 per share;

•

118,707 shares of common stock reserved for future issuance as of March 31, 2024 under the 2022 Plan, which will cease to be available for issuance at the time that our 2024 Stock Option and Incentive Plan (“2024 Plan”) becomes effective;

•

324,243 shares of common stock reserved for future issuance under our 2024 Employee Stock Purchase Plan (“ESPP”), which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; and

•

3,814,618 shares of our common stock that will become available for future issuance under our 2024 Plan, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2022 Plan that expire or are repurchased, forfeited, cancelled, or withheld.

Unless otherwise indicated, the information in this prospectus reflects or assumes the following:

•

a 1-for-8.5648 reverse split of our common stock, which we effected on May 31, 2024, and a corresponding adjustment to the ratio at which our preferred stock will convert into common stock;

•

the automatic conversion of all outstanding shares of our convertible preferred stock into an aggregate of 22,146,816 shares of common stock immediately prior to the completion of this offering;

•

the issuance of 1,058,824 shares of our common stock (assuming an initial public offering price of $17.00, the midpoint of the price range set forth on the cover page of this prospectus) in the concurrent private placement, which is to be completed concurrently with, and be contingent and conditioned upon consummation of, the closing of this offering.

•

no exercise of the outstanding stock options described above after March 31, 2024;

•

no exercise of the underwriters’ option to purchase up to an additional 1,200,000 shares of common stock in this offering; and

•

the filing and effectiveness of our third amended and restated certificate of incorporation immediately prior to the completion of this offering and the effectiveness of our amended and restated bylaws upon the effectiveness of the registration statement of which this prospectus forms a part.

SUMMARY CONSOLIDATED FINANCIAL DATA

The following tables set forth our summary consolidated statements of operations data for the period from February 10, 2022 (inception) to December 31, 2022, the year ended December 31, 2023, and the three months ended March 31, 2023 and 2024 and our summary consolidated balance sheet data as of March 31, 2024. We have derived the consolidated statement of operations data for the period from February 10, 2022 (inception) to December 31, 2022 and the year ended December 31, 2023 from our audited consolidated financial statements included elsewhere in this prospectus. The consolidated statement of operations data for the three months ended March 31, 2023 and 2024 and the consolidated balance sheet data as of March 31, 2024 have been derived from our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus, which have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of the results that may be expected for any period in the future and our results for the three months ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ending December 31, 2024. You should read the following summary financial data together with “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and our consolidated financial statements and the related notes included elsewhere in this prospectus. The summary consolidated financial data included in this section are not intended to replace the consolidated financial statements and are qualified in their entirety by our consolidated financial statements and the related notes included elsewhere in this prospectus.


	For the period from February 10, 2022 (inception) to December 31,			For the year ended December 31,			For the three months ended March 31,
	2022			2023			2023			2024
	(in thousands, except share and per share data)
Consolidated Statement of Operations Data
Operating expenses
Related party acquired in-process research and development	$	5,000		$	—		$	—		$	—
Research and development ⁽¹⁾		4,115			27,999			3,899			12,504
General and administrative ⁽²⁾		1,252			8,180			1,292			4,590

Total operating expenses		10,367			36,179			5,191			17,094

Loss from operations		(10,367	)		(36,179	)		(5,191	)		(17,094	)
Other income (expense):
Interest income		—			2,527			75			1,815
Interest expense		(285	)		—			—			—
Change in fair value of preferred stock tranche right liability		—			(1,124	)		(1,030	)		(7,390	)

Total other income (expense), net		(285	)		1,403			(955	)		(5,575	)

Net loss before income taxes		(10,652	)		(34,776	)		(6,146	)		(22,669	)
Provision for income taxes		—			10			1			—

Net loss	$	(10,652	)	$	(34,786	)	$	(6,147	)	$	(22,669	)

Net loss per share attributable to common stockholders, basic and diluted ⁽³⁾	$	(13.71	)	$	(23.10	)	$	(4.51	)	$	(11.07	)

Weighted-average common shares outstanding, basic and diluted ⁽³⁾		777,212			1,505,774			1,362,851			2,046,889


	For the period from February 10, 2022 (inception) to December 31,	For the year ended December 31,			For the three months ended March 31,
	2022	2023			2023	2024
	(in thousands, except share and per share data)
Pro forma net loss per share attributable to common stockholders, basic and diluted (unaudited) ⁽⁴⁾		$	(1.47	)		$	(0.94	)

Pro forma weighted-average common shares outstanding, basic and diluted (unaudited) ⁽⁴⁾			23,652,590				24,193,705

(1)

Includes related party amounts of $1.6 million, $0.7 million, $0.3 million and less than $0.1 million for the period from February 10, 2022 (inception) to December 31, 2022, for the year ended December 31, 2023, and for the three months ended March 31, 2023 and 2024, respectively (see Note 13—“Related Party Transactions” to our audited consolidated financial statements and Note 10—“Related Party Transactions” to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus).

(2)

Includes related party amount of $0.6 million, $0.9 million, $0.3 million and $0.1 million for the period from February 10, 2022 (inception) to December 31, 2022, for the year ended December 31, 2023 and for the three months ended March 31, 2023 and 2024, respectively (see Note 13—“Related Party Transactions” to our audited consolidated financial statements and Note 10—“Related Party Transactions” to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus).

(3)

See Note 15—“Net Loss per Share” to our audited consolidated financial statements and Note 12—“Net Loss per Share” to our unaudited interim condensed consolidated financial statements included elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders.

(4)

Pro forma basic and diluted net loss per share attributable to common stockholders has been prepared to give effect to adjustments to our capital structure arising in connection with the completion of this offering and the concurrent private placement and is calculated by dividing the pro forma net loss attributable to common stockholders by the pro forma weighted-average common shares outstanding for the period. Pro forma weighted-average common shares outstanding is computed by adjusting the weighted-average common shares outstanding to give pro forma effect to the automatic conversion of all shares of our convertible preferred stock outstanding as of March 31, 2024 into shares of common stock as if such conversion had occurred on January 1, 2023. Pro forma basic and diluted net loss per share attributable to common stockholders does not include the effect of the shares expected to be sold in this offering and the concurrent private placement.


	As of March 31, 2024
	Actual			Pro Forma ⁽¹⁾		Pro Forma As adjusted ⁽²⁾
	(in thousands)
Consolidated Balance Sheet Data:
Cash, cash equivalents and short-term investments	$	193,244		$	193,244	$	332,406
Working capital ⁽³⁾		188,843			188,843		329,477
Total assets		206,289			206,289		343,562
Total liabilities		11,183			11,183		9,711
Convertible preferred stock		234,739			—		—
Total stockholders’ (deficit) equity		(39,633	)		195,106		333,851

(1)	The pro forma consolidated balance sheet data give effect to the automatic conversion of all 189,613,384 shares of our convertible preferred stock outstanding as of March 31, 2024 into an aggregate of 22,146,816 shares of our common stock immediately prior to the completion of this offering.

(2)

The pro forma as adjusted consolidated balance sheet data give effect to (i) the pro forma adjustments set forth in footnote (1) above, (ii) the issuance and sale of 8,000,000 shares of our common stock in this offering at an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us and (iii) the sale of 1,058,824 shares of common stock in a concurrent private placement at an assumed initial public offering price of $17.00 per share, after deducting placement agent fees and estimated private placement expenses payable by us. Pro forma as adjusted balance sheet data is illustrative only and will change based on the actual initial public offering price and other terms of this offering and the concurrent private placement determined at pricing. Each $1.00 increase (decrease) in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash, cash equivalents and short term investments, working capital, total assets and total stockholders’ equity by approximately $8.4 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting underwriting discounts and commissions, placement agent fees and estimated offering and private placement expenses payable by us. Each 1,000,000 increase (decrease) in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash, cash equivalents and short-term investments, working capital, total assets and total stockholders’ equity by approximately $15.8 million, assuming no change in the assumed initial offering price per share, after deducting underwriting discounts and commissions, placement agent fees and estimated offering and private placement expenses payable by us.

(3)	We define working capital as current assets less current liabilities.

RISK FACTORS

Investing in our common stock involves a high degree of risk. You should consider and read carefully all of the risks and uncertainties described below, as well as the other information in this prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” before deciding whether to invest in our common stock. The risks described below are not the only ones facing us. The following risks or additional risks and uncertainties not presently known to us or that we currently believe to be immaterial could materially and adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the trading price of our common stock could decline, and you may lose all or part of your investment.

This prospectus also contains forward-looking statements and estimates that involve risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. Our actual results could differ materially from those anticipated in our forward-looking statements as a result of specific factors, including the risks and uncertainties described below.

Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital

We are a clinical-stage biopharmaceutical company with a limited operating history. We were formed in February 2022 and our operations to date have been limited to organizing and staffing our company, business planning, raising capital, developing our receptor associated protein (“RAP”) technology platform and technology, identifying potential product candidates, securing intellectual property rights, and planning and undertaking preclinical studies and clinical trials. Substantially all of our product candidates were initially developed by Janssen Pharmaceutica NV (“Janssen”), which we in-licensed pursuant to the option and license agreement with Janssen (the “Janssen License”), entered into shortly after our formation. We have not yet demonstrated an ability to generate revenues, obtain regulatory approvals, manufacture any product on a commercial scale or arrange for a third party to do so on our behalf or conduct sales and marketing activities necessary for successful product commercialization. Our limited operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks and difficulties successfully, our business will suffer.

The success of our business depends primarily upon our ability to identify, develop, and commercialize product candidates based on our RAP technology platform. We do not know whether we will be able to develop any product candidates that succeed through preclinical and clinical development or products of commercial value. We have no products approved for commercial sale and have not generated any revenue from product sales to date. We will continue to incur significant research and development and other expenses related to our preclinical and clinical development and ongoing operations. As a result, we are not profitable and have incurred losses in each period since our inception. Net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. Our net losses totaled $10.7 million and $34.8 million for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, respectively. Our net losses totaled $6.1 million and $22.7 million for the three months ended March 31, 2023 and 2024, respectively. As of March 31, 2024, we have not yet generated revenues and had an accumulated deficit of $68.1 million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates.

We anticipate that our expenses will increase substantially if, and as, we:

•

advance our product candidates through clinical development, including as we advance RAP-219 into later-stage clinical trials;

•

seek regulatory approvals for our product candidates that successfully complete clinical trials;

•

hire additional clinical, quality control, medical, scientific and other technical personnel to support the clinical development of our product candidates;

•

experience an increase in headcount as we expand our research and development organization and market development and pre-commercial planning activities;

•

undertake any pre-commercial or commercial activities to establish sales, marketing and distribution capabilities;

•

advance our preclinical-stage product candidates into clinical development;

•

seek to identify, acquire and develop additional product candidates using our RAP technology platform, including through business development efforts to invest in or in-license other technologies or product candidates;

•

maintain, expand and protect our intellectual property portfolio;

•

make milestone, royalty or other payments due under the Janssen License and any future in-license or collaboration agreements; and

•

make milestone, royalty, interest or other payments due under any future financing or other arrangements with third parties.

Biopharmaceutical product development entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate efficacy or an acceptable safety profile, gain regulatory approval, secure market access and reimbursement and become commercially viable, and therefore any investment in us is highly speculative. Accordingly, before making an investment in us, you should consider our prospects, factoring in the costs, uncertainties, delays and difficulties frequently encountered by companies in clinical development, especially clinical-stage biopharmaceutical companies such as ours. Any predictions you make about our future success or viability may not be as accurate as they would otherwise be if we had a longer operating history or a history of successfully developing and commercializing pharmaceutical products. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives.

Additionally, our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration (“FDA”), European Medicines Agency (“EMA”), or other comparable regulatory authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product candidates.

Developing biopharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes years to complete. We expect our expenses to continue to increase in connection with our ongoing activities, particularly as we conduct clinical trials of, and seek regulatory and marketing approval for, our product candidates. Even if our current or future product candidates are approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. To date, we have funded our operations principally through

private financings. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the clinical and preclinical development of our product candidates, continue to identify additional targets using our RAP technology platform, commence additional preclinical studies and clinical trials, and continue to identify and develop additional product candidates either through internal development or through acquisitions or in-licensing product candidates.

As of March 31, 2024, we had $193.2 million of cash, cash equivalents and short-term investments, excluding restricted cash. Based upon our current operating plan, we believe that our existing cash, cash equivalents and short-term investments, together with the net proceeds from this offering and the concurrent private placement, will enable us to fund our operating expenses and capital expenditure requirements through the end of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We may also raise additional financing on an opportunistic basis in the future. For example, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop our product candidates. Our future capital requirements will depend on many factors, including but not limited to:

•

the scope, timing, progress, costs and results of discovery, preclinical development and clinical trials for our current or future product candidates;

•

the number of clinical trials required for regulatory approval of our current or future product candidates;

•

the costs, timing and outcome of regulatory review of any of our current or future product candidates;

•

the costs associated with acquiring or licensing additional product candidates, technologies or assets, including the timing and amount of any milestones, royalties or other payments due in connection with our acquisitions and licenses;

•

the cost of manufacturing clinical and commercial supplies of our current or future product candidates;

•

the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights;

•

the effectiveness of our precision neuroscience approach at identifying target patient populations and utilizing our approach to enrich our patient population in our clinical trials;

•

our ability to maintain existing, and establish new, strategic collaborations or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;

•

the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;

•

the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;

•

expenses to attract, hire and retain skilled personnel;

•

the costs of operating as a public company;

•

our ability to establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors;

•

the effect of macroeconomic trends including inflation and rising interest rates;

•

addressing any potential supply chain interruptions or delays;

•

the effect of competing technological and market developments; and

•

the extent to which we acquire or invest in business, products and technologies.

Because of the numerous risks and uncertainties associated with research and development of product candidates, we are unable to predict the timing or amount of our working capital requirements. In addition, if we obtain regulatory approval for our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution which make it difficult to predict when or if we will be able to achieve or maintain profitability. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to support our continuing operations. Our ability to raise additional funds will depend on financial, economic, political and market conditions and other factors, over which we may have no or limited control. Additional funds may not be available when we need them, on terms that are acceptable to us, or at all. If we fail to obtain necessary capital when needed on acceptable terms, or at all, it could force us to delay, limit, reduce or terminate our product development programs, future commercialization efforts or other operations.

Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.

Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations with our existing cash, cash equivalents and short-term investments, the net proceeds from this offering and the concurrent private placement, any future equity or debt financings and upfront and milestone and royalty payments, if any, received under any future licenses or collaborations. If we raise additional capital through the sale of equity or convertible debt securities, or issue any equity or convertible debt securities in connection with a collaboration agreement or other contractual arrangement, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a holder of our common stock. In addition, the possibility of such issuance may cause the market price of our common stock to decline. Debt financing, if available, may result in increased fixed payment obligations and involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, declaring dividends or acquiring, selling or licensing intellectual property rights or assets, which could adversely impact our ability to conduct our business.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our intellectual property, technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. We could also be required to seek funds through arrangements with collaborators or others at an earlier stage than otherwise would be desirable. Any of these occurrences may have a material adverse effect on our business, operating results and prospects.

We maintain the majority of our cash and cash equivalents in accounts with major U.S. and multi-national financial institutions, and our deposits at certain of these institutions exceed insured limits. Market conditions and changes in financial regulations and policies can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. In addition, changes in regulations governing financial institutions are beyond our control and difficult to predict; consequently, the impact of such changes on our business and results of operations is difficult to predict and may have an adverse effect on us.

The obligations from our license agreement with Janssen may be a drain on our cash resources, or may cause us to incur debt obligations to satisfy the payment obligations.

Under the terms of the Janssen License, Janssen is entitled to substantial contingent payments upon the occurrence of certain events. For example, we will be required to pay Janssen up to $76.0 million in development

milestone payments and up to $40.0 million sales milestone payments for products containing RAP-219. See the section titled “Business—License and Collaboration Agreements” elsewhere in this prospectus for additional information regarding the Janssen Agreement. In order to satisfy our obligations to make these payments, if and when they are triggered, we may need to issue equity or convertible debt securities that may cause dilution to our stockholders, or we may use our existing cash and cash equivalents or incur debt obligations to satisfy the payment obligations in cash, which may adversely affect our financial position. In addition, these obligations may impede our ability to raise money in future public offerings of debt or equity securities or to obtain a third-party line of credit.

Risks Related to Our Business

To date, as an organization, we have not completed the development of any product candidates and nearly all of our candidates remain in early-stage clinical or preclinical development. Our future success and ability to generate revenue from our product candidates is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more of our product candidates. All of our product candidates will require substantial additional investment for clinical development, regulatory review and approval in one or more jurisdictions. If any of our product candidates, particularly RAP-219 for focal epilepsy, encounters safety or efficacy problems, development delays or regulatory issues or other problems, our development plans and business would be materially harmed.

We may not have the financial resources to continue development of our product candidates if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, our product candidates, including:

•

our inability to demonstrate to the satisfaction of the FDA, EMA, or other comparable regulatory authorities that our product candidates are safe and effective;

•

insufficiency of our financial and other resources to complete the necessary clinical trials and preclinical studies;

•

negative or inconclusive results from our clinical trials, preclinical studies or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional clinical trials or preclinical studies or abandon a program;

•

product-related adverse events (“AEs”) experienced by subjects in our clinical trials, including unexpected toxicity results, or by individuals using drugs or therapeutic biologics similar to our product candidates;

•

delays in submitting an Investigational New Drug (“IND”) application or other regulatory submission to the FDA, EMA, or other comparable regulatory authorities, or delays or failure in obtaining the necessary approvals from regulators to commence a clinical trial or a suspension or termination, or hold, of a clinical trial once commenced;

•

conditions imposed by the FDA, EMA, or other comparable regulatory authorities regarding the scope or design of our clinical trials;

•

poor effectiveness of our product candidates during clinical trials;

•

better than expected performance of control arms, such as placebo groups, which could lead to negative or inconclusive results from our clinical trials;

•

delays in enrolling subjects in our clinical trials;

•

high drop-out rates of subjects from our clinical trials;

•

inadequate supply or quality of product candidates or other materials necessary for the conduct of our clinical trials;

•

higher than anticipated clinical trial or manufacturing costs;

•

unfavorable FDA, EMA or comparable regulatory authority inspection and review of our clinical trial sites;

•

failure of our third-party contractors or investigators to comply with regulatory requirements or the clinical trial protocol or otherwise meet their contractual obligations in a timely manner, or at all;

•

delays and changes in regulatory requirements, policies and guidelines, including the imposition of additional regulatory oversight around clinical testing generally or with respect to our therapies in particular; or

•

varying interpretations of data by the FDA, EMA, or other comparable regulatory authorities.

In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country. We expect to conduct one or more of our clinical trials with one or more trial sites that are located outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to conditions imposed by the FDA, and there can be no assurance that the FDA will accept data from trials conducted outside of the United States. If the FDA does not accept the data from any trial that we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and could delay or permanently halt our development of the applicable product candidates.

The successful development of pharmaceutical products involves a lengthy and expensive process and is highly uncertain.

Successful development of pharmaceutical products involves a lengthy and expensive process, is highly uncertain, and is dependent on numerous factors, many of which are beyond our control. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including:

•

clinical trial results may show the product candidates to be less effective than expected (for example, a clinical trial could fail to meet its primary or key secondary endpoint(s)) or have an unacceptable safety or tolerability profile;

•

failure to receive the necessary regulatory approvals or a delay in receiving such approvals, which, among other things, may be caused by patients who fail the trial screening process, slow enrollment in clinical trials, patients dropping out of trials, patients lost to follow-up, length of time to achieve trial endpoints, additional time requirements for data analysis or New Drug Application (“NDA”) or similar foreign application preparation, discussions with the FDA, EMA, or other comparable regulatory authority an FDA, EMA, or other comparable regulatory request for additional preclinical or clinical data (such as long-term toxicology studies) or unexpected safety or manufacturing issues;

•

preclinical study results may show the product candidate to be less effective than desired or to have harmful side effects;

•

post-marketing approval requirements; or

•

the proprietary rights of others and their competing products and technologies that may prevent our product candidates from being commercialized.

For example, in December 2023, we withdrew the development of another TARPg8 targeted molecule (RAP-482) in-licensed from Janssen that received a full clinical hold from the FDA prior to initiation of a

Phase 1 trial, in order to prioritize development of our lead product candidate, RAP-219, and our other development candidates and programs. Furthermore, the length of time necessary to complete clinical trials and submit an application for marketing approval for a final decision by a regulatory authority varies significantly from one product candidate to the next and from one country or jurisdiction to the next and may be difficult to predict.

Even if we are successful in obtaining marketing approval, commercial success of any approved products will also depend in large part on the availability of coverage and adequate reimbursement from third-party payors, including government payors such as the Medicare and Medicaid programs and managed care organizations in the United States or country-specific governmental organizations in foreign countries, which may be affected by existing and future healthcare reform measures designed to reduce the cost of healthcare. Third-party payors could require us to conduct additional studies, including post-marketing studies related to the cost effectiveness of a product, to qualify for reimbursement, which could be costly and divert our resources. If government and other healthcare payors were not to provide coverage and adequate reimbursement for our products once approved, market acceptance and commercial success would be reduced. Even if we are able to obtain coverage and adequate reimbursement for our products once approved, there may be features or characteristics of our products, such as dose preparation requirements, that prevent our products from achieving market acceptance by the healthcare or patient communities.

In addition, if any of our product candidates receive marketing approval, we will be subject to significant regulatory obligations regarding the submission of safety and other post-marketing information and reports and registration, and will need to continue to comply (or ensure that our third-party providers comply) with current Good Manufacturing Practices (“cGMPs”) and Good Clinical Practices (“GCPs”) for any clinical trials that we conduct post-approval. In addition, there is always the risk that we, a regulatory authority or a third party might identify previously unknown problems with a product post-approval, such as AEs of unanticipated severity or frequency. Compliance with these requirements is costly, and any failure to comply or other issues with our product candidates post-approval could adversely affect our business, financial condition and results of operations.

Our lead product candidate, RAP-219 for the treatment of focal epilepsy, is currently in Phase 1 clinical development, and our other product candidates and programs are at various stages of preclinical development. We seek to rapidly advance discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders.

Due to the significant resources required for the development of our product candidates, we must decide which product candidates and indications to pursue and advance and the amount of resources to allocate to each. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates, therapeutic areas or indications may not lead to the development of viable commercial products and may divert resources away from better opportunities. If we make incorrect determinations regarding the viability or market potential of any of our product candidates or misread trends in the pharmaceutical industry, in particular for disorders of the brain and nervous system, our business, financial condition and results of operations could be materially and adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights.

We may seek to grow our business through acquisitions or investments in new or complementary businesses, products or technologies, through the licensing of products or technologies from third parties or other strategic alliances. The failure to manage acquisitions, investments, licenses or other strategic alliances, or the failure to integrate them with our existing business, could have a material adverse effect on our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.

Our success depends on our ability to continually enhance and broaden our product offerings in response to changing clinician and patients’ needs, competitive technologies and market pressures. Accordingly, from time to time we may consider opportunities to acquire, make investments in or license other technologies, products and businesses that may enhance our capabilities, complement our existing products and technologies or expand the breadth of our markets or customer base. Potential and completed acquisitions, strategic investments, licenses and other alliances involve numerous risks, including:

•

difficulty assimilating or integrating acquired or licensed technologies, products, employees or business operations;

•

issues maintaining uniform standards, procedures, controls and policies;

•

unanticipated costs associated with acquisitions or strategic alliances, including the assumption of unknown or contingent liabilities and the incurrence of debt or future write-offs of intangible assets or goodwill;

•

diversion of management’s attention from our core business and disruption of ongoing operations;

•

adverse effects on existing business relationships with suppliers, sales agents, health care facilities, surgeons and other health care providers;

•

risks associated with entering new markets in which we have limited or no experience;

•

potential losses related to investments in other companies;

•

potential loss of key employees of acquired businesses; and

•

increased legal and accounting compliance costs.

We do not know if we will be able to identify acquisitions or strategic relationships we deem suitable, whether we will be able to successfully complete any such transactions on favorable terms, if at all, or whether we will be able to successfully integrate any acquired business, product or technology into our business or retain any key personnel, suppliers, sales agent, health care facilities, physicians or other health care providers. Our ability to successfully grow through strategic transactions depends upon our ability to identify, negotiate, complete and integrate suitable target businesses, technologies or products and to obtain any necessary financing. These efforts could be expensive and time-consuming and may disrupt our ongoing business and prevent management from focusing on our operations.

To finance any acquisitions, investments or strategic alliances, we may choose to issue shares of our common stock as consideration, which could dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may be unable to consummate any acquisitions, investments or strategic alliances using our common stock as consideration. Additional funds may not be available on terms that are favorable to us, or at all.

We, our collaborators and our service providers are, or may become, subject to a variety of stringent and evolving privacy and data security laws, regulations, and rules, contractual obligations, industry standards, policies and other obligations related to privacy and data security. Any actual or perceived failure to comply with such obligations could expose us to significant fines or other penalties and otherwise harm our business and operations.

In the ordinary course of our business, we and the third parties upon which we rely (such as our third party Contract Research Organizations (“CROs”) and other contractors and consultants) collect, receive, store, process,

generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share (collectively, process) personal data and other sensitive information, including proprietary and confidential business data, trade secrets, intellectual property, sensitive third-party data, business plans, transactions, financial information and data we collect about trial participants in connection with clinical trials (collectively, sensitive data). Our data processing activities subject us to numerous evolving privacy and data security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to privacy and data security.

The legislative and regulatory framework for the processing of personal data worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. In the United States, numerous federal, state and local laws and regulations, including federal health information privacy laws, state information security and data breach notification laws, federal and state consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), and other similar laws (e.g., wiretapping laws) govern the processing of health-related and other personal data.

At the state level, numerous U.S. states—including California, Virginia, Colorado, Connecticut and Utah—have enacted comprehensive privacy laws that impose certain obligations on covered businesses, including providing specific disclosures in privacy notices and affording individuals certain rights concerning their personal data. Similar laws are being considered in several other states, as well as at the federal and local levels, and we expect more states to pass similar laws in the future. While these states exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and increase legal risk and compliance costs for us and the third parties upon whom we rely.

Additionally, we may be subject to new laws governing the privacy of consumer health data. For example, Washington’s My Health My Data Act broadly defines consumer health data, creates a private right of action to allow individuals to sue for violations of the law, imposes stringent consent requirements and grants consumers certain rights with respect to their health data, including to request deletion of their information. Connecticut and Nevada have also passed similar laws regulating consumer health data. These various privacy and data security laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.

Outside the United States, an increasing number of laws, regulations, and industry standards may govern privacy and data security. For example, the European Union’s General Data Protection Regulation (“EU GDPR”) and the United Kingdom’s GDPR (“UK GDPR”) impose strict requirements for processing personal data.

The EU GDPR and the UK GDPR (together, “GDPR”) establish stringent requirements regarding the processing of personal data, including strict requirements relating to processing of sensitive data (such as health data), ensuring there is a legal basis or condition to justify the processing of personal data, where required strict requirements relating to obtaining consent of individuals, expanded disclosures about how personal data is to be used, limitations on retention of information, implementing safeguards to protect the security and confidentiality of personal data, where required providing notification of data breaches, maintaining records of processing activities and documenting data protection impact assessments where there is high risk processing and taking certain measures when engaging third-party processors.

Under GDPR, companies may face temporary or definitive bans on data processing and other corrective activities, fines of up to €20 million (£17.5 million GBP) or 4% of annual global revenues, whichever is greater, and private litigation related to processing of personal data brought by classes of data subjects or consumer protection organizations authorized at law to represent their interests. Non-compliance could also result in a material adverse effect on our business, financial position and results of operations.

In addition, we may be unable to transfer personal data from Europe and other jurisdictions to the United States or other countries due to data localization requirements or limitations on cross-border data flows. Europe

and other jurisdictions have enacted laws requiring data to be localized or limiting the transfer of personal data to other countries. In particular, the European Economic Area (“EEA”) and the United Kingdom (“UK”) have significantly restricted the transfer of personal data to the United States and other countries whose privacy laws it generally believes are inadequate. Other jurisdictions may adopt similarly stringent interpretations of their data localization and cross-border data transfer laws. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA’s standard contractual clauses, the UK’s International Data Transfer Agreement / Addendum, and the EU-U.S. Data Privacy Framework and the UK extension thereto (which allows for transfers to relevant U.S.-based organizations who self-certify compliance and participate in the Framework), these mechanisms are subject to legal challenges, and there is no assurance that we can satisfy or rely on these measures to lawfully transfer personal data to the United States. If there is no lawful manner for us to transfer personal data from the EEA, the UK, or other jurisdictions to the United States, or if the requirements for a legally-compliant transfer are too onerous, we could face significant adverse consequences, including the interruption or degradation of our operations, the need to relocate part of or all of our business or data processing activities to other jurisdictions (such as Europe) at significant expense, increased exposure to regulatory actions, substantial fines and penalties, the inability to transfer data and work with partners, vendors and other third parties, and injunctions against our processing or transferring of personal data necessary to operate our business. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions, particularly to the United States, are subject to increased scrutiny from regulators, individual litigants, and activities activist groups. Some European regulators have ordered certain companies to suspend or permanently cease certain transfers of personal data out of Europe for allegedly violating the GDPR’s cross-border data transfer limitations.

In addition to privacy and data security laws, we are contractually subject to industry standards adopted by industry groups and may become subject to such obligations in the future. We are also bound by other contractual obligations related to privacy and data security, and our efforts to comply with such obligations may not be successful.

We publish privacy policies, and we may publish marketing materials, and other statements, such as compliance with certain certifications or self-regulatory principles, regarding privacy and data security. If these policies, materials or statements are found to be deficient, lacking in transparency, deceptive, unfair, or misrepresentative of our practices, we may be subject to investigation, enforcement actions by regulators, or other adverse consequences.

Obligations related to privacy and data security (and consumers’ data privacy expectations) are quickly changing, becoming increasingly stringent, and creating uncertainty. Additionally, these obligations may be subject to differing applications and interpretations, which may be inconsistent or conflict among jurisdictions. Preparing for and complying with these obligations requires us to devote significant resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf.

We may at times fail (or be perceived to have failed) in our efforts to comply with our privacy and data security obligations. Moreover, despite our efforts, our personnel or third parties on whom we rely may fail to comply with such obligations, which could negatively impact our business operations. If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable privacy and data security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims) and mass arbitration demands; additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. In particular, plaintiffs have become increasingly more active in bringing privacy-related claims against companies, including class claims and mass arbitration demands. Some of these claims allow for the recovery of statutory damages on a per violation basis, and, if viable, carry the potential for monumental statutory damages, depending on the volume of data and the number of violations. Any of these events could have a material adverse effect on our reputation, business, or

financial condition, including but not limited to: loss of customers; interruptions or stoppages in our business operations (including, as relevant, clinical trials); inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.

Our information technology systems and infrastructure, or those of our collaborators and service providers, or our data, may be subject to cyber-attacks, security breaches, compromises or other incidents, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand, material disruption of our development programs and operations, or other adverse consequences.

In the ordinary course of our business, we and the third parties upon which we rely, process sensitive data, and, as a result, we and the third parties upon which we rely face a variety of evolving threats that could cause cyber-attacks, security breaches, compromises, or other incidents. Although we take steps to develop and maintain systems and controls designed to protect our sensitive data, systems and infrastructure, there can be no assurance that our internal technology systems and infrastructure, or those of third parties upon which we rely, will be sufficient to protect against a cyber-attack, security breach, compromise or other incident such as an industrial espionage attack, ransomware, or insider threat attack, which may compromise our system infrastructure or lead to the loss, destruction, alteration or dissemination of, or damage to, our sensitive data. Such threats are prevalent and continue to rise, are increasingly difficult to detect, and come from a variety of sources, including traditional computer “hackers,” threat actors, “hacktivists,” organized criminal threat actors, personnel (such as through theft or misuse), sophisticated nation states, and nation-state-supported actors.

The risk of a cyber-attack, security breach, compromise, or other incident has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. Such risks come from a variety of evolving threats, including but not limited to, social-engineering attacks (including through deep fakes, which may be increasingly more difficult to identify as fake, and phishing attacks), malicious code (such as viruses and worms), malware (including as a result of advanced persistent threat intrusions), denial-of-service attacks, credential stuffing, credential harvesting, personnel misconduct or error, ransomware attacks, supply-chain attacks, software bugs, server malfunctions, software or hardware failures, loss of data or other information technology assets, adware, attacks enhanced or facilitated by AI, telecommunications failures, earthquakes, fires, floods, and other similar threats.

Individuals engage in and are expected to continue to engage in cyber-attacks, including without limitation nation-state actors for geopolitical reasons and in conjunction with military conflicts and defense activities. During times of war and other major conflicts, we and the third parties upon which we rely, may be vulnerable to a heightened risk of cyber-attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our services.

We also face increased risks of a cyber-attack, security breach, compromise, or other incident due to our reliance on internet technology and the number of our employees who work on a hybrid basis at home, in the office, or other public spaces. This may create additional opportunities for cybercriminals to exploit vulnerabilities. Additionally, business transactions (such as acquisitions or integrations) could expose us to additional cybersecurity risks and vulnerabilities, as our systems could be negatively affected by vulnerabilities present in acquired or integrated entities’ systems and technologies that were not found during due diligence of such acquired or integrated entities.

In addition, our reliance on third-party service providers could introduce new cybersecurity risks and vulnerabilities, including supply-chain attacks. We rely on third-party service providers and technologies to operate critical business systems to process sensitive data in a variety of contexts and our ability to monitor these third parties’ information security practices is limited. These third parties may not have adequate information security measures in place and if our third-party service providers experience a cyber-attack, security breach, compromise or incident, or other interruption, we could experience adverse consequences. While we may be

entitled to damages if our third-party service providers fail to satisfy their privacy or security-related obligations to us, any award may be insufficient to cover our damages, or we may be unable to recover such award.

We may be unable to detect vulnerabilities in our information technology systems and infrastructure on a timely basis or until after a cyber-attack, security breach, compromise, or other incident has occurred. Further, we may experience delays in developing and deploying remedial measures designed to adequately address any such identified vulnerabilities.

We have in the past experienced threats and security incidents related to our data and systems, and we may in the future experience additional threats, compromises, breaches or incidents. If we, or a third party upon whom we rely, experience a cyber-attack, security breach, compromise, or other incident, or are perceived to have experienced a cyber-attack, security breach, compromise, or other incident, we may experience adverse consequences, such as government enforcement actions (for example, investigations, fines, penalties, audits, and inspections); additional reporting requirements and/or oversight; restrictions on processing sensitive information (including personal data); litigation (including individual and group claims); indemnification obligations; negative publicity; reputational harm; monetary fund diversions; interruptions in our operations (including availability of data); financial loss; and other potentially significant harms. Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our privacy and data security obligations.

Further, applicable privacy and data security obligations may require us to notify relevant stakeholders of a cyber-attack, security breach, compromise, or other incident. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to adverse consequences. In addition, cyber-attacks, security breaches, compromises, or other incidents may cause stakeholders (including investors and potential customers) to stop supporting our business, deter new customers from using our products, and negatively impact our ability to grow and operate our business.

If we were to experience a cyber-attack, security breach, compromise, or other incident that causes interruptions in our operations, it could result in a material disruption of our product development programs.

The use of new and evolving technologies, such as artificial intelligence (“AI”) and machine learning (“ML”), in our operations, and the operations of third parties upon which we rely, may result in spending additional resources and present new risks and challenges that can impact our business including by posing security and other risks to our sensitive data, and as a result we may be exposed to reputational harm, other adverse consequences, and liability.

The use of new and evolving technologies, such as AI/ML, in our operations, and the operations of third parties upon which we rely presents new risks and challenges that could negatively impact our business. The use of certain AI/ML technologies can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, several jurisdictions around the globe, including Europe and certain U.S. states, have proposed, enacted, or are considering, laws governing the development and use of AI/ML, such as the European Union’s AI Act. We expect other jurisdictions will adopt similar laws. Additionally, certain privacy laws extend rights to consumers (such as the right to delete certain personal data) and regulate automated decision making, which may be incompatible with our use of AI/ML. These obligations may make it harder for us to conduct our business using AI/ML, lead to regulatory fines or penalties, require us to change our business practices, retrain our AI/ML, or prevent or limit our use of AI/ML. For example, the Federal Trade Commission has required other companies to turn over (or disgorge) valuable insights or trainings generated through the use of AI/ML where they allege the company has violated privacy and consumer protection laws. If we cannot use AI/ML or that use is restricted, our business may be less efficient, or we may be at a competitive disadvantage.

The rapid evolution of AI/ML will require the application of significant resources to design, develop, test and maintain our products and services to help ensure that AI/ML is implemented in accordance with applicable law and regulation and in a socially responsible manner and to minimize any real or perceived unintended harmful impacts. Our vendors may in turn incorporate AI/ML tools into their own offerings, and the providers of these AI/ML tools may not meet existing or rapidly evolving regulatory or industry standards, including with respect to privacy and data security. Further, bad actors around the world use increasingly sophisticated methods, including the use of AI/ML, to engage in illegal activities involving the theft and misuse of sensitive data. Any of these effects could damage our reputation, result in the loss of valuable property and information, cause us to breach applicable laws and regulations, and adversely impact our business.

Risks Related to the Discovery and Development of Our Current or Future Product Candidates

The regulatory approval processes of the FDA, EMA, and other comparable regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.

We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining regulatory approval from the FDA. Foreign regulatory authorities, such as the EMA, impose similar requirements. The time required to obtain approval by the FDA, EMA, or other comparable regulatory authorities is inherently unpredictable, but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. For instance, jurisdictions outside of the United States, such as the European Union or Japan, may have different requirements for regulatory approval, which may require us to conduct additional clinical, nonclinical or chemistry, manufacturing and control studies. To date, we have not submitted an NDA to the FDA or similar drug approval submissions to comparable foreign regulatory authorities for any product candidate. We must complete additional preclinical studies and clinical trials to demonstrate the safety and efficacy of our product candidates in humans before we will be able to obtain these approvals.

Clinical testing is expensive, difficult to design and implement, can take many years to complete and is inherently uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. The clinical development of our initial and potential additional product candidates is susceptible to the risk of failure inherent at any stage of development, including failure to demonstrate efficacy in a clinical trial or across a broad population of patients, the occurrence of AEs that are severe or medically or commercially unacceptable, failure to comply with protocols or applicable regulatory requirements and determination by the FDA, EMA, or other comparable regulatory authorities that a product candidate may not continue development or is not approvable. It is possible that even if any of our product candidates have a beneficial effect, that effect will not be detected during clinical evaluation as a result of one or more of a variety of factors, including the size, duration, design, measurements, conduct or analysis of our clinical trials. Conversely, as a result of the same factors, our clinical trials may indicate an apparent positive effect of such product candidate that is greater than the actual positive effect, if any. Similarly, in our clinical trials we may fail to detect toxicity of, or intolerability caused by, such product candidate, or mistakenly believe that our product candidates are toxic or not well tolerated when that is not in fact the case. Serious AEs or other AEs, as well as tolerability issues, could hinder or prevent market acceptance of the product candidate at issue.

Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:

•

the FDA, EMA, or other comparable regulatory authorities may disagree as to the design or implementation of our clinical trials;

•

we may be unable to demonstrate to the satisfaction of the FDA, EMA, or other comparable regulatory authorities that a product candidate is safe and effective for its proposed indication;

•

the results of clinical trials may not meet the level of statistical significance required by the FDA, EMA, or other comparable regulatory authorities for approval;

•

we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;

•

the FDA, EMA, or other comparable regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;

•

the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain regulatory approval in the United States, the European Union or elsewhere;

•

the FDA, EMA, or other comparable regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•

the approval policies or regulations of the FDA, EMA, or other comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would substantially harm our business, results of operations and prospects. The FDA, EMA, and other comparable regulatory authorities have substantial discretion in the approval process and determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA, EMA, or other comparable regulatory authorities.

In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

The FDA, EMA or comparable regulatory authorities may disagree with our regulatory plan for our product candidates.

The general approach for FDA approval of a new drug is dispositive data from two or more adequate and well-controlled clinical trials of the product candidate in the relevant patient population. Adequate and well-controlled clinical trials typically involve a large number of patients, have significant costs and take years to complete. The FDA, EMA or other comparable regulatory authorities may disagree with us about whether a clinical trial is adequate and well-controlled or may request that we conduct additional clinical trials prior to regulatory approval. In addition, there is no assurance that the doses, endpoints and trial designs that we intend to use for our planned clinical trials, including those that we have developed based on feedback from regulatory agencies or those that have been used for the approval of similar drugs, will be acceptable for future approvals. For instance, we may seek FDA regulatory flexibility and pursue marketing approval based on data from only one adequate and well-controlled clinical investigation. However, the FDA may be unwilling to apply regulatory flexibility and our clinical trial results may not support approval of our product candidates. In addition, our product candidates could fail to receive regulatory approval, or regulatory approval could be delayed, for many reasons, including the following:

•

the FDA, EMA, or comparable regulatory authorities may not file or accept our NDA or marketing application for substantive review;

•

the FDA, EMA, or comparable regulatory authorities may disagree with the dosing regimen, design or implementation of our clinical trials;

•

the FDA, EMA, or comparable regulatory authorities may determine there is not substantial evidence of effectiveness to support approval;

•

we may be unable to demonstrate to the satisfaction of the FDA, EMA, or comparable regulatory authorities that our product candidates are safe and effective for any of their proposed indications;

•

the results of our clinical trials may not meet the level of statistical significance required by the FDA, EMA, or comparable regulatory authorities for approval;

•

we may be unable to demonstrate that our product candidates’ clinical and other benefits outweigh their safety risks;

•

the FDA, EMA, or comparable regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;

•

the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA, EMA, or comparable regulatory authorities to support the submission of an NDA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;

•

the FDA, EMA, or comparable regulatory authorities may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and

•

the approval policies or regulations of the FDA, EMA, or comparable regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

Substantially all of our product candidates were initially developed by Janssen, which we in-licensed pursuant to the Janssen License shortly after our formation. We entered into this license on the basis of our interpretation of the medical and scientific meaningfulness of Janssen’s initial data. Therefore, we are dependent on Janssen having designed certain preclinical studies and clinical trials; conducted its research and development in accordance with the applicable protocols, legal and regulatory requirements, and scientific standards; having accurately reported the results of all preclinical studies conducted with respect to such product candidates; and having correctly collected and interpreted the data from these studies and trials. These risks also apply to any additional product candidates that we may acquire or in-license in the future. If these activities were not compliant, accurate or correct, the clinical development, regulatory approval or commercialization of our product candidates will be adversely affected and the earlier-reported results may not support data that we generate in our own preclinical or clinical work with those product candidates.

In addition, we rely on preclinical data using earlier generation TARPy8 NAMs and third-party published data with other TARPy8 NAMs for support of RAP-219. While we believe it is an accepted scientific practice to reference preclinical data generated using other molecules of the same class, it is possible that similar studies with RAP-219 would not have generated entirely consistent results and, as such, the studies performed with other molecules of the same class may not be reflective of the therapeutic potential of RAP-219.

The results observed from preclinical studies or early-stage clinical trials of our product candidates may not necessarily be predictive of the results of later-stage clinical trials that we conduct. Similarly, positive results

from such preclinical studies or early-stage clinical trials may not be replicated in our subsequent preclinical studies or clinical trials. For instance, results seen in preclinical animal models of epilepsy or pain may not translate to similar results in patients, and results from our upcoming Phase 2a proof-of-concept trial in focal epilepsy may not translate to clinical seizures. Furthermore, our product candidates may not be able to demonstrate similar activity or adverse event profiles as other product candidates that we believe may have similar profiles.

In addition, in our planned future clinical trials, we may utilize clinical trial designs or dosing regimens that have not been tested in prior clinical trials. For instance, our upcoming Phase 2a proof-of-concept trial in focal epilepsy utilizes a novel study design due to the biomarker-based primary endpoint, intracranial electroencephalography (“iEEG”) data. Specifically, iEEG data will be recorded by an implanted responsive neurostimulation (“RNS”) system, which includes an electrode that monitors intracranial brain waves and detects the magnitude, duration and frequency of electrographic activity associated with clinical seizures. We are not aware of any other trials that have used iEEG data as a primary endpoint and have not engaged and do not plan to engage with the FDA on the use of this endpoint in our Phase 2a proof-of-concept trial, as this trial will not be used as a registrational trial. Accordingly, the FDA, EMA, or other comparable regulatory authorities may have questions around the interpretability of this data, and iEEG data may not be translatable to a clinical seizure endpoint in future registrational trials.

There can be no assurance that any of our clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse effects or AEs.

Additionally, we may utilize an “open-label” clinical trial design. An “open-label” clinical trial is one where both the patient and investigator know whether the patient is receiving the investigational product candidate or either an existing approved drug or placebo. Our upcoming Phase 2a proof-of-concept study in focal epilepsy will be an open label study. Most open-label clinical trials test only the investigational product candidate and sometimes may do so at different dose levels. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. Open-label clinical trials may be subject to a “patient bias” where patients perceive their symptoms to have improved merely due to their awareness of receiving an experimental treatment. In addition, open-label clinical trials may be subject to an “investigator bias” where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. The results from an open-label trial may not be predictive of future clinical trial results of a product candidate when studied in a controlled environment with a placebo or active control.

Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA, EMA or comparable foreign regulatory authority approval.

We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing additional clinical trials or preclinical studies, including as a result of regulators not

allowing or delay in allowing clinical trials to proceed under an IND or similar foreign authorization, or not approving or delaying approval for any clinical trial grant or similar approval we need to initiate a clinical trial. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:

•

regulators, institutional review boards (“IRBs”) or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site;

•

we may not reach agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;

•

we may experience challenges or delays in recruiting principal investigators or study sites to lead our clinical trials;

•

the number of subjects or patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate;

•

our third-party contractors, including those manufacturing our product candidates or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;

•

we may have to amend clinical trial protocols submitted to regulatory authorities or conduct additional studies to reflect changes in regulatory requirements or guidance, which may be required to resubmit to an IRB and regulatory authorities for re-examination;

•

regulators or other reviewing bodies may find deficiencies with, fail to approve or subsequently find fault with the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for clinical and commercial supplies, or the supply or quality of any product candidate or other materials necessary to conduct clinical trials of our product candidates may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; and

•

the potential for approval policies or regulations of the FDA, EMA, or other comparable regulatory authorities to significantly change in a manner rendering our clinical data insufficient for approval.

Regulators or IRBs of the institutions in which clinical trials are being conducted may suspend, limit or terminate a clinical trial, or data monitoring committees may recommend that we suspend or terminate a clinical trial, due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA, or other comparable regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Negative or inconclusive results from our clinical trials or preclinical studies could mandate repeated or additional clinical trials and, to the extent we choose to conduct clinical trials in other indications, could result in changes to or delays in clinical trials of our product candidates in such other indications. We do not know whether any clinical trials that we conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market our product candidates for the indications that we are pursuing. If later-stage clinical trials do not produce favorable results, our ability to obtain regulatory approval for our product candidates will be adversely impacted.

Our failure to successfully initiate and complete clinical trials and to demonstrate the efficacy and safety necessary to obtain regulatory approval to market our product candidates would significantly harm our business. Our product candidate development costs will also increase if we experience delays in testing or regulatory

approvals and we may be required to obtain additional funds to complete clinical trials. We cannot assure you that our clinical trials will begin as planned or be completed on schedule, if at all, or that we will not need to restructure or otherwise modify our trials after they have begun. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates, which may harm our business and results of operations. In addition, many of the factors that cause, or lead to, delays of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.

Undesirable side effects caused by any of our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label, the inclusion of a Risk Evaluation and Mitigation Strategy, or the delay or denial of regulatory approval by the FDA, EMA, or other comparable regulatory authorities.

We may observe safety or tolerability issues beyond those we anticipate with our product candidates in ongoing or future clinical trials. For example, while no Grade 3 or higher AEs have been observed, to date, RAP-219 has only been tested in healthy volunteers and has not yet been tested in patients, so it is possible that such events may occur in our ongoing RAP-219 clinical program or in our clinical programs for other product candidates. Additionally, it is possible that human subjects with focal epilepsy may experience greater side effects in our clinical program for RAP-219 than observed in healthy volunteers. We continue to learn more about our product candidates, and unfavorable pharmacology profiles, including extended half-lives, could lead to adverse outcomes or concerns by the FDA, EMA, or other comparable regulatory authorities.

Many compounds that initially showed promise in clinical or earlier-stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Results of future clinical trials of our product candidates could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics, despite a favorable tolerability profile observed in earlier-stage testing. At any time, we may decide to terminate or greatly narrow the target population for a clinical development program due to unacceptable side effects or safety concerns.

If unacceptable side effects arise in the development of our product candidates, we, the FDA, EMA, or other comparable regulatory authorities, the IRBs, or independent ethics committees at the institutions in which our trials are conducted, could suspend, limit or terminate our clinical trials, or the independent safety monitoring committee could recommend that we suspend, limit or terminate our trials, or the FDA, EMA, or other comparable regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. We may be unable to overcome any such suspensions or holds that are placed on our clinical trials. Treatment-emergent side effects that are deemed to be drug-related could delay recruitment of clinical trial subjects or may cause subjects that enroll in our clinical trials to discontinue participation in our clinical trials. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We may need to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in harm to patients that are administered our product candidates. Any of these occurrences may adversely affect our business, financial condition and prospects significantly.

Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials. Consequently, it is possible that our clinical trials may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify undesirable side effects.

Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates.

Any product candidate we develop and the activities associated with its development and commercialization, including its design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale, and distribution, are subject to comprehensive regulation by the FDA and other regulatory authorities in the United States, and by the EMA and other comparable regulatory authorities in other countries. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate in a given jurisdiction. We have not received approval to market any product candidates from regulatory authorities in any jurisdiction and it is possible that none of the product candidates we are developing or may seek to develop in the future will ever obtain regulatory approval.

We have no experience in submitting and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs or regulatory consultants to assist us in this process. Securing regulatory approval requires the submission of extensive preclinical and clinical data and supporting information to the various regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. Securing regulatory approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the relevant regulatory authority. Any product candidates we develop may not be effective, may be only moderately effective, or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude its obtaining marketing approval or prevent or limit commercial use.

The process of obtaining marketing approvals, both in the United States and abroad, is expensive, may take many years if additional clinical trials are required, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity, and novelty of the product candidates involved. Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. The FDA, EMA, and other comparable regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit, or prevent marketing approval of a product candidate. Any marketing approval that we may ultimately obtain could be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

If we experience delays in obtaining approval or if we fail to obtain approval of any product candidates we may develop, the commercial prospects for those product candidates may be harmed, and our ability to generate revenues will be materially impaired.

Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.

From time to time, we may publish interim, topline or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects.

For planning purposes, we sometimes estimate the timing of the accomplishment of various scientific, clinical, regulatory and other product development objectives. These milestones may include our expectations regarding the commencement or completion of scientific studies and clinical trials, the submission of regulatory filings or commercialization objectives. From time to time, we may publicly announce the expected timing of some of these milestones, such as the completion of an ongoing clinical trial, the initiation of other clinical programs, receipt of marketing approval or a commercial launch of a product. The achievement of many of these milestones may be outside of our control. All of these milestones are based on a variety of assumptions which, if not realized as expected, may cause the timing of achievement of the milestones to vary considerably from our estimates, including:

•

our available capital resources or capital constraints we experience;

•

the rate of progress, costs and results of our clinical trials and research and development activities, including the extent of scheduling conflicts with participating clinicians and collaborators;

•

our ability to identify and enroll patients who meet clinical trial eligibility criteria;

•

our receipt of approvals by the FDA, EMA, and other comparable regulatory authorities and the timing thereof;

•

other actions, decisions or rules issued by regulators;

•

our ability to access sufficient, reliable and affordable supplies of materials used to manufacture our product candidates;

•

the efforts of our collaborators with respect to the commercialization of our product candidates; and

•

the securing of, costs related to, and timing issues associated with, product manufacturing as well as sales and marketing activities.

If we fail to achieve announced milestones in the timeframes we expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be harmed.

We have concentrated our research and development efforts on the treatment of disorders of the brain and nervous system, a field that faces certain challenges in drug development.

We have focused our research and development efforts on addressing disorders of the brain and nervous system. Efforts by pharmaceutical companies in this field have faced certain challenges in drug development. In particular, many neurological disorders, such as focal epilepsy, neuropathic pain and bipolar disorder, rely on subjective patient-reported outcomes as key endpoints. This makes them more difficult to evaluate than indications with more objective endpoints. For example, in our Phase 2a proof-of-concept trial, we plan to use change in clinical seizure frequency (measured by patient-recorded paper diaries) as a secondary endpoint. Furthermore, these indications are often subject to a placebo effect, which may make it more challenging to isolate the effects of our product candidates. There can be no guarantee that we will successfully overcome these challenges with RAP-219, even with the use of the RNS system from NeuroPace Inc. (“NeuroPace”) for primary and secondary endpoints in our Phase 2a proof-of-concept trial in focal epilepsy, or our other product candidates or that we will not encounter other challenges in the development of our product candidates. Moreover, given the history of clinical failures in this field, future clinical or regulatory failures by us or others may have result in further negative perception of the likelihood of success in this field, which may significantly and adversely affect the market price of our common stock.

We may be subject to additional risks because we intend to evaluate our product candidates in combination with the standard of care for the indications that we are pursuing.

We intend to evaluate our product candidates in combination with other compounds, specifically the standard of care for the indications that we are pursuing. The use of our product candidates in combination with such other compounds may subject us to risks that we would not face if our product candidates were being administered as a monotherapy. The outcome and cost of developing a product candidate to be used with other compounds is difficult to predict and dependent on a number of factors that are outside our control. If we experience efficacy or safety issues in our clinical trials in which our product candidates are being administered with other compounds, we may not receive regulatory approval for our product candidates, which could prevent us from ever generating revenue or achieving profitability.

If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.

We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with our protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion.

Patient enrollment is affected by many factors, including:

•

the patient eligibility criteria defined in the protocol;

•

the size of the patient population required for analysis of the trial’s primary endpoints;

•

the severity of the disease under investigation;

•

the proximity of patients to study sites;

•

the design of the trial;

•

our ability to recruit clinical trial investigators with the appropriate competencies and experience;

•

patients that enroll in our clinical trials may misrepresent their eligibility or may otherwise not comply with the clinical trial protocol, resulting in the need to drop such patients from the clinical trial, increase the needed enrollment size for the clinical trial or extend the clinical trial’s duration;

•

approval of new indications for existing therapies or approval of new therapies in general;

•

competing clinical trials and clinicians’ and patients’ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating;

•

our ability to obtain and maintain patient consents; and

•

the risk that patients enrolled in our clinical trials will drop out of the trials before completion.

We may experience challenges in recruiting principal investigators and patients to participate in ongoing and future clinical trials for such product candidates if we are unable to sufficiently demonstrate the potential of such product candidates to them. In addition, our clinical trials may compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials in such clinical trial site. Furthermore, if significant AEs or other side effects are observed in any of our clinical trials, we may have difficulty recruiting patients to our trials and patients may drop out of our trials. Additionally,

patients, including patients in any control groups, may withdraw from the clinical trial for various reasons, including but not limited to if they are not experiencing improvement in their underlying disease or condition, or if they experience other difficulties or issues relating to their underlying disease or condition. Participants with CNS disorders such as bipolar disorder constitute a vulnerable patient population and may withdraw from the clinical trial if they are not experiencing improvement in their underlying disease or condition or if they experience other difficulties or issues relating to their underlying disease or condition or otherwise, which may or may not be related to our product candidate in clinical trial. Withdrawal of patients from our clinical trials may compromise the quality of our data.

Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or might require us to abandon one or more clinical trials or our development efforts altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, product candidate development and approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to advance the development of our product candidates, cause our value to decline and limit our ability to obtain additional financing if needed.

We have never commercialized a product, and even if any of our product candidates is approved by the appropriate regulatory authorities for marketing and sale, it may nonetheless fail to achieve sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. Many of the indications for our product candidates have well-established standards of care that physicians, patients and payors are familiar with and, in some cases, are available generically. Even if our product candidates are successful in registrational clinical trials, they may not be successful in displacing these current standards of care if we are unable to demonstrate superior efficacy, safety, ease of administration and/or cost-effectiveness. For example, physicians may be reluctant to take their patients off their current medications and switch their treatment regimen to our product candidates. Further, patients often acclimate to the treatment regimen that they are currently taking and do not want to switch unless their physicians recommend switching products or they are required to switch due to lack of coverage and adequate reimbursement. Even if we are able to demonstrate our product candidates’ safety and efficacy to the FDA and other regulators, safety or efficacy concerns in the medical community may hinder market acceptance.

Efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, including management time and financial resources, and may not be successful. If any product candidate is approved but does not achieve an adequate level of market acceptance, we may not generate significant revenues and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including:

•

the efficacy and safety of the product;

•

the potential advantages of the product compared to competitive therapies;

•

the prevalence and severity of any side effects;

•

whether the product is designated under physician treatment guidelines as a first-, second- or third-line therapy;

•

our ability, or the ability of any future collaborators, to offer the product for sale at competitive prices;

•

the product’s convenience and ease of administration compared to alternative treatments;

•

the willingness of the target patient population to try, and of physicians to prescribe, the product;

•

the product’s acceptance into standard of care treatment algorithms by medical societies that could limit payor and physician uptake;

•

limitations or warnings, including distribution or use restrictions contained in the product’s approved labeling;

•

the strength of sales, marketing and distribution support;

•

changes in the standard of care for the targeted indications for the product; and

•

availability and adequacy of coverage and reimbursement from government payors, managed care plans and other third-party payors.

Any failure by one or more of our product candidates that obtains regulatory approval to achieve market acceptance or commercial success would adversely affect our business prospects.

If we fail to discover, develop and commercialize other product candidates, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired.

Although the development and commercialization of our current product candidates are our initial focus, as part of our longer-term growth strategy, we plan to develop other product candidates. In addition to the product candidates in our clinical-stage pipeline, we have in-licensed additional assets that are in earlier stages of development. We intend to evaluate internal opportunities from our existing product candidates or other potential product candidates, and also may choose to in-license or acquire other product candidates to treat patients suffering from other disorders with significant unmet medical needs and limited treatment options. These other potential product candidates will require additional, time-consuming development efforts prior to commercial sale, including preclinical studies, clinical trials and approval by the FDA, EMA, or other comparable regulatory authorities. All product candidates are prone to the risks of failure that are inherent in pharmaceutical product development, including the possibility that the product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any such products that are approved will be manufactured or produced economically, successfully commercialized or widely accepted in the marketplace or be more effective than other commercially available alternatives.

In addition, we intend to devote substantial capital and resources for basic research to discover and identify additional product candidates. These research programs require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:

•

the research methodology used may not be successful in identifying potential product candidates;

•

competitors may develop alternatives that render our product candidates obsolete;

•

product candidates that we develop may nevertheless be covered by third parties’ patents or other exclusive rights;

•

a product candidate may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;

•

a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and

•

a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors.

In the future, we may also seek to in-license or acquire product candidates or the underlying technology. The process of proposing, negotiating and implementing a license or acquisition is lengthy and complex. Other

companies, including some with substantially greater financial, marketing and sales resources, may compete with us for the license or acquisition of product candidates. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.

In addition, future acquisitions may entail numerous operational and financial risks, including:

•

exposure to unknown liabilities;

•

disruption of our business and diversion of management’s time and attention to develop acquired products or technologies;

•

incurrence of substantial debt, dilutive issuances of securities or depletion of cash to pay for acquisitions;

•

higher than expected acquisition and integration costs;

•

difficulty in combining the operations and personnel of any acquired businesses with our operations and personnel;

•

increased amortization expenses;

•

impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and

•

inability to motivate key employees of any acquired businesses.

If we are unsuccessful in identifying and developing additional product candidates, either through internal development or licensing or acquisition from third parties, our potential for growth and achieving our strategic objectives may be impaired.

Our pipeline includes product candidates for a variety of neuroscience diseases. There is no precise method of establishing the actual number of patients with any of these disorders in any geography over any time period. With respect to many of the indications in which we have developed, are developing, or plan to develop our product candidates, we have estimates of the prevalence of the disease or disorder. Our estimates as to prevalence may not be accurate, and the actual prevalence or addressable patient population for some or all of those indications, or any other indication that we elect to pursue, may be significantly smaller than our estimates. In estimating the potential prevalence of indications we are pursuing, or may in the future pursue, including our estimates as to the prevalence of focal epilepsy, neuropathic pain and bipolar disorder, we apply assumptions to available information that may not prove to be accurate. In each case, there is a range of estimates in the published literature and in marketing studies, which include estimates within the range that are lower than our estimates. The actual number of patients with these disease indications may, however, be significantly lower than we believe. Even if our prevalence estimates are correct, our product candidates may be developed for only a subset of patients with the relevant disease or disorder or our product candidates, if approved, may be indicated for or used by only a subset. In the event the number of patients with the diseases and disorders we are studying is significantly lower than we expect, we may have difficulties in enrolling patients in our clinical trials, which

may delay or prevent development of our product candidates. If any of our product candidates are approved and our prevalence estimates with respect to any indication or our other market assumptions are not accurate, the markets for our product candidates for these indications may be smaller than we anticipate, which could limit our revenues and our ability to achieve profitability or to meet our expectations with respect to revenues or profits.

Competitive products may reduce or eliminate the commercial opportunity for our product candidates, if approved. If our competitors develop technologies or product candidates more rapidly than we do, or their technologies or product candidates are more effective or safer than ours, our ability to develop and successfully commercialize our product candidates may be adversely affected.

The clinical and commercial landscapes for the treatment of neuroscience diseases are highly competitive and subject to rapid and significant technological change. We face competition with respect to our indications for our product candidates and will face competition with respect to any other drug candidates that we may seek to develop or commercialize in the future, from major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large pharmaceutical and biotechnology companies that currently market and sell drugs or are pursuing the development of drug candidates for the treatment of the indications that we are pursuing. Potential competitors also include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

We believe that a significant number of product candidates are currently under development for the same indications we are currently pursuing, and some or all may become commercially available in the future for the treatment of conditions for which we are trying or may try to develop product candidates. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, academic institutions, government agencies and research institutions. See the section titled “Business—Competition” included elsewhere in this prospectus for examples of the competition that our product candidates face.

In most cases, we do not currently plan to run head-to-head clinical trials evaluating our product candidates against the current standards of care, which may make it more challenging for our product candidates to compete against the current standards of care due to the lack of head-to-head clinical trial data.

Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Accordingly, our competitors may be more successful than we may be in obtaining regulatory approval for therapies and achieving widespread market acceptance. Our competitors’ products may be more effective, or more effectively marketed and sold, than any product candidate we may commercialize and may render our therapies obsolete or non-competitive before we can recover development and commercialization expenses. If any of our product candidates are approved, it could compete with a range of therapeutic treatments that are in development. In addition, our competitors may succeed in developing, acquiring or licensing technologies and drug products that are more effective or less costly than our product candidates, which could render our product candidates obsolete and noncompetitive.

If we obtain approval for any of our product candidates, we may face competition based on many different factors, including the efficacy, safety and tolerability of our products, the ease with which our products can be administered, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Existing and future competing products could present superior treatment alternatives, including being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and

commercializing our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.

In addition, our competitors may obtain patent protection, regulatory exclusivities or FDA approval and commercialize products more rapidly than we do, which may impact future approvals or sales of any of our product candidates that receive regulatory approval. If the FDA approves the commercial sale of any product candidate, we will also be competing with respect to marketing capabilities and manufacturing efficiency. We expect competition among products will be based on product efficacy and safety, the timing and scope of regulatory approvals, availability of supply, marketing and sales capabilities, product price, reimbursement coverage by government and private third-party payors, regulatory exclusivities and patent position. Our profitability and financial position will suffer if our product candidates receive regulatory approval but cannot compete effectively in the marketplace.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites, as well as in acquiring technologies complementary to, or necessary for, our programs.

If we are unable to develop our sales, marketing and distribution capability on our own or through collaborations with marketing partners, we will not be successful in commercializing our product candidates.

We currently have no marketing, sales or distribution capabilities. We intend to establish a sales and marketing organization, either on our own or in collaboration with third parties, with technical expertise and supporting distribution capabilities to commercialize one or more of our product candidates that may receive regulatory approval in key territories. These efforts will require substantial additional resources, some or all of which may be incurred in advance of any approval of the product candidate. Any failure or delay in the development of our or third parties’ internal sales, marketing and distribution capabilities would adversely impact the commercialization of our product candidates.

Factors that may inhibit our efforts to commercialize our product candidates on our own include:

•

our inability to recruit and retain adequate numbers of effective sales and marketing personnel;

•

the inability of sales personnel to obtain access to or our failure to educate an adequate number of physicians on the benefits of any future products;

•

the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and

•

unforeseen costs and expenses associated with creating an independent sales and marketing organization.

With respect to our existing and future product candidates, we may choose to collaborate with third parties that have direct sales forces and established distribution systems to serve as an alternative to our own sales force and distribution systems. Our future product revenue may be lower than if we directly marketed or sold our product candidates, if approved. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third parties, which may not be successful and are generally not within our control. If we are not successful in commercializing any approved products, our future product revenue will suffer and we may incur significant additional losses.

If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.

Risks Related to Employee Matters and Managing Growth

We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of regulatory affairs and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational, quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to implement our business strategy, including the successful commercialization of our product candidates.

Our ability to develop product candidates, leverage our RAP technology platform and our future growth depends on attracting, hiring and retaining our key personnel and recruiting additional qualified personnel.

Our success depends upon the continued contributions of our key management and scientific personnel, many of whom have been instrumental for us and have substantial experience with developing therapies, identifying potential product candidates and building the technologies related to the clinical development of our product candidates. Given the specialized nature of brain diseases and our approach, there is an inherent scarcity of experienced personnel in these fields. As we continue developing our product candidates in our pipeline, we will require personnel with medical, scientific, or technical qualifications specific to each program. The loss of key personnel, in particular our Chief Scientific Officer, neuropharmacologists and neuroscientists, would delay our research and development activities. We currently do not have “key person” insurance on any of our employees. Despite our efforts to retain valuable employees, members of our team may terminate their employment with us on short notice. The competition for qualified personnel in the biotechnology and biopharmaceutical industries is intense, and our future success depends upon our ability to attract, retain, and motivate highly skilled scientific, technical and managerial employees. We face competition for personnel from other companies, universities, public and private research institutions, and other organizations. If our recruitment and retention efforts are unsuccessful in the future, it may be difficult for us to implement our business strategy, which would have a material adverse effect on our business.

In addition, our clinical operations and research and development programs depend on our ability to attract and retain highly skilled scientists, data scientists, and engineers, particularly in Massachusetts and California. There is powerful competition for skilled personnel in these geographical markets, and we have from time to time experienced, and we expect to continue to experience, difficulty in hiring and retaining employees with appropriate qualifications on acceptable terms, or at all. Many of the companies with which we compete for experienced personnel have greater resources than we do, and any of our employees may terminate their employment with us at any time. If we hire employees from competitors or other companies, their former employers may attempt to assert that these employees or we have breached legal obligations, resulting in a diversion of our time and resources and, potentially, damages. In addition, job candidates and existing employees often consider the value of the stock awards they receive in connection with their employment. If the perceived benefits of our stock awards decline, it may harm our ability to recruit and retain highly skilled employees. If we fail to attract new personnel or fail to retain and motivate our current personnel, our business and future growth prospects would be harmed.

Risks Related to Our Dependence on Third Parties

We have relied upon and plan to continue to rely on third parties, such as CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our clinical trials and expect to rely on these third parties to conduct clinical trials of any other product candidate that we develop. Our ability to complete clinical trials in a timely fashion depends on a number of key factors. These factors include protocol design, regulatory and IRB approval, patient enrollment rates and compliance with GCPs. We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties, including CROs, to carry out our clinical trial-related activities and rely on such parties to accurately report their results. Our reliance on third parties for clinical development activities may impact or limit our control over the timing, conduct, expense and quality of our clinical trials. Moreover, the FDA requires us to comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected. The FDA enforces these GCPs through periodic inspections of clinical trial sponsors, principal investigators, clinical trial sites and IRBs. For certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must also meet chain of distribution requirements and build electronic, interoperable systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen and intentionally adulterated products or other products that are otherwise unfit for distribution in the United States.

We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. Our failure or the failure of third parties to comply with the applicable protocol, legal and regulatory requirements and scientific standards can result in rejection of our clinical trial data or other sanctions. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or be unsuccessful. Additionally, if we or our third-party contractors fail to comply with applicable GCPs for any reason, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval process. We cannot be certain that, upon inspection, the FDA will determine that any of our clinical trials comply with GCPs. We are also required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, ClinicalTrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Furthermore, the third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to our ongoing development programs. Moreover, many CROs, including some of those that we have engaged to conduct our clinical trials, are experiencing enrollment challenges as a result of, among other things, high employee turnover driven by the post-COVID macroeconomic environment and the inexperience of new employees. Furthermore, at clinical trial sites, the availability of staff and trial participants has been limited due to a decrease in the number of clinical investigative sites across the globe. These contractors may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. In such an event, our

financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be delayed, impaired or foreclosed.

In addition, we may rely on other third parties to collect, report and analyze data for our clinical trials. For example, our Phase 2a clinical trial will evaluate RAP-219 in adult patients with drug-resistant focal epilepsy who have been implanted with the RNS system from NeuroPace. NeuroPace will assist us with clinical trial readiness, including identifying patients for enrollment in our trial, as well as services for the collection, reporting and analysis of patient data collected from the implanted RNS systems throughout the Phase 2a clinical trial. If NeuroPace does not successfully carry out its contractual obligations for any reason, meet expected deadlines, conduct our Phase 2a clinical trial in accordance with applicable law, including regulatory and data privacy requirements, or encounters issues with its RNS system, including issues that raise questions of safety, effectiveness or data integrity, or we are otherwise unable to maintain our relationship with NeuroPace, we would have to redesign and conduct a new clinical trial to evaluate RAP-219 in patients with drug-resistant focal epilepsy and our business, financial condition and prospects would be harmed.

We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure on the part of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue.

Any of the third-party organizations we utilize may terminate their engagements with us under certain circumstances. The replacement of an existing CRO or other third party may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates. We may not be able to enter into alternative arrangements or do so on commercially reasonable terms. In addition, even if there are suitable replacements for one or more of these service providers, there is a natural transition period when a new service provider begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial condition and prospects.

Our use of third parties to manufacture our product candidates, including those located outside of the United States in jurisdictions such as China, may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients (“APIs”) or drug products when needed or at an acceptable cost.

We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates, and we lack the resources and the capabilities to do so. Our current strategy is to outsource all manufacturing of our product candidates to third parties, including in jurisdictions outside of the United States such as China.

We currently rely on and engage third-party manufacturers to provide all of the API and the final drug product formulation of all of our product candidates that are being used in our clinical trials and preclinical studies. If we were to need an alternate manufacturer, we would incur added costs and delays in identifying and qualifying any such replacement. In addition, we typically order raw materials, API and drug product and services on a purchase order basis and do not enter into long-term dedicated capacity or minimum supply arrangements with any commercial manufacturer. We may not be able to timely secure needed supply arrangements on satisfactory terms, or at all. Our failure to secure these arrangements as needed could have a material adverse effect on our ability to complete the development of our product candidates or, to commercialize them, if approved. We may be unable to conclude agreements for commercial supply with third-party manufacturers or may be unable to do so on acceptable terms. There may be difficulties in scaling up to commercial quantities and formulation of our product candidates, and the costs of manufacturing could be prohibitive.

Many of the third-party manufacturers we rely on have only recently begun working with us and have limited or no experience manufacturing our API and final drug products. If our manufacturers have difficulty or suffer delays in successfully manufacturing material that meets our specifications, it may limit supply of our product candidates and could delay our clinical trials.

Even if we are able to establish and maintain arrangements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including:

•

the failure of the third-party manufacturer to comply with applicable regulatory requirements and reliance on third parties for manufacturing process development, regulatory compliance and quality assurance;

•

manufacturing delays if our third-party manufacturers give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreement between us;

•

limitations on supply availability resulting from capacity and scheduling constraints of third parties;

•

the failure of the third-party manufacturer to produce materials with acceptable quality on a larger scale;

•

the possible breach of manufacturing agreements by third parties because of factors beyond our control;

•

the possible termination or non-renewal of the manufacturing agreements by the third party, at a time that is costly or inconvenient to us; and

•

the possible misappropriation of our proprietary information, including our trade secrets and know-how.

If we do not maintain our key manufacturing relationships, we may fail to find replacement manufacturers or develop our own manufacturing capabilities, which could delay or impair our ability to obtain regulatory approval for our product candidates. If we do find replacement manufacturers, we may not be able to enter into agreements with them on terms and conditions favorable to us and there could be a substantial delay before new facilities could be qualified and registered with the FDA, EMA, and other comparable regulatory authorities.

Additionally, if any third-party manufacturer with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different manufacturer. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change third-party manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA, EMA, or other comparable regulatory authorities. We may be unsuccessful in demonstrating the comparability of clinical supplies, which could require the conduct of additional clinical trials. The delays associated with the verification of a new third-party manufacturer could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a third-party manufacturer may possess technology related to the manufacture of our product candidate that such third party owns independently. This would increase our reliance on such third-party manufacturer or require us to obtain a license from such third-party manufacturer in order to have another third party manufacture our product candidates.

If any of our product candidates is approved by any regulatory agency, we intend to utilize arrangements with third-party contract manufacturers for the commercial production of those products. This process is difficult

and time consuming and we may face competition for access to manufacturing facilities as there are a limited number of contract manufacturers operating under cGMPs that are capable of manufacturing our product candidates. Consequently, we may not be able to reach agreement with third-party manufacturers on satisfactory terms, which could delay our commercialization.

Some of our manufacturers are located outside of the United States, including in China. There is currently significant uncertainty about the future relationship between the United States and various other countries, including China, with respect to trade policies, treaties, government regulations and tariffs. Increased tariffs or pending legislation that would impose federal contracting or federal funding limitations on parties directly using or connected to those using the services or equipment of certain foreign entities with known or alleged associations with foreign adversaries could potentially disrupt our existing supply chains and impose additional costs on our business. In particular, certain Chinese biotechnology companies and CMOs may become subject to trade restrictions, sanctions, and other regulatory requirements by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting our supplies and manufacturing. Additionally, it is possible further tariffs may be imposed that could affect imports of any APIs used in our product candidates in the future, or our business may be adversely impacted by retaliatory trade measures taken by China or other countries, including restricted access to such raw materials used in our product candidates. Given the unpredictable regulatory environment in China and the United States and uncertainty regarding how the U.S. or foreign governments will act with respect to tariffs, international trade agreements and policies, further governmental action related to tariffs, additional taxes, contracting matters, regulatory changes or other retaliatory trade measures in the future could occur with a corresponding detrimental impact on our business and financial condition.

Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or voluntary recalls of product candidates, operating restrictions and criminal prosecutions, any of which could significantly affect supplies of our product candidates. The facilities used by our contract manufacturers to manufacture our product candidates must be evaluated by the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA, or other comparable regulatory authorities, we may not be able to secure and/or maintain regulatory approval for our product candidates manufactured at these facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA finds deficiencies or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, EMA and comparable foreign regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products, if approved.

The FDA, EMA, or other comparable regulatory authorities require manufacturers to register manufacturing facilities, and also inspect these facilities to confirm compliance with cGMPs.

Contract manufacturers may face manufacturing or quality control problems causing drug substance production and shipment delays or a situation where the contractor may not be able to maintain compliance with the applicable cGMP requirements. Any failure to comply with cGMP requirements or other FDA, EMA, and other comparable regulatory requirements could adversely affect our clinical research activities and our ability to develop our product candidates and market our products following approval, if obtained.

Furthermore, should we decide to use any APIs in any of our product candidates that are proprietary to one or more third parties, we would need to maintain licenses to those APIs from those third parties. If we are unable to gain or continue to access rights to such APIs prior to conducting preclinical toxicology studies intended to support clinical trials, we may need to develop alternate product candidates from these programs by either accessing or developing alternate APIs, resulting in increased development costs and delays in commercialization of these product candidates. If we are unable to gain or maintain continued access rights to the desired APIs on commercially reasonable terms or develop suitable alternate APIs, we may not be able to commercialize product candidates from these programs.

We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.

We plan to opportunistically pursue strategic partnerships, as the advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. If we believe that partnerships can accelerate the development or maximize the market potential of our product candidates, we will consider entering into product, target and/or geographic specific strategic partnerships on an opportunistic basis. Likely collaborators may include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. In addition, if we are able to obtain regulatory approval for product candidates from foreign regulatory authorities, we may enter into partnerships or collaborations with international biotechnology or pharmaceutical companies for the commercialization of such product candidates.

We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a partnership or collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed partnerships or collaboration and the proposed collaborator’s evaluation of a number of factors. Those factors may include the potential differentiation of our product candidate from competing product candidates, design or results of clinical trials, the likelihood of approval by the FDA, EMA, or other comparable regulatory authorities and the regulatory pathway for any such approval, the potential market for the product candidate, the costs and complexities of manufacturing and delivering the product to patients and the potential of competing products. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available for partnership or collaboration and whether such a partnership or collaboration could be more attractive than the one with us for our product candidate. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.

Partnerships and collaborations are each complex and time-consuming to negotiate and document. Further, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Any partnership or collaboration agreements that we enter into in the future may contain restrictions on our ability to enter into potential partnerships or collaborations or to otherwise develop specified product candidates. We may not be able to negotiate partnerships or collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense.

Furthermore, if conflicts arise between our collaborators and us, the other party may act in a manner adverse to us and could limit our ability to implement our strategies. Our collaborators could conduct multiple product development efforts and could develop, either alone or with others, products in related fields that are competitive with the product candidates we may develop that are the subject of these partnerships or collaborations with us.

Competing products may preclude us from entering into partnerships or collaborations with their competitors, fail to obtain timely regulatory approvals, prevent us from obtaining timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the partnership or collaboration efforts, including development, delivery, manufacturing and commercialization of products. Any of these developments could harm our company and product development efforts.

If we enter into collaborations with third parties for the development and commercialization of our product candidates, our prospects with respect to those product candidates will depend in significant part on the success of those collaborations.

We may enter into collaborations for the development and commercialization of certain of our product candidates. If we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on any future collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. In addition, any future collaborators may have the right to abandon research or development projects and terminate applicable agreements, including funding obligations, prior to or upon the expiration of the agreed upon terms.

Collaborations involving our product candidates pose a number of risks, including the following:

•

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;

•

collaborators may not perform their obligations as expected;

•

collaborators may not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs, based on clinical trial results, changes in the collaborators’ strategic focus or available funding or external factors, such as an acquisition, which divert resources or create competing priorities;

•

collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;

•

collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates;

•

a collaborator with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products;

•

disagreements with collaborators, including disagreements over proprietary rights, including trade secrets and intellectual property rights, contract interpretation, or the preferred course of development might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;

•

collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;

•

collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and

•

collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates.

Collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If any future collaborator of ours is involved in a business combination, it could

decide to delay, diminish or terminate the development or commercialization of any product candidate licensed to it by us.

If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed.

In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of our product candidates. The transition to larger scale production could prove difficult. In addition, if our third-party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates while maintaining the same quality then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of operations.

Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.

As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as the vendors used to manufacture drug product or manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay or prevent completion of clinical trials, require conducting bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay or prevent approval of our product candidates and jeopardize our ability to commence sales and generate revenue.

Risks Related to Government Regulation

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.

Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, the European Commission or comparable foreign regulatory authorities must also approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.

We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent

the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.

Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.

If any of our product candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market information, including both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval.

Manufacturers and manufacturers’ facilities are required to comply with extensive FDA, EMA and other comparable regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP regulations and applicable product tracking and tracing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any NDA, other marketing application and previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control.

Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. Certain endpoint data we hope to include in any approved product labeling also may not make it into such labeling, including exploratory or secondary endpoint data such as patient-reported outcome measures. The FDA may also require a risk evaluation and mitigation strategies (“REMS”) program as a condition of approval of our product candidates, which could entail requirements for long-term patient follow-up, a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or other comparable regulatory authority approves our product candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration.

The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with our product candidates, including AEs of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary product recalls;

•

fines, warning letters or holds on clinical trials;

•

refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or withdrawal of approvals;

•

product seizure or detention or refusal to permit the import or export of our product candidates; and

•

injunctions or the imposition of civil or criminal penalties.

Additionally, under the Food and Drug Omnibus Reform Act (“FDORA”) sponsors of approved drugs and biologics must provide 6 months’ notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product’s ability to be marketed. The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. The policies of the FDA, EMA and other comparable regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

While we may in the future seek designations for our product candidates with the FDA, EMA and other comparable regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.

The FDA, EMA, and other comparable regulatory authorities offer certain designations for product candidates that are designed to encourage the research and development of product candidates that are intended to address conditions with significant unmet medical need. These designations may confer benefits such as additional interaction with regulatory authorities, a potentially accelerated regulatory pathway and priority review. However, there can be no assurance that we will successfully obtain such designations for our product candidates. In addition, while such designations could expedite the development or approval process, they generally do not change the standards for approval. Even if we obtain such designations for our product candidates, there can be no assurance that we will realize their intended benefits.

For example, we may seek a Fast Track Designation for future product candidates we develop. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular product candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA may rescind the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development activities.

We may seek Breakthrough Therapy Designation for any product candidate that we develop. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval and priority review.

Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of Breakthrough Therapy

Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if any product candidate we develop qualifies as a breakthrough therapy, the FDA may later decide that the drug no longer meets the conditions for qualification and rescind the designation.

Even in the absence of obtaining Fast Track and/or Breakthrough Therapy Designations, a sponsor can seek priority review at the time of submitting a marketing application. The FDA may designate a product for priority review if it is a product that treats a serious condition and, if approved, would provide a significant improvement in safety or effectiveness when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting adverse reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from ten months to six months. Priority review designation may be rescinded if a product no longer meets the qualifying criteria.

Where appropriate, we may secure approval from the FDA, EMA or other comparable regulatory authorities through the use of expedited approval pathways, such as accelerated approval. If we are unable to obtain such approvals, we may be required to conduct additional preclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, EMA, or other comparable regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA, EMA, or such other regulatory authorities may seek to withdraw the accelerated approval.

Where possible, we plan to pursue accelerated development strategies in areas of high unmet need. We may seek an accelerated approval pathway for our one or more of our therapeutic candidates from the FDA, EMA, or other comparable regulatory authorities. Under the accelerated approval provisions in the Federal Food, Drug, and Cosmetic Act, and the FDA’s implementing regulations, the FDA may grant accelerated approval to a therapeutic candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the therapeutic candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug’s clinical benefit. Under FDORA, the FDA is permitted to require, as appropriate, that a post-approval confirmatory study or studies be underway prior to approval or within a specified time period after the date of approval for a product granted accelerated approval. FDORA also gives the FDA increased authority to withdraw approval of a drug or biologic granted accelerated approval on an expedited basis if the sponsor fails to conduct such studies in a timely manner, send status updates on such studies to the FDA every 180 days to be publicly posted by the agency, or if such post-approval studies fail to verify the drug’s predicted clinical benefit. The FDA is empowered to take action, such as issuing fines, against companies that fail to conduct with due diligence any post-approval confirmatory study or submit timely reports to the agency on their progress.

Prior to seeking accelerated approval, we would seek feedback from the FDA, EMA, or other comparable regulatory authorities and would otherwise evaluate our ability to seek and receive such accelerated approval.

There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA or BLA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent feedback from the FDA, EMA, or other comparable regulatory authorities, we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval, there can be no assurance that such application will be accepted or that any approval will be granted on a timely basis, or at all. The FDA, EMA or other comparable regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type, including, for example, if other products are approved via the accelerated pathway and subsequently converted by FDA to full approval. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our therapeutic candidate would result in a longer time period to commercialization of such therapeutic candidate, could increase the cost of development of such therapeutic candidate and could harm our competitive position in the marketplace.

Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.

It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. These laws include anti-kickback statutes, false claims statutes, data privacy and security laws, as well as transparency laws regarding payments or other items of value provided to healthcare providers. Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we conduct research and would sell, market and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations that may affect our ability to operate may apply. For more information on healthcare laws and regulations that may impact our company, see the section titled “Business—Government Regulation—Other Healthcare Laws” included elsewhere in this prospectus.

The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring business arrangements comply with applicable healthcare and privacy laws, as well as responding to possible investigations by government authorities, can be time and resource-consuming and can divert a company’s attention from the business.

It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that

may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business is found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.

Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.

The success of our product candidates, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates or assure that coverage and reimbursement will be available for any product that we may develop. For more information on the laws and regulations that may impact coverage and reimbursement of our product candidates, see the section titled “Business—Government Regulation—Coverage and Reimbursement” included elsewhere in this prospectus.

Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance.

Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor’s determination that use of a product is:

•

a covered benefit under its health plan;

•

safe, effective and medically necessary;

•

appropriate for the specific patient;

•

cost-effective; and

•

neither experimental nor investigational.

In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. In the United States, the principal decisions about reimbursement for new medicines are typically made by U.S. Centers for Medicare & Medicaid Services (“CMS”). CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. Patients are unlikely to use our product candidates, once approved, unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives.

Moreover, increasing efforts by governmental and other third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs.

At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.

We expect that healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our product candidates, if any, may be.

In addition, in some foreign countries, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing vary widely from country to country. For example, the European Union provides options for its Member States to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.

Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.

Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, (1) changes to our manufacturing arrangements, (2) additions or modifications

to product labeling, (3) the recall or discontinuation of our products or (4) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. See the section titled “Business—Current and Future U.S. Healthcare Reform” included elsewhere in this prospectus.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. For instance, the Inflation Reduction Act of 2022 (the “IRA”) includes several provisions that will impact our business to varying degrees, including provisions that allow the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, among others. All of our disclosed product candidates are small molecule drugs and certain of them are being developed in indications that may rely heavily on Medicare reimbursement, such as neuropathic pain. Accordingly, these new price-negotiation provisions may have a negative impact on our future revenue and profits. Further, the IRA imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our revenue generated from the sale of any approved products.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has resulted in several Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs.

These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk of employee fraud or other illegal activity by our current and any future employees, independent contractors, consultants, CMOs, and vendors. Misconduct by these parties could include intentional, reckless, and/or negligent conduct that fails to comply with FDA or other regulations, provide true, complete and accurate information to the FDA, EMA, and other comparable regulatory authorities, comply with manufacturing standards we may establish, comply with healthcare fraud and abuse laws and regulations, report financial information or data accurately, or disclose unauthorized activities to us. If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States, our potential exposure under these laws will increase significantly, and our costs associated with compliance with these laws are likely to increase. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in

protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business, financial condition, results of operations, and prospects.

Off-label use or misuse of our product candidates may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.

If our product candidates are approved by the FDA, we may only promote or market our product candidates in a manner consistent with their FDA-approved labeling. We will train our marketing and sales force against promoting our product candidates for uses outside of the approved indications for use, known as “off-label uses.” We cannot, however, prevent a physician from using our product candidates off-label, when in the physician’s independent professional medical judgment he or she deems it appropriate. Furthermore, the use of our product candidates for indications other than those approved by the FDA may not effectively treat such conditions. Any such off-label use of our product candidates could harm our reputation in the marketplace among physicians and patients. There may also be increased risk of injury to patients if physicians attempt to use our product candidates for these uses for which they are not approved, which could lead to product liability suits that might require significant financial and management resources and that could harm our reputation.

Inadequate funding for the FDA or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.

The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.

Disruptions at the FDA or other government agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, including as a result of reaching the debt ceiling, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

EU drug marketing and reimbursement regulations may materially affect our ability to market and receive coverage for our products in the EU Member States.

We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of products is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures.

Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the European Union. The provision of benefits or advantages to reward improper performance generally is typically governed by the national anti-bribery laws of EU Member States and the Bribery Act 2010 in the United Kingdom. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the United Kingdom despite its departure from the European Union.

Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician’s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.

In addition, in some foreign countries, including some countries in the European Union, the proposed pricing for a product must be approved before it may be lawfully marketed. The requirements governing product pricing and reimbursement vary widely from country to country. For example, some EU Member States have the option to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU Member States and parallel distribution, or arbitrage between low-priced and high-priced EU Member States, can further reduce prices. An EU Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. In some countries, we may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential profitability of any of our product candidates in those countries would be negatively affected.

We are subject to export and import controls, economic sanctions, and anti-corruption laws and regulations of the United States and other jurisdictions. We can face criminal liability and other serious consequences for violations of these laws and regulations, which can harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Control. Export controls and trade sanctions laws and regulations may restrict or prohibit altogether the provision, sale, or supply of our products to certain governments, persons, entities, countries, and territories, including those that are the target of comprehensive sanctions or an embargo. We are also subject to anti-corruption and anti-bribery laws, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, and other state and national anti-bribery laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners from authorizing, promising, offering, or providing, directly or indirectly, improper payments

or anything else of value to recipients in the public or private sector. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. We can be held liable for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm, and other consequences.

If we or any third-party manufacturer we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs or liabilities that could have a material adverse effect on our business.

We and third-party manufacturers we engage now are, and any third-party manufacturer we may engage in the future will be, subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.

Although we maintain general liability insurance as well as workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, hazardous or radioactive materials.

In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.

Further, with respect to the operations of our current and any future third-party contract manufacturers, it is possible that if they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of wastes associated with our products, we could be held liable for any resulting damages, suffer reputational harm or experience a disruption in the manufacture and supply of our product candidates or products. In addition, our supply chain may be adversely impacted if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance with environmental, health and safety laws and regulations.

Risks Related to Our Intellectual Property

We are a party to the Janssen License, which is a non-exclusive, fully paid up, and royalty-free intellectual property license agreement. In connection with our efforts to expand our pipeline of product candidates, we expect to enter into additional license agreements in the future. We have certain obligations under the Janssen License and expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance, and other obligations on us. If we fail to comply with these obligations, our licensors may have the

right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property, or to pursue other remedies.

We may not be able to obtain licenses at a reasonable cost or on reasonable terms, or at all. Furthermore, if we lose intellectual property rights licensed under existing agreements or fail to obtain future licenses, we may be required to expend considerable time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected proprietary technologies and product candidates, which could harm our business significantly.

If we or our licensors are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or identical to our product candidates, and our ability to successfully commercialize our product candidates may be adversely affected.

Our success depends in large part on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates, their respective components, formulations, combination therapies, methods used to manufacture them and methods of treatment that are important to our business. If we or our licensors do not adequately protect our or our licensors’ intellectual property rights, competitors may be able to erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. We and our licensors seek to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. We may in the future also license or purchase patent applications filed by others. If we or our licensors are unable to secure or maintain patent protection with respect to our product candidates and any proprietary product candidates and technology we develop, our business, financial condition, results of operations, and prospects could be materially harmed.

If the scope of the patent protection we or our licensors obtain is not sufficiently broad, we may not be able to prevent others from developing and commercializing products and technology similar or identical to our product candidates or otherwise maintain a competitive advantage. The degree of patent protection we require to successfully compete in the marketplace may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We cannot provide any assurances that any of our or our licensors’ patents have, or that any of our or our licensors’ pending patent applications that mature into issued patents will include, claims with a scope sufficient to protect our product candidates or otherwise provide any competitive advantage. In addition, to the extent that we license intellectual property, we cannot make assurances that those licenses will remain in force.

Even if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The scope of the invention claimed in a patent application can be significantly reduced before the patent is issued, and this scope can be reinterpreted after issuance. Any patents that eventually issue may be challenged, narrowed or invalidated by third parties. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by valid and enforceable patent rights. Our competitors or other third parties may be able to circumvent our owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner.

The patent prosecution process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition, we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering product candidates that we license from third parties and are reliant on our licensors. Therefore, we cannot be certain that these patents and applications will be prosecuted

and enforced in a manner consistent with the best interests of our business. If such licensors fail to maintain such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated.

Furthermore, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however, the life of a patent, and the protection it affords, is limited. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases, at all. Therefore, we cannot be certain that we or our licensors were the first to make the inventions claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability, and commercial value of our and our licensors’ patent rights are highly uncertain. Our and our licensors’ pending and future patent applications may not result in patents being issued which protect our product candidates or which effectively prevent others from commercializing competitive products.

The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. There may be prior art of which we are not aware that may affect the validity or enforceability of a patent claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. We or our licensors may in the future, become subject to a third-party pre-issuance submission of prior art, opposition, derivation, revocation, re-examination, post-grant and inter partes review, or interference proceeding and other similar proceedings challenging our patent rights or the patent rights of others in the U.S. Patent and Trademark Office (the “USPTO”) or other foreign patent office. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated, or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical products, or limit the duration of the patent protection of our product candidates.

Furthermore, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to our product candidates.

In addition, we rely on certain of our licensors to prosecute patent applications and maintain patents and otherwise protect the intellectual property we license from them and may continue to do so in the future. We have limited control over these activities or any other intellectual property that may be related to our in-licensed intellectual property. For example, we cannot be certain that such activities by these licensors have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights or defend certain of the intellectual property that is licensed to us. It is possible that any licensors’ infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves.

Moreover, some of our owned and in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners’ interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In addition, we or our licensors may need the cooperation of any such co-owners of our owned and in-licensed patents in order to enforce such patents against third parties, and such cooperation may not be provided to us or our licensors. Any

of the foregoing could have a material adverse effect on our competitive position, business, financial conditions, results of operations and prospects.

If our efforts to protect the proprietary nature of the intellectual property related to our product candidates are not adequate, we may not be able to compete effectively in our market.

We rely upon a combination of patents, confidentiality agreements, trade secret protection and license agreements to protect the intellectual property related to our product candidates. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. We, or any partners, collaborators, or licensors, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position.

It is possible that defects of form in the preparation or filing of our or our licensors’ patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our partners, collaborators, or licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our partners, collaborators, or licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

We anticipate additional patent applications will be filed both in the United States and in other countries, as appropriate. However, we cannot predict:

•

if additional patent applications covering new technologies related to our product candidates will be filed;

•

if and when patents will issue;

•

the degree and range of protection any issued patents will afford us against competitors, including whether third parties will find ways to invalidate or otherwise circumvent our patents;

•

whether any of our intellectual property will provide any competitive advantage;

•

whether any of our patents that may be issued may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;

•

whether or not others will obtain patents claiming aspects similar to those covered by our or our licensors’ patents and patent applications; or

•

whether we or our licensors will need to initiate or defend litigation or administrative proceedings which may be costly regardless of whether we or our licensors win or lose.

Additionally, we cannot be certain that the claims in our pending patent applications covering our product candidates and their methods of use will be considered patentable by the USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid or patentable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. These types of patents do not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products “off-label.” Although off-label prescriptions may, but not necessarily, contribute to a finding of infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

We cannot be certain that an allowed patent application will become an issued patent because there may be events that cause withdrawal of the allowance of a patent application. For example, after a patent application has been allowed, but prior to being issued, material that could be relevant to patentability may be identified. In such circumstances, the applicant may pull the application from allowance in order for the USPTO to review the application in view of the new material. We cannot be certain that the USPTO will issue the application in view of the new material. Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign countries may require the payment of maintenance fees or patent annuities during the lifetime of a patent application and/or any subsequent patent that issues from the application. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process and following the issuance of a patent. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application. Such noncompliance can result in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. Such an event could have a material adverse effect on our business.

Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO.

If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could counterclaim that the patent covering our product candidates, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are various grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, inter partes review, post grant review and equivalent proceedings in foreign jurisdictions (such as opposition proceedings). Such proceedings could result in revocation or amendment to our or our licensors’ patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, our licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we are otherwise unable to adequately protect our or our licensors’ rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.

Changes to patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biotechnology and biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology and biopharmaceutical industry involves both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Obtaining and enforcing patents in the biotechnology and biopharmaceutical industry involve both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Recent patent reform legislation in the U.S. and other countries, including the Leahy-Smith America Invents Act (the “Leahy-Smith Act”), signed into law on September 16, 2011, could increase those uncertainties

and costs. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art and provide more efficient and cost-effective avenues for competitors to challenge the validity of patents. In addition, the Leahy-Smith Act has transformed the U.S. patent system into a “first-to-file” system. The first-to-file provisions, however, only became effective on March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could make it more difficult to obtain patent protection for our inventions and increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could harm our business, results of operations and financial condition.

Moreover, recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors’ ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors’ ability to obtain new patents or to enforce our or our licensors’ existing patents and patents that we or our licensors might obtain in the future. We cannot predict how future decisions by the courts, Congress or the USPTO may impact the value of our or our licensors’ patents. Similarly, any adverse changes in the patent laws of other jurisdictions could have a material adverse effect on our business and financial condition. Changes in the laws and regulations governing patents in other jurisdictions could similarly have an adverse effect on our ability to obtain and effectively enforce our patent rights.

We may not be able to protect our intellectual property rights throughout the world.

We may not be able to pursue patent coverage of our product candidates in certain countries outside of the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. The breadth and strength of our or our licensors’ patents issued in foreign jurisdictions or regions may not be the same as the corresponding patents issued in the United States. Consequently, we may not be able to prevent third parties from practicing our or our licensors’ inventions in all countries outside the United States, or from selling or importing products made using our or our licensors’ inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to certain territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our product candidates and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protections, particularly those relating to biotechnology and biopharmaceutical products. This difficulty with enforcing patents could make it difficult for us to stop the infringement of our or our licensors’ patents or marketing of competing products otherwise generally in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our licensors’ patents at risk of being invalidated or interpreted narrowly, put our or our licensors’ patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

If we do not obtain patent term extension for any of our current product candidates, our business may be materially harmed.

Depending upon the timing, duration and specifics of any FDA marketing approval of our current product candidates, one or more of our or our licensors’ U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Hatch-Waxman Amendments”). The Hatch-Waxman Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply for a patent extension within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we believe we are entitled to, our competitors may obtain approval of competing products sooner than we would expect, and our business, financial condition, results of operations, and prospects could be materially harmed.

Third parties may initiate legal proceedings alleging that we are infringing or otherwise misappropriating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of our collaborators to commercialize, develop, manufacture, market, and sell our product candidates without infringing the proprietary rights of third parties. We have yet to conduct comprehensive freedom to operate searches to determine whether we would infringe patents issued to third parties. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates, including interference proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing product. In addition, we could be found liable for monetary damages. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

If a third party alleges that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to:

•

infringement and other intellectual property misappropriation which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management’s attention from our core business;

•

substantial damages for infringement or misappropriation, which we may have to pay if a court decides that the product or technology at issue infringes on or violates the third-party’s rights, and, if the court finds we have willfully infringed intellectual property rights, we could be ordered to pay treble damages and the patent owner’s attorneys’ fees;

•

an injunction prohibiting us from manufacturing, marketing or selling our product candidates, or from using our proprietary technologies, unless the third party agrees to license its patent rights to us;

•

even if a license is available from a third party, we may have to pay substantial royalties, upfront fees and other amounts, and/or grant cross-licenses to intellectual property rights protecting our product candidates; and

•

we may be forced to try to redesign our product candidates or processes so they do not infringe third-party intellectual property rights, an undertaking which may not be possible or which may require substantial monetary expenditures and time.

Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.

Third parties may assert that we are employing their proprietary technology without authorization. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is “clear and convincing,” a heightened standard of proof. There may be issued third-party patents of which we are currently unaware with claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Patent applications can take many years to issue. There may be currently pending patent applications which may later result in issued patents that may be infringed by our product candidates. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents, held now or obtained in the future by a third party, were found by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product or methods use of the product, the holders of any such patents may be able to block our ability to commercialize the product unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover any aspect of our formulations, any combination therapies or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize our product candidates.

Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing product candidates, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.

We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming, and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time consuming.

In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors’ is invalid or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. Defense against these assertions, non-infringement, invalidity or unenforceability regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.

Post-grant proceedings provoked by third parties or brought by the USPTO may be brought to determine the validity or priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as those within the United States.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, our licensors may have rights to file and prosecute such claims, and we are reliant on them.

Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities.

Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions, or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.

We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.

We generally enter into confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the

course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such a dispute could be expensive and time-consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.

In addition to seeking patents for some of our product candidates, we also rely on trade secrets, including unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time consuming, and the outcome is unpredictable. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.

We may be subject to claims that we wrongfully hired an employee from a competitor or that our employees have misappropriated intellectual property, including trade secrets of their former employers.

Many of our employees were previously employed at, or may have previously provided or may be currently providing consulting services to, universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We could in the future be subject to claims that we or our employees have inadvertently or otherwise used or disclosed alleged trade secrets or other confidential information of former employers or competitors. Although we try to ensure that our employees do not use the proprietary information or know how of others in their work for us, we may be subject to claims that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement, or that we or these employees have, inadvertently or otherwise, used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee’s former employer or competitor. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.

If our trademarks and trade names are not adequately protected then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We rely on both registration and common law protection for our

trademarks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in our markets of interest. During the trademark registration process, we may receive Office Actions from the USPTO objecting to the registration of our trademark. Although we would be given an opportunity to respond to those objections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and/or to seek the cancellation of registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected.

European patents and patent applications could be challenged in the recently created Unified Patent Court for the European Union.

Our or our licensors’ European patents and patent applications could be challenged in the recently created Unified Patent Court (“UPC”) for the European Union. We may decide to opt out our European patents and patent applications from the UPC. However, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. We cannot be certain that our or our licensors’ European patents and patent applications will avoid falling under the jurisdiction of the UPC, if we decide to opt out of the UPC. Under the UPC, a granted European patent would be valid and enforceable in numerous European countries. A successful invalidity challenge to a European patent under the UPC would result in loss of patent protection in those European countries. Accordingly, a single proceeding under the UPC could result in the partial or complete loss of patent protection in numerous European countries, rather than in each validated European country separately as such patents always have been adjudicated. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize our technology and product candidates and, resultantly, on our business, financial condition, prospects and results of operations.

Risks Related to this Offering and Ownership of Our Common Stock

There has been no prior public market for our common stock, and an active trading market may not develop or be sustained.

There has been no public market for our common stock prior to this offering. The initial public offering price for our common stock was determined through negotiations among the underwriters and us and may vary from the market price of our common stock following this offering. An active or liquid market in our common stock may not develop upon closing of this offering or, if it does develop, it may not be sustainable. The lack of an active market may impair the value of your shares, your ability to sell your shares at the time you wish to sell them and the prices that you may obtain for your shares. An inactive market may also impair our ability to raise capital by selling our common stock and our ability to acquire other companies, products, or technologies by using our common stock as consideration.

The price of our stock may be volatile, and you could lose all or part of your investment.

The trading price of our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this section and elsewhere in this prospectus, these factors include:

•

the commencement, enrollment, completion or results of our current or future preclinical and clinical trials for our product candidates;

•

any delay in identifying and advancing a clinical candidate for our other programs;

•

any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority’s review of such filings, including without limitation the FDA’s issuance of a “refusal to file” letter or a request for additional information;

•

adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;

•

our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;

•

adverse regulatory decisions, including failure to receive regulatory approval of our product candidates or the failure of a regulatory authority to accept data from preclinical studies or clinical trials conducted in other countries;

•

changes in laws or regulations applicable to our product candidates, including but not limited to clinical trial requirements for approvals;

•

adverse developments concerning our manufacturers;

•

our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;

•

our inability to establish collaborations, if needed;

•

our failure to commercialize our product candidates, if approved;

•

additions or departures of key scientific or management personnel;

•

unanticipated serious safety concerns related to any of our current or future product candidates;

•

introduction of new products or services offered by us or our competitors;

•

announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors;

•

our ability to effectively manage our growth;

•

actual or anticipated variations in quarterly operating results;

•

our cash position;

•

our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the public;

•

publication of research reports about us or our industry, or product candidates in particular, or positive or negative recommendations or withdrawal of research coverage by securities analysts;

•

changes in the market valuations of similar companies;

•

changes in the structure of the healthcare payment systems;

•

overall performance of the equity markets;

•

sales of our common stock by us or our stockholders in the future;

•

trading volume of our common stock;

•

changes in accounting practices;

•

ineffectiveness of our internal controls;

•

disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;

•

significant lawsuits, including patent or stockholder litigation;

•

general political and economic conditions; and

•

other events or factors, many of which are beyond our control.

In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company’s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management’s attention and resources.

Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.

Our quarterly and annual operating results may fluctuate significantly, due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:

•

the timing and cost of, and level of investment in, research, development and, if approved, commercialization activities relating to our current and future product candidates, which may change from time to time;

•

the timing and status of enrollment for clinical trials;

•

the cost of manufacturing our product candidates, as well as building out our supply chain, which may vary depending on the quantity of production and the terms of our agreements with manufacturers;

•

expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies;

•

timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement, including the Janssen License;

•

future accounting pronouncements or changes in our accounting policies;

•

the timing and success or failure of preclinical studies and clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;

•

the timing of receipt of approvals for our product candidates from regulatory authorities in the United States and internationally;

•

exchange rate fluctuations;

•

coverage and reimbursement policies with respect to our product candidates, if approved, and potential future drugs that compete with our products; and

•

the level of demand for our product candidates, if approved, which may vary significantly over time.

The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance.

This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our future revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if any forecasts we

provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.

If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

Our executive officers, directors, principal stockholders and their respective affiliates own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Based on the beneficial ownership of our common stock as of May 10, 2024, prior to this offering and the concurrent private placement, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 88.7% of our voting stock and, upon the completion of this offering and the concurrent private placement, that same group will hold approximately 66.0% of our outstanding voting stock (assuming no exercise of the underwriters’ option to purchase additional shares, no exercise of outstanding options and no purchases of shares in this offering or in the concurrent private placement by any of this group), in each case assuming the conversion of all outstanding shares of our convertible preferred stock into shares of our common stock. As a result, these stockholders, if acting together, will continue to have significant influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, amendment of our organizational documents, any merger, consolidation or sale of all or substantially all of our assets and any other significant corporate transaction. In addition, certain of our principal stockholders, including Third Rock Ventures V, L.P. and ARCH Venture Fund XII, L.P., have designated certain members of our board of directors. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could delay or prevent a change of control of our company, even if such a change of control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of our company or our assets and might affect the prevailing market price of our common stock. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise.

Future sales of our common stock in the public market could cause our common stock price to fall.

Our common stock price could decline as a result of sales of a large number of shares of common stock after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.

Upon the completion of this offering and the concurrent private placement, 35,376,457 shares of common stock will be outstanding (or 36,576,457 shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of March 31, 2024.

All shares of common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended (the “Securities Act”) unless held by our

“affiliates” as defined in Rule 144 under the Securities Act. The resale of the remaining 26,312,614 shares, or 74.4% of our outstanding shares of common stock following this offering and the concurrent private placement, is currently prohibited or otherwise restricted, subject to certain limited exceptions, as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning on the 181st day after the date of this prospectus. Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see the section titled “Shares Eligible for Future Sale” included elsewhere in this prospectus.

Upon the completion of this offering and the concurrent private placement, the holders of approximately 22,146,816 shares, or 62.6% of our outstanding shares following this offering and the concurrent private placement, of our common stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also intend to register the offer and sale of all shares of common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares that may be issued under our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the lock-up agreements described under the section titled “Underwriting” included elsewhere in this prospectus.

In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities convertible into common stock, in connection with a financing, acquisition, employee arrangement, or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our common stock to decline.

We will have broad discretion in how we use the proceeds of this offering and the concurrent private placement and may not use these proceeds effectively, which could affect our results of operations and cause our stock price to decline.

We will have considerable discretion in the application of the net proceeds of this offering and the concurrent private placement, including for any of the purposes described in the section titled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. As a result, investors will be relying upon management’s judgment with only limited information about our specific intentions for the use of the net proceeds of this offering and the concurrent private placement. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering and the concurrent private placement in a manner that does not produce income or that loses value.

If you purchase shares of our common stock in our initial public offering, you will experience substantial and immediate dilution.

The assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately following the completion of this offering and the concurrent private placement. If you purchase shares of common stock in this offering, you will experience substantial and immediate dilution in the pro forma as adjusted net tangible book value per share of $7.56 per share as of March 31, 2024. That is because the price that you pay will be substantially greater than the pro forma as adjusted net tangible book value per share of the common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution if the underwriters exercise

their option to purchase additional shares in this offering, when those holding stock options exercise their right to purchase common stock under our equity incentive plans, upon the vesting of outstanding restricted stock awards or when we otherwise issue additional shares of common stock. For additional details see the section titled “Dilution” included elsewhere in this prospectus.

Participation in this offering and the concurrent private placement by our existing stockholders and/or their affiliated entities will reduce the public float for our common stock.

To the extent our existing stockholders who are our affiliates or their affiliated entities participate in this offering or the concurrent private placement, such purchases would reduce the non-affiliate public float of our common stock after this offering, which is the number of shares of common stock that are not held by our officers, directors and affiliated stockholders. Furthermore, the sale of shares to certain of our existing investors in the concurrent private placement will not be registered in this offering, and certain of these shares are subject to a 180-day lock-up agreement with the underwriters in this offering and with the Financial Industry Regulatory Authority (“FINRA”). As a result, the number of freely tradeable shares of our common stock following this offering and the concurrent private placement will be reduced relative to what it would have been had these shares been sold to investors that were not existing stockholders, affiliates or purchasers in the concurrent private placement. This could adversely impact the liquidity of our common stock and depress the price at which you may be able to sell shares of common stock purchased in this offering.

Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other stockholders.

We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary companies, products or technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of their ownership interests and the per share value of our common stock to decline.

We do not currently intend to pay dividends on our common stock and, consequently, our stockholders’ ability to achieve a return on their investment will depend on appreciation of the value of our common stock.

We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.

Our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, will contain provisions that may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

•

establish a classified board of directors such that only one of three classes of directors is elected each year;

•

allow the authorized number of our directors to be changed only by resolution of our board of directors;

•

limit the manner in which stockholders can remove directors from our board of directors;

•

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;

•

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;

•

limit who may call stockholder meetings;

•

authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and

•

require the approval of not less than two-thirds of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our third amended and restated certificate of incorporation or amended and restated bylaws.

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law (the “DGCL”), which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our amended and restated bylaws that will become effective upon the effectiveness of this registration statement designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.

Our amended and restated bylaws that will become effective upon effectiveness of the registration statement of which this prospectus forms a part provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of, or a claim based on, fiduciary duty owed by any of our current or former directors, officers, and employees to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our third amended and restated certificate of incorporation or our amended and restated bylaws (including the interpretation, validity or enforceability thereof) or (iv) any action asserting a claim that is governed by the internal affairs doctrine (the “Delaware Forum Provision”). The Delaware Forum Provision will not apply to any causes of action arising under the Securities Act or the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our amended and restated bylaws further provide that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the U.S. shall be the sole and exclusive forum for resolving any complaint asserting a cause or causes of action arising under the Securities Act (the “Federal Forum Provision”). In addition, our amended and restated bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.

The Delaware Forum Provision and the Federal Forum Provision in our amended and restated bylaws may impose additional litigation costs on stockholders in pursuing any such claims. Additionally, the forum selection clauses in our amended and restated bylaws may limit our stockholders’ ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the

validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce our Federal Forum Provision. If the Federal Forum Provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The Federal Forum Provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of Chancery of the State of Delaware and the federal district courts of the U.S. may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.

We may not be able to satisfy listing requirements of The Nasdaq Stock Market (“Nasdaq”) or obtain or maintain a listing of our common stock on Nasdaq.

If our common stock is listed on Nasdaq, we must meet certain financial and liquidity criteria to maintain such listing. If we violate Nasdaq’s listing requirements, our common stock may be delisted. If we fail to meet any of Nasdaq’s listing standards, our common stock may be delisted. In addition, our board of directors may determine that the cost of maintaining our listing on a national securities exchange outweighs the benefits of such listing. A delisting of our common stock from Nasdaq may materially impair our stockholders’ ability to buy and sell our common stock and could have an adverse effect on the market price of, and the efficiency of the trading market for, our common stock. The delisting of our common stock could significantly impair our ability to raise capital and the value of your investment.

Other General Risks

Unfavorable global economic conditions could adversely affect our business, financial condition, stock price, and results of operations.

The global credit and financial markets have experienced extreme volatility and disruptions (including as a result of actual or perceived changes in interest rates, inflation and macroeconomic uncertainties), which has included severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, high inflation, uncertainty about economic stability, global supply chain disruptions, and increases in unemployment rates. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the ongoing conflicts between Russia and Ukraine, and Israel and Hamas, terrorism, or other geopolitical events. Sanctions imposed by the U.S. and other countries in response to such conflicts, including the one in Ukraine, may also continue to adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decrease in the demand for our drug candidates and in our ability to raise additional capital when needed on acceptable terms, if at all. For example, there has been proposed U.S. legislation that may restrict the ability of U.S. biopharmaceutical companies to purchase services or products from, or otherwise collaborate with, certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We continue to assess the legislation as it develops to determine whether it could have an effect on our contractual relationships. Furthermore, any disruptions to our supply chain as a result of unfavorable global economic conditions, including due to geopolitical conflicts or public health crises, could negatively impact the timely execution of our ongoing and future clinical trials. In addition, current inflationary trends in the global economy may impact salaries and wages, costs of goods and transportation expenses, among other things, and recent and potential future disruptions in access to bank deposits or lending commitments due to bank failures may create market and economic instability. We cannot anticipate all of the ways in which the foregoing, and the current economic climate and financial market conditions generally, could adversely impact our business.

We, or the third parties upon whom we depend, may be adversely affected by natural disasters, public health crises or other business interruptions and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.

Natural disasters or public health crises could severely disrupt our operations, and have a material adverse impact on our business, results of operations, financial condition, and prospects. If a natural disaster, power outage, public health crisis or other event occurred that prevented us from conducting our clinical trials, releasing clinical trial results or delaying our ability to obtain regulatory approval for our product candidates, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time.

We are eligible to be treated as an “emerging growth company” and a “smaller reporting company” and our election of reduced reporting requirements applicable to emerging growth companies and smaller reporting companies may make our common stock less attractive to investors.

We are an “emerging growth company” as defined in the Jumpstart Our Business Startups Act (“JOBS Act”). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. In addition, as an emerging growth company, we are only required to provide two years of audited financial statements in this prospectus. We could be an emerging growth company for up to five years following the completion of this offering, although circumstances could cause us to lose that status earlier, including if we are deemed to be a “large accelerated filer,” which occurs when the market value of our common stock that is held by non-affiliates exceeds $700 million as of the prior June 30, or if we have total annual gross revenue of $1.235 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31, or if we issue more than $1.0 billion in non-convertible debt during any three-year period before that time, in which case we would no longer be an emerging growth company immediately. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include:

•

not being required to comply with the auditor attestation requirements of Section 404;

•

providing only two years of audited financial statements in addition to any required unaudited interim financial statements and a correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure in this prospectus;

•

reduced disclosure obligations regarding executive compensation; and

•

exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. In this prospectus, we have not included all of the executive compensation-related information that would be required if we were not an emerging growth company.

Even after we no longer qualify as an emerging growth company, we could still qualify as a “smaller reporting company,” which would allow us to take advantage of many of the same exemptions from disclosure requirements and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.

In addition, the JOBS Act provides that an emerging growth company can also take advantage of an extended transition period for complying with new or revised accounting standards until such time as those

standards apply to private companies. We have elected to avail ourselves of this exemption from new or revised accounting standards, and therefore we will not be subject to the same requirements to adopt new or revised accounting standards as other public companies that are not emerging growth companies.

We are also a “smaller reporting company” as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.

We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.

As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers.

If we fail to establish and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.

Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that needs to be reevaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in

accordance with generally accepted accounting principles. In connection with this offering, we began the process of documenting, reviewing and improving our internal controls and procedures for compliance with Section 404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control over financial reporting. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company or a non-accelerated filer, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act. We could be an emerging growth company for up to five years following completion of this initial public offering. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

Upon the completion of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.

Our ability to use our net operating loss carryforwards and other tax attributes may be limited.

As of December 31, 2023, we had approximately $6.0 million of federal net operating losses (“NOLs”). Federal NOLs generated in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOL carryforwards in a taxable year is limited to 80% of our taxable income in such year. As of December 31, 2023, we had approximately $1.6 million of state NOLs. Of the state NOLs, some are of indefinite life, but most expire at various dates, beginning in 2042. As of December 31, 2023, we had approximately $1.5 million of federal research and development tax credit carryforwards. Federal tax credit carryforwards expire at various dates, beginning in 2042. As of December 31, 2023, we had approximately $0.5 million of state research and development tax credit carryforwards. The state tax credits, which have various carryforward rules, begin to expire in 2037.

Under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the “Code”), if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by “5 percent shareholders” over a three-year period, the corporation’s ability

to use its pre-change NOLs and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. A corporation that experiences an ownership change will generally be subject to an annual limitation on the use of its pre-ownership change NOLs equal to the value of the corporation immediately before the ownership change, multiplied by the long-term tax-exempt rate (subject to certain adjustments). We may have experienced ownership changes in the past and may experience ownership changes as a result of this offering and the concurrent private placement and/or subsequent shifts in our stock ownership (some of which are outside our control). There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs by federal or state taxing authorities or other unforeseen reasons, portions of our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities. As a result, our ability to use our pre-change NOLs and tax credits to offset future taxable income, if any, or taxes could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we attain profitability, we may be unable to use a material portion of our NOLs and tax credits.

Changes in tax law could adversely affect our business and financial condition.

U.S. federal, state, local and foreign tax laws, regulations and administrative guidance are subject to change as a result of the legislative process and review and interpretation by the U.S. Internal Revenue Service, the U.S. Treasury Department and other taxing authorities. Changes to tax laws (which changes may have retroactive application), including with respect to net operating losses and research and development tax credits, could adversely affect us or holders of our common stock. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.

Clinical trial and product liability lawsuits against us could divert our resources and could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.

We face an inherent risk of clinical trial and product liability exposure related to the testing of our product candidates in clinical trials, and we will face an even greater risk if we commercially sell any products that we develop. While we currently have no products that have been approved for commercial sale, the ongoing, planned and future use of product candidates by us in clinical trials, and the sale of any approved products in the future, may expose us to liability claims. These claims might be made by patients that use the product, healthcare providers, pharmaceutical companies or others selling such products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:

•

decreased demand for any product candidates or products that we may develop;

•

termination of clinical trials;

•

injury to our reputation and significant negative media attention;

•

withdrawal of clinical trial participants;

•

significant costs to defend any related litigation;

•

substantial monetary awards to trial participants or patients;

•

loss of revenue;

•

reduced resources of our management to pursue our business strategy; and

•

the inability to commercialize any products that we may develop.

Although we currently hold clinical trial liability insurance, we will need to maintain and this such insurance coverage as we expand our clinical trials or if we commence commercialization of our product

candidates. Insurance coverage is increasingly expensive. We may not be able to obtain and maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. If a successful clinical trial or product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such claims and our business operations could be impaired.

We may become involved in litigation that could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.

From time to time we may be subject to litigation claims through the ordinary course of our business operations regarding, but not limited to, securities litigation, employment matters, security of patient and employee personal data, contractual relations with collaborators and licensors and intellectual property rights. In the past, securities class action litigation has often followed certain significant business transactions, such as the sale of a company or announcement of any other strategic transaction, the announcement of negative events, such as negative results from clinical trials, or periods of volatility in the market price of a company’s securities. These events may also result in or be concurrent with investigations by the SEC. We may be exposed to such litigation or investigation even if no wrongdoing occurred. Litigation and investigations are usually expensive and divert management’s attention and resources, which could adversely affect our business and cash resources and our ability to consummate a potential strategic transaction or the ultimate value our stockholders receive in any such transaction.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of preclinical studies, clinical trials, research and development costs, regulatory approvals, commercial strategy, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that are in some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about:

•

our ability to identify, develop, and commercialize current and future product candidates based on our RAP technology platform;

•

the initiation, timing, progress, and results of our research and development programs, preclinical studies and clinical trials;

•

the translation of endpoints in our current and planned clinical trials to future registrational trials;

•

our ability to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties in current or future clinical trials;

•

our ability to demonstrate that our current and future product candidates are safe and effective for their proposed indications;

•

the number of patients with the diseases or disorders we elect to pursue with our product candidates, and the willingness of those patient populations to use and adhere to our product candidates if approved in the future;

•

the implementation of our business model, and strategic plans for our business, programs, future product candidates, platform, and technology;

•

our ability to advance any product candidates through applicable regulatory approval processes;

•

our ability to obtain additional cash and the sufficiency of our existing cash, cash equivalents and short-term investments to fund our future operating expenses and capital expenditure requirements;

•

the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;

•

our ability to comply with our obligations under our intellectual property licenses with third parties, including Janssen;

•

our ability to maintain, expand and protect our intellectual property portfolio;

•

developments relating to our competitors and our industry;

•

existing regulations and regulatory developments in the United States and other jurisdictions;

•

our ability to identify and enter into future license agreements and collaborations;

•

general economic, industry, and market conditions, including rising interest rates and inflation;

•

our ability to attract, hire, and retain our key personnel and additional qualified personnel; and

•

our anticipated use of our existing cash, cash equivalents and short-term investments and the proceeds from this offering and the concurrent private placement.

We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled “Risk Factors” and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

You should read this prospectus and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which this prospectus is a part with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

USE OF PROCEEDS

We estimate that the net proceeds from this offering will be approximately $122.1 million (or approximately $141.1 million if the underwriters exercise their option to purchase additional shares of our common stock in full) based on an assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. We also expect to receive net proceeds of approximately $16.7 million from the sale of shares of our common stock to certain existing stockholders in the concurrent private placement, based on an assumed initial public offering price of $17.00 per share, after deducting placement agent fees and estimated private placement expenses payable by us.

Each $1.00 increase or decrease in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering and concurrent private placement by $8.4 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting underwriting discounts and commissions, placement agent fees and estimated offering and private placement expenses payable by us. Similarly, each increase or decrease of 1.0 million shares in the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, would increase or decrease, as applicable, the net proceeds to us from this offering by $15.8 million, assuming the assumed initial public offering price of $17.00 per share remains the same, and after deducting underwriting discounts and commissions, placement agent fees and estimated offering and private placement expenses payable by us.

The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public equity markets, increase our visibility in the marketplace, and obtain additional capital to support our operations. We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments, as follows:

•

approximately $100 million to advance the Phase 2a development of our lead TARPγ8 AMPAR program, RAP-219, including the completion of our proof-of-concept trials in focal epilepsy, peripheral neuropathic pain and bipolar disorder;

•

approximately $40 million to conduct our second MAD trial and PET trial, for the advancement of a long-acting injectable formulation of RAP-219, and to advance our second TARPγ8 AMPAR program, RAP-199, through Phase 1 of development; and

•

the remainder for other research and development activities, including the development of our nAChR discovery programs, costs associated with operating as a public company, and general corporate purposes.

We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and short-term investments to in-license, acquire, or invest in complementary businesses, technologies, products, or assets. However, we have no current commitments, agreements, understandings or obligations to do so.

We believe, based on our current operating plan, that the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments, will be sufficient to fund our operations through the end of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. We do not have any committed external source of funds.

Our expected use of proceeds from this offering and the concurrent private placement described above represents our current intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the completion of this offering and the concurrent private placement or the actual amounts that we will spend on the

uses set forth above. We expect that we will require additional funds in order to fully accomplish the specified uses of the proceeds of this offering and the concurrent private placement. The amounts and timing of our actual expenditures will depend on numerous factors, including progress of our research and development, the status of and results from preclinical studies and clinical trials that we are conducting or may conduct in the future, and other factors described in the section titled “Risk Factors” in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes.

We will have broad discretion over how to use the net proceeds to us from this offering and the concurrent private placement and investors will be relying on the judgment of our management regarding the application of the net proceeds. Pending our use of the net proceeds from this offering and the concurrent private placement, we intend to invest the net proceeds in a variety of capital preservation instruments, including short-term and long-term interest-bearing instruments, investment-grade securities, and direct or guaranteed obligations of the U.S. government. We cannot predict whether the proceeds invested will yield a favorable return.

DIVIDEND POLICY

We have never declared or paid cash dividends on our capital stock. We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.

In addition, our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or preferred securities we issue or any credit facilities we enter into.

CAPITALIZATION

The following table sets forth our existing cash, cash equivalents and short-term investments, excluding restricted cash, and our total capitalization as of March 31, 2024:

•

on an actual basis;

•

on a pro forma basis, giving effect to (i) the automatic conversion of all 189,613,384 shares of our convertible preferred stock outstanding as of March 31, 2024 into an aggregate of 22,146,816 shares of our common stock immediately prior to the completion of this offering and (ii) the filing and effectiveness of our third amended and restated certificate of incorporation, which will occur immediately prior to the completion of this offering; and

•

on a pro forma as adjusted basis, giving effect to (i) the pro forma adjustments set forth above, (ii) the issuance and sale of 8,000,000 shares of our common stock in this offering at the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and (iii) the sale of 1,058,824 shares of common stock in a concurrent private placement at the assumed initial public offering price of $17.00 per share, after deducting placement agent fees and estimated private placement expenses payable by us.

The pro forma as adjusted information below is illustrative only, and our capitalization following the completion of this offering and the concurrent private placement will be adjusted based on the actual initial public offering price and other terms of this offering and the concurrent private placement determined at pricing.

You should read this information together with our consolidated financial statements and the related notes included elsewhere in this prospectus, and the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”


	As of March 31, 2024
	Actual			Pro Forma			Pro Forma As adjusted ⁽¹⁾
	(in thousands, except share and per share data)
Cash, cash equivalents and short-term investments	$	193,244		$	193,244		$	332,406

Convertible preferred stock (Series A and B), $0.001 par value; 189,613,384 shares authorized; 189,613,384 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and pro forma as adjusted	$	234,739		$	—		$	—
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual; 10,000,000 shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted
Common stock, $0.001 par value; 250,000,000 shares authorized, 4,170,817 shares issued and outstanding, actual; 500,000,000 shares authorized, 26,317,633 issued and outstanding, pro forma; 500,000,000 shares authorized, 35,376,457 shares issued and outstanding and pro forma as adjusted		4			26			35
Additional paid-in capital		28,630			263,347			402,083
Accumulated other comprehensive income		(160	)		(160	)		(160	)
Accumulated deficit		(68,107	)		(68,107	)		(68,107	)

Total stockholders’ equity (deficit)		(39,633	)		195,106			333,851

Total capitalization	$	195,106		$	195,106		$	333,851

(1)

Each $1.00 increase or decrease, as applicable, in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, for this offering and the concurrent private placement, would increase or decrease, as applicable, the pro forma as adjusted amount of each of cash, cash equivalents and short-term investments, additional paid-in capital, total stockholders’ equity and total capitalization by $8.4 million, assuming that the number of shares offered by us in this offering and the concurrent private placement remains the same and after deducting underwriting discounts and commissions, placement agent fees and estimated offering and concurrent private placement expenses payable by us. Similarly, each increase or decrease, as applicable, of 1,000,000 shares in the number of shares of common stock offered by us in this offering and the concurrent private placement would increase or decrease, as applicable the pro forma as adjusted amount of each of cash, cash equivalents and short-term investments, additional paid-in capital, total stockholders’ equity and total capitalization by $15.8 million, assuming no change in the assumed initial public offering price per share, after deducting underwriting discounts and commissions, placement agent fees and estimated offering and concurrent private placement expenses payable by us.

•

2,677,487 shares of common stock issuable upon exercise of outstanding stock options as of March 31, 2024 under our 2022 Plan, with a weighted average exercise price of $5.23 per share;

•

92,234 shares of common stock issuable upon exercise of outstanding stock options granted after March 31, 2024 pursuant to our 2022 Plan, with a weighted average exercise price of $11.57 per share;

•

118,707 shares of common stock reserved for future issuance as of March 31, 2024 under the 2022 Plan, which will cease to be available for issuance at the time that our 2024 Plan becomes effective;

•

324,243 shares of common stock reserved for future issuance under the ESPP, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; and

•

DILUTION

If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering and the concurrent private placement.

Our historical net tangible book deficit as of March 31, 2024 was $(41.5) million, or $(9.96) per share of our common stock. Our historical net tangible book deficit represents the amount of our total tangible assets less our total liabilities and the carrying value of our convertible preferred stock, which is not included within stockholders’ deficit. Historical net tangible book deficit per share represents historical net tangible book deficit divided by 4,170,817 shares of our common stock outstanding (which includes 2,030,242 shares of unvested restricted common stock) as of March 31, 2024.

Our pro forma net tangible book value as of March 31, 2024 was $193.2 million, or $7.34 per share. Pro forma net tangible book value per share represents the amount of our total tangible assets less our total liabilities, divided by the number of shares of our common stock outstanding as of March 31, 2024 (which includes 2,030,242 shares of unvested restricted common stock outstanding as of March 31, 2024), after giving effect to the automatic conversion of all 189,613,384 shares of our convertible preferred stock outstanding as of March 31, 2024 into 22,146,816 shares of common stock immediately prior to the completion of this offering.

After giving further effect to the sale of 8,000,000 shares of common stock and 1,058,824 shares of common stock that we are offering in this offering and the concurrent private placement, respectively, at the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions, placement agent fees and estimated offering and concurrent private placement expenses payable by us for the sale of up to 1,058,824 shares of common stock to certain of our existing stockholders in the concurrent private placement at an assumed initial public offering price of $17.00 per share, our pro forma as adjusted net tangible book value as of March 31, 2024 would have been $333.9 million, or $9.44 per share. This amount represents an immediate increase in pro forma net tangible book value of $2.10 per share to our existing stockholders and an immediate dilution in pro forma net tangible book value of $7.56 per share to new investors purchasing shares of common stock in this offering.

Dilution per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering and the concurrent private placement from the initial public offering price per share paid by new investors. The following table illustrates this dilution (without giving effect to any exercise by the underwriters of their option to purchase additional shares):


Assumed initial public offering price per share				$	17.00
Historical net tangible book value (deficit) per share as of March 31, 2024	$	(9.96	)
Increase per share as of March 31, 2024 attributable to the pro forma adjustment described above		17.30

Pro forma net tangible book value per share as of March 31, 2024		7.34

Increase in pro forma as adjusted net tangible book value per share attributable to new investors participating in this offering and in the concurrent private placement		2.10

Pro forma as adjusted net tangible book value per share after this offering and the concurrent private placement					9.44

Dilution per share to new investors purchasing common stock in this offering and in the concurrent private placement				$	7.56

The dilution information discussed above is illustrative only and may change based on the actual initial public offering price and other terms of this offering and the concurrent private placement. Each $1.00 increase

or decrease, as applicable, in the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease, as applicable, the pro forma as adjusted net tangible book value per share after this offering and the concurrent private placement by $0.24, and dilution per share to new investors purchasing common stock in this offering and in the concurrent private placement by $0.76, assuming that the number of shares of common stock offered by us, as set forth on the cover page of this prospectus, remains the same, that the number of shares sold in the concurrent private placement are increased or decreased accordingly, and after deducting underwriting discounts and commissions, placement agent fees, and estimated offering and concurrent private placement expenses payable by us. Similarly, each increase or decrease, as applicable, of 1.0 million shares in the number of shares of common stock offered by us would increase or decrease, as applicable, our pro forma as adjusted net tangible book value per share after this offering and the concurrent private placement by $0.17 per share, in each case, and increase or decrease, as applicable, the dilution to investors participating in this offering and the concurrent private placement by $0.17 per share, assuming no change in the assumed initial public offering price, and after deducting underwriting and placement agent discounts and commissions and estimated offering and concurrent private placement expenses payable by us.

If the underwriters exercise their option to purchase additional shares of our common stock in full, our pro forma as adjusted net tangible book value after the offering and the concurrent private placement would be $9.65 per share, representing an immediate increase in pro forma as adjusted net tangible book value of $2.31 per share to existing stockholders and immediate dilution in pro forma as adjusted net tangible book value dilution of $7.35 per share to new investors, in each case assuming an initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions, placement agent fees, and estimated offering and concurrent private placement expenses payable by us.

The following table summarizes on the pro forma as adjusted basis described above, as of March 31, 2024, the total number of shares of common stock purchased from us on an as converted basis, the total consideration paid or to be paid to us, and the average price per share paid by existing stockholders or to be paid by new investors in this offering and in the concurrent private placement, based on the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, before deducting underwriting discounts and commissions and estimated offering expenses payable by us. New investors purchasing shares of our common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid.


	Shares Purchased					Total Consideration					Average Price Per Share
	Number		Percent			Amount		Percent			Average Price Per Share
Existing stockholders before this offering and concurrent private placement		26,317,633		74	%	$	250,094,673		62	%	$	9.50
Investors participating in this offering and the concurrent private placement		9,058,824		26	%	$	154,000,000		38	%	$	17.00

Total		35,376,457		100	%	$	404,094,673		100	%

The table above assumes no exercise of the underwriters’ option to purchase additional shares in this offering. If the underwriters exercise their option to purchase additional shares of common stock from us in full, our existing stockholders would own 72%, and new investors purchasing shares of our common stock in this offering would own 28%, of the total number of shares of our common stock outstanding immediately after the completion of this offering and the concurrent private placement.

includes 2,030,242 shares of unvested restricted common stock outstanding as of March 31, 2024), after giving effect to the automatic conversion of all 189,613,384 shares of our convertible preferred stock outstanding as of March 31, 2024 into 22,146,816 shares of common stock immediately prior to the completion of this offering, and excludes:

•

2,677,487 shares of common stock issuable upon exercise of outstanding stock options as of March 31, 2024 under our 2022 Plan, with a weighted average exercise price of $5.23 per share;

•

92,234 shares of common stock issuable upon exercise of outstanding stock options granted after March 31, 2024 pursuant to our 2022 Plan, with a weighted average exercise price of $11.57 per share;

•

118,707 shares of common stock reserved for future issuance as of March 31, 2024 under the 2022 Plan, which will cease to be available for issuance at the time that our 2024 Plan becomes effective;

•

324,243 shares of common stock reserved for future issuance under our ESPP, which will become effective on the date immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP; and

•

To the extent any outstanding options are exercised, new options or other equity awards are issued under our equity incentive plans, or we issue additional shares of common stock in the future, there will be further dilution to new investors. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND

RESULTS OF OPERATIONS

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and related notes and other financial information included elsewhere in this prospectus. This discussion and analysis and other parts of this prospectus contain forward-looking statements based upon our current plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, strategies, objectives, expectations, intentions and beliefs. Our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” and elsewhere in this prospectus. You should carefully read the “Risk Factors” section of this prospectus to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see “Special Note Regarding Forward-Looking Statements.” Our historical results are not necessarily indicative of the results that may be expected for any period in the future.

Overview

Since our inception in February 2022, we have not generated any revenue from product sales or other sources and have incurred significant operating losses and negative cash flows from our operations. We have devoted substantially all of our efforts to organizing and staffing our company, business planning, research and development activities, building our intellectual property portfolio, and providing general and administrative support for these operations. To date, we have funded our operations primarily with proceeds from the issuance and sale of our convertible notes and convertible preferred stock. As of March 31, 2024, we had raised aggregate gross proceeds of $250.0 million from these financings, and had cash, cash equivalents and short-term investments of $193.2 million, excluding our restricted cash.

We have incurred significant operating losses in each year since our inception. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of any product candidates we may develop. Our net losses were $10.7 million, $34.8 million, $6.1 million, and $22.7 million for the period from February 10, 2022 (inception) to December 31, 2022, the year ended December 31, 2023, and for the three months ended March 31, 2023 and 2024, respectively. As of March 31, 2024, we had an accumulated deficit of $68.1 million. We expect our expenses and operating losses will increase substantially as we:

•

continue to conduct our ongoing clinical trials of RAP-219, including advancement into late-stage global clinical trials, as well as initiate and complete additional clinical trials of future product candidates or current product candidates in new indications or patient populations;

•

conduct our ongoing preclinical studies and ongoing and planned clinical trials;

•

utilize third parties to manufacture our potential future product candidates and related raw materials;

•

continue our early research and development activities;

•

seek to identify additional research programs and program candidates to expand our pipeline;

•

hire additional research and development, clinical, commercial, and operational personnel;

•

maintain, expand, enforce, defend and protect our intellectual property portfolio and provide reimbursement of third-party expenses related to our patent portfolio;

•

seek regulatory approvals for any potential future product candidates for which we successfully complete clinical trials;

•

acquire or in-license product candidates, intellectual property and technologies;

•

establish and maintain collaborations;

•

ultimately establish a sales, marketing and distribution infrastructure to commercialize any therapies for which we may obtain regulatory approval; and

•

incur additional costs associated with being a public company, including audit, legal, regulatory, and tax-related services associated with maintaining compliance with an exchange listing and Securities Exchange Commission (“SEC”) requirements, director and officer insurance premiums and investor relations costs.

In addition, we have several preclinical and clinical development, regulatory, and commercial milestone payment obligations under our licensing arrangements. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our preclinical studies and planned clinical trials and our expenditures on other research and development activities.

We do not expect to generate any revenue from product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our potential future product candidates, which will not be for at least the next several years, if ever. If we obtain regulatory approval for any of our potential future product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. Accordingly, until such time as we can generate significant revenue from sales of our potential future product candidates, if ever, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. See the section titled “—Liquidity and Capital Resources” included elsewhere in this prospectus. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market potential future product candidates that we would otherwise prefer to develop and market ourselves.

We believe that the net proceeds from this offering and the concurrent private placement, together with our existing cash and cash equivalents, and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through the end of 2026. See the sections titled “—Liquidity and Capital Resources” and “Risk Factors—Risks Related to Our Limited Operating History, Financial Condition and Need for Additional Capital” included elsewhere in this prospectus.

License and Collaboration Agreements

Option and License Agreement with Janssen Pharmaceutical NV

In August 2022, we entered into an option and license agreement with Janssen Pharmaceutical NV, as amended on April 3, 2023, April 18, 2023, May 2, 2023, October 2, 2023, and April 9, 2024 (collectively, the “Janssen License”), under which we received an exclusive option to obtain from Janssen (a) a worldwide exclusive license for the research, development, and commercialization of transmembrane TARPg8 AMPAR products for the diagnosis, treatment, prophylaxis or palliation of any disease or condition in humans or other animals (the “Field”) and (b) an assignment of certain patents related to TARPg8, in each case of (a)-(b), subject to certain retained rights by Janssen. Pursuant to the Janssen License, we also received a worldwide, royalty-free, non-exclusive license (exclusive under certain joint patents) for the research, development, and commercialization of certain neuronal nicotinic acetylcholine (“nACh”) products in the Field.

We made a non-refundable, non-creditable upfront payment of $1.0 million to Janssen after we entered into the Janssen License. In October 2022, we exercised the option and paid a non-refundable, non-creditable option fee of $4.0 million to Janssen. If we succeed in developing and commercializing TARPg8 products, Janssen will be eligible to receive (i) up to $76.0 million in development milestone payments and up to $40.0 million sales milestone payments for the product containing the lead TARPg8 development candidate, and (ii) up to $25.0 million in development milestone payments and up to $42.0 million sales milestone payments for other TARPg8 products containing a non-lead TARPg8 development candidate.

Janssen is also eligible to receive (a) royalties ranging from mid-single digits to high single digits on worldwide net sales of any products containing a TARPg8 development candidate and (b) royalties ranging from low-single digits to mid-single digits for other TARPg8 products that do not contain a TARPg8 development candidate, in each case of (a) and (b), subject to potential reductions following the expiration of valid claims and regulatory exclusivity covering such TARPg8 products, the launch of certain generic products and the application of certain anti-stacking reductions for third party intellectual property payments, subject to a customary reduction floor. The royalties for any TARPg8 product will expire on a country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering such product in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) a specified number of years following the first commercial sale of such product in such country. The Janssen License provides us with certain other exclusive rights with respect to small molecules with activity against TARPg8 and nACh.

We have the right to terminate the Janssen License for any or no reason upon providing prior written notice to Janssen upon ninety (90) days’ prior written notice to Janssen. Either party may terminate the license agreement in its entirety for the other party’s material breach if such party fails to cure the breach or upon certain insolvency events involving the other party.

We determined that the Janssen License represented an asset acquisition, rather than a business combination, as substantially all of the fair value of the assets acquired in the Janssen License was concentrated in a single asset, the TARPg8 compound, which was in the early stage of development at the time of acquisition. As the IPR&D asset was determined to have no alternative future use, we recognized the aggregate acquisition cost as related party acquired in-process research and development expense in the consolidated statement of operations and comprehensive loss for the period from February 10, 2022 (inception) to December 31, 2022. We recognized the $5.0 million of related party acquired in-process research and development expense in connection with the consideration due under the Janssen License during the period from February 10, 2022 (inception) to December 31, 2022.

NeuroPace Master Services Agreement and Statement of Work

In November 2023, we entered into a master services agreement (the “NeuroPace Agreement”) with NeuroPace Inc. (“NeuroPace”), the manufacturer and distributor of the responsive neurostimulation (“RNS”) system. Pursuant to the NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides us with certain services with respect to data from the RNS systems used in our clinical trials. The NeuroPace Agreement also grants us a royalty-free, worldwide, exclusive, non-transferable license to all data collected by the RNS systems in our Phase 2a clinical trial and the outcomes of algorithms that are applied to such data, as well as the ability to publish the outcomes of algorithms, subject to certain conditions. The consideration we will pay to NeuroPace for such services is set out in each statement of work agreement.

The NeuroPace Agreement contains an exclusivity provision providing that, at any time while providing services under the NeuroPace Agreement and for a period after the final clinical study report, NeuroPace may not perform any services that are the same as the services covered by the NeuroPace Agreement to any business that directly competes with us, subject to the specific terms of the NeuroPace Agreement. The NeuroPace Agreement also contains standard representations and warranties, confidentiality and intellectual property protective provisions and indemnification terms.

The NeuroPace Agreement expires on the later of three years from the effective date or the completion of all services under all statement of work agreements entered into prior to the third anniversary of the effective date. Either party may terminate the NeuroPace Agreement or any statement of work agreement (i) without cause by giving written notice to the other party within a specified period of time, (ii) by giving written notice upon a curable material breach that is not remediated within a specified period of time, or (iii) immediately upon written notice in the event of a material breach that cannot be cured.

Concurrently with the execution of the NeuroPace Agreement, the parties also entered into an initial statement of work, as amended in March 2024 (the “NeuroPace SOW”), under the NeuroPace Agreement, pursuant to which NeuroPace agreed to provide services related to our Phase 2a clinical trial of RAP-219, including, among other things, clinical trial readiness support, identification of potential patients satisfying the enrollment criteria and RNS system data reporting and data analysis. Pursuant to the payment schedule set out in the NeuroPace SOW, we will pay NeuroPace an aggregate of up to $3.7 million over a period of approximately two years in connection with NeuroPace’s provision of services and achievement of certain patient enrollment and deliverable milestones.

During the year ended December 31, 2023, we paid NeuroPace $1.5 million, which is recorded as prepaid expenses and other current assets in the consolidated balance sheet as of December 31, 2023. During the three months ended March 31, 2024, we paid NeuroPace an additional $0.3 million and recognized $0.3 million in research and development expense for services performed, resulting in a prepaid expense balance of $1.5 million as of March 31, 2024.

Components of Results of Operations

Operating Expenses

Related Party Acquired In-Process Research and Development Expenses

We measure and recognize asset acquisitions or licenses to intellectual property that are not deemed to be business combinations based on the cost to acquire or license the asset or group of assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition or license to intellectual property, the cost allocated to acquire in-process research and development (“IPR&D”) with no alternative future use is recognized as research and development expense on the acquisition date. For the period from February 10, 2022 (inception) to December 31, 2022, we recorded $5.0 million of research and development expense related

to the acquired IPR&D from Janssen. There were no research and development expenses related to the acquired IPR&D recognized during the three months ended March 31, 2023 or 2024. We will recognize additional acquired IPR&D expenses in the future if and when we are successful in meeting specified development milestones for TARPg8 products.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred in connection with the development and research of our clinical and pre-clinical potential future product candidates. Our research and development expenses include:

•

personnel-related costs, including salaries, bonuses, benefits, and stock-based compensation for employees engaged in manufacturing, research and development functions;

•

the costs to acquire IPR&D with no alternative future use acquired in an asset acquisition;

•

external expenses, including expenses incurred under arrangements with third parties, such as contract research organizations, contract manufacturing organizations, consultants and our clinical and scientific advisors;

•

the cost of developing and validating our outsourced manufacturing process for use in our preclinical studies and future clinical trials;

•

the cost to obtain licenses to intellectual property and related future payments should certain development milestones be achieved;

•

costs for laboratory supplies, research materials, and reagents; and

•

facility costs, depreciation, and other expenses related to research and development activities, which include direct or allocated expenses for rent, maintenance of facilities, and utilities.

Our primary focus since inception has been the development of RAP-219. Our research and development costs consist primarily of personnel-related costs and external costs, such as fees paid to Contract Manufacturing Organizations (“CMOs”), Contract Research Organizations (“CROs”) and consultants in connection with our non-clinical studies, preclinical studies and clinical trials. We expense all research and development costs in the periods in which they are incurred. Because we are working on multiple research and development programs at one time, we track many of our external expenses on a program-by-program basis. We do not allocate personnel-related costs or other indirect costs, to specific product development programs because these costs are deployed across multiple programs and, as such, are not separately classified.

Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher and more variable development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will increase substantially in the near term as we advance RAP-219 through clinical development, pursue regulatory approval of RAP-219, continue to discover and develop additional product candidates and incur expenses associated with hiring additional personnel to support our research and development efforts, including the associated manufacturing activities.

Upfront and milestone payments made are accrued for and expensed when the achievement of the milestone is probable up to the point of regulatory approval. Milestone payments made upon regulatory approval will be capitalized and amortized over the remaining useful life of the related product.

At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of any of our product candidates. We are also unable to predict

when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to the numerous risks and uncertainties associated with drug development, including the uncertainty of:

•

the timing and progress of preclinical and clinical development activities;

•

timely and successful completion of preclinical studies, including toxicology studies, biodistribution studies and minimally efficacious dose studies in animals, where applicable;

•

effective Investigational New Drugs (“INDs”) or comparable foreign applications that allow commencement of our planned clinical trials or future clinical trials for any product candidates we may develop;

•

successful enrollment and completion of clinical trials, including under the U.S. Food and Drug Administration’s (“FDA’s”) current Good Clinical Practices, (“GCPs”) current Good Laboratory Practices, (“GLPs”) and any additional regulatory requirements from foreign regulatory authorities;

•

positive results from our future clinical trials that support a finding of safety and effectiveness and an acceptable risk-benefit profile in the intended populations;

•

receipt of marketing approvals from applicable regulatory authorities;

•

establishment of arrangements through our own facilities or with third-party manufacturers for clinical supply and, where applicable, commercial manufacturing capabilities;

•

establishment, maintenance, defense and enforcement of patent, trademark, trade secret and other intellectual property protection or regulatory exclusivity for any product candidates we may develop; and

•

maintenance of a continued acceptable safety, tolerability and efficacy profile of any product candidates we may develop following approval.

A change in the outcome of any of these variables with respect to the development of any of our product candidates or potential future product candidate could mean a significant change in the costs and timing associated with the development of that product candidate or potential future product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate would be required for the completion of clinical development of a product candidate or potential future product candidate, or if we experience significant delays in our clinical trials due to slower than expected patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. We may never obtain regulatory approval for any of our product candidates, and, even if we do, drug commercialization takes several years and millions of dollars in development costs.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel-related costs, including salaries, bonuses, benefits, and stock-based compensation charges for those individuals in executive, finance, human resources, facility operations, and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for auditing, accounting, tax and consulting services, office and information technology costs, insurance costs, and facilities, depreciation and other general and administrative expenses, which include direct or allocated expenses for rent and maintenance of facilities and utilities.

We anticipate that our general and administrative expenses will increase for the foreseeable future to support development of product candidates and our continued research activities. These increases will likely include additional costs related to the hiring of additional personnel and fees paid to outside consultants, among other expenses. We also anticipate increased expenses related to audit, accounting, legal, regulatory, and

tax-related services associated with maintaining compliance with The Nasdaq Global Market (“Nasdaq”) and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company.

Other Income (Expense)

Change in Fair Value of Preferred Stock Tranche Right Liabilities

Our Series A and Series B convertible preferred stock purchase agreements provided the investors the obligation to participate in subsequent offerings of Series A and Series B convertible preferred stock upon achievement of certain specified milestones, upon the waiver of such milestone achievement by a majority vote of the respective series convertible preferred stockholders, or with respect to the Series B convertible preferred stock, upon exercise of the stockholders right to early exercise the preferred stock tranche right. The preferred stock tranche rights are classified as liabilities and initially recorded at fair value upon the issuance date of the rights. The liabilities were subsequently remeasured to fair value at each reporting date and immediately prior to being settled, and changes in fair value of the preferred stock tranche right liabilities were recognized as a component of other income (expense), net in our consolidated statements of operations and comprehensive loss. In February 2023, we closed the Series A second and third financings, resulting in full settlement of the tranche right, upon both of which we issued additional shares of Series A convertible preferred stock. Immediately prior to the issuance of such shares, the preferred stock tranche right liability was remeasured to fair value with the change in fair value recognized as a component of other income (expense), net. As a result of the Series A preferred stock tranche right settlement in February 2023, we will no longer recognize changes in the fair value of the Series A preferred stock tranche liability in our consolidated statements of operations and comprehensive loss. In March 2024, we closed the Series B second financing, resulting in full settlement of the tranche right, upon which we issued additional shares of Series B convertible preferred stock. Immediately prior to the issuance of such shares, the preferred stock tranche right liability was remeasured to fair value with the change in fair value recognized as a component of other income (expense), net. As a result of the Series B preferred stock tranche right settlement in March 2024, we will no longer recognize changes in the fair value of the Series B preferred stock tranche liability in our consolidated statements of operations and comprehensive loss.

Interest Income

Interest income consists of interest earned from our cash, cash equivalents and short-term and long term investments.

Interest Expense

In August and September 2022, we issued a total of four convertible promissory notes (the “Notes” or the “Convertible Notes”) as part of a series of Convertible Notes. The Convertible Notes bore interest at a rate of 8.0% per annum computed on the basis of a 365-day year and maturity dates 12 months from the date of issuance. Upon initial issuance the Notes were recorded net of $0.1 million of related issuance costs which were amortized on a straight-line basis to interest expense over the term of the notes. The Notes provided a share-settled redemption feature whereby upon the closing of specified financing events, the Notes would automatically settle into shares of the same class and series of capital stock that are issued to other investors in the financing at a price equal to the 100% of the price per share paid by the other investors. In addition, upon specified events such as a change of control or sale of substantially all of our assets, the Notes are redeemable at 100% of principal and accrued interest. In December, 2022, in conjunction with our Series A convertible preferred stock financing, the Holders exercised their right to exchange the Notes, plus accrued interest, for shares of Series A convertible preferred stock. The unamortized debt issuance costs at the time of conversion were recorded as a loss on extinguishment of debt within interest expense in the consolidated statement of operations and comprehensive loss.

Income Taxes

For the period from February 10, 2022 (inception) to December 31, 2022, the year ended December 31, 2023, and the three months ended March 31, 2023 and 2024, we recorded an income tax provision of $0, $10 thousand, $1 thousand and $0, respectively. As of December 31, 2022 and 2023 and March 31, 2024, we recorded a full valuation allowance of our net deferred tax assets, as we believed it was more likely than not we would not be able to utilize our deferred tax assets prior to their expiration.

Since our inception, we have not recorded any income tax benefits for the net losses we have incurred in each year or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our net operating losses (“NOLs”), carryforwards and tax credits will be not realized. As of December 31, 2023, we had federal NOL carryforwards of approximately $6.0 million and state NOL carryforwards of approximately $1.6 million which may be available to offset future taxable income and begin to expire in 2042. The total federal NOLs of $6.0 million are not subject to expiration. As of December 31, 2023, we also had federal and state tax research and development credit carryforwards of approximately $1.5 million and $0.5 million, respectively to offset future tax liabilities, which begin to expire in 2037 and 2042, respectively. We have recorded a full valuation allowance against our net deferred tax assets at December 31, 2023. As of December 31, 2023, we had no unrecognized tax benefits.

Results of Operations

Comparison of the three months ended March 31, 2023 and 2024

The following table summarizes our results of operations for the three months ended March 31, 2023 and 2024:


	For the three months ended March 31,
	2023			2024			Change
	(in thousands)
Operating expenses
Research and development	$	3,899		$	12,504		$	8,605
General and administrative		1,292			4,590			3,298

Total operating expenses		5,191			17,094			11,903

Loss from operations		(5,191	)		(17,094	)		(11,903	)

Other income (expense):
Interest income		75			1,815			1,740
Change in fair value of preferred stock tranche right liability		(1,030	)		(7,390	)		(6,360	)

Total other income (expense), net		(955	)		(5,575	)		(4,620	)

Net loss before income taxes		(6,146	)		(22,669	)		(16,523	)
Provision for income taxes		1			—			(1	)

Net loss	$	(6,147	)	$	(22,669	)	$	(16,522	)

100

Operating Expenses

Research and Development Expenses


	For the three months ended March 31,
	2023		2024		Change
	(in thousands)
Direct external program expenses:
RAP-219 program	$	1,117	$	3,901	$	2,784
Preclinical programs		711		3,934		3,223
Internal and unallocated expenses:
Personnel-related costs (including stock-based compensation)		1,940		4,017		2,077
Other costs		131		652		521

Total research and development expenses	$	3,899	$	12,504	$	8,605

Research and development expenses were $3.9 million for the three months ended March 31, 2023, as compared to $12.5 million for the three months ended March 31, 2024. The increase of $8.6 million consisted of the following:

•

$2.8 million increase in RAP-219 program costs, which consisted primarily of an increase of $0.9 million in clinical trial costs primarily driven by the initiation of our Phase 2 trial, $1.2 million increase in preclinical toxicology studies driven by initiation of long-term toxicology work, $0.4 million increase in contract manufacturing costs related to the production of materials to support our additional Phase 1 and 2a trials, and an increase of $0.2 million for consulting related to the peripheral neuropathic pain program;

•

$3.2 million increase in preclinical program costs, which consisted primarily of a $1.4 million increase in toxicology and animal studies related to our discovery programs, a $0.6 million increase in external chemistry efforts related to our discovery programs, a $0.4 million increase in contract manufacturing costs related to the production of materials for use in our preclinical studies, a $0.5 million increase in lab supply costs due to increased headcount, and a $0.2 million increase in discovery program consulting costs;

•

$2.1 million increase in personnel-related costs due to an increase in headcount, which consisted primarily of salaries, bonuses, and other compensation-related costs of $2.1 million and stock-based compensation of $0.2 million. These increases were partially offset by a decrease in consulting costs unrelated to discovery programs of $0.2 million; and

•

$0.5 million increase in other costs consisting primarily of research and development facilities expenses and depreciation expense related to opening our Boston office in September 2023 and continuing to expand our San Diego site.

General and Administrative Expenses


	For the three months ended March 31,
	2023		2024		Change
	(in thousands)
Personnel-related (including stock-based compensation)	$	392	$	2,397	$	2,005
Professional and consulting costs		692		1,865		1,173
Facility related and other		208		328		120

Total general and administrative expense	$	1,292	$	4,590	$	3,298

101

General and administrative expense were $1.3 million for the three months ended March 31, 2023, as compared to $4.6 million for the three months ended March 31, 2024. The increase of $3.3 million consisted of the following:

•

$2.0 million increase in workforce expense due to an increase in headcount, consisting primarily of salaries, bonuses, and other compensation-related costs of $1.5 million and stock-based compensation of $0.5 million;

•

$1.2 million increase in professional and consulting fees related to expanding our administrative support, including outsourced legal and accounting expenses; and

•

$0.1 million increase in other expenses consisting primarily of administrative expenses due to increased business activities and expanded general and administrative support.

Other Income (Expense)


	For the three months ended March 31,
	2023			2024			Change
	(in thousands)
Other income (expense):
Interest income	$	75		$	1,815		$	1,740
Change in fair value of preferred stock tranche right liability		(1,030	)		(7,390	)		(6,360	)

Total other income (expense), net	$	(955	)	$	(5,575	)	$	(4,620	)

Interest Income

Interest income was $0.1 million for the three months ended March 31, 2023, as compared to $1.8 million for the three months ended March 31, 2024. The increase of $1.7 million is primarily due to opening additional interest-bearing accounts subsequent to March 31, 2023 in addition to the increased cash, cash equivalent and short-term investments balances from the Series B convertible preferred stock financing in August 2023.

Change in Fair Value of Preferred Stock Tranche Right Liability

The change in fair value of the preferred stock tranche right liability expense was $1.0 million for the three months ended March 31, 2023, as compared to $7.4 million for the three months ended March 31, 2024. The change in fair value of preferred stock tranche right liability for the three months ended March 31, 2023 consisted of an increase in the fair value of the Series A preferred stock tranche right liability of $1.0 million as a result of the waiver of the second and third milestones and settlement of the Series A tranche right liability. The change in fair value of preferred stock tranche right liabilities for the three months ended March 31, 2024 consisted of an increase in the fair value of the Series B preferred stock tranche right liability of $7.4 million. In conjunction with the waiver of the second tranche milestone in February 2024 and the settlement of the Series B tranche right in March 2024, the Series B tranche right liability was remeasured immediately prior to the waiver, resulting in a $7.4 million increase in fair value.

Income Taxes

For the three months ended March 31, 2023 and the three months ended March 31, 2024, we recorded an income tax provision of $1 thousand and $0, respectively.

102

Comparison for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023

The following table summarizes our results of operations for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023:


	For the period from February 10, 2022 (inception) to December 31, 2022			For the year ended December 31, 2023			Change
	(in thousands)
Operating expenses
Related party acquired in-process research and development	$	5,000		$	—		$	(5,000	)
Research and development		4,115			27,999			23,884
General and administrative		1,252			8,180			6,928

Total operating expenses		10,367			36,179			25,812

Loss from operations		(10,367	)		(36,179	)		(25,812	)

Other income (expense):
Interest income		—			2,527			2,527
Interest expense		(285	)		—			285
Change in fair value of preferred stock tranche right liability		—			(1,124	)		(1,124	)

Total other income (expense), net		(285	)		1,403			1,688

Net loss before income taxes		(10,652	)		(34,776	)		(24,124	)
Provision for income taxes		—			10			10

Net loss	$	(10,652	)	$	(34,786	)	$	(24,134	)

We were formed in February 2022, but did not have substantial operations until the completion of the acquired IPR&D from Janssen in August and October 2022. As such, we do not believe that a description of material changes from period to period would be useful to an investor. Accordingly, the following discussion presents the components of our expenses for the periods presented.

Operating Expenses

Related Party Acquired In-Process Research and Development Expenses

Acquired IPR&D expenses of $5.0 million for the period from February 10, 2022 (inception) to December 31, 2022 consisted of a $5.0 million payment to Janssen for the Janssen License, which granted us a non-exclusive, royalty-free, sublicensable license to exploit certain nACh products in the Field as well as an option for an exclusive, royalty-bearing sublicensable license to certain intellectual property rights owned or controlled by Janssen, to commercially develop, manufacture, use, distribute and sell therapeutic products containing TARPg8 compounds and related products. The $5.0 million payment consisted of a one-time, non-creditable, non-refundable upfront payment in August 2022 of $1.0 million to Janssen, for an exclusivity period to evaluate the results of toxicology studies related to TARPg8 technology in order to decide on whether it would exercise the option to license this technology and a one-time, non-creditable, non-refundable option fee payment in October 2022 of $4.0 million to Janssen when we exercised our option to license the TARPg8 compounds. We expensed the cost of the IPR&D asset acquired because it had no alternative future use as of the acquisition date. There was no acquired IPR&D expense for the year ended December 31, 2023 as no license agreements were acquired.

103

Research and Development Expenses


	For the period from February 10, 2022 (inception) to December 31, 2022		For the year ended December 31, 2023		Change
	(in thousands)
Direct external program expenses:
RAP-219 program	$	752	$	10,202	$	9,450
Preclinical programs		544		6,335		5,791
Internal and unallocated expenses:
Personnel-related costs (including stock-based compensation)		2,667		9,939		7,272
Other costs		152		1,523		1,371

Total research and development expenses	$	4,115	$	27,999	$	23,884

Research and development expenses of $4.1 million for the period from February 10, 2022 (inception) to December 31, 2022 consisted primarily of the following:

•

$0.8 million in clinical and manufacturing costs related to the RAP-219 program;

•

$0.5 million in discovery, pre-clinical toxicology and lab supply costs related to our preclinical programs; and

•

$2.7 million of personnel-related costs, including $2.1 million of consulting costs and stock-based compensation of $0.5 million. Included in these costs are consulting costs and stock-based compensation for consultants that became our full time employees in 2023. We had no full-time employees in the period from February 10, 2022 (inception) to December 31, 2022.

Research and development expenses of $28.0 million for the year ended December 31, 2023 consisted primarily of the following:

•

$10.2 million of costs related to the RAP-219 program, including $6.7 million clinical trial costs for conduct of our first-in-human Phase 1 trials, $2.2 million for preclinical toxicology studies and $1.1 million of contract manufacturing costs related to the production of materials for use in our preclinical studies and Phase 1 trials for the RAP-219 program;

•

$6.3 million related to our preclinical programs, including $4.3 million of discovery activities, $0.7 million in contract manufacturing costs related to the production of materials for use in our preclinical studies, $0.5 million in lab supply costs and $0.5 million for preclinical toxicology studies;

•

$9.9 million of personnel-related costs, including salaries, bonuses, and other compensation-related costs, including; stock-based compensation costs of $1.9 million for 26 full-time employees hired during the year ended December 31, 2023; and $0.3 million unallocated consulting expense; and

•

$1.5 million of other costs consisting primarily of research and development facilities expenses and depreciation expense related to opening and/or expanding our Boston and San Diego sites in the year ended December 31, 2023.

104

General and Administrative Expenses


	For the period from February 10, 2022 (inception) to December 31, 2022		For the year ended December 31, 2023		Change
	(in thousands)
Personnel-related (including stock-based compensation)	$	—	$	4,324	$	4,324
Professional and consulting costs		1,165		3,158		1,993
Facility related and other		87		698		611

Total general and administrative expense	$	1,252	$	8,180	$	6,928

General and administrative expense for the period from February 10, 2022 (inception) to December 31, 2022 consisted primarily of the following:

•

$1.2 million of professional and consulting costs, which consisted primarily of $0.4 million of outsourced legal and accounting expenses and $0.8 million in consulting costs, including costs for two consultants that became our full-time employees in 2023. We had no full-time G&A employees in the year ended December 31, 2022; and

•

$0.1 million of facility related and other expenses, which consisted primarily of IT costs of $74 thousand.

General and administrative expense for the year ended December 31, 2023 consisted primarily of the following:

•

$4.3 million of workforce expense including salaries and benefits, including stock-based compensation expenses of $1.6 million as we hired 11 full-time general and administrative employees in 2023;

•

$3.1 million of professional and consulting fees related to expanding our administrative support, including outsourced legal and accounting expenses; and

•

$0.7 million of facility related and other expenses related to opening and/or expanding our Boston and San Diego sites, which consisted primarily of lease costs of $0.1 million, IT costs of $0.3 million, and $0.2 million of other office expenses.

Other Income (Expense)


	For the period from February 10, 2022 (inception) to December 31, 2022			For the year ended December 31, 2023			Change
	(in thousands)
Other income (expense):
Interest income	$	—		$	2,527		$	2,527
Interest expense		(285	)		—			285
Change in fair value of preferred stock tranche right liability		—			(1,124	)		(1,124	)

Total other income (expense), net	$	(285	)	$	1,403		$	1,688

Interest Income

Interest income for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023 was $0 and $2.5 million, respectively. The interest was earned from our interest

105

bearing cash, cash equivalent and short-term investment accounts, which were first opened in the year ended December 31, 2023.

Interest Expense

Interest expense for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023 was $0.3 million and $0, respectively. Interest expense for the period from February 10, 2022 (inception) to December 31, 2022 was driven by $0.2 million of interest expense related to the Convertible Notes, $26 thousand of debt issuance cost amortization, and $77 thousand loss on extinguishment of debt. There was no interest expense recorded for the year ended December 31, 2023 due to the exchange of the Convertible Notes for shares of Series A convertible preferred stock in December 2022.

Change in Fair Value of Preferred Stock Tranche Right Liability

The change in fair value of the preferred stock tranche right liability expense for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023 was $0 and $1.1 million, respectively. There was no change in the fair value of the Series A preferred stock tranche right liability from December 9, 2022 (“date of issuance”) to December 31, 2022 and therefore, we did not recognize any other income or expenses related to the tranche right liability for the year ended December 31, 2022. The change in fair value of preferred stock tranche right liabilities for the year ended December 31, 2023 consisted of an increase in the fair value of Series A preferred stock tranche right liability of $1.0 million and an increase in the fair value of Series B preferred stock tranche right liability of $0.1 million, which were recorded upon remeasurement of the liabilities.

Income Taxes

For the period from February 10, 2022 (inception) to December 31, 2022 and the year ended December 31, 2023, we recorded an income tax provision of $0 and $10 thousand, respectively.

Liquidity and Capital Resources

Sources of Liquidity

Since our inception in February 2022, we have not generated any revenue from any sources and have incurred significant operating losses and negative cash flows from operations. We expect to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates and pipeline. Further, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. To date, we have funded our operations with proceeds from the sale of the Convertible Notes and convertible preferred stock. Through March 31, 2024, we have received aggregate gross proceeds of $250.0 million from the issuance of convertible promissory notes and the sale of our convertible preferred stock. As of March 31, 2024, we had cash and cash equivalents of $74.3 million and short-term investments of $119.0 million.

106

Cash Flows

The following table summarizes our sources and uses of cash for each of the periods presented:


	For the period from February 10, 2022 (inception) to December 31, 2022			For the year ended December 31, 2023			For the three months ended March 31,
				For the year ended December 31, 2023			2023			2024
	(in thousands)
Net cash used in operating activities	$	(3,242	)	$	(27,181	)	$	(4,801	)	$	(17,615	)
Net cash used in investing activities		(5,284	)		(78,860	)		(61	)		(41,926	)
Net cash provided by financing activities		39,685			145,136			60,006			63,659

Net increase in cash, cash equivalents and restricted cash	$	31,159		$	39,095		$	55,144		$	4,118

Operating Activities

During the three months ended March 31, 2023, operating activities used $4.8 million of cash, resulting primarily from our net loss of $6.1 million and changes in operating assets and liabilities of $0.4 million, partially offset by $0.7 million of non-cash stock-based compensation expense and non-cash change in fair value of preferred stock tranche right liability of $1.0 million.

During the three months ended March 31, 2024, operating activities used $17.6 million of cash, resulting primarily from our net loss of $22.7 million, non-cash accretion of investments in marketable securities of $1.0 million, and changes in operating assets and liabilities of $3.2 million, partially offset by $1.5 million of non-cash stock-based compensation expense and non-cash change in fair value of preferred stock tranche right liability of $7.4 million. The $3.2 million change in operating assets and liabilities is primarily driven by an increase in prepaid expenses and other current assets of $2.1 million primarily due to advanced payments on new contracts related to our clinical trials, and a decrease in accounts payable of $1.1 million due to payment to vendors.

During the period from February 10, 2022 (inception) to December 31, 2022, operating activities used $3.2 million of cash, resulting primarily from our net loss of $10.7 million, partially offset by $5.0 million of related party acquired IPR&D related to the Janssen License, $0.6 million of non-cash stock-based compensation expense, and net cash provided by changes in operating assets and liabilities of $1.5 million which consisted primarily of increases in accounts payable of $1.4 million. The increases in accounts payable were primarily due to amounts owed to vendors in connection with our research and development activities.

During the year ended December 31, 2023, operating activities used $27.2 million of cash, resulting primarily from our net loss of $34.8 million, partially offset by $3.5 million of non-cash stock-based compensation expense and non-cash change in fair value of preferred stock tranche right liability of $1.1 million, and net cash provided by changes in operating assets and liabilities of $2.7 million. Net cash provided by changes in operating assets and liabilities consisted primarily of increases in accrued expenses and other current liabilities of $5.4 million, partially offset by increases in prepaid expenses and other current assets of $3.2 million. The increases in accrued expenses and prepaid expenses were primarily due to increased internal and external costs associated with our research and development activities, including clinical trials and manufacturing.

Investing Activities

During the three months ended March 31, 2023, net cash used in investing activities was $0.1 million, primarily consisting of purchases of property and equipment of $61 thousand.

107

During the three months ended March 31, 2024, net cash used in investing activities was $41.9 million, primarily consisting of purchases of short-term investments of $44.8 million and purchases of property and equipment of $1.1 million, partially offset by maturities of short-term investments of $3.9 million.

During the period from February 10, 2022 (inception) to December 31, 2022, net cash used in investing activities was $5.3 million, primarily consisting of $5.0 million of related party acquired IPR&D related to the Janssen License and purchases of property and equipment of $0.3 million.

During the year ended December 31, 2023, net cash used in investing activities was $78.9 million, primarily consisting of purchases of short-term investments of $77.2 million and purchases of property and equipment of $1.6 million.

Financing Activities

During the three months ended March 31, 2023, net cash provided by financing activities was $60.0 million, primarily consisting of net proceeds of $60.0 million from our additional issuance of Series A convertible preferred stock.

During the three months ended March 31, 2024, net cash provided by financing activities was $63.7 million, primarily consisting of net proceeds of $63.9 million from our additional issuance of Series B convertible preferred stock and payments of $0.3 million for deferred offering costs.

During the period from February 10, 2022 (inception) to December 31, 2022, net cash provided by financing activities was $39.7 million, primarily consisting of net proceeds of $31.8 million from our initial issuance of Series A convertible preferred stock, including tranche rights, and net proceeds of $7.9 million from our issuance of convertible promissory notes.

During the year ended December 31, 2023, net cash provided by financing activities was $145.1 million, primarily consisting of net proceeds of $59.9 million from our additional issuance of Series A convertible preferred stock, and net proceeds of $85.3 million from our initial issuance of Series B convertible preferred stock, including tranche rights.

Future Funding Requirements

As of March 31, 2024, we had cash, cash equivalents and short-term investments of $193.2 million, excluding our restricted cash. As of the issuance date of the condensed consolidated financial statements for the three months ended March 31, 2024, we expect that our cash, cash equivalents and short-term investments will be sufficient to fund our operating expenses and capital expenditure requirements through at least 12 months from the issuance of the condensed consolidated financial statements. We believe that the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements through the end of 2026. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. However, our forecast for the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Additionally, the process of conducting preclinical studies and testing potential future product candidates in clinical trials is costly, and the timing of progress and expenses in these studies and trials is uncertain. We will need to raise substantial additional capital in the future.

We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the non-clinical and preclinical studies and the current and future clinical trials of our product

108

candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including:

•

the rate of progress in the development of RAP-219 and our other product candidates;

•

the type, number, scope, progress, expansions, results, costs, and timing of, discovery efforts, preclinical studies and clinical trials of RAP-219 and potential future product candidates;

•

the costs and timing of manufacturing for RAP-219 and our potential future product candidates and commercial manufacturing;

•

the costs, timing, and outcome of regulatory review of our product candidates;

•

the terms and timing of establishing and maintaining licenses and other similar arrangements;

•

the legal costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights;

•

our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company;

•

the costs associated with hiring additional personnel and consultants as our preclinical and future clinical activities increase;

•

the costs and timing of establishing or securing sales and marketing capabilities if any potential future product candidate is approved;

•

our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products; and

•

costs associated with any products or technologies that we may in-license or acquire.

Until such time, if ever, as we can generate substantial product revenue to support our cost structure, we expect to finance our cash needs through equity offerings, debt financings, or other capital sources, potentially including collaborations, licenses, and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Additional debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise funds through collaborations, license arrangements, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or potential future product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. Our failure to raise capital or enter into such other arrangements when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise additional funds through equity or debt financings, or through other sources when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates and potential future product candidates even if we would otherwise prefer to develop and market such potential future product candidates ourselves.

Contractual Obligations and Commitments

Leases

As of the March 31, 2024, we had future minimum operating lease payments under non-cancelable leases of $2.2 million related to leases we have recognized on our consolidated balance sheet, which are due over the following 2.8 years. In addition, we have one lease that has been entered into but has not yet commenced, for which we expect to pay approximately $9.6 million over the five-year lease term.

109

Option and License Agreement with Janssen Pharmaceutical NV

We made an upfront non-refundable, non-creditable payment of $1.0 million to Janssen after we entered into the Janssen License. In October 2022, we exercised the option and made a non-refundable, non-creditable option fee of $4.0 million to Janssen. If we succeed in developing and commercializing TARPg8 products, Janssen will be eligible to receive (i) up to $76.0 million in development milestone payments and up to $40.0 million sales milestone payments for the product containing the lead TARPg8 development candidate and (ii) up to $25.0 million in development milestone payments and up to $42.0 million sales milestone payments for the other products containing a non-lead TARPg8 development candidate. We are also required to pay tiered royalties related to the TARPg8 development candidate of a mid to high single-digit percentage on worldwide net sales and tiered royalties related to the TARPg8 products that do not contain a TARPg8 development candidate of low to mid single-digit percentages on annual net sales of the products covered by the license.

NeuroPace Master Services Agreement and Statement of Work

In connection with the execution of the NeuroPace Agreement, the parties also entered into an initial statement of work under the NeuroPace Agreement, pursuant to which NeuroPace agreed to provide services related to our Phase 2a proof-of-concept clinical trial of RAP-219, including, among other things, clinical trial readiness support, data analysis and data reporting. Pursuant to the payment schedule set out in the statement of work, we will pay NeuroPace an aggregate of up to $3.7 million over a period of approximately two years in connection with NeuroPace’s provision of services and achievement of certain patient enrollment and deliverable milestones.

Apart from the contracts with payment commitments that we have documented above, we have entered into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice and, as a result, are not included in the table of contractual obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including non-cancelable obligations of our service providers, up to the date of cancellation.

Critical Accounting Polices and Estimates

Our management’s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses incurred during the reporting periods. We base our estimates on historical experience, known trends and events, and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and expenses that are not readily apparent from other sources. We evaluate our estimates and judgments on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.

While our significant accounting policies are described in Note 2—“Summary of Significant Accounting Policies” to our annual consolidated financial statements and interim condensed consolidated financial

110

statements included elsewhere in this prospectus, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.

Research and Development Expenses and Accruals

We expense research and development expenses as incurred. Research and development expenses represent costs incurred by us for the discovery and development of our product candidates and include employee salaries and benefits, including stock-based compensation, third-party research and development expenses, including amounts incurred under agreements with our external vendors and consultants engaged to perform preclinical and clinical studies, contract manufacturing and research services, consulting costs, laboratory supplies, and certain allocated expenses, as well as amounts incurred under third-party license agreements.

As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses. We estimate preclinical study and clinical trial and other research and development expenses based on the services performed, pursuant to contracts with research institutions and third-party service providers that conduct and manage preclinical studies and clinical trials and research services on our behalf. We record the costs of research and development activities based upon the estimated services provided but not yet invoiced and include these costs in accrued expenses and other current liabilities in our consolidated balance sheets and in research and development expense in our consolidated statements of operations and comprehensive loss. We make significant judgments and estimates in determining the accrued balance in each reporting period. As actual costs become known, we adjust our accrued estimates. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed may vary from our estimates and could result in us reporting amounts that are too high or too low in any particular period. Our accrued expenses are dependent, in part, upon the receipt of timely and accurate reporting from external third-party service providers. Contingent milestone payments, if any, are expensed when the milestone results are probable and estimable, which is generally upon the achievement of the milestone.

Our expenses related to clinical trials are based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services provided and efforts expended pursuant to contracts with multiple research institutions and contract research organizations that may be used to conduct and manage clinical trials on our behalf. We generally accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we modify our estimates of accrued expenses accordingly on a prospective basis.

Asset Acquisitions and Acquired In-Process Research and Development Expenses

We measure and recognize asset acquisitions or licenses of intellectual property that are not deemed to be business combinations based on the cost to acquire the asset or group of assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition or license of intellectual property, the cost allocated to acquire IPR&D with no alternative future use is recognized as expense on the acquisition date.

Stock-Based Compensation

We measure stock-based awards granted to employees, directors, and nonemployees based on their fair value on the date of the grant. We recognize compensation expense for awards to employees and directors over

111

the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to non-employees with service-based vesting conditions is recognized in the same manner as if we had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. For stock-based awards with service-based vesting conditions, we recognize compensation expense using the straight-line method. For stock-based awards with performance-based vesting conditions, we recognize compensation expense using the graded-vesting method over the requisite service period using the accelerated attribution method, commencing when achievement of the performance condition becomes probable. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and our expected dividend yield. For awards to non-employees, the expected term of the option is equal to the contractual term of the non-employees’ service agreement. The fair value of each restricted common stock award is estimated on the date of grant based on the fair value of our common stock on that same date.

Determination of the Fair Value of Common Stock

As there has been no public market for our common stock to date, the estimated fair value of our common stock has been determined by our board of directors as of the date of each option grant with input from management, considering our most recently available third-party valuations of common stock, and our board of directors’ assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants’ Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Our common stock valuation was prepared using either the option-pricing method (“OPM”) or the hybrid method, both of which used a market approach to estimate our enterprise value. The OPM treats common stock and convertible preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company’s securities changes. Under this method, the common stock has value only if the funds available for distribution to stockholders exceeded the value of the convertible preferred stock liquidation preferences at the time of the liquidity event, such as a strategic sale or a merger. The hybrid method is a probability-weighted expected return method (“PWERM”) where the equity value in one or more of the scenarios is calculated using an OPM. The PWERM is a scenario-based methodology that estimates the fair value of common stock based upon an analysis of future values for us, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and probability weighted to arrive at an indication of value for the common stock. A discount for lack of marketability of the common stock is then applied to arrive at an indication of value for the common stock.

These third-party valuations were performed at various dates, which resulted in valuation of our common stock of $11.57 per share as of March 31, 2024. Our board of directors considered various objective and subjective factors to determine the fair value of our common stock as of each grant date, including:

•

the prices at which we sold shares of convertible preferred stock and the superior rights and preferences of the convertible preferred stock relative to our common stock at the time of each grant;

•

the progress of our research and development programs, including the status and results of clinical and preclinical studies for our product candidates;

•

our stage of development and our business strategy;

•

external market conditions affecting the biopharmaceutical industry and trends within the biopharmaceutical industry;

112

•

our financial position, including cash on hand, and our historical and forecasted performance and operating results;

•

the lack of an active public market for our common stock and our convertible preferred stock;

•

the likelihood of achieving a liquidity event, such as an initial public offering (“IPO”) or sale of our company in light of prevailing market conditions; and

•

the analysis of IPOs and the market performance of similar companies in the biopharmaceutical industry.

The assumptions underlying these valuations were highly complex and subjective and represented management’s best estimates, which involved inherent uncertainties and the application of management’s judgment. As a result, if we had used significantly different assumptions or estimates, the fair value of our common stock and our stock-based compensation expense could be materially different.

Once a public trading market for our common stock has been established in connection with the completion of this offering, it will no longer be necessary for our board of directors to estimate the fair value of our common stock in connection with our accounting for granted stock options and other such awards we may grant, as the fair value of our common stock will be determined based on the quoted market price of our common stock.

Grant of Stock-Based Awards

The following table sets forth by grant date the number of shares subject to common stock options and common stock awards granted since February 10, 2022 (inception) through May 17, 2024, the per share exercise price of the options or purchase price of common stock awards, the fair value of common stock on each grant date, and the per share estimated fair value of the options or common stock awards:


Grant Date	Type of Award	Number of Shares Subject to Award		Per Share Exercise or Purchase Price of Award		Per Share Fair Value of Common Stock on Grant Date			Per Share Estimated Fair Value of Awards on Grant Date
November 28, 2022	Restricted Stock		856,202	$	0.01	$	2.92	⁽¹⁾	$	2.92
November 29, 2022	Restricted Stock		4,106	$	0.01	$	2.92	⁽¹⁾	$	2.92
November 30, 2022	Restricted Stock		87,905	$	0.01	$	2.92	⁽¹⁾	$	2.92
December 9, 2022	Restricted Stock		477,642	$	0.01	$	2.92	⁽¹⁾	$	2.92
January 9, 2023	Restricted Stock		197,426	$	0.01	$	2.92	⁽¹⁾	$	2.92
January 30, 2023	Restricted Stock		6,791	$	0.01	$	2.92	⁽¹⁾	$	2.92
February 6, 2023	Restricted Stock		225,784	$	0.09	$	2.92	⁽²⁾	$	2.92
February 14, 2023	Restricted Stock		47,382	$	0.09	$	2.92	⁽²⁾	$	2.92
March 1, 2023	Restricted Stock		789,705	$	0.01	$	4.54	⁽³⁾	$	4.54
May 19, 2023	Restricted Stock		199,067	$	0.09	$	4.54	⁽⁴⁾	$	4.54
September 7, 2023	Restricted Stock		157,941	$	0.09	$	5.32	⁽⁵⁾	$	5.32
December 6, 2023	Option		1,353,831	$	1.80	$	6.34	⁽⁶⁾	$	5.74
December 6, 2023	Option		22,765	$	1.80	$	6.34	⁽⁷⁾	$	6.09
January 13, 2024	Option		35,027	$	1.80	$	6.34	⁽⁸⁾	$	5.74
February 7, 2024	Option		131,930	$	4.46	$	9.60	⁽⁹⁾	$	8.14
March 25, 2024	Option		1,129,849	$	9.60	$	11.57	⁽¹⁰⁾	$	9.08
March 25, 2024	Option		4,085	$	9.60	$	11.57	⁽¹¹⁾	$	10.45
May 7, 2024	Option		92,234	$	11.57	$	11.57		$	9.08

(1)

At the time of the restricted stock grants from November 28, 2022 to January 30, 2023, our board of directors determined that the fair value of our common stock of $0.01 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our

113

common stock as of the dates of these grants was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(2)

At the time of the restricted stock grants from February 6, 2023 to February 14, 2023, our board of directors determined that the fair value of our common stock of $0.09 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of these grants was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(3)

This grant was legally issued on December 2, 2022, but not considered granted for accounting purposes until March 1, 2023, when the grantees began providing services to us. At the time of the restricted stock grant on December 2, 2022, our board of directors determined that the fair value of our common stock of $0.01 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(4)

At the time of the restricted stock grant on May 19, 2023, our board of directors determined that the fair value of our common stock of $0.09 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(5)

At the time of the restricted stock grant on September 7, 2023, our board of directors determined that the fair value of our common stock of $0.09 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(6)

At the time of the option grant to employees on December 6, 2023, our board of directors determined that the fair value of our common stock of $1.80 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(7)

At the time of the option grant to consultants on December 6, 2023, our board of directors determined that the fair value of our common stock of $1.80 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(8)

At the time of the option grant on January 13, 2024, our board of directors determined that the fair value of our common stock of $1.80 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(9)

At the time of the option grant on February 7, 2024, our board of directors determined that the fair value of our common stock of $4.46 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(10)

At the time of the option grant to employees on March 25, 2024, our board of directors determined that the fair value of our common stock of $9.60 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

(11)

At the time of the option grant to consultants on March 25, 2024, our board of directors determined that the fair value of our common stock of $9.60 per share reasonably reflected the fair value of our common stock as of the grant date. However, as described below, the fair value of our common stock as of the date of this grant was adjusted in connection with a retrospective fair value assessment for accounting purposes.

The fair value of our common stock of $2.92 per share from November 28, 2022 to February 14, 2023 was determined by us, based, in part, on the $2.92 per share value indicated in the retrospective third-party valuation prepared as of December 9, 2022. In particular, the retrospective valuation determined our equity value using an OPM back-solve approach that was primarily based on the $1.00 price per share paid by new and existing investors in the first closing of our Series A convertible preferred stock on December 9, 2022 less the value of the anticipated additional Series A tranche closings, which were treated as call options for the purposes of

114

allocating value to the various equity. A discount for lack of marketability (“DLOM”) of the common stock was then applied to arrive at an indication of value for our common stock.

The fair value of our common stock of $4.54 per share from March 1, 2023 to May 19, 2023 was determined by us, based, in part, on the $4.54 per share value indicated in the retrospective third-party valuation prepared as of February 17, 2023. In particular, the retrospective valuation determined our equity value using an OPM back-solve approach that was primarily based on the $1.00 price per share paid by new and existing investor in the second and third closing of our Series A convertible preferred stock on February 21, 2023. A DLOM of the common stock was then applied to arrive at an indication of value for our common stock.

The fair value of our common stock of $5.32 per share on September 7, 2023 was determined by us, based, in part, on the $5.32 per share value indicated in the retrospective third-party valuation prepared as of August 31, 2023. In particular, the retrospective valuation determined our equity value using an OPM back-solve approach that was primarily based on the $1.67727 per share paid by new and existing investors in the first closings of our Series B convertible preferred stock in August 2023, less the value of the anticipated additional Series B tranche closings, which were treated as call options for the purposes of allocating value to the various equity. A DLOM of the common stock was then applied to arrive at an indication of value for our common stock.

The fair value of our common stock of $6.34 per share on December 6, 2023 was determined by us, based, in part, on the $6.34 per share value indicated in the retrospective third-party valuation prepared as of December 31, 2023. In particular, the retrospective valuation determined our enterprise value using the hybrid method, which included a PWERM, with an IPO scenario, and a sale scenario. Our enterprise value in the IPO scenario was based on guideline IPO transactions identified within the last one to three years, which was adjusted by a risk-adjusted discount rate. The IPO scenario also assumed an estimated timeline for the IPO to occur. Our enterprise value for the sale scenario was based on an OPM market-adjusted back-solve method based on the $1.67727 price per share paid by new and existing investors in the closing of our Series B convertible preferred stock in August 2023. The market adjustment applied to the equity value considered the performance of guideline public companies and the biotech indices since the most recent sale of our convertible preferred stock through the valuation date. A DLOM of the common stock was then applied to arrive at an indication of value for our common stock. In addition, we determined that the fair value of our common stock remained at $6.34 per share through January 13, 2024.

The fair value of our common stock of $9.60 per share on February 7, 2024, was determined by us, in part, on the $9.60 per share value indicated in the retrospective third-party valuation prepared as of February 26, 2024.

The valuation as of February 26, 2024 determined our enterprise value using the hybrid method, which included a PWERM scenario-based approach, with an IPO scenario, and a continued operation scenario. Our enterprise value in the IPO scenario was based on guideline IPO transactions identified within the last one to three years, which was adjusted by a risk-adjusted discount rate. The probabilities assigned to each scenario reflected the progress we made towards an IPO event since December 31, 2023. Our enterprise value for the continued operation scenario reflected the market adjustment to our equity value since December 31, 2023, based on consideration given to the performance of guideline public companies and the biotech indices as well as our entity specific factors. A DLOM of the common stock was then applied to arrive at an indication of value for our common stock.

The fair value of our common stock of $11.57 per share on March 25, 2024, was determined by us, in part, on the $11.57 per share value indicated in the retrospective third-party valuation prepared as of March 31, 2024. The valuation as of March 31, 2024 determined our enterprise value using the hybrid method, which included a PWERM scenario-based approach, with an IPO scenario, and a continued operation scenario. Our enterprise value in the IPO scenario was based on guideline IPO transactions identified within the last one to three years, which was adjusted by a risk-adjusted discount rate. The probabilities assigned to each scenario reflected the progress we made towards an IPO event since February 26, 2024. Our enterprise value for the continued

115

operation scenario reflected the market adjustment to our equity value since February 26, 2024, based on consideration given to the performance of guideline public companies and the biotech indices as well as our entity specific factors. A DLOM of the common stock was then applied to arrive at an indication of value for our common stock. In addition, the board of directors determined that the fair value of our common stock remained at $11.57 per share through May 7, 2024, as the board of directors did not identify any significant events that would have had a material change on the fair value of our common stock between March 31, 2024 and May 7, 2024.

In the course of preparing for this offering, we applied the fair values of our common stock from our retrospective fair value assessments in December 2022, February 2023, August 2023, December 2023, February 2024 and March 2024 to determine the fair value of each of the November 2022, December 2022, January 2023, February 2023, March 2023, May 2023, September 2023, December 2023, January 2024, February 2024, and March 2024 awards as of the respective grant date and calculated stock-based compensation expense for accounting purposes based on applicable fair values.

We used different expected term to estimate the fair value of options granted to employees and nonemployees, resulting in a difference in the grant-date fair value of the options issued on December 6, 2023 and March 25, 2024.

Equity Grants in Connection with this Offering

In connection with this offering, our board of directors has approved the grant of options for the purchase of an aggregate of 1,040,071 shares of common stock to certain employees, including certain of our executive officers, assuming the number of shares outstanding following this offering and the contingent private placement will be equal to 35,376,457 based on an assumed initial public offering price of $17.00, which is the midpoint of the price range set forth on the cover page of this prospectus. The effectiveness of this grant of stock options is contingent on, and effective immediately following, the effectiveness of the registration statement of which this prospectus forms a part. The stock options will have a per share exercise price equal to initial public offering price set forth on the cover page of the final prospectus included in the registration statement, which will be the fair market value of a share of our common stock on the grant date of the stock options. The stock options will be subject to the terms and conditions of the 2024 Stock Option and Incentive Plan, and the applicable stock option agreements thereunder. Based on an assumed exercise price of $17.00 per share, which is the midpoint of the estimated price range set forth on the cover page of this prospectus, we estimate that the aggregate grant-date fair value of the options granted is $17.7 million, which is expected to be recognized as stock-based compensation expense over a period of four years.

Valuation of Preferred Stock Tranche Liability

Our Series A and Series B convertible preferred stock purchase agreements obligated the Series A and Series B investors to participate in a subsequent offering of Series A and Series B convertible preferred stock upon certain conditions being met, which we refer to as the preferred stock tranche rights. We determined that the preferred stock tranche rights were required to be recorded as liabilities because they are freestanding financial instruments that would require us to transfer assets upon exercises of the right. The preferred stock tranche rights met the definition of a freestanding financial instrument because they are legally detachable and separately exercisable from the Series A and Series B convertible preferred stock. The preferred stock tranche rights were classified as a liability and initially recorded at fair value upon the issuance date of the right. The liabilities are remeasured to fair value at each reporting date until settled, and changes in the fair value of the preferred stock tranche right liabilities are recognized as a component of other income (expense) in our consolidated statements of operations and comprehensive loss.

In February 2023, in conjunction with the amendment to the Series A convertible preferred stock purchase agreement, our existing Series A convertible preferred stockholders voted to waive the second and third tranche milestones and exercised their tranche right. As a result, an aggregate of 50,000,000 shares of Series A

116

convertible preferred stock were issued and sold at a price of $1.00 per share, resulting in total cash proceeds of $50 million, less $61 thousand of issuance costs. As a result of this issuance, the Series A preferred stock tranche right liability, with a then fair value of $11.5 million immediately prior to the amendment and waiver, was settled in full and recognized in additional paid-in capital.

In August 2023 and concurrent with the original issuance of the Series B convertible preferred stock, two stockholders exercised their right to early exercise the Series B preferred stock tranche right and purchased 10,731,725 shares. Consequently, we recognized $1.2 million in additional paid-in capital associated with the simultaneous original issuance and early exercise. Additionally, the investors paid a premium of $1.7 million for these shares over their fair value which was also recorded in additional paid-in capital.

Subsequent to the original issuance, one stockholder exercised its right to early exercise the Series B preferred stock tranche right and purchased 4,769,655 shares of Series B convertible preferred stock for cash proceeds of $8.0 million. The fair value of the associated tranche right liability that was settled at the time of the sale of $0.5 million was recognized in additional paid-in capital. Additionally, the investor paid a premium of $0.8 million for these shares over their fair value which was also recorded in additional paid-in capital.

In February 2024, our Series B convertible preferred stockholders voted to waive the second tranche milestones and purchase the remaining Series B milestone tranche shares. Immediately prior to the waiver, we remeasured the Series B tranche right liability to be $11.6 million and recognized $7.4 million in other expense for the change in the fair value of the Series B tranche right liability during the period. As a result of the waiver, we remeasured the Series B tranche right liability to be $4.2 million and recognized the change in fair value of $7.4 million in additional paid-in capital as a capital contribution. In conjunction with the closing that occurred in March 2024, an aggregate of 38,157,240 shares of Series B convertible preferred stock were issued at a price of $1.67727 per share, resulting in total cash proceeds of $64.0 million, less $87 thousand of issuance costs. As a result of this issuance, the Series B preferred stock tranche right liability with a then fair value of $4.2 million was settled in full and recognized as part of the carrying value of the Series B convertible preferred stock.

The fair value of the tranche right liabilities was determined based on significant inputs not observable in the market, which represented a Level 3 measurement within the fair value hierarchy. The fair value of the tranche right liabilities was determined using a Contingent Forward Analysis, which is a scenario-based lattice model that accounts for the different possible milestone scenarios and their associated probabilities, as estimated by us. The valuation model considered the probability of closing the tranche, the estimated future value of the convertible preferred stock to be issued at each closing and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. The most significant assumptions in the Contingent Forward Analysis impacting the fair value of the preferred stock tranche rights were the fair value of the Series A and Series B convertible preferred stock as of each remeasurement date, the estimated remaining term of the tranche right as of each remeasurement date, and the probabilities of success for each tranche milestone as of each measurement date. We determined the fair value per share of the underlying convertible preferred stock by taking into consideration the most recent sales of our convertible preferred stock as well as additional factors that we deemed relevant. We assessed these assumptions and estimates on a quarterly basis as additional information impacting the assumptions was obtained. The risk-free rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time to each tranche closing.

As of December 31, 2022, the fair value of each Series A convertible preferred stock was $0.74 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred stock tranche right. As of December 31, 2022, an immediate 10 percent increase in the fair value of our Series A convertible preferred stock would have resulted in a $2.9 million increase, and in the case of a 10 percent decrease, a $2.9 million decrease to the fair value of the preferred stock tranche right liability.

117

As of December 31, 2023, the fair value of each Series B convertible preferred stock was $1.68 per share. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time period of achievement of the specified milestones underlying the preferred stock tranche right. As of December 31, 2023, an immediate 10 percent increase in the fair value of our Series B convertible preferred stock would have resulted in a $0.9 million increase, and in the case of a 10 percent decrease, a $0.9 million decrease to the fair value of the preferred stock tranche right liability.

The fair value of each share of Series B convertible preferred stock was estimated to be $1.79 per share on February 26, 2024 and March 19, 2024.

Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk

As of March 31, 2024, we had $193.2 million in cash, cash equivalents and short-term investments, excluding our restricted cash, which consisted of cash, money market funds, and government securities. Our cash and cash equivalents are primarily maintained in accounts with multiple financial institutions in the United States. At times, we may maintain cash and cash equivalent balances in excess of Federal Deposit Insurance Corporation (FDIC) limits. We do not believe that we are subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term duration of our investment portfolio and the low risk profile of our investments, we believe an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our investment portfolio. We have the ability to hold our investments until maturity, and therefore, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investment portfolio.

Inflation Risk

Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented.

Emerging Growth Company and Smaller Reporting Company Status

The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected not to “opt out” such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we will adopt the new or revised standard at the time private companies adopt the new or revised standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company. As a result of this election, our consolidated financial statements may not be comparable to other public companies that comply with new or revised accounting pronouncements as of public company effective dates. We may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for private companies.

Recent Accounting Pronouncements

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2—“Summary of Significant Accounting Policies” to our consolidated financial statements included elsewhere in this prospectus.

118

BUSINESS

Overview

We are a clinical-stage biopharmaceutical company focused on becoming the leader in precision neuroscience through discovery and development of transformational small molecule medicines for patients suffering from central nervous system (“CNS”) disorders. Our foundational science has elucidated complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function. We believe that our deep expertise in RAP biology provides an opportunity for us to interrogate previously inaccessible targets and develop CNS drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. Most neuroactive drugs lack this specificity, often resulting in undesired and intolerable side effects. Leveraging our expertise, we are developing a portfolio of precision product candidates that we believe has the potential to transform the standard of care of many CNS disorders.

Our founders have made pioneering discoveries related to RAP function and structure. Their findings form the basis of our RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates. RAP-219, our most advanced product candidate, is an AMPA receptor (“AMPAR”) negative allosteric modulator (“NAM”). RAP-219 is designed to achieve neuroanatomical specificity through its selective targeting of a RAP known as TARPg8, which is associated with the neuronal AMPAR, a clinically validated target for epilepsy. Whereas AMPARs are distributed widely in the CNS, TARPg8 is expressed only in discrete regions, including the hippocampus, a key site involved in focal epilepsy. We believe this provides RAP-219 with a high level of neuroanatomical specificity. We completed our Phase 1 trials in healthy adults to assess the safety and tolerability of RAP-219, and we intend to initiate a Phase 2a proof-of-concept trial in adult patients with drug-resistant focal epilepsy in the second or third quarter of (“mid”) 2024, with topline results expected in mid 2025. We believe RAP-219 also has therapeutic potential in peripheral neuropathic pain and bipolar disorder, and we intend to initiate Phase 2a trials in these indications in the second half of 2024 and in 2025, respectively. We have also identified another TARPg8 targeted molecule with differentiated chemical and pharmacokinetic properties, RAP-199, for which we expect to initiate a Phase 1 trial in the first half of 2025.

Beyond TARPg8, we have two advanced discovery-stage nicotinic acetylcholine receptor (“nAChR”) programs stemming from our RAP technology platform. Our first discovery-stage nAChR program comprises modulators of a6 nAChRs that we are developing for the treatment of chronic pain. Our second discovery-stage nAChR program comprises modulators of a9a10 nAChRs that we are developing for the treatment of hearing disorders. Third-party genetic data suggest that these nAChR subtypes could be attractive drug targets for these diseases. We continue to leverage our RAP technology platform to discover additional product candidates that we believe have the potential to provide a transformative benefit for large patient populations in CNS diseases with significant unmet need.

119

Our Pipeline

Our current portfolio of programs from our RAP technology platform is summarized in the pipeline chart below:

LOGO

Introduction to RAP-219

Epilepsy is estimated to affect 50 million people worldwide, including approximately 3.0 million adults in the United States. In 2022, the total branded market for epilepsy was approximately $2.8 billion, and this is expected to grow to approximately $3.6 billion by 2028. There are an estimated 1.8 million people in the United States who suffer from focal epilepsy, accounting for approximately 60 percent of patients with epilepsy. Focal epilepsy is characterized by seizures caused by intermittent abnormal electrical activity originating in specific areas of the brain. The hippocampus, located within the temporal lobe, is commonly associated with focal epilepsy, with approximately 50 percent of all seizures originating in or around this area. The cerebral cortex is another common site of focal onset seizure initiation, originating up to 50 percent of all seizures. However, the hippocampus often plays a role in these seizures as well, with the abnormal electrical brain activity that arises in the cerebral cortex often traveling to and being perpetuated by the hippocampus.

Epilepsy has profound negative impacts on a patient’s quality of life, including limitations on social engagement, physical activity and independence. Recent studies have also found that epilepsy can result in cognitive impairment. The treatment goal for all patients with epilepsy, including focal epilepsy, is complete freedom from seizures. Despite there being more than 20 antiseizure medications (“ASMs”) approved by the U.S. Food and Drug Administration (“FDA”), 30 to 40 percent of patients with epilepsy continue to experience recurring seizures despite taking two or more ASMs. This is termed “drug-resistant epilepsy.” In addition to providing sub-optimal efficacy, ASMs are commonly associated with risks of intolerable and debilitating adverse events (“AEs”). These side effects, such as cognitive impairment, sedation, ataxia and dizziness, are believed to result from drug actions in brain regions unrelated to epilepsy. These AEs often lead to dosing adjustments and patient nonadherence, both of which can limit efficacy. We believe tolerability, adherence and clinical benefit can be improved with RAP-219, an investigational therapy that is designed to precisely modulate only diseased brain regions.

120

Patients with epilepsy commonly take ASM combinations, which is referred to as polypharmacy. Drug-drug interactions make polypharmacy complex and add a further challenge to managing persistent seizures in epilepsy. When a physician adds a drug to a patient’s regimen, they typically prioritize one with a differentiated mechanism of action, an approach referred to as rational polypharmacy. Therefore, there is a critical need for therapies with new mechanisms of action, fewer AEs and a mitigated risk of drug-drug interaction for the treatment of focal epilepsy.

AMPAR inhibition is a clinically validated approach for the treatment of epilepsy, with perampanel (marketed as FYCOMPA) approved by the FDA in 2012 for the treatment of both focal and generalized epilepsy. Whereas perampanel binds to AMPARs throughout the CNS and periphery, preclinical studies have shown that RAP-219 actions on AMPARs are restricted to those few specific regions where TARPg8 is expressed, most notably the hippocampus. This leads us to believe that the tolerability profile of RAP-219 could be significantly differentiated from that of perampanel and other currently available ASMs.

TARPg8 is expressed in specific brain regions, being most enriched in the hippocampus and other forebrain structures, which are key sites associated with focal onset seizures. As brain regions with TAPRg8 expression closely overlay with the brain sites most often involved with the pathophysiology of focal epilepsy, we believe that RAP-219, which has been shown in preclinical studies to bind to TARPg8, has potential to provide a differentiated profile. Furthermore, preclinical studies also demonstrated TARPg8 expression is enriched in the hippocampus, amygdala, cerebral cortex and striatum and has minimal or no expression in certain other areas that are critical for normal brain functions, including the cerebellum and brainstem. In contrast to the precision mechanism of RAP-219, the majority of ASMs, including perampanel, bind their target receptors throughout the brain, and we believe this lack of anatomical specificity may contribute to their side effect profiles. We believe that RAP-219, as compared to currently available ASMs, has the potential to have a greater therapeutic index, meaning a wider range of doses at which it is likely to be effective without causing unacceptable AEs. If RAP-219 is approved, this could have important clinical utility for the management of focal epilepsy.

In addition to treating seizures, we believe RAP-219 has the potential to provide therapeutic benefit in additional CNS indications such as peripheral neuropathic pain and bipolar disorder. We intend to initiate proof-of-concept clinical trials of RAP-219 in peripheral neuropathic pain and bipolar disorder in the second half of 2024 and in 2025, respectively.

Introduction to Our Discovery-Stage Nicotinic Acetylcholine Receptor Programs

In addition to RAP-219, we have two discovery-stage programs stemming from our RAP technology platform. Our a6 nAChR and a9a10 nAChR programs were both enabled by our discovery of RAPs that drive the assembly of functional versions of these receptors in cell lines. Based on third-party genetic data, we believe each of these nAChR subtypes could be attractive drug targets. However, it was not until our identification of these RAPs that it became possible to create cell lines for in vitro compound screening and optimization against these important targets.

121

We are pursuing agonists and positive allosteric modulators (“PAMs”) of the a6 nAChR for the treatment of chronic pain. Gain-of-function variants in the gene encoding the a6 subunit is responsible for attenuated pain levels. A previous third-party investigational pan-nAChR agonist demonstrated clinical activity in a randomized placebo controlled study in painful diabetic neuropathy but this experimental therapeutic was associated with intolerable side effects that led to the discontinuation of its development. We believe that these side effects were primarily due to the non-selective nature of that agonist. Through our ability to functionally express and pharmacologically screen for a6 nAChR modulators, we have identified small molecule agonists and PAMs that showed a6 nAChR selectivity as well as beneficial activity in a preclinical model of neuropathic pain. We are optimizing these molecules in anticipation of selecting candidates to advance into the clinic.

Our a9a10 nAChR program focuses on the discovery of small molecule modulators of this receptor as potential therapies for hearing disorders. Third-party studies observed a loss-of-function mutation of the gene for the a9 subunit in mice associated with increased sensitivity to noise-induced hearing loss. Conversely, we observed a gain-in-function mutation in a9 protected against hearing loss. We have identified small molecule modulators of a9a10 nAChR and are now optimizing these molecules in anticipation of selecting candidates to advance into the clinic.

Our Company’s History and Our Team

Rapport was formed in February 2022, with founding support from Third Rock Ventures and Johnson & Johnson Innovation-JJDC, to advance the discovery and development of RAP-targeted precision neuromedicines. Our scientific founder and Chief Scientific Officer, David Bredt, M.D., Ph.D., pioneered the discovery of RAPs and their targeting by small molecules while serving as Global Head of Neuroscience Discovery at Janssen Pharmaceutica NV (“Janssen”) and prior to that as Vice President of Neuroscience at Eli Lilly and Company and as a Professor of Physiology at the University of California, San Francisco. Dr. Bredt was subsequently joined at Rapport by additional scientists who previously worked on the RAP platform at Janssen.

In August 2022, we entered into a license agreement with Janssen (the “Janssen License”) for the research, development and commercialization of certain TARPg8 products, including RAP-219 and RAP-199, and nAChR products created by Dr. Bredt and his colleagues at Janssen. We are furthering development of these assets and extending discovery efforts into novel areas. Under the terms of the Janssen License, certain TARPg8 and nAChR patents, materials and know-how were transferred to us. All discovery and development efforts related to our pipeline programs are herein referred to as “ours,” although some of these preclinical efforts were completed at Janssen prior to the Janssen License. In many cases, these efforts were made by certain of the same personnel who have since joined Rapport.

In addition to Dr. Bredt, we have a seasoned leadership team with deep expertise in building novel therapeutic platforms, bringing therapeutics to market and supporting the growth of public biopharmaceutical companies. Abraham N. Ceesay, M.B.A., our Chief Executive Officer and a member of our board of directors, has extensive biopharmaceutical leadership experience, most recently as President of Cerevel Therapeutics Holdings, Inc. and prior to that as Chief Executive Officer of Tiburio Therapeutics, Inc. Bradley S. Galer, M.D., our Chief Medical Officer, has over twenty years of experience leading and building global drug development and medical affairs teams in epilepsy and pain, including as Executive Vice President and Chief Medical Officer at Zogenix, Inc. Dr. Galer was involved in the clinical development of fenfluramine (Fintepla), lidocaine patch (Lidoderm), gabapentin (Neurontin) and pregabalin (Lyrica) and previously acted as an academic key opinion leader in neuropathic pain. Troy Ignelzi, our Chief Financial Officer, has served in a similar role for several biopharmaceutical companies, most recently as Chief Financial Officer at Karuna Therapeutics, Inc. (“Karuna”). Cheryl Gault, our Chief Operating Officer, has over twenty years of biopharmaceutical experience, most recently serving as Chief Operating Officer at Cyclerion Therapeutics, Inc. Swamy Yeleswaram, Ph.D., our Chief Development Officer was a founding scientist at Incyte Corporation, most recently serving as Group Vice President of Drug Metabolism, Pharmacokinetics and Clinical Pharmacology. Kathy Wilkinson, our Chief People Officer, has previously served in similar roles at public companies, including 2seventy bio, Inc. and bluebird bio, Inc. Karina Chmielewski, our Chief Information Officer, previously served as Vice President, Platform Operations at Third Rock Ventures.

122

Our board of directors is composed of accomplished leaders in the life sciences industry, including board chair Steven M. Paul, M.D., former President and Chief Executive Officer of Karuna, Terry-Ann Burrell, M.B.A., Chief Financial Officer of Beam Therapeutics, Inc., James I. Healy, M.D., Ph.D., Managing Partner of Sofinnova Investments, Inc., Reid Huber, Ph.D., Partner of Third Rock Ventures, Raymond Kelleher, M.D., Ph.D., Managing Director at Cormorant Asset Management LLC, John Maraganore, Ph.D., former founding Chief Executive Officer of Alnylam Pharmaceuticals, Inc. and Venture Partner at both ARCH Venture Partners and Atlas Ventures, Jeffery K. Tong, Ph.D., Partner of Third Rock Ventures, and Mr. Ceesay, our Chief Executive Officer.

We have also assembled a scientific advisory board, composed of leading experts, who have made significant contributions in the fields of neuroscience, pain and pharmaceutical chemistry. Our scientific advisory board includes co-chairs David Julius, Ph.D., Chair of Physiology at the University of California San Francisco and 2021 Nobel Prize laureate in physiology or medicine, and Sir David MacMillan, Ph.D., Professor of Chemistry at Princeton University and 2021 Nobel Prize laureate in chemistry, as well as members Allan Basbaum, Ph.D., FRS, Chair of Anatomy at the University of California San Francisco, David Clapham, M.D., Ph.D., Professor of Cardiovascular Research and Professor Emeritus of Neurobiology at Harvard Medical School, Jeffrey L. Noebels, M.D., Ph.D., Chair in Neurogenetics and Professor of Neurology, Neuroscience and Molecular and Human Genetics at Baylor College of Medicine, and Wendy Young, Ph.D., an advisor at Google Ventures who previously served as senior vice president, small molecule drug discovery at Genentech, Inc. where she actively built and led the research and discovery organization.

Since our inception, we have raised approximately $250 million in equity capital from our syndicate of premier life sciences investors. Potential investors should not consider investments made by our existing investors as a factor when making a decision to purchase shares in this offering since our existing investors likely have different risk tolerances and paid significantly less per share than the price at which the shares are being offered in this offering.

Our Strategy

•

Advance RAP-219 clinical development for the treatment of focal epilepsy. RAP-219 is designed as a highly potent and selective NAM of TARPg8-AMPAR which has demonstrated antiseizure activity in preclinical epilepsy models without evidence of motoric impairment or sedation characteristic of many approved ASMs. We conducted two Phase 1 trials where RAP-219 was observed to be well tolerated in healthy adults with once-daily dosing. We anticipate initiating a Phase 2a proof-of-concept trial of RAP-219 in mid 2024 in adult patients with drug-resistant focal epilepsy.

•

Expand the potential of RAP-219 in additional neurological indications. We believe that RAP-219’s ability to precisely modulate the activity of AMPAR within specific CNS regions, as demonstrated in preclinical studies, provides the potential for clinical applications in neurological indications beyond focal epilepsy. We intend to initiate a proof-of-concept clinical trial in peripheral neuropathic pain in the second half of 2024 and in bipolar disorder in 2025.

•

Extend the life cycle of RAP-219 and expand the TARPg8 franchise. We are exploring a long-acting injectable formulation of RAP-219, which we believe will expand the potential clinical utility across all RAP-219’s indications and potentially extend the molecule’s lifecycle. We have also nominated another TARPg8 targeting molecule, RAP-199, as a development candidate. This molecule has demonstrated differentiated chemical and pharmacokinetic properties in preclinical studies and may be suitable for additional indications beyond those being pursued with RAP-219, which we intend to evaluate in a Phase 1 trial to be initiated in the first half of 2025.

123

•

Advance development of our RAP-enabled nAChR programs. Our RAP platform has enabled identification of small molecules specific for nAChR drug targets we find compelling. We believe that our a6 nAChR program may deliver clinical benefits in chronic pain while avoiding the AEs associated with non-selective nAChR agonists. We believe that compounds specific to the a9a10 receptor could provide therapeutic benefit in hearing disorders and are optimizing molecules for both programs, in anticipation of selecting lead candidates to advance into the clinic.

•

Fortify our leadership position in RAP-enabled drug discovery to expand our pipeline of transformative precision neuroscience therapies for patients. We believe the science underpinning our RAP technology platform can serve as the foundation for a broad portfolio of precision neuroscience product candidates that have the potential to transform the current treatment armamentarium for many CNS disorders. We are committed to leveraging our expertise in RAP biology to develop a portfolio of small molecule therapies to deliver potentially more effective, better tolerated and safer treatments to large and underserved CNS patient populations.

•

Pursue strategic partnerships opportunistically. We currently have exclusive global rights to use our technology platform and commercialize our product candidates. If we believe that partnerships can accelerate the development or maximize the market potential of our product candidates, we will consider entering into product, target and/or geographic specific strategic partnerships on an opportunistic basis.

Our RAP Technology Platform

Due to the complexities of studying drugs directly in the brain, the standard approach to discovery and optimization of neurology drugs is through in vitro cellular assays involving recombinant receptors. This approach often fails to amplify the function of relevant targets in their natural contexts and has resulted in the approval of neurology drugs that are not designed to be selective for specific forms of their targets, which can contribute to unwanted toxicities and limit therapeutic indexes.

We believe that leveraging RAPs can overcome many limitations of conventional neurology drug discovery. RAPs have defining characteristics that we believe make them ideal tools in the development of precision neuromedicines. First, because RAPs play critical roles in modulating receptor assembly and function, understanding RAP biology provides powerful insights into neuronal signaling. Second, because RAPs can be differentially expressed in specific brain regions, we believe they can serve as drug targets with neuroanatomical specificity.

Using two distinct strategies, we are leveraging our expertise in RAP biology to develop a portfolio of precision neuroscience product candidates that we believe will transform the treatment of many CNS disorders. One strategy uses a RAP as a direct target, which can be more precise than drugging a receptor itself. RAP-219 exemplifies this, as it has been shown in preclinical studies to bind to an AMPA RAP, TARPg8, which is enriched in brain regions that initiate or perpetuate seizures in focal epilepsy.

A second strategy uses RAPs to “unlock” receptors for potentially first-in-class drug discovery programs. Many receptors cannot function without their RAPs, and such receptors have therefore been inaccessible to study in vitro. Our discovery platform integrates cutting-edge genetics with functional proteomics to discover RAPs that are regionally localized and involved in disease-related signaling. We have designed our platform to prosecute a wide range of validated therapeutic targets. This second strategy enabled our discovery stage nAChR programs, which focus on a6 and a9a10.

124

RAP-219, Our TARPg8 Specific Product Candidate

The ionotropic receptors for glutamate (“iGluR”) are ligand gated ion channels activated by the neurotransmitter glutamate. These receptors mediate the majority of excitatory synaptic transmission throughout the CNS. iGluRs comprise four subtypes based on their ligand binding properties: AMPARs, kainate receptors, N-methyl-D-aspartate (“NMDA”) receptors and delta receptors. There are many FDA approved drugs that block the glutamate signaling pathway, which are approved for indications such as epilepsy, schizophrenia, Alzheimer’s disease and Parkinson’s disease. However, these drugs are associated with numerous side effects, such as sedation, ataxia, cognitive impairment and neuropsychiatric symptoms. These undesired effects can be exacerbated by broad interactions of these drugs with glutamate receptors throughout the brain.

AMPARs are cation, or positively charged ion, channels that permit influx of sodium ions (Na⁺) to depolarize postsynaptic membranes. Our lead asset, RAP-219, is an investigational small molecule that is designed to potently and specifically inhibit activity of TARPg8-containing AMPARs. Because TARPg8 expression is restricted to specific brain regions such as the hippocampus, which is often involved in focal epilepsies, we believe RAP-219 has the potential to provide a differentiated clinical profile, including improved activity and tolerability along with a higher therapeutic index, potentially providing more patients with sustained therapeutic benefit without intolerable side effects, as compared to traditional ASMs.

In preclinical epilepsy models, RAP-219 significantly reduced seizures without inducing sedation or motoric impairment, which are side effects that plague most existing ASMs. In addition, we believe that RAP-219 has the potential to provide therapeutic benefit in other indications, such as peripheral neuropathic pain and bipolar disorder, and we are actively exploring these opportunities. The initial formulation of RAP-219 is planned to be a once-per-day oral tablet. We are also developing a long-acting injectable formulation for once every month or less frequent dosing, which we believe will result in better compliance and patient outcomes. We have conducted two Phase 1 trials in healthy adults to assess RAP-219’s safety and pharmacokinetic profile, and we expect to initiate a Phase 2a proof-of-concept trial in mid 2024 in adult patients with drug-resistant focal epilepsy, with topline results expected in mid 2025.

Background to Focal Epilepsy

Epilepsy is a chronic neurological disorder characterized by spontaneous recurrence of sudden abnormal bursts of brain electrical activity that disrupt brain function and cause seizures. Epilepsy is estimated to affect 50 million people worldwide including 3.0 million adults in the United States. Epilepsy is the third most common neurological disorder, with almost 10 percent of people experiencing a seizure during their lives. The annual direct costs, including outpatient, inpatient, emergency care and treatment costs, of epilepsy in the United States are estimated to be $28 billion.

Epilepsy can be divided into subgroups defined by the types of seizures that occur:

•

Generalized epilepsy is characterized by seizures affecting broad areas of the brain. The most severe type is known as tonic-clonic seizures, which involve sudden loss of consciousness, body stiffening, twitching and shaking. In other cases, these patients can experience subsets of these symptoms. Generalized seizures account for 40 percent of all epilepsies.

•

Focal epilepsy is characterized by seizures affecting more restricted areas of the brain. Focal epilepsy, which sometimes results in loss of consciousness or awareness, can lead to changes in the way things look, smell, feel, taste or sound. These seizures may be accompanied by involuntary jerking of a body part or by repetitive movements such as hand rubbing, chewing, or swallowing. Focal epilepsies account for 60 percent of all epilepsies. Figure 1 below illustrates the prevalence of focal epilepsy in the United States.

125

LOGO

Figure 1. The prevalence of focal epilepsy in the United States is estimated to be 1.8 million patients.

The unpredictable nature of epilepsy has a profound negative impact on patient quality of life. Patients often limit their social engagement and physical activity for fear of seizures. Epilepsy also limits patients’ ability to function independently. For instance, in some U.S. states, individuals with epilepsy are required to have a record of being seizure-free for 3 to 12 months in order to drive. Epilepsy is often associated with depression, anxiety and psychosis and doubles the incidence of mental health disorders. Furthermore, epilepsy also presents serious mortality risk with approximately one percent of patients suffering sudden unexpected death in epilepsy (“SUDEP”). Having uncontrolled seizures increases the risk of SUDEP. Both treatment and indirect costs for individuals with uncontrolled epilepsy are significantly higher than for those with stable epilepsy.

Current Standard of Care and Limitations

Treatment strategies for focal epilepsy can include both medical and surgical options, which strive to achieve seizure control with minimal AEs. Although there are over 20 FDA approved ASMs, 30 to 40 percent of patients have drug-resistant epilepsy and continue to experience uncontrolled seizures despite taking two or more ASMs. First-line treatment for focal epilepsy is monotherapy, prescribing one ASM which is selected based on a patient’s seizure type, medical history and their physician’s experience with a drug’s efficacy, tolerability and convenience.

Approved ASMs have many mechanisms of action, and most work by either inhibiting neuronal excitation or augmenting neuronal inhibition. Some ASMs blunt excitation by inhibiting voltage sensitive sodium or calcium channels or by blocking excitatory AMPA or NMDA receptors. Alternatively, some ASMs augment inhibition by enhancing g-aminobutyric acid type A (“GABA_A”) receptors or voltage-gated potassium channels. In addition, there are some ASMs for which the precise mechanism of action is not known and some which engage multiple targets. Most ASMs bind to targets expressed throughout the brain, and we believe this broad pharmacology can drive their side effects.

If a single ASM fails to prevent seizures, physicians often prescribe a different ASM or begin polypharmacy. When a prescribing physician decides which ASM to add to a refractory patient’s drug regimen, one important factor is the desire to add a new ASM with a different mechanism of action from those ASMs the patient is already taking. The process of polypharmacy involves trial and errorwhich can elevate risk of AEs and drug-drug interactions.Tolerability issues can lead patients to take suboptimal doses to minimize side effects or can lead to treatment discontinuation, which occurs in 30 to 40 percent of patients. AEs commonly reported with ASMs include systemic effects such as nausea and vomiting, neurologic effects such as sedation, cognitive effects, ataxia and dizziness. In addition, some ASMs are associated with severe medical safety risks, for example, rare idiosyncratic reactions such as the life-threatening multi-organ hypersensitivity reaction known as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS), serious skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis, bone marrow suppression, significant liver and kidney abnormalities, and cardiac arrhythmias.

126

Antiseizure Therapy Through Modulation of Glutamate Signaling

Glutamate is the major excitatory neurotransmitter in the brain. Both glutamate’s release from presynaptic nerve terminals and its activation of postsynaptic receptors are critical for neurotransmission. Correspondingly, processes associated with glutamate release and its downstream signaling are highly regulated. Elevation in extracellular glutamate levels can lead to seizures, and many ASMs target this pathway.

ASMs can blunt glutamate-dependent signaling through diverse mechanisms. Drugs such as phenytoin, carbamazepine, lamotrigine and lacosamide molecule voltage-gated sodium channels and inhibit action potentials from reaching the glutamate release machinery within the presynaptic nerve terminal. Other drugs such as ethosuximide and ezogabine modulate voltage-gated calcium and potassium channels, respectively, which also can prevent the presynaptic release of glutamate. Figure 2 below shows the mechanisms of currently approved ASMs, including many that modulate glutamate signaling.

LOGO

Source: Created with Biorender.com. Bialer M, White HS. (2010). Key factors in the discovery and development of new antiepileptic drugs. Nature Reviews Drug Discovery, 9(1):68–82. doi: 10.1038/nrd2997. Löscher W, Klein P. (2021). The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond. CNS Drugs (2021) 35:935 -963. doi: 10.1007/s40263-021-00827-8.

Figure 2. Mechanistic cartography of currently approved ASMs acting on the excitatory synapse (Left) and the inhibitor synapse (Right).

After being released into the synaptic cleft, glutamate can bind to AMPARs on postsynaptic neurons. This process permeates sodium and other cations, triggering a series of events that can ultimately lead to the generation of an action potential and the propagation of neuronal signals. Perampanel directly blocks the gating of all AMPARs, while other drugs, such as phenobarbital and tiagabine, oppose glutamate signaling by

127

increasing the activity of inhibitory synaptic signaling driven by the GABA_A receptors. Figure 2 above shows the mechanistic cartography of existing ASMs, including many that modulate glutamate signaling in the excitatory synapse.

Validation of AMPAR as a Target for the Treatment of Epilepsy

Perampanel, developed by Eisai Co. Ltd. and currently marketed as FYCOMPA by Catalyst Pharmaceuticals, Inc., is an FDA approved ASM that directly antagonizes all AMPARs throughout the brain. In three clinical trials of patients with drug-resistant focal epilepsy, perampanel reduced the frequency of partial onset (focal) seizures by 31 to 34 percent compared to 10 to 21 percent in the placebo group. However, perampanel’s efficacy was accompanied by frequent AEs consistent with its pan-AMPAR activity. At the highest recommended dose of perampanel (12 mg per day), over 40 percent of patients experienced dizziness, 18 percent reported somnolence, and at least 10 percent reported headaches, irritability, fatigue and falls. Perampanel’s FDA approval label is accompanied by a black box warning for serious psychiatric and behavioral reactions, including aggression, hostility and homicidal ideation and threats. Furthermore, significant drug-drug interactions were reported for perampanel. The concomitant use with the other ASMs carbamazepine, phenytoin and oxcarbazepine decreased plasma levels of perampanel by approximately 50 to 67 percent. In addition, perampanel at a dose of 12 mg per day reduced exposure of levonorgestrel, an oral contraceptive, by approximately 40 percent.

We believe there are at least three critical differences between perampanel and RAP-219. First, their chemical structures are completely different. Second, perampanel and RAP-219 have entirely distinct binding sites. Whereas perampanel binds directly to AMPAR GluA subunits, RAP-219 is designed to interact with g8, but not other TARP subtypes, and only when TARPg8 is associated with GluA proteins. Third, whereas perampanel blocks AMPARs throughout the brain and body, RAP-219 activity on AMPARs has been observed to be restricted to those specific neurons that express TARPg8, which are primarily located in the select forebrain regions. As such, we believe the tolerability profile of RAP-219 will be differentiated from that of perampanel, and may not induce the intolerable side effects associated with perampanel, such as dizziness, somnolence, fatigue, falls and vertigo.

Preclinical Studies Supportive of RAP-219

Preclinical studies have demonstrated RAP-219’s pharmacology and pharmacodynamic properties, as summarized below. In addition, preclinical studies have been conducted with third-party and earlier generation TARPg8 NAMs by us and third-parties, the results of which we believe are supportive of RAP-219 because these third-party and earlier generation TARPg8 NAMs share the same binding site and have similar pharmacological effects as RAP-219.

TARPg8 Expression is Localized

TARPg8 is expressed in specific brain regions, being most enriched in the hippocampus, and also present in the amygdala and cortex. In a study completed by Janssen, radiolabeled TARPg8 ligands, such as [3H]JNJ-56022486 (an earlier generation TARPg8 NAM), were shown to bind selectively to regions of the mouse brain in a distribution that overlapped TARPg8 protein expression. The highest radioactive [3H]JNJ-56022486 density occurred in the hippocampus, which is also the region where the majority of focal seizures originate and the brain region where focal seizures originating in the cortex often spread. Radioligand binding of [3H]JNJ-56022486 also occurred in other brain regions that contain TARPg8, including the amygdala, cerebral cortex and striatum, which can also be involved in seizure initiation and propagation. Importantly, the spread of seizures from the hippocampus into the amygdala has been shown in a third-party study to increase the risk of SUDEP in patients.

Figure 3 below illustrates the enrichment of TARPg8 in mouse hippocampus. The left image derives from the Allen Brain Atlas, a publicly available database of gene expression in the brain, and depicts in red high levels of TARPg8 messenger ribonucleic acid detected by in situ hybridization. The right image depicts with yellow and orange high levels of [3H]JNJ-56022486 binding detected by autoradiography.

128

LOGO

Figure 3. TARPg8 is expressed in the mouse hippocampus.

TARPg8 Ligands are Highly Selective Inhibitors of AMPAR

Structural analyses performed by a third party using cryogenic electron microscopy (“Cryo-EM”) have shown that a TARPg8 AMPAR NAM, JNJ-55511118 (an earlier generation TARPg8 NAM), binds to an interface between TARPg8 and AMPAR, which leads to alterations in the structure of the AMPAR, thereby negatively modulating receptor function and its ability to respond to glutamate. Third-party structural studies indicated that all TARPg8 AMPAR NAMs tested bind in a similar mode, suggesting the potential for RAP-219 to also bind in this pocket between GluA and TARPg8. Figure 4 illustrates TARPg8 ligands binding to the interface between TARPg8 and AMPAR.

LOGO

Figure 4. TARPg8 ligands bind to the interface between TARPg8 and AMPAR.

129

RAP-219 Was Observed to Be a Potent TARPg8-Specific Inhibitor of AMPAR

Janssen tested RAP-219’s effect on recombinant human GluA1-TARPg8 complexes in mice and rats. The study found that RAP-219 inhibited the function of GluA1-TARPg8 receptors with half maximal effect, referred to as the IC₅₀, at a concentration of approximately 100 pM, demonstrating RAP-219’s potency. By contrast, as exemplified in Figure 5 below, RAP-219 was found to be far less potent on complexes of GluA1 with other relevant TARP isoforms, including g2, g3, g4 or g7 or on other receptor types, such as NMDA receptors, G protein-coupled receptors (“GPCRs”), enzymes or and kinases.

LOGO

Figure 5. RAP-219 observed to be a highly selective inhibitor of TARPg8 AMPAR.

RAP-219 Was Observed to Be Bioavailable and CNS Penetrant in Animal Models

Oral doses of RAP-219 were rapidly absorbed with over 80 percent bioavailability in mice, rats, dogs and non-human primates. In these animal studies, completed by Janssen, RAP-219 had a half-life of 17.8 to 38.3 hours and was observed to distribute into the brain with a brain-to-plasma ratio of 0.96 in rats. Figure 6 below shows that oral doses of 0.02 mg/kg in the mouse and 0.01 mg/kg in the rat resulted in 50 percent TARPg8-receptor/AMPAR occupancy for RAP-219 in the hippocampus, referred to as “ED₅₀.”

LOGO

Figure 6. Dose dependent receptor occupancy of RAP-219. Following oral dosing of RAP-219, AMPAR occupancy was quantified in the hippocampus of the mouse (A) at 24 hours and rat (B) at 4 hours after dosing using ex-vivo autoradiography.

130

RAP-219 has the Potential for Reduced Drug-Drug Interactions Versus Approved ASMs

RAP-219 is neither a substrate nor an inhibitor of cytochrome P450 (“CYP”) enzymes. CYPs comprise a large and diverse family of enzymes, responsible for the detoxification of many drugs, including ASMs. Drug-drug interactions with CYPs can decrease or increase ASM blood levels, which can reduce drug effectiveness or increase relevant drug side effects, respectively. RAP-219 has not been observed to induce or inhibit or be metabolized by any evaluated CYPs at clinically relevant concentrations. RAP-219 has been shown to be metabolized in vitro primarily by an enzyme in a different family, termed UDP-glucuronosyltransferase1A4 (“UGT1A4”). We believe that RAP-219’s lack of interaction with the CYP pathway has the potential to reduce drug-drug interactions, which would serve as an advantage given the widespread use of polypharmacy in focal epilepsy, peripheral neuropathic pain and bipolar disorder.

RAP-219 Preclinical Trials in Focal Epilepsy

Multiple preclinical epilepsy models were used by Janssen to assess the potential of ASMs. In the pentylenetetrazol (“PTZ”) infusion mouse model of acute seizures, RAP-219 administration was associated with an increased seizure threshold. PTZ is a GABA_A receptor antagonist, which causes acute severe seizures in animals when infused at a high dose. As shown in Figure 7 below, RAP-219 led to a dose-dependent increase in the threshold concentration required to trigger both twitch and clonus in the Metrazol mouse model. Significant differences compared to vehicle treatment were detected in 0.1 and 1 mg/kg doses (P<0.01) for both twitch and clonus. ED₅₀ values were 0.02 mg/kg for both twitch and clonus responses.

LOGO

Figure 7. RAP-219 led to a dose dependent increase in the threshold concentration required to trigger both twitch and clonus responses in the IV Metrazol model.

The corneal kindling induced seizure model in mice is considered to be a valid model in focal epilepsy. In this model studied by Janssen, repeated application of an electrical stimulus, which is initially subconvulsive, resulted in alterations in brain function that led to progressive sensitization to seizures. As illustrated in Figure 8 below, in fully kindled mice, oral administration of a single dose of RAP-219 at doses of 0.02 mg/kg to 3 mg/kg prevented seizures with an estimated half maximal effective concentration (“EC50”) occurring at 2.3 ng/mL plasma concentration. Immediately prior to the corneal kindling test, the same mice were assessed with a rotarod test. This is a performance test widely used to assess motor impairment and sedation in rodents. The lack of

131

motoric impairment with RAP-219, even at approximately 100-fold higher exposures, is consistent with the lack of expression of TARPg8 in brain regions involved in motor coordination and sedation, such as the hindbrain.

LOGO

Figure 8. RAP-219 had an estimated EC50 of 2.3 ng/mL in the corneal kindling mouse model of focal epilepsy.

Maximal seizure protection, based on the percentage of responding animals, was observed at a plasma concentration of approximately 10 ng/mL, and significant seizure reduction was seen at a plasma concentration of approximately 7 ng/mL. This corresponds to a projected receptor occupancy of approximately 50 to 70 percent based on data generated in rats as measured by ex-vivo autoradiography, as shown in Figure 9 below.

132

LOGO

Figure 9. A plasma concentration of 7 ng/mL of RAP-219 corresponded to approximately a 70 percent receptor occupancy in rats.

Data from a separate study completed by us, in fully kindled mice, suggests that oral administration of RTX-1738 (a TARPg8 NAM licensed to us under the same patent as RAP-219) at 3 mg/kg prevented seizures after either a single administration or after seven consecutive days of dosing, indicating that antiseizure activity was maintained with repeat dosing, i.e. no tolerance to the antiseizure activity was observed.

We believe that one potential advantage of the precision targeting observed with RAP-219 in preclinical models is a wide therapeutic index that may be achieved by avoiding AMPAR modulation in the hindbrain. The therapeutic index measures the general tolerability of a drug, reflecting the range of doses at which a medication is effective without causing unacceptable adverse effects. Drugs with narrow therapeutic indexes have a lesser difference between doses that produce therapeutic effects and doses that cause adverse effects. In preclinical animal studies, we found the ratio between doses of RAP-219 that did not produce a toxic effect in 50 percent of the population (“TD₅₀”) on the rotarod test were greater than 150 higher than those with ED₅₀ for beneficial activity in the corneal kindling test. This compares favorably to that same ratio derived from preclinical animal models for other approved and widely prescribed ASMs which range from 1.3 for phenytoin to greater than 44 for levetiracetam. Thus, we believe RAP-219’s potentially wider therapeutic index could translate to patients, providing sustained therapeutic benefit without intolerable side effects, improving upon the traditional ASMs.

133

RAP-219 Preclinical Toxicity Studies

In vivo GLP and non-GLP toxicology studies have also been conducted with RAP-219. In a 28-day GLP toxicology study in rats completed by Janssen, once-daily administration of RAP-219 was generally well-tolerated and no adverse effects were observed at any dose. Non-adverse effects including clinical signs were observed, and all non-adverse findings appeared to be reversible following completion of the 28-day recovery period. In a 28-day GLP toxicology study in dogs, once-daily administration of RAP-219 at doses of up to 10 mg/kg per day yielded overall exposures approximately 100-fold higher than those required to inhibit seizures in the mouse corneal kindling model. RAP-219 was generally well-tolerated and no adverse effects were observed at any dose. The non-adverse effects included CNS-related clinical signs, minor changes in a limited number of clinical pathology parameters, as well as minimal microscopic changes in the adrenal gland and thymus. All drug related RAP-219 effects observed either reversed completely or were in the process of reversing following the 28-day recovery period. Similar results were observed in 13-week toxicology studies in rats and dogs completed by us. Based on the preclinical toxicology data collected to date across these models, we believe RAP-219 has a low genotoxic potential and a favorable tolerability profile. These data supported further development through clinical investigation for once-daily oral dosing of RAP-219 up to three months.

Additional toxicology studies including a chronic (6-months in rats and 9-months in dogs) study as well as reproduction toxicology studies (in rats and rabbits) are ongoing to support longer-term dosing and dosing women of childbearing potential in subsequent clinical trials. In these ongoing studies, convulsion was observed in two instances. A female rabbit dosed at 40 mg/kg per day showed convulsion on the last day of the 10-day pilot tolerability or range finding study to enable GLP reproduction toxicology study. This dose level was considered not tolerated. The no observed effect level (“NOEL”) dose for convulsion was 30 mg/kg per day. A male dog in the ongoing 9-month chronic toxicology study developed convulsion following the first dose of 20 mg/kg. As demonstrated in the 28-day GLP toxicology study in dogs, the highest dose level tested in dogs and the NOEL dose for convulsion was 10 mg/kg per day. The margins for the mean maximum exposures (Cmax) from the Phase 2a proof-of-concept trial dose (0.75 mg per day for 5 days followed by 1.25 mg per day) over that from the NOEL in rabbits and dogs were greater than 700-fold and 500-fold, respectively. To deal with convulsion in nonclinical studies, we plan to use one-tenth of the exposure from the no-effect dose level for convulsion as the highest exposure for clinical trials. Using this approach, we expect the margins will be greater than 70-fold and 50-fold in rabbits and dogs, respectively. Therefore, we believe the potential for convulsion risk to patients is low.

RAP-219 Phase 1 Trials in Healthy Volunteers

We have conducted two Phase 1 trials in healthy adult volunteers to assess the safety, tolerability and pharmacokinetics of RAP-219. The first Phase 1 trial had two parts. Part 1 was a randomized, double-blind and placebo-controlled single ascending dose (“SAD”) trial that evaluated doses from 0.25 mg to 3 mg and Part 2 was an open label single cohort evaluation of the effect of a high-fat meal on the pharmacokinetics of a 1 mg single dose of RAP-219. The second Phase 1 trial was a randomized, double-blind and placebo-controlled multiple ascending dose (“MAD”) trial that evaluated once-daily doses ranging from 0.25 mg to 1.25 mg over two or four weeks. Each cohort for the SAD Part 1 and MAD trials consisted of six subjects receiving RAP-219 and two subjects receiving a placebo. In Part 2 of the SAD trial, there were six subjects who all received RAP-219.

For both Phase 1 trials, no clinically meaningful abnormal changes in laboratory values or electrocardiograms (“ECG”) were observed, nor were there any relevant vital sign changes. In the SAD Part 1 trial, all doses were well tolerated with no serious adverse events (“SAEs”), and all drug related treatment-emergent adverse events (“TEAEs”) were rated as mild (grade 1) or moderate (grade 2). All moderate drug-related TEAEs observed were at the two highest doses (2 mg and 3 mg) and were generally consistent with the effects seen in nonclinical toxicology studies with RAP-219. These included agitation and amnesia, each reported in two subjects, and anxiety, dizziness, visual hallucination, sinus tachycardia and hypertension, each reported in one subject.

134

There were five cohorts in the Phase 1 SAD trial. The pharmacokinetics of RAP-219 in the SAD Part 1 trial were consistent with the observations from the nonclinical studies, characterized by low clearance and a long terminal elimination half-life of approximately 8 to 14 days. The maximum exposures (Cmax) at the 2 mg and 3 mg doses corresponded to approximately 50 percent receptor occupancy, based on data from preclinical studies. In the SAD Part 2 trial, a modest increase in overall exposure (25 percent increase in area under the curve) and maximum exposure (42 percent increase in Cmax) were observed when RAP-219 was dosed with a high-fat, high-calorie meal. Based on the emerging safety profile and the observed food effect, we believe RAP-219 can be dosed without regard to food.

There were five cohorts in the Phase 1 MAD trial. In the MAD trial, all doses were well tolerated with no SAEs, all drug related TEAEs were rated as mild (grade 1), and no dose response was observed with regards to drug-related TEAEs. The most common TEAEs (without regard for determinations of relatedness) and those occurring in two or more of thirty subjects who received RAP-219 across the five cohorts included sinus tachycardia (4 subjects, or 13.3%), headache (3 subjects, or 10%), insomnia (3 subjects, or 10%), medical device site reactions (3 subjects, or 10%), dizziness (2 subjects, or 6.7%), contact dermatitis (2 subjects, or 6.7%), atrial tachycardia (2 subjects, or 6.7%), chills (2 subjects, or 6.7%), constipation (2 subjects, or 6.7%) and vomiting (2 subjects, or 6.7%). The most common TEAEs reported as drug-related were sinus tachycardia (4 subjects, or 13.3%), dizziness (2 subjects, or 6.7%) and atrial tachycardia (2 subjects, or 6.7%). The highest dose cohort (0.75 mg per day for 5 days followed by 1.25mg per day for 23 days) had no treatment related TEAEs. The TEAEs that were observed in individuals who received placebo were each observed in one of ten patients (10%) across all five cohorts, and included dizziness, second degree atrioventricular (“AV”) block (in a subject who had first-degree AV block at baseline), medical device site reaction, constipation and abdominal pain.

Figure 10 below shows the pharmacokinetic profile of RAP-219 following the two highest single doses from the SAD trial and following the last dose (Day 28) of the two highest dose levels (Cohorts 4 and 5) in the MAD trial. Cohort 4 of the MAD trial was dosed at 0.75 mg per day for 28 days and achieved projected receptor occupancy of 70 percent at day 28 trough. Cohort 5 of the MAD trial was dosed at 0.75 mg per day for 5 days followed by 1.25 mg per day for 23 days. Data from Cohort 5 indicated maximum exposures (Cmax) up to 3-fold higher than those achieved following the highest single dose (3 mg) in the Phase 1 SAD trial (see Figure 10 below). Furthermore, in Cohort 5, 50 percent projected receptor occupancy first occurred at approximately day 6 of dosing (at trough). No drug related TEAEs were observed in any subject in Cohort 5. Based on these results, the dosing regimen used in Cohort 5 has been chosen as the proposed dose for our Phase 2a proof-of-concept trial. These observations from the MAD trial, notably the absence of any drug related CNS AEs in Cohort 5, are consistent with the targeted action of RAP-219 to regions of the CNS where TARPg8 AMPAR is present, in contrast to the effects of other approved ASMs.

LOGO

Figure 10. SAD Exposures vs. MAD Exposures.

135

Clinical Development Plan of RAP-219 in Focal Epilepsy

We intend to initiate a Phase 2a proof-of-concept, open label trial of RAP-219 in adults with drug-resistant focal epilepsy in mid 2024. The planned Phase 2a proof-of-concept trial will enroll approximately 20 participants who have previously been implanted with an intracranial RNS system, marketed by NeuroPace, Inc. (“NeuroPace”), to monitor and manage their epilepsy. Additional key participant eligibility criteria include implantation of the RNS system at least 15 months before screening, stable device configuration, stimulation and detection settings (including the duration of “long episodes” (“LEs”) recorded by the RNS system) for at least eight weeks before screening, at least an average of eight LEs per 4-week interval and at least one clinical seizure in the 8-week retrospective eligibility period, treatment with a maximum of four concomitant medications and no generalized onset seizures in the past ten years. Participants in this trial will receive a dose of 0.75 mg per day for 5 days, followed by 1.25 mg per day for the remainder of the treatment period. Our Phase 2a proof-of-concept trial design is further detailed in Figure 11 below.

LOGO

Figure 11. Phase 2a Proof-of-Concept Trial Schema.

The primary endpoint of our Phase 2a proof-of-concept trial will be a reduction in frequency of LEs recorded by the RNS system, specifically the change in LE frequency during the second 4-week interval of the treatment period (weeks 5-8) compared to baseline frequency (frequency per 28 days determined across 8-week retrospective and 4-week prospective baseline intervals). The key secondary endpoints of this proof-of-concept trial include change in clinical seizure frequency (measured using the RNS system and patient-recorded paper diaries), change in electrographic biomarkers (including spike frequency, detection frequency, episode duration, saturation frequency, and other RNS system data outputs) and number and percent of participants who achieve any improvement as assessed by the investigator (measured by Clinical Global Impression of Change scores of minimally, much or very much improved).

In November 2023, we established a collaboration with NeuroPace to leverage the RNS system’s data to track responses of patients receiving RAP-219 in our Phase 2a proof-of-concept trial. We believe this collaboration will allow us to more rapidly identify study sites and efficiently screen appropriate patients in the recruitment of our Phase 2a proof-of-concept trial. In addition, we believe access to NeuroPace’s data collection and analysis capabilities will enable us to efficiently prepare our proof-of-concept data package.

The RNS system is FDA approved for the treatment of refractory focal epilepsy. The RNS system involves a surgeon implanting a small battery-powered device called a responsive neurostimulator in the patient’s skull. The neurostimulator is connected to thin wires, or electrodes, that the surgeon places in areas of the brain where the patient’s seizures originate. The device continuously monitors and records the brain’s abnormal electrical activity. Abnormal brain electrical activity detected by the RNS system that could likely lead to a seizure is referred to as a LE. When a LE is detected, the device delivers a pulse of electrical stimulation that may halt the seizure and prevent it from spreading to other brain regions. As of December 31, 2023, over 5,000 patients have been implanted with the RNS system.

Patients with the implanted RNS system typically also receive ASMs, and additional oral therapies may be prescribed to optimize treatment since many patients continue to have seizures after implantation of the device.

136

Two retrospective studies published in peer reviewed epilepsy journals have demonstrated that when new ASMs are added to an RNS system patient’s treatment regimen, LE changes detected by the RNS system within one to four weeks of new ASM treatment initiation are predictive of long-term clinical response (i.e., a clinically meaningful reduction in focal seizures) to the new ASM. In addition, other iEEG measures obtained from the RNS system have also been shown to be predictive of clinical response, such as spike frequency and spectral power, and will be used as secondary endpoints in this trial.

Testing RAP-219 in patients with the RNS system provides the opportunity to objectively quantify changes in LE frequency as a potential biomarker of efficacy. Because LEs have been shown to provide an early and objective indicator of clinical response to an ASM, and because the population of patients with the RNS system is representative of the refractory focal epilepsy population that will be the focus of future registrational trials, quantifying LEs after the addition of RAP-219 may provide a clearer perspective on the potential of RAP-219 to provide clinical benefit in future focal epilepsy trials. We intend to enroll patients who have been treated with an RNS system for at least 15 months, have stable device configuration settings, stimulation and detection settings (including LE duration) for at least eight weeks before screening and continue to have seizures while also on a stable ASM regimen. Due to an increasing number of patients in the United States implanted with an RNS system for their focal epilepsy, the support from NeuroPace in identifying patients eligible for our Phase 2a proof-of-concept trial and RAP-219’s minimal drug-drug interactions observed to date, we expect enrollment in this Phase 2a proof-of-concept trial will be completed in mid 2024 and, if the trial is positive, would provide translatable proof-of-concept for RAP-219.

The RNS proof-of-concept protocol was chosen after discussions with key opinion leaders, consultants, and clinical advisory boards, and it was determined that it provided the best chance of translatability to registrational trial outcomes in focal epilepsy. We considered other clinical models commonly used in proof-of-concept studies in epilepsy. We considered the photosensitive epilepsy proof-of-concept model, where patients with known visually evoked epileptiform discharges are purposely provoked using a strobe light. We believe the photosensitivity model is sub-optimal because it is a single-dose study and its relevance to focal epilepsy is limited since photosensitive discharges are found in patients with generalized epilepsy. We also considered transcranial magnetic stimulation (“TMS”), where healthy volunteers are subjected to TMS and changes in TMS-evoked potentials are measured to assess cortical excitability. We believe the TMS model has limited relevance to focal epilepsy since it does not evaluate patients with epilepsy.

Assuming a successful outcome of our Phase 2a proof-of-concept clinical trial, we plan to discuss these results with the FDA and initiate registrational clinical trials to assess RAP-219 for the treatment of adults with focal epilepsy. We anticipate the design of these registrational trials and patient population to be studied will be similar to those conducted for other approved therapies and, if RAP-219 is eventually approved, that RAP-219’s indication will be similar to currently approved ASMs.

Opportunities to Expand the Potential for RAP-219 in Epilepsy

The ultimate goal of antiseizure therapy is complete freedom from seizures and improvement in patient quality of life. We believe that RAP-219 has the potential to significantly reduce or possibly eliminate focal epilepsy seizures while avoiding many of the common intolerable AEs associated with many approved ASMs. The differentiated target and mechanism of action of RAP-219 in combination with its neuroanatomical precision within the most common seizure onset-zones as demonstrated in preclinical models provides the opportunity for potentially superior clinical activity compared to currently approved ASMs. Certain patients who are refractory to treatment with other ASMs have been found to respond favorably to combination therapies, especially when rational polypharmacy is employed. We believe that the unique proposed mechanism of RAP-219 and its potential for reduced drug-drug interactions, if approved, would make it a drug of choice for rational polypharmacy by improving clinical benefit without changing drug levels of other ASMs.

We are also exploring the development of a long-acting injectable formulation of RAP-219 with the goal of reducing dosing frequency to once every one or two months, thereby helping to improve adherence. We envision

137

patients would first be stabilized on an oral dose of RAP-219 and then transitioned to the long-acting injectable formulation. For many patients, nonadherence to prescribed ASMs is a major issue in optimizing benefit from pharmacotherapy. This nonadherence rate can be up to approximately 50 percent. One study found that patients who were not adherent to their ASMs had less seizure control as compared with patients who were adherent. We believe that, in addition to the potential reduced side effect profile of RAP-219, its high potency and long half-life, each observed to date in our Phase 1 studies, provide additional opportunities to improve patient adherence. In addition, we believe the potential to dose RAP-219 once per day would be preferred by patients and should improve adherence. A long-acting formulation of RAP-219 has the potential to be the first long-acting injectable ASM. We intend to advance such a formulation into clinical development if and when we establish a tolerable and efficacious once-daily oral formulation.

Other Potential Clinical Applications for RAP-219 and TARPg8 Modulators

Many ASMs blunt excitatory neurotransmission in the CNS and some have been shown to provide clinical benefit in other indications, including neuropathic pain and psychiatric diseases. However, the same issues that are problematic in ASMs used to treat epilepsy, such as intolerable AEs and drug-drug interactions, are also present when treating these other indications. Because monotherapy also commonly fails in the treatment of neuropathic pain and psychiatric conditions, polypharmacy is a widespread practice. We believe that RAP-219, with its neuroanatomical specificity and potency, has the potential to provide a differentiated clinical profile in the treatment of peripheral neuropathic pain and bipolar disorder. In the second half of 2024, we intend to initiate a Phase 2a trial evaluating RAP-219 in patients with peripheral neuropathic pain, which may include painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia and idiopathic sensory polyneuropathy. Based on the results from this proof-of-concept trial, we expect to select one or more peripheral neuropathic pain conditions for subsequent development. For our Phase 2a trial in bipolar disorder, which we intend to initiate in 2025, we plan to evaluate RAP-219 in bipolar patients with acute mania.

Background of Neuropathic Pain and Peripheral Neuropathic Pain

Neuropathic pain is a chronic condition caused by dysfunctional or damaged nerves, classified either as peripheral or central, depending on whether the primary dysfunction or damage is in the peripheral nervous system or in the CNS. Neuropathic pain is a common condition estimated to affect up to 17 percent of the global population. Neuropathic pain is a large market, estimated at $6.6 billion globally in 2021 and forecasted to grow at over four percent annually. Peripheral neuropathic pain indications reflect large patient populations in the United States, including, for example, painful diabetic peripheral neuropathy at approximately 2.8 million, post-herpetic neuralgia at approximately 1.8 million and trigeminal neuralgia at approximately 1.0 million diagnosed patients.

It is generally accepted that peripheral neuropathic pain often begins with an injury to or dysfunction of a peripheral nerve resulting in abnormal, spontaneous activity, known as ectopic discharges, akin to epileptic activity in the brain, that results in abnormal spontaneous pain and abnormal painful and uncomfortable sensations. The ectopic discharges from peripheral nerves travel to the dorsal horn of the spinal cord and then to the brain and can cause sensitization and hyperexcitability in both the spinal cord and the brain. It is hypothesized that inflammation associated with the injury also drives chronic stimulation of neurons, leading to prolonged sensations of pain. Although peripheral neuropathic pain may start with dysfunction or damage in the peripheral nervous system, aberrant signaling into the spinal cord generally progresses with functional chronic changes to the CNS, both in the spinal cord and brain.

There is significant unmet need in the treatment of peripheral neuropathic pain, with most available treatments only having moderate efficacy and all having side effects that limit their use. First-line therapy with gabapentin or pregabalin is associated with lethargy, vertigo, cognitive issues and peripheral swelling. Opioid analgesics are typically not efficacious in peripheral neuropathic pain and are associated with nausea, lethargy, cognitive slowing and constipation. Opiates also have abuse potential that limits widespread use. Nonsteroidal

138

anti-inflammatory drugs are often prescribed but rarely have meaningful efficacy and are associated with gastrointestinal, renal and cardiovascular AEs.

Evidence for the Importance of AMPAR and TARPg8 in Pain

TARPg8 is expressed in areas of the CNS associated with pain including the anterior cingulate cortex and the dorsal horn of the spinal cord. It is hypothesized that the anterior cingulate cortex registers the affective aspect of pain while the dorsal horn processes nociceptive inputs from peripheral nerves. TARPg8 inhibition has demonstrated preclinical activity in third-party pain models. For instance, a TARPg8 AMPAR selective inhibitor, LY3130481, was found by third-party researchers to suppress excitatory synaptic transmission in pain pathways and significantly reduce pain-related behaviors in mouse models of neuropathic and inflammatory pain without impairing motor function. This study also reported that the magnitude of improved pain behavioral effects were positively correlated with occupancy of TARPg8 containing AMPARs in the CNS and were lost in TARPg8 knock-out mice, supporting the dependence of the antinociceptive action of LY3130481 on TARPg8.

Our preclinical studies with RTX-1738 have demonstrated pain behavior improvements in animal models of acute, inflammatory and neuropathic pain. For example, in the rat formalin induced pain model, we observed that RTX-1738 administered 60 minutes before formalin attenuated nocifensive behavior during both phase 1 (acute pain, 0-10 minutes after formalin injection) and phase 2 (persistent pain, 20-60 minutes after formalin injection). In another study, RTX-1738 showed attenuation of tactile allodynia in the spinal nerve ligation (“SNL”) rat model of neuropathic pain. In this test, RTX-1738 was administered daily 7 days after nerve ligation, and pain behavior was assessed 90 minutes post-dose. Starting at day 16 after surgery, which corresponds to day three of dosing with RTX-1738, paw withdrawal threshold was elevated, reflecting a decrease in pain behavior.

In addition, there has been encouraging evidence from prior clinical trials of perampanel in neuropathic pain associated with diabetic neuropathy and post-herpetic neuralgia. While the randomized placebo-controlled studies failed to show a significant reduction in pain scores, subjects that tolerated perampanel reported moderate but meaningful pain relief in the subsequent open-label study. We believe that the trial’s failure to show reduction in pain in the overall population was likely driven by perampanel’s intolerable AEs. We intend to initiate a Phase 2a trial of RAP-219 in peripheral neuropathic pain in the second half of 2024.

Bipolar Disorder Background and TARPg8 as a Potential Treatment

Bipolar disorder, commonly referred to as manic-depressive illness, is characterized by extreme shifts in mood. Individuals with bipolar disorder have manic episodes characterized by intense feelings of over-excitement, irritability, impulsivity, grandiose beliefs and racing thoughts. Individuals may then experience symptoms of depression, including feelings of tiredness, hopelessness, sadness, distraction and thoughts of suicide. Some people experience both manic and depressive symptoms in a single “mixed” episode. Severe bipolar disorder can be associated with hallucinations or delusions, which are symptoms of psychosis.

Bipolar disorder affects 2.8 percent of the adult population in the United States, or approximately 7.2 million adults. The global bipolar disorder market was approximately $1.4 billion in 2022, and sales are expected to grow to over $4 billion by 2028. Bipolar disorder is often treated with antipsychotic medications as a monotherapy or in combination with mood stabilizers. The side effects and safety risks associated with antipsychotic drugs in patients with bipolar disorder include dizziness, sedation, weight gain, movement disorders and agitation.

We believe that RAP-219 has the potential to provide a clinical benefit to patients with bipolar disorder for multiple reasons. First, there are several ASMs, including valproate, lamotrigine, and carbamazepine, that have shown clinical benefit in epilepsy and bipolar disorder and are FDA approved for both indications. The corneal kindling model of epilepsy is also believed by some experts to be predictive of bipolar treatments. Second, third-party functional neuro-imaging studies in patients with bipolar disorder typically show that the hippocampus, a

139

brain region where TARPg8 is expressed, exhibits abnormal activation and hyperactivity as well as elevated responses to emotional stimuli, attentional activities and memory tasks. Finally, a third-party genome-wide association study of 40,000 patients with bipolar disorder reported that bipolar disorder risk alleles were enriched in genes in synaptic signaling pathways and brain-expressed genes, particularly those with high specificity of expression in neurons of the prefrontal cortex and hippocampus. We believe that by selective targeting TARPg8 and blunting abnormal hippocampal activity, RAP-219 may normalize these responses and thereby improve the symptoms of bipolar disorder.

In addition, we intend to conduct a second MAD trial of RAP-219 to assess dosing regimens that may enable reaching therapeutic exposure more quickly than in our first MAD trial. We believe more rapidly reaching therapeutic exposures is important for the treatment of acute mania in bipolar disorder patients, as clinical response is generally expected by such patients within a week or two. Based upon results from our second MAD trial, we will determine the dosing paradigm for our Phase 2a trial in bipolar disorder, which we plan to initiate in 2025, which will evaluate RAP-219 in patients with acute mania.

Phase 1 RAP-219 PET Trial

Concurrent with our Phase 2a proof-of-concept trial in patients with drug-resistant focal epilepsy, we are planning to initiate a Phase 1 human positron emission tomography (“PET”) trial in healthy adult volunteers. The PET trial will utilize a companion PET radiotracer to confirm brain target receptor occupancy across a range of RAP-219 dosing and exposure levels. This PET trial will be conducted in Belgium at a site experienced with the radiotracer. This trial will initiate in mid 2024, with PET results expected in the first half of 2025.

Our nAChR Programs

We have a portfolio of discovery projects that leverage RAPs for ion channel targets that we believe have potential for generating product candidates, namely the neuronal nAChRs. Neuronal nAChRs are transmembrane ligand-gated ion channels composed of five subunits from a set of 11 a or b types in the human genome. Upon binding to acetylcholine, the nAChR ion channel opens to allow cations to permeate the cell. nAChRs are expressed throughout the CNS as well as the periphery. They have critical roles in diverse aspects of neuronal signaling in the CNS and in the autonomic nervous system. We are optimizing these molecules in anticipation of selecting candidates to advance into the clinic.

Our a6 nAChR Program

We are developing agonists and PAMs of the a6 nAChR for the treatment of chronic pain, which may include neuropathic pain, inflammatory pain and nociceptive pain. Pan-nAChR agonists have been shown to significantly reduce pain in third-party clinical trials, but these agonists were associated with side effects that have limited their development potential. We believe that our RAP platform technology, which allows identification of agonists and PAMs that are selective for a6 nAChR, has the potential enable the discovery of molecules with clinical activity in pain and improved tolerability.

a6 nAChR as a Potential Target for the Treatment of Chronic Pain

Nicotine and certain nAChR agonists have analgesic properties, but their development for chronic pain has been unsuccessful. Epibatidine, a naturally occurring compound, is a pan-nAChR agonist with high affinity for a4b2 and a3b4 nAChRs, the most widely expressed subtypes in the mammalian nervous system. Epibatidine has potent analgesic properties. However, it is associated with toxic side effects that have precluded its development. ABT-594, an investigational third-party pan-nAChR agonist, demonstrated significant improvements in patients with diabetic neuropathic pain in a Phase 2 randomized placebo-controlled study, but up to 66 percent of patients withdrew from the trial due to AEs such as nausea, dizziness, vomiting, abnormal dreams and asthenia (weakness

140

or lack of energy). Following these results, further development of ABT-594 was discontinued. There are currently no approved drugs for pain that specifically target nAChRs.

Third-party animal and human studies have implicated the a6 nAChR as a potential target for chronic pain. This nAChR subtype is enriched in sensory neurons of dorsal root ganglia (“DRG”), and a6 nAChR activity is associated with reduced pain. Mouse strains with increased levels of a6 in DRG showed reduced pain in a spared nerve injury (“SNI”) model of neuropathic pain. Conversely, complete inactivation of the gene for a6 in mice blocked the analgesic effects of nicotinic compounds. In humans, genetic variants with reduced a6 nAChR activity showed increased levels of postoperative pain.

Although the potential for selective a6 agonists as a therapeutic agent for pain have been acknowledged, discovery efforts have been hampered by difficulty in establishing functional assays for a6 containing nAChRs in cell lines. Recombinant a6 does not assemble into functional multi-subunit nAChRs; therefore, its activity could not be measured in cell lines used for drug discovery. Our Chief Scientific Officer, Dr. Bredt, and his colleagues, overcame this impediment through the identification of RAPs, which serve as chaperones and auxiliary subunits that drive the assembly of functional a6-containing nAChRs. This enabled us to functionally express a6 nAChR and ultimately discover a series of a6 selective PAMs and agonists. We believe that these a6 selective nAChR PAMs and agonists have the potential to alleviate chronic pain while avoiding the AEs that have precluded human development in earlier non-selective nAChRs agonists.

Preclinical Validation of Our Approach

Based on preclinical results, we plan to advance our discovery-stage a6 nAChR program into further development. Janssen conducted high-throughput screen of cells engineered to express a6 nAChRs and identified PAMs that were selective for this nAChR subtype. These PAMs were further characterized in patch clamp assays where they were shown to be selective modulators of a6b4 compared to nAChRs that did not contain the a6 subunit, including the more ubiquitously expressed a4b2 and a3b4 nAChRs. One of these PAMs, RTX-2621, was a potent potentiator of a6b4 and had low activity on a4b2 and a3b4 nAChR subtypes.

We tested RTX-2621 in the rat SNI model for neuropathic pain. In this model, damage to the sciatic nerve results in hypersensitivity of the rat paw to stimuli. This is generally recognized to be a robust model of neuropathic pain, as it replicates many of the neuronal signaling changes and physiological responses observed in humans. It was observed that treatment with RTX-2621 mitigated this hypersensitivity. We believe this demonstrates the potential for a6 to be a therapeutic target in chronic pain.

Our a9a10 nAChR Program

Another program of our interest involves the a9a10 nAChR. We are developing an agonist to the a9a10 nAChR for the treatment of hearing disorders, which may include age-related hearing loss, acoustic trauma and tinnitus, as well as vestibular disorders. Third-party genetic studies in mice have shown that augmenting the a9 nAChR pathway can help prevent hearing loss associated with aging, acoustic trauma and vestibular disorders. Despite this genetic validation, discovery of selective a9a10 nAChR agonists has been challenging because recombinant nAChRs containing a9a10 in cell lines fail to create a functional receptor, as observed with the a6 nAChRs. Our ability to identify agonists that are selective for a9a10 nAChR was made possible by the application of our RAP platform technology. We are currently developing an oral therapeutic targeting the a9a10 nAChR, which we believe has a high potential target for the treatment of hearing disorders. We also believe the a9a10 nAChR is a potential target for the treatment of vestibular disorders, and we may develop an oral product candidate for this indication in the future.

Background to Hearing Disorders

Hearing disorders impact a large percentage of the population. For example, approximately one third of people aged 65 to 74 and nearly half aged 75 and older have age-related hearing loss. Acoustic trauma effects

141

approximately five percent of the global population, and surveys estimate that 10 to 25 percent of adults in the United States have tinnitus. Many hearing disorder patients start their treatment by using a hearing aid, with cochlear implantation given to the most severely affected patients. Despite this high prevalence, there are few pharmacotherapeutic treatments to prevent or reverse hearing disorders.

a9a10 nAChR as a Potential Target for the Treatment of Hearing Disorders

In the inner ear, the cochlea converts mechanical sound vibrations into nerve signals, which are transmitted to the brain. Sound vibrations are detected by a combination of outer hair cells, which amplify sound, and inner hair cells (“IHCs”), which receive the amplified sound signals. The IHCs, in turn, translate the incoming signals into release of neurotransmitters, which traverse the synapse to stimulate neurons that send electrochemical signals to the brain. One of the key receptors in this process is the a9a10 nAChR, which is highly enriched in cochlear hair cells.

The role of the a9a10 nAChR in hearing loss has been demonstrated by third-party genetic experiments. Gain and loss of function mutations to the gene encoding a9 demonstrated its role in experimentally induced hearing loss. In these experiments, the thresholds to elicit auditory brain stem responses (“ABR”) to various frequencies of sound were found to be elevated one day after auditory trauma, consistent with hearing loss. In wild-type mice, this effect of auditory trauma was temporary and after seven days, the ABR profile was similar to that observed prior to the insult. In mice with a null mutation of the gene encoding a9, the ABR threshold was increased at day one, and this increase persisted at day seven, demonstrating increased vulnerability to hearing loss. By contrast, mice with a gain-of-function mutation in the gene for a9 were protected from any significant change in ABR on either day one or day seven.

We believe that a selective agonist of a9a10 nAChR may help treat hearing disorders while avoiding many of the side effects that have limited the clinical application of other nAChR modulators.

Preclinical Validation of Our Approach

In vitro studies of a9a10 nAChR physiology have been challenging because this receptor could not be functionally expressed in recombinant cell lines in the absence of it RAPs. Through a genome-wide screen using our discovery platform, RAPs that drive the assembly of functional a9a10 nAChRs were identified by Janssen. Expression of these RAPs along with the a9 and a10 subunits enabled functional a9a10 nAChR expression in cell lines that we believe are suitable for drug discovery.

Janssen conducted a high throughput screen of cells engineered to express a9a10 nAChR and identified a number of small molecule agonists of a9a10. Through our medicinal chemistry efforts, a9a10 agonists with low nanomolar potency, inner ear penetration and high selectivity against other nAChR family members have been identified and are being optimized. The use of these orally administered molecules in physiological hearing models may demonstrate the potential of a9a10 agonists to address hearing disorders.

Manufacturing and Supply

We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We have engaged, and expect to continue to rely on, well-established third-party contract manufacturing organizations (“CMOs”) to supply our product candidates for use in our preclinical studies and clinical trials. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, analytical, and quality experience to oversee contract manufacturing and testing activities, and to compile manufacturing and quality information for our regulatory submissions. We believe our current manufacturers have the scale, systems, and experience to supply our currently planned clinical trials.

Additionally, we intend to rely on third-party CMOs for later-stage development and commercial manufacturing, if our product candidates receive marketing approval. As our lead product candidates advance

142

through clinical development, we expect to enter into longer-term commercial supply agreements to fulfill and secure our production needs. While the drug substances used in our product candidates are manufactured by more than one supplier, the number of manufacturers is limited. In the event it is necessary or advisable to acquire supplies from an alternative supplier, we might not be able to obtain them on commercially reasonable terms, if at all. It could also require significant time and expense to redesign our manufacturing processes to work with another company. If we need to change manufacturers during the clinical or development stage for product candidates or after commercialization for our product candidates, if approved, the FDA and corresponding foreign regulatory agencies must approve these new manufacturers in advance, which will involve testing and additional inspections to ensure compliance with FDA regulations and standards and may require significant lead times and delay.

To adequately meet our projected commercial manufacturing needs, our CMOs will need to scale-up production, or we will need to secure additional suppliers. Processes for producing drug substances and drug product for commercial supply are currently being developed, with the goal of achieving reliable, reproducible, and cost-effective production. We believe the drug substance and drug product processes for our current product candidates can be appropriately scaled.

Competition

The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe our product candidates, platform, knowledge, experience and scientific personnel provide us with competitive advantages, we face potential competition from many different sources, including large and small pharmaceutical and biotechnology companies, academic institutions and governmental agencies as well as public and private research institutions. Any product candidates that we successfully develop and commercialize, including RAP-219, may compete with existing therapies and new therapies that may become available in the future.

Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of competitors. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.

The key competitive factors affecting the success of RAP-219, and any other product candidates that we develop to address focal epilepsy and other CNS disorders, if approved, are likely to be efficacy, safety, convenience, price, the level of generic competition and the availability of reimbursement from government and other third-party payors.

Focal Epilepsy

In the field of focal epilepsy, we face competition from a variety of currently marketed therapies such as generic anticonvulsants, ASMs, sodium channel modulators and benzodiazepines, as well as surgical options such as deep brain stimulation like the RNS system in patients who have failed polypharmacy. RAP-219 may face competition from a variety of ASMs, including currently marketed therapies such as XCOPRI (cenobamate), which was developed by SK Life Science Inc. and approved by the FDA in November 2019 and FYCOMPA (perampanel), which was developed by Eisai Co. Ltd. and approved by the FDA in 2012. Our competition for RAP-219 may also include therapies in clinical development, such as XEN1101 being developed by Xenon Pharmaceuticals Inc., BHV-7000 being developed by Biohaven Ltd. (“Biohaven”), PRAX-628 being developed by Praxis Precision Medicines, Inc., darigabet being developed by Cerevel Therapeutics Holdings, Inc., ES-481

143

being developed by ES Therapeutics Australia Pty Ltd., SPN-817 being developed by Supernus Pharmaceuticals, Inc. and ADX71149 being developed by Addex Therapeutics Ltd. in partnership with Janssen Pharmaceuticals, Inc.

Peripheral Neuropathic Pain

In the field of peripheral neuropathic pain, our principal competition is from existing therapies, which include antidepressants (e.g., duloxetine, venlafaxine, amitriptyline and other tricyclic drugs), gabapentinoids (e.g., gabapentin, pregabalin), or opioids (e.g., tapentadol hydrochloride). We are also aware that various therapies are used off-label to treat peripheral neuropathic pain. Our competition may also include other programs in clinical development for the treatment of peripheral neuropathic pain, such as VX-548 being developed by Vertex, Inc., LX9211 being developed by Lexicon Pharmaceuticals, Inc. and BHV-2100 being developed by Biohaven.

Bipolar Disorder

In the field of bipolar disorder, RAP-219 faces competition from mood stabilizers (e.g. lithium and Lamictal) and antidepressants (e.g. selective serotonin reuptake inhibitors and serotonin and norepinephrine reuptake inhibitors). Our competition may also include other programs in clinical development for the treatment of mania in bipolar disorder, such as BHV-7000 being developed by Biohaven.

Intellectual Property

We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We may also rely on trademarks, copyrights and trade secrets relating to our proprietary technology platform and on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary and intellectual property position. We additionally may rely on regulatory and other protections afforded through data exclusivity, market exclusivity and patent term extensions, where available.

Our commercial success depends in part upon our ability to obtain and maintain patent and other proprietary protection for commercially important technologies, inventions and trade secrets related to our business, defend and enforce our intellectual property rights, particularly our patent rights, preserve the confidentiality of our trade secrets and operate without infringing valid and enforceable intellectual property rights of others.

The patent positions for biotechnology and pharmaceutical companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.

TARPg8 Program

We own six patent families directed to TARPg8 modulators. A first patent family is directed to compositions of matter of certain TARPg8 modulators, including RAP-219, and methods of use and expires in 2036, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. patent, one European patent, validated in 40 states, over 20 patents in various other foreign jurisdictions, one U.S. pending application, and over 15 applications pending in foreign jurisdictions. A second patent family is

144

directed to compositions of matter of certain TARPg8 modulators and methods of use and expires in 2037, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. patent. A third patent family is directed to compositions of matter of certain TARPg8 modulators and methods of use and expires in 2037, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. patent, one European patent, validated in eight states, over 10 patents in various other foreign jurisdictions, and two applications pending in foreign jurisdictions. A fourth patent family is directed to compositions of matter of certain TARPg8 modulators and methods of use and expires in 2037, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. patent, one European patent, validated in six states, more than 10 patents in various other foreign jurisdictions, and three applications pending in foreign jurisdictions. A fifth patent family is directed to crystalline forms of a TARPg8 modulator and methods of use and expires in 2045, if granted, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one pending priority application. A sixth patent family is directed to methods of use and oral doses of a TARPg8 modulator and expires in 2045, if granted, without taking a potential patent term extension into account.

nAChR Program

We have non-exclusively in-licensed from Janssen Pharmaceutica NV three patent families directed to recombinant cells for the expression of nACh receptors. A first patent family is directed to expression systems for the a9a10 nicotinic acetylcholine receptor and methods of use and expires in 2040, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. pending application and three applications pending in foreign jurisdictions. A second patent family is directed to expression systems for the a2a5b2 nicotinic acetylcholine receptor and methods of use and expires in 2042, if granted, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. pending application and multiple applications in foreign jurisdictions. A third patent family is directed to a6b4 nicotinic acetylcholine receptor and methods of use and expires in 2042, if granted, without taking a potential patent term extension into account. As of May 10, 2024, this patent family has one U.S. pending application and multiple applications in foreign jurisdictions.

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application.

In the United States, the term of a patent covering an FDA-approved drug may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended, and a given patent may only be extended once. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdictions where they are available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.

In addition to patent protection, we also rely on know-how and trade secret protection for our proprietary information to develop and maintain our proprietary position. However, trade secrets can be difficult to protect. Although we take steps to protect our proprietary information, including restricting access to our premises and our confidential information, as well as entering into agreements with our employees, consultants, advisors and potential collaborators, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our know-how, trade secrets, and other proprietary information.

145

In addition, we plan to rely on regulatory protection based on orphan drug exclusivities, data exclusivities, and market exclusivities. See the section titled “—Government Regulation” for additional information.

License and collaboration agreements

Option and License Agreement with Janssen Pharmaceutica NV

In August 2022, we entered into the Janssen License, as amended on April 3, 2023, April 18, 2023, May 2, 2023, October 2, 2023 and April 9, 2024, under which we received an exclusive option to obtain from Janssen (a) a worldwide exclusive license for the research, development, and commercialization of transmembrane TARPg8 AMPAR products for the diagnosis, treatment, prophylaxis or palliation of any disease or condition in humans or other animals (the “Field”) and (b) an assignment of certain patents related to TARPg8, in each case of (a)-(b), subject to certain retained rights by Janssen. Pursuant to the Janssen License, we also received a worldwide, royalty-free, non-exclusive license (exclusive under certain joint patents) for the research, development, and commercialization of certain neuronal nicotinic acetylcholine (“nACh”) products in the Field.

NeuroPace Master Services Agreement

In November 2023, we entered into a master services agreement (the “NeuroPace Agreement”) with NeuroPace, the manufacturer and distributor of the RNS system. Pursuant to the NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides us with certain services with respect to data from the RNS systems used in our clinical trials. The NeuroPace Agreement also grants us a royalty-free, worldwide, exclusive, non-transferable license to all data collected by the RNS systems in our Phase 2a clinical trial and the outcomes of algorithms that are applied to such data, as well as the ability to publish the outcomes of algorithms, subject to certain conditions. The consideration we will pay to NeuroPace for such services is set out in each statement of work agreement.

146

perform any services that are the same as the services covered by the NeuroPace Agreement to any business that directly competes with us, subject to the specific terms of the Agreement. The NeuroPace Agreement also contains standard representations and warranties, confidentiality and intellectual property protective provisions and indemnification terms.

Concurrently with the execution of the NeuroPace Agreement, the parties also entered into an initial statement of work (as amended, the “NeuroPace SOW”) under the NeuroPace Agreement, pursuant to which NeuroPace agreed to provide services related to our Phase 2a clinical trial of RAP-219, including, among other things, clinical trial readiness support, identification of potential patients satisfying the enrollment criteria and RNS system data reporting and data analysis. Pursuant to the payment schedule set out in the NeuroPace SOW, we will pay NeuroPace an aggregate of up to $3.7 million over a period of approximately two years in connection with NeuroPace’s provision of services and achievement of certain patient enrollment and deliverable milestones.

Government Regulation

Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, including the European Union (“EU”), extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining regulatory approvals in the United States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.

Review and Approval of Drugs in the United States

In the United States, the FDA regulates drugs under the U.S. Federal Food, Drug, and Cosmetic Act (“FDCA”) and its implementing regulations. The failure to comply with applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant and/or sponsor to a variety of administrative or judicial sanctions, including refusal by the FDA to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters and other types of letters, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA and the U.S. Department of Justice or other governmental entities. In addition, an applicant may need to recall a product.

An applicant seeking approval to market and distribute a new drug product in the United States must typically undertake the following:

•

completion of nonclinical, or preclinical, laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice (“GLP”) regulations;

•

submission to the FDA of an investigational new drug application (“IND”) which must take effect before human clinical trials may begin;

•

approval by an institutional review board (“IRB”) representing each clinical site before each clinical trial may be initiated at that site;

147

•

performance of adequate and well-controlled human clinical trials in accordance with good clinical practices (“GCPs”) to establish the safety and efficacy of the proposed drug product for each indication;

•

preparation and submission to the FDA of a New Drug Application (“NDA”) and payment of user fees;

•

review of the product by an FDA advisory committee, where appropriate or if applicable;

•

satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product, or components thereof, are produced to assess compliance with current Good Manufacturing Practices (“cGMP”) requirements and to assure that the facilities, methods and controls are adequate to preserve the product’s identity, strength, quality and purity;

•

satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;

•

FDA review and approval of the NDA; and

•

compliance with any post-approval requirements, including risk evaluation and mitigation strategies (“REMS”) and post-approval studies required by the FDA.

Preclinical Studies

Before an applicant begins testing a compound in humans, the drug candidate enters the preclinical testing stage. Preclinical studies include laboratory evaluation of the purity and stability of the manufactured drug substance or active pharmaceutical ingredient (“API”) and the formulated drug or drug product, as well as in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Some long-term preclinical testing, such as animal tests of reproductive adverse effects and carcinogenicity, may continue after the IND is submitted.

The IND and IRB Processes

An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational drug to humans. Such authorization must be secured prior to interstate shipment and administration of the investigational drug. In an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments. In addition, the results of the preclinical tests, manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time, the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. The FDA also may impose a clinical hold or partial clinical hold after commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation (or full investigation in the case of a partial clinical hold) may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.

A sponsor may choose, but is not required, to conduct a foreign clinical trial under an IND. When a foreign clinical trial is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical trial is not conducted under an IND, the sponsor must ensure that the study is conducted in accordance with GCP, including review and approval by an independent ethics committee (“IEC”) and informed consent from subjects. The GCP requirements are intended to help ensure the protection of human subjects

148

enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. FDA must also be able to validate the data from the study through an on-site inspection if necessary.

In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review of the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product candidate has been associated with unexpected serious harm to patients.

Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or competitive climate.

Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (“NIH”) for public dissemination on its ClinicalTrials.gov website.

Human Clinical Trials in Support of an NDA

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects, or their legal representative, provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

•

Phase 1. The drug is initially introduced into healthy human subjects or, in certain indications such as cancer, patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine maximal dosage.

•

Phase 2. The drug is administered to a limited patient population to identify possible AEs and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.

•

Phase 3. The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product and to provide adequate information for the labeling of the product.

Post-approval studies, often referred to as Phase 4 studies, may be conducted after initial regulatory approval. These studies are used to gain additional experience from the treatment of patients in the intended therapeutic indication.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA. In addition, within 15 calendar days after the sponsor determines that the information qualifies for reporting, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans

149

exposed to the drug; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor’s initial receipt of the information. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.

Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the applicant must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.

Review of an NDA by the FDA

Assuming successful completion of required clinical testing and other requirements, the results of the preclinical studies and clinical trials, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to a significant application user fee as well as annual prescription drug product program fees. These fees are typically increased annually. Certain exceptions and waivers are available for some of these fees.

The FDA conducts a preliminary review of an NDA within 60 days of its receipt, before accepting the NDA for filing, to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Applications for drugs containing new molecular entities are meant to be reviewed within 10 months from the date of filing, and applications for “priority review” products containing new molecular entities are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission.

During its review of an NDA, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA, including drug component manufacturing (such as APIs), finished drug product manufacturing, and control testing laboratories. The FDA will not approve an NDA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.

In addition, as a condition of approval, the FDA may require an applicant to develop a REMS. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential AEs, and whether the product is a new molecular entity. REMS can include medication guides, physician communication plans for healthcare professionals, and elements to assure safe use (“ETASU”). ETASU may include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries.

150

The FDA may require a REMS before approval or post-approval if it becomes aware of a serious risk associated with use of the product.

The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.

Fast Track, Breakthrough Therapy, and Priority Review

The FDA has a number of programs intended to facilitate and expedite development and review of new drugs if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. Three of these programs are referred to as Fast Track Designation, Breakthrough Therapy Designation, and priority review designation.

Specifically, the FDA may designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. However, the FDA’s time period goal for reviewing a Fast Track application does not begin until the last section of the application is submitted. In addition, the Fast Track Designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process.

Second, a product may be designated as a Breakthrough Therapy if it is intended, either alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The FDA may take certain actions with respect to Breakthrough Therapies, including holding meetings with the sponsor throughout the development process; providing timely advice to the product sponsor regarding development and approval; involving more senior staff in the review process; assigning a cross-disciplinary project lead for the review team; and taking other steps to design the clinical trials in an efficient manner.

Third, the FDA may designate an NDA review for a priority review if it is for a product that treats a serious or life-threatening disease or condition and, if approved, would provide a significant improvement in safety or effectiveness. The FDA determines, on a case-by-case basis, whether the proposed product represents a significant improvement when compared with other available therapies. Significant improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting product reaction, documented enhancement of patient compliance that may lead to improvement in serious outcomes, and evidence of safety and effectiveness in a new subpopulation. A priority designation is intended to direct overall attention and resources to the evaluation of such applications, and to shorten the FDA’s goal for taking action on a marketing application from 10 months to six months.

Accelerated Approval Pathway

The FDA may grant accelerated approval to a product for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on an

151

intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality (“IMM”), and that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Products granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a product, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a product.

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly.

The accelerated approval pathway is contingent on a sponsor’s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the product’s clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Under the Food and Drug Omnibus Reform Act of 2022 (“FDORA”), the FDA is now permitted to require, as appropriate, that such trials be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. Sponsors are also required to send updates to the FDA every 180 days on the status of such studies, including progress toward enrollment targets, and the FDA must promptly post this information publicly. Under FDORA, the FDA has increased authority for expedited procedures to withdraw approval of a drug or indication approved under accelerated approval if, for example, the sponsor fails to conduct such studies in a timely manner and send the necessary updates to the FDA, or if a confirmatory trial fails to verify the predicted clinical benefit of the product. In addition, the FDA generally requires, unless otherwise informed by the agency, pre-approval of promotional materials for product candidates approved under accelerated regulations, which could adversely impact the timing of the commercial launch of the product.

The FDA’s Decision on an NDA

On the basis of the FDA’s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities and select clinical trial sites, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If a complete response letter is issued, the applicant may resubmit the NDA to address all of the deficiencies identified in the letter, withdraw the application, or request a hearing. If the applicant resubmits the NDA, the FDA will issue an approval letter only when the deficiencies have been addressed to the FDA’s satisfaction. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.

If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s safety or effectiveness after approval,

152

require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.

Post-Approval Requirements

Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion, reporting of adverse experiences with the product and applicable product tracking and tracing requirements. After approval, many changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are annual prescription drug product program fee requirements for certain marketed products.

In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the NDA holder and any third-party manufacturers that the NDA holder may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance.

Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

•

restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or voluntary product recalls;

•

fines, warning or untitled letters or holds on post-approval clinical trials;

•

refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;

•

product seizure or detention, or refusal to permit the import or export of products; or

•

injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. However, companies may share truthful and not misleading information that is otherwise consistent with a product’s FDA approved labeling. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (“PDMA”), which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.

153

Hatch-Waxman Amendments

Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA’s prior findings of safety and efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an Abbreviated New Drug Application (“ANDA”). An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a previously approved product, known as a reference listed drug (“RLD”). ANDAs are termed “abbreviated” because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo, or other testing. The generic version must deliver the same amount of active ingredients into a subject’s bloodstream in the same amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug.

Non-Patent Exclusivity

Under the Hatch-Waxman Amendments, the FDA may not approve (or in some cases accept) an ANDA or 505(b)(2) application until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity (“NCE”). For the purposes of this provision, an NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, which states the proposed generic drug will not infringe one or more of the already approved product’s listed patents or that such patents are invalid or unenforceable, in which case the applicant may submit its application four years following the original product approval.

The FDCA also provides for a period of three years of exclusivity for non-NCE drugs if the NDA or a supplement to the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application or supplement. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication, but it generally would not protect the original, unmodified product from generic competition. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product; it only prevents FDA from approving such ANDAs.

A drug product can obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing exclusivity periods for all formulations, dosage forms, and indications of the active moiety and to patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection and patent term, may be granted based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study, provided that at the time pediatric exclusivity is granted there is not less than nine months of term remaining.

154

Hatch-Waxman Patent Certification and the 30-Month Stay

In seeking approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant’s product or an approved method of using the product. Upon approval, each of the patents listed by the NDA sponsor is published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Upon submission of an ANDA or 505(b)(2) NDA, an applicant is required to certify to the FDA concerning any patents listed for the RLD in the Orange Book that:

•

no patent information on the drug product that is the subject of the application has been submitted to the FDA;

•

such patent has expired;

•

the date on which such patent expires; or

•

such patent is invalid, unenforceable or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted.

Generally, the ANDA or 505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. If the ANDA or 505(b)(2) NDA applicant has provided a paragraph IV certification the applicant must send notice of the paragraph IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was favorably decided in the applicant’s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent certification the applicant makes and the reference drug sponsor’s decision to initiate patent litigation. If the drug has NCE exclusivity and the ANDA is submitted four years after approval, the 30-month stay is extended so that it expires seven and a half years after approval of the innovator drug, unless the patent expires or there is a decision in the infringement case that is favorable to the ANDA applicant before then.

Patent Term Restoration and Extension

A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments, which permits a patent term restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the ultimate approval date, provided the sponsor acted with diligence. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question and within 60 days of drug approval. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office (“USPTO”) reviews and approves the application for any patent term extension or restoration in consultation with the FDA.

155

Review and Approval of Medicinal Products in the European Union

In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, an applicant will need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. Specifically, the process governing approval of medicinal products in the EU generally follows similar lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires a submission to the relevant competent authorities of a marketing authorization application (“MAA”) and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU.

Clinical Trial Approval

In the EU, an applicant for authorization of a clinical trial must obtain prior approval from the national competent authority of the EU Member States in which the clinical trial is to be conducted. Furthermore, the applicant may only start a clinical trial at a specific study site after the relevant independent ethics committee has issued a favorable opinion. In April 2014, the Clinical Trials Regulation, (EU) No 536/2014 (the “Clinical Trials Regulation”) was adopted in the EU. The Clinical Trials Regulation is directly applicable in all the EU Member States and repealed the Clinical Trials Directive 2001/20/EC, as of January 31, 2022.

The Clinical Trials Regulation aims to simplify and streamline the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single entry point, known as the “Clinical Trials Information System”; a single set of documents to be prepared and submitted for the application, as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by an elected Reference Member State, with support of the competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted (the “Member States Concerned”). Part II is assessed separately by each Member State Concerned. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure continues to be governed by the national law of the concerned EU Member State, however, overall related timelines are defined by the Clinical Trials Regulation.

Marketing Authorization

To obtain a marketing authorization for a product in the EU, an applicant must submit an MAA either under a centralized procedure administered by the European Medicines Agency (“EMA”) or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure) for obtaining a marketing authorization in multiple EU Member States. A marketing authorization may be granted only to an applicant established in the European Economic Area (“EEA”) (which is comprised of the EU Member States plus Norway, Iceland and Liechtenstein).

The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid throughout the EEA. Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products (gene therapy, somatic cell therapy and tissue-engineered products) and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of HIV, AIDS, cancer, diabetes, neurodegenerative diseases, auto-immune and other immune dysfunctions and viral diseases. The centralized procedure is optional for products containing a new active substance not yet authorized in the EU, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.

156

Under the centralized procedure, the Committee for Medicinal Products for Human Use (“CHMP”) established at the EMA is responsible for conducting the initial assessment of a product. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from a public health perspective and in particular from the point of view of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days, excluding clock stops, but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 67 days from the date of the CHMP opinion, the European Commission will adopt its final decision on the MAA.

Now that the United Kingdom (which comprises Great Britain and Northern Ireland) (“UK”) has left the EU, Great Britain is no longer covered by centralized marketing authorizations (under the Northern Ireland Protocol, centralized marketing authorizations currently continue to be recognized in Northern Ireland). On January 1, 2024, a new international recognition framework was put in place by the Medicines and Healthcare products Regulatory Agency (“MHRA”), the UK medicines and medical devices regulator, under which the MHRA may have regard to decisions on the approval of marketing authorizations made by the EMA and certain other regulators when determining an application for the grant of a UK or Great Britain marketing authorization. The MHRA also has the power to have regard to marketing authorizations approved in EU Member States through decentralized or mutual recognition procedures with a view to more quickly granting a marketing authorization in the UK or Great Britain. For additional information related to the regulatory framework in the UK, please refer to the discussion below under the section titled “—Brexit and the Regulatory Framework in the United Kingdom.”

The decentralized marketing authorization procedure allows an applicant to apply for simultaneous authorization in more than one EU Member State of medicinal products that have not yet been authorized in any EU Member State and that do not fall within the mandatory scope of the centralized procedure. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The Reference Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the Concerned Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a Concerned Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all Member States.

The mutual recognition procedure is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of another EU Member State. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.

Pediatric Development

Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, applicants have to demonstrate compliance with all measures included in an EMA-approved Pediatric Investigation Plan (“PIP”) covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the

157

product for which a marketing authorization is being sought. Products that are granted a marketing authorization with the results of the pediatric clinical trials conducted in accordance with the PIP are eligible for a six-month extension of the protection under a supplementary protection certificate (“SPC”) provided an application for such extension is made at the same time as filing the SPC application for the product, or at any point up to two years before the SPC expires, even where the trial results are negative. In the case of orphan medicinal products, a two-year extension of the orphan market exclusivity may be available. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the PIP are developed and submitted.

Data and Market Exclusivity

In the EU, innovative medicinal products approved on the basis of a complete and independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity. Data exclusivity prevents applicants for authorization of generics or biosimilars of these innovative products from referencing the innovator’s preclinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar (abbreviated) marketing authorization, for a period of eight years from the date on which the reference product was first authorized in the EU. During an additional two-year period of market exclusivity, a generic or biosimilar MAA can be submitted, and the innovator’s data may be referenced, but no generic or biosimilar medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall 10-year period will be extended to a maximum of 11 years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. There is no guarantee that a product will be considered by the EMA to be an innovative medicinal product, and products may not qualify for data exclusivity. Even if a product is considered to be an innovative medicinal product so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained a marketing authorization based on an MAA with a complete and independent data package of pharmaceutical tests, preclinical tests and clinical trials.

Orphan Designation and Exclusivity

Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan medicinal product by the European Commission if its sponsor can establish that: (1) the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition, (2) either (i) such condition affects no more than five in ten thousand persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it is unlikely that the marketing of the product in the EU would generate sufficient return to justify the necessary investment in its development and (3) there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the product would be of significant benefit to those affected by that condition.

An orphan designation provides a number of benefits, including fee reductions, regulatory assistance and the possibility to apply for a centralized EU marketing authorization. Marketing authorization for an orphan medicinal product leads to a ten-year period of market exclusivity being granted following marketing approval of the orphan product. During this market exclusivity period, the EMA, the European Commission or the competent authorities of the EU Member States may only grant marketing authorization to a “similar medicinal product” for the same therapeutic indication if: (i) a second applicant can establish that its product, although similar to the authorized product, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder for the authorized product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product. A “similar medicinal product” is defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may, however, be reduced to

158

six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation because, for example, the product is sufficiently profitable not to justify market exclusivity. Orphan designation must be requested before submitting an application for marketing approval. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.

Periods of Authorization and Renewals

A marketing authorization has an initial validity of five years. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the relevant EU Member State for a nationally authorized product. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least nine months before the marketing authorization ceases to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent authorities of the relevant Member States decide, on justified grounds relating to pharmacovigilance, to proceed with one further five year renewal period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (for centrally-authorized products) or on the market of the authorizing EU Member State (for nationally-authorized products) within three years after authorization ceases to be valid (the so-called “sunset clause”).

Regulatory Requirements after a Marketing Authorization has been Obtained

Where an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include:

•

Compliance with the EU’s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations.

•

The manufacturing of authorized medicinal products, for which a separate manufacturer’s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive (EU) 2017/1572, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and APIs, including the manufacture of APIs outside of the EU with the intention to import the APIs into the EU.

•

The marketing and promotion of authorized products, including industry-sponsored continuing medical education and advertising directed toward the prescribers of products and/or the general public, are strictly regulated in the EU notably under Directive 2001/83/EC, as amended, and EU Member State laws.

The aforementioned EU rules are generally applicable in the EEA.

Reform of the Regulatory Framework in the European Union

The European Commission introduced legislative proposals in April 2023 that, if implemented, will replace the current regulatory framework in the EU for all medicines (including those for rare diseases and for children). The European Commission has provided the legislative proposals to the European Parliament and the European Council for their review and approval. In October 2023, the European Parliament published draft reports proposing amendments to the legislative proposals, which will be debated by the European Parliament. Once the European Commission’s legislative proposals are approved (with or without amendment), they will be adopted into EU law.

Brexit and the Regulatory Framework in the United Kingdom

The UK ceased being a Member State of the EU on January 31, 2020, and the EU and the UK have concluded a trade and cooperation agreement (“TCA”), which was provisionally applicable since January 1, 2021

159

and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not provide for wholesale mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented previous EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework continues to apply in Northern Ireland). Except in respect of the EU Clinical Trials Regulation, the regulatory regime in Great Britain therefore aligns in many ways with current EU medicines regulations, however it is possible that these regimes will diverge more significantly in the future now that Great Britain’s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. However, notwithstanding that there is no wholesale recognition of EU pharmaceutical legislation under the TCA, under a new international recognition framework which was put in place by the MHRA on January 1, 2024, the MHRA may take into account decisions on the approval of marketing authorizations from the EMA (and certain other regulators) when considering an application for a Great Britain or UK marketing authorization.

On February 27, 2023, the UK government and the European Commission announced a political agreement in principle to replace the Northern Ireland Protocol with a new set of arrangements, known as the “Windsor Framework.” This new framework fundamentally changes the existing system under the Northern Ireland Protocol, including with respect to the regulation of medicinal products in the UK. In particular, the MHRA will be responsible for approving all medicinal products destined for the UK market (i.e., Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. A single UK-wide marketing authorization will be granted by the MHRA for all medicinal products to be sold in the UK, enabling products to be sold in a single pack and under a single authorization throughout the UK. The Windsor Framework was approved by the EU-UK Joint Committee on March 24, 2023, so the UK government and the EU will enact legislative measures to bring it into law. On June 9, 2023, the MHRA announced that the medicines aspects of the Windsor Framework will apply from January 1, 2025.

Other Healthcare Laws

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. The laws that may affect our ability to operate include, but are not limited to:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations are subject to civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs;

•

federal civil and criminal false claims laws, including the False Claims Act (“FCA”), which can be enforced through civil “qui tam” or “whistleblower” actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent

160

claims. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;

•

the federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating these statutes without actual knowledge of the statutes or specific intent to violate them in order to have committed a violation;

•

HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”), imposes requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions;

•

Even when HIPAA does not apply, according to the Federal Trade Commission (“FTC”), failing to take appropriate steps to keep consumers’ personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C. § 45(a). The FTC expects a company’s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards;

•

the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “ACA”) and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program (with certain exceptions) to report annually to the Department of Health and Human Services (“HHS”) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed healthcare professionals (i.e., physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists, and certified nurse midwives), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;

•

federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;

•

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and

•

analogous state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales, and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor,

161

including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; and state and local laws requiring the registration of pharmaceutical sales representatives.

If our operations are found to be in violation of any of such laws or any other governmental regulations that apply, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations, exclusion from participation in federal and state healthcare programs and responsible individuals may be subject to imprisonment.

Privacy and Data Security

In the ordinary course of business, we process sensitive data Accordingly, we are, or may be become, subject to numerous privacy and data security obligations, including global, federal, state, and local laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements and other obligations related to privacy and data security.

These privacy and data security laws are evolving and may impose potentially conflicting obligations. Such obligations may include, without limitation, federal health information privacy laws, state information security and data breach notification laws, state health information privacy laws, and federal and state consumer protection laws (e.g., the Federal Trade Commission Act). In addition, in the past few years, numerous U.S. states have passed, or are in the process of enacting comprehensive privacy laws, rules, and regulations that impose certain obligations on covered businesses, and similar laws are being considered in several other states, as well as at the federal and state levels. While these states exempt some data processed in the context of clinical trials, these developments may further complicate compliance efforts, and are examples of the increasingly stringent and evolving regulatory frameworks related to personal data processing, as more fully discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

Additionally, to the extent we collect personal data from individuals outside of the United States, through clinical trials or otherwise, we are, or may become, subject to foreign data and data security laws, such as the European Union’s General Data Protection Regulation 2016/679 (“EU GDPR”) and other national data protection legislation in force in relevant EEA Member States, and the EU GDPR as it forms part UK law by virtue of section 3 of the European Union (Withdrawal) Act 2018 (“UK GDPR”). Foreign privacy and data security laws impose significant and complex compliance obligations on entities that are subject to those laws, as more fully discussed in the section titled “Risk Factors” included elsewhere in this prospectus.

Coverage and Reimbursement

In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate reimbursement levels for, the product. Factors payors consider in determining coverage and reimbursement are based on whether the product is:

•

a covered benefit under its health plan;

•

safe, effective and medically necessary;

•

appropriate for the specific patient;

162

•

cost-effective; and

•

neither experimental nor investigational.

In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost- effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.

In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a third-party payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor.

The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of products have been a focus in this effort. There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical products, limiting coverage and the amount of reimbursement for drugs and other medical products, government control and other changes to the healthcare system in the United States. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product candidate that we commercialize and, if reimbursement is available, the level of reimbursement. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price (“ASP”) and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any approved products. Even if we do receive a favorable coverage determination for approved products by third-party payors, coverage policies and third-party payor reimbursement rates may change at any time.

Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the U.S. Centers for Medicare & Medicaid Services (“CMS”) may develop new payment and delivery models, such as bundled payment models. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their commercial products, which has

163

resulted in several U.S. Congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Congress has indicated that it will continue to seek new legislative measures to control drug costs.

Outside the United States, ensuring coverage and adequate payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to government control in many countries. Pricing negotiations with government authorities can extend well beyond the receipt of regulatory approval for a product and may require a clinical trial that compares the cost-effectiveness of a product to other available therapies. The conduct of such a clinical trial could be expensive and result in delays in commercialization.

In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, the EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on healthcare costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.

Current and Future U.S. Healthcare Reform

In the U.S., there have been a number of legislative and regulatory changes to the healthcare system that could impact our ability to sell our products profitably. For example, in March 2010, the ACA was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA, among other things:

•

increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the average manufacturer price;

•

required collection of rebates for drugs paid by Medicaid managed care organizations;

•

required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 50 percent point-of-sale discount off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D (later increased to 70%); and

•

imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell “branded prescription drugs” to specified federal government programs.

Since its enactment, there have been judicial, administrative, executive, and legislative challenges to certain aspects of the ACA as well as executive orders related to the ACA’s implementation. For example, President

164

Biden has issued multiple executive orders that have sought to reduce prescription drug costs. In addition, on June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. It is unclear how other healthcare reform measures of the Biden administrations or other efforts, if any, to challenge repeal or replace the ACA, will impact our business.

There has been increasing legislative and enforcement interest in the United States with respect to drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, the Inflation Reduction Act of 2022 (“IRA”), among other things, (i) directs HHS to negotiate the price of certain high-expenditure, single-source drugs and biologics covered under Medicare, and subject drug manufacturers to civil monetary penalties and a potential excise tax by offering a price that is not equal to or less than the negotiated “maximum fair price” for such drugs and biologics under the law and (ii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation. The IRA permits HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years. These provisions take effect progressively starting in fiscal year 2023. On August 29, 2023, HHS announced the list of the first ten drugs that will be subject to price negotiations, although the Medicare drug price negotiation program is currently subject to legal challenges. It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry. Further, on December 7, 2023, the Biden administration announced an initiative to control the price of prescription drugs through the use of march-in rights under the Bayh-Dole Act. On December 8, 2023, the National Institute of Standards and Technology published for comment a Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights which for the first time includes the price of a product as one factor an agency can use when deciding to exercise march-in rights. While march-in rights have not previously been exercised, it is uncertain if that will continue under the new framework.

In 2020, FDA released its implementing regulations regarding section 804 Importation Programs under the Medicare Prescription Drug Improvement and Modernization Act of 2003. These regulations provide guidance for states to build and submit importation plans for certain drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for “best price” or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. On January 5, 2024, the FDA authorized Florida’s drug importation plan, the first in the country to be so-authorized. If broadly implemented, importation of drugs under this program from Canada may materially and adversely affect the price we receive for any of our product candidates.

Additionally, on December 2, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. The IRA delayed implementation of this rule to January 1, 2032.

Other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted:

•

The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year, and, due to subsequent legislative amendments to the statute, will remain in effect until 2032.

•

The U.S. American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several types of providers.

165

•

The American Rescue Plan Act of 2021 eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug’s average manufacturer price, for single source and innovator multiple source drugs, effective January 1, 2024. These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product candidate is prescribed or used.

•

The IRA also includes several other provisions that may impact our business to varying degrees, including provisions that create a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, and impose new manufacturer financial liability on all drugs in Medicare Part D.

Individual states have also been increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. We expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration, any of which could limit the amounts that federal and state governments will pay for healthcare products and services.

Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.

Facilities

Our corporate headquarters are located in Boston, Massachusetts, where we lease and occupy approximately 11,000 square feet of office space. Our Boston lease expires in December 2026. We also lease and occupy approximately 10,000 square feet of office and laboratory space in San Diego, California. We will continue to lease this space in San Diego until the commencement of our lease of a larger space in San Diego, comprised of approximately 21,000 square feet of office and laboratory space, which is expected to commence in December 2024 and will expire in December 2029.

We believe our existing facilities in Boston and San Diego are sufficient for our needs for the foreseeable future. To meet the future needs of our business, we may lease additional or alternate space, and we believe suitable additional or alternative space will be available in the future on commercially reasonable terms.

Employees and human capital resources

As of May 10, 2024, we had 58 full-time employees and 61 consultants, and approximately 17 of our employees have M.D. or Ph.D. degrees. Within our workforce, 39 employees are engaged in research and development and 19 are engaged in business development, finance, legal, and general management and administration. Our human capital resources objectives include identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. None of our employees are represented by a labor union or covered by a collective bargaining agreement. We consider our relationship with our employees to be good.

Legal proceedings

From time to time, we may become involved in litigation or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

166

MANAGEMENT

Executive Officers and Directors

The following table sets forth information regarding our executive officers and directors as of May 10, 2024:


Name	Age		Position
Executive Officers:
Abraham N. Ceesay, M.B.A.		46	Chief Executive Officer and Director
Troy Ignelzi		56	Chief Financial Officer
David Bredt, M.D., Ph.D.⁽⁴⁾		59	Chief Scientific Officer and Director
Bradley S. Galer, M.D.		62	Chief Medical Officer
Cheryl Gault		45	Chief Operating Officer
Swamy Yeleswaram, Ph.D.		61	Chief Development Officer

Non-Employee Directors:
Steven M. Paul, M.D.		73	Director and Chairman
Terry-Ann Burrell, M.B.A.		47	Director
James I. Healy, M.D., Ph.D.		59	Director
Reid Huber, Ph.D.		52	Director
Raymond Kelleher, M.D., Ph.D.⁽⁴⁾		59	Director
John Maraganore, Ph.D.		61	Director
Jeffrey K. Tong, Ph.D.		49	Director

(1)	Member of the compensation committee.

(2)	Member of the nominating and corporate governance committee.

(3)	Member of the audit committee.

(4)	Dr. Bredt and Dr. Kelleher have each notified us that they will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.

Executive Officers

Abraham N. Ceesay, M.B.A. Mr. Ceesay has served as our President and Chief Executive Officer since February 2023 and has been a member of our board of directors since March 2023. Prior to joining us, from April 2021 to March 2023, Mr. Ceesay served as President of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE). Mr. Ceesay served as the Chief Executive Officer at Tiburio Therapeutics Inc. from January 2019 to April 2021. Mr. Ceesay has served on the board of directors of Pacira Biosciences, Inc. (Nasdaq: PCRX) since October 2023. Mr. Ceesay also currently serves as Chairman of the Board for Life Science Cares and on the Board of Trustees at The Museum of Science in Boston, Massachusetts. Mr. Ceesay received a Bachelor of Science degree from Ithaca College and a Master of Business Administration degree from Suffolk University’s Sawyer School of Management. We believe Mr. Ceesay is qualified to serve as a member of our board of directors because of his prior experiences serving as an officer and director in, and his extensive knowledge of, the biopharmaceutical industry.

Troy Ignelzi. Mr. Ignelzi has served as our Chief Financial Officer since November 2023. Prior to joining us, from March 2019 to September 2023, Mr. Ignelzi served as Chief Financial Officer at Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers Squibb Company). Mr. Ignelzi has served on the boards of directors of Contineum Therapeutics, Inc. (Nasdaq: CTNM) since May 2024, Vedanta Biosciences, Inc. since November 2020, and Abivax S.A. (Nasdaq: ABVX) since July 2023. Mr. Ignelzi has also served as an advisor to Sofinnova Investments, Inc. since March 2024. Mr. Ignelzi previously served on the board of directors of CinCor Pharma, Inc. (Nasdaq: CINC, prior to its recent acquisition by AstraZeneca PLC) from March 2021 to February 2023. Mr. Ignelzi received a Bachelor of Science degree in accounting from Ferris State University.

167

David Bredt, M.D., Ph.D. Dr. Bredt has served as our Chief Scientific Officer since January 2023 and a member of our board of directors since December 2022. Prior to joining us, from February 2022 to December 2022, Dr. Bredt served as an Entrepreneur in Residence at Third Rock Ventures LLC (“Third Rock”). From March 2021 to August 2021, Dr. Bredt served as Executive Partner at MPM Capital LLC. From March 2011 to March 2021, Dr. Bredt served as Global Head of Neuroscience Discovery at Janssen Global Services, LLC, a wholly-owned subsidiary of Johnson & Johnson Services, Inc. (NYSE: JNJ) (“J&J Services”). Dr. Bredt has served on the Neuroscience Forum, Institute of Medicine for National Academy of Sciences, and the Advisory Panel for the National Institute of Neurological Disorders and Stroke. Dr. Bredt received a Bachelor of Arts degree in chemistry from Princeton University, a Doctor of Philosophy degree from the Johns Hopkins School of Medicine and a Doctor of Medicine degree from the Johns Hopkins School of Medicine. We believe that Dr. Bredt is qualified to serve on our board of directors due to his extensive expertise in neuroscience.

Dr. Bredt has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Dr. Bredt’s resignation is in accordance with Section 2.2(g) of our Amended and Restated Stockholders Agreement, dated April 7, 2023, and not due to any disagreement with us or any matters relating to our operations, policies or practices. Following his resignation from our board of directors, Dr. Bredt will continue to serve as our Chief Scientific Officer.

Bradley S. Galer, M.D. Dr. Galer has served as our Chief Medical Officer since January 2023. Prior to joining us, Dr. Galer served as Executive Vice President and Chief Medical Officer at Zogenix, Inc. from December 2013 to April 2022. Early in his career, Dr. Galer served as an Assistant Professor at the University of Washington School of Medicine and an Associate Professor at Albert Einstein School of Medicine. Dr. Galer had pain fellowships at Memorial Sloane-Kettering in New York and University of California, San Francisco, as well as headache training at Montefiore Headache Clinic in New York and University of California, San Francisco. Dr. Galer has a Bachelor of Arts degree in biology-psychology (with a focus in neuroscience) from Wesleyan University. He received his Doctor of Medicine from Albert Einstein College of Medicine in New York where he also completed his neurology residency and was appointed Chief Resident.

Cheryl Gault. Ms. Gault has served as our Chief Operating Officer since September 2023. Prior to joining us, Ms. Gault was employed by Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) from April 2019 to July 2023, where she held various positions of increasing responsibility, including Vice President of Head of Strategy from April 2019 to May 2020, Senior Vice President of Strategy and Corporate Development from May 2020 to January 2021, and most recently, Chief Operating Officer from January 2021 to July 2023. From February 2017 to April 2019, Ms. Gault served as Vice President of Commercial Strategy & New Product Planning at Ironwood. Ms. Gault received a Bachelor of Science degree in marketing from Boston College.

Swamy Yeleswaram, Ph.D. Dr. Yeleswaram has served as our Chief Development Officer since January 2023. Prior to joining us, from August 2022 to December 2022, Dr. Yeleswaram served as an Entrepreneur in Residence at Third Rock. Prior to this, Dr. Yeleswaram was a founding scientist at Incyte Corporation (Nasdaq: INCY), where he held positions of increasing responsibility from January 2002 to July 2022, most recently as Group Vice President of Drug Metabolism, Pharmacokinetics, and Clinical Pharmacology from February 2016 to August 2022. Dr. Yeleswaram received a Bachelor Degree in pharmacy from Madras Medical College, a Master’s Degree in pharmaceutical sciences from Banaras Hindu University and a Doctor of Philosophy degree in pharmaceutical sciences from the University of British Columbia.

Non-Executive Directors

Steven M. Paul, M.D. Dr. Paul has been a member and chairman of our board of directors since December 2022. From August 2018 to January 2024, Dr. Paul served in senior leadership roles at Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers Squibb Company), including as Chief Scientific Officer and President of Research and Development from January 2023 to January 2024, and President, Chief Executive Officer and Chairman of the board of directors from August 2018 to January 2023. Dr. Paul has also

168

served as a Venture Partner at Third Rock since 2010. Dr. Paul is also board certified by the American Board of Psychiatry and Neurology. Dr. Paul has served on the board of directors of Sage Therapeutics, Inc. (Nasdaq: SAGE) since September 2011 and is also the chairman of the board of the Foundation for the National Institutes of Health. Previously, Dr. Paul served on the boards of directors of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) from September 2010 to April 2022, Voyager Therapeutics, Inc. (Nasdaq: VYGR) from September 2014 to June 2022 and Karuna Therapeutics, Inc. from March 2018 to March 2024. Dr. Paul also previously spent 17 years at Eli Lilly and Company (NYSE: LLY), during which time he held several leadership roles, including Executive Vice President for Science and Technology, and President of the Lilly Research Laboratories. Dr. Paul received a Bachelor of Arts degree in biology and psychology from Tulane University and Master of Science and Doctor of Medicine degrees from the Tulane University School of Medicine. We believe that Dr. Paul is qualified to serve on our board of directors due to his numerous leadership roles in the pharmaceutical and biotechnology industry and his expertise in neuroscience.

Terry-Ann Burrell, M.B.A. Ms. Burrell has been a member of our board of directors since January 2024. Since August 2019, Ms. Burrell has served as the Chief Financial Officer and Treasurer of Beam Therapeutics Inc. (Nasdaq: BEAM). Prior to this, from May 2008 to August 2019, Ms. Burrell worked at J.P. Morgan Chase & Co., most recently as a Managing Director in the healthcare investment banking group from May 2018 to August 2019. Since April 2020, Ms. Burrell has served on the board of directors of Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX). Ms. Burrell received a Bachelor of Arts degree in social studies from Harvard University and a Master of Business Administration degree from New York University Leonard N. Stern School of Business. We believe Ms. Burrell is qualified to serve on our board of directors because of her broad range of financial expertise and her senior management experience in the biotechnology and pharmaceutical industries.

James I. Healy, M.D., Ph.D. Dr. Healy has been a member of our board of directors since August 2023. Dr. Healy has served as Managing Partner of Sofinnova Investments, Inc. since June 2000. Dr. Healy has served on the boards of directors of ArriVent Biopharma, Inc. (Nasdaq: AVBP) since March 2023, Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) since January 2021, Natera, Inc. (Nasdaq: NTRA) since November 2014, and Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) since November 2017. Previously, Dr. Healy served on numerous public company boards of directors including Ascendis Pharma A/S (Nasdaq: ASND) from November 2014 to May 2022, Amarin Corporation PLC (Nasdaq: AMRN) from May 2008 to December 2016, CinCor Pharma, Inc. (Nasdaq: CINC, prior to its recent acquisition by AstraZeneca PLC) from May 2019 to February 2023, Coherus BioSciences, Inc. (Nasdaq: CHRS) from February 2014 to February 2022, Karuna Therapeutics, Inc. (Nasdaq: KRTX, prior to its recent acquisition by Bristol Myers Squibb Company) from June 2019 to March 2024, Iterum Therapeutics plc (Nasdaq: ITRM) from November 2015 to February 2020, ObsEva SA (Nasdaq: OBSEF) from August 2013 to May 2021, and NuCana PLC (Nasdaq: NCNA) from March 2014 to April 2022. He also previously served as a director on the Board of the National Venture Capital Association (NVCA) and the Board of the Biotechnology Industry Organization (BIO). Dr. Healy holds Bachelor of Arts degrees in molecular biology and Scandinavian studies from the University of California, Berkeley, and Doctor of Medicine and Doctor of Philosophy degrees in immunology from Stanford University School of Medicine. We believe that Dr. Healy is qualified to serve on our board of directors due to his extensive experience and leadership roles in the biopharmaceutical industry and expertise in healthcare investing.

Reid Huber, Ph.D. Dr. Huber has been a member of our board of directors since February 2022 and previously served as our President and Chief Executive Officer from February 2022 to February 2023. Dr. Huber also served as a Partner at Third Rock since December 2018 and currently serves as the Chief Executive Officer of Merida Biosciences, a position he has held since July 2022. From April 2021 to April 2022 Dr. Huber served as Chief Executive Officer of MOMA Therapeutics, Inc. (“MOMA”). Dr. Huber has served on the boards of directors of Bellicum Pharmaceuticals, Inc. (previously Nasdaq: BLCM) since October 2014 and CARGO Therapeutics, Inc. (Nasdaq: CRGX) since March 2023, and previously served on the board of directors of Tango Therapeutics, Inc. (Nasdaq: TNGX) from July 2019 to November 2023. Dr. Huber also serves on the board of directors of The American Cancer Society. Dr. Huber received a Bachelor of Science degree in molecular genetics/biochemistry from Murray State University, a Doctor of Philosophy degree in molecular genetics from

169

the Washington University School of Medicine and held pre-and post-doctoral fellowships at the National Institutes of Health. We believe that Dr. Huber is qualified to serve on our board of directors due to his extensive background in the pharmaceutical industry and senior management experience.

Raymond Kelleher, M.D., Ph.D. Dr. Kelleher has been a member of our board of directors since August 2023. Dr. Kelleher has served as Managing Director at Cormorant Asset Management LLC since July 2020. Dr. Kelleher has also maintained an active clinical neurology practice at Massachusetts General Hospital specializing in neurodegenerative disorders, particularly Alzheimer’s disease and related dementias, since 1994. Dr. Kelleher served as an Assistant Professor of Neurology at Harvard Medical School from July 2005 to October 2023. Dr. Kelleher received his Bachelor of Science degree from Massachusetts Institute of Technology, his Doctor of Philosophy degree from Stanford University and his Doctor of Medicine degree from Stanford University School of Medicine. We believe that Dr. Kelleher is qualified to serve on our board of directors due to his extensive expertise in neurology and background in healthcare investing.

Dr. Kelleher has notified us that he will resign from our board of directors immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. Dr. Kelleher’s resignation is not due to any disagreement with us or any matters relating to our operations, policies or practices.

John Maraganore, Ph.D. Dr. Maraganore has been a member of our board of directors since March 2024. Since January 2022, Dr. Maraganore has served as the principal of JMM Innovations, LLC. He has also served as a Venture Partner at ARCH Venture Partners since October 2021, a Venture Advisor at Atlas Venture since January 2022, and a Senior Advisor at Blackstone Life Sciences since January 2022. Previously, Dr. Maraganore was the founding Chief Executive Officer of Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and a member of its board of directors from December 2002 to December 2021. Dr. Maraganore has been a member of the board of directors of Beam Therapeutics Inc. (Nasdaq: BEAM) since November 2021, ProKidney Corporation (Nasdaq: PROK) since July 2022, Takeda Pharmaceutical Company Limited (NYSE: TAK) since June 2022, and Kymera Therapeutics, Inc. (Nasdaq: KYMR) since January 2023. He has also been a member of the board of the Biotechnology Industry Organization since 2017, of which he was chair from 2017 to 2019 and has served as chair emeritus since 2022, and a member of the BIO Executive Committee since June 2013. Dr. Maraganore also previously served on the board of directors of Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) from June 2010 to May 2023. Dr. Maraganore holds a Bachelor of Arts degree in biological sciences, and Master of Science and Doctor of Philosophy degrees in biochemistry and molecular biology, in each case from the University of Chicago. We believe that Dr. Maraganore’s experience as chief executive officer of a public biotechnology company and as a board member of other public biotechnology companies qualify him to serve as a member of our board of directors.

Jeffrey K. Tong, Ph.D. Dr. Tong has been a member of our board of directors since December 2022 and previously served as our Treasurer from December 2022 to August 2023. Dr. Tong is a Partner at Third Rock which he joined in May 2016. Earlier in his career, Dr. Tong served as Executive Chairman of the board of directors of Delinia, Inc. (acquired by Celgene Corporation), and President and Chief Executive Officer of Nora Therapeutics, Inc., a private company. He was also a member of the management team at Infinity Pharmaceuticals, Inc. (Nasdaq: INFIQ). Dr. Tong previously served on the board of directors of Nurix Therapeutics, Inc. (Nasdaq: NRIX) from February 2018 to May 2022. Dr. Tong received his educational training at the interface of molecular biology, organic chemistry, and medicine and holds a Bachelor of Arts degree from Harvard College, a Master of Arts degree and Doctor of Philosophy degree from Harvard University, and a Master of Medical Sciences degree from the Harvard Medical School. We believe that Dr. Tong is qualified to serve on our board of directors based on his significant experience building and leading successful biotechnology companies and his scientific expertise.

Family Relationships

There are no family relationships among any of our executive officers or directors.

170

Composition of Our Board of Directors

Our business and affairs are managed under the direction of our board of directors, which will consist of seven members after giving effect to the resignations of Dr. Bredt and Dr. Kelleher immediately prior to the effectiveness of the registration statement of which this prospectus forms a part. The primary responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required.

Certain members of our board of directors were elected under the provisions of our second amended and restated certificate of incorporation and agreements with our stockholders. These board composition provisions will terminate upon the completion of this offering. Upon the termination of these provisions, there will be no further contractual obligations regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the qualifications and background of nominees. Our nominating and corporate governance committee’s and our board of directors’ priority in selecting board members is identification of persons who will further the interests of our stockholders through their established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board members, knowledge of our business, understanding of the competitive landscape, professional and personal experiences, and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified or until the earlier of their resignation or removal. Our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, also provide that our directors may be removed only for cause by the affirmative vote of the holders of at least two-thirds of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office.

Staggered Board

Our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, will permit our board of directors to establish the authorized number of directors from time to time by resolution. Each director serves until the expiration of the term for which such director was elected or appointed, or until such director’s earlier death, resignation or removal. In accordance with our third amended and restated certificate of incorporation, our board of directors will be divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and qualification until the third annual meeting following election. Our directors will be divided among the three classes as follows:

•

the Class I directors will be Reid Huber, Ph.D., John Maraganore, Ph.D. and Jeffrey K. Tong, Ph.D. and their terms will expire at our first annual meeting of stockholders following this offering, to be held in 2025;

•

the Class II directors will be Terry-Ann Burrell and James I. Healy, M.D., Ph.D. and their terms will expire at our second annual meeting of stockholders following this offering, to be held in 2026; and

•

the Class III directors will be Abraham N. Ceesay, M.B.A. and Steven M. Paul, M.D. and their terms will expire at our third annual meeting of stockholders following this offering, to be held in 2027.

We expect that any additional directorships resulting from an increase in the number of directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control.

171

This classification of our board of directors may have the effect of delaying or preventing changes in control of our company.

Director Independence

Under the listing standards, requirements and rules of The Nasdaq Stock Market LLC (“Nasdaq Listing Rules”), independent directors must comprise a majority of our board of directors as a listed company within one year of the listing date.

Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning her or his background, employment, and affiliations, including family relationships, our board of directors has determined that Dr. Paul, Ms. Burrell, Dr. Healy, Dr. Maraganore and Dr. Tong do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the Nasdaq Listing Rules. Our board of directors has determined that Mr. Ceesay and Dr. Bredt, by virtue of their employment relationships with us, and Dr. Huber, by virtue of his former position as our President and Chief Executive Officer, are not independent under applicable rules and regulations of the SEC and the Nasdaq Listing Rules. In making these determinations, our board of directors considered the current and prior relationships that each non-employee director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each non-employee director and the transactions described in the section titled “Certain Relationships and Related Person Transactions.”

Board Diversity Policies

In connection with this offering, we have adopted policies and procedures for director candidates for our nominating and corporate governance committee, which provide that the value of diversity should be considered in determining director candidates, as well as other factors, such as a candidate’s character, judgment, skills, education, expertise, and absence of conflicts of interest. Our priority in selection of board members will be identification of members who will further the interests of our stockholders through their established records of professional accomplishment, their ability to contribute positively to the collaborative culture among board members, and their knowledge of our business and understanding of the competitive landscape in which we operate and adherence to high ethical standards. The nominating and corporate governance committee and the full board of directors are committed to creating a board of directors with diversity, including diversity of expertise, experience, background, and gender, and are committed to identifying, recruiting, and advancing candidates offering such diversity in future searches.

Board Leadership Structure and Board’s Role in Risk Oversight

Currently, the role of chairman of our board of directors is separated from the role of chief executive officer. We believe that separating these positions allows our chief executive officer to focus on our day-to-day business, while allowing the chairman of our board to lead the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that the chief executive officer is required to devote to his position in the current business environment, as well as the commitment required to serve as our chair of our board of directors, particularly as the board of directors’ oversight responsibilities continue to grow. While our bylaws and corporate governance guidelines do not require that our board chair and chief executive officer positions be separate, our board of directors believes that having separate positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance.

172

Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a number of risks, including risks relating to our financial condition, development and commercialization activities, operations, strategic direction, and intellectual property as more fully discussed in the section titled “Risk Factors” included elsewhere in this prospectus. Management is responsible for the day-to-day management of risks we face, while our board of directors, as a whole and through its committees, has responsibility for the oversight of risk management. In its risk oversight role, our board of directors has the responsibility to satisfy itself that the risk management processes designed and implemented by management are adequate and functioning as designed.

The role of the board of directors in overseeing the management of our risks is conducted primarily through committees of the board of directors, as disclosed in the descriptions of each of the committees below and in the charters of each of the committees. The full board of directors (or the appropriate board committee in the case of risks that are under the purview of a particular committee) discusses with management our major risk exposures, their potential impact on us, and the steps we take to manage them. When a board committee is responsible for evaluating and overseeing the management of a particular risk or risks, the chairperson of the relevant committee reports on the discussion to the full board of directors during the committee reports portion of the next board meeting. This enables the board of directors and its committees to coordinate the risk oversight role, particularly with respect to risk interrelationships.

Committees of Our Board of Directors

Our board of directors has established an audit committee, a compensation committee, and a nominating and corporate governance committee. The composition and responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Each committee has adopted a written charter that satisfies the rules and regulations of the SEC and the Nasdaq Listing Rules, which we will post to our website at www.rapportrx.com upon the completion of this offering. Our board of directors may establish other committees as it deems necessary or appropriate from time to time.

Audit Committee

Upon the effectiveness of the registration statement of which this prospectus forms a part, our audit committee will consist of Terry-Ann Burrell, James I. Healy, M.D., Ph.D. and Jeffrey K. Tong, Ph.D., and the chair of our audit committee will be Ms. Burrell. Our board of directors has determined that Ms. Burell and Dr. Healy are each independent under Nasdaq Listing Rules and Rule 10A-3(b)(1) of the Exchange Act, and each of Ms. Burrell, Dr. Healy and Dr. Tong can read and understand fundamental financial statements in accordance with applicable requirements. Our board of directors has also determined that Ms. Burrell is an “audit committee financial expert” within the meaning of SEC regulations. In arriving at these determinations, our board of directors has examined each audit committee member’s scope of experience and the nature of their employment in the corporate finance sector. We are relying on the phase-in exemption provided under Rule 10A-3 of the Exchange Act and the Nasdaq Listing Rules with respect to the composition of our audit committee. Dr. Tong is an affiliate of Third Rock and may be deemed to beneficially own in excess of 10% of our common stock, as of the date of this prospectus, which would leave him outside the safe harbor provision of Rule 10A-3 of the Exchange Act. Dr. Tong will serve on the Audit Committee under the phase-in exemption referenced above. In accordance with the phase-in exemption, a majority of the members of our audit committee will satisfy the independence standards under the Exchange Act and Nasdaq Listing Rules within 90 days of the date of effectiveness of the registration statement of which this prospectus forms a part and all members of our audit committee will satisfy the independence standards under the Exchange Act and Nasdaq Listing Rules within 12 months.

173

The primary purpose of the audit committee is to discharge the responsibilities of our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered public accounting firm. Specific responsibilities of our audit committee include:

•

helping our board of directors oversee our corporate accounting and financial reporting processes;

•

managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the independent registered public accounting firm to audit our financial statements;

•

discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with management and the independent accountants, our interim and year-end operating results;

•

developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;

•

reviewing related person transactions;

•

establishing insurance coverage for our officers and directors;

•

overseeing the preparation of our annual proxy statement, reviewing with management our financial statements to be included in our quarterly reports to be filed with the SEC, and reviewing with management the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosures in our periodic reports filed with the SEC; and

•

approving, or, as permitted, pre-approving, audit and permissible non-audit services to be performed by the independent registered public accounting firm.

Our audit committee will operate under a written charter, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, that satisfies the applicable Nasdaq Listing Rules.

Compensation Committee

Upon the effectiveness of the registration statement of which this prospectus forms a part, our compensation committee will consist of Terry-Ann Burrell, James I. Healy, M.D., Ph.D, John Maraganore, Ph.D. and Steven M. Paul, M.D., and the chair of our compensation committee will be Dr. Healy. Our board of directors has determined that each member of the compensation committee is independent under the Nasdaq Listing Rules and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act.

The primary purpose of our compensation committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans, and programs and to review and determine the compensation to be paid to our executive officers, directors, and other senior management, as appropriate. Specific responsibilities of our compensation committee include:

•

reviewing and approving the compensation of our chief executive officer, other executive officers, and senior management;

•

reviewing and recommending to our board of directors the compensation paid to our directors;

•

reviewing and approving the compensation arrangements with our executive officers and other senior management;

•

administering our equity incentive plans and other benefit programs;

•

reviewing, adopting, amending, and terminating incentive compensation and equity plans, severance agreements, profit sharing plans, bonus plans, change-of-control protections, and any other compensatory arrangements for our executive officers and other senior management;

174

•

reviewing, evaluating and recommending to our board of directors succession plans for our executive officers; and

•

reviewing and establishing general policies relating to compensation and benefits of our employees, including our overall compensation philosophy.

Our compensation committee will operate under a written charter, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, that satisfies the applicable Nasdaq Listing Rules.

Nominating and Corporate Governance Committee

Upon the effectiveness of the registration statement of which this prospectus forms a part, our nominating and corporate governance committee will consist of Steven M. Paul, M.D. and Jeffrey K. Tong, Ph.D., and the chair of our nominating and corporate governance committee will be Dr. Tong. Our board of directors has determined that each member of the nominating and corporate governance committee is independent under the Nasdaq Listing Rules, a non-employee director, and free from any relationship that would interfere with the exercise of his or her independent judgment.

The primary purpose of the nominating and corporate governance committee is to discharge the responsibilities of our board of directors with respect to our corporate governance functions and to identify, communicate with, evaluate and recommend candidates for our board of directors. Specific responsibilities of our nominating and corporate governance committee include:

•

identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees recommended by stockholders, to serve on our board of directors;

•

considering and making recommendations to our board of directors regarding the composition and chairmanship of the committees of our board of directors;

•

instituting plans or programs for the continuing education of our board of directors and orientation of new directors;

•

developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and

•

overseeing periodic evaluations of the board of directors’ performance, including committees of the board of directors and management.

Our nominating and corporate governance committee will operate under a written charter, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, that satisfies the applicable Nasdaq Listing Rules.

Code of Business Conduct and Ethics

In connection with this offering, our board of directors adopted a written code of business conduct and ethics, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, that applies to all our employees, officers, and directors. This includes our principal executive officer, principal financial officer, and principal accounting officer or controller, or persons performing similar functions. The full text of our code of business conduct and ethics will be posted on our website at www.rapportrx.com. We intend to disclose on our website any future amendments of our code of business conduct and ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions, or our directors from provisions in the code of business conduct and ethics. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference.

175

Compensation Committee Interlocks and Insider Participation

None of the members of the compensation committee is currently, or has been at any time, one of our officers or employees. None of our officers currently serve, or have served during the last calendar year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee.

Compensation Recovery

In connection with this offering, our board of directors adopted a compensation recovery policy, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, that is compliant with the Nasdaq Listing Rules, as required by the Dodd-Frank Act, to be effective in connection with the effectiveness of the registration statement of which this prospectus forms a part. The compensation recovery policy provides that in the event we are required to prepare a restatement of financial statements due to material noncompliance with any financial reporting requirement under securities laws, we will seek to recover any incentive-based compensation that was based, in whole or in part, upon the attainment of a financial reporting measure and that was received by any current or former executive officer during the three-year period preceding the date that the restatement was required if such compensation exceeds the amount that the executive officers would have received based on the restated financial statements.

Limitations on Liability and Indemnification Agreements

As permitted by Delaware law, provisions in our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and our amended and restated bylaws, which will be effective upon the effectiveness of the registration statement of which this prospectus forms a part, limit or eliminate the personal liability of directors and officers for a breach of their fiduciary duty of care as a director or officer. The duty of care generally requires that, when acting on behalf of the corporation, a director and or officer exercise an informed business judgment based on all material information reasonably available to him or her. Consequently, a director or officer will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director or officer, except for liability for:

•

any breach of the director or officer’s duty of loyalty to us or our stockholders;

•

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

•

for our directors, unlawful payments of dividends or unlawful stock repurchases, or redemptions as provided in Section 174 of the Delaware General Corporation Law (“DGCL”);

•

for our officers, any derivative action by or in the right of the corporation; or

•

any transaction from which the director or officer derived an improper personal benefit.

These limitations of liability do not limit or eliminate our rights or any stockholder’s rights to seek non-monetary relief, such as injunctive relief or rescission. These provisions will not alter a director or officer’s liability under other laws, such as the federal securities laws or other state or federal laws. Our third amended and restated certificate of incorporation that will become effective upon the closing of this offering also authorizes us to indemnify our officers, directors and other agents to the fullest extent permitted under Delaware law.

As permitted by Delaware law, our amended and restated bylaws will provide that:

•

we will indemnify our directors, officers, employees and other agents to the fullest extent permitted by law;

•

we must advance expenses to our directors and officers, and may advance expenses to our employees and other agents, in connection with a legal proceeding to the fullest extent permitted by law; and

•

the rights provided in our amended and restated bylaws are not exclusive.

176

If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director or officer, then the liability of our directors or officers will be so eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated bylaws will also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in connection with their services to us, regardless of whether our amended and restated bylaws permit such indemnification. We have obtained such insurance.

In addition to the indemnification that will be provided for in our third amended and restated certificate of incorporation and amended and restated bylaws, we plan to enter into separate indemnification agreements with each of our directors and executive officers, which may be broader than the specific indemnification provisions contained in the DGCL. These indemnification agreements may require us, among other things, to indemnify our directors and executive officers for some expenses, including attorneys’ fees, expenses, judgments, fines and settlement amounts incurred by a director or executive officer in any action or proceeding arising out of his service as one of our directors or executive officers or any other company or enterprise to which the person provides services at our request. We believe that these provisions and agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

This description of the indemnification provisions of our third amended and restated certificate of incorporation, our amended and restated bylaws and our indemnification agreements is qualified in its entirety by reference to these documents, each of which is attached as an exhibit to the registration statement of which this prospectus forms a part.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable.

There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer.

177

EXECUTIVE COMPENSATION

The following discussion contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding our future compensation programs. The actual amount and form of compensation and the compensation policies and practices that we adopt in the future may differ materially from currently planned programs as summarized in this discussion.

As an emerging growth company, we have opted to comply with the executive compensation disclosure rules applicable to “smaller reporting companies,” as such term is defined in the rules promulgated under the Securities Act. The compensation provided to our named executive officers for the fiscal year ended December 31, 2023 is detailed in the 2023 Summary Compensation Table and accompanying footnotes and narrative that follow. Our named executive officers for the fiscal year ended December 31, 2023 are:

•

Abraham N. Ceesay, M.B.A., our Chief Executive Officer;

•

Reid Huber, Ph.D., our former Chief Executive Officer*;

•

Troy Ignelzi, our Chief Financial Officer; and

•

Cheryl Gault, our Chief Operations Officer.

*	Dr. Huber served as our Chief Executive Officer until Mr. Ceesay commenced employment with us in February 2023.

To date, the compensation of our named executive officers has consisted of a combination of base salary, cash bonuses and long-term incentive compensation in the form of restricted stock awards and stock options. Our named executive officers who are full-time employees are eligible to participate in our health and welfare benefit plans and 401(k) plan like all of our full-time employees. As we transition from a private company to a publicly traded company, we intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require.

2023 Summary Compensation Table

The following table shows the total compensation earned by, or paid to, our named executive officers for services rendered to us in all capacities during the fiscal year ended December 31, 2023.


Name and Principal Position	Year		Salary ($)		Bonus ($)			Option Awards ⁽¹⁾ ($)		Stock Awards ⁽¹⁾ ($)		Non-Equity Incentive Plan Compensation ⁽²⁾ ($)		All Other Compensation ($)			Total ($)
Abraham N. Ceesay, M.B.A.
Chief Executive Officer ⁽³⁾		2023		400,096		250,000	⁽⁴⁾		1,513,805		—		231,167		20,772	⁽⁵⁾		2,415,840
Reid Huber, Ph.D.
Former Chief Executive Officer		2023		—		—			—		—		—		400,225	⁽⁶⁾		400,225
Troy Ignelzi
Chief Financial Officer ⁽⁷⁾		2023		69,462		—			2,018,084		—		35,770		7,141	⁽⁸⁾		2,130,457
Cheryl Gault
Chief Operations Officer ⁽⁹⁾		2023		132,462		75,000	⁽¹⁰⁾		662,259		838,696		71,540		2,108	⁽¹¹⁾		1,782,065

178

(1)

The amounts reported in this column represent the aggregate grant date fair value of stock awards and option awards granted to the named executive officers during 2023, as calculated in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date fair value of the awards in this column are described in Note 9—“Stock-Based Compensation” to our consolidated financial statements included elsewhere in this prospectus. These awards are described in more detail under the section titled “Narrative Disclosure to Summary Compensation Table—Equity-Based Compensation” below.

(2)

The amounts reported represent the prorated annual bonuses each named executive officer earned under our annual cash bonus program based on achievement of company performance and individual performance during the year ended December 31, 2023 for their partial year of employment. For more information on these bonuses, see description of the annual performance bonuses under the section titled “Narrative Disclosure to Summary Compensation Table—2023 Cash Bonuses” below.

(3)	Mr. Ceesay commenced employment with us on February 28, 2023. The amount reported as salary reflects the salary actually earned for his partial year of employment.

(4)

The amount reported represents a $250,000 signing bonus paid to Mr. Ceesay in connection with the commencement of his employment pursuant to the terms of his offer letter, as described below under the section titled “—Executive Compensation Arrangements—Employment Arrangements in Place Prior to the Offering for Named Executive Officers.”

(5)

The amount reflects (i) our 401(k) matching contribution in the amount of $6,755, (ii) the reimbursement of legal fees associated with the negotiation of Mr. Ceesay’s offer letter in the amount of $10,000, (iii) the reimbursement of Mr. Ceesay’s personal expense in the amount of $2,292, (iv) Mr. Ceesay’s cell phone reimbursement in the amount of $675 and (v) company-paid parking passes in the amount of $1,050.

(6)

Dr. Huber did not receive any cash compensation from us for his services as our Chief Executive Officer, as his services were provided to us through a service agreement with Third Rock Ventures, LLC (the “TRV Agreement”). As described below under the section titled “Certain Relationships and Related Person Transactions,” we incurred costs totaling $1.2 million during the fiscal year ended December 31, 2023 for the services provided by Third Rock Ventures, LLC, which included, among other things, the services of Dr. Huber. Of the total fees we incurred under the TRV Agreement in the year ended December 31, 2023, $400,225 was related to the services provided by Dr. Huber.

(7)	Mr. Ignelzi commenced employment with us on November 1, 2023. The amount reported as salary reflects the salary actually earned for his partial year of employment.

(8)

The amount reflects (i) our 401(k) matching contribution in the amount of $1,292, (ii) Mr. Ignelzi’s cell phone reimbursement in the amount of $150, (iii) the reimbursement of legal fees associated with the negotiation of Mr. Ignelzi’s offer letter in the amount of $2,365, and (iv) the reimbursement of commuting expenses incurred in connection with his employment in the amount of $3,334.

(9)	Ms. Gault commenced employment with us on September 7, 2023. The amount reported as salary reflects the salary actually earned for her partial year of employment.

(10)

The amount reported represents a $75,000 sign-on bonus paid to Ms. Gault in connection with the commencement of her employment pursuant to the terms of her offer letter, as described below under the section titled “—Executive Compensation Arrangements—Employment Arrangements in Place Prior to the Offering for Named Executive Officers.”

(11)	The amount reflects (i) our 401(k) matching contribution in the amount of $833, (ii) Ms. Gault’s cell phone reimbursement in the amount of $225 and (iii) company-paid parking passes in the amount of $1,050.

Narrative Disclosure to Summary Compensation Table

Compensation Philosophy

Our executive compensation philosophy is to provide a competitive and market-based total compensation program to attract, motivate, and retain our executive team. Our compensation is based heavily on performance, which aligns with our goal to drive long-term growth and value creation.

179

2023 Base Salaries

Our named executive officers each receive a base salary to compensate them for services rendered to our company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive’s skill set, experience, role and responsibilities. Base salaries may be adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. As of December 31, 2023, the base salaries for Mr. Ceesay, Mr. Ignelzi and Ms. Gault were $475,000, $420,000 and $420,000, respectively.

2023 Cash Bonuses

For the fiscal year ended December 31, 2023, each of the named executive officers was eligible to earn an annual cash bonus determined by our board of directors in its sole discretion, based on individual performance and achievement of certain corporate performance milestones, including advancing our research and development goals, specifically as it relates to our RAP-219 program, building the leadership team of the organization, and ensuring funding to advance our pipeline. The target annual bonus for each of our named executive officers for the fiscal year ended December 31, 2023 was equal to the percentage of the executive’s respective annual base salary specified below:


Name	Target Bonus Percentage
Abraham N. Ceesay, M.B.A.		40	%
Troy Ignelzi		35	%
Cheryl Gault		35	%

Equity-Based Compensation

Although we did not yet have a formal policy with respect to the grant of equity incentive awards to our executive officers for the fiscal year ended December 31, 2023, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. We have granted our named executive officers restricted stock awards or stock options pursuant to each executive’s respective offer letter with us.

For additional information regarding outstanding equity awards held by our named executive officers as of December 31, 2023, see the “Outstanding Equity Awards at 2023 Fiscal Year End” table below.

Perquisites/Personal Benefits

We have provided limited perquisites or personal benefits primarily in the form of (i) legal fee reimbursement in connection with the negotiation of Mr. Ceesay’s offer letter and Mr. Ignelzi’s offer letter and (ii) reasonable commuting expenses and a potential relocation bonus pursuant to Mr. Ignelzi’s offer letter, in each case, as described below under the section titled “—Executive Compensation Arrangements—Employment Arrangements in Place Prior to the Offering for Named Executive Officers.”

401(k) Plan

We maintain a retirement savings plan (“401(k) plan”) that is intended to qualify for favorable tax treatment under Section 401(a) of the Code, and contains a cash or deferred feature that is intended to meet the requirements of Section 401(k) of the Code. U.S. employees are generally eligible to participate in the 401(k) plan, subject to certain criteria. Participants may make pre-tax and certain after-tax (Roth) salary deferral contributions to the plan from their eligible earnings up to the statutorily prescribed annual limit under the Code.

180

Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits for catch-up contributions. Participant contributions are held in trust as required by law. We make matching contributions equal to 100% of salary deferrals up to 4% of eligible compensation, with 100% immediate vesting.

Outstanding Equity Awards at 2023 Fiscal Year End

The following table lists all outstanding equity awards held by our named executive officers as of December 31, 2023.


				Option Awards ⁽¹⁾								Stock Awards
Name ⁽²⁾	Vesting Commencement Date			Number of Securities Underlying Unexercised Options (#) Exercisable		Number of Securities Underlying Unexercised Options (#) Unexercisable		Option Exercise Price ($)		Option Expiration Date		Number of Shares or Units of Stock that have Not Vested (#) ⁽³⁾		Market Value of Shares or Units of Stock that have Not Vested ($) ⁽⁴⁾
Abraham N. Ceesay, M.B.A.		8/7/2023 12/9/2022 2/21/2023	⁽⁵⁾		— —		263,801 —	$	1.80 —		12/05/2033 —		— 322,500 284,766		—
Troy Ignelzi		11/1/2023	⁽⁵⁾		—		351,679	$	1.80		12/05/2033
Cheryl Gault		8/7/2023 9/7/2023	⁽⁵⁾		— —		115,407	$	1.80		12/05/2033		157,941

(1)

Each stock option award is subject to the terms of our 2022 Stock Option and Grant Plan, as amended. Unless otherwise noted below, each stock option vests as follows: 25% of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the stock option vest on a monthly basis thereafter, in each case, subject to the NEO’s continuous service relationship with us through each applicable vesting date. Each stock option is subject to acceleration in the event of a qualified termination within the change in control period, as described below under the section titled “—Executive Compensation Arrangements—Employment Arrangements in Place Prior to the Offering for Named Executive Officers.”

(2)	Dr. Huber served as our Chief Executive Officer until Mr. Ceesay commenced employment with us in February 2023. Dr. Huber did not receive any equity compensation from us for his services as our Chief Executive Officer.

(3)

Each restricted stock award is subject to an individual restricted stock award agreement. The restricted shares shall vest over a four-year period, as follows: 25% of the restricted shares shall vest on the first anniversary following the vesting commencement date, and the remaining 75% of the restricted shares vest on each monthly anniversary thereafter over the following three years, subject to the NEO’s continuous service relationship with us through each applicable vesting date. The restricted shares are also subject to certain acceleration of vesting provisions as provided in the each named executive officer’s restricted stock agreement and as summarized below under the section titled “—Executive Compensation Arrangements—Employment Arrangements in Place Prior to the Offering for Named Executive Officers.”

(4)	The market price for our common stock is based on the assumed initial public offering price of our common stock is based on the assumed initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus.

(5)	This stock option award was granted on December 6, 2023.

Executive Compensation Arrangements

We have entered into offer letters with each of our named executive officers. Each offer letter or employment agreement provides for “at-will” employment and the compensation and benefits described below. In connection with this offering, we intend to enter into a new employment agreement with our named executive

181

officers that will be effective as of the closing of this offering, including new severance and change in control benefits.

Employment Arrangements in Place Prior to the Offering for Named Executive Officers

Abraham N. Ceesay, M.B.A.

On December 12, 2022, we entered into an executive offer letter with Mr. Ceesay (the “Ceesay Offer Letter”) for the position of Chief Executive Officer. The Ceesay Offer Letter provides for Mr. Ceesay’s at-will employment. Mr. Ceesay’s current base salary is $475,000 and he is eligible to receive an annual bonus with an annual target amount of 40% of his annual base salary. Mr. Ceesay is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. Pursuant to the Ceesay Offer Letter, Mr. Ceesay received a legal fee reimbursement in connection with the negotiation of the Ceesay Offer Letter. Mr. Ceesay also received a $250,000 signing bonus in connection with the commencement of his employment. This signing bonus is subject to repayment if Mr. Ceesay’s employment is terminated for Cause (as defined in the Ceesay Offer Letter) or he resigns without Good Reason (as defined in the Ceesay Offer Letter) prior to the third anniversary of his start date as follows: 100% must be repaid if the termination occurs less than 12 months following his start date; 50% must be repaid if the termination occurs at least 12 months and less than 24 months following his start date; and 25% must be repaid if the termination occurs at least 24 months but less than 36 months following his start date.

Upon a termination of Mr. Ceesay’s employment by us without Cause or his resignation for Good Reason outside of the Change in Control Period (which is the twelve (12) month period that immediately follows the first event constituting a Change in Control), as such terms are defined in the Ceesay Offer Letter, subject to (i) signing a general release of claims in favor of us and (ii) not breaching any of the post-employment covenants and contractual obligations to us Mr. Ceesay shall be entitled to (A) continued payment of his then current base salary for a period of twelve (12) months (or the base salary in effect prior to the applicable material diminution that constitutes Good Reason, in the event of a resignation for Good Reason) and (B) if Mr. Ceesay was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ceesay had Mr. Ceesay remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Mr. Ceesay’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA. In addition, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, in addition to the severance pay and benefits set forth in (A) and (B) above, Mr. Ceesay shall be entitled to (i) a lump sum cash payment equal to Mr. Ceesay’s target bonus for the year in which the date of termination occurs, (ii) any bonus award to Mr. Ceesay for the prior calendar year but has not yet been paid, other than the target bonus and (iii) full acceleration of his then outstanding and unvested time-based equity awards.

Mr. Ceesay has entered into an Employee Confidentiality, Assignment, and Nonsolicitation Agreement that contains various restrictive covenants, including confidentiality and nonsolicitation.

Troy Ignelzi

On October 24, 2023, we entered into an executive offer letter with Mr. Ignelzi (the “Ignelzi Offer Letter”) for the position of Chief Financial Officer. The Ignelzi Offer Letter provides for Mr. Ignelzi’s at-will employment. Mr. Ignelzi’s current base salary is $420,000 and he is eligible to receive an annual bonus with an annual target amount of 35% of his annual base salary. Mr. Ignelzi is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. Mr. Ignelzi is also eligible to receive (a) a reimbursement for all reasonable commuting expenses incurred in performing services, (b) a relocation bonus in the event Mr. Ignelzi purchases a new residence in the Cambridge/Boston area within three (3) years of the employment start date, specific terms of which shall be determined at a future date, and (c) a reimbursement for legal expenses incurred of up to $5,000.

182

Upon a termination of Mr. Ignelzi’s employment by us without Cause or his resignation for Good Reason outside of the Change in Control Period (which is the two (2) months before or the twelve (12) month period that immediately follows the first event constituting a Change in Control), as such terms are defined in the Ignelzi Offer Letter, subject to (i) signing a general release of claims in favor of us and (ii) not breaching any of the post-employment covenants and contractual obligations to us Mr. Ignelzi shall be entitled to (A) continued payment of his then current base salary for a period of twelve (12) months, and (B) if Mr. Ignelzi was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ignelzi had Mr. Ignelzi remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Mr. Ignelzi’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA. In addition, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, in addition to the severance pay and benefits set forth in (A) and (B) above, Mr. Ignelzi shall be entitled to full acceleration of his then outstanding and unvested time-based equity awards.

Mr. Ignelzi has entered into an Employee Confidentiality, Assignment, and Nonsolicitation Agreement that contains various restrictive covenants, including confidentiality and nonsolicitation.

Cheryl Gault

On June 29, 2023, we entered into an executive offer letter with Ms. Gault (the “Gault Offer Letter”) for the position of Chief Operating Officer. The Gault Offer Letter provides for Ms. Gault’s at-will employment. Ms. Gault’s current base salary is $420,000 and she is eligible to receive an annual bonus with an annual target amount of 35% of her annual base salary. Ms. Gault is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans. Ms. Gault also received a $75,000 signing bonus in connection with the commencement of her employment. This signing bonus is subject to 100% repayment if Ms. Gault’s employment is terminated for Cause (as defined in the Gault Offer Letter) or she resigns without Good Reason (as defined in the Offer Letter) prior to the first anniversary of her start date.

Upon a termination of Ms. Gault’s employment by us without Cause or her resignation for Good Reason outside of the Change in Control Period (which is the two (2) months before or the twelve (12) month period that immediately follows the first event constituting a Change in Control), as such terms are defined in the Gault Offer Letter, subject to (i) signing a general release of claims in favor of us and (ii) not breaching any of the post-employment covenants and contractual obligations to us Ms. Gault shall be entitled to (A) continued payment of her then current base salary for a period of nine (9) months and (B) if Ms. Gault was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Ms. Gault had Ms. Gault remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Ms. Gault’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA for a period of twelve (12) months. In addition, and subject to the same conditions, upon a termination by us without Cause or her resignation for Good Reason during the Change in Control Period, in addition to the severance pay and benefits set forth in (A) and (B) above, Ms. Gault shall be entitled to a full acceleration of her then outstanding and unvested time-based equity awards.

Ms. Gault has entered into an Employee Confidentiality, Assignment, and Nonsolicitation Agreement that contains various restrictive covenants, including confidentiality and nonsolicitation.

Employment Arrangements in Place as of the Offering for Named Executive Officers

Abraham N. Ceesay, M.B.A.

We entered into a new employment agreement with Mr. Ceesay that will be effective as of the closing of this offering. (the “Ceesay Employment Agreement”). The Ceesay Employment Agreement provides for Mr. Ceesay’s

183

continued at-will employment as our Chief Executive Officer, an annual base salary of $628,000 and eligibility to receive an annual bonus with a target amount of 55% of his annual base salary. Mr. Ceesay is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans and receive prompt reimbursement for all reasonable expenses incurred. Pursuant to the Ceesay Offer Letter, Mr. Ceesay received a $250,000 signing bonus in connection with the commencement of his employment. This signing bonus remains subject to repayment if Mr. Ceesay’s employment is terminated for Cause (as defined in the Ceesay Employment Agreement) or he resigns without Good Reason (as defined in the Ceesay Employment Agreement) prior to the third anniversary of the date Mr. Ceesay commenced employment with us as follows: 50% must be repaid if the termination occurs at least 12 months and less than 24 months following his start date; and 25% must be repaid if the termination occurs at least 24 months but less than 36 months following his start date.

Upon a termination of Mr. Ceesay’s employment by us without Cause or his resignation for Good Reason outside of the Change in Control Period (which is the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control), as such terms are defined in the Ceesay Employment Agreement, subject to signing an irrevocable separation agreement and general release of claims in favor of us, Mr. Ceesay shall be entitled to (A) continued payment of his then current base salary for a period of twelve (12) months, and (B) if Mr. Ceesay was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ceesay had Mr. Ceesay remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Mr. Ceesay’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA. In lieu of the foregoing, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, Mr. Ceesay shall be entitled to (A) a lump sum in cash in an amount equal to one and one-half (1.5) times the sum of Mr. Ceesay’s (i) then current base salary (or the base salary in effect immediately prior to the Change in Control, if higher) plus (ii) target bonus for the then current year (or the target bonus in effect immediately prior to the Change in Control, if higher), (B) full acceleration of his then outstanding and unvested time-based equity awards, (C) if Mr. Ceesay was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ceesay had Mr. Ceesay remained employed by us until the earliest of (a) the eighteen (18) month anniversary of the date of termination; (b) Mr. Ceesay’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA.

The Ceesay Employment Agreement contains a Section 280G “better off cutback,” such that he would retain the greater, on an after-tax basis, of the amount resulting from (i) payment of the full amount of all compensation payable under the Ceesay Employment Agreement (taking into account the 20% excise tax imposed by Section 4999 of the Code) and (ii) application of a straight cutback.

Troy Ignelzi

We entered into a new employment agreement with Mr. Ignelzi that will be effective as of the closing of this offering (the “Ignelzi Employment Agreement”). The Ignelzi Employment Agreement provides for Mr. Ignelzi’s continued at-will employment as our Chief Financial Officer, an annual base salary of $500,000 and eligibility to receive an annual bonus with a target amount of 40% of his annual base salary. Mr. Ignelzi is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans and receive prompt reimbursement for all reasonable expenses incurred. Mr. Ignelzi is also eligible to receive a relocation benefit in the event Mr. Ignelzi purchases a new residence in the Cambridge/Boston area within three (3) years of the date Mr. Ignelzi commenced employment with us, specific terms of which shall be determined at a future date.

Upon a termination of Mr. Ignelzi’s employment by us without Cause or his resignation for Good Reason outside of the Change in Control Period (which is the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control), as such terms are defined in the Ignelzi

184

Employment Agreement, subject to signing an irrevocable separation agreement and general release of claims in favor of us Mr. Ignelzi shall be entitled to (A) continued payment of his then current base salary for a period of twelve (12) months, and (B) if Mr. Ignelzi was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ignelzi had Mr. Ignelzi remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Mr. Ignelzi’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA. In lieu of the foregoing, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, Mr. Ignelzi shall be entitled to (A) a lump sum in cash in an amount equal to one (1) times the sum of Mr. Ignelzi’s (i) then current base salary (or the base salary in effect immediately prior to the Change in Control, if higher) plus (ii) target bonus for the then current year (or the target bonus in effect immediately prior to the Change in Control, if higher), (B) full acceleration of his then outstanding and unvested time-based equity awards, (C) if Mr. Ignelzi was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Mr. Ignelzi had Mr. Ignelzi remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Mr. Ignelzi’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA.

The Ignelzi Employment Agreement contains a Section 280G “better off cutback,” such that he would retain the greater, on an after-tax basis, of the amount resulting from (i) payment of the full amount of all compensation payable under the Ignelzi Employment Agreement (taking into account the 20% excise tax imposed by Section 4999 of the Code) and (ii) application of a straight cutback.

Cheryl Gault

We entered into a new employment agreement with Ms. Gault that will be effective as of the closing of this offering (the “Gault Employment Agreement”). The Gault Employment Agreement provides for Ms. Gault’s continued at-will employment as our Chief Operating Officer, an annual base salary of $455,000 and she is eligible to receive an annual bonus with an annual target amount of 40% of her annual base salary. Ms. Gault is eligible to participate in the employee benefit plans available to our employees, subject to the terms of such plans and receive prompt reimbursement for all reasonable expenses incurred. Pursuant to the Gault Offer Letter, Ms. Gault received a $75,000 signing bonus in connection with the commencement of her employment. This signing bonus remains subject to 100% repayment if Ms. Gault’s employment is terminated for Cause (as defined in the Gault Employment Agreement) or she resigns without Good Reason (as defined in the Gault Employment Agreement) prior to the first anniversary of the date Ms. Gault commenced employment with us.

Upon a termination of Ms. Gault’s employment by us without Cause or her resignation for Good Reason outside of the Change in Control Period (which is the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control), as such terms are defined in the Gault Employment Agreement, subject to signing an irrevocable separation agreement and general release of claims in favor of us Ms. Gault shall be entitled to (A) continued payment of her then current base salary for a period of twelve (12) months, and (B) if Ms. Gault was participating in our group health plan immediately prior to the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Ms. Gault had Ms. Gault remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Ms. Gault’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA. In lieu of the foregoing, and subject to the same conditions, upon a termination by us without Cause or his resignation for Good Reason during the Change in Control Period, Ms. Gault shall be entitled to (A) a lump sum in cash in an amount equal to one (1) times the sum of Ms. Gault’s (i) then current base salary (or the base salary in effect immediately prior to the Change in Control, if higher) plus (ii) target bonus for the then current year (or the target bonus in effect immediately prior to the Change in Control, if higher), (B) full acceleration of her then outstanding and unvested time-based equity awards, (C) if Ms. Gault was participating in our group health plan immediately prior to

185

the termination date and timely elects continuation coverage under COBRA, a monthly payment equal to the monthly employer contribution that we would have made to provide health insurance to Ms. Gault had Ms. Gault remained employed by us until the earliest of (a) the twelve (12) month anniversary of the date of termination; (b) Ms. Gault’s eligibility for group health plan benefits under any other employer’s group health plan; or (c) cessation of the continuation rights under COBRA.

The Gault Employment Agreement contains a Code Section 280G “better off cutback,” such that she would retain the greater, on an after-tax basis, of the amount resulting from (i) payment of the full amount of all compensation payable under the Gault Employment Agreement (taking into account the 20% excise tax imposed by Section 4999 of the Code) and (ii) application of a straight cutback.

Employee Benefit and Equity Compensation Plans

2022 Stock Option and Grant Plan

Our 2022 Stock Option and Grant Plan was adopted by our board of directors on December 9, 2022 and approved by our stockholders on December 9, 2022. On August 7, 2023, our board of directors adopted and our stockholders approved an amendment to the 2022 Stock Option and Grant Plan (as amended, the “2022 Plan”). On February 7, 2024, our board of directors adopted a second amendment to the 2022 Plan and our stockholders approved this amendment on February 26, 2024. The 2022 Plan will continue to govern outstanding equity awards granted thereunder. As of May 10, 2024, options to purchase 2,769,721 shares of our common stock at a weighted-average exercise price of $5.45 per share and 150,626 shares of restricted stock were outstanding under the 2022 Plan, and 26,473 shares of our common stock remained available for future issuance under the 2022 Plan. Following this offering, we will not grant any further awards under our 2022 Plan, but all outstanding awards under the 2022 Plan will continue to be governed by their existing terms.

The shares of common stock underlying any awards under the 2022 Plan that are forfeited, canceled, reacquired by us prior to vesting, satisfied without the issuance of stock or otherwise terminated (other than by exercise) and shares withheld upon exercise of an option or settlement of an award to cover the exercise price or tax withholding, are currently added back to the shares of common stock available for issuance under the 2022 Plan. Following this offering, such shares will be added to the shares of common stock available for issuance under the 2024 Plan.

Our board of directors and our compensation committee have acted as administrators of the 2022 Plan. The administrator has the full power, among other things, to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2022 Plan. Persons eligible to participate in the 2022 Plan are officers, employees, non-employee directors, consultants and advisors as selected from time to time by our board in its discretion.

The 2022 Plan permits the granting of nonqualified stock options and options intended to qualify as incentive stock options under Section 422 of the Code. The per share exercise price of each option is determined by our board of directors but may not be less than 100% of the fair market value of the common stock on the date of grant. The term of each option is fixed by the administrator but may not exceed 10 years from the date of grant. The administrator determines at what time or times each option may be exercised.

The 2022 Plan permits the granting of restricted stock awards. Restricted stock awards are grants of common stock that are subject to various restrictions, including restrictions on transferability and forfeitures provisions. Shares of restricted stock will vest, and the restrictions on such shares will lapse, in accordance with terms and conditions established by the plan administrator.

186

In addition, the 2022 Plan permits the granting of unrestricted stock awards and restricted stock units.

The 2022 Plan provides that upon the effectiveness of a “sale event,” as defined in the 2022 Plan, the administrator may take any one or more of the following actions as to all or any (or any portion of) outstanding option awards: (i) provide that all such awards will be assumed or substituted with substantially equivalent awards by the acquiring or succeeding corporation (or affiliate thereof); (ii) provide that all such awards will terminate or forfeit upon the effective time of any such sale event unless assumed or continued by the successor entity, or new stock options or other awards are substituted therefor; or (iii) provide for a cash payment to the holders of awards for each vested award canceled in the sale event. In addition, the administrator may take one or more of the following actions as to all or any (or any portion of) outstanding restricted stock awards and restricted stock units: (i) provide that all unvested awards will be forfeited immediately prior to the effective time of the sale event unless assumed or continued by the successor entity, or awards of the successor entity or parent thereof are substituted therefore; (ii) in the event of the forfeiture of restricted stock, provide that such restricted stock shall be repurchased; or (iii) provide for a cash payment to the holders of awards for the cancellation of the awards. Upon the occurrence of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in common stock, the administrator will equitably adjust the outstanding awards, which may include adjustments to the number and type of securities subject to such outstanding award and/or the exercise price or grant price, thereof.

Unless otherwise determined by the administrator, awards may generally not be sold, assigned, transferred, pledged or otherwise encumbered by the person to whom they are granted, either voluntarily or by operation of law, except by will or the laws of descent and distribution.

The board of directors may amend, suspend or terminate the 2022 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2022 Plan may also amend, modify or cancel any outstanding award, provided that no amendment to an award may materially and adversely affect a participant’s rights without his or her consent.

2024 Stock Option and Incentive Plan

Our 2024 Plan was adopted by our board of directors on, May 29, 2024, approved by our stockholders on May 30, 2024 and will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2024 Plan will replace the 2022 Plan as our board of directors has determined not to make additional awards under the 2022 Plan following the closing of our initial public offering. However, the 2022 Plan will continue to govern outstanding equity awards granted thereunder. The 2024 Plan allows us to make equity-based and cash-based incentive awards to our officers, employees, directors and consultants.

We have initially reserved 3,814,618 shares of our common stock for the issuance of awards under the 2024 Plan (the “Initial Limit”). The 2024 Plan provides that the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter, by five percent of the outstanding number of shares of our common stock on the immediately preceding December 31 or such lesser number of shares as determined by our compensation committee (the “Annual Increase”). The number of shares reserved under the 2024 Plan is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

The shares we issue under the 2024 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common stock underlying any awards under the 2024 Plan and the 2022 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan.

187

The maximum number of shares of common stock that may be issued in the form of incentive stock options shall not exceed the Initial Limit, cumulatively increased on January 1, 2025 and on each January 1 thereafter by the lesser of the Annual Increase for such year or 3,814,618 shares of common stock.

The grant date fair value of all awards made under our 2024 Plan and all other cash compensation paid by us to any non-employee director in any calendar year for services as a non-employee director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the board of directors.

The 2024 Plan will be administered by our compensation committee. Our compensation committee has the full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to determine the specific terms and conditions of each award, subject to the provisions of the 2024 Plan. Persons eligible to participate in the 2024 Plan will be those full or part-time officers, employees, non-employee directors and consultants as selected from time to time by our compensation committee in its discretion.

The 2024 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section 422 of the Code and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but generally may not be less than 100 percent of the fair market value of our common stock on the date of grant unless the option (i) is granted pursuant to a transaction described in, and in a manner consistent with Section 424(a) of the Code, (ii) is granted to an individual who is not subject to U.S. income tax or (iii) complies with Section 409A of the Code. The term of each option will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised.

Our compensation committee may award stock appreciation rights under the 2024 Plan subject to such conditions and restrictions as it may determine. Stock appreciation rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right will be determined by our compensation committee but generally may not be less than 100 percent of the fair market value of our common stock on the date of grant unless the stock appreciation right (i) is granted pursuant to a transaction described in, and in a manner consistent with Section 424(a) of the Code, (ii) is granted to an individual who is not subject to U.S. income tax or (iii) complies with Section 409A of the Code. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may be exercised.

Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee may also grant shares of common stock that are free from any restrictions under the 2024 Plan. Unrestricted stock may be granted to participants in recognition of past services or for other valid consideration and may be issued in lieu of cash compensation due to such participant.

Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits for dividends that would be paid if the recipient had held a specified number of shares of common stock.

Our compensation committee may grant cash bonuses under the 2024 Plan to participants, subject to the achievement of certain performance goals.

The 2024 Plan provides that upon the effectiveness of a “sale event,” as defined in the 2024 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2024 Plan. To the

188

extent that awards granted under the 2024 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, such awards shall terminate. In the event of such termination, (i) individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time prior to the sale event or (ii) we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation rights equal (A) the difference between the per share cash consideration payable to stockholders in the sale event and the per share exercise price of the options or stock appreciation rights, multiplied by (B) the number of shares subject to such outstanding vested and exercisable options and stock appreciation rights (to the extent exercisable at prices not in excess of the per share cash consideration), and we may make or provide for a payment, in cash or in kind, to participants holding other vested awards equal to the per share cash consideration multiplied by the number of vested shares underlying such awards.

Our board of directors may amend or discontinue the 2024 Plan and our compensation committee may amend or cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose, but no such action may adversely affect rights under an award without the holder’s consent. Certain amendments to the 2024 Plan require the approval of our stockholders. The administrator of the 2024 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding stock options and stock appreciation rights or effect the repricing of such awards through cancellation and re-grants without stockholder consent. No awards may be granted under the 2024 Plan after the date that is 10 years from the effective date of the 2024 Plan. No awards under the 2024 Plan have been made prior to the date of this prospectus.

2024 Employee Stock Purchase Plan

Our ESPP was adopted by our board of directors on May 29, 2024, approved by our stockholders on May 30, 2024 and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus forms a part is declared effective by the SEC. The ESPP is intended to qualify as an “employee stock purchase plan” within the meaning of Section 423 of the Code. The ESPP initially reserves and authorizes the issuance of up to a total of 324,243 shares of our common stock to participating employees. The ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 648,486 shares of common stock, (ii) one percent of the outstanding number of shares of common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the ESPP. The number of shares reserved under the ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

All employees employed by us or any designated subsidiary or affiliate as of the first day of an offering are eligible to participate; provided that the administrator of the ESPP may determine that employees must satisfy one or more of the following service requirements before participating in the ESPP: (1) customary employment with us for more than 20 hours per week and 5 or more months per calendar year, (2) continuous employment with us for a minimum period of time, not to exceed two years, prior to the first date of an offering or (3) such other criteria as the administrator of the ESPP may determine consistent with the requirements of section 423 of the Code. However, any employee who owns 5 percent or more of the total combined voting power or value of all classes of our stock will not be eligible to purchase shares of common stock under the ESPP.

We may make one or more offerings each year to our employees to purchase shares under the ESPP, consisting of one or more purchase periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least 15 business days before the applicable offering date.

Each employee who is a participant in the ESPP may purchase shares of our common stock by authorizing payroll deductions of up to percent of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of our common stock on the last business day of the offering period at a price

189

equal to 85 percent of the fair market value of the shares of our common stock on the first business day of the offering period or the last business day of the purchase period, whichever is lower, provided that no more than the number of shares of common stock determined by dividing $25,000 by the fair market value of our common stock on the offering date of the offering (or such other number as established by the administrator in advance of the offering period) may be purchased by any one employee during each offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of our common stock, valued at the start of the purchase period, under the ESPP in any calendar year.

The accumulated payroll deductions of any employee who is not a participant on the last day of an offering period will be refunded. An employee’s rights under the ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason.

The ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of our common stock authorized under the ESPP and certain other amendments require the approval of our stockholders.

Senior Executive Cash Incentive Bonus Plan

On May 29, 2024, our board of directors adopted the Senior Executive Cash Incentive Bonus Plan (the “Bonus Plan”), which will become effective upon effectiveness of the registration statement of which this prospectus forms a part. The Bonus Plan provides for annual cash bonus payments based upon the attainment of company and individual performance targets established by our compensation committee. The payment targets will be related to financial and operational measures or objectives with respect to our company (the “Corporate Performance Goals”) as well as individual performance objectives.

Our compensation committee may select Corporate Performance Goals from among the following: developmental, publication, clinical or regulatory milestones; scientific or technological advances; R&D capabilities; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation, and amortization; net income (loss) (either before or after interest, taxes, depreciation, and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions, licenses, collaborations or strategic transactions; financing or other capital raising transactions; operating income (loss); return on capital assets, equity, or investment; stockholder returns; return on sales; total shareholder return; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of our common stock; bookings, new bookings, or renewals; sales or market shares; number of prescriptions or prescribing physicians; coverage decisions; leadership development, employee retention and recruiting and other human resources matters; operating income and/or net annual recurring revenue, or any other performance goal as selected by the compensation committee, any of which may be measured in absolute terms, as compared to any incremental increase, in terms of growth, as compared to results of a peer group, against the market as a whole, compared to applicable market indices, and/or measured on a pre-tax or post-tax basis.

Each executive officer who is selected to participate in the Bonus Plan will have a target bonus opportunity set for each performance period. The bonus formulas will be adopted in each performance period by the compensation committee and communicated to each executive. The Corporate Performance Goals will be measured at the end of each performance period after our financial reports have been published or such other appropriate time as the compensation committee determines. If the Corporate Performance Goals and individual performance objectives are met, payments will be made as soon as practicable following the end of each performance period, but no later than two and one-half months after the end of the fiscal year in which such performance period ends. Subject to the rights contained in any agreement between the executive officer and us, an executive officer must be employed by us on the bonus payment date to be eligible to receive a bonus payment. The Bonus Plan also permits the compensation committee to approve additional bonuses to executive officers in its sole discretion.

190

Equity Grants in Connection with this Offering

In connection with this offering, our board of directors has approved the grant of options for the purchase of an aggregate of 1,040,071 shares of common stock to certain employees, including certain of our executive officers, based on the number of shares outstanding following this offering and the concurrent private placement, which will be equal to 35,376,457 based on an assumed initial public offering price of $17.00, which is the midpoint of the price range set forth on the cover page of this prospectus. The effectiveness of this grant of stock options is contingent on, and effective immediately following, the effectiveness of the registration statement of which this prospectus forms a part. The stock options will have a per share exercise price equal to initial public offering price set forth on the cover page of the final prospectus included in the registration statement, which will be the fair market value of a share of our common stock on the grant date of the stock options. The stock options will be granted under and subject to the terms and conditions of the 2024 Stock Option and Incentive Plan, and the applicable stock option agreements thereunder. The stock options will vest and become exercisable as follows: 25% of the shares subject to the stock option vested on the one-year anniversary of the vesting commencement date, and the remaining 75% of the shares subject to the stock option vest on a monthly basis thereafter, in each case, subject to the individual’s continuous service relationship with us through each applicable vesting date. Our board of directors has approved such option grants for Messrs. Ceesay and Ignelzi to purchase 530,647 and 81,366 shares of our common stock, respectively, and for Ms. Gault to purchase 88,442 shares of our common stock.

191

DIRECTOR COMPENSATION

2023 Director Compensation Table

The following table presents the total compensation paid by us to non-employee members of our board of directors during the fiscal year ended December 31, 2023. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or non-equity awards to, or pay any other compensation to any of the members of our board of directors in 2023 for their services as members of the board of directors. Mr. Ceesay, our Chief Executive Officer, does not receive any compensation from us for his service on our board of directors. See the section titled “Executive Compensation” for more information on the compensation paid to or earned by Mr. Ceesay as an employee for year ended December 31, 2023. In addition, Dr. Huber did not receive any compensation from us for his service on our board of directors for year ended December 31, 2023. See the section titled “Executive Compensation” for more information on the compensation paid to or earned by Dr. Huber for his services to us as our former Chief Executive Officer through the TRV Agreement for year ended December 31, 2023.


Name ⁽¹⁾	Fees Earned or Paid in Cash ($)		Option Awards($) ⁽²⁾		All Other Compensation ($)			Total ($)
Steven Paul, M.D. ⁽³⁾		—		548,822		20,165	⁽⁴⁾		568,987
Reid Huber, Ph.D.		—		—		400,255	⁽⁴⁾		400,255
Jeffrey K. Tong, Ph.D.		—		—		55,500	⁽⁴⁾		55,500
James I. Healy, M.D., Ph.D.		—		—		—			—
Raymond Kelleher, M.D., Ph.D.		—		—		—			—
Sanjay Mistry, Ph.D.		—		—		—			—

(1)	As permitted by SEC rules, David Bredt, M.D., Ph.D., our Chief Scientific Officer, has been omitted from the table as he does not earn compensation for his services as a director.

(2)

The amounts reported in this column represent the aggregate grant date fair value of a stock option granted to Dr. Paul during 2023, as calculated in accordance with FASB ASC Topic 718. Such grant date value does not take into account any estimated forfeitures related to service-based vesting conditions. The assumptions used in the grant date fair value of the awards in this column are described in Note 9—“Stock-Based Compensation” to our consolidated financial statements included elsewhere in this prospectus.

(3)	As of December 31, 2023, Dr. Paul held 477,642 unvested shares of restricted stock and an unexercised stock option to purchase 95,640 shares of our common stock. None of our other non-employee directors held any outstanding unvested stock awards or unexercised stock option.

(4)

Dr. Huber and Dr. Tong did not receive any cash compensation from us for their services as our Chief Executive Officer and Treasurer, respectively, or as members of our board of directors. Dr. Paul did not receive any cash compensation from us for his services as a director. During the year ended December 31, 2023, each of Dr. Paul, Dr. Huber and Dr. Tong provided consulting services to us through the TRV Agreement. As described below under the section titled “Certain Relationships and Related Party Transactions,” we incurred costs totaling $1.2 million during the fiscal year ended December 31, 2023 for the services provided by Third Rock Ventures, LLC, which included, among other things, the consulting services of Dr. Paul, Dr. Huber and Dr. Tong. Of the total fees we incurred under the TRV Agreement in the year ended December 31, 2023, (i) $20,165 was related to the consulting services provided by Dr. Paul, (ii) $400,225 was related to the consulting services provided by Dr. Huber and (iii) $55,500 was related to the consulting services provided by Dr. Tong.

Non-Employee Director Compensation

Prior to this offering and in connection with Ms. Burrell’s appointment to the board of directors in January 2024, Ms. Burrell entered into an offer letter agreement, pursuant to which she is eligible to receive an annual cash retainer of $30,000 per year, payable in equal quarterly installments, and a stock option award to purchase 35,027 shares of our common stock. In addition, prior to this offering and in connection with John Maraganore, Ph.D.’s appointment to the board of directors in March 2024, Dr. Maraganore entered into an offer letter agreement, pursuant to which he is eligible to receive an annual cash retainer of $30,000 per year, payable in equal quarterly installments, and a stock option award to purchase 87,567 shares of our common stock.

192

In connection with this offering, on May 29, 2024, our board of directors adopted a non-employee director compensation policy, which will become effective upon effectiveness of the registration statement of which this prospectus forms a part. The policy is designed to enable us to attract and retain, on a long-term basis, highly qualified non-employee directors. Under the policy, our non-employee directors will be eligible to receive cash retainers (which will be payable quarterly in arrears and prorated for partial years of service) and equity awards as set forth below:


Annual Retainer for Board Membership
$40,000 for general availability and participation in meetings and conference calls of our Board of Directors
Additional Annual Retainer for Committee Membership
Audit Committee Chairperson:	$	15,000
Audit Committee member (other than Chairperson):	$	7,500
Compensation Committee Chairperson:	$	10,000
Compensation Committee member (other than Chairperson):	$	5,000
Nominating and Corporate Governance Committee Chairperson:	$	8,000
Nominating and Corporate Governance Committee member (other than Chairperson):	$	4,000
Science & Technology Committee Chairperson:	$	8,000
Science & Technology Committee member (other than Chairperson):	$	4,000

In addition, our policy will provide that, upon initial election or appointment to our board of directors, each new non-employee director will be granted a one-time grant of a non-statutory stock option to purchase 29,756 shares of our common stock on the date of such director’s election or appointment to the board of directors (the “Director Initial Grant”). The Director Initial Grant will vest over three years, with 1/3 of the Director Initial Grant vesting upon the first anniversary of the vesting commencement date and the remaining 2/3 of the Director Initial Grant vesting in 24 monthly installments thereafter, subject to the non-employee director’s continued service to us on the board of directors. On the date of each annual meeting of stockholders of our company following the completion of this offering, each non-employee director who will continue as a non-employee director following such meeting will be granted an annual award of a non-statutory stock option to purchase 14,878 shares of common stock (the “Director Annual Grant”). The Director Annual Grant will vest in full on the earlier of the first anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director’s continued service to us on the board of directors. If a new non-employee director joins our Board on a date other than the date of our annual meeting of stockholders, then such non-employee director will be granted a pro-rata portion of the Director Annual Grant based on the number of months between such non-employee director’s appointment and the next annual meeting of stockholders. Such awards are subject to full accelerated vesting upon the sale of our company.

The aggregate amount of compensation, including both equity compensation and cash compensation, paid to any non-employee director for service as a non-employee director in a calendar year period will not exceed $1,000,000 in the first calendar year such individual becomes a non-employee director and $750,000 in any other calendar year.

We will reimburse all reasonable out-of-pocket expenses incurred by directors for their attendance at meetings of our board of directors or any committee thereof.

Employee directors will receive no additional compensation for their service as a director.

193

CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS

In addition to the compensation arrangements, including employment, termination of employment and change in control arrangements, and indemnification arrangements discussed, when required, in the sections titled “Management” and “Executive Compensation” and the registration rights described in the section titled “Description of Capital Stock—Registration Rights,” the following is a description of all transactions since our date of incorporation and each currently proposed transaction in which:

•

we have been or are to be a participant;

•

the amounts involved exceeded or will exceed the lesser of $120,000 or 1% of the average of our total assets at year-end for the last two completed fiscal years; and

•

any of our directors, executive officers or holders of more than 5% or more of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities or affiliated entities, had or will have a direct or indirect material interest.

Convertible Promissory Notes

In August 2022, we issued convertible promissory notes to Third Rock Ventures V, L.P. and Johnson & Johnson Innovation—JJDC, Inc. (“JJDC”), each in the principal amount of $2,000,000. In September 2022, we issued additional convertible promissory notes to Third Rock Ventures V, L.P. and JJDC, each in the principal amount of $2,000,000. Each of notes accrued interest at a rate of 8% per year and converted into shares of our Series A convertible preferred stock, as further described below.

Series A Convertible Preferred Stock Financing

In December 2022, we issued and sold an aggregate of 40,182,354 of Series A convertible preferred stock at a price per share of $1.00 to Third Rock Ventures V, L.P. and JJDC, for an aggregate purchase price of approximately $40.2 million. Included in this amount was approximately $8.2 million of outstanding principal and interest on convertible promissory notes issued in August and September 2022, all of which converted into Series A convertible preferred stock in this financing in accordance with their terms.

In February 2023, we amended the Series A convertible preferred stock purchase agreement to add an additional investor, ARCH Venture Fund XII, L.P. In conjunction with this amendment, the existing requisite stockholders waived certain milestones to accelerate the milestone tranches. As a result, during February 2023, we issued and sold an aggregate of 60,000,000 of Series A convertible preferred stock at a price per share of $1.00 to Third Rock Ventures V, L.P., Third Rock Ventures VI, L.P., JJDC and ARCH Venture Fund XII, L.P., for an aggregate purchase price of $60.0 million.

Each outstanding share of Series A convertible preferred stock will convert into shares of common stock at a ratio of 1-for-8.5648 immediately prior to the completion of this offering. The following table summarizes the shares of our Series A convertible preferred stock issued to our related parties:


Purchasers ⁽¹⁾	Series A Convertible Preferred Stock		Total Purchase Price
Third Rock Ventures V, L.P. ⁽²⁾		56,091,177	$	56,091,177	⁽³⁾
Third Rock Ventures VI, L.P. ⁽²⁾		8,000,000	$	8,000,000
Johnson & Johnson Innovation—JJDC, Inc. ⁽⁴⁾		16,091,177	$	16,091,177	⁽⁵⁾
ARCH Venture Fund XII, L.P. ⁽⁶⁾		20,000,000	$	20,000,000

(1)	Additional details regarding these stockholders and their equity holdings are included in the section titled “Principal Stockholders.”

194

(2)	Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. Dr. Huber and Dr. Tong, members of our board of directors, were designated to our board of directors by Third Rock Ventures and are each partners at Third Rock Ventures.

(3)	$52,000,000 of the total purchase price was funded in cash and $4,091,177 was funded by the conversion of Third Rock Ventures V, L.P.’s convertible promissory note (inclusive of principal and accrued interest).

(4)	JJDC beneficially owns more than 5% of our outstanding capital stock. Dr. Mistry, a former member of our board of directors, was designated to our board of directors by JJDC and is the Vice President of Venture Investments at JJDC.

(5)	$12,000,000 of the total purchase price was funded in cash and $4,091,177 was funded by the conversion of JJDC’s convertible promissory note (inclusive of principal and accrued interest).

(6)	ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Dr. Maraganore, a member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a venture partner at ARCH Venture Partners.

Series B Convertible Preferred Stock Financing

In August 2023, we issued and sold an aggregate of 51,273,790 of Series B convertible preferred stock at a price per share of $1.67727, for an aggregate purchase price of approximately $86.0 million, which included the voluntary early exercise of certain stockholders’ milestone tranche shares of Series B convertible preferred stock. In March 2024, we issued and sold an aggregate of 38,157,240 of Series B convertible preferred stock at a price per share of $1.67727, for an aggregate purchase price of approximately $64.0 million.

Each outstanding share of Series B convertible preferred stock will convert into shares of common stock at a ratio of 1-for-8.5648 immediately prior to the completion of this offering. The following table summarizes the shares of our Series B convertible preferred stock issued to our related parties:


Purchasers ⁽¹⁾	Series B Convertible Preferred Stock		Total Purchase Price
Third Rock Ventures VI, L.P. ⁽²⁾		298,103	$	499,999
Johnson & Johnson Innovation—JJDC, Inc. ⁽³⁾		298,103	$	499,999
ARCH Venture Fund XII, L.P. ⁽⁴⁾		11,924,138	$	19,999,999
Entities affiliated with Cormorant ⁽⁵⁾		14,905,172	$	24,999,998
Sofinnova Venture Partners XI, L.P. ⁽⁶⁾		11,924,138	$	19,999,999
Entities affiliated with Fidelity ⁽⁷⁾		14,905,173	$	25,000,000
SMALLCAP World Fund, Inc. ⁽⁸⁾		14,905,173	$	25,000,000

(1)	Additional details regarding these stockholders and their equity holdings are included in the section titled “Principal Stockholders.”

(2)	Entities affiliated with Third Rock Ventures beneficially own more than 5% of our outstanding capital stock. Dr. Huber and Dr. Tong, members of our board of directors, were designated to our board of directors by Third Rock Ventures and are each partners at Third Rock Ventures.

(3)	JJDC beneficially owns more than 5% of our outstanding capital stock. Dr. Mistry, a former member of our board of directors, was designated to our board of directors by JJDC and is the Vice President of Venture Investments at JJDC.

(4)	ARCH Venture Fund XII, L.P. beneficially owns more than 5% of our outstanding capital stock. Dr. Maraganore, a member of our board of directors, was designated to our board of directors by ARCH Venture Fund XII, L.P. and is a venture partner at ARCH Venture Partners.

(5)

Cormorant collectively refers to Cormorant Global Healthcare Master Fund, LP, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare Fund IV, LP and Cormorant Private Healthcare Fund V, LP. Dr. Kelleher, a member of our board of directors, was designated to our board of directors by Cormorant and is a Managing Director at Cormorant.

(6)	Dr. Healy, a member of our board of directors, was designated to our board of directors by Sofinnova Venture Partners XI, L.P. and is Managing Partner of Sofinnova Investments, Inc.

195

(7)

Fidelity collectively refers to Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund, Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund, Fidelity Growth Company Commingled Pool and Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. Entities affiliated with Fidelity beneficially own more than 5% of our outstanding capital stock.

(8)	SMALLCAP World Fund, Inc. beneficially owns more than 5% of our outstanding capital stock.

Concurrent Private Placement

Sofinnova Venture Partners XI, L.P. (“Sofinnova”), a beneficial owner of more than 5% of our outstanding capital stock and an affiliate of Dr. Healy, a member of our board of directors, is expected to purchase from us an aggregate of $8.0 million in shares of our common stock in a concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a per share price equal to the initial public offering price. Based upon an assumed initial public offering price of $17.00, the midpoint of the estimated price range set forth on the cover page of this prospectus, this would be 470,589 shares of common stock. The private placement would close concurrently with, and be contingent and conditioned upon consummation of, this offering, as well as certain other customary closing conditions. However, this offering is not contingent on the consummation of the concurrent private placement. In connection with the concurrent private placement, we will enter into a stock purchase agreement with Sofinnova. Because we have not yet entered into the stock purchase agreement, we could determine to sell more, fewer or no shares to Sofinnova, and Sofinnova could determine to purchase more, fewer or no shares in the concurrent private placement.

Agreements with Stockholders

License and Collaboration Agreements

On August 9, 2022, we entered into an Option and License Agreement with Janssen Pharmaceutica NV (“Janssen”), as amended (the “Janssen License”). Sanjay Mistry, Ph.D., a former member of our board of directors, is Vice President of Venture Investments at JJDC, and JJDC, which is a beneficial owner of more than 5% of our outstanding capital stock, is an affiliate of Janssen. Please see the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—License and Collaboration Agreements” for a description of and payments made under the Janssen License.

Service Agreement with Third Rock Ventures

Third Rock Ventures, a beneficial owner of more than 5% of our outstanding capital stock, has provided us with business, technical, financial, IT or scientific advice pursuant to a service agreement with Third Rock Ventures, dated August 9, 2022 (“service agreement”). In accordance with the service agreement, during the period from February 10, 2022 (inception) to December 31, 2022, the year ended December 31, 2023, and the three months ended March 31, 2023 and 2024 we incurred costs for services totaling $2.1 million, $1.2 million, $0.5 million and $0.1 million, respectively, which were reimbursed to Third Rock Ventures. Such costs were invoiced without service markups.

Investors’ Rights Agreement

We are a party to an amended and restated investors’ rights agreement, dated as of August 7, 2023 (“investors’ rights agreement”), with certain holders of more than 5% of our outstanding capital stock, including entities affiliated with our directors.

The investors’ rights agreement provides certain holders of our convertible preferred stock with a participation right to purchase their pro rata share of new securities that we may propose to sell and issue, subject to certain exceptions. Such participation right will terminate upon the completion of this offering. The investors’ rights agreement further provides certain holders of our convertible preferred stock with certain rights, including

196

certain registration rights with respect to the registrable securities held by them. See the section titled “Description of Capital Stock—Registration Rights” for additional information.

Stockholders Agreement

We are a party to an amended and restated stockholders agreement, dated as of August 7, 2023 (“stockholders agreement”), with certain holders of more than 5% of our outstanding capital stock, including entities affiliated with our directors. The stockholders agreement provides for drag-along rights in respect of sales by certain holders of our capital stock. The stockholders agreement also contains provisions with respect to the elections of our board of directors and its composition.

The stockholders agreement also provides certain investors the right to purchase all or any portion of transfer stock, as well as the right of co-sale and participate in any proposed transfers. The stockholders agreement will terminate upon completion of this offering.

Employment Arrangements

We have entered into offer letter agreements with certain of our executive officers, and granted stock options to our executive officers, as more fully described in the section titled “Executive Compensation.”

Equity Grants

We have granted options to purchase shares of our common stock to certain of our executive officers and directors. For more information regarding the options granted to our executive officers and directors, see the sections titled “Executive Compensation” and “Director Compensation” included elsewhere in this prospectus.

Indemnification Agreements

Our third amended and restated certificate of incorporation will contain provisions limiting the liability of directors and officers, and our amended and restated bylaws will provide that we will indemnify each of our directors and officers to the fullest extent permitted under Delaware law. Our third amended and restated certificate of incorporation and amended and restated bylaws will also provide our board of directors with discretion to indemnify our employees and other agents when determined appropriate by our board of directors. In addition, we have entered into or intend to enter into an indemnification agreement with each of our directors and executive officers, which will require us to indemnify them. For more information regarding these agreements, see the section titled “Management—Limitations on Liability and Indemnification Agreements” included elsewhere in this prospectus.

Policies and Procedures for Transactions with Related Persons

Prior to completion of this offering, we intend to adopt a written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any series of our common stock, and any members of the immediate family of any of the foregoing persons are not permitted to enter into a related person transaction with us without the approval or ratification of our board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of any series of our common stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in a fiscal year) and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee for review, consideration, and approval. In approving or rejecting any such proposal, our board of directors or our audit committee is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related person’s interest in the transaction.

197

PRINCIPAL STOCKHOLDERS

The following table sets forth information regarding beneficial ownership of our capital stock as of May 10, 2024 by:

•

each person, or group of affiliated persons, known by us to beneficially own more than 5% of our common stock;

•

each of our directors;

•

each of our named executive officers; and

•

all of our current executive officers and directors as a group.

We have determined beneficial ownership in accordance with the rules of the SEC. Under these rules, beneficial ownership includes any shares of common stock as to which the individual or entity has sole or shared voting power or investment power. Unless otherwise indicated below, to our knowledge the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have deemed shares of common stock subject to options that are currently exercisable or exercisable within 60 days of May 10, 2024 to be outstanding and to be beneficially owned by the person holding the option for the purpose of computing the percentage ownership of that person but have not treated them as outstanding for the purpose of computing the percentage ownership of any other person.

Applicable percentage ownership before the offering and concurrent private placement is based on an aggregate of 26,317,633 shares of common stock (which includes 2,030,242 shares of unvested restricted common stock) deemed to be outstanding as of May 10, 2024, after giving effect to the automatic conversion of all 189,613,384 shares of our convertible preferred stock into 22,146,816 shares of common stock immediately prior to the completion of this offering and the concurrent private placement.

Applicable percentage ownership after the offering and concurrent private placement is based on 35,376,457 shares of common stock assumed to be outstanding immediately after the completion of this offering and the concurrent private placement (assuming the sale of 1,058,824 shares of common stock based on an initial public offering price of $17.00, which is the midpoint of the price range set forth on the cover page of this prospectus, and no exercise of the underwriters’ option to purchase additional shares).

Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Rapport Therapeutics, Inc., 1325 Boylston Street, Suite 401, Boston, MA 02215.


			Percentage of Shares Beneficially Owned
Name of Beneficial Owner	Number of Shares Beneficially Owned		Before Offering			After Offering
5% or Greater Shareholders:
ARCH Venture Fund XII, L. P.⁽¹⁾		3,728,738		14.17	%		10.54	%
Entities affiliated with Cormorant⁽²⁾		1,740,921		6.62	%		4.92	%
Johnson & Johnson Innovation—JJDC, Inc.⁽³⁾		2,498,051		9.49	%		7.06	%
Entities affiliated with Fidelity⁽⁴⁾		1,740,922		6.62	%		4.92	%
One or more entities advised by Capital Research and Management Company⁽⁵⁾		1,740,922		6.62	%		4.92	%
Entities affiliated with Third Rock Ventures⁽⁶⁾		8,104,451		30.79	%		22.91	%
Sofinnova Venture Partners, XI, L.P.⁽⁷⁾		1,392,738		5.29	%		3.94	%

198


			Percentage of Shares Beneficially Owned
Name of Beneficial Owner	Number of Shares Beneficially Owned		Before Offering			After Offering
Named Executive Officers and Directors:
Abraham N. Ceesay, M.B.A., Chief Executive Officer and Director⁽⁸⁾		789,703		3.00	%		2.23	%
Troy Ignelzi, Chief Financial Officer		—		—			—
Cheryl Gault, Chief Operations Officer⁽⁹⁾		157,941		*			*
Reid Huber, Ph.D., Former Chief Executive Officer and Director⁽⁶⁾		—		—			—
Steven M. Paul, M.D.⁽¹⁰⁾		477,642		1.81	%		1.35	%
Terry-Ann Burrell, M.B.A.⁽¹¹⁾		2,189		*			*
James I. Healy, M.D., Ph.D.⁽⁷⁾		—		—			—
Raymond Kelleher, M.D., Ph.D.		—		—			—
John Maraganore, Ph.D.⁽¹²⁾		5,472		*			*
Jeffrey K. Tong, Ph.D.⁽⁶⁾		—		—			—
All executive officers and directors as a group (13 persons)⁽¹³⁾		2,398,846		45.22	%		31.51	%

*	Represents beneficial ownership of less than 1%.

(1)

Consists of (i) 2,336,000 shares of common stock issuable upon conversion of Series A preferred stock held by ARCH Venture Fund XII, L.P. (“ARCH XII”) and (ii) 1,392,738 shares of common stock issuable upon conversion of Series B preferred stock held by ARCH XII. ARCH Venture Partners XII, L.P. (“AVP XII LP”) is the general partner of ARCH XII. ARCH Venture Partners XII, LLC (“AVP XII LLC”) is the general partner of AVP XII LP. Keith Crandell, Kristina Burow, Steven Gillis and Robert Nelsen comprise the investment committee of AVP XII LLC (the “AVP XII LLC Committee Members”). Each of AVP XII LP and AVP XII LLC may be deemed to beneficially own the shares held by ARCH XII, and each of the AVP XII LLC Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH XII. Each of AVP XII LP, AVP XIILLC and the AVP XII LLC Committee Members disclaim beneficial ownership except to the extent of their pecuniary interest therein, if any. The address of ARCH Venture Partners is 8755 West Higgins Road, Suite 1025, Chicago, IL 60631.

(2)

Consists of (i) 83,702 shares of common stock issuable upon conversion of Series B preferred stock held by Cormorant Global Healthcare Master Fund, LP, (ii) 694,698 shares of common stock issuable upon conversion of Series B preferred stock held by Cormorant Private Healthcare Fund III, LP, (iii) 229,802 shares of common stock issuable upon conversion of Series B preferred stock held by Cormorant Private Healthcare Fund IV, LP and (iv) 732,719 shares of common stock issuable upon conversion of Series B preferred stock held by Cormorant Private Healthcare Fund V, LP. Cormorant Asset Management LP (“Cormorant Management”) serves as the investment manager to the Cormorant funds listed above (the “Cormorant Funds”), and Bihua Chen serves as the managing member of Cormorant Management. Ms. Chen may be deemed to beneficially own the shares held by the Cormorant Funds. The business address of the Cormorant Funds, Cormorant Management and Ms. Chen is 200 Clarendon Street, 52nd Floor, Boston, MA 02116.

(3)

Consists of (i) 583,784 shares of common stock held by Johnson & Johnson Innovation—JJDC, Inc. (“JJDC”), (ii) 1,879,449 common stock issuable upon conversion of Series A preferred stock held by JJDC and (iii) 34,818 common stock issuable upon conversion of Series B preferred stock held by JJDC. JJDC is a wholly owned subsidiary of Johnson & Johnson (“J&J”). J&J may be deemed to indirectly beneficially own the shares that are directly beneficially owned by JJDC. The principal business address of J&J is One Johnson & Johnson Plaza, New Brunswick, NJ 08933, and the principal business address of JJDC is 410 George Street, New Brunswick, NJ 08901.

(4)

Consists of (i) 167,046 shares of common stock issuable upon conversion of Series B preferred stock held by Bangle & Co fbo Fidelity Advisor Series VII: Fidelity Advisor Biotechnology Fund, (ii) 723,107 shares of common stock issuable upon conversion of Series B preferred stock held by Mag & Co fbo Fidelity Growth Company Commingled Pool, (iii) 130,906 shares of common stock issuable upon conversion of Series B preferred stock held by Mag & Co fbo Mt. Vernon Street Trust: Fidelity Series Growth Company

199

Fund, (iv) 516,185 shares of common stock issuable upon conversion of Series B preferred stock held by Powhatan & Co., LLC fbo Fidelity Mt. Vernon Street Trust: Fidelity Growth Company Fund and (v) 203,678 shares of common stock issuable upon conversion of Series B preferred stock held by Powhatan & Co., LLC FBO Fidelity Mt. Vernon Street Trust: Fidelity Growth Company K6 Fund. All of the securities listed in the table above are beneficially owned, or may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders’ voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders’ voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of FMR LLC is 245 Summer Street, Boston, MA 02210.

(5)

Consists of 1,740,922 shares of Series B Preferred Stock held by SMALLCAP World Fund, Inc. (the “CRMC Stockholder”). Capital Research and Management Company (“CRMC”) is the investment adviser for the CRMC Stockholder. CRMC and/or Capital International Investors (“CII”) may be deemed to be the beneficial owner of the shares held by the CRMC Stockholder; however, each of CRMC and CII expressly disclaims that it is the beneficial owner of such securities. Julian N. Abdey, Peter Eliot, Brady L. Enright, Bradford F. Freer, Peter Gusev, Leo Hee, M. Taylor Hinshaw, Roz Hongsaranagon, Akira Horiguchi, Shlok Melwani, Dimitrije M. Mitrinovic, Aidan O’Connell, Samir Parekh, Piyada Phanaphat, Andraz Razen, Renaud H. Samyn, Arun Swaminathan, Thatcher Thompson and Gregory W. Wendt, as portfolio managers, have voting and investment power over the shares held by the CRMC Stockholder. The business address for each of the CRMC Stockholder, CMRC and CII is 333 South Hope Street, Los Angeles, California 90071. The CRMC Stockholder acquired the securities described above in the ordinary course of its business.

(6)

Consists of (i) 583,784 shares of common stock held by Third Rock Ventures V, L.P. (“TRV V”), (ii) 6,551,449 shares of common stock issuable upon conversion of Series A preferred stock held by TRV V, (iii) 934,400 shares of common stock issuable upon conversion of Series A preferred stock held by Third Rock Ventures VI, L.P. (“TRV VI”) and (iv) 34,818 shares of common stock issuable upon the conversion of Series B preferred stock held by TRV VI. The sole general partner of TRV V is Third Rock Ventures GP V, L.P. (“TRV GP V”). The sole general partner of TRV GP V is TRV GP V, LLC (“TRV GP V LLC”). The sole general partner of TRV VI is Third Rock Ventures GP VI, L.P. (“TRV GP VI”). The sole general partner of TRV GP VI is TRV GP VI, LLC (“TRV GP VI LLC”). Abbie Celniker, Ph.D., Robert Tepper, M.D., Reid Huber, Ph.D., Jeffrey Tong, Ph.D., Kevin Gillis, Neil Exter and Cary Pfeffer, M.D. are the managing members of TRV GP V LLC and TRV GP VI LLC and collectively make voting and investment decisions with respect to shares held by TRV V and TRV VI. David Kaufman is also a managing member of TRV GP VI LLC and contributes to voting decisions with respect to shares held by TRV VI. Dr. Huber and Dr. Tong are members of our board of directors. The principal address for the entities and individuals named in this paragraph is 201 Brookline Avenue, Suite 1401, Boston, Massachusetts 02215.

(7)

Consists of 1,392,738 shares of Series B Preferred Stock held by Sofinnova Venture Partners XI, L.P. (“SVP XI”), except that Sofinnova Management XI, L.P. (“SM XI LP”), the general partner of SVP XI, may be deemed to have sole voting power, Sofinnova Management XI, L.L.C. (“SM XI LLC”), the general partner of SM XI LP, may be deemed to have sole voting power, and James I. Healy, M.D., Ph.D. and Maha Katabi, Ph.D., the managing members of SM XI LLC, may be deemed to have shared power to vote these shares. Shares of common stock beneficially owned after this offering does not include the shares of common stock that SVP XI intends to purchase in the concurrent private placement. For additional information on SVP XI’s expected participation in the concurrent private placement, see the section titled “Certain Relationships and Related Person Transactions—Concurrent Private Placement” included elsewhere in this prospectus. Each of SM XI LP, SM XI LLC, Dr. Healy and Dr. Katabi disclaim beneficial ownership of the shares held by SVP XI, except to the extent of their respective pecuniary interest therein.

200

The principal address for the entities and individuals named in this paragraph is 3000 Sand Hill Road, Building 4, Suite 250, Menlo Park, CA 94025.

(8)

Consists of (i) 626,245 shares of common stock (including shares of unvested restricted common stock) held by Mr. Ceesay, (ii) 81,729 shares of common stock held by the The Ceesay Family Irrevocable Trust u/t/d March 27, 2024 and (iii) 81,729 shares of common stock held by The Dorothy Ceesay Irrevocable Trust u/t/d dated March 27, 2024 .

(9)	Consists of 157,941 shares of common stock (including unvested restricted common stock) held by Ms. Gault.

(10)	Consists of 477,642 shares of common stock (including unvested restricted common stock) held by Dr. Paul.

(11)	Consists of 2,189 shares of common stock issuable upon the exercise of options exercisable within 60 days of May 10, 2024 held by Ms. Burrell.

(12)	Consists of 5,472 shares of common stock issuable upon the exercise of options exercisable within 60 days of May 10, 2024 held by Dr. Maraganore.

(13)

Consists of (i) 2,974,969 shares of common stock (including unvested restricted common stock), (ii) 7,485,849 shares of common stock issuable upon conversion of Series A preferred stock, (iii) 1,427,556 shares of common stock issuable upon conversion of Series B preferred stock and (iv) 7,661 shares of common stock issuable upon the exercise of options exercisable within 60 days of May 10, 2024.

201

DESCRIPTION OF CAPITAL STOCK

General

The following description of our capital stock and certain provisions of our third amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part. Copies of these documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will be in effect on the completion of this offering.

Upon filing of our third amended and restated certificate of incorporation and the completion of this offering and the concurrent private placement, our authorized capital stock will consist of 500,000,000 shares of common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share, all of which shares of preferred stock will be undesignated.

As of March 31, 2024, there were 26,317,633 shares of common stock outstanding (which includes 2,030,242 shares of unvested restricted common stock) and held of record by 57 stockholders. This amount assumes the conversion of all outstanding shares of our convertible preferred stock into common stock, which will occur immediately prior to the completion of this offering.

Common Stock

Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.

In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering and the concurrent private placement will be, when issued and paid for, validly issued, fully paid and non-assessable.

Preferred Stock

Immediately prior to the completion of this offering, all outstanding shares of our convertible preferred stock will be converted into shares of our common stock. Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges, and restrictions thereof. These rights, preferences, and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms, and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock.

202

Stock Options

As of May 10, 2024, 2,769,721 shares of common stock were issuable upon the exercise of outstanding stock options under the 2022 Plan, at a weighted-average exercise price of $5.45 per share. Following this offering, 3,814,618 shares of our common stock will be reserved for future issuance under the 2024 Plan, which will become effective once the registration statement of which this prospectus forms a part is declared effective, as well as any future automatic annual increases in the number of shares of common stock reserved for issuance under the 2024 Plan and any shares underlying outstanding stock awards granted under the 2022 Plan, that expire or are repurchased, forfeited, cancelled, or withheld. For additional information regarding terms of our equity incentive plans, see the section titled “Executive Compensation—Employee Benefit and Equity Compensation Plans” included elsewhere in this prospectus.

Registration Rights

Upon the completion of this offering and subject to the lock-up agreements entered into in connection with this offering and federal securities laws, certain holders of shares of our common stock, including those shares of our common stock that will be issued upon the conversion of our convertible preferred stock in connection with this offering, will initially be entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess registration rights pursuant to the terms of our third amended and restated investors’ rights agreement and are described in additional detail below. The registration of shares of our common stock pursuant to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay all registration expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form S-3 registrations described below.

Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and Form S-3 registration rights described below will expire no later than four years after the completion of this offering.

Demand Registration Rights

Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our convertible preferred stock upon completion of this offering, will be entitled to certain demand registration rights. At any time beginning 180 days after the completion of this offering, the holders of at least 25% of these shares may request that we register all or a portion of their shares. We are not required to effect more than two registration statements which are declared or ordered effective. Such request for registration must cover shares with an anticipated aggregate offering price of at least $5 million. With certain exceptions, we are not required to effect the filing of a registration statement during the period starting with the date of the filing of, and ending on a date 60 days following the effective date of the registration statement for this offering.

Piggyback Registration Rights

In connection with this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our convertible preferred stock upon completion of this offering, were entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this offering. After this offering, in the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the holders of these shares will be entitled to certain piggyback registration rights allowing the holder to include their shares in such registration, subject to certain marketing and other limitations.

203

Form S-3 Registration Rights

Upon the completion of this offering, certain holders of our common stock, including those issuable upon the conversion of shares of our convertible preferred stock upon completion of this offering, will be entitled to certain Form S-3 registration rights. Holders of at least 10% of these shares can make a request that we register their shares on Form S-3 if we are qualified to file a registration statement on Form S-3 and if the reasonably anticipated aggregate net proceeds of the shares offered would equal or exceed $1 million. We will not be required to effect more than two registrations on Form S-3 within any twelve-month period. The right to have such shares registered on Form S-3 is further subject to other specified conditions and limitations.

Expiration of Registration Rights

The demand registration rights and short-form registration rights granted under the investor rights agreement will terminate upon the earliest of (i) the closing of a “Deemed Liquidation Event,” as such term is defined in our amended and restated certificate of incorporation (as currently in effect), (ii) with respect to each stockholder, such date, on or after the completion of this offering, on which all registrable shares held by such stockholder may immediately be sold during any three-month period pursuant to Rule 144 of the Securities Act or another similar exemption and (iii) the fifth anniversary of the completion of this offering.

Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws and Delaware Law

Our third amended and restated certificate of incorporation and amended and restated bylaws will include a number of provisions that may have the effect of delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue non-negotiated takeover attempts. These provisions include the items described below.

Board Composition and Filling Vacancies

Our third amended and restated certificate of incorporation will provide for the division of our board of directors into three classes serving staggered three-year terms, with one class being elected each year. Our third amended and restated certificate of incorporation also will provide that directors may be removed only for cause and then only by the affirmative vote of the holders of two-thirds or more of the shares then entitled to vote at an election of directors. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of our board, may only be filled by the affirmative vote of a majority of our directors then in office even if less than a quorum. The classification of directors, together with the limitations on removal of directors and treatment of vacancies, has the effect of making it more difficult for stockholders to change the composition of our board of directors.

No Written Consent of Stockholders

Our third amended and restated certificate of incorporation provides that all stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting, and that stockholders may not take any action by written consent in lieu of a meeting. This limit may lengthen the amount of time required to take stockholder actions and would prevent the amendment of our amended and restated bylaws or removal of directors by our stockholders without holding a meeting of stockholders.

Meetings of Stockholders

Our third amended and restated certificate of incorporation and amended and restated bylaws provide that only a majority of the members of our board of directors then in office may call special meetings of stockholders and only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders. Our bylaws limit the business that may be conducted at an annual meeting of stockholders to those matters properly brought before the meeting.

204

Advance Notice Requirements

Our amended and restated bylaws establish advance notice procedures with regard to stockholder proposals relating to the nomination of candidates for election as directors or new business to be brought before meetings of our stockholders. These procedures provide that notice of stockholder proposals must be timely given in writing to our corporate secretary prior to the meeting at which the action is to be taken. Generally, to be timely, notice must be received at our principal executive offices not less than 90 days nor more than 120 days prior to the first anniversary date of the annual meeting for the preceding year. Our amended and restated bylaws specify the requirements as to form and content of all stockholders’ notices. These requirements may preclude stockholders from bringing matters before the stockholders at an annual or special meeting.

Amendment to Certificate of Incorporation and Bylaws

Any amendment of our third amended and restated certificate of incorporation must first be approved by a majority of our board of directors, and if required by law or our third amended and restated certificate of incorporation, must thereafter be approved by a majority of the outstanding shares entitled to vote on the amendment and a majority of the outstanding shares of each class entitled to vote thereon as a class, except that the amendment of the provisions relating to stockholder action, board composition, and limitation of liability must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class. Our amended and restated bylaws may be amended by the affirmative vote of a majority of the directors then in office, subject to any limitations set forth in the amended and restated bylaws; and may also be amended by the affirmative vote of a majority of the outstanding shares entitled to vote on the amendment, voting together as a single class, except that the amendment of the provisions relating to notice of stockholder business and nominations and special meetings must be approved by not less than two-thirds of the outstanding shares entitled to vote on the amendment, and not less than two-thirds of the outstanding shares of each class entitled to vote thereon as a class, or, if our board of directors recommends that the stockholders approve the amendment, by the affirmative vote of the majority of the outstanding shares entitled to vote on the amendment, in each case voting together as a single class.

Undesignated Preferred Stock

Our third amended and restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest, or otherwise. For example, if in the due exercise of its fiduciary obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our third amended and restated certificate of incorporation grants our board of directors broad power to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock. The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control of us.

Section 203 of the Delaware General Corporation Law

Upon completion of this offering, we will be subject to the provisions of Section 203 of the DGCL. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination” with an “interested stockholder” for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business combination is approved in a prescribed manner. Under Section 203, a

205

business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions:

•

before the stockholder became interested, our board of directors approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;

•

upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers, and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or

•

at or after the time the stockholder became interested, the business combination was approved by our board of directors and authorized at an annual or special meeting of the stockholders by the affirmative vote of at least two-thirds of the outstanding voting stock which is not owned by the interested stockholder.

Section 203 defines a business combination to include:

•

any merger or consolidation involving the corporation and the interested stockholder;

•

any sale, transfer, lease, pledge, or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;

•

subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;

•

subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and

•

the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges, or other financial benefits provided by or through the corporation.

In general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person.

Choice of Forum

Our amended and restated bylaws will provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any of our current or former directors, officers, or other employees or stockholders to us or our stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or our third amended and restated certificate of incorporation or amended and restated bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (iv) any action asserting a claim governed by the internal affairs doctrine.

However, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Consequently, this choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction or the Securities Act. Moreover, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all claims brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder.

206

In addition, our amended and restated bylaws will provide that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or certified any part of the documents underlying the offering.

While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. We note that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.

Additionally, our amended and restated bylaws will provide that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and consented to these provisions.

Limitations on Liability and Indemnification

See the section titled “Management—Limitations on Liability and Indemnification Agreements” included elsewhere in this prospectus.

Exchange Listing

Our common stock is currently not listed on any securities exchange. We have applied to have our common stock approved for listing on The Nasdaq Global Market under the symbol “RAPP.”

Transfer Agent and Registrar

On the completion of this offering, the transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent’s address is 150 Royall Street, Canton, Massachusetts 02021.

207

SHARES ELIGIBLE FOR FUTURE SALE

Prior to this offering, there has been no public market for our common stock. Future sales of substantial amounts of our common stock, including shares issued on the exercise of outstanding options, in the public market after this offering, or the possibility of these sales or issuances occurring, could adversely affect the prevailing market price for our common stock or impair our ability to raise equity capital. Although we have applied to list our common stock on The Nasdaq Global Market, we cannot assure you that there will be an active public market for our common stock.

Following the completion of this offering and the concurrent private placement, based on our shares outstanding as of March 31, 2024, a total of 35,376,457 shares of common stock will be outstanding, assuming no exercise of the underwriters’ option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule 144 under the Securities Act, may only be sold in compliance with the limitations described below. All remaining shares of common stock held by existing stockholders immediately prior to the completion of this offering, including those sold in the concurrent private placement, will be “restricted securities” as such term is defined in Rule 144. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule 144 or Rule 701, summarized below.

Rule 144

In general, under Rule 144 as currently in effect, once we have been subject to public company reporting requirements of Section 13 or Section 15(d) of the Exchange Act for at least 90 days, an eligible stockholder is entitled to sell such shares without complying with the manner of sale, volume limitation, or notice provisions of Rule 144, subject to compliance with the public information requirements of Rule 144. To be an eligible stockholder under Rule 144, such stockholder must not be deemed to have been one of our affiliates for purposes of the Securities Act at any time during the 90 days preceding a sale and must have beneficially owned the shares proposed to be sold for at least six months, including the holding period of any prior owner other than our affiliates. If such a person has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than our affiliates, then such person is entitled to sell such shares without complying with any of the requirements of Rule 144, subject to the expiration of the lock-up agreements described below.

In general, under Rule 144, as currently in effect, our affiliates or persons selling shares on behalf of our affiliates are entitled to sell shares on expiration of the lock-up agreements described below. Beginning 90 days after the date of this prospectus, within any three-month period, such stockholders may sell a number of shares that does not exceed the greater of:

•

1% of the number of shares of common stock then outstanding, which will equal approximately 353,765 shares immediately after this offering and the concurrent private placement, assuming no exercise of the underwriters’ option to purchase additional shares of common stock from us; or

•

the average weekly trading volume of our common stock on Nasdaq during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale.

Sales under Rule 144 by our affiliates or persons selling shares on behalf of our affiliates are also subject to certain manner of sale provisions and notice requirements and to the availability of current public information about us.

Rule 701

Rule 701 under the Securities Act (“Rule 701”) generally allows a stockholder who was issued shares under a written compensatory plan or contract and who is not deemed to have been an affiliate of our company during

208

the immediately preceding 90 days, to sell these shares in reliance on Rule 144, but without being required to comply with the public information, holding period, volume limitation, or notice provisions of Rule 144. Rule 701 also permits affiliates of our company to sell their Rule 701 shares under Rule 144 without complying with the holding period requirements of Rule 144. All holders of Rule 701 shares, however, are required by that rule to wait until 90 days after the date of this prospectus before selling those shares under Rule 701, subject to the expiration of the lock-up agreements described below.

Form S-8 Registration Statements

We intend to file one or more registration statements on Form S-8 under the Securities Act with the SEC to register the offer and sale of shares of our common stock that are issuable under the 2022 Plan, the 2024 Plan, and the ESPP. These registration statements will become effective immediately upon filing. Shares covered by these registration statements will then be eligible for sale in the public markets, subject to vesting restrictions, any applicable lock-up agreements described below, and Rule 144 limitations applicable to affiliates.

Lock-up Arrangements

We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock have entered into lock-up agreements with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from selling any of our common stock (including certain shares of common stock to be issued in the concurrent private placement) or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180 days from the date of this prospectus without the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, subject to certain exceptions. See the section titled “Underwriting” included elsewhere in this prospectus for more information.

Registration Rights

Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of their shares under the Securities Act. Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See the section titled “Description of Capital Stock—Registration rights” included elsewhere in this prospectus for more information.

209

MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES FOR NON-U.S. HOLDERS

The following discussion is a summary of material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the ownership and disposition of our common stock issued pursuant to this offering. This discussion is based on the Internal Revenue Code of 1986, as amended (referred to as the “Code”), Treasury Regulations promulgated thereunder, published rulings and administrative pronouncements of the U.S. Internal Revenue Service (“IRS”) and judicial decisions, all as in effect on the date hereof. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions.

This discussion is limited to non-U.S. holders who purchase our common stock pursuant to this offering and who hold our common stock as a “capital asset” within the meaning of Section 1221 of the Code (generally, property held for investment). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, the alternative minimum tax, or the special tax accounting rules under Section 451(b) of the Code, and also does not address any U.S. federal non-income tax consequences, such as estate or gift tax consequences, or any tax consequences arising under any state, local or non-U.S. tax laws. This discussion does not address all of the U.S. federal income tax consequences that may be relevant to a non-U.S. holder in light of such non-U.S. holder’s particular circumstances. This discussion also does not consider any specific facts or circumstances that may be relevant to non-U.S. holders subject to special rules under the U.S. federal income tax laws, including:

•

certain former citizens, or long-term residents of the United States;

•

partnerships or other entities or arrangements treated as pass-through or disregarded entities for U.S. federal income tax purposes (and investors therein);

•

“controlled foreign corporations”;

•

“passive foreign investment companies”;

•

corporations that accumulate earnings to avoid U.S. federal income tax;

•

banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;

•

tax-exempt organizations and governmental organizations;

•

tax-qualified retirement plans;

•

persons who acquire our common stock through the exercise of an option or otherwise as compensation;

•

qualified foreign pension funds as defined in Section 897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds;

•

persons that elect to apply Section 1400Z-2 of the Code to gains recognized with respect to shares of our common stock;

•

persons that own, or have owned, actually or constructively, more than 5% of our common stock;

•

persons who have elected to mark securities to market; and

•

persons holding our common stock as part of a hedging or conversion transaction or straddle, or synthetic security or a constructive sale, or other risk reduction strategy or integrated investment.

If an entity or arrangement that is classified as a partnership for U.S. federal income tax purposes holds our common stock, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the

210

status of the partner, the activities of the partnership and certain determinations made at the partner level. Partnerships holding our common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of owning and disposing of our common stock.

THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR NON-U.S. TAX LAWS AND ANY OTHER U.S. FEDERAL TAX LAWS OR UNDER ANY APPLICABLE INCOME TAX TREATY.

Definition of non-U.S. holder

For purposes of this discussion, a non-U.S. holder is any beneficial owner of our common stock that is for U.S. federal income tax purposes:

•

a non-resident alien individual;

•

a corporation or any organization taxable as a corporation for U.S. federal income taxes that is not created or organized under the laws of the United States, any state thereof, or the District of Columbia; or

•

a foreign trust or estate, the income of which is not subject to U.S. federal income tax on a net income basis.

Distributions on our common stock

As described under “Dividend Policy,” we do not currently anticipate declaring or paying, for the foreseeable future, any distributions on our capital stock. However, if we were to distribute cash or other property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder’s tax basis in our common stock, but not below zero. Any excess will be treated as gain realized on the sale or other disposition of our common stock and will be treated as described under “—Gain on sale or other taxable disposition of our common stock” below.

Subject to the discussions below regarding effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a non-U.S. holder of our common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income tax treaty. To receive the benefit of a reduced treaty rate, a non-U.S. holder must furnish us or our withholding agent with a valid IRS Form W-8BEN (in the case of individuals) or IRS Form W-8BEN-E (in the case of entities), or other appropriate form, certifying such holder’s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the payment of the dividends and must be updated periodically. If the non-U.S. holder holds our common stock through a financial institution or other agent acting on the non-U.S. holder’s behalf, the non-U.S. holder will be required to provide appropriate documentation to the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries.

If a non-U.S. holder holds our common stock in connection with the conduct of a trade or business in the United States, and dividends paid on our common stock are effectively connected with such holder’s U.S. trade or business (and, if required by an applicable tax treaty, are attributable to such holder’s permanent establishment or fixed base in the United States), the non-U.S. holder generally will be exempt from U.S. federal withholding

211

tax. To claim the exemption, the non-U.S. holder generally must furnish a valid IRS Form W-8ECI (or applicable successor form), certifying that the dividends are effectively connected with the non-U.S. Holder’s conduct of a trade or business within the United States to the applicable withholding agent.

However, any such effectively connected dividends paid on our common stock generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected dividends, as adjusted for certain items.

Non-U.S. holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate, may obtain a refund or credit of any excess amounts withheld by timely filing an appropriate claim with the IRS. Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.

Gain on disposition of our common stock

Subject to the discussions below regarding backup withholding and FATCA (as defined below), a non-U.S. holder generally will not be subject to U.S. federal income tax on any gain realized on the sale or other taxable disposition of our common stock, unless:

•

the gain is effectively connected with the non-U.S. holder’s conduct of a trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States;

•

the non-U.S. holder is a nonresident alien individual who is present in the United States for a period or periods aggregating 183 days or more during the taxable year of the disposition, and certain other requirements are met; or

•

our common stock constitutes a “United States real property interest” by reason of our status as a United States real property holding corporation (“USRPHC”) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the non-U.S. holder’s holding period for our common stock, and our common stock is not “regularly traded” on an established securities market during the calendar year in which the sale or other disposition occurs.

Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A non-U.S. holder that is a foreign corporation also may be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items.

Gain described in the second bullet point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.- source capital losses of the non-U.S. holder (even though the individual is not considered a resident of the United States), provided that the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses.

Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our worldwide real property interests and our other trade or business assets. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC. Even if we are treated as a USRPHC, gain realized by a non-U.S. holder on a disposition of our common stock will not be subject to U.S. federal income tax so long as (1) the non-U.S. holder owned, directly, indirectly and constructively, no more

212

than 5% of our common stock at all times within the shorter of (a) the five-year period preceding the disposition or (b) the holder’s holding period and (2) our common stock is “regularly traded” on an established securities market within the meaning of applicable U.S. Treasury regulations. There can be no assurance that our common stock qualifies as regularly traded on an established securities market for purposes of the rules described above. Prospective investors are encouraged to consult their own tax advisors regarding the possible consequences to them if we are, or were to become, a USRPHC.

Non-U.S. holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules.

Information reporting and backup withholding

Annual reports are required to be filed with the IRS and provided to each non-U.S. holder indicating the amount of distributions on our common stock paid to such holder and the amount of any tax withheld with respect to those distributions. These information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the holder’s conduct of a U.S. trade or business, or withholding was reduced or eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the non-U.S. holder resides or is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a non-U.S. holder of distributions on or the gross proceeds of a disposition of our common stock provided the non-U.S. holder furnishes the required certification for its non-U.S. status, such as by providing a valid IRS Form W-8BEN, IRS Form W-8BEN-E or IRS Form W-8ECI, or otherwise establishes an exemption, and if the payor does not have actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient.

Backup withholding is not an additional tax. If any amount is withheld under the backup withholding rules, the non-U.S. holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a credit against the non-U.S. holder’s U.S. federal income tax liability, if any.

Withholding on foreign entities

Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain payments made to a “foreign financial institution” (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption applies. FATCA also generally imposes a U.S. federal withholding tax of 30% on certain payments made to a “non-financial foreign entity” (as specially defined under these rules) unless such entity provides the withholding agent a certification that it does not have any “substantial United States owners” or provides information identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a non-U.S. holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our common stock and would have applied also to payments of gross proceeds from the sale or other disposition of our common stock. However, proposed regulations under FATCA provide for the elimination of the federal withholding tax of 30% applicable to gross proceeds of a sale or other disposition of from property of a type that can produce U.S. source dividends or interest. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to finalization), FATCA withholding does not apply to gross proceeds from sales or other dispositions of our common stock.

Prospective investors are encouraged to consult with their tax advisors regarding the possible implications of FATCA on their investment in our common stock.

213

EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS TAX ADVISOR REGARDING THE TAX CONSEQUENCES OF OWNING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT AND PROPOSED CHANGE IN APPLICABLE LAW, AS WELL AS TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL, NON-U.S. OR U.S. FEDERAL NON-INCOME TAX LAWS.

214

UNDERWRITING

We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated are the representatives of the underwriters.


Underwriters	Number of Shares
Goldman Sachs & Co. LLC
Jefferies LLC
TD Securities (USA) LLC
Stifel, Nicolaus & Company, Incorporated

Total		8,000,000

The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below unless and until this option is exercised.

The underwriters have an option to buy up to an additional 1,200,000 shares of our common stock from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above.

The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters’ option to purchase up to an additional 1,200,000 shares of our common stock from us.


	No Exercise	Full Exercise
Per Share	$	$
Total	$	$

Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $ per share from the initial public offering price. After the initial offering of the shares, the representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters’ right to reject any order in whole or in part.

We and our officers, directors, and holders of substantially all of our capital stock and securities convertible into or exchangeable for our common stock have agreed or will agree with the underwriters, subject to certain exceptions, not to dispose of or hedge any of our or their common stock (including certain shares of common stock to be issued in the concurrent private placement) or securities convertible into or exchangeable for shares of common stock (collectively, “Lock-Up Securities”) during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC. See the section titled “Shares Eligible for Future Sale” for a discussion of certain transfer restrictions.

The restrictions described in the immediately preceding paragraph do not apply to our officers, directors and holders of substantially all of our capital stock and securities convertible into or exchangeable for our common stock with respect to:

Transfers of Lock-Up Securities (i) as one or more bona fide gifts or charitable contributions, or for bona fide estate planning purposes, (ii) upon death by will, testamentary document or intestate succession, (iii) if the

215

lock-up party is a natural person, to any member of the lock-up party’s immediate family or to any trust for the direct or indirect benefit of such lock-up party or the immediate family of such lock-up party or, if such lock-up party is a trust, to a trust or beneficiary of the trust or the estate of a beneficiary of such trust, (iv) to a corporation, partnership, limited liability company or other entity of which the lock-up party and the immediate family of the lock-up party are the legal and beneficial owner of all of the outstanding equity securities or similar interests, (v) to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (i) through (iv) above, (vi) if the lock-up party is a corporation, partnership, limited liability company or other business entity, (A) to another corporation, partnership, limited liability company or other business entity that is a subsidiary or an affiliate (as defined in Rule 405 under the Securities Act) of such lock-up party, or to any investment fund or other entity which fund or entity is controlled or managed by the lock-up party or affiliates of such lock-up party (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a disposition, transfer or distribution by the lock-up party to its stockholders, partners, members or other equityholders or to the estate of any such stockholders, partners, members or other equityholders, (vii) by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement, (viii) to us from one of our employees upon death, disability or termination of employment, in each case, of such employee, (ix) if the lock-up party is not one of our officers or directors, in connection with a sale of such lock-up party’s shares of common stock acquired (A) from the underwriters in this offering or in the concurrent private placement or (B) in open market transactions after the closing date of this offering or (x) to us in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of common stock (including, in each case, by way of “net” or “cashless” exercise), including any transfer to us for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible securities, each as described in this prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of the lock-up agreement; provided that (A) in the case of clauses (i), (ii), (iii), (iv), (v) and (vi) above, such transfer or distribution shall not involve a disposition for value, (B) in the case of clauses (i), (ii), (iii), (iv), (v), (vi) and (vii) above, it shall be a condition to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a lock up agreement containing the same restrictions set forth above, (C) in the case of clauses (ii), (iii), (iv), (v) and (vi) above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee, distributor or distributee) under the Exchange Act or other public filing, report or announcement reporting a reduction in beneficial ownership of Lock-Up Securities shall be required or shall be voluntarily made in connection with such transfer or distribution, and (D) in the case of clauses (i), (vii), (viii), (ix) and (x) above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A) the circumstances of such transfer or distribution and (B) in the case of a transfer or distribution pursuant to clauses (i) or (vii) above, that the donee, devisee, transferee or distributee has agreed to be bound by a lock-up agreement containing the same restrictions set forth above.

In addition, the lock-up party may (a) enter into a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act relating to the transfer, sale or other disposition of the lock-up party’s Lock-Up Securities, if then permitted by us, provided that none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the lock-up period and no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the lock-up period, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate in the footnotes thereto that that none of the securities subject to such plan may be transferred, sold or otherwise disposed of pursuant to such plan until after the expiration of the lock-up period, (b) transfer the lock-up party’s Lock-Up Securities to us pursuant to an agreement under which we have the option to repurchase shares or a right of first refusal with respect to transfer of such shares, provided that no filing under

216

the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the lock-up period, such filing, report or announcement shall clearly indicate in the footnotes thereto the circumstances of such transfer or distribution, (c) (i) transfer its Lock-Up Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all holders of our capital stock involving a change of control of us, in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of our outstanding voting securities (or the voting securities of the surviving entity) and (ii) enter into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of common stock or other such securities in connection with a transaction described in clause (i); provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the lock-up party’s Lock-Up Securities shall remain subject to the provisions of the lock-up agreement, or (d) convert outstanding shares of our convertible preferred stock into shares of common stock, provided that any such shares received upon such conversion shall remain subject to the provisions of the lock-up agreement.

The restrictions on transfers or other dispositions by us described above do not apply to us with respect to (i) the sale of shares of common stock pursuant to this offering, (ii) the issuance of shares of common stock or any securities (or any securities (including without limitation options, restricted stock or restricted stock units) convertible into, or exercisable for, shares of common stock pursuant to any employee stock option plan, incentive plan, stock plan, dividend reinvestment plan or otherwise in equity compensation arrangements in place as of the date of the underwriting agreement and described in this prospectus, (iii) the grant of awards pursuant to employee equity-based compensation plans, incentive plans, stock plans, or other arrangements in place as of the date of the underwriting agreement and described in this prospectus, (iv) the filing of a registration statement on Form S-8 in connection with the registration of shares of common stock issuable under any employee equity-based compensation plan, incentive plan, stock plan, dividend reinvestment plan adopted and approved by the our board of directors prior to the date of the underwriting agreement and described in this prospectus, (v) the issuance of up to 5% of the outstanding shares of our common stock in connection with the acquisition of the assets of, or a majority or controlling portion of the equity of, or a joint venture with another entity in connection with its acquisition us of such entity and (vi) the offer and sale of shares of our common stock pursuant to the concurrent private placement; provided that each recipient of any shares of common stock issued or sold pursuant to (ii)-(iii) and (v) above enter into a lock-up agreement with the underwriters with the same restrictions set forth above.

Prior to this offering, there has been no public market for the shares of our common stock. The initial public offering price has been negotiated among us and the representatives. Among the factors to be considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, will be our historical performance, estimates of the business potential and earnings prospects of us, an assessment of our management and the consideration of the above factors in relation to market valuation of companies in related businesses.

We have applied to list our common stock on the Nasdaq Global Market under the symbol “RAPP.”

In connection with the offering, the underwriters may purchase and sell shares of our common stock in the open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A “covered short position” is a short position that is not greater than the amount of additional shares for which the underwriters’ option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.

217

“Naked” short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering.

The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions.

Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of our common stock. As a result, the price of our common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the Nasdaq Global Market, in the over-the-counter market or otherwise.

We estimate that our share of the total expenses of the offering and the concurrent private placement, excluding underwriting discounts and commissions and placement agent fees, will be approximately $4.5 million. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $40,000 relating to the clearance of this offering with FINRA.

We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act.

The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial activities and services. Certain of the underwriters and their respective affiliates may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for which they will receive customary fees and expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of ours (directly, as collateral securing other obligations or otherwise) and/or persons and entities with relationships with us. For example, affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC, own an aggregate of 5,365,861 shares of our Series B preferred stock, which will automatically convert into an aggregate of 626,724 shares of our common stock (reflecting a proportional adjustment to the conversion ratios of our convertible preferred stock as a result of the 1-to-8.5648 reverse stock split of our common stock effected on May 31, 2024) in connection with this offering. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments.

218

concurrent private placement exempt from the registration requirements of the Securities Act of 1933, as amended, at a per share price equal to the initial public offering price (or an aggregate of 1,058,824 shares based on the initial public offering price of $17.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus). The private placement would close concurrently with, and be contingent and conditioned upon consummation of, this offering, as well as certain other customary closing conditions. However, this offering is not contingent on the consummation of the concurrent private placement. Because we have not yet entered into a binding agreement with such existing stockholders, we could determine to sell more, fewer or no shares to each of these existing stockholders, and any of such existing stockholders could determine to purchase more, fewer or no shares in this offering. The underwriters are acting as placement agents in connection with the concurrent private placement and will receive a placement agent fee equal to 7.0% of the total purchase price of the private placement shares.

The shares to be purchased in the concurrent private placement by affiliates of Goldman Sachs & Co. LLC, including certain investment funds managed by Goldman Sachs & Co. LLC, will be deemed to be underwriting compensation by FINRA, and therefore will be subject to a 180-day lock-up period pursuant to FINRA Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1), such shares may not be sold, transferred, assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result in the effective economic disposition of such securities by any person, for a period of 180 days beginning on the date of commencement of sale of the concurrent private placement, subject to certain exceptions permitted by FINRA Rule 5110(e)(2).

European Economic Area

In relation to each Member State of the European Economic Area (each a Relevant Member), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant Member prior to the publication of a prospectus in relation to the shares which has been approved by the competent authority in that Relevant Member or, where appropriate, approved in another Relevant Member and notified to the competent authority in that Relevant Member, all in accordance with the Prospectus Regulation, except that the shares may be offered to the public in that Relevant Member at any time:

(a)

to any legal entity which is a qualified investor as defined under Article 2 of the Prospectus Regulation;

(b)

to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or

(c)

in any other circumstances falling within Article 1(4) of the Prospectus Regulation,

provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation.

For the purposes of this provision, the expression an “offer to the public” in relation to the shares in any Relevant Member means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression “Prospectus Regulation” means Regulation (EU) 2017/1129.

United Kingdom

No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time:

(a)

to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation;

219

(b)

to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or

(c)

in any other circumstances falling within Section 86 of the FSMA;

provided that no such offer of the shares shall require the Issuer or Manager to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an “offer to the public” in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression. “UK Prospectus Regulation” means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.

Canada

The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws.

Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser’s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser’s province or territory of these rights or consult with a legal advisor.

Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering.

Hong Kong

The shares may not be offered or sold in Hong Kong by means of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (Companies (Winding Up and Miscellaneous Provisions) Ordinance) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (Securities and Futures Ordinance), or (ii) to “professional investors” as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii) in other circumstances which do not result in the document being a “prospectus” as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to “professional investors” in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder.

Singapore

This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation

220

for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor (as defined under Section 4A of the Securities and Futures Act, Chapter 289 of Singapore (the SFA)) under Section 274 of the SFA, (ii) to a relevant person (as defined in Section 275(2) of the SFA) pursuant to Section 275(1) of the SFA, or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions specified in Section 275 of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA.

Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section 4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section 239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer in that corporation’s securities pursuant to Section 275(1A) of the SFA, (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (Regulation 32).

Where the shares are subscribed or purchased under Section 275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in Section 4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries’ rights and interest (howsoever described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section 275 of the SFA except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person (as defined in Section 275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4) where the transfer is by operation of law, (5) as specified in Section 276(7) of the SFA, or (6) as specified in Regulation 32.

Solely for the purposes of its obligations pursuant to Section 309B of the SFA, we have determined, and hereby notify all relevant persons (as defined in the CMP Regulations 2018), that the shares are “prescribed capital markets products” (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).

Japan

The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No. 25 of 1948, as amended) (“FIEA”). The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan.

Australia

No placement document, prospectus, product disclosure statement or other disclosure document has been lodged with the Australian Securities and Investments Commission, in relation to the offering. This offering

221

document does not constitute a prospectus, product disclosure statement or other disclosure document under the Corporations Act 2001 (the “Corporations Act”), and does not purport to include the information required for a prospectus, product disclosure statement or other disclosure document under the Corporations Act.

Any offer in Australia of the shares may only be made to persons (“Exempt Investors”) who are “sophisticated investors” (within the meaning of Section 708(8) of the Corporations Act), “professional investors” (within the meaning of Section 708(11) of the Corporations Act) or otherwise pursuant to one or more exemptions contained in Section 708 of the Corporations Act so that it is lawful to offer the shares without disclosure to investors under Chapter 6D of the Corporations Act.

The shares applied for by Exempt Investors in Australia must not be offered for sale in Australia in the period of 12 months after the date of allotment under the offering, except in circumstances where disclosure to investors under Chapter 6D of the Corporations Act would not be required pursuant to an exemption under Section 708 of the Corporations Act or otherwise or where the offer is pursuant to a disclosure document which complies with Chapter 6D of the Corporations Act. Any person acquiring shares must observe such Australian on-sale restrictions.

This offering document contains general information only and does not take account of the investment objectives, financial situation or particular needs of any particular person. It does not contain any securities recommendations or financial product advice. Before making an investment decision, investors need to consider whether the information in this offering document is appropriate to their needs, objectives and circumstances, and, if necessary, seek expert advice on those matters.

Dubai International Financial Centre

This offering document relates to an Exempt Offer in accordance with the Offered Securities Rules of the Dubai Financial Services Authority (“DFSA”). This offering document is intended for distribution only to persons of a type specified in the Offered Securities Rules of the DFSA. It must not be delivered to, or relied on by, any other person. The DFSA has no responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus nor taken steps to verify the information set forth in this prospectus and has no responsibility for the offering document. The securities to which this offering document relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you do not understand the contents of this offering document you should consult an authorized financial advisor.

Switzerland

This offering document is not intended to constitute an offer or solicitation to purchase or invest in the shares of our common stock. The shares of common stock may not be publicly offered, directly or indirectly, in Switzerland within the meaning of the Swiss Financial Services Act (“FinSA”), and no application has or will be made to admit the shares of common stock to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. Neither this offering document nor any other offering or marketing material relating to the shares of common stock constitutes a prospectus pursuant to the FinSA, and neither this offering document nor any other offering or marketing material relating to the shares of common stock may be publicly distributed or otherwise made publicly available in Switzerland.

Neither this offering document nor any other offering or marketing material relating to the offering, us or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this offering document will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (“CISA”). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities.

222

LEGAL MATTERS

The validity of the shares of our common stock being offered in this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Cooley LLP, New York, New York, is representing the underwriters in this offering.

EXPERTS

The financial statements as of December 31, 2023 and 2022 and for the year ended December 31, 2023 and the period from February 10, 2022 (inception) to December 31, 2022 included in this prospectus have been so included in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.

WHERE YOU CAN FIND ADDITIONAL INFORMATION

We have filed with the SEC a registration statement on Form S-1 (File Number 333-279486) under the Securities Act with respect to the shares of common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov/edgar.

We currently do not file periodic reports with the SEC. On the completion of this offering, we will be subject to the information reporting requirements of the Exchange Act, and we will file reports, proxy statements and other information with the SEC. These reports, proxy statements and other information will be available for review at the website of the SEC referred to above.

We also maintain a website at www.rapportrx.com. Information contained in, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only as an inactive textual reference. Upon completion of this offering, you may access, free of charge, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendment to those reported filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC.

223

INDEX TO THE CONSOLIDATED FINANCIAL STATEMENTS



Report of Independent Registered Public Accounting Firm			F-2

Audited Consolidated Financial Statements

Consolidated Balance Sheets as of December 21, 2023 and 2022			F-3

Consolidated Statements of Operations and Comprehensive Loss for the Year Ended December 31, 2023 and for the Period from February 10, 2022 (inception) to December 31, 2022			F-4

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the Year Ended December 31, 2023 and for the Period from February 10, 2022 (inception) to December 31, 2022			F-5

Consolidated Statements of Cash Flows			F-6

Notes to Consolidated Financial Statements			F-8



Unaudited Interim Condensed Consolidated Financial Statements

Condensed Consolidated Balance Sheets as of December 31, 2023 and March 31, 2024			F-39

Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended March 31, 2023 and 2024			F-40

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit for the Three Months Ended March 31, 2023 and 2024			F-41

Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2023 and 2024			F-42

Notes to Condensed Consolidated Financial Statements			F-43

F-1

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders of Rapport Therapeutics, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Rapport Therapeutics, Inc. and its subsidiary (the “Company”) as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, of convertible preferred stock and stockholders’ deficit and of cash flows for the year ended December 31, 2023 and for the period from February 10, 2022 (inception) to December 31, 2022, including the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the year ended December 31, 2023 and for the period from February 10, 2022 (inception) to December 31, 2022 in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these consolidated financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

March 27, 2024, except for the effects of the reverse stock split discussed in Note 16 to the consolidated financial statements, as to which the date is June 3, 2024

We have served as the Company’s auditor since 2023.

F-2

Rapport Therapeutics, Inc.

Consolidated Balance Sheets

(In Thousands, Except Share Data)


	December 31,
	2022			2023
Assets
Current assets
Cash and cash equivalents	$	31,159		$	70,169
Short-term investments		—			77,309
Restricted cash		—			85
Prepaid expenses and other current assets		109			3,309

Total current assets		31,268			150,872
Property and equipment, net		335			1,916
Operating lease right-of-use asset		—			2,084
Other assets		—			551

Total assets	$	31,603		$	155,423

Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities
Accounts payable ⁽¹⁾	$	1,450		$	2,502
Accrued expenses and other current liabilities ⁽¹⁾		213			5,631
Operating lease liability		—			670

Total current liabilities		1,663			8,803
Series A preferred stock tranche right liability		10,435			—
Series B preferred stock tranche right liability		—			4,200
Operating lease liability, net of current portion		—			1,476

Total liabilities		12,098			14,479
Commitments and contingencies (Note 14)
Series A convertible preferred stock, $0.001 par value; 100,182,354 shares authorized as of December 31, 2022 and 2023; 40,182,354 and 100,182,354 shares issued and outstanding as of December 31, 2022 and 2023, respectively; liquidation preference of $40,182 and $100,182 as of December 31, 2022 and 2023, respectively		29,567			89,487
Series B convertible preferred stock, $0.001 par value; zero and 89,431,030 shares authorized as of December 31, 2022 and 2023, respectively; zero and 51,273,790 shares issued and outstanding as of December 31, 2022 and 2023, respectively; liquidation preference of zero and $86,000 as of December 31, 2022 and 2023, respectively		—			77,091
Stockholders’ deficit
Common stock, $0.001 par value; 150,000,000 and 250,000,000 shares authorized at December 31, 2022 and 2023, respectively; 3,587,345 and 4,170,817 shares issued and outstanding as of December 31, 2022 and 2023, respectively		4			4
Additional paid-in capital		586			19,796
Accumulated other comprehensive income		—			4
Accumulated deficit		(10,652	)		(45,438	)

Total stockholders’ deficit		(10,062	)		(25,634	)

Total liabilities, convertible preferred stock, and stockholders’ deficit	$	31,603		$	155,423

(1)	Includes related party amounts of $0.7 million and $0.2 million (accounts payable) and less than $0.1 million and zero (accrued expenses) as of December 31, 2022 and 2023, respectively (see Notes 5 and 13).

The accompanying notes are an integral part of these consolidated financial statements.

F-3

Rapport Therapeutics, Inc.

Consolidated Statements of Operations and Comprehensive Loss

(In Thousands, except share and per share data)


	For the period from February 10, 2022 (inception) to December 31, 2022			For the year ended December 31, 2023
Operating expenses
Related party acquired in-process research and development	$	5,000		$	—
Research and development ⁽¹⁾		4,115			27,999
General and administrative ⁽²⁾		1,252			8,180

Total operating expenses		10,367			36,179

Loss from operations		(10,367	)		(36,179	)
Other income (expense):
Interest income		—			2,527
Interest expense		(285	)		—
Change in fair value of preferred stock tranche right liability		—			(1,124	)

Total other income (expense), net		(285	)		1,403

Net loss before income taxes		(10,652	)		(34,776	)
Provision for income taxes		—			10

Net loss	$	(10,652	)	$	(34,786	)

Net loss per share attributable to common stockholders, basic and diluted		(13.71	)		(23.10	)

Weighted-average common shares outstanding, basic and diluted		777,212			1,505,774
Comprehensive loss:
Net loss	$	(10,652	)	$	(34,786	)
Change in unrealized gains on investments, net of tax		—			4

Total other comprehensive income		—			4

Comprehensive loss	$	(10,652	)	$	(34,782	)

(1)	Includes related party amounts of $1.6 million and $0.7 million for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, respectively (see Note 13).

(2)	Includes related party amount of $0.6 million and $0.9 million for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, respectively (see Note 13).

The accompanying notes are an integral part of these consolidated financial statements.

F-4

Rapport Therapeutics, Inc.

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit

(In Thousands, Except Share Data)


	Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Common Stock					Additional Paid-in Capital			Accumulated Other Comprehensive Income		Accumulated Deficit			Total Stockholders’ Deficit
	Shares		Amount		Shares		Amount		Shares			Amount		Additional Paid-in Capital			Accumulated Other Comprehensive Income		Accumulated Deficit			Total Stockholders’ Deficit
Balance at February 10, 2022 (inception)		—	$	—		—	$	—		—		$	—	$	—		$	—	$	—		$	—
Settlement of convertible promissory notes and accrued interest to Series A convertible preferred stock, net of Series A preferred stock tranche right liability of $2,125		8,182,354		6,057		—		—		—			—		—			—		—			—
Issuance of Series A convertible preferred stock, net of Series A preferred stock tranche right liability of $8,310 and issuance costs of $180		32,000,000		23,510		—		—		—			—		—			—		—			—
Issuance of common stock		—		—		—		—		1,167,568			1		9			—		—			10
Issuance of restricted common stock		—		—		—		—		2,419,777			2		19			—		—			21
Stock-based compensation expense		—		—		—		—		—			—		559			—		—			559
Net loss		—		—		—		—		—			—		—			—		(10,652	)		(10,652	)

Balance at December 31, 2022		40,182,354	$	29,567		—	$	—		3,587,345		$	4	$	586		$	—	$	(10,652	)	$	(10,062	)

Issuance of Series A convertible preferred stock for the settlement of the second and third tranche right liability, net of issuance costs of $80		60,000,000		59,920		—		—		—			—		11,465			—		—			11,465
Issuance of Series B convertible preferred stock, net of Series B preferred stock tranche right liability of $4,619 and issuance costs of $632		—		—		46,504,135		69,860		—			—		2,887			—		—			2,887
Issuance of Series B convertible preferred stock for the settlement of the second tranche right liability		—		—		4,769,655		7,231		—			—		1,283			—		—			1,283
Issuance of restricted common stock		—		—		—		—		630,174			1		53			—		—			54
Repurchase of unvested restricted common stock		—		—		—		—		(46,702	)		—		(4	)		—		—			(4	)
Stock-based compensation expense		—		—		—		—		—			—		3,525			—		—			3,525
Net loss		—		—		—		—		—			—		—			—		(34,786	)		(34,786	)
Change in unrealized gain on investments, net of tax		—		—		—		—		—			—		—			4		—			4

Balance at December 31, 2023		100,182,354	$	89,487		51,273,790	$	77,091		4,170,817		$	4	$	19,796		$	4	$	(45,438	)	$	(25,634	)

The accompanying notes are an integral part of these consolidated financial statements.

F-5

Rapport Therapeutics, Inc.

Consolidated Statements of Cash Flows

(In Thousands)


	For the period from February 10, 2022 (inception) to December 31, 2022			For the year ended December 31, 2023
Cash flows from operating activities:
Net loss	$	(10,652	)	$	(34,786	)
Adjustments to reconcile net loss to net cash used in operating activities
Related party acquired in-process research & development		5,000			—
Non-cash interest (income) expense		285			(6	)
Depreciation and amortization		15			112
Net (accretion) and amortization of investments in marketable securities		—			(75	)
Change in fair value of preferred stock tranche right liability		—			1,124
Non-cash lease expense		—			206
Stock-based compensation expense		559			3,525
Series A and B preferred stock issuance costs allocated to tranche right liabilities		63			67
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(109	)		(3,200	)
Other assets		—			(240	)
Accounts payable		1,445			856
Accrued expenses and other current liabilities		152			5,380
Operating lease liabilities		—			(144	)

Net cash used in operating activities		(3,242	)		(27,181	)

Cash flows from investing activities
Related party acquired in-process research & development		(5,000	)		—
Purchases of short-term investments		—			(77,224	)
Purchases of property and equipment		(284	)		(1,636	)

Net cash used in investing activities		(5,284	)		(78,860	)

Cash flows from financing activities
Proceeds from issuance of Series A convertible preferred stock, including tranche rights, net of issuance costs paid		31,756			59,920
Proceeds from issuance of Series B convertible preferred stock, including tranche rights, net of issuance costs paid		—			85,300
Proceeds from issuance of convertible promissory notes		8,000			—
Payment of debt issuance costs		(102	)		—
Proceeds from issuance of common stock and restricted common stock		31			54
Repurchase of unvested restricted common stock		—			(4	)
Payment of deferred offering costs		—			(134	)

Net cash provided by financing activities		39,685			145,136

Net increase in cash, cash equivalents, and restricted cash		31,159			39,095
Cash, cash equivalents, and restricted cash at beginning of period		—			31,159

Cash, cash equivalents, and restricted cash at end of period	$	31,159		$	70,254

The accompanying notes are an integral part of these consolidated financial statements.

F-6

Rapport Therapeutics, Inc.

Consolidated Statements of Cash Flows

(In Thousands)


	For the period from February 10, 2022 (inception) to December 31, 2022		For the year ended December 31, 2023
Supplemental cash flow information:
Right-of-use assets obtained in exchange for operating lease liabilities	$	—	$	2,290
Supplemental disclosure for noncash investing and financing activities:
Settlement of Series A preferred stock tranche right liability	$	—	$	11,465
Settlement of Series B preferred stock tranche right liability	$	—	$	513
Settlement of convertible promissory notes and accrued interest to Series A convertible preferred stock	$	8,182	$	—
Deferred offering costs included in accrued expenses at period end	$	—	$	177
Purchases of property and equipment included in accounts payable and accrued expenses at period end	$	66	$	123
Unrealized gain on short-term investments	$	—	$	4
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	$	31,159	$	70,169
Restricted cash		—		85

Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	31,159	$	70,254

The accompanying notes are an integral part of these consolidated financial statements.

F-7

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

1. Nature of the Business and Basis of Presentation

Rapport Therapeutics, Inc., together with its consolidated subsidiary (the “Company”) is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. The Company was incorporated in the state of Delaware in February 2022 as Precision Neuroscience NewCo, Inc. In October 2022, the Company changed its name to Rapport Therapeutics, Inc. The Company is located in Boston, Massachusetts and San Diego, California.

The Company is subject to risks and uncertainties common to early stage companies in the biotechnology industry, including, but not limited to, completing preclinical studies and clinical trials, obtaining regulatory approval for product candidates, market acceptance of products, development by competitors of new technological innovations, dependence on key personnel, the ability to attract and retain qualified employees, reliance on third-party organizations, protection of proprietary technology, compliance with government regulations, and the ability to raise additional capital to fund operations. The Company’s product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting capabilities. Even if the Company’s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.

The accompanying consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through December 31, 2023, the Company has funded its operations primarily with proceeds from the sale of convertible notes and convertible preferred stock. The Company has incurred recurring losses since its inception, including net losses of $10.7 million for the period from February 10, 2022 (inception) to December 31, 2022 and $34.8 million for the year ended December 31, 2023. In addition, as of December 31, 2023, the Company had an accumulated deficit of $45.4 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of the consolidated financial statements for the year ended December 31, 2023, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.

The Company is seeking to complete an initial public offering (“IPO”) of its common stock. Upon the completion of a qualified public offering on specified terms, the Company’s outstanding convertible preferred stock will convert into shares of common stock (see Note 7). In the event the Company does not complete an IPO, the Company will seek additional funding through private equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders.

If the Company is unable to obtain funding it could be forced to delay, reduce or eliminate some or all of its research and development programs, which could adversely affect its business prospects, or it may be unable to continue operations. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.

F-8

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Basis of Presentation

The accompanying consolidated financial statements reflect the operations of the Company. Intercompany balances and transactions have been eliminated in consolidation. The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

2. Summary of Significant Accounting Policies

Use of Estimates

The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these consolidated financial statements include, but are not limited to, research and development expenses and accruals, the valuation of the Company’s common stock and stock-based awards and the valuation of preferred stock tranche right liability. The Company bases its estimates on known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.

Concentrations of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed federally insured limits. Cash equivalents are invested in money market funds. However, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s short-term investments consist of U.S. Treasury bills and government securities and as a result, the Company believes represent minimal credit risk.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at the time of initial purchase to be cash equivalents. As of December 31, 2022 and 2023 the amount of cash equivalents included in cash and cash equivalents totaled zero and $47.3 million, respectively.

Restricted cash

Restricted cash consisted of a letter of credit totaling zero and $85 thousand as of December 31, 2022 and 2023, respectively, that is required to be maintained in connection with the Company’s lease arrangement. The letter of credit is in the name of the Company’s landlord and is required to fulfill lease requirements in the event the Company should default on its lease obligation.

Short-term investments

The Company’s short-term investments consist of investments in debt securities, including U.S. Treasury securities, with remaining maturities beyond three months at the date of purchase that are available to be

F-9

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

converted into cash to fund its current operations. The Company had no short-term investments as of December 31, 2022. As of December 31, 2023, all of the Company’s debt securities were classified as available-for-sale and were carried at fair market value (see Note 3). The unrealized gains on the Company’s available-for-sale debt securities are recorded in other comprehensive income in the consolidated statements of operations and comprehensive loss.

Short-term debt securities in an unrealized loss position are evaluated for impairment at least quarterly. For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether or not it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the investment security’s amortized cost basis is written down to fair value through net income.

For available-for-sale debt securities that do not meet the aforementioned criteria, the Company evaluates whether the decline in fair value has resulted from credit losses or other factors. In conducting this assessment for debt securities in an unrealized loss position, management evaluates the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security, among other factors.

If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the investment security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized cost basis. Any unrealized loss that has not been recorded through an allowance for credit loss is recognized in other comprehensive income. As of December 31, 2022 and 2023, there was no allowance for credit losses recorded on the Company’s consolidated balance sheet.

The Company’s interest income consists of interest earned from cash, cash equivalents, and short-term investments.

Deferred Offering Costs

The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the convertible preferred stock or in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the consolidated statements of operations and comprehensive loss. As of December 31, 2022 and 2023, there were zero and $0.3 million, respectively, of deferred offering costs capitalized and included in other assets on the balance sheet.

Fair Value Measurements

Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be

F-10

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.

Level 3—Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.

The Company’s cash equivalents, short-term investments, and preferred stock tranche right liabilities are carried at fair value, determined according to the fair value hierarchy described above (see Note 3). The carrying values of the Company’s accounts payable and accrued expenses approximate their fair values due to the short-term nature of these liabilities.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization expense is recognized using the straight-line method over the estimated useful life of each asset as follows:


Asset Classification		Estimated Useful Life
Computer equipment		3 years
Lab equipment		5 years
Leasehold Improvements		Shorter of remaining lease term or useful life

Costs for capital assets not yet placed into service are capitalized and are depreciated once placed into service. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation and amortization are removed from the accounts and any resulting gain or loss is included in loss from operations. Expenditures for repairs and maintenance that do not improve or extend the life of the respective assets are charged to expense as incurred.

Impairment of Long-Lived Assets

Long-lived assets consist primarily of property and equipment, and operating lease right-of-use assets. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived asset group to its carrying value. If such asset group is considered to not be recoverable, the impairment loss to be recognized is measured based on the excess of the carrying value of the impaired asset group over its fair value.

For the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, the Company did not recognize any impairment losses on long-lived assets.

F-11

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Segment Information

The Company operates and manages its business as a single segment for the purposes of assessing performance and making operating decisions. The Company’s chief executive officer, who is the chief operating decision maker, reviews the Company’s financial information on a consolidated basis for purposes of evaluating financial performance and allocating resources. All of the Company’s long-lived assets are located in the United States.

Classification and Accretion of Convertible Preferred Stock

The Company’s Series A convertible preferred stock and Series B convertible preferred stock (together, the “Convertible Preferred Stock”) are classified outside of stockholders’ deficit on the Company’s consolidated balance sheet because the holders of such stock have certain liquidation preference in the event of a deemed liquidation that, in certain situations, is not solely within the control of the Company and would result in the redemption of the then-outstanding Convertible Preferred Stock. Because the occurrence of a deemed liquidation event is not currently probable, the carrying values of the Convertible Preferred Stock are not being accreted to their redemption values. Subsequent adjustments to the carrying values of the Convertible Preferred Stock would be made only when a deemed liquidation event becomes probable.

The Company recorded the Convertible Preferred Stock at fair value upon issuance, net of tranche right liabilities (see Note 7) and associated issuance costs.

Preferred Stock Tranche Right Liabilities

The purchase agreements for the Company’s Convertible Preferred Stock (see Note 7) provided investors the obligation to participate in subsequent offerings of Convertible Preferred Stock and the Company an obligation to issue additional Convertible Preferred Stock, at the initial offering price, when certain conditions are met.

The Company classified the preferred stock tranche right as a liability on its consolidated balance sheet as each preferred stock tranche right is a freestanding financial instrument that may require the Company to transfer assets to settle its obligation (upon events that are outside of its control). The preferred stock tranche right liability was initially recorded at fair value upon the date of issuance and is subsequently remeasured to fair value at each reporting date. Changes in the fair value of the preferred stock tranche right liability are recognized as a component of other income (expense) in the consolidated statement of operations and comprehensive loss. Any issuance costs allocated to the preferred stock tranche right liability were immediately expensed.

Research and Development Expenses

Costs for research and development activities are expensed as incurred. Research and development expenses consist of costs incurred in connection with performing research and development activities, including amounts incurred under agreements with external vendors and consultants engaged to perform preclinical and clinical studies and to manufacture research and development materials for use in such studies, salaries and related personnel costs, stock-based compensation, consultant fees, and third-party license fees.

Upfront payments under license agreements are expensed upon receipt of the license, and annual maintenance fees under license agreements are expensed over the maintenance period. Milestone payments under license agreements are accrued, with a corresponding expense being recognized, in the period in which the milestone is determined to be probable of achievement and the related amount is reasonably estimable. Contingent milestone payments, if any, are expensed when the milestone results are probable and estimable, which is generally upon the achievement of the milestone.

F-12

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed.

Acquired In-Process Research and Development

The Company measures and recognizes asset acquisitions or licenses of intellectual property that are not deemed to be business combinations based on the cost to acquire or license the asset or group of assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition or license of intellectual property, the cost allocated to acquire in-process research and development (“IPR&D”) with no alternative future use is recognized as research and development expense on the acquisition date.

Upfront payments are expensed in the period in which they are incurred and milestone payments are accrued for and expensed in the period in which achievement of the milestone is probable. These costs are immediately expensed provided that the product candidate has not achieved regulatory approval for marketing and absent obtaining such approval, has no alternative future use. Once regulatory approval has been obtained, milestone payments are capitalized and amortized over the remaining useful life of the related product. Acquired IPR&D for the period from February 10, 2022 (inception) to December 31, 2022 consisted of $5.0 million of upfront and option payments to a Related Party in conjunction with the technology license arrangement (see Note 12). There was no acquired IPR&D for the year ended December 31, 2023.

Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the consolidated statements of operations and comprehensive loss.

Contingencies

The Company is subject to contingent liabilities, such as legal proceedings and claims, that arise in the ordinary course of business activities. The Company accrues for loss contingencies when losses become probable and are reasonably estimable. If the reasonable estimate of the loss is a range and no amount within the range is a better estimate, the minimum amount of the range is recorded as a liability on the consolidated balance sheets. The Company does not accrue for contingent losses that, in its judgment, are considered to be reasonably possible, but not probable; however, it discloses the range of reasonably possible losses. As of December 31, 2022 and 2023, no liabilities were recorded for loss contingencies (see Note 14).

Stock-Based Compensation

The Company measures all stock options granted to employees, directors and non-employees based on the fair value of the awards on the date of grant using the Black-Scholes option-pricing model. For awards to non-employees, the expected term of the option is equal to the contractual term of the non-employees’ service agreement. The Company measures restricted stock awards using the difference, if any, between the purchase price per share of the award and the fair value of the Company’s common stock at the date of grant.

The Company grants stock options and restricted stock awards that are subject to either service or performance-based vesting conditions. Compensation expense for awards to employees and directors with service-based vesting conditions is recognized using the straight-line method over the requisite service period, which is generally the vesting period of the respective award. Compensation expense for awards to

F-13

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

non-employees with service-based vesting conditions is recognized in the same manner as if the Company had paid cash in exchange for the goods or services, which is generally over the vesting period of the award. Forfeitures are accounted for as they occur. Compensation expense for awards to employees and non-employees with service and performance-based vesting conditions is recognized based on the grant-date fair value over the requisite service period using the accelerated attribution method to the extent achievement of the performance condition is probable. As of each reporting date, the Company estimates the probability that specified performance criteria will be met and does not recognize compensation expense until it is probable that the performance-based vesting condition will be achieved.

The Company classifies stock-based compensation expense in its consolidated statements of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.

Comprehensive Loss

Comprehensive loss includes net loss as well as other changes in stockholders’ deficit that result from transactions and economic events other than those with stockholders. For the period from February 10, 2022 (inception) to December 31, 2022 there was no difference between net loss and comprehensive loss. For the year ended December 31, 2023, comprehensive loss includes unrealized gains on short-term investments.

Net Loss per Share Attributable to Common Stockholders

The Company applies the two-class method when computing net loss per share attributable to common stockholders as the Company has issued shares that meet the definition of participating securities. The two-class method determines net loss per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common stockholders for the period to be allocated between common and participating securities based upon their respective rights to share in the undistributed earnings as if all income (loss) for the period had been distributed. The Company considers its Convertible Preferred Stock to be participating securities as, in the event a dividend is paid on common stock, the holders of Convertible Preferred Stock would be entitled to receive dividends on a basis consistent with the common stockholders. There is no allocation required under the two-class method during periods of loss since the participating securities do not have a contractual obligation to share in the losses of the Company.

Basic net income (loss) per share attributable to common stockholders is computed by dividing the net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period, excluding potentially dilutive common shares and unvested restricted common stock. Diluted net income (loss) per share attributable to common stockholders is computed by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive securities. Diluted net income (loss) per share attributable to common stockholders is computed by dividing the diluted net income (loss) attributable to common stockholders by the weighted-average number of common shares outstanding for the period, including potential dilutive common shares. For purposes of this calculation, the Company’s outstanding stock options, unvested restricted common stock, and convertible preferred stock are considered potential dilutive common shares.

The Company reported net loss and net loss attributable to common stockholders for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023.

F-14

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Leases

The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As the Company’s leases do not provide an implicit rate, it uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made and is reduced by lease incentives. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term in general and administrative expenses. The Company classifies leases at the lease commencement date as operating or finance leases and records a right-of-use asset and a lease liability on the consolidated balance sheet for all leases with an initial lease term of greater than 12 months. Leases with an initial term of 12 months or less are not recorded in the balance sheet, but payments are recognized as expense on a straight-line basis over the lease term. The Company has elected not to recognize leases with terms of 12 months or less. The Company enters into contracts that contain both lease and non-lease components. Non-lease components may include maintenance, utilities, and other operating costs. The Company combines the lease and non-lease components of fixed costs in its lease arrangements as a single lease component. Variable costs, such as utilities or maintenance costs, are not included in the measurement of right-of-use assets and lease liabilities, but rather are expensed when the event determining the amount of variable consideration to be paid occurs.

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company’s tax returns. Deferred tax assets and liabilities are determined based on the differences between the financial statement basis and tax basis of assets and liabilities using enacted tax rates in effect for the years in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies.

The Company accounts for uncertainty in income taxes recognized in the consolidated financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more likely than not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the consolidated financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50 percent likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. The Company had accrued no amounts for interest or penalties related to uncertain tax positions as of December 31, 2022 and 2023.

Recently Adopted Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842), which requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. The new standard includes a short-term lease exception

F-15

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

for leases with a term of 12 months or less, as part of which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases using classification criteria that are substantially similar to the previous guidance. Finally, in June 2020, the FASB issued ASU 2020-05, Revenue from Contracts with Customers (Topic 606) and Leases (Topic 842): Effective Dates for Certain Entities, whereby the effective date of this standard was deferred to annual reporting periods beginning after December 15, 2021 and interim periods within annual reporting periods beginning after December 15, 2022, and early adoption was still permitted. The Company adopted ASC 842, as amended on February 10, 2022 (inception). Adoption of the standard had no impact on the Company’s consolidated statement of operations and comprehensive loss or statement of cash flows.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU 2016-13 replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in the earlier recognition of credit losses, if any. In May 2019, the FASB issued ASU No. 2019-05, Financial Instruments—Credit Losses (Topic 326): Targeted Transition Relief (“ASU 2019-05”), which provides additional implementation guidance on the previously issued ASU 2016-13. For the Company, both ASU 2016-13 and ASU 2019-05 are effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted the standard effective February 10, 2022 (inception) on a prospective basis which did not have a material impact on the Company’s consolidated financial statements.

In August 2020, the FASB issued ASU No. 2020-06, Debt, Debt with Conversion and Other Options (Subtopic 470-20g) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which, among other things, provides guidance on how to account for contracts on an entity’s own equity. This ASU simplifies the accounting for certain financial instruments with characteristics of liabilities and equity. Specifically, the ASU eliminated the need for the Company to assess whether a contract on the entity’s own equity (1) permits settlement in unregistered shares, (2) whether counterparty rights rank higher than shareholder’s rights, and (3) whether collateral is required. In addition, the ASU requires incremental disclosure related to contracts on the entity’s own equity and clarifies the treatment of certain financial instruments accounted for under this ASU on earnings per share. The ASU also simplifies the accounting for convertible instruments by removing the beneficial conversion feature and cash conversion feature separation models. This ASU may be applied on a full retrospective or modified retrospective basis. This ASU is effective for (i) smaller reporting companies for fiscal years beginning after December 15, 2023 and (ii) all other public entities for fiscal years beginning after December 15, 2021. Early adoption is permitted. The Company adopted this standard on February 10, 2022 (inception). Adoption of the standard had no impact on the Company’s financial position or results of operations.

In October 2021, the FASB issued ASU No. 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (Topic 805), which requires contract assets and contract liabilities acquired in a business combination to be recognized and measured by the acquirer on the acquisition date in accordance with ASC 606, Revenue from Contracts with Customers, as if it had originated the contracts. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. The amendments in this update are effective for (i) public business entities for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years and (ii) all other entities for fiscal years beginning after December 15, 2023, including interim periods within those fiscal

F-16

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

years. Early adoption is permitted for both interim and annual financial statements that have not yet been issued or made available for issuance. The amendments in this update are to be applied prospectively to business combinations occurring on or after the effective date. The Company adopted this standard effective January 1, 2023. Adoption of the standard has had no impact on the Company’s consolidated financial statements.

Recently Issued Accounting Pronouncements Not Yet Adopted

From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company qualifies as an ‘‘emerging growth company’’ as defined in the Jumpstart Our Business Startups Act of 2012 and has elected not to ‘‘opt out’’ of the extended transition related to complying with new or revised accounting standards, which means that when a standard is issued or revised and it has different application dates for public and non-public companies, the Company can adopt the new or revised standard at the time non-public companies adopt the new or revised standard and can do so until such time that the Company either (i) irrevocably elects to ‘‘opt out’’ of such extended transition period or (ii) no longer qualifies as an emerging growth company. The Company may choose to early adopt any new or revised accounting standards whenever such early adoption is permitted for non-public companies.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting-Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The guidance is to be applied retrospectively to all prior periods presented in the financial statements. Upon transition, the segment expense categories and amounts disclosed in the prior periods should be based on the significant segment expense categories identified and disclosed in the period of adoption. We are currently evaluating the potential impact of adopting this new guidance on our consolidated financial statements and related disclosures. This ASU will have no impact on the Company’s consolidated balance sheet or results of operations.

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities to disclose specific categories in the effective tax rate reconciliation, as well as additional information for reconciling items that exceed a quantitative threshold. ASU 2023-09 also requires all entities to disclose income taxes paid disaggregated by federal, state and foreign taxes, and further disaggregated for specific jurisdictions that exceed 5% of total income taxes paid, among other expanded disclosures. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2023-09.

3. Fair Value Measurements

The following tables present the Company’s fair value hierarchy for its assets and liabilities that are measured at fair value on a recurring basis and indicate the level within the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value (in thousands):


	Fair Value Measurements at December 31, 2022:
	Level 1		Level 2		Level 3		Total
Liabilities:
Series A preferred stock tranche right liability	$	—	$	—	$	10,435	$	10,435

	$	—	$	—	$	10,435	$	10,435

F-17

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements


	Fair Value Measurements at December 31, 2023:
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	23,441	$	—	$	—	$	23,441
US Treasury bills		—		23,832		—	$	23,832
Short-term investments:
U.S. Treasury bills and government securities		—		77,309		—	$	77,309

	$	23,441	$	101,141	$	—	$	124,582

Liabilities
Series B preferred stock tranche right liability	$	—	$	—	$	4,200	$	4,200

	$	—	$	—	$	4,200	$	4,200

Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $1.00 net asset value representing its estimated fair value. For the period from February 10, 2022 (inception) to December 31, 2022 and the year ended December 31, 2023, there were no transfers between Level 1, Level 2 and Level 3.

The Company classifies its U.S. Treasury securities as short-term because they are available to be converted into cash to fund current operations. The fair value of the Company’s U.S. Treasury bills and government securities are classified as Level 2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and U.S. Treasury securities.

The underlying securities held in the money market funds held by the Company are all government backed securities.

Short-term investments consisted of the following (in thousands):


	December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized Losses		Fair Value
Short-term investments:
U.S. Treasury bills and government securities	$	77,305	$	4	$	—	$	77,309

	$	77,305	$	4	$	—	$	77,309

The contractual maturities of the Company’s short-term investments in available-for-sale debt securities held were as follows (in thousands):


	December 31, 2022		December 31, 2023
Due within one year	$	—	$	77,309

	$	—	$	77,309

Valuation of Preferred Stock Tranche Right Liability

F-18

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

respectively (see Note 7), either upon achievement of certain specified milestones, upon the waiver of such milestone achievement by a majority vote of the respective series convertible preferred stockholders or in relation to the Series B convertible preferred stock, upon a shareholder exercising its right to early exercise the tranche right. The fair value of the tranche right liability was determined based on significant inputs not observable in the market, which represented a Level 3 measurement within the fair value hierarchy. The fair value of the tranche right liabilities were determined using a Contingent Forward Analysis, which is a scenario-based lattice model that accounts for the different possible milestone scenarios and their associated probabilities, as estimated by the Company. The valuation model considered the probability of closing the tranche, the estimated future value of the Convertible Preferred Stock to be issued at each closing and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. The risk-free rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time to each tranche closing.

Series A Preferred Stock Tranche Right Liability

The significant unobservable inputs used in the valuation model to measure the Series A preferred stock tranche right liability that is categorized within Level 3 of the fair value hierarchy as of December 31, 2022 are as follows:


	Second Tranche Milestone		Third Tranche Milestone
Probability of meeting Series A milestones		50%		30%
Milestone achievement date		6/30/2023		12/31/2023
Risk-free rate		4.70%		4.70%
Expected value of Series A if milestones are not met	$	0.33	$	0.53

The following table provides a roll-forward of the aggregate fair value of the Company’s Series A preferred stock tranche right liability, for which fair value is determined using Level 3 inputs (in thousands):


	Series A Preferred Stock Tranche Right Liability
Balances at February 10, 2022 (inception)	$	—
Initial fair value of Series A preferred stock tranche right liability		10,435

Balance as of December 31, 2022		10,435
Change in fair value of Series A preferred stock tranche right liability		1,030
Settlement of Series A preferred stock tranche right liability upon waiver		(11,465	)

Balance as of December 31, 2023	$	—

Series B Preferred Stock Tranche Right Liability

The significant unobservable inputs used in the valuation model to measure the Series B preferred stock tranche right liability that is categorized within Level 3 of the fair value hierarchy as of December 31, 2023 are as follows:


	Second Tranche Milestone
Probability of meeting Series B milestone		80%
Milestone achievement date		12/31/2024
Risk-free rate		4.79%
Expected value of Series B if milestones are not met	$	0.84

F-19

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

The following table provides a roll-forward of the aggregate fair value of the Company’s Series B preferred stock tranche right liability, for which fair value is determined using Level 3 inputs (in thousands):


	Series B Preferred Stock Tranche Right Liability
Balance as of December 31, 2022	$	—
Initial fair value of Series B preferred stock tranche right liability		4,619
Settlement of Series B preferred stock tranche right liability upon early exercise		(513	)
Change in fair value of Series B preferred stock tranche right liability		94

Balance as of December 31, 2023	$	4,200

4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	As of December 31,
	2022			2023
Lab equipment	$	295		$	1,719
Computer equipment		—			43
Leasehold improvements		—			255
Construction in process		55			26

Total property and equipment	$	350		$	2,043
Less: Accumulated depreciation		(15	)		(127	)

		335			1,916

Depreciation expense of property and equipment for the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023 was $15 thousand and $0.1 million, respectively.

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	As of December 31,
	2022		2023
Research and development	$	120	$	2,645
Professional fees		49		459
Related party consulting fees		30		—
Employee related		—		2,413
Accrued other		14		114

	$	213	$	5,631

6. Convertible Promissory Notes

In August and September 2022, the Company issued a total of four Convertible Promissory Notes (the “Notes” or the “Convertible Notes”) as part of a series of Convertible Notes to two Related Parties (the “Holders”) (see Note 13). The Convertible Notes had an aggregate principal amount of $8.0 million, which

F-20

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

consisted of $4.0 million to each of the Holders, and bore interest at a rate of 8% per annum computed on the basis of a 365-day year and maturity dates 12 months from the date of issuance. Upon initial issuance the Notes were recorded net of $0.1 million of related issuance costs.

The Notes are automatically converted into the series of convertible preferred equity securities sold in a qualified financing event with total proceeds not less than $30 million upon the closing of such financing. Holders of the Notes also have the option to convert their Notes into the series of capital stock sold in a non-qualifying financing event. The conversion price shall equal to the lesser of (i) 100% of the per share price paid by investors in the financing event or (ii) a per share price derived from assuming a fully-diluted pre-money valuation for a financing of $10 million.

In addition, upon specified events such as a change of control or sale of substantially all of the Company’s assets, the Notes are redeemable at 100% of principal and accrued interest.

In December 2022, in conjunction with the Company’s Series A convertible preferred stock financing, the Holders exercised their right to exchange the Notes, plus accrued interest, for an aggregate of 8,182,354 shares of Series A convertible preferred stock. At the time of settlement, the Notes had an unamortized discount of $77 thousand, which was recorded as a loss on extinguishment of debt within interest expense in the consolidated statement of operations and comprehensive loss. The fair value of the Series A convertible preferred stock issued in exchange for the Notes of $8.2 million was offset by $2.1 million related to the Series A preferred stock tranche right liability, as discussed below.

7. Convertible Preferred Stock

The Company has issued Series A convertible preferred stock and Series B convertible preferred stock.

Series A Convertible Preferred Stock and Series A Preferred Stock Tranche Right Liability

In December 2022, the Company completed its first closing of Series A convertible preferred stock and issued and sold 32,000,000 shares of Series A convertible preferred stock, at a price of $1.00 per share, for cash proceeds of $31.8 million, net of issuance costs of $0.2 million, of which $63 thousand was allocated to the tranche right and recognized in the statement of operations and comprehensive loss as general and administrative expense. Contemporaneously, investors converted their Convertible Promissory Notes (Note 6) with a principal and accrued interest amount of $8.2 million for 8,182,354 shares of Series A convertible preferred stock, bringing the total number of shares of Series A convertible preferred stock issued to 40,182,354.

The purchase agreement for the Series A convertible preferred stock provided investors the obligation to purchase an additional 60,000,000 shares of Series A convertible preferred stock (the “Series A Milestone Tranches”) at a price of $1.00 per share in the subsequent second and third tranche closings upon the achievement of specified second and third tranche milestones by the Company or the right to purchase additional shares upon waiving of such milestone achievement by a majority vote of Series A convertible preferred stockholders. Within 30 days prior to a Deemed Liquidation Event (see definition below), investors can also choose to early exercise their tranche right by providing the Company a written notice.

Upon the first closing of the Series A convertible preferred stock in December 2022, the Company recorded a preferred stock tranche right liability of $10.4 million and a corresponding reduction to the carrying value of the Series A convertible preferred stock. There was no change in the fair value of the Series A preferred stock tranche right liability from December 9, 2022, to December 31, 2022 and therefore, the Company did not recognize any other income or expenses related to the tranche right liability for the year ended December 31, 2022.

F-21

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

In February 2023, the Company amended the Series A convertible preferred stock purchase agreement to add an additional investor, who purchased 10,000,000 shares, at the price of $1.00 per share, resulting in cash proceeds of $10.0 million, less $19 thousand of issuance costs and to amend the total number of shares subject to the Series A Milestone Tranches from 60,000,000 to 50,000,000.

In conjunction with the amendment to the Series A convertible preferred stock purchase agreement, the Company’s existing Series A convertible preferred stockholders agreed to waive the second and third tranche milestones and exercised the tranche right in February 2023. As a result, an aggregate of 50,000,000 shares of Series A convertible preferred stock were issued and sold at a price of $1.00 per share, resulting in total cash proceeds of $50 million, less $61 thousand of issuance costs. As a result of this issuance, the Series A preferred stock tranche right liability with a then fair value of $11.5 million immediately prior to the amendment and waiver, was settled in full and recognized in additional paid-in capital as a capital contribution.

Series B Convertible Preferred Stock and Series B Preferred Stock Tranche Right Liability

In August 2023, the Company issued and sold 46,504,135 shares of Series B convertible preferred stock, at a price of $1.67727 per share for cash proceeds of $77.3 million, net of issuance costs of $0.7 million, of which $67 thousand was allocated to the tranche right and recognized in the statement of operations and comprehensive loss as general and administrative expense. The 46,504,135 shares include the 10,731,725 shares that were early exercised on the original issuance date (discussed below).

The purchase agreement for the Series B convertible preferred stock provided investors the obligation to purchase an additional 42,926,895 shares of Series B convertible preferred stock (the “Series B Milestone Tranche”) at a price of $1.67727 per share in the subsequent closing upon the achievement of a specified milestone by the Company or the right to purchase additional shares upon waiving of such milestone achievement by a majority vote of Series B convertible preferred stockholders. Additionally, each stockholder of Series B convertible preferred stock has the right to early exercise the tranche right by providing three days advance written notice. Upon the closing of the Series B convertible preferred stock, the Company recorded a preferred stock tranche right liability of $4.6 million and a corresponding reduction to the carrying value of the Series B convertible preferred stock.

Concurrent with the original issuance of the Series B convertible preferred stock, six stockholders exercised their right to early exercise the Series B preferred stock tranche right and purchased 10,731,725 shares. Consequently, the Company recognized $1.2 million in additional paid-in capital associated with the simultaneous original issuance and early exercise. Additionally, the investors paid a premium of $1.7 million for these shares over their fair value which was also recorded in additional paid-in capital.

As of December 31, 2023, the Company remeasured the Series B tranche right liability to be $4.2 million and recognized $0.1 million in other expense for the change in the fair value of the Series B tranche right liability during the year.

Upon issuance of each series of Preferred Stock, the Company assessed the embedded conversion and liquidation features of the securities and determined that such features did not require the Company to separately account for these features.

F-22

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Convertible Preferred Stock consisted of the following (in thousands, except share amounts):


	December 31, 2022
	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Preference		Conversion Price per share		Common Stock Issuable Upon Conversion
Series A convertible preferred stock		100,182,354		40,182,354	$	29,567	$	40,182		8.5648		4,693,298

		100,182,354		40,182,354	$	29,567	$	40,182				4,693,298


	December 31, 2023
	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Preference		Conversion Price per share		Common Stock Issuable Upon Conversion
Series A convertible preferred stock		100,182,354		100,182,354	$	89,487	$	100,182		8.5648		11,701,298
Series B convertible preferred stock		89,431,030		51,273,790		77,091		86,000		14.3655		5,988,764

		189,613,384		151,456,144	$	166,578	$	186,182				17,690,062

The holders of the Convertible Preferred Stock have the following rights and preferences:

Voting

The holders of the Convertible Preferred Stock are entitled to vote, together with the holders of common stock, as a single class, on all matters submitted to the shareholders for a vote and are entitled to the number of votes equal to the number of shares of common stock into which the Convertible Preferred Stock could convert on the record date for determination of shareholders entitled to vote. A majority vote of the holders of Convertible Preferred Stock along with a majority vote of the Series B convertible preferred stock (the “Required Vote”) is required to, among others, liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of Convertible Preferred Stock, declare a dividend or make a distribution, or change the authorized number of directors constituting the board of directors.

In addition, the holders of shares of Series A convertible preferred stock, voting exclusively and as a separate class, are entitled to elect up to three directors of the Company. The holders of shares of Series B convertible preferred stock, voting exclusively and as a separate class, are entitled to elect up to two directors of the Company.

Conversion

F-23

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

such holder’s obligation to purchase its Second Tranche Shares is fulfilled, (iv) the termination of such holder’s obligations to complete the Series B Milestone Tranche closing and (v) such date as agreed to by the Company and the holders of a majority of the then outstanding shares of Series B convertible preferred stock, voting as a separate, exclusive class. In addition, each share of Convertible Preferred Stock will be automatically converted into shares of common stock at the then-effective applicable conversion ratio upon either (i) the closing of a firm-commitment underwritten public offering of its common stock at a price per share of at least $14.70302 resulting in at least $50.0 million of gross proceeds, net of underwriting discount and commissions, to the Company, or (ii) the date specified by vote or written consent of the holders of the Required Vote, voting as a single class.

The conversion ratio of each class of Convertible Preferred Stock is determined by dividing the Applicable Original Issue Price of each class of Convertible Preferred Stock by the Conversion Price of each class. As of December 31, 2022 and 2023, the Conversion Price was $8.5648 per share for Series A convertible preferred stock and $14.3655 per share for Series B convertible preferred stock, each subject to appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization with respect to the Convertible Preferred Stock.

There shall be no adjustment in the conversion price of the Convertible Preferred Stock as the result of the issuance or deemed issuance of additional shares of the Company’s common stock if the Company receives written notice from the holders of the Required Vote of the then outstanding shares of Convertible Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of additional shares of the Company’s common stock.

In the event that any holder of Convertible Preferred Stock who is required to participate in a subsequent closing pursuant to the purchase agreement does not purchase the aggregate number of subsequent closing shares, then each share of Convertible Preferred Stock held by such holder shall automatically be converted into shares of common stock at a ratio of one share of common stock for every ten shares of Convertible Preferred Stock held immediately prior to the consummation of such subsequent closing.

Dividends

The holders of the Convertible Preferred Stock shall be entitled to receive, only when, as and if declared by the Board of Directors, non-cumulative dividends at the rate of 8% of the Applicable Original Issue Price of the Convertible Preferred Stock (the “Preferred Dividend”).

The Company shall not declare, pay or set aside any dividends on common shares of the Company unless the holders of Convertible Preferred Stock then outstanding shall first receive, or simultaneously receive, the Preferred Dividend on each outstanding Convertible Preferred Stock and a dividend on each outstanding Convertible Preferred Stock in an amount at least equal to the product of (1) the dividend payable on each share of such class or series determined, as if all shares of such class or series had been converted into common stock and (2) the number of shares of common stock issuable upon conversion of a share of such series of Convertible Preferred Stock, in each case calculated on the record date for determination of the holders entitle to receive such dividend. As of December 31, 2022 and 2023, no cash dividends have been declared or paid.

Liquidation

F-24

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

share equal to the greater of (i) the Applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) the amount that would have been payable had all shares of each series of Convertible Preferred Stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (as defined below). After the payment in full of the Convertible Preferred Stock preference amount, the remaining assets of the Company available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis.

Unless at least the holders of the Required Vote, elect otherwise, a Deemed Liquidation Event shall include a merger, consolidation, or share exchange (other than one in which stockholders of the Company own a majority by voting power of the outstanding shares of the surviving or acquiring corporation) or a sale, lease, transfer, exclusive license or other disposition of all or substantially all of the assets of the Company, or the closing of the transfer of 50% or more of the Company’s outstanding voting stock, or any merger or consolidation in connection with a SPAC transaction or reverse merger transaction.

Redemption

The Convertible Preferred Stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.

8. Common Stock

The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of the holders of the Convertible Preferred Stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of the Convertible Preferred Stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company’s board of directors, subject to the preferential dividend rights of Convertible Preferred Stock. As of December 31, 2022 and 2023, no dividends have been declared or paid.

As of December 31, 2022 and 2023, the Company had reserved 12,022,379 and 23,890,096 shares of common stock, respectively, of which 11,701,298 and 22,146,816 were reserved for the potential conversion of shares of Series A convertible preferred stock and Series B convertible preferred stock, respectively, and 321,081 and 1,743,280 for issuance under the 2022 Stock Option and Grant Plan.

9. Stock-Based Compensation

The Company’s 2022 Stock Option and Grant Plan (the “2022 Plan”) provides for the Company to grant incentive stock options (“ISO”) or non-qualified stock options, unrestricted stock awards, restricted stock awards and restricted stock units (collectively, the “Awards”) to the employees, directors, and consultants of the Company. The 2022 Plan is administered by the board of directors, or at the discretion of the board of directors, by a committee of the board of directors. The exercise prices, vesting and other restrictions are determined at the discretion of the board of directors, or its committee if so delegated.

As of December 31, 2022, the total number of shares of common stock authorized and issuable under the 2022 Plan was 321,081. In August 2023, the Company’s board of directors further increased the number of shares of common stock reserved for issuance under the plan from 321,081 shares to 1,743,280 shares. As of December 31, 2023, 214,319 shares remain available for future grants. Shares of unused common stock underlying any Awards that are forfeited, canceled or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2022 Plan. As of December 31, 2023, the Company has issued 2,850,884 shares of restricted stock awards outside of the 2022 plan which will be settled using the Company’s authorized common shares.

F-25

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

The exercise price for stock options granted may not be less than the 100% of the fair market value of the Company’s common stock on the date of grant, as determined by the board of directors. In the case of an ISO granted to an employee who owns stock representing more than 10% of the voting power of all classes of stock (“10% Owner”) as determined by the board of directors as of the date of grant, the exercise price per share shall not be less than 110% of the fair market value on the grant date. The Company’s board of directors determines the fair market value of the Company’s common stock, taking into consideration its most recently available valuation of common stock performed by third parties as well as additional factors which may have changed since the date of the most recent contemporaneous valuation through the date of grant. Unless otherwise provided, at the time of grant, the options granted pursuant to the 2022 Plan have a ten year contractual term from the date of grant, or five years from the date of grant in the case of an ISO that is granted to a 10% Owner.

The vesting periods for awards issued inside of the plan generally vest over four years and for awards issued outside of the plan, vesting can differ, however they generally vest over a period of 4 years. Some grantees’ stock-compensation awards may contain an acceleration vesting clause that would result in their unvested shares to become fully vested upon the occurrence of a change in control event.

Stock Option Valuation

The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model. The Company historically has been a private company and lacks company-specific historical and implied volatility information. Therefore, it estimates its expected stock volatility based on the historical volatility of a publicly traded set of peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. For options with service-based vesting conditions, the expected term of the Company’s options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.

The following table presents the assumptions used in the Black-Scholes option-pricing model to determine the fair value of stock options granted:


	For the period from February 10, 2022 (inception) to December 31,		Year Ended December 31,
	2022		2023
Expected volatility		—		95.45% - 99.20%
Risk-free interest rate		—		4.14% - 4.23%
Expected dividend yield		—		0.00%
Expected term (in years)		—		4.0 - 6.0
Fair value of common stock		—	$	6.34

Stock Options

There were no stock options granted for the period from February 10, 2022 (inception) to December 31, 2022.

F-26

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

The following table summarizes the Company’s stock option activity for the year ended December 31, 2023:


	Number of Shares		Weighted- Average Exercise Price per share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2022		—	$	—		—	$	—
Granted		1,376,596		1.80
Exercised		—		—
Forfeited		—		—
Expired		—		—

Options outstanding at December 31, 2023		1,376,596	$	1.80		9.83	$	$6,249

Options vested and exercisable at December 31, 2023		—		—		—		—
Options vested and expected to vest at December 31, 2023		1,376,596	$	1.80		9.83	$	$6,249

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the estimated fair value of the Company’s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company’s common stock.

The weighted-average grant-date fair value of stock options granted for the year ended December 31, 2023 was $5.74 per share. As of December 31, 2023, there was $7.7 million of total unrecognized compensation cost related to unvested stock options. The Company expects to recognize such amount over a remaining weighted-average period of 3.68 years.

Restricted Stock Awards (“RSA”)

The Company awards restricted stock both under the 2022 Plan as well as outside of the 2022 Plan. During the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, the Company issued service-based RSAs and performance-based RSAs.

For restricted stock issued under the 2022 Plan, for a period of up to 6 months from a grantee’s termination, the Company has the right and option to repurchase unvested RSAs at the lower of (i) the original purchase price per share or (ii) the fair market value per share as of the date of the Company elects to exercise its repurchase right. In September 2023, the Company exercised its option to repurchase 46,702 unvested RSAs at their original purchase price after the grantee ceased providing services.

For restricted stock issued outside of the 2022 Plan, for a period of up to 90 days from a grantee’s termination, the Company has the right and option to repurchase unvested restricted common stock at the original repurchase price per share paid by the grantee.

For the period from February 10, 2022 (inception) to December 31, 2022, the Company issued 1,425,855 shares of restricted stock outside of the 2022 Plan. For the year ended December 31, 2023, the Company issued 1,425,029 shares of restricted stock outside of the 2022 Plan and 199,067 shares of restricted stock under the 2022 Plan. Shares of restricted common stock granted to employees and directors are not deemed, for accounting purposes, to be outstanding until those shares have vested.

F-27

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

During the period from February 10, 2022 (inception) to December 31, 2022, 1,700,368 service-based restricted shares and 719,409 performance-based restricted shares were legally issued, but 544,291 and 449,631 shares, respectively, were not considered granted for accounting purposes because individuals did not begin providing services until the year ended December 31, 2023.

Each award type is discussed below.

Service-Based RSAs

The majority of the RSAs have service-based vesting conditions and vest over a period from immediately to four years. Compensation expense is recognized on a straight-line basis over the requisite service period.

The following table summarizes the Company’s service-based RSA grant activity for the year ended December 31, 2023:


	RSAs			Weighted- Average Grant Date Fair Value
Unvested shares at December 31, 2022		986,443		$	2.92
Granted		1,073,749			4.22
Vested		(427,492	)		3.33
Forfeited		(46,702	)		4.54

Unvested shares at December 31, 2023		1,585,998		$	3.64

The aggregate fair value of service-based RSAs that vested during the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, was $0.5 million and $2.2 million, respectively. The aggregate intrinsic value of restricted stock awards is calculated as the positive difference between the prices paid, if any, of the restricted stock awards and the fair value of the Company’s common stock

As of December 31, 2023, there was $5.4 million of total unrecognized compensation cost related to unvested service-based RSAs which the Company expects to recognize over a weighted-average period of 2.96 years.

Performance-Based RSAs

The Company has also granted performance-based RSAs to certain employees and directors with a vesting commencement date contingent upon the subsequent closing of the Company’s Series A convertible preferred stock financing. The Company has determined that it has met all the conditions to establish the grant date for these performance-based RSAs at the original issuance date. Therefore, these awards are deemed to contain an implied performance condition. The vesting of the performance-based RSAs is also subject to grantees’ continued service until the 4^th anniversary date of the closing of a subsequent financing.

Share-based compensation expense associated with the performance-based RSAs is recognized if the performance condition is considered probable of achievement. As of December 31, 2022, the Company has concluded that it was not probable that the performance condition related to performance-based RSAs would be achieved, and as a result no compensation expense was recorded. In February 2023, the existing Series A convertible preferred stock investors waived the second and third tranche milestones and the Company closed on the sale of its second and third tranches of Series A convertible preferred stock. As a result, the performance condition was deemed to be met. The Company recognized $1.6 million of compensation expense for the performance-based RSAs for the year ended December 31, 2023.

F-28

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

The following table summarizes the Company’s performance-based RSA grant activity for the year ended December 31, 2023:


	RSAs			Weighted- Average Grant Date Fair Value
Unvested shares at December 31, 2022		269,778		$	2.92
Granted		550,347			3.98
Vested		(170,861	)		3.63
Forfeited		—			—

Unvested shares at December 31, 2023		649,264		$	3.63

The aggregate fair value of performance-based RSAs that vested during the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, was zero and $0.8 million, respectively.

The aggregate intrinsic value of restricted stock awards is calculated as the positive difference between the prices paid, if any, of the restricted stock awards and the fair value of the Company’s common stock.

As of December 31, 2023, there was $1.3 million of total unrecognized compensation cost related to unvested performance-based restricted common stock which the Company expects to recognize over a weighted-average period of 1.88 years.

Stock-Based Compensation

The Company recorded stock-based compensation expense for stock options of zero and $0.2 million and for RSAs of $0.6 million and $3.3 million in the period from February 10, 2022 (inception) to December 31, 2022, and during the year ended December 31, 2023, respectively. The following table below summarizes the classification of the Company’s stock-based compensation expense related to stock options and restricted common stock awards in the consolidated statements of operations and comprehensive loss (in thousands):


	Period from February 10, 2022 (inception) to December 31, 2022		For the year ended December 31, 2023
General and Administrative	$	53	$	1,637
Research and Development		506		1,888

	$	559	$	3,525

10. Leases

Operating Lease

In June 2023, the Company entered into a lease for its corporate headquarters in Boston, Massachusetts. The lease commenced August 31, 2023 with an initial term of 40 months. The monthly lease payments are $66 thousand for the first 12 months, with 2% escalation each year. In conjunction with the lease, the Company paid a security deposit of $0.1 million, which is recorded on the Company’s consolidated balance sheet as restricted cash as of December 31, 2023.

F-29

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows (in thousands):


	Period from February 10, 2022 (inception) to December 31, 2022		Year Ended December 31, 2023
Operating lease
Operating lease right-of-use assets, net	$	—	$	2,084
Operating lease right-of-use liabilities, current		—		670
Operating lease right-of-use liabilities, non-current		—		1,476

Total operating lease liabilities	$	—	$	2,146

The components of operating lease costs were as follows (in thousands):


	Period from February 10, 2022 (inception) to December 31, 2022		Year Ended December 31, 2023
Operating lease costs	$	—	$	261
Variable lease costs		—		9
Short-term lease costs		71		382

Other information related to leases was as follows (in thousands):

Supplemental cash flow information


	Period from February 10, 2022 (inception) to December 31, 2022		Year Ended December 31, 2023
Cash flows included in the measurement of lease liabilities:
Cash paid for amounts included in the measurement of operating lease liabilities	$	—	$	199
Right-of-use lease assets obtained in exchange for new operating lease liabilities	$	—	$	2,290

Lease term and discount rate


	December 31,
	2022		2023
Weighted-average remaining lease term—operating lease		—		3
Weighted-average discount rate—operating lease		—		7.29	%

F-30

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

As of December 31, 2023, maturities of operating lease liabilities for each of the following five years and a total thereafter were as follows (in thousands):


2024	$	805
2025		820
2026		766

Total minimum future lease payments	$	2,391
Less: Imputed interest		(245	)

Total lease liabilities	$	2,146

11. Income Taxes

For the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, the Company recorded a tax provision of zero and $10 thousand, respectively. In addition, the Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2022 and 2023.

The components of income tax provision are as follows (in thousands):


	Period from February 10, 2022 (inception) to December 31, 2022		Year Ended December 31, 2023
Components of income tax provision
Current Provision:
Federal	$	—	$	—
State		—		10

Total current provision		—		10
Deferred income tax provision (benefit)		—		—
Federal		—		—
State		—		—

Total deferred income tax provision (benefit)		—		—

Total provision for (benefit from) income taxes	$	—	$	10

A reconciliation of the U.S. federal statutory income tax rate to the Company’s effective income tax rate is as follows:


	Period from February 10, 2022 (inception) to December 31, 2022			Year Ended December 31, 2023
Rate Reconciliation
Statutory U.S. federal rate		21.00	%		21.00	%
Permanent Differences		-0.69	%		-0.84	%
State income taxes, net of federal benefit		2.32	%		6.47	%
Research and development credits		1.86	%		3.64	%
Valuation allowance		-24.50	%		-30.30	%

Effective tax rate		-0.01	%		-0.03	%

F-31

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

The Company accounts for income taxes in accordance with ASC Topic 740. Deferred income tax assets and liabilities are determined based upon temporary differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

Net deferred tax assets (liabilities) consisted of the following (in thousands):


	As of December 31,
	2022			2023
Deferred Tax Summary
Deferred tax assets:
US and State net operating loss carryforwards	$	119		$	1,345
Capitalized research and development costs		972			7,307
Depreciation		9			—
License fees capitalization		1,131			1,211
Stock-based compensation		128			1,041
Research and development credit carryforwards		250			1,837
Lease liability		—			567
Accruals and other		—			635

Total deferred tax assets		2,609			13,943

Deferred tax liabilities
Depreciation		—			(27	)
Right-of-Use Asset		—			(551	)
481(a) Adjustment		—			(220	)

Total deferred tax liabilities		—			(798	)

Valuation Allowance		(2,609	)		(13,145	)

Net deferred tax assets (liabilities)	$	—		$	—

As of December 31, 2022 and 2023, the Company had U.S. federal net operating loss carryforwards of $0.6 million and $6.0 million and state net operating loss carryforwards of zero and $1.6 million, respectively. Federal losses have an indefinite carryforward period, but can only offset 80% of federal taxable income in a given year. Losses for state purposes begin to expire in 2042. As of December 31, 2022 and 2023, the Company had federal research and development tax credit carryforwards of $0.2 million and $1.5 million, respectively, and state research and development tax credit carryforwards of $0.1 million and $0.5 million, respectively, which begin to expire in 2042 and 2037.

F-32

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which are comprised principally of amortizable license fees, capitalized research and development expenses, and net operating loss carryforwards. Under the applicable accounting standards, management has considered the Company’s activity and concluded that it is more likely than not that the Company will not recognize the benefits of domestic deferred tax assets. Accordingly, a full valuation allowance of $2.6 million as of December 31, 2022 and $13.1 million as of December 31, 2023, respectively, was recorded. Changes in valuation allowance for deferred tax assets during the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023 related primarily to the increases in NOLs, research and development tax credit carryforwards, capitalized research and development expenses pursuant to IRC Section 174, and stock-based compensation were as follows:


	Period from February 10, 2022 (inception) to December 31, 2022			Year Ended December 31, 2023
Valuation allowance at February 10, 2022 (inception)	$	—		$	(2,609	)
Decreases recorded as benefit to income tax provision		—			—
Increases recorded to income tax provision		(2,609	)		(10,536	)

Valuation allowance as of end of year	$	(2,609	)	$	(13,145	)

The federal and state net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 of the Internal Revenue Code of 1986, and similar state provisions, due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2023, the Company has not completed a 382 study to assess whether a change of ownership has occurred since its formation.

Section 174 made by the Tax Cuts and Jobs Act of 2017 (the TCJA) for tax year beginning on or after Jan. 1, 2022, no longer permits an immediate deduction for research and development expenditures in the tax year that such costs are incurred. Section 174 costs are expenditures which represent research and development costs that are incident to the development or improvement of a product, process, formula, invention, computer software or technique. The research and experimental (“R&E”) expenses under Section 174 must be capitalized and amortized over five years for research performed in the U.S. and 15 years for research performed outside the U.S. We have included the impact of this provision, which results in a deferred tax asset of approximately $1.0 million as of December 31, 2022 and $7.3 million as of December 31, 2023.

The Company adopted the authoritative guidance on accounting for and disclosure of uncertain tax positions, which requires the Company to determine whether a tax position of the Company is more likely than not to be sustained upon examination, including resolution of any related appeals of litigation processes, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the tax amount recognized in the financial statements is reduced by the largest benefit that has a greater than fifty percent likelihood of being realized upon the ultimate settlement with the relevant taxing authority. As of December 31, 2023, the Company had not recorded any reserves for uncertain tax positions or related interest and penalties. The Company’s policy is to record interest and penalties related to income taxes as part of the tax provision.

The Company files income tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions in the United States and other countries, where applicable. There are currently no pending tax examinations. The

F-33

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Company is open to federal and state tax examination under statute from 2022 to present. Carryforward attributes from prior years can be adjusted upon examination by federal and state tax authorities to the extent utilized in an open tax year or in future periods.

There are no tax matters under discussion with taxing authorities that are expected to have a material effect on the Company’s consolidated financial statements.

12. Related Party License Agreement

In August 2022, the Company entered into an option and license agreement with Janssen Pharmaceutical NV (“Janssen License”) under which the Company received an exclusive option to obtain from Janssen (a) a worldwide exclusive license for the research, development, and commercialization of transmembrane AMPAR regulatory protein-g8 (“TARPg8”) products for the diagnosis, treatment, prophylaxis or palliation of any disease or condition in humans or other animals (the “Field”) and (b) an assignment of certain patents related to TARPg8, in each case of (a)-(b), subject to certain retained rights by Janssen. Pursuant to the Janssen License, the Company also received a worldwide, royalty-free, non-exclusive license (exclusive under certain joint patents) for the research, development, and commercialization of certain neuronal nicotinic acetylcholine (“nACh”) products in the Field.

In conjunction with the Janssen License, the Company made a non-refundable, non-creditable upfront payment of $1.0 million to Janssen after entering into the Janssen License. In October 2022, the Company exercised the option and paid a non-refundable, non-creditable option fee of $4.0 million to Janssen. If the Company succeeds in developing and commercializing TARPg8 products, Janssen will be eligible to receive (i) up to $76.0 million in development milestone payments and up to $40.0 million in sales milestone payments for the product containing the lead TARPg8 development candidate, and (ii) up to $25.0 million in development milestone payments and up to $42.0 million in sales milestone payments for other products containing a non-lead TARPg8 development candidate.

Janssen is also eligible to receive (a) royalties ranging from mid-single digits to high single digits on worldwide net sales of any products containing a TARPg8 development candidate and (b) royalties ranging from low-single digits to mid-single digits for other TARPg8 products that do not contain a TARPg8 development candidate, in each case of (a) and (b), subject to potential reductions following the expiration of valid claims and regulatory exclusivity covering such TARPg8 products, the launch of certain generic products and the application of certain anti-stacking reductions for third party IP payments, subject to a customary reduction floor. The royalties for any TARPg8 product will expire on a country-by-country basis upon the latest to occur of (i) the expiration of all valid patent claims covering such product in such country, (ii) the expiration of all regulatory exclusivities in such country, and (iii) a specified number of years following the first commercial sale of such product in such country.

The Company has the right to terminate the Janssen License for any or no reason upon providing prior written notice to Janssen upon ninety (90) days’ prior written notice to Janssen. Either party may terminate the license agreement in its entirety for the other party’s material breach if such party fails to cure the breach or upon certain insolvency events involving the other party.

The Company determined that the Janssen License represented an asset acquisition, rather than a business combination, as substantially all of the fair value of the assets acquired in the Janssen License was concentrated in a single asset, the TARPg8 compound, which was in early stage of development at the time of acquisition. As the IPR&D asset was determined to have no alternative future use, the Company recognized the aggregate acquisition cost as related party acquired in-process research and development expense in the consolidated statement of operations and comprehensive loss for the period from February 10, 2022 (inception) to

F-34

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

December 31, 2022. For the period from February 10, 2022 (inception) to December 31, 2022 and the year ended December 31, 2023, the Company recognized $5.0 million and zero of related party acquired in-process research and development expense in connection with the consideration due under the Janssen License.

13. Related Party Transactions

Janssen

Janssen, counterparty to the Janssen License, is a related party to a founding investor in the Company, Johnson & Johnson Innovation—JJDC, Inc., as both entities are direct subsidiaries of Johnson & Johnson, Inc. For the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, the Company incurred costs of $0.1 million and $0.4 million, respectively, which was recognized as research and development expense in the consolidated statement of operations and comprehensive loss, to Janssen for the use of lab space in California. As of December 31, 2022 and 2023, there were no related party transactions in accounts payable. As of December 31, 2022 and 2023, $11 thousand and zero was included in accrued expenses, respectively.

Third Rock Ventures

Third Rock Ventures LLC (“Third Rock”) is a founding investor in the Company. For the period from February 10, 2022 (inception) to December 31, 2022 and for the year ended December 31, 2023, the Company incurred costs of $2.1 million and $1.2 million, respectively, of which $1.5 million and $0.3 million, respectively was recognized as research and development expense, and $0.6 million and $0.9 million, respectively, was recognized as general and administrative expense in the consolidated statement of operations and comprehensive loss, to Third Rock primarily for management consulting and other various start-up support activities. As of December 31, 2022 and 2023, $0.7 million and $0.2 million, respectively, was included in accounts payable. As of December 31, 2022 and 2023, $19 thousand and zero, respectively was included in accrued expenses.

14. Commitments and Contingencies

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with the board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2022 and 2023.

Legal Proceedings

F-35

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

other costs associated with such proceedings are expensed as incurred. As of December 31, 2022 and 2023, the Company was not a party to any material legal proceedings or claims.

NeuroPace Master Services Agreement and Statement of Work

In November 2023, the Company entered into a master services agreement (the “NeuroPace Agreement”) with NeuroPace Inc. (“NeuroPace”), the manufacturer and distributor of the RNS system. Pursuant to the NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides the Company with certain services with respect to data from the RNS systems used in our clinical trials. The NeuroPace Agreement also grants the Company a royalty-free, worldwide, exclusive, non-transferable license to all data collected by the RNS systems in its Phase 2a clinical trial and the outcomes of algorithms that are applied to such data, as well as the ability to publish the outcomes of algorithms, subject to certain conditions. The consideration the Company will pay to NeuroPace for such services is set out in each statement of work agreement.

Concurrently with the execution of the NeuroPace Agreement, the parties also entered into an initial statement of work under the NeuroPace Agreement, as amended in March 2024 (the “NeuroPace SOW”), pursuant to which NeuroPace agreed to provide services related to the Company’s Phase 2a clinical trial of RAP-219, including, among other things, clinical trial readiness support, identification of potential patients satisfying the enrollment criteria and RNS system data reporting and data analysis. Pursuant to the payment schedule set out in the NeuroPace SOW, we will pay NeuroPace an aggregate of up to $3.7 million over a period of approximately two years in connection with NeuroPace’s provision of services and achievement of certain patient enrollment and deliverable milestones. During the year ended December 31, 2023, the Company paid NeuroPace $1.5 million, which is recorded as prepaid expenses and other current assets in the consolidated balance sheet.

15. Net Loss per Share

The Company calculated basic and diluted net loss per share attributable to common stockholders using the two-class method required for companies with participating securities. The Company considers Series A convertible preferred stock and Series B convertible preferred stock to be participating securities as the holders are entitled to receive cumulative dividends as well as residuals in liquidation.

F-36

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

stockholders was not allocated to the Series A convertible preferred stock or Series B convertible preferred stock as the holders of Convertible Preferred Stock did not have a contractual obligation to share in losses. Diluted net loss per share available to common stockholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock and stock options were considered common stock equivalents but had been excluded from the calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.


	Period from February 10, 2022 (inception) to December 31, 2022		Year ended December 31, 2023
Numerator:
Net loss attributable to common stockholders	$	(10,652)	$	(34,786	)
Denominator:
Weighted average common shares outstanding, basic and diluted		777,212		1,505,774
Net loss per share attributable to common stockholders, basic and diluted	$	(13.71)	$	(23.10)

For purposes of this calculation, the Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share available to common shareholders for the periods indicated because including them would have had an anti-dilutive effect:


	Period from February 10, 2022 (inception) to December 31, 2022		Year ended December 31, 2023
Series A convertible preferred stock		4,693,298		11,701,298
Series B convertible preferred stock		—		5,988,764
Options to purchase common stock		—		1,376,596
Unvested restricted common stock—service based		986,443		1,585,998
Unvested restricted common stock—performance based		269,778		649,264

		5,949,519		21,301,920

16. Reverse Stock Split

On May 31, 2024, the Company effected a one-for-8.5648 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios of each series of the Company’s preferred stock (see Note 7). Accordingly, all share and per share amounts for all periods presented in the accompanying consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.

17. Subsequent Events

For its consolidated financial statements as of December 31, 2023, the Company has evaluated subsequent events through March 27, 2024, the date on which those consolidated financial statements were available to be issued. In connection with the reissuance of the financial statements, the Company has evaluated subsequent events through June 3, 2024, the date the financial statements were available to be reissued.

F-37

Rapport Therapeutics, Inc.

Notes to Consolidated Financial Statements

Leases

Grant of Stock Options under the 2022 Plan

In January, February and March 2024, the Company granted options for the purchase of an aggregate of 35,027, 131,930 and 1,133,934 shares of common stock, at an exercise price of $1.80, $4.46 and $9.60 per share, respectively. The aggregate grant-date fair value of the options granted has not yet been determined. It is expected to be recognized as stock-based compensation expense over a period of 4.0 years.

Series B Preferred Stock Tranche Right Settlement

In February 2024, the Company’s existing Series B convertible preferred stockholders voted to waive the second tranche milestones and subsequently exercised the tranche right in March 2024. As a result, an aggregate of 38,157,240 shares of Series B convertible preferred stock were issued and sold at a price of $1.67727 per share, resulting in total cash proceeds of $64.0 million, less $87 thousand of issuance costs.

Increase in Shares Authorized for Issuance under the 2022 Plan

In March 2024, the Company amended the 2022 Plan to increase the aggregate number of shares of the Company’s common stock reserved for issuance pursuant to the 2022 Plan by 1,205,279 shares for a total reserved for issuance of 2,948,559 shares.

F-38

Rapport Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In Thousands)

(Unaudited)


	December 31, 2023			March 31, 2024
Assets
Current assets
Cash and cash equivalents	$	70,169		$	74,267
Short-term investments		77,309			118,977
Restricted cash		85			105
Prepaid expenses and other current assets		3,309			5,379

Total current assets		150,872			198,728
Property and equipment, net		1,916			3,560
Operating lease right-of-use asset		2,084			1,928
Other assets		551			2,073

Total assets	$	155,423		$	206,289

Liabilities, Convertible Preferred Stock and Stockholders’ Deficit
Current liabilities
Accounts payable (1)	$	2,502		$	1,448
Accrued expenses and other current liabilities (1)		5,631			7,751
Operating lease liability		670			686

Total current liabilities		8,803			9,885
Series B preferred stock tranche right liability		4,200			—
Operating lease liability, net of current portion		1,476			1,298

Total liabilities		14,479			11,183
Commitments and contingencies (Note 11)
Series A convertible preferred stock, $0.001 par value; 100,182,354 shares authorized as of December 31, 2023 and March 31, 2024; 100,182,354 shares issued and outstanding as of December 31, 2023 and March 31, 2024; liquidation preference of $100,182 as of December 31, 2023 and March 31, 2024		89,487			89,487
Series B convertible preferred stock, $0.001 par value; 89,431,030 shares authorized as of December 31, 2023 and March 31, 2024; 51,273,790 and 89,431,030 shares issued and outstanding as of December 31, 2023 and March 31, 2024, respectively; liquidation preference of $86,000 and $150,000 as of December 31, 2023 and March 31, 2024, respectively		77,091			145,252
Stockholders’ deficit
Common stock, $0.001 par value; 250,000,000 shares authorized at December 31, 2023 and March 31, 2024; 4,170,817 shares issued and outstanding as of December 31, 2023 and March 31, 2024		4			4
Additional paid-in capital		19,796			28,630
Accumulated other comprehensive income (loss)		4			(160	)
Accumulated deficit		(45,438	)		(68,107	)

Total stockholders’ deficit		(25,634	)		(39,633	)

Total liabilities, convertible preferred stock, and stockholders’ deficit	$	155,423		$	206,289

(1)	Includes related party amounts of $0.2 million and zero (accounts payable) and zero and less than $0.1 million (accrued expenses) as of December 31, 2023 and March 31, 2024, respectively (see Notes 5 and 10).

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-39

Rapport Therapeutics, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In Thousands)

(Unaudited)


	For the three months ended March 31,
	2023			2024
Operating expenses
Research and development (1)	$	3,899		$	12,504
General and administrative (2)		1,292			4,590

Total operating expenses		5,191			17,094

Loss from operations		(5,191	)		(17,094	)
Other income (expense):
Interest income		75			1,815
Change in fair value of preferred stock tranche right liability		(1,030	)		(7,390	)

Total other income (expense), net		(955	)		(5,575	)

Net loss before income taxes		(6,146	)		(22,669	)
Provision for income taxes		1			—

Net loss	$	(6,147	)	$	(22,669	)

Net loss per share attributable to common stockholders, basic and diluted		(4.51	)		(11.07	)

Weighted-average common shares outstanding, basic and diluted		1,362,851			2,046,889
Comprehensive loss:
Net loss	$	(6,147	)	$	(22,669	)
Change in unrealized gains (losses) on investments, net of tax		—			(164	)

Total other comprehensive income		—			(164	)

Comprehensive loss	$	(6,147	)	$	(22,833	)

(1)	Includes related party amounts of $0.3 million and less than $0.1 million for the three months ended March 31, 2023 and 2024, respectively (see Note 10).

(2)	Includes related party amounts of $0.3 million and $0.1 million for the three months ended March 31, 2023 and 2024, respectively (see Note 10).

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-40

Rapport Therapeutics, Inc.

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Deficit

(In Thousands, Except Share Data)

(Unaudited)


	Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Common Stock				Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Total Stockholders’ Deficit
	Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital					Accumulated Deficit			Total Stockholders’ Deficit
Balance at December 31, 2022		40,182,354	$	29,567		—	$	—		3,587,345	$	4	$	586	$	—		$	(10,652)		$	(10,062	)
Issuance of Series A convertible preferred stock for the settlement of the second and third tranche right liability, net of issuance costs of $87		60,000,000		59,920		—		—		—		—		11,465		—			—			11,465
Issuance of restricted common stock		—		—		—		—		273,166		—		24		—			—			24
Stock-based compensation expense		—		—		—		—		—		—		723		—			—			723
Net loss		—		—		—		—		—		—		—		—			(6,147	)		(6,147	)

Balance at March 31, 2023		100,182,354	$	89,487		—	$	—		3,860,511	$	4	$	12,798	$	—		$	(16,799	)	$	(3,997	)


	Series A Convertible Preferred Stock				Series B Convertible Preferred Stock				Common Stock				Additional Paid-in Capital		Accumulated Other Comprehensive Income (Loss)			Accumulated Deficit			Total Stockholders’ Deficit
	Shares		Amount		Shares		Amount		Shares		Amount		Additional Paid-in Capital					Accumulated Deficit			Total Stockholders’ Deficit
Balance at December 31, 2023		100,182,354	$	89,487		51,273,790	$	77,091		4,170,817	$	4	$	19,796	$	4		$	(45,438)		$	(25,634	)
Issuance of Series B convertible preferred stock for the settlement of the tranche right liability, net of issuance costs of $87		—		—		38,157,240		68,161		—		—		7,343		—			—			7,343
Stock-based compensation expense		—		—		—		—		—		—		1,491		—			—			1,491
Net loss		—		—		—		—		—		—		—		—			(22,669	)		(22,669	)
Change in unrealized gain (loss) on investments, net of tax		—		—		—		—		—		—		—		(164	)		—			(164	)

Balance at March 31, 2024		100,182,354	$	89,487		89,431,030	$	145,252		4,170,817	$	4	$	28,630	$	(160	)	$	(68,107	)	$	(39,633	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-41

Rapport Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(In Thousands)

(Unaudited)


	For the three months ended March 31,
	2023			2024
Cash flows from operating activities:
Net loss	$	(6,147	)	$	(22,669	)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization		15			152
Net (accretion) and amortization of investments in marketable securities		—			(978	)
Change in fair value of preferred stock tranche right liability		1,030			7,390
Non-cash lease expense		—			156
Stock-based compensation expense		723			1,491
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		(606	)		(2,070	)
Other assets		(172	)		27
Accounts payable		(454	)		(1,134	)
Accrued expenses and other current liabilities		810			181
Operating lease liabilities		—			(161	)

Net cash used in operating activities		(4,801	)		(17,615	)

Cash flows from investing activities
Purchases of short-term investments		—			(44,801	)
Maturities of short-term investments		—			3,947
Purchases of property and equipment		(61	)		(1,072	)

Net cash used in investing activities		(61	)		(41,926	)

Cash flows from financing activities
Proceeds from issuance of Series A convertible preferred stock, net of issuance costs paid		60,000			—
Proceeds from issuance of Series B convertible preferred stock, net of issuance costs paid		—			63,942
Proceeds from issuance of common stock and restricted common stock		24			—
Payment of deferred offering costs		(18	)		(283	)

Net cash provided by financing activities		60,006			63,659

Net increase in cash, cash equivalents, and restricted cash		55,144			4,118
Cash, cash equivalents, and restricted cash at beginning of period		31,159			70,254

Cash, cash equivalents, and restricted cash at end of period	$	86,303		$	74,372

Supplemental cash flow information:
Supplemental disclosure for noncash investing and financing activities:
Settlement of Series A preferred stock tranche right liability	$	11,465		$	—
Settlement of Series B preferred stock tranche right liability	$	—		$	11,590
Deferred offering costs included in accounts payable and accrued expenses at period end	$	120		$	1,472
Purchases of property and equipment included in accounts payable and accrued expenses at period end	$	134		$	847
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	$	86,303		$	74,267
Restricted cash	$	—		$	105

Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$	86,303		$	74,372

The accompanying notes are an integral part of these condensed consolidated financial statements.

F-42

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

1. Nature of the Business and Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. Through March 31, 2024, the Company has funded its operations primarily with proceeds from the sale of convertible notes and convertible preferred stock. The Company has incurred recurring losses since its inception, including net losses of $34.8 million and $22.7 million for the year ended December 31, 2023 and the three months ended March 31, 2024, respectively. In addition, as of March 31, 2024, the Company had an accumulated deficit of $68.1 million. The Company expects to continue to generate operating losses for the foreseeable future. As of the issuance date of the condensed consolidated interim financial statements for the three months ended March 31, 2024, the Company expects that its cash and cash equivalents and short-term investments will be sufficient to fund its operating expenses and capital expenditure requirements through at least 12 months from the issuance of the condensed consolidated financial statements. The future viability of the Company beyond that point is dependent on its ability to raise additional capital to finance its operations.

The Company is seeking to complete an initial public offering (“IPO”) of its common stock. Upon the completion of a qualified public offering on specified terms, the Company’s outstanding convertible preferred stock will convert into shares of common stock (see Note 6). In the event the Company does not complete an IPO, the Company will seek additional funding through private equity financings, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. The Company may not be able to obtain funding on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s stockholders.

F-43

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial reporting and as required by Regulation S-X, Rule 10-01. The accompanying unaudited condensed consolidated financial statements reflect the operations of the Company. Intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).

The condensed consolidated interim financial statements have been prepared on the same basis as the audited annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for a fair statement of the Company’s financial position as of March 31, 2024 and the results of operations for the three-month interim periods ended March 31, 2023 and 2024. The condensed balance sheet as of December 31, 2023 was derived from audited annual financial statements but does not include all disclosures required by GAAP. The results of operations for the interim periods are not necessarily indicative of results to be expected for the year ending December 31, 2024, any other interim periods, or any future year or period.

2. Summary of Significant Accounting Policies

Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the “Notes to Consolidated Financial Statements” included in our audited annual financial statements included elsewhere in this Prospectus.

Use of Estimates

The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Significant estimates and assumptions reflected within these condensed consolidated financial statements include, but are not limited to, research and development expenses and accruals, the valuation of the Company’s common stock and stock-based awards and the valuation of preferred stock tranche right liability. The Company bases its estimates on known trends and other market-specific or relevant factors that it believes to be reasonable under the circumstances. On an ongoing basis, management evaluates its estimates, as there are changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ materially from those estimates or assumptions.

Concentrations of Credit Risk

Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents at high-quality and accredited financial institutions in amounts that could exceed federally insured limits. Cash equivalents are invested in money market funds. However, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company’s short-term investments consist of U.S. Treasury bills, government securities, and government agency securities and as a result, the Company believes represent minimal credit risk.

F-44

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Restricted cash

Restricted cash as of December 31, 2023 consisted of a letter of credit totaling $85 thousand that was established in connection with an anticipated lease arrangement, which was cancelled prior to commencement due to failure of the landlord to complete its obligations. Consequently, the letter of credit and related cash restriction were released in March 2024. Restricted cash at March 31, 2024 was $105 thousand, which was restricted as cash collateral for the Company’s business credit card program.

Short-term investments

The Company’s short-term investments consist of investments in debt securities, including U.S. Treasury bills, government securities, and U.S. agency securities with remaining maturities beyond three months at the date of purchase that are available to be converted into cash to fund its current operations. As of December 31, 2023 and March 31, 2024, all of the Company’s debt securities were classified as available-for-sale and were carried at fair market value (see Note 3). The unrealized gains and losses on the Company’s available-for-sale debt securities are recorded in other comprehensive income (loss) in the condensed consolidated statements of operations and comprehensive loss.

Debt securities in an unrealized loss position are evaluated for impairment at least quarterly. For available-for-sale debt securities in an unrealized loss position, the Company first assesses whether or not it intends to sell, or it is more likely than not that it will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the investment security’s amortized cost basis is written down to fair value through net loss.

If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the investment security are compared to the amortized cost basis of the security. If the present value of cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized cost basis. Any unrealized loss that has not been recorded through an allowance for credit loss is recognized in other comprehensive income (loss). As of December 31, 2023 and March 31, 2024, there was no allowance for credit losses recorded on the Company’s condensed consolidated balance sheet.

The Company’s interest income consists of interest earned from cash, cash equivalents, and short-term investments.

Deferred Offering Costs

The Company capitalizes certain legal, professional, accounting and other third-party fees that are directly associated with in-process equity financings as deferred offering costs until such financings are consummated. After consummation of an equity financing, these costs are recorded as a reduction of the proceeds from the offering, either as a reduction of the carrying value of the convertible preferred stock or in stockholders’ equity (deficit) as a reduction of additional paid-in capital generated as a result of the offering. Should the in-process equity financing be abandoned, the deferred offering costs would be expensed immediately as a charge to operating expenses in the condensed consolidated statements of operations and comprehensive loss. As of

F-45

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

December 31, 2023 and March 31, 2024, there were $0.3 million and $1.9 million, respectively, of deferred offering costs capitalized and included in other assets on the balance sheet.

Comprehensive Loss

Comprehensive loss includes net loss as well as other changes in stockholders’ deficit that result from transactions and economic events other than those with stockholders. For the three months ended March 31, 2023, there was no difference between net loss and comprehensive loss. For the three months ended March 31, 2024, comprehensive loss includes unrealized losses on short-term investments.

Recently Issued Accounting Pronouncements Not Yet Adopted

Accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our financial statements upon adoption.

3. Fair Value Measurements


	Fair Value Measurements at December 31, 2023
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	23,441	$	—	$	—	$	23,441
U.S. Treasury bills		—		23,832		—		23,832
Short-term investments:
U.S. Treasury bills and government securities		—		77,309		—		77,309

	$	23,441	$	101,141	$	—	$	124,582

Liabilities
Series B preferred stock tranche right liability	$	—	$	—	$	4,200	$	4,200

	$	—	$	—	$	4,200	$	4,200


	Fair Value Measurements at March 31, 2024
	Level 1		Level 2		Level 3		Total
Assets:
Cash equivalents:
Money market funds	$	7,024	$	—	$	—	$	7,024
Short-term investments:
U.S. Treasury bills, government securities, and government agency securities		—		118,977		—		118,977

	$	7,024	$	118,977	$	—	$	126,001

F-46

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Money market funds are highly liquid and actively traded marketable securities that generally transact at a stable $1.00 net asset value representing its estimated fair value. For the year ended December 31, 2023 and for the three months ended March 31, 2024, there were no transfers between Level 1, Level 2 and Level 3.

The Company classifies its U.S. Treasury securities as short-term because they are available to be converted into cash to fund current operations. The fair value of the Company’s U.S. Treasury bills, government securities, and government agency securities are classified as Level 2 because they are valued using observable inputs to quoted market prices, benchmark yields, reported trades, broker/dealer quotes or alternative pricing sources with reasonable levels of price transparency and U.S. Treasury securities.

The underlying securities held in the money market funds held by the Company are all government backed securities.

Short-term investments consisted of the following (in thousands):


	December 31, 2023
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Short-term investments:
U.S. Treasury bills and government securities	$	77,305	$	4	$	—		$	77,309

	$	77,305	$	4	$	—		$	77,309


	March 31, 2024
	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
Short-term investments:
U.S. Treasury bills, government securities, and government agency securities	$	119,137	$	—	$	(160	)	$	118,977

	$	119,137	$	—	$	(160	)	$	118,977

The contractual maturities of the Company’s short-term investments in available-for-sale debt securities held were as follows (in thousands):


	December 31, 2023		March 31, 2024
Due within one year	$	77,309	$	101,154
Due between one and two years		—		17,823

	$	77,309	$	118,977

As of March 31, 2024, all investments in an unrealized loss position were in this position for less than 12 months. The Company evaluated its securities for potential other-than-temporary impairment and considered the decline in market value to be primarily attributable to current economic and market conditions. Additionally, the Company does not intend to sell the securities in an unrealized loss position and does not expect it will be required to sell the securities before recovery of the unamortized cost basis. Given the Company’s intent and ability to hold such securities until recovery, and the lack of a significant change in credit risk for these investments, the Company does not consider these investments to be impaired as of March 31, 2024. The Company did not recognize any credit losses during the three months ended March 31, 2024.

F-47

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Valuation of Preferred Stock Tranche Right Liability

The Series A and Series B preferred stock tranche right liabilities in the table above are composed of the fair value of obligations to issue Series A convertible preferred stock and Series B convertible preferred stock, respectively (see Note 6), either upon achievement of certain specified milestones, upon the waiver of such milestone achievement by a majority vote of the respective series convertible preferred stockholders or in relation to the Series B convertible preferred stock, upon a shareholder exercising its right to early exercise the tranche right. The fair value of the tranche right liability was determined based on significant inputs not observable in the market, which represented a Level 3 measurement within the fair value hierarchy. The fair value of the tranche right liabilities were determined using a Contingent Forward Analysis, which is a scenario-based lattice model that accounts for the different possible milestone scenarios and their associated probabilities, as estimated by the Company. The valuation model considered the probability of closing the tranche, the estimated future value of the Convertible Preferred Stock to be issued at each closing and the investment required at each closing. Future values were converted to present value using a discount rate appropriate for probability-adjusted cash flows. The risk-free rate was determined by reference to the U.S. Treasury yield curve for time periods approximately equal to the remaining estimated time to each tranche closing.

Series A Preferred Stock Tranche Right Liability

The following tables provide a roll-forward of the aggregate fair value of the Company’s Series A preferred stock tranche right liability during the three months ended March 31, 2023, for which fair value is determined using Level 3 inputs (in thousands):


	Series A Preferred Stock Tranche Right Liability
Balance as of December 31, 2022	$	10,435
Change in fair value of Series A preferred stock tranche right liability		1,030
Settlement of Series A preferred stock tranche right liability upon waiver of milestone		(11,465	)

Balance as of March 31, 2023	$	—

Series B Preferred Stock Tranche Right Liability


	Second Tranche Milestone
Probability of meeting Series B milestone		80	%
Milestone achievement date		12/31/2024
Risk-free rate		4.79	%
Expected value of Series B if milestones are not met	$	0.84

F-48

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

The following tables provide a roll-forward of the aggregate fair value of the Company’s Series B preferred stock tranche right liability during the three months ended March 31, 2024, for which fair value is determined using Level 3 inputs (in thousands):


	Series B Preferred Stock Tranche Right Liability
Balance as of December 31, 2023	$	4,200
Change in fair value of Series B preferred stock tranche right liability		7,390
Settlement of Series B preferred stock tranche right liability upon waiver of milestone		(11,590	)

Balance as of March 31, 2024	$	—

4. Property and Equipment, Net

Property and equipment, net consisted of the following (in thousands):


	As of December 31, 2023			As of March 31, 2024
Lab equipment	$	1,719		$	2,694
Computer equipment		43			61
Leasehold improvements		255			281
Construction in process		26			803

Total property and equipment		2,043			3,839
Less: Accumulated depreciation		(127	)		(279	)

	$	1,916		$	3,560

Depreciation expense of property and equipment for the three months ended March 31, 2023 and 2024 was $15 thousand and $0.2 million, respectively.

5. Accrued Expenses and Other Current Liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31, 2023		March 31, 2024
Research and development	$	2,645	$	4,360
Professional fees		459		2,091
Related party consulting fees		—		89
Employee related		2,413		1,044
Accrued other		114		167

	$	5,631	$	7,751

6. Convertible Preferred Stock

The Company has issued Series A convertible preferred stock and Series B convertible preferred stock.

Series A Convertible Preferred Stock and Series A Preferred Stock Tranche Right Liability

F-49

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Contemporaneously, investors converted their Convertible Promissory Notes for 8,182,354 shares of Series A convertible preferred stock, bringing the total number of shares of Series A convertible preferred stock issued to 40,182,354.

Series B Convertible Preferred Stock and Series B Preferred Stock Tranche Right Liability

In August 2023, the Company issued and sold 46,504,135 shares of Series B convertible preferred stock, at a price of $1.67727 per share. The 46,504,135 shares include the 10,731,725 shares that were early exercised on the original issuance date (discussed below).

Subsequent to the original issuance in August 2023, one stockholder exercised its right to early exercise the Series B preferred stock tranche right and purchased 4,769,655 shares of Series B convertible preferred stock for

F-50

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

cash proceeds of $8.0 million. The fair value of the associated tranche right liability that was settled at the time of the sale of $0.5 million was recognized in additional paid-in capital. Additionally, the investor paid a premium of $0.8 million for these shares over their fair value which was also recorded in additional paid-in capital as a capital contribution.

As of December 31, 2023, the Company remeasured the Series B tranche right liability to be $4.2 million.

In February 2024, the Company’s Series B convertible preferred stockholders voted to waive the second tranche milestones and purchase the remaining Series B Milestone Tranche shares. Immediately prior to the waiver, the Company remeasured the Series B tranche right liability to be $11.6 million and recognized $7.4 million in other expense for the change in the fair value of the Series B tranche right liability during the period. As a result of the waiver, the Company remeasured the Series B tranche right liability to be $4.2 million and recognized the change in fair value of $7.4 million in additional paid-in capital, as a capital contribution. In conjunction with the closing that occurred in March 2024, an aggregate of 38,157,240 shares of Series B convertible preferred stock were issued at a price of $1.67727 per share, resulting in total cash proceeds of $64.0 million, less $87 thousand of issuance costs. As a result of this issuance, the Series B preferred stock tranche right liability with a then fair value of $4.2 million was settled in full and recognized as part of the carrying value of the Series B convertible preferred stock.

Convertible preferred stock consisted of the following (in thousands, except share amounts):


	December 31, 2023
	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Preference		Conversion Price per share		Common Stock Issuable Upon Conversion
Series A convertible preferred stock		100,182,354		100,182,354	$	89,487	$	100,182		8.5648		11,701,298
Series B convertible preferred stock		89,431,030		51,273,790		77,091		86,000		14.3655		5,988,764

		189,613,384		151,456,144	$	166,578	$	186,182				17,690,062


	March 31, 2024
	Preferred Stock Authorized		Preferred Stock Issued and Outstanding		Carrying Value		Liquidation Preference		Conversion Price per share		Common Stock Issuable Upon Conversion
Series A convertible preferred stock		100,182,354		100,182,354	$	89,487	$	100,182		8.5648		11,701,298
Series B convertible preferred stock		89,431,030		89,431,030		145,252		150,000		14.3655		10,445,518

		189,613,384		189,613,384	$	234,739	$	250,182				22,146,816

The holders of the convertible preferred stock have the following rights and preferences:

Voting

The holders of the convertible preferred stock are entitled to vote, together with the holders of common stock, as a single class, on all matters submitted to the shareholders for a vote and are entitled to the number of

F-51

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

votes equal to the number of shares of common stock into which the convertible preferred stock could convert on the record date for determination of shareholders entitled to vote. A majority vote of the holders of convertible preferred stock along with a majority vote of the Series B convertible preferred stock (the “Required Vote”) is required to, among others, liquidate or dissolve the Company, amend the certificate of incorporation or bylaws, reclassify common stock or establish another class of capital stock, create shares that would rank senior to or authorize additional shares of convertible preferred stock, declare a dividend or make a distribution, or change the authorized number of directors constituting the board of directors.

Conversion

Each share of Series A convertible preferred stock is convertible into common stock, at any time, at the option of the holder, and without the payment of additional consideration, at the applicable conversion ratio then in effect, provided that such holder may waive such option to convert upon written notice to the Company. Holders of Series B convertible preferred stock are not entitled to elect to convert shares of Series B convertible preferred stock into shares of Common Stock at any time during the period commencing on the date of the first issuance of the Series B convertible preferred stock and ending immediately following the earliest to occur of (i) the Series B Milestone Tranche closing, (ii) the achievement of the second tranche milestone, (iii) the date such holder’s obligation to purchase its Second Tranche Shares is fulfilled, (iv) the termination of such holder’s obligations to complete the Series B Milestone Tranche closing and (v) such date as agreed to by the Company and the holders of a majority of the then outstanding shares of Series B convertible preferred stock, voting as a separate, exclusive class. In addition, each share of convertible preferred stock will be automatically converted into shares of common stock at the then-effective applicable conversion ratio upon either (i) the closing of a firm-commitment underwritten public offering of its common stock at a price per share of at least $14.70302 resulting in at least $50.0 million of gross proceeds, net of underwriting discount and commissions, to the Company, or (ii) the date specified by vote or written consent of the holders of the Required Vote, voting as a single class.

The conversion ratio of each class of convertible preferred stock is determined by dividing the Applicable Original Issue Price of each class of convertible preferred stock by the Conversion Price of each class. As of December 31, 2023 and March 31, 2024, the Conversion Price was $8.5648 per share for Series A convertible preferred stock and $14.3655 per share for Series B convertible preferred stock, each subject to appropriate adjustment in the event of any share dividend, share split, combination or other similar recapitalization with respect to the convertible preferred stock.

There shall be no adjustment in the conversion price of the convertible preferred stock as the result of the issuance or deemed issuance of additional shares of the Company’s common stock if the Company receives written notice from the holders of the Required Vote of the then outstanding shares of convertible preferred stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of additional shares of the Company’s common stock.

In the event that any holder of convertible preferred stock who is required to participate in a subsequent closing pursuant to the purchase agreement does not purchase the aggregate number of subsequent closing shares, then each share of convertible preferred stock held by such holder shall automatically be converted into shares of common stock at a ratio of one share of common stock for every ten shares of convertible preferred stock held immediately prior to the consummation of such subsequent closing.

F-52

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Dividends

The holders of the convertible preferred stock shall be entitled to receive, only when, as and if declared by the Board of Directors, non-cumulative dividends at the rate of 8% of the Applicable Original Issue Price of the convertible preferred stock (the “Preferred Dividend”).

The Company shall not declare, pay or set aside any dividends on common shares of the Company unless the holders of convertible preferred stock then outstanding shall first receive, or simultaneously receive, the Preferred Dividend on each outstanding convertible preferred stock and a dividend on each outstanding convertible preferred stock in an amount at least equal to the product of (1) the dividend payable on each share of such class or series determined, as if all shares of such class or series had been converted into common stock and (2) the number of shares of common stock issuable upon conversion of a share of such series of convertible preferred stock, in each case calculated on the record date for determination of the holders entitle to receive such dividend. As of December 31, 2023 and March 31, 2024, no cash dividends have been declared or paid.

Liquidation

In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or upon the occurrence of a Deemed Liquidation Event (as defined below), the holders of shares of convertible preferred stock then outstanding shall be entitled, on a pari passu basis among the series of convertible preferred stock, to be paid out of the assets or funds of the Company available for distribution to stockholders before any payment is made to the holders of common stock. The holders of convertible preferred stock are entitled to an amount per share equal to the greater of (i) the Applicable Original Issue Price, plus any dividends declared but unpaid thereon, or (ii) the amount that would have been payable had all shares of each series of convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (as defined below). After the payment in full of the convertible preferred stock preference amount, the remaining assets of the Company available for distribution to stockholders shall be distributed among the holders of common stock on a pro rata basis.

Redemption

The convertible preferred stock does not have redemption rights, except for the contingent redemption upon the occurrence of a Deemed Liquidation Event.

7. Common Stock

The voting, dividend and liquidation rights of the holders of the Company’s common stock are subject to and qualified by the rights, powers and preferences of the holders of the convertible preferred stock set forth above. Each share of common stock entitles the holder to one vote, together with the holders of the convertible preferred stock, on all matters submitted to the stockholders for a vote. The holders of common stock are entitled to receive dividends, if any, as declared by the Company’s board of directors, subject to the preferential dividend rights of convertible preferred stock. As of December 31, 2023 and March 31, 2024, no dividends have been declared or paid.

F-53

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

As of December 31, 2023 and March 31, 2024, the Company had reserved 23,890,096 and 25,095,375 shares of common stock, respectively, of which 22,146,816 and 22,146,816 were reserved for the potential conversion of shares of Series A convertible preferred stock and Series B convertible preferred stock, respectively, and 1,743,280 and 2,958,559 for issuance under the 2022 Stock Option and Grant Plan, respectively.

8. Stock-Based Compensation

As of December 31, 2023, the total number of shares of common stock authorized and issuable under the 2022 Plan was 1,743,280. In March 2024, the Company’s board of directors increased the number of shares of common stock reserved for issuance under the plan from 1,743,280 to 2,948,559 shares. As of March 31, 2024, 118,707 shares remain available for future grants. Shares of unused common stock underlying any Awards that are forfeited, canceled or reacquired by the Company prior to vesting will again be available for the grant of awards under the 2022 Plan.

Stock Options

The Company has granted stock options with service-based vesting conditions. Stock options generally vest over four years and have a maximum term of ten years. The Company typically grants stock options to employees and non-employees at exercise prices deemed by the Board to be equal to the fair value of the common stock at the time of grant. The following table summarizes the Company’s stock option activity for the three months ended March 31, 2024:


	Number of Shares		Weighted- Average Exercise Price per share		Weighted- Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value (in thousands)
Balance at December 31, 2023		1,376,596	$	1.80		9.83	$	6,249
Granted		1,300,891		8.87
Exercised		—		—
Forfeited		—		—
Expired		—		—

Options outstanding at March 31, 2024		2,677,487	$	5.23		9.77	$	16,955

Options vested and exercisable at March 31, 2024		—		—		—		—
Options vested and expected to vest at March 31, 2024		2,677,487	$	5.23		9.77	$	16,955

The weighted-average grant-date fair value of stock options granted for the three months ended March 31, 2023 and 2024 was zero and $8.90 per share, respectively. As of March 31, 2024, there was $18.5 million of total unrecognized compensation cost related to unvested stock options, which is expected to be recognized over a remaining weighted average period of 3.75 years.

F-54

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

Restricted Stock Awards (“RSA”)

The Company awards restricted stock both under the 2022 Plan as well as outside of the 2022 Plan.

Service-Based RSAs

The following table summarizes the Company’s service-based RSA grant activity for the three months ended March 31, 2024:


	RSAs			Weighted- Average Grant Date Fair Value
Unvested shares at December 31, 2023		1,585,998		$	3.64
Granted		—			—
Vested		(153,763	)		3.22
Forfeited		—			—

Unvested shares at March 31, 2024		1,432,235		$	3.69

The aggregate fair value of service-based RSAs that vested during three months ended March 31, 2023 and 2024, was $0.1 million and $1.3 million, respectively. As of March 31, 2024, there was $4.9 million of total unrecognized compensation cost related to unvested service-based RSAs, which is expected to be recognized over a remaining weighted average period of 2.72 years.

Performance-Based RSAs

The Company has also granted performance-based RSAs to certain employees and directors with a vesting commencement date contingent upon the subsequent closing of the Company’s Series A convertible preferred stock financing. The Company has determined that it has met all the conditions to establish the grant date for these performance-based RSAs at the original issuance date. Therefore, these awards are deemed to contain an implied performance condition. The vesting of the performance-based RSAs is also subject to grantees’ continued service until the 4th anniversary date of the closing of a subsequent financing.

Share-based compensation expense associated with the performance-based RSAs is recognized if the performance condition is considered probable of achievement. In February 2023, the existing Series A convertible preferred stock investors waived the second and third tranche milestones and the Company closed on the sale of its second and third tranches of Series A convertible preferred stock. As a result, the performance condition was deemed to be met. The Company recognized $0.4 million and $0.3 million of compensation expense for the performance-based RSAs for the three-months ended March 31, 2023 and 2024, respectively.

F-55

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

The following table summarizes the Company’s performance-based RSA grant activity for the three months ended March 31, 2024:


	RSAs			Weighted- Average Grant Date Fair Value
Unvested shares at December 31, 2023		649,264		$	3.63
Granted		—			—
Vested		(51,257	)		3.63
Forfeited		—			—

Unvested shares at March 31, 2024		598,007		$	3.63

The aggregate fair value of performance-based RSAs that vested during the three months ended March 31, 2023 and 2024, was $78 thousand and $0.4 million, respectively. As of March 31, 2024, there was $1.1 million of total unrecognized compensation cost related to unvested performance-based restricted common stock, which is expected to be recognized over a remaining weighted average period of 1.76 years.

Stock-Based Compensation

The Company recorded stock-based compensation expense for stock options of zero and $0.8 million and for RSAs of $0.7 million and $0.7 million in the three months ended March 31, 2023 and 2024, respectively. The following table below summarizes the classification of the Company’s stock-based compensation expense related to stock options and restricted common stock awards in the consolidated statements of operations and comprehensive loss (in thousands):


	For the three months ended March 31,
	2023		2024
General and Administrative	$	215	$	769
Research and Development		508		722

	$	723	$	1,491

9. Leases

Operating Lease

In June 2023, the Company entered into a lease for its corporate headquarters in Boston, Massachusetts. The lease commenced August 31, 2023 with an initial term of 40 months. The monthly lease payments are $66 thousand for the first 12 months, with 2% escalation each year. In conjunction with the lease, the Company paid a security deposit of $0.1 million that is recorded on the Company’s condensed consolidated balance sheet in other assets as of March 31, 2024.

In February 2024, the Company entered into a lease for laboratory and office space in San Diego, California with a lease term of 5 years for which the Company expects to pay $9.6 million over the lease term. Per the terms of the lease, the landlord will deliver the space to the Company on the lease Commencement date, which is no earlier than November 2024. As the Company has not yet occupied the lease space, the Company has not recorded a corresponding right-of-use asset or liability on the condensed consolidated balance sheet as of March 31, 2024.

F-56

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

10. Related Party Transactions

Janssen

Janssen Pharmaceutical NV (“Janssen”), is a related party to a founding investor in the Company, Johnson & Johnson Innovation—JJDC, Inc., as both entities are direct subsidiaries of Johnson & Johnson, Inc. For the three months ended March 31, 2023 and 2024, the Company incurred costs of $75 thousand and $69 thousand, respectively, which was recognized as research and development expense in the condensed consolidated statement of operations and comprehensive loss, to Janssen for the use of lab space in California. As of December 31, 2023 and March 31, 2024, there were no related party transactions in accounts payable or accrued expenses, respectively.

Third Rock Ventures

Third Rock Ventures LLC (“Third Rock”) is a founding investor in the Company. For the three months ended March 31, 2023 and 2024, the Company incurred costs of $0.5 million and $0.1 million, respectively, of which $0.2 million and zero, respectively was recognized as research and development expense, and $0.3 million and $0.1 million, respectively, was recognized as general and administrative expense in the condensed consolidated statement of operations and comprehensive loss, to Third Rock primarily for management consulting and other various start-up support activities. As of December 31, 2023 and March 31, 2024, $0.2 million and zero, respectively, was included in accounts payable. As of December 31, 2023 and March 31, 2024, zero and $89 thousand, respectively was included in accrued expenses.

11. Commitments and Contingencies

Indemnification Agreements

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with the board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its condensed consolidated financial statements as of December 31, 2023 and March 31, 2024.

Legal Proceedings

From time to time, the Company may become involved in legal proceedings or other litigation relating to claims arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and estimated exposure amount. Legal fees and other costs associated with such proceedings are expensed as incurred. As of December 31, 2023 and March 31, 2024, the Company was not a party to any material legal proceedings or claims.

NeuroPace Master Services Agreement and Statement of Work

F-57

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

NeuroPace Agreement and in accordance with statement of work agreements entered into from time to time, NeuroPace provides the Company with certain services with respect to data from the RNS systems used in our clinical trials. The NeuroPace Agreement also grants the Company a royalty-free, worldwide, exclusive, non-transferable license to all data collected by the RNS systems in its Phase 2a clinical trial and the outcomes of algorithms that are applied to such data, as well as the ability to publish the outcomes of algorithms, subject to certain conditions. The consideration the Company will pay to NeuroPace for such services is set out in each statement of work agreement.

Concurrently with the execution of the NeuroPace Agreement, the parties also entered into an initial statement of work under the NeuroPace Agreement, as amended in March 2024 (the “NeuroPace SOW”), pursuant to which NeuroPace agreed to provide services related to the Company’s Phase 2a clinical trial of RAP-219, including, among other things, clinical trial readiness support, identification of potential patients satisfying the enrollment criteria and RNS system data reporting and data analysis. Pursuant to the payment schedule set out in the NeuroPace SOW, we will pay NeuroPace an aggregate of up to $3.7 million over a period of approximately two years in connection with NeuroPace’s provision of services and achievement of certain patient enrollment and deliverable milestones. As of December 31, 2023, $1.5 million is recorded as prepaid expenses and other current assets in the condensed consolidated balance sheet. During the three months ended March 31, 2024, the Company paid NeuroPace an additional $0.3 million and recognized $0.3 million in research and development expense for services performed, resulting in a prepaid expense balance of $1.5 million as of March 31, 2024.

12. Net Loss per Share

Under the two-class method, basic net loss per share available to common stockholders was calculated by dividing the net loss available to common stockholder by the weighted-average number of shares of common stock outstanding during the period, which excludes unvested restricted stock. The net loss available to common stockholders was not allocated to the Series A convertible preferred stock or Series B convertible preferred stock as the holders of convertible preferred stock did not have a contractual obligation to share in losses. Diluted net loss per share available to common stockholders was computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock and stock options were considered common stock equivalents but had been excluded from the

F-58

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive.


	Three months ended March 31,
	2023			2024
Numerator:
Net loss attributable to common stockholders	$	(6,147	)	$	(22,669	)
Denominator:
Weighted average common shares outstanding, basic and diluted		1,362,851			2,046,889
Net loss per share attributable to common stockholders, basic and diluted	$	(4.51	)	$	(11.07	)


	Three months ended March 31,
	2023		2024
Series A convertible preferred stock		11,701,298		11,701,298
Series B convertible preferred stock		—		10,445,518
Options to purchase common stock		—		2,677,487
Unvested restricted common stock—service based		1,662,831		1,432,235
Unvested restricted common stock—performance based		803,037		598,007

		14,167,166		26,854,545

13. Subsequent Events

For its condensed consolidated financial statements as of March 31, 2024, the Company has evaluated subsequent events through May 17, 2024, the date on which those condensed consolidated financial statements were available to be issued. In connection with the reissuance of the financial statements, the Company has evaluated subsequent events through June 3, 2024, the date the financial statements were available to be reissued.

Grant of Stock Options under the 2022 Plan

In May 2024, the Company granted options for the purchase of an aggregate of 92,234 shares of common stock, at an exercise price of $11.57 per share, respectively. The aggregate grant-date fair value of the options granted is $0.8 million. It is expected to be recognized as stock-based compensation expense over a period of 4.0 years.

Reverse stock split

On May 31, 2024, the Company effected a one-for 8.5648 reverse stock split of its issued and outstanding shares of common stock and a proportional adjustment to the existing conversion ratios of each series of the Company’s preferred stock (see Note 6). Accordingly, all share and per share amounts for all periods presented in the accompanying condensed consolidated financial statements and notes thereto have been adjusted retroactively, where applicable, to reflect this reverse stock split and adjustment of the preferred stock conversion ratios.

F-59

Rapport Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

2024 Stock Option Plan

As of May 30, 2024, the Company’s board of directors adopted, and its stockholders approved, the 2024 Stock Option and Incentive Plan (the “2024 Plan”), which will become effective immediately preceding the date on which the registration statement for the Company’s IPO is declared effective by the SEC. The 2024 Plan allows the Company to make equity-based and cash-based incentive awards to its officers, employees, directors, and consultants. The 2024 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. The number of shares initially reserved for issuance under the 2024 Plan is 3,814,618 shares. In addition, the number of shares reserved and available for issuance under the 2024 Plan will automatically increase on January 1, 2025 and each January 1 thereafter, by five percent of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser number of shares as determined by the compensation committee.

The shares of common stock underlying any awards under the 2024 Plan and the 2022 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of stock, expire, or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2024 Plan.

2024 Employee Stock Purchase Plan (“ESPP”)

As of May 30, 2024, the Company’s board of directors adopted, and its stockholders approved, the 2024 Employee Stock Purchase Plan (the “2024 ESPP”), which will become effective immediately preceding the date on which the registration statement for the Company’s IPO is declared effective by the SEC. A total of 324,243 (the “ESPP Initial Limit”) shares of common stock were initially reserved for issuance under this plan. The 2024 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2025 and each January 1 thereafter through January 1, 2034, by the least of (i) 648,486 shares of common stock, (ii) one percent of the outstanding number of shares of common stock on the immediately preceding December 31, or (iii) such lesser number of shares of common stock as determined by the administrator of the 2024 ESPP. The number of shares reserved under the 2024 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization.

Amended Certificate of Incorporation

As of May 30, 2024, the Company’s board of directors adopted, and its stockholders approved, the Third Amended and Restated Charter, which, among other things, increases the number of shares of common stock authorized for issuance from 250,000,000 to 500,000,000 shares of common stock.

F-60

8,000,000 Shares

LOGO

Common Stock

Goldman Sachs & Co. LLC

Jefferies

TD Cowen

Stifel

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Unless otherwise indicated, all references to “Rapport,” the “company,” “we,” “our,” “us” or similar terms refer to Rapport Therapeutics, Inc. and its wholly owned, consolidated subsidiary, or either or both of them as the context may require.

Item 13. Other Expenses of Issuance and Distribution.

The following table sets forth all expenses to be paid by us, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates except for the Securities and Exchange Commission (“SEC”) registration fee, the Financial Industry Regulatory Authority, Inc. (“FINRA”) filing fee and The Nasdaq Global Market (“Nasdaq”) listing fee.


SEC registration fee	$	24,443
FINRA filing fee	$	25,340
Nasdaq Global Market listing fee		25,000
Printing and mailing expenses		451,841
Legal fees and expenses		2,000,000
Accounting fees and expenses		1,584,000
Custodian transfer agent and registrar fees and expenses		3,500
Miscellaneous expenses		285,876

Total	$	4,400,000

Item 14. Indemnification of Directors and Officers.

Section 145 of the Delaware General Corporation Law (“DGCL”) authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section 145 permits corporations to pay expenses (including attorneys’ fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section 145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section 145.

We will adopt provisions in our third amended and restated certificate of incorporation, which will become effective immediately prior to the completion of this offering, and the amended and restated bylaws, which will become effective upon the effectiveness of the registration statement of which this prospectus forms a part, that limit or eliminate the personal liability of our directors and officers to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, our directors and officers will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as directors or officers, except for liability for:

•

any breach of their duty of loyalty to us or our stockholders;

•

any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

II-1

•

for our directors, any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions;

•

any transaction from which they derived an improper personal benefit; or

•

for our officers, any derivative action by or in the right of the corporation.

These limitations of liability do not alter director and officer liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission.

In addition, our amended and restated bylaws will provide that:

•

we will indemnify our directors, officers and, in the discretion of our board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and

•

we will advance reasonable expenses, including attorneys’ fees, to our directors and, in the discretion of our board of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions.

We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with our executive officers. These agreements provide that we will indemnify each of our directors, our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys’ fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for any action or proceeding arising out of that person’s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification, advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director’s or officer’s services as a director referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide indemnification for the expenses or liabilities incurred by those directors are secondary.

We also maintain general liability insurance which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act of 1933, as amended (“Securities Act”).

The underwriting agreement filed as Exhibit 1.1 to this registration statement provides for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Securities Exchange Act of 1934.

Item 15. Recent Sales of Unregistered Securities.

Set forth below is information regarding securities we have issued within the past three years that were not registered under the Securities Act.

(a) Preferred Stock Issuances

From December 2022 through February 2023, we sold an aggregate of 100,182,354 shares of Series A convertible preferred stock to accredited investors at a purchase price of $1.00 per share, for an aggregate purchase price of approximately $100.2 million.

From August 2023 through March 2024, we sold an aggregate of 89,431,030 shares of Series B convertible preferred stock to accredited investors at a purchase price of $1.67727 per share, for an aggregate purchase price of approximately $150.0 million.

II-2

(b) Common Stock Issuances

From February 2022 through May 2022, we sold an aggregate of 1,167,568 shares of Common Stock to accredited investors at a purchase price of $0.01 per share, for an aggregate purchase price of approximately $10 thousand.

From November 2022 through May 2023, we granted to our employees, consultants and other service providers shares of restricted Common Stock representing an aggregate of 2,892,010 shares of restricted Common Stock.

(c) Convertible Notes

From August 2022 to September 2022, we issued convertible promissory notes having an aggregate principal amount of $8.0 million.

The offers, sales and issuances of the securities described above were deemed to be exempt under Section 4(a)(2) of the Securities Act or Rule 506 of Regulation D under the Securities Act as a transaction by an issuer not involving a public offering. The recipients of securities in each of these transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions was an accredited investor within the meaning of Rule 501 of Regulation D under the Securities Act and had adequate access, through employment, business or other relationships, to information about us. No underwriters were involved in these transactions.

(d) Grants and exercises of stock options

In May 2023, we granted to our employees, consultants and other service providers shares of restricted Common Stock representing an aggregate of 199,067 shares of restricted Common Stock under our 2022 Plan.

Since December 2023, we have granted certain employees, consultants and directors options to purchase an aggregate of 2,769,721 shares of our common stock under our 2022 Plan, at exercise prices ranging from $1.80 to $11.57 per share.

The offers, sales and issuances of the securities described above were deemed to be exempt from registration under Rule 701 promulgated under the Securities Act as transactions under compensatory benefit plans and contracts relating to compensation, or under Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The recipients of such securities were our directors, employees or bona fide consultants and received the securities under our equity incentive plans. Appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of securities in these transactions had adequate access, through employment, business or other relationships, to information about us.

Item 16. Exhibits and Financial Statement Schedules.

(a) Exhibits.


Exhibit Number		Description
1.1		Form of Underwriting Agreement.

3.1		Second Amended and Restated Certificate of Incorporation, as amended, as currently in effect.

3.2		Form of Third Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering.

3.3*		Bylaws, as currently in effect.

II-3


Exhibit Number		Description

3.4		Form of Amended and Restated Bylaws, to be in effect as of the effectiveness of the registration statement of which this prospectus forms a part.

4.1*		Specimen Common Stock Certificate.

4.2+*		Amended and Restated Investors’ Rights Agreement, by and between the Registrant and certain of its stockholders, dated as of August 7, 2023.

5.1		Opinion of Goodwin Procter LLP.

10.1#*		2022 Stock Option and Grant Plan, as amended, and form of award agreements thereunder.

10.2#		Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan and form of award agreements thereunder.

10.3#		Rapport Therapeutics, Inc. 2024 Employee Stock Purchase Plan.

10.4#		Form of Indemnification Agreement, by and between the Registrant and its directors and executive officers.

10.5#		Senior Executive Cash Incentive Bonus Plan.

10.6#		Non-Employee Director Compensation Policy.

10.7#		Employment Agreement, by and between the Registrant and Abraham N. Ceesay, M.B.A., to be in effect upon the closing of this offering.

10.8#		Employment Agreement, by and between the Registrant and Troy Ignelzi, to be in effect upon the closing of this offering.

10.9#		Employment Agreement, by and between the Registrant and Cheryl Gault, to be in effect upon the closing of this offering.

10.10†+*		Option and License Agreement, by and between the Registrant and Janssen Pharmaceutica NV, dated August 9, 2022, as amended.

10.11†+*		Master Services Agreement, by and between the Registrant and NeuroPace Inc., dated November 28, 2023.

10.12†+*		Statement of Work #1, by and between the Registrant and NeuroPace Inc., dated November 28, 2023, as amended March 1, 2024.

10.13+*		Sublease Agreement, by and between the Registrant and Whoop, Inc., dated June 15, 2023.

10.14+*		License Agreement, by and between the Registrant and ARE-SD Region No. 61, LLC, dated December 21, 2023.

10.15+*		Lease Agreement, by and between the Registrant and ARE-9880 Campus Point, LLC, dated February 12, 2024.

21.1*		Subsidiaries of Registrant.

23.1		Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.

23.2		Consent of Goodwin Procter LLP (included in Exhibit 5.1).

24.1*		Power of Attorney (included on signature page).

107		Filing Fee Table.

*	Previously filed.

#	Indicates a management contract or any compensatory plan, contract or arrangement.

†	Certain portions of this document that constitute confidential information have been redacted pursuant to Item 601(b)(10) of Regulation S-K.

+	Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601(a)(5) and (6) of Regulation S-K. The registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request.

II-4

(b) Financial Statement Schedules.

All financial statement schedules are omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or the notes thereto.

Item 17. Undertakings.

Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

The registrant hereby undertakes that:

(a)

The Registrant will provide to the underwriter at the closing as specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser.

(b)

For purposes of determining any liability under the Securities Act of 1933, as amended, the information omitted from a form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in the form of prospectus filed by the Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933, as amended, shall be deemed to be part of this registration statement as of the time it was declared effective.

(c)

For the purpose of determining any liability under the Securities Act of 1933, as amended, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-5

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boston, Massachusetts, on the 3^rd of June, 2024.


RAPPORT THERAPEUTICS, INC.

By:		/s/ Abraham N. Ceesay
		Name: Abraham N. Ceesay, M.B.A.
		Title: Chief Executive Officer and Director

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.


Signature	Title	Date

/s/ Abraham N. Ceesay Abraham N. Ceesay, M.B.A.	Chief Executive Officer and Director (Principal Executive Officer)	June 3, 2024

/s/ Troy Ignelzi Troy Ignelzi	Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)	June 3, 2024

* Steven M. Paul, M.D.	Director and Chairman	June 3, 2024

* David Bredt, M.D., Ph.D.	Chief Scientific Officer and Director	June 3, 2024

* Terry-Ann Burrell, M.B.A.	Director	June 3, 2024

* James I. Healy, M.D., Ph.D.	Director	June 3, 2024

* Reid Huber, Ph.D.	Director	June 3, 2024

* Raymond Kelleher, M.D., Ph.D.	Director	June 3, 2024

* John Maraganore, Ph.D.	Director	June 3, 2024

* Jeffrey K. Tong, Ph.D.	Director	June 3, 2024

*By: /s/ Abraham N. Ceesay

Abraham N. Ceesay, M.B.A.

Attorney-in-Fact

II-6

EX-1.1 2 d803738dex11.htm EX-1.1 EX-1.1

Exhibit 1.1

Rapport Therapeutics, Inc.

Common Stock, par value $0.001 per share

Underwriting Agreement

[•], 2024

Goldman Sachs & Co. LLC

Jefferies LLC

TD Securities (USA) LLC

Stifel, Nicolaus & Company, Incorporated

As representatives (the “Representatives”) of the several Underwriters

named in Schedule I hereto,

c/o Goldman Sachs & Co. LLC

200 West Street

New York, New York 10282

c/o Jefferies LLC

520 Madison Avenue

New York, New York 10022

c/o TD Securities (USA) LLC

1 Vanderbilt Avenue

New York, New York 10017

c/o Stifel, Nicolaus & Company, Incorporated

787 7th Avenue, 11th Floor

New York, New York 10019

Ladies and Gentlemen:

Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [•] shares (the “Firm Shares”) and, at the election of the Underwriters, up to [•] additional shares (the “Optional Shares”) of common stock, par value $0.001 per share (“Stock”) of the Company. The Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof are herein collectively called the “Shares.”

1. The Company represents and warrants to, and agrees with, each of the Underwriters that:

(a) A registration statement on Form S-1 (File No. 333-279486) (the “Initial Registration Statement”) in respect of the Shares has been filed with the Securities and Exchange Commission (the “Commission”); the Initial Registration Statement and any post-effective amendment thereto, each in the form heretofore delivered to you, have been declared effective

by the Commission in such form; other than a registration statement, if any, increasing the size of the offering (a “Rule 462(b) Registration Statement”), filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the “Act”), which became effective upon filing, no other document with respect to the Initial Registration Statement has been filed with the Commission; and no stop order suspending the effectiveness of the Initial Registration Statement, any post-effective amendment thereto or the Rule 462(b) Registration Statement, if any, has been issued and no proceeding for that purpose or pursuant to Section 8A of the Act has been initiated or, to the Company’s knowledge, threatened by the Commission (any preliminary prospectus included in the Initial Registration Statement or filed with the Commission pursuant to Rule 424(a) of the rules and regulations of the Commission under the Act is hereinafter called a “Preliminary Prospectus”; the various parts of the Initial Registration Statement and the Rule 462(b) Registration Statement, if any, including all exhibits thereto and including the information contained in the form of final prospectus filed with the Commission pursuant to Rule 424(b) under the Act in accordance with Section 5(a) hereof and deemed by virtue of Rule 430A under the Act to be part of the Initial Registration Statement at the time it was declared effective, each as amended at the time such part of the Initial Registration Statement became effective or such part of the Rule 462(b) Registration Statement, if any, became or hereafter becomes effective, are hereinafter collectively called the “Registration Statement”; the Preliminary Prospectus relating to the Shares that was included in the Registration Statement immediately prior to the Applicable Time (as defined in Section 1(c) hereof) is hereinafter called the “Pricing Prospectus”; such final prospectus, in the form first filed pursuant to Rule 424(b) under the Act, is hereinafter called the “Prospectus”; any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the Act or Rule 163B under the Act is hereinafter called a “Testing-the-Waters Communication”; any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the Act is hereinafter called a “Written Testing-the-Waters Communication”; any “issuer free writing prospectus” as defined in Rule 433 under the Act relating to the Shares is hereinafter called an “Issuer Free Writing Prospectus”); and any “bona fide electronic road show” as defined in Rule 433(h)(5) under the Act that has been made available without restriction to any person is hereinafter called a “broadly available road show”;

(b) (A) No order preventing or suspending the use of any Preliminary Prospectus or any Issuer Free Writing Prospectus has been issued by the Commission, (B) no proceeding for that purpose or pursuant to Section 8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or threatened by the Commission, and (C) each Preliminary Prospectus, at the time of filing thereof, conformed in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder, and did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information (as defined in Section 9(b) of this Agreement);

(c) For the purposes of this Agreement, the “Applicable Time” is [•] p.m., New York time, on the date of this Agreement. The Pricing Prospectus, as supplemented by the information listed on Schedule II(c) hereto, taken together (collectively, the “Pricing Disclosure Package”), as of the Applicable Time, did not, and as of each Time of Delivery (as defined in Section 4(a) of this Agreement), will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; and each Issuer Free Writing

Prospectus, each broadly available road show and each Written Testing-the-Waters Communication does not conflict with the information contained in the Registration Statement, the Pricing Prospectus or the Prospectus, and each Issuer Free Writing Prospectus, each broadly available road show and each Written Testing-the-Waters Communication, as supplemented by and taken together with the Pricing Disclosure Package, as of the Applicable Time, did not , and as of each Time of Delivery, will not, include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information;

(d) No documents were filed by the Company with the Commission since the Commission’s close of business on the business day immediately prior to the date of this Agreement and prior to the execution of this Agreement, except as set forth on Schedule II(b) hereto;

(e) The Registration Statement, at the time it was declared effective, conformed, and the Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus, as of the date of the Prospectus or such amendment or supplement, will conform, in all material respects to the requirements of the Act and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement, as of the applicable filing date as to the Prospectus and any amendment or supplement thereto, and as of each Time of Delivery, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however, that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Underwriter Information;

(f) Neither the Company nor any of its subsidiaries has, since the date of the latest audited financial statements included in the Pricing Prospectus, (i) sustained any material loss or material interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree or (ii) entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries, taken as a whole, or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries, taken as a whole, in each case otherwise than as set forth or contemplated in the Pricing Prospectus; and, since the respective dates as of which information is given in the Registration Statement and the Pricing Prospectus, there has not been (x) any change in the capital stock (other than as a result of (i) the exercise, if any, of stock options or the award, if any, of stock options or restricted stock in the ordinary course of business pursuant to the Company’s equity plans that are described in the Pricing Prospectus and the Prospectus or (ii) the issuance, if any, of stock upon conversion of the Company’s securities as described in the Pricing Prospectus and the Prospectus) or long-term debt of the Company or any of its subsidiaries or (y) any Material Adverse Effect (as defined below); as used in this Agreement, “Material Adverse Effect” shall mean any material adverse change or effect, or any development involving a prospective material adverse change or effect, in or affecting (i) the business, properties, general affairs, management, financial position, stockholders’ equity, prospects or results of operations of the Company and its subsidiaries, taken as a whole, or (ii) the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus;

(g) The Company and its subsidiaries have good and marketable title in fee simple to all real property and good and marketable title to all personal property owned by them, in each case free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and any real property and buildings held under lease by the Company and its subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as are not material and do not materially interfere with the use made and proposed to be made of such property and buildings by the Company and its subsidiaries;

(h) Each of the Company and each of its subsidiaries has been (i) duly organized and is validly existing and in good standing under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own its properties and conduct its business as described in the Pricing Prospectus, and (ii) duly qualified as a foreign corporation or other business entity for the transaction of business and is in good standing (where such concept exists) under the laws of each other jurisdiction in which it owns or leases properties or conducts any business so as to require such qualification, except, in the case of this clause (ii), where the failure to be so qualified or in good standing would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, and each subsidiary of the Company has been identified in Exhibit 21.1 to the Registration Statement;

(i) The Company has an authorized capitalization as set forth in the Pricing Prospectus and all of the issued shares of capital stock of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and conform, in all material respects, to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and all of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid and non-assessable and (except, in the case of any foreign subsidiary, for directors’ qualifying shares) are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims; and none of the outstanding capital stock or equity interest in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary;

(j) The Shares to be issued and sold by the Company to the Underwriters hereunder have been duly and validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and fully paid and non-assessable and will conform, in all material respects, to the description of the Stock contained in the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights, except as have been duly and validly waived or complied with;

(k) The issue and sale of the Shares and the compliance by the Company with this Agreement and the consummation of the transactions contemplated in this Agreement and the Pricing Prospectus will not conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, (A) any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject, (B) the certificate of incorporation or by-laws (or other applicable organizational document) of the Company or any

of its subsidiaries, or (C) any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, except, in the case of clauses (A) and (C) for such defaults, breaches, or violations that would not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect; and no consent, approval, authorization, order, registration or qualification of or with any such court or governmental agency or body is required for the issue and sale of the Shares or the consummation by the Company of the transactions contemplated by this Agreement, except such as have been obtained under the Act, the approval by the Financial Industry Regulatory Authority (“FINRA”) of the underwriting terms and arrangements, the approval for listing the Shares on The Nasdaq Global Market (the “Exchange”) and such consents, approvals, authorizations, orders, registrations or qualifications as may be required under state securities or Blue Sky laws in connection with the purchase and distribution of the Shares by the Underwriters;

(l) Neither the Company nor any of its subsidiaries is (i) in violation of its certificate of incorporation or by-laws (or other applicable organizational document), (ii) in violation of any statute or any judgment, order, rule or regulation of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties, or (iii) in default in the performance or observance of any obligation, agreement, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which it is a party or by which it or any of its properties may be bound, except, in the case of the foregoing clauses (ii) and (iii), for such defaults as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;

(m) The statements set forth in the Pricing Prospectus and the Prospectus under the captions “Description of Capital Stock” and “Shares Eligible for Future Sale,” insofar as they purport to constitute a summary of the terms of the Stock and under the captions “Material U.S. Federal Income Tax Consequences to Non-U.S. Holders” and “Underwriting,” insofar as they purport to describe the provisions of the laws and documents referred to therein, are accurate, complete and fair in all material respects;

(n) Other than as set forth in the Pricing Prospectus, there are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations, inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries or any of their properties or assets or, to the Company’s knowledge, any officer or director of the Company is a party or of which any property or assets of the Company or any of its subsidiaries or, to the Company’s knowledge, any of their properties or assets or any officer or director of the Company is the subject which, if determined adversely to the Company or any of its subsidiaries or any of their properties or assets (or such officer or director), would individually or in the aggregate have a Material Adverse Effect or which are required to be described in the Registration Statement and Prospectus and are not so described; and no such proceedings are threatened or, to the Company’s knowledge, contemplated by governmental authorities or others; there are no current or pending Actions that are required under the Act to be described in the Registration Statement or the Pricing Prospectus that are not so described therein; and there are no statutes, regulations or contracts or other documents that are required under the Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement and the Pricing Prospectus;

(o) The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds thereof as described in the Pricing Prospectus and the Prospectus, will not be an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended (the “Investment Company Act”);

(p) At the time of filing the Initial Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) under the Act) of the Shares, and at the date hereof, the Company was not and is not an “ineligible issuer,” as defined under Rule 405 under the Act;

(q) PricewaterhouseCoopers LLP, who have certified certain financial statements of the Company and its subsidiaries, are independent public accountants as required by the Act and the rules and regulations of the Commission thereunder;

(r) The Company maintains a system of internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that (i) complies with the requirements of the Exchange Act as applicable to the Company, (ii) has been designed by the Company’s principal executive officer and principal financial officer, or under their supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principles (“GAAP”) and (iii) is designed to provide reasonable assurance that (A) transactions are executed in accordance with management’s general or specific authorization, (B) transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain accountability for assets, (C) access to assets is permitted only in accordance with management’s general or specific authorization and (D) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and the Company’s internal control over financial reporting is effective and the Company is not aware of any material weaknesses in its internal control over financial reporting (it being understood that this subsection shall not require the Company to comply with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (the “Sarbanes-Oxley Act”) as of an earlier date than it would otherwise be required to so comply under applicable law). There are no material weaknesses in the Company’s internal controls;

(s) Since the date of the latest audited financial statements included in the Pricing Prospectus, there has been no change in the Company’s internal control over financial reporting that has materially and adversely affected, or is reasonably likely to materially and adversely affect, the Company’s internal control over financial reporting;

(t) The Company maintains disclosure controls and procedures (as such term is defined in Rule 13a-15(e) under the Exchange Act) that comply with the requirements of the Exchange Act applicable to the Company; such disclosure controls and procedures have been designed to ensure that material information relating to the Company and its subsidiaries is made known to the Company’s principal executive officer and principal financial officer by others within those entities; and such disclosure controls and procedures are effective;

(u) This Agreement has been duly authorized, executed and delivered by the Company;

(v) The Company has full right, power and authority to execute and deliver this Agreement and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by the Company of this Agreement and the consummation by the Company of the transactions contemplated hereby has been duly and validly taken;

(w) (A) None of the Company or its subsidiaries, or any director or officer thereof, nor, to the knowledge of the Company any affiliate, employee, or agent or other person associated with or acting on behalf of the Company or any of its subsidiaries or affiliates, has (i) made, offered, promised or authorized any unlawful contribution, gift, entertainment or other unlawful expense (or taken any act in furtherance thereof), (ii) taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval of the payment, giving or receipt of money, property, gifts, entertainment, other expense or anything else of value, directly or indirectly, to any government official (including any officer or employee of a government or government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office) in order to improperly influence official action, or to any person in violation of any applicable anti-corruption laws; or (iii) violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the rules and regulations thereunder, the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or anti-corruption laws (collectively, “Anti-Corruption Laws”); (B) the Company and its subsidiaries have conducted their businesses in compliance with Anti-Corruption Laws and have instituted and maintained, and will continue to maintain, policies and procedures reasonably designed to promote and achieve compliance with such laws and with the representations and warranties contained herein; and (C) neither the Company nor any of its subsidiaries will use, directly or indirectly, the proceeds of the offering of the Shares hereunder in furtherance of any unlawful expense or any direct or indirect unlawful payment in violation of any Anti-Corruption Laws;

(x) The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with the requirements of applicable financial recordkeeping and reporting requirements and anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and any similar rules, regulations or guidelines issued, administered or enforced by any governmental agency, of the various jurisdictions in which the Company and its subsidiaries conduct business (collectively, the “Money Laundering Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened;

(y) (A) None of the Company or any of its subsidiaries, nor any director, officer or employee thereof, nor, to the knowledge of the Company, any agent, affiliate or other person acting on behalf of the Company or any of its subsidiaries is a person or entity that is, or is 50% or more owned or, where relevant under applicable Sanctions, controlled by one or more persons or entities that are, currently the subject or the target of any sanctions administered or enforced by the U.S. government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”), or the U.S. Department of State (and including, without limitation, the designation as a “specially designated national” or “blocked person”), the European Union, His Majesty’s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, “Sanctions”), or located, organized, or resident in a country or territory that is the subject or target of Sanctions (currently, Crimea, Cuba, Iran, North Korea,

Syria, the so-called Donetsk People’s Republic and so-called Luhansk People’s Republic and the non-government controlled areas of Zaporizhzhia and Kherson regions of Ukraine (each a “Sanctioned Jurisdiction”)); (B) the Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any unlawful activities of or business with any Sanctioned Jurisdiction or any person or entity, that, at the time of such funding or facilitation, is the subject or the target of Sanctions or (ii) in any other manner that will result in a violation by any person or entity (including any person or entity participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; and (C) the Company and its subsidiaries have not since April 24, 2019 knowingly engaged in, are not now knowingly engaged in and will not engage in any unlawful dealings or transactions with any Sanctioned Jurisdiction or involving any person or entity, that, at the time of such dealing or transaction, is or was the subject or the target of Sanctions; the Company and its subsidiaries have instituted, and maintain, policies and procedures designed to promote and achieve continued compliance with Sanctions;

(z) The financial statements included in the Registration Statement, the Pricing Prospectus and the Prospectus, together with the related schedules and notes, present fairly, in all material respects, the financial position of the Company and its subsidiaries at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company and its subsidiaries for the periods specified; said financial statements have been prepared in conformity with GAAP applied on a consistent basis throughout the periods involved, except in the case of any unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission. The supporting schedules, if any, present fairly, in all material respects in accordance with GAAP the information required to be stated therein. The selected financial data and the summary financial information included in the Registration Statement, the Pricing Prospectus and the Prospectus present fairly in all material respects the information shown therein and have been compiled on a basis consistent with that of the audited financial statements included therein. Except as included therein, no historical or pro forma financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Prospectus or the Prospectus under the Act or the rules and regulations promulgated thereunder;

(aa) The Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or contaminants (“Environmental Laws”), (ii) have received all permits, licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses and (iii) are in compliance with all terms and conditions of such permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;

(bb) There are no costs or liabilities associated with Environmental Laws (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties) which would, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect;

(cc) There are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the Act with respect to any securities of the Company or to require the Company to include such securities with the Shares registered pursuant to the Registration Statement, except as otherwise have been validly waived in connection with the issuance and sale of Shares contemplated hereby and as described in the Time of Sale Prospectus and Prospectus;

(dd) The Company and its subsidiaries and their respective directors, officers and employees, and to the Company’s knowledge, their respective agents, affiliates and representatives, are, and at all times have been, in compliance with all applicable Health Care Laws. For purposes of this Agreement, “Health Care Laws” shall mean the federal Anti-kickback Statute (42 U.S.C. § 1320a-7b(b)), the Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31 U.S.C. §§ 3729 et seq.), the criminal False Claims Act (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287 and 1349, and the health care fraud criminal provisions under the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. §§ 1320d et seq.) (“HIPAA”), the exclusion law (42 U.S.C. § 1320a-7), the civil monetary penalties law (42 U.S.C. § 1320a-7a), HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. §§ 17921 et seq.), the Federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 301 et seq.), the Public Health Service Act (42 U.S.C. §§ 201 et seq.), the statutes, regulations and directives of applicable federal healthcare programs, including but not limited to Medicare (Title XVIII of the Social Security Act) and Medicaid (Title XIX of the Social Security Act), any rules and regulations promulgated pursuant to the statutes listed herein, and any other applicable federal, state, or foreign health care laws. The Company is not a party to nor has any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. The Company has not received any notification, correspondence or any other written communication, including, without limitation, any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the FDA or any similar regulatory authority, or any notification of any pending or threatened claim, suit, proceeding, hearing, enforcement, investigation, arbitration or other action, from any court, arbitrator, governmental or regulatory authority or third party, of potential or actual non-compliance by, or liability of, the Company under any Health Care Laws;

(ee) Each of the Company and its subsidiaries possesses, and is in compliance with the terms of, all applications, certificates, approvals, clearances, registrations, exemptions, franchises, licenses, permits, consents and other authorizations necessary to conduct their respective businesses (collectively, “Licenses”), issued by the appropriate governmental authorities, including, without limitation, all Licenses required by the FDA, or any component thereof and/or by any other U.S., state, local or foreign government or drug regulatory agency (collectively, the “Regulatory Agencies”). All Licenses are in full force and effect and the Company is not in violation of any term or conditions of any License. The Company has not received any written notice of proceedings relating to the revocation or modification of any Licenses and no Regulatory Agency has taken any action to limit, suspend or revoke any License possessed by the Company;

(ff) The pre-clinical studies and clinical trials that are described in the Registration Statement, the Pricing Prospectus and the Prospectus were and, if still pending, are being, conducted in all material respects in accordance with the protocols submitted to the FDA or any foreign governmental body exercising comparable authority, procedures and controls pursuant to, where applicable, accepted professional and scientific standards, and all applicable laws and regulations; the descriptions of the pre-clinical studies and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company, and the results thereof, contained in the Registration Statement, the Pricing Prospectus and the Prospectus are accurate and complete in all material respects; the Company is not aware of any other pre-clinical studies or clinical trials, the results of which reasonably call into question the results described in the Registration Statement, the Pricing Prospectus and the Prospectus; and the Company has not received any written notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board requiring the termination, suspension, material modification or clinical hold of any pre-clinical studies or clinical trials conducted by or on behalf of the Company;

(gg) Neither the Company nor its subsidiaries any of its or their respective officers, employees, directors, nor to the Company’s knowledge, their agents or clinical investigators, has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion, or has been convicted of any crime or engaged in any conduct that would reasonably be expected to result in debarment under 42 U.S.C. § 1320a-7 or 21 U.S.C. § 335a;

(hh) The Company and its subsidiaries own, or possess valid and enforceable license rights in, all patents, patent applications, inventions, copyrights and registrations and applications thereof, works of authorship, know how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, domain names, trade names, software, systems and technology (collectively, “Intellectual Property”) as described in the Registration Statement, the Pricing Prospectus and the Prospectus (collectively, “Company Intellectual Property”). To the Company’s knowledge, the Company and its subsidiaries, and the conduct of their respective businesses and the proposed conduct of their businesses, does not and will not infringe, misappropriate or otherwise violate any Intellectual Property rights of others. Neither the Company nor any of its subsidiaries has received any written notice of infringement of or conflict with asserted rights of others with respect to any of the Company Intellectual Property and there is no pending or threatened action, suit, proceeding or claim by others (i) challenging the Company’s or its subsidiaries’ rights in or to any Company Intellectual Property, and the Company and its subsidiaries are unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (ii) challenging the validity, enforceability or scope of any Company Intellectual Property, and the Company and its subsidiaries are unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (iii) asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon the commercialization of any product or service described in the Pricing Prospectus or the Prospectus as under development, infringe or violate, any Intellectual Property of third parties, and the Company and its subsidiaries have not received any notice of, and are unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company Intellectual Property is enforceable, subsisting and, to the knowledge of Company, valid. To the Company’s knowledge, the Company Intellectual Property is free and clear of all material liens, security interests, or encumbrances, other than non-exclusive licenses granted in the ordinary course of business. To the Company’s knowledge,

there are no material defects in any of the patents or patent applications, trademark applications or trademark registration, or copyright registrations included in the Company Intellectual Property. To the Company’s knowledge, there is no infringement, misappropriation or other violation by third parties of any Company Intellectual Property owned by the Company or its subsidiaries. The Company and its subsidiaries have complied with the terms of each agreement pursuant to which Company Intellectual Property has been licensed to the Company or any subsidiary, and all such agreements are in full force and effect, except as would not have a Material Adverse Effect. To the Company’s knowledge, the Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard the Company Intellectual Property, including payment of applicable maintenance fees, filing of applicable statements of use, timely responding to office actions, complying with the duties of candor and good faith required by the United States Patent and Trademark Office, and the disclosure of any required information, and the execution of appropriate nondisclosure, confidentiality agreements, invention or intellectual property assignments or assignment agreements with their employees, consultants and contractors. To the Company’s knowledge, no employee, consultant or independent contractor of the Company is in or has ever been in violation in any material respect of any term of any invention assignment agreement, non-competition agreement, non-solicitation agreement, or non-disclosure agreement. The Company and each of its subsidiaries have taken reasonable measures to protect their confidential information and trade secrets, including the execution of appropriate nondisclosure and confidentiality agreements;

(ii) No material labor dispute with the employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing, threatened or imminent labor disturbance by the employees of any of its principal suppliers or contractors, except as would not have a Material Adverse Effect;

(jj) (A) The Company and each of its subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks and in such amounts as are prudent and customary in the businesses in which they are engaged; (B) neither the Company nor any of its subsidiaries has been refused any insurance coverage sought or applied for; and (C) neither the Company nor any of its subsidiaries has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would not, taken as a whole, be reasonably expected to have a Material Adverse Effect;

(kk) Except as otherwise disclosed in the Registration Statement, the Company has not sold, issued or distributed any shares of its common stock during the six-month period preceding the date of this Agreement, including any sales pursuant to Regulation D or S of the Act, other than shares issued pursuant to employee benefit plans, qualified stock option plans or other employee compensation plans or pursuant to outstanding options, rights or warrants;

(ll) All U.S. federal income tax returns of the Company and its subsidiaries required by law to be filed have been filed and all taxes shown as due on such returns or that otherwise have been assessed that are due and payable have been paid, except assessments against which appeals have been promptly taken and as to which adequate reserves have been established in the audited financial statements included in the Pricing Prospectus. The Company and each of its subsidiaries have timely filed all other U.S. federal, state, local and foreign tax returns required to be filed through the date of this Agreement, or have requested extensions thereof, and have paid all taxes required to be paid thereon (except where the failure to file or pay would not, individually or in the aggregate, have a Material Adverse Effect, or except as currently

being contested in good faith and for which adequate reserves have been established in the audited financial statements included in the Pricing Prospectus), no tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company nor any of its subsidiaries have any notice or knowledge of any tax deficiency that could reasonably be expected to be determined adversely to the Company or its subsidiaries and that could reasonably be expected to have) a Material Adverse Effect and no audit or other examination of or with respect to any tax return or taxes of the Company or any of its subsidiaries is presently in progress, nor has the Company or any of its subsidiaries been notified in writing of any request for an audit or other examination that has not been finally resolved and that in each case could reasonably be expected to have a Material Adverse Effect;

(mm) From the time of initial confidential submission of a registration statement relating to the Shares with the Commission through the date of this Agreement, the Company has been and is an “emerging growth company” as defined in Section 2(a)(19) of the Act (an “Emerging Growth Company”);

(nn) The Company’s and its subsidiaries’ information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications and databases, and any other information technology systems owned, licensed, leased, or otherwise used by the Company, and any such equipment or technology maintained or provided by any third parties to the Company or its subsidiaries (collectively, “IT Systems”) are (A) adequate for, and operate and perform in all material respects as necessary for the uninterrupted operation of the business of the Company and its subsidiaries as currently conducted and as anticipated to be conducted as described in the Registration Statement, the Pricing Disclosure Package, and the Prospectus, and (B) are free and clear of all bugs, errors, defects, Trojan horses, time bombs, malware, harmful code, or other corruptants. The Company and its subsidiaries have at all times implemented and maintained reasonable and appropriate controls, policies, procedures and safeguards designed to maintain and protect its confidential, proprietary, and sensitive information and the privacy, confidentiality, integrity, availability, continuous operation, redundancy and security of all IT Systems and data (including any and all (A) information that (i) relates to an identified or identifiable individual, or (ii) is defined as “personal information,” “personally identifiable information,” “personal data,” or similar term under applicable Data Protection Requirements (as defined below) (collectively, “Personal Data”), and (B) confidential, sensitive, or proprietary data (collectively “Protected Information”)) used in connection with the business of the Company or its subsidiaries. The Company and its subsidiaries have at all times established and maintained reasonable and appropriate disaster recovery and security plans and procedures for their business, including, without limitation, for the IT Systems and Protected Information. The security programs of the Company and its subsidiaries comply and have at all times complied, in all material respects, with all applicable Data Protection Requirements. There have been no actual or reasonably suspected breaches or attacks involving the accidental, unlawful, or unauthorized destruction of, loss of, alteration of, uses of, or accesses to, any IT Systems or Protected Information (collectively, a “Data Breach”) except for those that have been remedied without material cost or liability or the duty to notify any other person. There are no Data Breaches under internal review or investigations relating to the same. The Company and its subsidiaries have not been notified of, and have no knowledge of, any fact or circumstance that would reasonably be expected to result in any such Data Breach;

(oo) The Company and its subsidiaries have at all times materially complied with all of the following, as they relate to the protection, collection, use, disclosure, transfer, storage, disposal, confidentiality, integrity, availability, processing, privacy, and security of IT Systems and Personal Data: (A) applicable laws, statutes, regulations, directives, self-regulatory guidelines and standards, in all relevant jurisdictions (including, but not limited to, in each case as applicable, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679); the United Kingdom General Data Protection Regulation (“UK GDPR”); and the California Consumer Privacy Act (“CCPA”)); (B) all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority; (C) internal or external policies; and (D) contractual obligations (collectively, “Data Protection Requirements”);

(pp) The Company and its subsidiaries have at all times made all disclosures to, and obtained all consents from, individuals as required by Data Protection Requirements for the Company’s and its subsidiaries’ collection, use, disclosure or other processing of Personal Data. None of such disclosures have been materially inaccurate, deceptive, misleading, incomplete, or in violation of Data Protection Requirements;

(qq) The Company and each of its subsidiaries (A) have not received written notice of any actual or potential liability under or relating to, or actual or potential violation of, Data Protection Requirements, (B) have no knowledge of any fact or circumstance that would reasonably indicate the Company or one of its subsidiaries is not in compliance with any of the Data Protection Requirements; (C) are not currently participating, in whole or in part, in any investigation, remediation, or other corrective action relating to a violation of any of the Data Protection Requirements; and (D) are not a party to any order, decree, or agreement by any court or arbitrator or governmental or regulatory authority that imposes any obligation or liability relating to any Data Protection Requirement;

(rr) Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included in each of the Registration Statement, the Pricing Prospectus, and the Prospectus, each Issuer Free Writing Prospectus and each Section 5(d) Writing, as supplemented by and taken together with the Pricing Disclosure Package, is not based on or derived from sources that are reliable and accurate in all material respects;

(ss) There is and has been no failure on the part of the Company or any of the Company’s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act, including Section 402 related to loans and Sections 302 and 906 related to certifications;

(tt) There are no debt securities or preferred stock issued or guaranteed by the Company that are rated by a “nationally recognized statistical rating organization,” as such term is defined under Section 3(a)(62) under the Exchange Act;

(uu) (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b),(c),(m) or (o) of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or

administrative exemption; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or “critical status” (within the meaning of Sections 304 and 305 of ERISA) (v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified, and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii) neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company’s and its Controlled Group affiliates’ most recently completed fiscal year; or (B) a material increase in the Company and its subsidiaries’ “accumulated post-retirement benefit obligations” (within the meaning of Accounting Standards Codification Topic 715-60) compared to the amount of such obligations in the Company and its subsidiaries’ most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect;

(vv) There are no off-balance sheet arrangements (as defined in Regulation S-K Item 303(a)(4)(ii)) that have or are reasonably likely to have a material current or future effect on the Company’s financial condition, changes in financial condition, results of operations, liquidity, capital expenditures or capital resources;

(ww) There are no contracts, arrangements or other documents that are required to be described in the Registration Statement, the Pricing Prospectus or the Prospectus or to be filed as exhibits to the Registration Statement that are not described or filed as required;

(xx) The Company and each of its subsidiaries have such permits, licenses, approvals, consents, franchises, certificates of need and other approvals or authorizations of governmental or regulatory authorities (“Permits”) as are necessary under applicable law to own their respective properties and conduct their respective businesses in the manner described in the Registration Statement, the Pricing Prospectus and the Prospectus, except for any of the foregoing that would not, individually or in the aggregate, have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received notice of any proceedings related to the revocation or modification of any such Permits that, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a Material Adverse Effect;

(yy) Neither the Company nor any of its controlled affiliates has taken or will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company or any of its subsidiaries in connection with the offering of the Shares;

(zz) The Company is not a party to any contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s fee or like payment in connection with the offering and sale of the Shares;

(aaa) No relationship, direct or indirect, exists between or among the Company on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other, that is required by the Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents and in the Registration Statement, the Pricing Prospectus and the Prospectus; and

(bbb) No forward-looking statement (within the meaning of Section 27A of the Act and Section 21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Prospectus or the Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith.

2. Subject to the terms and conditions herein set forth, (a) the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at a purchase price per share of $[•], the number of Firm Shares set forth opposite the name of such Underwriter in Schedule I hereto and (b) in the event and to the extent that the Underwriters shall exercise the election to purchase Optional Shares as provided below, the Company agrees to issue and sell to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the purchase price per share set forth in clause (a) of this Section 2 (provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares), that portion of the number of Optional Shares as to which such election shall have been exercised (to be adjusted by you so as to eliminate fractional shares) determined by multiplying such number of Optional Shares by a fraction, the numerator of which is the maximum number of Optional Shares which such Underwriter is entitled to purchase as set forth opposite the name of such Underwriter in Schedule I hereto and the denominator of which is the maximum number of Optional Shares that all of the Underwriters are entitled to purchase hereunder.

The Company hereby grants to the Underwriters the right to purchase at their election up to [•] Optional Shares, at the purchase price per share set forth in the paragraph above, provided that the purchase price per Optional Share shall be reduced by an amount per share equal to any dividends or distributions declared by the Company and payable on the Firm Shares but not payable on the Optional Shares. Any such election to purchase Optional Shares may be exercised only by written notice from you to the Company, given within a period of 30 calendar days after the date of this Agreement and setting forth the aggregate number of Optional Shares to be purchased and the date on which such Optional Shares are to be delivered, as determined by you but in no event earlier than the First Time of Delivery (as defined in Section 4 hereof) or, unless you and the Company otherwise agree in writing, earlier than two or later than ten business days after the date of such notice.

3. Upon the authorization by you of the release of the Shares, the several Underwriters propose to offer the Shares for sale upon the terms and conditions set forth in the Pricing Disclosure Package and the Prospectus.

4. (a) The Shares to be purchased by each Underwriter hereunder, in definitive or book-entry form, and in such authorized denominations and registered in such names as the Representatives may request upon at least forty-eight hours’ prior notice to the Company shall be delivered by or on behalf of the Company to the Representatives, through the facilities of the Depository Trust Company (“DTC”), for the account of such Underwriter, against payment by or on behalf of such Underwriter of the purchase price therefor by wire transfer of Federal (same-day) funds to the account specified by the Company to the Representatives at least forty-eight hours in advance. The Company will cause the certificates, if any, representing the Shares to be made available for checking and packaging at least twenty-four hours prior to the Time of Delivery (as defined below) with respect thereto at the office of DTC or its designated custodian (the “Designated Office”). The time and date of such delivery and payment shall be, with respect to the Firm Shares, 9:30 a.m., New York time, on [•], 2024 or such other time and date as the Representatives and the Company may agree upon in writing, and, with respect to the Optional Shares, 9:30 a.m., New York time, on the date specified by the Representatives in the written notice given by the Representatives of the Underwriters’ election to purchase such Optional Shares, or such other time and date as the Representatives and the Company may agree upon in writing. Such time and date for delivery of the Firm Shares is herein called the “First Time of Delivery,” such time and date for delivery of the Optional Shares, if not the First Time of Delivery, is herein called the “Second Time of Delivery,” and each such time and date for delivery is herein called a “Time of Delivery.”

(b) The documents to be delivered at each Time of Delivery by or on behalf of the parties hereto pursuant to Section 8 hereof, including the cross receipt for the Shares and any additional documents requested by the Underwriters pursuant to Section 8(l) hereof, will be delivered at the offices of Cooley LLP, 55 Hudson Yards, New York, New York 10001 (the “Closing Location”), and the Shares will be delivered at the Designated Office, all at such Time of Delivery. A meeting will be held at the Closing Location at [•] p.m., New York time, on the New York Business Day next preceding such Time of Delivery, at which meeting the final drafts of the documents to be delivered pursuant to the preceding sentence will be available for review by the parties hereto. For the purposes of this Section 4, “New York Business Day” shall mean each Monday, Tuesday, Wednesday, Thursday and Friday which is not a day on which banking institutions in New York City are generally authorized or obligated by law or executive order to close.

5. The Company agrees with each of the Underwriters:

(a) To prepare the Prospectus in a form approved by you and to file such Prospectus pursuant to Rule 424(b) under the Act prior to the earlier of (i) the First Time of Delivery and (ii) the Commission’s close of business on the second business day following the execution and delivery of this Agreement, or, if applicable, such earlier time as may be required by Rule 430A(a)(3) under the Act; to make no further amendment or any supplement to the Registration Statement or the Prospectus prior to the last Time of Delivery which shall be disapproved by you promptly after reasonable notice thereof; to advise you, promptly after it receives notice thereof, of the time when any amendment to the Registration Statement has been filed or becomes effective or any amendment or supplement to the Prospectus has been filed and to furnish you with copies thereof; to file promptly all material required to be filed by the Company

with the Commission pursuant to Rule 433(d) under the Act; to advise you, promptly after it receives notice thereof, of the issuance by the Commission of any stop order or of any order suspending the effectiveness of the Registration Statement or any part thereof preventing or suspending the use of any Issuer Free Writing Prospectus, Preliminary Prospectus or other prospectus in respect of the Shares, of the suspension of the qualification of the Shares for offering or sale in any jurisdiction, of the initiation or threatening of any proceeding for any such purpose or pursuant to Section 8A of the Act, or of any request by the Commission for the amending or supplementing of the Registration Statement or the Prospectus or for additional information; and, in the event of the issuance of any stop order suspending the effectiveness of the Registration Statement or any part thereof or of any order preventing or suspending the use of any Issuer Free Writing Prospectus, Preliminary Prospectus or other prospectus relating to the Shares or suspending any such qualification, to promptly use its best efforts to obtain the withdrawal of such order;

(b) Promptly from time to time to take such action as you may reasonably request to qualify the Shares for offering and sale under the securities laws of such jurisdictions as you may request and to comply with such laws so as to permit the continuance of sales and dealings therein in such jurisdictions for as long as may be necessary to complete the distribution of the Shares, provided that in connection therewith the Company shall not be required to qualify as a foreign corporation (where not otherwise required), or to file a general consent to service of process in any jurisdiction (where not otherwise required);

(c) Prior to 10:00 a.m., New York time, on the New York Business Day next succeeding the date of this Agreement (or such other time as may be agreed to by the Representatives and the Company) and from time to time, to furnish the Underwriters with written and electronic copies of the Prospectus, Preliminary Prospectus and any supplements and amendments thereto or to the Registration Statement in such quantities as the Representatives may reasonably request, and, if the delivery of a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is required at any time prior to the expiration of nine months after the time of issue of the Prospectus in connection with the offering or sale of the Shares and if at such time any event shall have occurred as a result of which the Prospectus as then amended or supplemented would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made when such Prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) is delivered, not misleading, or, if for any other reason it shall be necessary during such same period to amend or supplement the Prospectus in order to comply with the Act, to notify you and, before amending or supplementing the Registration Statement, the Pricing Disclosure Package or the Prospectus, to furnish you a copy of each such proposed amendment or supplement and not file any such proposed amendment or supplement to which you reasonably object, and upon your request to prepare and furnish without charge to each Underwriter and to any dealer in securities (whose name and address the Underwriters shall furnish to the Company) as many written and electronic copies as you may from time to time reasonably request of an amended Prospectus or a supplement to the Prospectus which will correct such statement or omission or effect such compliance; and in case any Underwriter is required to deliver a prospectus (or in lieu thereof, the notice referred to in Rule 173(a) under the Act) in connection with sales of any of the Shares at any time nine months or more after the time of issue of the Prospectus, upon your request but at the expense of such Underwriter, to prepare and deliver to such Underwriter as many written and electronic copies as you may request of an amended or supplemented Prospectus complying with Section 10(a)(3) of the Act;

(d) To make generally available to its securityholders as soon as practicable (which may be satisfied by filing with the Commission’s Electronic Data Gathering, Analysis and Retrieval System (“EDGAR”)), but in any event not later than sixteen months after the effective date of the Registration Statement (as defined in Rule 158(c) under the Act), an earnings statement of the Company and its subsidiaries (which need not be audited) complying with Section 11(a) of the Act and the rules and regulations of the Commission thereunder (including, at the option of the Company, Rule 158);

(e) (1) During the period beginning from the date of this Agreement and continuing to and including the date 180 days after the date of the Prospectus (the “Lock-Up Period”), not to (i) offer, sell, contract to sell, pledge, grant any option to purchase, loan, hedge, make any short sale or otherwise transfer or dispose of, directly or indirectly, or file with or confidentially submit to the Commission a registration statement under the Act relating to, any securities of the Company that are substantially similar to the Shares, including but not limited to any options or warrants to purchase shares of Stock or any securities that are convertible into or exchangeable for, or that represent the right to receive, Stock or any such substantially similar securities, (ii) enter into any hedging, swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise (other than the Shares to be sold hereunder or pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities outstanding as of, the date of this Agreement) or (iii) publicly disclose the intention to do any of the foregoing, in each case, without the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC; provided, however, that the restrictions in the foregoing sentence shall not apply to (a) the Shares to be sold hereunder; (b) shares of common stock or any securities (including without limitation options, restricted stock or restricted stock units) convertible into, or exercisable for, shares of common stock pursuant to any employee stock option plan, incentive plan, stock plan, dividend reinvestment plan or otherwise in equity compensation arrangements in place as of the Applicable Time and as described in the Pricing Disclosure Package; (c) the grant of awards pursuant to employee equity-based compensation plans, incentive plans, stock plans, or other arrangements in place as of the Applicable Time and as described in the Pricing Disclosure Package; (d) the filing of a registration statement on Form S-8 in connection with the registration of shares of common stock issuable under any employee equity-based compensation plan, incentive plan, stock plan, dividend reinvestment plan adopted and approved by the Company’s board of directors prior to the Applicable Time and as described in the Pricing Disclosure Package; (e) the issuance of up to five percent (5%) of the outstanding shares of common stock in connection with the acquisition of the assets of, or a majority or controlling portion of the equity of, or a joint venture with another entity in connection with its acquisition by the Company or any of its subsidiaries of such entity; and (f) the offering and sale of common stock pursuant to the concurrent private placement described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided that each recipient of any shares of common stock issued or sold pursuant to clause (b), (c), (e) or (f) above executes and delivers to the Representatives prior to such issuance or sale (as the case may be) an agreement having substantially the same terms as set forth in Annex II hereto;

(2) If Goldman Sachs & Co. LLC and Jefferies LLC, in their sole discretion, agree to release or waive the restrictions in lock-up letters delivered pursuant to Section 8(i) hereof for an officer or director of the Company and provide the Company with notice of the impending release or waiver at least three business days before the effective date of the release or waiver, the Company agrees, in each case, to announce the impending release or waiver by a press release substantially in the form of Annex I hereto through a major news service at least two business days before the effective date of the release or waiver;

(3) To enforce all existing agreements between the Company and any of its securityholders that prohibit the sale, transfer, assignment, pledge or hypothecation of any of the Company’s securities in connection with the Company’s initial public offering until, in respect of any particular securityholder, the earlier to occur of (i) the expiration of the Lock-Up Period or (ii) the expiration of any similar arrangement entered into by such securityholder with the Representatives; to direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such existing “lock-up,” “market stand-off,” “holdback” or similar provisions of such agreements for the duration of the periods contemplated in the preceding clause; and not to release or otherwise grant any waiver of such provisions in such agreements during such periods without the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC, on behalf of the Underwriters;

(f) During a period of three years from the effective date of the Registration Statement, so long as the Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act, to furnish to its stockholders as soon as practicable after the end of each fiscal year an annual report (including a balance sheet and statements of income, stockholders’ equity and cash flows of the Company and its consolidated subsidiaries certified by independent public accountants) and, as soon as practicable after the end of each of the first three quarters of each fiscal year (beginning with the fiscal quarter ending after the effective date of the Registration Statement), to make available to its stockholders consolidated summary financial information of the Company and its subsidiaries for such quarter in reasonable detail, provided that no reports, documents or other information need to be furnished pursuant to this Section 5(f) to the extent that they are available on the Commission’s EDGAR system;

(g) During a period of three years from the effective date of the Registration Statement, so long as the Company is subject to the reporting requirements of either Section 13 or Section 15(d) of the Exchange Act, to furnish to you copies of all reports or other communications (financial or other) furnished to stockholders, and to deliver to you (i) as soon as they are available, copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange on which any class of securities of the Company is listed; and (ii) such additional information concerning the business and financial condition of the Company as you may from time to time reasonably request (such financial statements to be on a consolidated basis to the extent the accounts of the Company and its subsidiaries are consolidated in reports furnished to its stockholders generally or to the Commission), provided that no reports, documents or other information need to be furnished pursuant to this Section 5(g) to the extent that they are available on the Commission’s EDGAR system;

(h) To use the net proceeds received by it from the sale of the Shares pursuant to this Agreement in the manner specified in the Pricing Prospectus under the caption “Use of Proceeds”;

(i) To use its best efforts to list for trading, subject to official notice of issuance, the Shares on the Exchange;

(j) To file with the Commission such information on Form 10-Q or Form 10-K as may be required by Rule 463 under the Act;

(k) If the Company elects to rely upon Rule 462(b) under the Act, the Company shall file a Rule 462(b) Registration Statement with the Commission in compliance with Rule 462(b) under the Act by 10:00 P.M., Washington, D.C. time, on the date of this Agreement, and the Company shall at the time of filing either pay to the Commission the filing fee for the Rule 462(b) Registration Statement or give irrevocable instructions for the payment of such fee pursuant to Rule 3a(c) of the Commission’s Informal and Other Procedures (16 CFR 202.3a);

(l) Upon reasonable request of any Underwriter, to furnish, or cause to be furnished, to such Underwriter an electronic version of the Company’s trademarks, servicemarks and corporate logo for use on the website, if any, operated by such Underwriter for the purpose of facilitating the on-line offering of the Shares (the “License”); provided, however, that the License shall be used solely for the purpose described above, is granted without any fee and may not be assigned or transferred;

(m) To promptly notify you if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of the Shares within the meaning of the Act and (ii) the last Time of Delivery.

(n) To deliver to each Underwriter (or its agent), on or before the date of execution of this Agreement, a properly completed and executed Certification Regarding Beneficial Owners of Legal Entity Customers, together with copies of identifying documentation, and the Company undertakes to provide such additional supporting documentation as each Underwriter may reasonably request in connection with the verification of the foregoing Certification;

(o) Neither the Company nor any of its subsidiaries or affiliates will take, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Shares; and

(p) To indemnify and hold harmless the Underwriters against any documentary, stamp, registration or similar issuance tax, including any interest and penalties, on the sale, issuance or delivery of the Shares by the Company to the Underwriters and on the execution and delivery of this Agreement.

6. (a) The Company represents and agrees that, without the prior consent of the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a “free writing prospectus” as defined in Rule 405 under the Act; each Underwriter represents and agrees that, without the prior consent of the Company and the Representatives, it has not made and will not make any offer relating to the Shares that would constitute a free writing prospectus required to be filed with the Commission; and any such free writing prospectus the use of which has been consented to by the Company and the Representatives is listed in Schedule II(a) hereto;

(b) The Company has complied and will comply with the requirements of Rule 433 under the Act applicable to any Issuer Free Writing Prospectus, including timely filing with the Commission or retention where required and legending; and the Company represents that it has satisfied and agrees that it will satisfy the conditions under Rule 433 under the Act to avoid a requirement to file with the Commission any electronic road show;

(c) The Company agrees that if at any time following issuance of an Issuer Free Writing Prospectus or Written Testing-the-Waters Communication any event occurred or occurs as a result of which such Issuer Free Writing Prospectus or Written Testing-the-Waters Communication would conflict with the information in the Registration Statement, the Pricing Prospectus or the Prospectus or would include an untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances then prevailing, not misleading, the Company will give prompt notice thereof to the Representatives and, if requested by the Representatives, will prepare and furnish without charge to each Underwriter an Issuer Free Writing Prospectus, Written Testing-the-Waters Communication or other document which will correct such conflict, statement or omission, provided, however, that this covenant shall not apply to any statements or omissions in a Written Testing-the-Waters Communication prepared or authorized by the Company made in reliance upon and in conformity with the Underwriter Information;

(d) The Company represents and agrees that (i) it has not engaged in, or authorized any other person to engage in, any Testing-the-Waters Communications, other than Testing-the-Waters Communications with the prior consent of the Representatives with entities that the Company reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Act, and (ii) it has not distributed, or authorized any other person to distribute, any Written Testing-the-Waters Communications, other than those distributed with the prior consent of the Representatives that are listed on Schedule III(d) hereto; and the Company reconfirms that the Underwriters have been authorized to act on its behalf in engaging in Testing-the-Waters Communications; and

(e) Each Underwriter represents and agrees that any Testing-the-Waters Communications undertaken by it were with entities that such Underwriter reasonably believes are qualified institutional buyers as defined in Rule 144A under the Act or institutions that are accredited investors as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12) or (a)(13) under the Act.

7. The Company covenants and agrees with the several Underwriters that the Company will pay or cause to be paid the following: (i) the fees, disbursements and expenses of the Company’s counsel and accountants in connection with the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing of the Registration Statement, any Preliminary Prospectus, any Written Testing-the-Waters Communication, any Issuer Free Writing Prospectus and the Prospectus and amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriters and dealers; (ii) the cost of printing or producing any agreement among Underwriters, this Agreement, the Blue Sky Memorandum, closing documents (including any compilations thereof) and any other documents in connection with the offering, purchase, sale and delivery of the Shares; (iii) all expenses in connection with the qualification of the Shares for offering and sale under state securities laws as provided in Section 5(b) hereof, including the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with such qualification and in connection with the Blue Sky survey; (iv) all fees and expenses in connection with listing the Shares on the Exchange; (v) the filing fees incident to, and the reasonable and documented fees and disbursements of counsel for the Underwriters in connection with, any required review by FINRA of the terms of the sale of the Shares, provided, however, that the reasonable and documented fees and disbursements of counsel for the Underwriters related to clauses (iii) and (v) shall not exceed $40,000 in the aggregate; (vi) the cost of preparing stock certificates; if applicable; (vii) the cost and charges of any transfer agent or registrar; (viii) the costs and expenses of the Company relating to investor presentations on any “road show” undertaken in

connection with the marketing of the offering of the Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives and officers of the Company and any such consultants, and 50% of the cost of any aircraft chartered in connection with the road show; (ix) all other costs and expenses incident to the performance of its obligations hereunder which are not otherwise specifically provided for in this Section; and (x) any documentary, stamp, registration or other similar taxes on the sale, issuance and delivery of the Shares to the Underwriters and on the execution and delivery of this Agreement. It is understood, however, that, except as provided in this Section, and Sections 9 and 12 hereof, the Underwriters will pay all of their own costs and expenses, including the fees of their counsel, stock transfer taxes on the resale of any of the Shares by them, any advertising expenses connected with any offers they may make and the travel and lodging expenses incurred by representatives of the Underwriters in connection with any road show.

8. The obligations of the Underwriters hereunder, as to the Shares to be delivered at each Time of Delivery, shall be subject, in their discretion, to the condition that all representations and warranties and other statements of the Company herein are, at and as of the Applicable Time and such Time of Delivery, true and correct, the condition that the Company shall have performed all of its obligations hereunder theretofore to be performed, and the following additional conditions:

(a) The Prospectus shall have been filed with the Commission pursuant to Rule 424(b) under the Act within the applicable time period prescribed for such filing by the rules and regulations under the Act and in accordance with Section 5(a) hereof; all material required to be filed by the Company pursuant to Rule 433(d) under the Act shall have been filed with the Commission within the applicable time period prescribed for such filing by Rule 433 under the Act; if the Company has elected to rely upon Rule 462(b) under the Act, the Rule 462(b) Registration Statement shall have become effective by 10:00 P.M., Washington, D.C. time, on the date of this Agreement; no stop order suspending the effectiveness of the Registration Statement or any part thereof shall have been issued and no proceeding for that purpose or pursuant to Section 8A of the Act shall have been initiated or threatened by the Commission; no stop order suspending or preventing the use of the Pricing Prospectus, Prospectus or any Issuer Free Writing Prospectus shall have been initiated or threatened by the Commission; and all requests for additional information on the part of the Commission shall have been complied with to your reasonable satisfaction;

(b) Cooley LLP, counsel for the Underwriters, shall have furnished to you such written opinion and negative assurance letter, dated such Time of Delivery, in form and substance satisfactory to you, and such counsel shall have received such papers and information as they may reasonably request to enable them to pass upon such matters;

(c) Goodwin Procter LLP, counsel for the Company, shall have furnished to you their written opinion and negative assurance letter, dated such Time of Delivery, in form and substance reasonably satisfactory to you;

(d) Goodwin Procter LLP, intellectual property counsel for the Company, shall have furnished to you their written opinion, dated such Time of Delivery, in form and substance reasonably satisfactory to you;

(e) On the date of the Prospectus at a time prior to the execution of this Agreement, at 9:30 a.m., New York time, on the effective date of any post-effective amendment to the Registration Statement filed subsequent to the date of this Agreement and also at each Time of Delivery, PricewaterhouseCoopers LLP shall have furnished to you a letter or letters, dated the respective dates of delivery thereof, in form and substance satisfactory to you;

(f) (i) Neither the Company nor any of its subsidiaries shall have sustained since the date of the latest audited financial statements included in the Pricing Prospectus any loss or interference with its business from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, otherwise than as set forth or contemplated in the Pricing Prospectus, and (ii) since the respective dates as of which information is given in the Pricing Prospectus there shall not have been any change in the capital stock (other than as a result of the exercise of stock options or the award of stock options or restricted stock in the ordinary course of business pursuant to the Company’s equity plans that are described in the Pricing Prospectus) or long-term debt of the Company or any of its subsidiaries or any change or effect, or any development involving a prospective change or effect, in or affecting (x) the business, properties, general affairs, management, financial position, stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, except as set forth or contemplated in the Pricing Prospectus, or (y) the ability of the Company to perform its obligations under this Agreement, including the issuance and sale of the Shares, or to consummate the transactions contemplated in the Pricing Prospectus and the Prospectus, the effect of which, in any such case described in clause (i) or (ii), is in your judgment so material and adverse as to make it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;

(g) On or after the Applicable Time there shall not have occurred any of the following: (i) a suspension or material limitation in trading in securities generally on the New York Stock Exchange or the Exchange; (ii) a suspension or material limitation in trading in the Company’s securities on the Exchange; (iii) a general moratorium on commercial banking activities declared by either Federal or New York State authorities or a material disruption in commercial banking or securities settlement or clearance services in the United States; (iv) the outbreak or escalation of hostilities involving the United States or the declaration by the United States of a national emergency or war or (v) the occurrence of any other calamity or crisis or any change in financial, political or economic conditions in the United States or elsewhere, if the effect of any such event specified in clause (iv) or (v) in your judgment makes it impracticable or inadvisable to proceed with the public offering or the delivery of the Shares being delivered at such Time of Delivery on the terms and in the manner contemplated in the Pricing Prospectus and the Prospectus;

(h) The Shares to be sold at such Time of Delivery shall have been duly listed, subject to official notice of issuance, on the Exchange;

(i) The Company shall have obtained and delivered to the Underwriters executed copies of an agreement from each (i) officer and director of the Company and (ii) other securityholders of the Company representing all outstanding securities of the Company, substantially to the effect set forth in Annex II hereto in form and substance satisfactory to you;

(j) The Company shall have complied with the provisions of Section 5(c) hereof with respect to the furnishing of prospectuses on the New York Business Day next succeeding the date of this Agreement; and

(k) The Company shall have furnished or caused to be furnished to you at such Time of Delivery certificates of officers of the Company satisfactory to you as to the accuracy of the representations and warranties of the Company herein at and as of such Time of Delivery, as to the performance by the Company of all of its obligations hereunder to be performed at or prior to such Time of Delivery, as to the matters set forth in subsections (a) and (f) of this Section 8 and as to such other matters as you may reasonably request.

9. (a) The Company will indemnify and hold harmless each Underwriter against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, any Issuer Free Writing Prospectus, any “roadshow” as defined in Rule 433(h) under the Act (a “roadshow”), any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Act or any Testing-the-Waters Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, and will reimburse each Underwriter for any legal or other expenses reasonably incurred by such Underwriter in connection with investigating or defending any such action or claim as such expenses are incurred; provided, however, that the Company shall not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information.

(b) Each Underwriter, severally and not jointly, will indemnify and hold harmless the Company against any losses, claims, damages or liabilities to which the Company may become subject, under the Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Testing-the-Waters Communication, or arise out of or are based upon the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or the Prospectus, or any amendment or supplement thereto, or any Issuer Free Writing Prospectus, or any roadshow or any Testing-the-Waters Communication, in reliance upon and in conformity with the Underwriter Information; and will reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending any such action or claim as such expenses are incurred. As used in this Agreement with respect to an Underwriter and an applicable document, “Underwriter Information” shall mean the written information furnished to the Company by such Underwriter through the Representatives expressly for use therein; it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the concession and reallowance figures appearing in the [•] paragraph under the caption “Underwriting,” and the information contained in the [•] paragraph under the caption “Underwriting.”

(c) Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection, notify the indemnifying party in writing of the commencement thereof; provided that the failure to notify the indemnifying party shall not relieve it from any liability that it may have under the preceding paragraphs of this Section 9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided further that the failure to notify the indemnifying party shall not relieve it from any liability that it may have to an indemnified party otherwise than under the preceding paragraphs of this Section 9. In case any such action shall be brought against any indemnified party and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be entitled to participate therein and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and, after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party shall not be liable to such indemnified party under such subsection for any reasonable and documented legal expenses of other counsel or any other reasonable and documented expenses, in each case, subsequently incurred by such indemnified party, in connection with the defense thereof other than reasonable costs of investigation. No indemnifying party shall, without the written consent of the indemnified party, effect the settlement or compromise of, or consent to the entry of any judgment with respect to, any pending or threatened action or claim in respect of which indemnification or contribution may be sought hereunder (whether or not the indemnified party is an actual or potential party to such action or claim) unless such settlement, compromise or judgment (i) includes an unconditional release of the indemnified party from all liability arising out of such action or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.

(d) If the indemnification provided for in this Section 9 is unavailable to or insufficient to hold harmless an indemnified party under subsection (a) or (b) above in respect of any losses, claims, damages or liabilities (or actions in respect thereof) referred to therein, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of such losses, claims, damages or liabilities (or actions in respect thereof) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriters on the other from the offering of the Shares. If, however, the allocation provided by the immediately preceding sentence is not permitted by applicable law, then each indemnifying party shall contribute to such amount paid or payable by such indemnified party in such proportion as is appropriate to reflect not only such relative benefits but also the relative fault of the Company on the one hand and the Underwriters on the other in connection with the statements or omissions which resulted in such losses, claims, damages or liabilities (or actions in respect thereof), as well as any other relevant equitable considerations. The relative benefits received by the Company on the one hand and the Underwriters on the other shall be deemed to be in the same proportion as the total net proceeds from the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by the Underwriters, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by reference to, among other things, whether the untrue or

alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company on the one hand or the Underwriters on the other and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and equitable if contribution pursuant to this subsection (d) were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation which does not take account of the equitable considerations referred to above in this subsection (d). The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this subsection (d) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this subsection (d), no Underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds the amount of any damages which such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters’ obligations in this subsection (d) to contribute are several in proportion to their respective underwriting obligations and not joint.

(e) The obligations of the Company under this Section 9 shall be in addition to any liability which the Company may otherwise have and shall extend, upon the same terms and conditions, to each employee, officer and director of each Underwriter and each person, if any, who controls any Underwriter within the meaning of the Act and each broker-dealer or other affiliate of any Underwriter; and the obligations of the Underwriters under this Section 9 shall be in addition to any liability which the respective Underwriters may otherwise have and shall extend, upon the same terms and conditions, to each officer and director of the Company (including any person who, with his or her consent, is named in the Registration Statement as about to become a director of the Company) and to each person, if any, who controls the Company within the meaning of the Act.

10. (a) If any Underwriter shall default in its obligation to purchase the Shares that it has agreed to purchase hereunder at a Time of Delivery, you may in your discretion arrange for you or another party or other parties to purchase such Shares on the terms contained herein. If within thirty-six hours after such default by any Underwriter you do not arrange for the purchase of such Shares, then the Company shall be entitled to a further period of thirty-six hours within which to procure another party or other parties satisfactory to you to purchase such Shares on such terms. In the event that, within the respective prescribed periods, you notify the Company that you have so arranged for the purchase of such Shares, or the Company notifies you that it has so arranged for the purchase of such Shares, you or the Company shall have the right to postpone such Time of Delivery for a period of not more than seven days, in order to effect whatever changes may thereby be made necessary in the Registration Statement or the Prospectus, or in any other documents or arrangements, and the Company agrees to file promptly any amendments or supplements to the Registration Statement or the Prospectus which in your opinion may thereby be made necessary. The term “Underwriter” as used in this Agreement shall include any person substituted under this Section with like effect as if such person had originally been a party to this Agreement with respect to such Shares.

(b) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased does not exceed one-eleventh of the aggregate number of all the Shares to be purchased at such Time of Delivery, then the Company shall have the right to require each non-defaulting Underwriter to purchase the number of Shares which such Underwriter agreed to purchase hereunder at such Time of Delivery and, in addition, to require each non-defaulting Underwriter to purchase its pro rata share (based on the number of Shares which such Underwriter agreed to purchase hereunder) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made; but nothing herein shall relieve a defaulting Underwriter from liability for its default.

(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by you and the Company as provided in subsection (a) above, the aggregate number of such Shares which remains unpurchased exceeds one-eleventh of the aggregate number of all of the Shares to be purchased at such Time of Delivery, or if the Company shall not exercise the right described in subsection (b) above to require non-defaulting Underwriters to purchase Shares of a defaulting Underwriter or Underwriters, then this Agreement (or, with respect to the Second Time of Delivery, the obligations of the Underwriters to purchase and of the Company to sell the Optional Shares) shall thereupon terminate, without liability on the part of any non-defaulting Underwriter or the Company, except for the expenses to be borne by the Company and the Underwriters as provided in Section 7 hereof and the indemnity and contribution agreements in Section 9 hereof; but nothing herein shall relieve a defaulting Underwriter from liability for its default.

11. The respective indemnities, rights of contribution, agreements, representations, warranties and other statements of the Company and the several Underwriters, as set forth in this Agreement or made by or on behalf of them, respectively, pursuant to this Agreement, shall remain in full force and effect, regardless of any investigation (or any statement as to the results thereof) made by or on behalf of any Underwriter or any director, officer, employee, broker-dealer, affiliate or controlling person of any Underwriter, or the Company, or any officer or director or controlling person of the Company, and shall survive delivery of and payment for the Shares.

12. If this Agreement shall be terminated pursuant to Section 10 hereof, the Company shall not then be under any liability to any Underwriter except as provided in Sections 7 and 9 hereof; but, if for any other reason, any Shares are not delivered by or on behalf of the Company as provided herein, or the Underwriters decline to purchase the Shares for any reason permitted under this Agreement, the Company will reimburse the Underwriters through you for all out-of-pocket expenses approved in writing by you, including fees and disbursements of counsel, reasonably incurred by the Underwriters in making preparations for the purchase, sale and delivery of the Shares not so delivered, but the Company shall then be under no further liability to any Underwriter except as provided in Sections 7 and 9 hereof.

13. In all dealings hereunder, the Representatives shall act on behalf of each of the Underwriters, and the parties hereto shall be entitled to act and rely upon any statement, request, notice or agreement on behalf of any Underwriter made or given by you jointly or by Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated on behalf of you as the Representatives.

All statements, requests, notices and agreements hereunder shall be in writing, and (A) if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to the Representatives (i) in care of Goldman Sachs & Co. LLC, at 200 West Street, New York, New York 10282-2198, Attention: Registration Department, (ii) in care of Jefferies LLC, at 520 Madison Avenue, New York, New York 10022, Attention: General Counsel, (iii) in care TD Securities (USA) LLC, at 1 Vanderbilt Avenue, New York, New York 10017, Attention: Head of Equity Capital Markets, Fax: 646-562-1249 with a copy to the General Counsel, Fax: 646-562-1130 and (iv) Stifel, Nicolaus & Company, Incorporated, at 787 7^th Avenue, 11^th Floor, New York, New York 10019, Attention: Equity Capital Markets; (B) if to the Company shall be delivered or sent by mail, telex or facsimile transmission to the address of the Company set forth on the cover of the Registration Statement, Attention: Chief Financial Officer, with a copy to Goodwin Procter LLP, 100 Northern Avenue, Boston, Massachusetts 02210, Attention: Kingsley L. Taft and Stephanie A. Richards; provided, however, that any notice to an Underwriter pursuant to Section 9(c) hereof shall be delivered or sent by mail, telex or facsimile transmission to such Underwriter at its address set forth in its Underwriters’ Questionnaire, or telex constituting such Questionnaire, which address will be supplied to the Company by you upon request; provided further, however, that notices under subsection 5(e) shall be in writing, and if to the Underwriters shall be delivered or sent by mail, telex or facsimile transmission to (i) Goldman Sachs & Co. LLC, 200 West Street, New York, New York 10282-2198, Attention: Control Room; (ii) Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: General Counsel. Any such statements, requests, notices or agreements shall take effect upon receipt thereof.

In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients.

14. This Agreement shall be binding upon, and inure solely to the benefit of, the Underwriters, the Company and, to the extent provided in Sections 9 and 11 hereof, the officers and directors of the Company and each person who controls the Company or any Underwriter, or any director, officer, employee, broker-dealer or affiliate of any Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of any of the Shares from any Underwriter shall be deemed a successor or assign by reason merely of such purchase.

15. Time shall be of the essence of this Agreement. As used herein, the term “business day” shall mean any day when the Commission’s office in Washington, D.C. is open for business.

16. The Company acknowledges and agrees that (i) the purchase and sale of the Shares pursuant to this Agreement is an arm’s-length commercial transaction between the Company, on the one hand, and the several Underwriters, on the other, and does not constitute a recommendation, investment advice, or solicitation of any action by the Underwriters, (ii) in connection therewith and with the process leading to such transaction each Underwriter is acting solely as a principal and not the agent or fiduciary of the Company, (iii) no Underwriter has assumed an advisory or fiduciary responsibility in favor of the Company with respect to the offering contemplated hereby or the process leading thereto (irrespective of whether such Underwriter has advised or is currently advising the Company on other matters) or any other obligation to the

Company except the obligations expressly set forth in this Agreement, (iv) the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, (iv) the Underwriters have not provided any legal, accounting, regulatory, investment or tax advice with respect to the offering of the Shares and the Company has consulted its own legal, accounting, financial, regulatory and tax advisors to the extent it deemed appropriate, and (v) none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes a recommendation, investment advice, or solicitation of any action by the Underwriters with respect to any entity or natural person. The Company agrees that it will not claim that the Underwriters, or any of them, has rendered advisory services of any nature or respect, or owes a fiduciary or similar duty to the Company, in connection with such transaction or the process leading thereto.

17. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof.

18. This Agreement and any transaction contemplated by this Agreement and any claim, controversy or dispute arising under or related thereto shall be governed by and construed in accordance with the laws of the State of New York without regard to principles of conflict of laws that would result in the application of any other law than the laws of the State of New York. The Company agrees that any suit or proceeding arising in respect of this Agreement or any transaction contemplated by this Agreement will be tried exclusively in the U.S. District Court for the Southern District of New York or, if that court does not have subject matter jurisdiction, in any state court located in The City and County of New York and the Company agrees to submit to the jurisdiction of, and to venue in, such courts.

19. The Company and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.

20. This Agreement may be executed by any one or more of the parties hereto in any number of counterparts, each of which shall be deemed to be an original, but all such counterparts shall together constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

21. Notwithstanding anything herein to the contrary, the Company is authorized to disclose to any persons the U.S. federal and state income tax treatment and tax structure of the potential transaction and all materials of any kind (including tax opinions and other tax analyses) provided to the Company relating to that treatment and structure, without the Underwriters imposing any limitation of any kind. However, any information relating to the tax treatment and tax structure shall remain confidential (and the foregoing sentence shall not apply) to the extent necessary to enable any person to comply with securities laws. For this purpose, “tax structure” is limited to any facts that may be relevant to that treatment.

22. Recognition of the U.S. Special Resolution Regimes.

(a) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States.

(b) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States.

“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

“Covered Entity” means any of the following:

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

If the foregoing is in accordance with your understanding, please sign and return to us one for the Company and each of the Representatives plus one for each counsel counterparts hereof, and upon the acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on your part as to the authority of the signers thereof.


Very truly yours,

Rapport Therapeutics, Inc.

By:
Name:
Title:


Accepted as of the date hereof:

Goldman Sachs & Co. LLC

By:
Name:
Title:

Jefferies LLC

By:
Name:
Title:

TD Securities (USA) LLC

By:
Name:
Title:

Stifel, Nicolaus & Company, Incorporated

By:
Name:
Title:

On behalf of each of the Underwriters

SCHEDULE I


Underwriter	Total Number of Firm Shares to be Purchased	Number of Optional Shares to be Purchased if Maximum Option Exercised
Goldman Sachs & Co. LLC	[•]	[•]
Jefferies LLC	[•]	[•]
TD Securities (USA) LLC	[•]	[•]
Stifel, Nicolaus & Company, Incorporated	[•]	[•]
[•]
Total

SCHEDULE II

(a) Issuer Free Writing Prospectuses not included in the Pricing Disclosure Package:

[Electronic Roadshow dated [•], 2024.]

(b) Additional Documents Incorporated by Reference:

[None]

The initial public offering price per share for the Shares is $[•]

The number of Shares purchased by the Underwriters is [•].

[Add any other pricing disclosure.]

(d)	Written Testing-the-Waters Communications:

[To add TTW Presentations]

ANNEX I

FORM OF PRESS RELEASE

Rapport Therapeutics, Inc.

[Date]

Rapport Therapeutics, Inc. (the “Company”) announced today that Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated, the lead book-running managers in the Company’s recent public sale of shares of common stock, are [waiving] [releasing] a lock-up restriction with respect to shares of the Company’s common stock held by [certain officers or directors] [an officer or director] of the Company. The [waiver] [release] will take effect on [date], and the shares may be sold on or after such date.

This press release is not an offer for sale of the securities in the United States or in any other jurisdiction where such offer is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended.

ANNEX II

FORM OF LOCK-UP AGREEMENT

RAPPORT THERAPEUTICS, INC.

Lock-Up Agreement

[•], 2024

Goldman Sachs & Co. LLC

Jefferies LLC

TD Securities (USA) LLC

Stifel, Nicolaus & Company, Incorporated

As Representatives of the several Underwriters

named in Schedule I to the Underwriting Agreement

c/o Goldman Sachs & Co. LLC

200 West Street

New York, NY 10282-2198

c/o Jefferies LLC

520 Madison Avenue

New York, NY 10022

c/o TD Securities (USA) LLC

1 Vanderbilt Avenue

New York, NY 10017

c/o Stifel, Nicolaus & Company, Incorporated

787 7^th Avenue, 11^th Floor

New York, NY 10019

Re:

Rapport Therapeutics, Inc. - Lock-Up Agreement

Ladies and Gentlemen:

The undersigned understands that you, as representatives (the “Representatives”), propose to enter into an underwriting agreement (the “Underwriting Agreement”) on behalf of the several Underwriters named in Schedule I to such agreement (collectively, the “Underwriters”), with Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), providing for a public offering (the “Public Offering”) of shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”) pursuant to a Registration Statement on Form S-1 (the “Registration Statement”) to be filed with the Securities and Exchange Commission (the “SEC”).

In consideration of the agreement by the Underwriters to offer and sell the Shares, and of other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, the undersigned agrees that, during the period beginning from the date of this Lock-Up Agreement and continuing to and including the date 180 days after the date of the final prospectus relating to the Public Offering (the “Prospectus”) (such period, the “Lock-Up Period”), the undersigned shall not, and shall not cause or direct any of its affiliates to, (i) offer, sell, contract to sell, pledge, grant any option, right or warrant to purchase, purchase any option or contract to sell, lend or otherwise transfer or dispose of any shares of Common Stock, or any options or warrants to purchase any shares of Common Stock, or any securities convertible into, exchangeable for or that represent the right to receive shares of Common Stock (such shares of Common Stock, options, rights, warrants or other securities, collectively, “Lock-Up Securities”), including without limitation any such Lock-Up Securities now owned or hereafter acquired by the undersigned, (ii) engage in any hedging or other transaction or arrangement (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument, however described or defined) which is designed to or which reasonably could be expected to lead to or result in a sale, loan, pledge or other disposition (whether by the undersigned or someone other than the undersigned), or transfer of any of the economic consequences of ownership, in whole or in part, directly or indirectly, of any Lock-Up Securities, whether any such transaction or arrangement (or instrument provided for thereunder) would be settled by delivery of Common Stock or other securities, in cash or otherwise (any such sale, loan, pledge or other disposition, or transfer of economic consequences, a “Transfer”), (iii) make any demand for or exercise any right with respect to the registration of any Lock-Up Securities or (iv) otherwise publicly announce any intention to engage in or cause any action, activity, transaction or arrangement described in clause (i), (ii) or (iii) above. The undersigned represents and warrants that the undersigned is not, and has not caused or directed any of its affiliates to be or become, currently a party to any agreement or arrangement that provides for, is designed to or reasonably could be expected to lead to or result in any Transfer during the Lock-Up Period.

Notwithstanding the foregoing, the undersigned may:

(a) transfer the undersigned’s Lock-Up Securities

as one or more bona fide gifts or charitable contributions, or for bona fide estate planning purposes;

ii.

upon death by will, testamentary document or intestate succession;

iii.

if the undersigned is a natural person, to any member of the undersigned’s immediate family (for purposes of this Lock-Up Agreement, “immediate family” shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin) or to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned or, if the undersigned is a trust, to a trustor or beneficiary of the trust or the estate of a beneficiary of such trust;

iv.

to a corporation, partnership, limited liability company or other entity of which the undersigned and the immediate family of the undersigned are the legal and beneficial owner of all of the outstanding equity securities or similar interests;

to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (a)(i) through (iv) above;

vi.

if the undersigned is a corporation, partnership, limited liability company or other business entity, (A) to another corporation, partnership, limited liability company or other business entity that is a subsidiary or an affiliate (as defined in Rule 405 under the Securities Act of 1933, as amended) of the undersigned, or to any investment fund or other entity which fund or entity is controlled or managed by the undersigned or affiliates of the undersigned (including, for the avoidance of doubt, where the undersigned is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B) as part of a disposition, transfer or distribution by the undersigned to its stockholders, partners, members or other equityholders or to the estate of any such stockholders, partners, members or other equityholders;

vii.

by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation agreement;

viii.

to the Company from an employee of the Company upon death, disability or termination of employment, in each case, of such employee;

ix.

if the undersigned is not an officer or director of the Company, in connection with a sale of the undersigned’s shares of Common Stock acquired (A) from the Underwriters in the Public Offering or (B) in open market transactions after the closing date of the Public Offering;

to the Company in connection with the vesting, settlement or exercise of restricted stock units, options, warrants or other rights to purchase shares of Common Stock (including, in each case, by way of “net” or “cashless” exercise), including any transfer to the Company for the payment of tax withholdings or remittance payments due as a result of the vesting, settlement or exercise of such restricted stock units, options, warrants or other rights, or in connection with the conversion of convertible securities, in all such cases pursuant to equity awards granted under a stock incentive plan or other equity award plan, or pursuant to the terms of convertible securities, each as described in the Registration Statement, the preliminary prospectus relating to the Shares included in the Registration Statement immediately prior to the time the Underwriting Agreement is executed and the Prospectus, provided that any securities received upon such vesting, settlement, exercise or conversion shall be subject to the terms of this Lock-Up Agreement; or

xi.

with the prior written consent of Goldman Sachs & Co. LLC and Jefferies LLC on behalf of the Underwriters;

provided that (A) in the case of clauses (a)(i), (ii), (iii), (iv), (v) and (vi) above, such transfer or distribution shall not involve a disposition for value, (B) in the case of clauses (a)(i), (ii), (iii), (iv), (v), (vi) and (vii) above, it shall be a condition to the transfer or distribution that the donee, devisee, transferee or distributee, as the case may be, shall sign and deliver a lock-up agreement in the form of this Lock-Up Agreement, (C) in the case of clauses (a)(ii), (iii), (iv), (v) and (vi) above, no filing by any party (including, without limitation, any donor, donee, devisee, transferor, transferee, distributor or distributee) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other public filing, report or announcement reporting a reduction in beneficial ownership of Lock-Up Securities shall be required or shall be voluntarily made in connection with such transfer or distribution, and (D) in the case of clauses (a)(i), (vii), (viii), (ix) and (x) above, no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto (A) the circumstances of such transfer or distribution and (B) in the case of a transfer or distribution pursuant to clauses (a)(i) or (a)(vii) above, that the donee, devisee, transferee or distributee has agreed to be bound by a lock-up agreement in the form of this Lock-Up Agreement;

(b)

transfer the undersigned’s Lock-Up Securities to the Company pursuant to an agreement under which the Company has the option to repurchase shares or a right of first refusal with respect to transfer of such shares, provided that no filing under the Exchange Act or other public filing, report or announcement shall be voluntarily made, and if any such filing, report or announcement shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto the circumstances of such transfer or distribution;

(c)

enter into a written plan meeting the requirements of Rule 10b5-1 under the Exchange Act relating to the transfer, sale or other disposition of the undersigned’s Lock-Up Securities, if then permitted by the Company, provided that none of the securities subject to such plan may be transferred, sold or otherwise disposed of until after the expiration of the Lock-Up Period and no public announcement, report or filing under the Exchange Act, or any other public filing, report or announcement, shall be voluntarily made regarding the establishment of such plan during the Lock-Up Period, and if any such filing, report or announcement shall be legally required during the Lock-Up Period, such filing, report or announcement shall clearly indicate in the footnotes thereto that that none of the securities subject to such plan may be transferred, sold or otherwise disposed of pursuant to such plan until after the expiration of the Lock-Up Period;

(d)

(i) transfer the undersigned’s Lock-Up Securities pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by the Board of Directors of the Company and made to all holders of the Company’s capital stock involving a Change of Control of the Company (for purposes hereof, “Change of Control” shall mean the transfer (whether by tender offer, merger, consolidation or other similar transaction), in one transaction or a series of related transactions, to a person or group of affiliated persons, of shares of capital stock if, after such transfer, such person or group of affiliated persons would hold at least a majority of the outstanding voting securities of the Company (or the surviving entity)) and (ii) enter into any lock-up, voting or similar agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Common Stock or such other securities in connection with a transaction described in clause (i) above; provided that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the undersigned’s Lock-Up Securities shall remain subject to the provisions of this Lock-Up Agreement; and

(e)

convert outstanding preferred stock of the Company into shares of Common Stock, provided that any such shares received upon such conversion shall remain subject to the provisions of this Lock-Up Agreement.

If the undersigned is an officer or director of the Company, the undersigned further agrees that the foregoing provisions shall be equally applicable to any issuer-directed or other Shares the undersigned may purchase in the Public Offering.

If the undersigned is not a natural person, the undersigned represents and warrants that no single natural person, entity or “group” (within the meaning of Section 13(d)(3) of the Exchange Act), other than a natural person, entity or “group” (as described above) that has executed a Lock-Up Agreement in substantially the same form as this Lock-Up Agreement, beneficially owns, directly or indirectly, 50% or more of the common equity interests, or 50% or more of the voting power, in the undersigned.

If the undersigned is an officer or director of the Company, (i) Goldman Sachs & Co. LLC and Jefferies LLC agree that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Lock-Up Securities, Goldman Sachs & Co. LLC and Jefferies LLC will notify the Company of the impending release or waiver, and (ii) the Company has agreed in the Underwriting Agreement to announce the impending release or waiver by press release through a major news service (or such other method approved by Goldman Sachs & Co. LLC and Jefferies LLC that satisfies the requirements of FINRA Rule 5131(d)(2)) at least two business days before the effective date of the release or waiver. Any release or waiver granted by Goldman Sachs & Co. LLC and Jefferies LLC hereunder to any such officer or director shall only be effective two business days after the publication date of such announcement. The provisions of this paragraph will not apply if (i) the release or waiver is effected solely to permit a transfer not for consideration or that is to an immediate family member as defined in FINRA Rule 5130(i)(5) and (ii) the transferee has agreed in writing to be bound by the same terms described in this Lock-Up Agreement to the extent and for the duration that such terms remain in effect at the time of the transfer.

The undersigned now has, and, except as contemplated by clauses (a) and (d) of the third paragraph of this Lock-Up Agreement, for the duration of this Lock-Up Agreement will have, good and marketable title to the undersigned’s Lock-Up Securities, free and clear of all liens, encumbrances and claims whatsoever. The undersigned also agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent and registrar against the transfer of the undersigned’s Lock-Up Securities except in compliance with the foregoing restrictions.

The undersigned acknowledges and agrees that none of the Underwriters has made any recommendation or provided any investment or other advice to the undersigned with respect to this Lock-Up Agreement or the subject matter hereof, and the undersigned has consulted its own legal, accounting, financial, regulatory, tax and other advisors with respect to this Lock-Up Agreement and the subject matter hereof to the extent the undersigned has deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may have provided or hereafter provide to the undersigned in connection with the Public Offering a Form CRS and/or certain other disclosures as contemplated by Regulation Best Interest, the Underwriters have not made and are not making a recommendation to the undersigned to enter into this Lock-Up Agreement or to transfer, sell or dispose of, or to refrain from transferring, selling or disposing of, any shares of Common Stock, and nothing set forth in such disclosures or herein is intended to suggest that any Underwriter is making such a recommendation.

This Lock-Up Agreement shall automatically terminate and the undersigned shall be released from all of his, her or its obligations hereunder upon the earlier of (i) the date on which the Registration Statement filed with the SEC with respect to the Public Offering is withdrawn, (ii) the date on which for any reason the Underwriting Agreement is terminated (other than the provisions thereof that survive termination) prior to payment for and delivery of the Shares to be sold thereunder (other than pursuant to the Underwriters’ option thereunder to purchase additional Shares), (iii) the date on which the Company notifies the Representatives, in writing and prior to the execution of the Underwriting Agreement, that it does not intend to proceed with the Public Offering and (iv) September 30, 2024, in the event that the Underwriting Agreement has not been executed by such date (provided, however, that the Company may, by written notice to the undersigned prior to such date, extend such date by a period of up to an additional 90 days).

The undersigned understands that the Company and the Underwriters are relying upon this Lock-Up Agreement in proceeding toward consummation of the Public Offering. The undersigned further understands that this Lock-Up Agreement is irrevocable and shall be binding upon the undersigned’s heirs, legal representatives, successors and assigns. The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement. This Lock-Up Agreement shall be governed by, and construed in accordance with, the laws of the State of New York,

without regard to principles of conflict of laws that would result in the application of any law other than the laws of the State of New York. This Lock-Up Agreement may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com or www.echosign.com) or other transmission method, and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

[Signature Page Follows]

Very truly yours,


IF AN INDIVIDUAL:		IF AN ENTITY:

By:
	(duly authorized signature)	(please print complete name of entity)

Name:		By:
	(please print full name)		(duly authorized signature)

		Name:
			(please print full name)

		Title:
			(please print full title)

[Signature Page to Lock-Up Agreement]

EX-3.1 3 d803738dex31.htm EX-3.1 EX-3.1

Exhibit 3.1

SECOND AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

RAPPORT THERAPEUTICS, INC.

(Pursuant to Sections 242 and 245 of the

General Corporation Law of the State of Delaware)

Rapport Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”).

DOES HEREBY CERTIFY:

1. That the name of this corporation is Rapport Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on February 10, 2022 under the name Precision Neuroscience NewCo, Inc. The name of the corporation was changed on October 7, 2022 to Rapport Therapeutics, Inc. The corporation’s certificate of incorporation was amended by that certain certificates of amendment dated as of May 10, 2022, August 9, 2022, October 7, 2022 and November 28, 2022 and further amended by that certain Amended and Restated Certificate of Incorporation dated as of December 9, 2022.

2. That the Board of Directors (as defined below) duly adopted resolutions proposing to amend and restate the Amended and Restated Certificate of Incorporation (as defined below) of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows:

RESOLVED, that the Amended and Restated Certificate of Incorporation of this corporation, as amended, be amended and restated in its entirety to read as follows:

FIRST: The name of this corporation is Rapport Therapeutics, Inc. (the “Corporation”).

SECOND: The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.

THIRD: The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law.

FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 250,000,000 shares of Common Stock, $0.001 par value per share (“Common Stock”) and (ii) 189,613,384 shares of Preferred Stock, $0.001 par value per share (“Preferred Stock”).

The following is a statement of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation.

A. COMMON STOCK

1. General. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and preferences of the holders of the Preferred Stock set forth herein.

2. Voting. The holders of the Common Stock are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to the Corporation’s Certificate of Incorporation (as amended and/or restated from time to time, the “Certificate of Incorporation”) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation Law.There shall be no cumulative voting.The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the Corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the General Corporation Law.

B. PREFERRED STOCK

Preferred Stock may be issued from time to time in one or more series, each of such series to consist of such number of shares and to have such terms, rights, powers and preferences, and the qualifications and limitations with respect thereto, as stated or expressed herein.

100,182,354 shares of the authorized Preferred Stock of the Corporation are hereby designated the “Series A Preferred Stock” and 89,431,030 shares of the authorized Preferred Stock of the Corporation are hereby designated “Series B Preferred Stock”, each with the following rights, preferences, powers, privileges and restrictions, qualifications and limitations. Unless otherwise indicated, references to “sections” or “subsections” in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth. The Series A Preferred Stock and the Series B Preferred Stock may be referred to collectively as the “Preferred Stock.”

1. Dividends.

The holders of then outstanding shares of Preferred Stock shall be entitled to receive, only when, as and if declared by the Board of Directors, out of any funds and assets legally available therefor, dividends at the rate of 8% of the Applicable Original Issue Price (as defined below) for each share of Preferred Stock from and after the Filing Date, prior and in preference to any declaration or payment of any other dividend (other than dividends on shares of Common Stock payable in shares of Common Stock). The right to receive dividends on shares of Preferred Stock pursuant to the preceding sentence of this Section 1 shall not be cumulative, and no right to dividends shall accrue to holders of Preferred Stock by reason of the fact that dividends on said shares are not declared. The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in this Amended and Restated Certificate of Incorporation) the holders of the Preferred Stock then outstanding shall first receive, or simultaneously receive, in addition to the dividends payable pursuant to the first sentence of this Section 1, a dividend on each outstanding share of Preferred Stock in an amount at least equal to (i) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Preferred Stock as would equal the product of (A) the dividend payable on each share of such class or series determined, if applicable, as if all

shares of such class or series had been converted into Common Stock and (B) the number of shares of Common Stock issuable upon conversion of a share of such class or series of Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (ii) in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Preferred Stock determined by (A) dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (B) multiplying such fraction by an amount equal to the Applicable Original Issue Price (as defined below); provided that, if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one (1) class or series of capital stock of the Corporation, the dividend payable to the holders of Preferred Stock pursuant to this Section 1 shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Preferred Stock dividend. As of the date and time of the filing of the Certificate of Incorporation (such date and time, the “Filing Date”), the “Series A Original Issue Price” shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock occurring after the Filing Date. As of the Filing Date, the “Series B Original Issue Price” shall mean $1.67727 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred Stock occurring after the Filing Date. The Series A Original Issue Price, in the case of the Series A Preferred Stock, and the Series B Original Issue Price in the case of the Series B Preferred Stock, are individually or collectively, as applicable, referred to herein as the “Applicable Original Issue Price.”

2. Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales.

2.1 Preferential Payments to Holders of Preferred Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of shares of Preferred Stock then outstanding shall be entitled to be paid, pari passu among the series of Preferred Stock, out of the assets of the Corporation available for distribution to its stockholders, and in the event of a Deemed Liquidation Event (as defined below), the holders of shares of Preferred Stock then outstanding shall be entitled to be paid, pari passu among the series of Preferred Stock, out of the assets of the consideration payable to stockholders in such Deemed Liquidation Event or out of the Available Proceeds (as defined below), as applicable, before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i) the Applicable Original Issue Price, plus any dividends declared but unpaid thereon,or (ii) such amount per share as would have been payable had all shares of Series A Preferred Stock or Series B Preferred Stock, as applicable, been converted into Common Stock pursuant to Section 4 immediately prior to such liquidation, dissolution, winding up of the Corporation or Deemed Liquidation Event. The amount which a holder of a share of Preferred Stock is entitled to receive pursuant to the first sentence of this Subsection 2.1 in the case of the Series A Preferred Stock is hereinafter referred to as the “Series A Liquidation Amount” and in the case of the Series B Preferred Stock is hereinafter referred to as the “Series B Liquidation Amount”. “Applicable Liquidation Amount” refers to the Series A Liquidation Amount with respect to the Series A Preferred Stock and the Series B Liquidation Amount with respect to the Series B Preferred Stock. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Preferred Stock the full amount to which they shall be entitled under this Subsection 2.1, the holders of shares of Preferred Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full.

2.2 Payments to Holders of Common Stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, after the payment in full of all Applicable Liquidation Amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation available for distribution to its stockholders or, in the case of a Deemed Liquidation Event, the consideration not payable to holders of shares of Preferred Stock pursuant to Section 2.1 or the remaining Available Proceeds, as the case may be, shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder.

2.3 Deemed Liquidation Events.

2.3.1 Definition. Each of the following events shall be considered a “Deemed Liquidation Event” unless the holders of (i) a majority of the then outstanding shares of Preferred Stock, voting or consenting together as a single class on an as-converted basis, and (ii) a majority the then outstanding shares of Series B Preferred Stock, voting as a separate, exclusive class (clauses (i) and (ii) collectively, the “Required Vote”), elect otherwise by written notice sent to the Corporation at least ten (10) days prior to the effective date of any such event:

(a) a merger or consolidationin which

(i) the Corporation is a constituent party or

(ii) a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock pursuant to such merger or consolidation, except any such merger or consolidation involving the Corporation or a subsidiary in which the shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or consolidation, at least a majority, by voting power, of the capital stock of (1) the surviving or resulting corporation; or (2) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such merger or consolidation, the parent corporation of such surviving or resulting corporation;

(b) (1) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets of the Corporation and its subsidiaries taken as a wholeor (2) the sale or disposition (whether by merger, consolidation or otherwise, and whether in a single transaction or a series of related transactions) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation;

(c) The closing of the transfer in one transaction or series of related transactions to a group of affiliated persons (other than an underwriter of the Corporation’s securities), of the Corporation’s securities if, after such closing, such person or group of affiliated persons would hold shares fifty percent (50%) or more of the outstanding voting stock of the Corporation (or surviving entity) other than in connection with a bona fide equity financing primarily for capital raising purposes; or

(d) any merger or consolidation in connection with a SPAC Transaction (as defined below) or Reverse Merger Transaction (as defined below):

“SPAC Transaction” is any business combination pursuant to which the Corporation is merged into, or otherwise combines with, a special purpose acquisition company (a “SPAC”) listed on a “national securities exchange”, or a subsidiary of such SPAC, and the shares of capital stock of the Corporation

outstanding immediately prior to such transaction continue to represent, or are converted into or exchanged for shares of capital stock (or securities convertible into or exchangeable for shares of capital stock) that represent, immediately following such combination, a majority, by voting power, of the capital stock of (A) the surviving or resulting corporation; or (B) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such combination or consolidation, the parent corporation of such surviving or resulting corporation; provided that the cash resources of the SPAC, excluding the cash resources of the Corporation, but inclusive of amounts released from the SPAC’s associated trust fund and other proceeds to the SPAC from contemporaneous sales of securities upon the consummation of the SPAC’s business combination with the Corporation, exceeds $10,000,000.

“Reverse Merger Transaction” is any business combination pursuant to which the Corporation is merged into, or otherwise combines with, a public company (a “Pubco”) listed on a “national securities exchange”, or a subsidiary of such Pubco, and the shares of capital stock of the Corporation outstanding immediately prior to such transaction continue to represent, or are converted into or exchanged for shares of capital stock (or securities convertible into or exchangeable for shares of capital stock) that represent, immediately following such combination, a majority, by voting power, of the capital stock of (A) the surviving or resulting corporation; or (B) if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such combination or consolidation, the parent corporation of such surviving or resulting corporation, provided that the cash resources of the Pubco, excluding the cash resources of the Corporation, but inclusive of proceeds to the Pubco or the Corporation from contemporaneous sales of securities upon the consummation of the Reverse Merger Transaction, exceeds $10,000,000.

2.3.2 Effecting a Deemed Liquidation Event; Redemption.

(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in Subsection 2.3.1(a)(i) above unless the agreement or plan of merger or consolidation for such transaction (the “Merger Agreement”) provides that the consideration payable to the stockholders of the Corporation in such Deemed Liquidation Event shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1 and 2.2 above.

(b) In the event of a Deemed Liquidation Event referred to in Subsection 2.3.1(a)(ii), or 2.3.1(b) above, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within thirty (30) days after such Deemed Liquidation Event, then (i) the Corporation shall send a written notice to each holder of Preferred Stock no later than the thirtieth (30^th) day after the Deemed Liquidation Event advising such holders of their right (and the requirements to be met to secure such right) pursuant to the terms of the following clause (ii) to require the redemption of such shares of Preferred Stock, and (ii) if the holders representing the Required Vote request in a written instrument delivered to the Corporation, the Corporation shall use the consideration received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board of Directors of the Corporation (the “Board of Directors”) (together with any other assets of the Corporation available for distribution to its stockholders as determined in good faith by the Board of Directors, the “Available Proceeds”)), all to the extent permitted by Delaware law governing distributions to stockholders, on the sixtieth (60^th) day after such Deemed Liquidation Event (the “Redemption Date”), to redeem all outstanding shares of Preferred Stock at a price per share equal to the Applicable Liquidation Amount (the “Redemption Price”). Notwithstanding the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, or if the Corporation does not have sufficient lawfully available funds to effect such redemption, the Corporation shall ratably redeem a pro rata portion of each holder’s shares of Preferred Stock to the fullest extent of such Available Proceeds or such lawfully available funds, as the case may be, based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds or such lawfully available funds were sufficient to redeem all such shares, and shall redeem the

remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. The provisions of Subsections 2.3.2(c)(i) through 2.3.2(c)(iii) below shall apply to the redemption of the Preferred Stock pursuant to this Subsection 2.3.2(b). Prior to the distribution or redemption provided for in this Subsection 2.3.2(b), the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business.

(c) In connection with this Section 2.3.2 only, the holders of the Preferred Stock shall have redemption rights as follows:

(i) If on the Redemption Date, Delaware law governing distributions to stockholders prevents the Corporation from redeeming all shares of Preferred Stock to be redeemed, the Corporation shall ratably (in proportion to each holder’s respective aggregate Applicable Liquidation Amounts) redeem the maximum number of shares that it may redeem consistent with such law, and shall redeem the remaining shares as soon as it may lawfully do so under such law.

(ii) If on the applicable Redemption Date the applicable Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on such Redemption Date is paid or tendered for payment or deposited with an independent payment agent so as to be available therefor, then notwithstanding that the certificates evidencing any of the shares of Preferred Stock so called for redemption shall not have been surrendered, all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of the holders to receive the applicable Redemption Price without interest upon surrender of their certificate or certificates therefor.

(iii) Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption.

2.3.3 Amount Deemed Paid or Distributed. If the amount deemed paid or distributed under this Subsection 2.3 is made in property other than in cash, the value of such payment or distribution shall be the fair market value of such property, determined as follows:

(a) For securities not subject to investment letters or other similar restrictions on free marketability,

(i) if traded on a securities exchange, the value shall be deemed to be the average of the closing prices of the securities on such exchange or market over the 30-period ending three (3) days prior to the closing of such transaction;

(ii) if actively traded over-the-counter, the value shall be deemed to be the average of the closing bid prices over the 30-day period ending three (3) days prior to the closing of such transaction; or

(iii) if there is no active public market, the value shall be the fair market value thereof, as determined in good faith by the Board of Directors.

(b) The method of valuation of securities subject to investment letters or other similar restrictions on free marketability (other than restrictions arising solely by virtue of a stockholder’s status as an affiliate or former affiliate) shall take into account an appropriate discount (as determined in good faith by the Board of Directors) from the market value as determined pursuant to clause (a) above so as to reflect the approximate fair market value thereof.

(c) For any property not addressed by Subsection 2.3.3(a) or Subsection 2.3.3(b), the value of such property, shall be determined in good faith by the Board of Directors, including a majority of the Preferred Directors (as defined below).

2.3.4 Allocation of Escrow or Contingent Payments. In the event of a Deemed Liquidation Event pursuant to Subsection 2.3.1(a)(i), if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the “Additional Consideration”), the Merger Agreement shall provide that (a) the portion of such consideration that is not Additional Consideration (such portion, the “Initial Consideration”) shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1 and 2.2 as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event and (b) any Additional Consideration which becomes payable to the stockholders of the Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with Subsections 2.1 and 2.2 after taking into account the previous payment of the Initial Consideration as part of the same transaction. For the purposes of this Subsection 2.3.4, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations or otherwise subject to contingencies in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration.

3. Voting.

3.1 General. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Certificate of Incorporation, holders of Preferred Stock shall vote together with the holders of Common Stock as a single class and on an as-converted to Common Stock basis.

3.2 Election of Directors. The holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, shall be entitled to elect up to three (3) directors of the Corporation (each, a “Series A Director” and collectively, the “Series A Directors”). The holders of record of the shares of Series B Preferred Stock, exclusively and as a separate class, shall be entitled to elect up to two (2) directors of the Corporation (the “Series B Directors” and, together with the Series A Directors, the “Preferred Directors”). Any Preferred Directors elected as provided in the preceding sentences may be removed without cause by, and only by, the affirmative vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders in lieu of a meeting duly called for that purpose or pursuant to a written consent of stockholders.If the holders of shares of Preferred Stock fail to elect a sufficient number of directors to fill all directorships for which they are entitled to elect directors, voting exclusively and as a separate class, then any directorship not so filled shall remain vacant until such time as the holders of the Preferred Stock elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate class. The holders of record of the shares of Common Stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. Except as otherwise provided in this Subsection 3.2, a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series or by any remaining director or directors elected by the holders of such class or series pursuant to this Subsection 3.2.

3.3 Preferred Stock Protective Provisions. At any time when any shares of Preferred Stock are outstanding, the Corporation or any of its subsidiaries, shall not, either directly or indirectly by amendment, merger, consolidation, recapitalization, reclassification, statutory conversion or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the holders representing the Required Vote, given in writing or by vote at a meeting,and any such act or transaction entered into without such consent or vote shall be null and void ab initio, and of no force or effect.

3.3.1 liquidate, dissolve or wind-up the business and affairs of the Corporation, effect any merger, acquisition or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing;

3.3.2 amend, alter, waive or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation;

3.3.3 create or authorize the creation of or issue or obligate itself to issue shares of any other security convertible into or exercisable for any equity security or increase the authorized number of shares of Preferred Stock or of any additional class or series of capital stock unless it ranks junior to the Preferred Stock with respect to its rights, preferences and privileges;

3.3.4 (i) reclassify, alter or amend any existing security of the Corporation that is pari passu with the Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to the Preferred Stock in respect of any such right, preference, or privilege or (ii) reclassify, alter or amend any existing security of the Corporation that is junior to the A Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other security senior to or pari passu with the Preferred Stock in respect of any such right, preference or privilege;

3.3.5 purchase or redeem or pay or declare any dividend, other than dividends on the Preferred Stock, or make any distribution on any shares of capital stock prior to the Preferred Stock, other than Common Stock or Options to acquire Common Stock repurchased from former employees or consultants in connection with the cessation of their employment/services, pursuant to the provisions of existing plans or agreements;

3.3.6 create, adopt, amend, terminate or repeal any equity (or equity-linked) compensation plan;

3.3.7 increase or decrease the authorized number of directors constituting the Board of Directors;

3.3.8 create or hold capital stock in any subsidiary that is not a wholly-owned subsidiary of the Corporation or dispose of any subsidiary stock or all or substantially all of any subsidiary assets;

3.3.9 sell, assign, license, pledge or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or

3.3.10 issue shares of Series B Preferred Stock other than pursuant to the Purchase Agreement (as defined below).

4. Optional Conversion.

The holders of the Preferred Stock shall have conversion rights as follows (the “Conversion Rights”):

4.1 Right to Convert.

4.1.1 Conversion Ratio. Subject to the provisions of Section 4.1.3 below, each share of Preferred Stock shall be convertible, at the option of the holder thereof, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and non-assessable shares of Common Stock as is determined by dividing the Applicable Original Issue Priceby the Applicable Conversion Price (as defined below) in effect at the time of conversion; provided that such holder may waive such option to convert upon written notice to the Company. As of the Filing Date, the “Series A Conversion Price” is equal to $1.00. As of the Filing Date, the “Series B Conversion Price” is equal to $1.67727. The Series A Conversion Price, in the case of the Series A Preferred Stock, and the Series B Conversion Price in the case of the Series B Preferred Stock, are individually or collectively, as applicable, referred to herein as the “Applicable Conversion Price”.Such Applicable Conversion Price, and the rate at which shares of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below after the Filing Date.

4.1.2 Termination of Conversion Rights. In the event of a notice of redemption of any shares of Preferred Stock pursuant to Subsection 2.3.2(b), the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the Redemption Price is not fully paid on such Redemption Date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock; provided that the foregoing termination of Conversion Rights shall not affect the amount(s) otherwise paid or payable in accordance with Subsection 2.1 to holders of Preferred Stock pursuant to such liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event.

4.1.3 Non-Conversion Period. Notwithstanding anything to the contrary contained in the Certificate of Incorporation, a holder of Series B Preferred Stock shall not be entitled pursuant to this Section 4.1 to elect to convert shares of Series B Preferred Stock into shares of Common Stock at any time during the period commencing on the date and time of the first issuance of the Series B Preferred Stock and ending on the Business Day immediately following the earliest to occur of (i) the Second Tranche Closing (if such holder is not a Defaulting Purchaser), (ii) the Outside Date, (iii) the date such holder’s obligation to purchase its Second Tranche Shares is fulfilled whether by such holder or its Affiliates, (iv) the termination of such holder’s obligations to complete the Second Tranche Closing pursuant to the Purchase Agreement and (v) such date as agreed to by the Corporation and the holders of a majority of the then outstanding shares of Series B Preferred Stock, voting as a separate, exclusive class. Capitalized terms used in this Section 4.1.3 and not defined in this Section 4.1.3 shall have the meanings ascribed to such terms in the Purchase Agreement. For the avoidance of doubt, nothing in this Section 4.1.3 shall interfere with the treatment of the Series B Preferred Stock on an as-converted to Common Stock basis where the context so requires in the Certificate of Incorporation, including, without limitation, voting provisions and determination of the Series B Liquidation Amount.

4.2 Fractional Shares. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board of Directors. Whether or not fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock issuable upon such conversion.

4.3 Mechanics of Conversion.

4.3.1 Notice of Conversion. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of Common Stock, such holder shall (a) provide written notice to the Corporation’s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent) that such holder elects to convert all or any number of such holder’s shares of Preferred Stock and, if applicable, any event on which such conversion is contingent and (b), if such holder’s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent), together with written notice that such holder elects to convert all or any number of the shares of Preferred Stock represented by such certificate or certificates and, if applicable, any event on which such conversion is contingent. Such notice shall state such holder’s name or the names of the nominees in which such holder wishes the certificate or certificates for shares of Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the “Conversion Time”), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i) issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into Common Stock, (ii) pay in cash such amount as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii) pay all declared but unpaid dividends on the shares of Preferred Stock converted.

4.3.2 Reservation of Shares. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which would cause an adjustment reducing the Applicable Conversion Price below the then par value of the shares of Common Stock issuable upon conversion of the Preferred Stock, the Corporation will take any corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and non-assessable shares of Common Stock at such adjusted Applicable Conversion Price.

4.3.3 Effect of Conversion. All shares of Preferred Stock which shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders thereof to receive shares of Common Stock in exchange therefor, to receive payment of any dividends declared but unpaid thereon and to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in Subsection 4.2.Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

4.3.4 No Further Adjustment. Upon any such conversion, no adjustment to the Applicable Conversion Price shall be made for any dividends on the Preferred Stock surrendered for conversion or on the Common Stock delivered upon conversion.

4.3.5 Taxes. The Corporation shall pay any and all issue and other similar taxes that may be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this Section 4. The Corporation shall not, however, be required to pay any tax which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid.

4.4 Adjustments to Conversion Price for Diluting Issues.

4.4.1 Special Definitions. For purposes of this Article Fourth, the following definitions shall apply:

(a) “Option” shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or Convertible Securities.

(b) “Convertible Securities” shall mean any evidences of indebtedness, shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options.

(c) “Additional Shares of Common Stock” shall mean all shares of Common Stock issued (or, pursuant to Subsection 4.4.3 below, deemed to be issued) by the Corporation after the Filing Date, other than (1) the following shares of Common Stock and (2) shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1) and (2), collectively, “Exempted Securities”):

(i) shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on, or upon the conversion of, Preferred Stock and shares of Common Stock actually issued upon the exercise of such Options, or upon the conversion or exchange of such Convertible Securities or, in the case of Convertible Securities and Options therefor, upon the conversion or exchange of such Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;

(ii) shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock that is covered by Subsection 4.5, 4.6, 4.7 or 4.8 below, and shares of Common Stock actually issued upon the exercise of such Options, or upon the conversion or exchange of such Convertible Securities or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;

(iii) shares of Common Stock issued in a QPO (as defined below).

(iv) shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors, including a majority of the Preferred Directors, and shares of Common Stock actually issued upon the exercise or conversion of such Options, in each case provided such issuance is pursuant to the terms of such Option;

(v) shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors, including a majority of the Preferred Directors, and shares of Common Stock actually issued upon the exercise of such Options, or upon the conversion or exchange of such Convertible Securities or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security;

(vi) shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors, including a majority of the Preferred Directors, and shares of Common Stock issuable upon the exercise of such Options, or upon the conversion or exchange of such Convertible Securities or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security; and

(vii) shares of Common Stock, Options or Convertible Securities issued as acquisition consideration pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint venture agreement, provided that such issuances are approved by the Board of Directors, including a majority of the Preferred Directors, and shares of Common Stock issuable upon the exercise of such Options, or upon the conversion or exchange of such Convertible Securities or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, in each case provided such issuance is pursuant to the terms of such Option or Convertible Security.

4.4.2 No Adjustment of Applicable Conversion Price. No adjustment in the Applicable Conversion Price of a series of Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders representing the Required Vote agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock.

4.4.3 Deemed Issue of Additional Shares of Common Stock.

(a) If the Corporation at any time or from time to time after the Filing Date shall issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such Options or Convertible Securities, then the

maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date.

(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Applicable Conversion Price pursuant to the terms of Subsection 4.4.4, are revised as a result of an amendment to such terms or if any other adjustment is made pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security)to provide for either (1) any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any such Option or Convertible Security or (2) any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming effective, the Applicable Conversion Price computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Applicable Conversion Price as would have been obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this clause (b) shall have the effect of increasing the Applicable Conversion Price to an amount which exceeds the lower of (i) the Applicable Conversion Price in effect immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii) the Applicable Conversion Price that would have resulted from any issuances of Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date.

(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities), the issuance of which did not result in an adjustment to the Applicable Conversion Price pursuant to the terms of Subsection 4.4.4 (either because the consideration per share (determined pursuant to Subsection 4.4.5) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Applicable Conversion Price then in effect, or because such Option or Convertible Security was issued before the Filing Date), are revised after the Filing Date as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security)to provide for either (1) any increase in the number of shares of Common Stock issuable upon the exercise, conversion or exchange of any such Option or Convertible Security or (2) any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the Additional Shares of Common Stock subject thereto (determined in the manner provided in Subsection 4.4.3(a)) shall be deemed to have been issued effective upon such increase or decrease becoming effective.

(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Applicable Conversion Price pursuant to the terms of Subsection 4.4.4, the Applicable Conversion Price shall be readjusted to such Applicable Conversion Price as would have been obtained had such Option or Convertible Security (or portion thereof) never been issued.

(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment to the Applicable Conversion Price provided for in this Subsection 4.4.3 shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b) and (c) of this Subsection 4.4.3). If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or Convertible Security is issued or amended, any adjustment to the Applicable Conversion Price that would result under the terms of this Subsection 4.4.3 at the time of such issuance or amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Applicable Conversion Price that such issuance or amendment took place at the time such calculation can first be made.

4.4.4 Adjustment of Applicable Conversion Price Upon Issuance of Additional Shares of Common Stock.In the event the Corporation shall at any time or from time to time after the Filing Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to Subsection 4.4.3), without consideration or for a consideration per share less than the Applicable Conversion Price as in effect immediately prior to such issuance or deemed issuance, then the Applicable Conversion Price shall be reduced, concurrently with such issuance or deemed issuance, to a price (calculated to the nearest one-hundredth of a cent) determined in accordance with the following formula:

CP₂ = CP₁* (A + B) ÷ (A + C).

For purposes of the foregoing formula, the following definitions shall apply:

(a) “CP₂” shall mean such Applicable Conversion Price in effect immediately after such issuance or deemed issuance of Additional Shares of Common Stock;

(b) “CP₁” shall mean such Applicable Conversion Price in effect immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock;

(c) “A” shall mean the number of shares of Common Stock outstanding immediately prior to such issuance or deemed issuance of Additional Shares of Common Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issuance or deemed issuance or upon conversion or exchange of Convertible Securities (including the Preferred Stock) outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue);

(d) “B” shall mean the number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued or deemed issued at a price per share equal to CP₁ (determined by dividing the aggregate consideration received by the Corporation in respect of such issue by CP₁); and

(e) “C” shall mean the number of such Additional Shares of Common Stock issued or deemed issued in such transaction.

4.4.5 Determination of Consideration. For purposes of this Subsection 4.4, the consideration received by the Corporation for the issuance or deemed issuance of any Additional Shares of Common Stock shall be computed as follows:

(a) Cash and Property: Such consideration shall:

(i) insofar as it consists of cash, be computed at the aggregate amount of cash received by the Corporation, excluding amounts paid or payable for accrued interest;

(ii) insofar as it consists of property other than cash, be computed at the fair market value thereof at the time of such issue, as determined in good faith by the Board of Directors; and

(iii) in the event Additional Shares of Common Stock are issued together with other shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received that is attributable to the Additional Shares of Common Stock, computed as provided in clauses (i) and (ii) above, as determined in good faith by the Board of Directors.

(b) Options and Convertible Securities. The consideration per share received by the Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to Subsection 4.4.3, relating to Options and Convertible Securities, shall be determined by dividing:

(i) the total amount, if any, received or receivable by the Corporation as consideration for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities, by

(ii) the maximum number of shares of Common Stock (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.

4.4.6 Multiple Closing Dates. In the event the Corporation shall issue on more than one date Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Applicable Conversion Price pursuant to the terms of Subsection 4.4.4 above then, upon the final such issuance, the Applicable Conversion Price shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving effect to any additional adjustments as a result of any such subsequent issuances within such period).

4.5 Adjustment for Stock Splits and Combinations.If the Corporation shall at any time or from time to time after the Filing Date effect a subdivision of the outstanding Common Stock, the Applicable Conversion Price in effect immediately before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common Stock outstanding. If the Corporation shall at any time or from time to time after the Filing Date combine the outstanding shares of Common Stock, the Applicable Conversion Price in effect immediately before such combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in the aggregate number of shares of Common Stock outstanding. Any adjustment under this Subsection 4.5 shall become effective at the close of business on the date the subdivision or combination becomes effective.

4.6 Adjustment for Certain Dividends and Distributions. In the event the Corporation at any time or from time to time after the Filing Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional shares of Common Stock, then and in each such event the Applicable Conversion Price in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall have been fixed, as of the close of business on such record date, by multiplying the Applicable Conversion Price then in effect by a fraction:

(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date, and

(2) the denominator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution.

Notwithstanding the foregoing, (a) if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made on the date fixed therefor, the Applicable Conversion Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Applicable Conversion Price shall be adjusted pursuant to this Subsection 4.6 as of the time of actual payment of such dividends or distributions; and (b) no such adjustment shall be made with respect to the Applicable Conversion Price if the holders of the applicable series of Preferred Stock simultaneously receive a dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of the applicable series of Preferred Stock had been converted into Common Stock on the date of such event.

4.7 Adjustments for Other Dividends and Distributions. In the event the Corporation at any time or from time to time after the Filing Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of Section 1 do not apply to such dividend or distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event.

4.8 Adjustment for Merger or Reorganization, etc. Subject to the provisions of Subsection 2.3, if there shall occur any reorganization, recapitalization, reclassification, consolidation, merger or statutory conversion involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for securities, cash or other property (other than a transaction covered by Subsections 4.5, 4.6 or 4.7), then, following any such reorganization, recapitalization, reclassification, consolidation, merger or statutory conversion, each share of Preferred Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the Corporation issuable upon conversion of one share of the applicable series of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation, merger or statutory conversion would have been entitled to receive pursuant to such transaction; and, in such case, appropriate adjustment (as determined in good faith by the Board of Directors, including a majority of the Preferred Directors)

shall be made in the application of the provisions in this Section 4 with respect to the rights and interests thereafter of the holders of Preferred Stock, to the end that the provisions set forth in this Section 4 (including provisions with respect to changes in and other adjustments of the Applicable Conversion Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of the applicable series of Preferred Stock. For the avoidance of doubt, nothing in this Section 4.8 shall be construed as preventing the holders of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the General Corporation Law in connection with a merger or statutory conversion triggering an adjustment hereunder, nor shall this Subsection 4.8 be deemed conclusive evidence of the fair value of the shares of Preferred Stock in any such appraisal proceeding.

4.9 Certificate as to Adjustments. Upon the occurrence of each adjustment or readjustment of the Applicable Conversion Price pursuant to this Section 4, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than fifteen (15) days thereafter, compute such adjustment or readjustment in accordance with the terms hereof and furnish to each holder of the applicable series of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the applicable series of Preferred Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in any event not later than fifteen (15) days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (i) the Applicable Conversion Price then in effect, and (ii) the number of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of the applicable series of Preferred Stock.

4.10 Notice of Record Date. In the event:

(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or to receive any other security; or

(b) of any capital reorganization of the Corporation, any reclassification of the Common Stock, or any Deemed Liquidation Event; or

(c) of the voluntary or involuntary dissolution, liquidation or winding-up of the Corporation, then, and in each such case, the Corporation will send or cause to be sent to the holders of the Preferred Stock a notice specifying, as the case may be, (i) the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii) the effective date on which such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up or a Deemed Liquidation Event is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation, winding-up or a Deemed Liquidation Event, and the amount per share and character of such exchange applicable to the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10) days prior to the record date or effective date for the event specified in such notice.

5. Mandatory Conversion.

5.1 Trigger Events. Upon either (a) the date and time, or the occurrence of an event, specified by vote or written consent of holders representing the Required Vote or (b) the closing of the sale of shares of Common Stock to the public at a price per share of at least $1.71668 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), provided that such offering results in at least $50 million of gross proceeds, after deducting the underwriting discounts and commissions, to the Corporation and in connection with such offering the Common Stock is listed for trading on the Nasdaq Stock Market’s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors, including the approval of a majority of the Preferred Directors (such an event a “QPO”) (the date and time specified or the time of the event specified in such vote or written consent, or the time of such closing, respectively, is referred to herein as the “Mandatory Conversion Time”), (i) all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate thereof, and (ii) such shares of Preferred Stock may not be reissued by the Corporation.

5.2 Procedural Requirements. All holders of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this Section 5. Such notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to Subsection 5.1, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this Subsection 5.2. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly.

5A. Special Mandatory Conversion.

5A.1. Milestone Trigger Event. If a holder of Series B Preferred Stock becomes a Defaulting Purchaser (as defined in the Series B Preferred Stock Purchase Agreement, dated on or about the Filing Date, by and among the Corporation and the other parties listed therein as “Purchasers” (as such may be amended in accordance with the terms thereof, the “Purchase Agreement”)), then each share of Series B Preferred Stock held by such holder shall then be automatically, and without any further action on

the part of such holder, be converted into that number of shares of Common Stock equal to the product of (a) 0.10 multiplied by (b) the quotient of the Series B Original Issue Price divided by the Series B Conversion Price then in effect for such share of Series B Preferred Stock immediately prior to the consummation of the Second Tranche Closing, rounding down to the nearest whole share, effective concurrently with the Second Tranche Closing. Such conversion is referred to as a “Special Mandatory Conversion.”

5A.2. Procedural Requirements. Upon a Special Mandatory Conversion, each holder of shares of Series B Preferred Stock converted pursuant to Subsection 5A.1 shall be sent written notice of such Special Mandatory Conversion and the place designated for mandatory conversion of all such shares of Series B Preferred Stock pursuant to this Subsection 5A. Upon receipt of such notice, each holder of such shares of Series B Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all such shares (or, if such holder alleges that any such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its attorney duly authorized in writing. All rights with respect to the Series B Preferred Stock converted pursuant to Subsection 5A.1, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at the time of the Special Mandatory Conversion (notwithstanding the failure of the holder or holders thereof to surrender any certificates for such shares at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of such holders therefor (or lost certificate affidavit and agreement), to receive the items provided for in the next sentence of this Subsection 5A.2. As soon as practicable after the Special Mandatory Conversion and, if applicable, the surrender of any certificate or certificates (or lost certificate affidavit and agreement) for Series B Preferred Stock so converted, the Corporation shall (a) issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b) pay cash as provided in Subsection 4.2 in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and the payment of any declared but unpaid dividends on the shares of Series B Preferred Stock converted.

5A.3. Effect of Mandatory Conversion. Such converted Series B Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Series B Preferred Stock accordingly.

6. Redeemed or Otherwise Acquired Shares. Any shares of Preferred Stock that are redeemed, converted or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued, sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption, conversion or acquisition.

7. Waiver. Any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all holders of Preferred Stock by the affirmative written consent or vote of the holders representing the Required Vote.

8. Notices. Any notice required or permitted by the provisions of this Article Fourth to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General Corporation Law, and shall be deemed sent upon such mailing or electronic transmission.

FIFTH: Subject to any additional vote required by the Certificate of Incorporation, in furtherance and not in limitation of the powers conferred by statute, the Board of Directors is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.

SIXTH: Subject to any additional vote required by the Certificate of Incorporation, the number of directors of the Corporation shall be determined in the manner set forth in the Bylaws of the Corporation. Each director shall be entitled to one (1) vote on each matter presented to the Board of Directors; provided, however, that, so long as the holders of Preferred Stock are entitled to elect a Preferred Director, the affirmative vote of a majority of the Preferred Directors shall be required for the authorization by the Board of Directors of any of the matters set forth in Section 5.4 of the Amended and Restated Investors’ Rights Agreement, dated on or about the Filing Date, by and among the Corporation and the other parties thereto, as such agreement may be amended from time to time.

SEVENTH: Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.

EIGHTH: Meetings of stockholders may be held within or without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board of Directors or in the Bylaws of the Corporation.

NINTH: To the fullest extent permitted by law, a director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so amended. Solely for purposes of this Article Ninth, “officer” shall have the meaning provided in Section 102(b)(7) of the General Corporation Law as amended from time to time.

Any repeal or modification of the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of, or increase the liability of any director or officer of the Corporation with respect to any acts or omissions of such director or officer occurring prior to, such repeal or modification.

TENTH:To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by Section 145 of the General Corporation Law.

Any amendment, repeal or modification of the foregoing provisions of this Article Tenth shall not (a) adversely affect any right or protection of any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification or (b) increase the liability of any director of the Corporation with respect to any acts or omissions of such director, officer or agent occurring prior to, such amendment, repeal or modification.

ELEVENTH: The Corporation renounces, to the fullest extent permitted by law, any interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An “Excluded Opportunity” is any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of (i) any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii) any holder of Preferred Stock or any partner, member, director, stockholder, employee, affiliate or agent of any such holder, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, the persons referred to in clauses (i) and (ii) are “Covered Persons”), unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person’s capacity as a director of the Corporation.Any repeal or modification of this Article Eleventh will only be prospective and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or omissions to act giving rise to liability.

TWELFTH: Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation’s certificate of incorporation or bylaws or (iv) any action asserting a claim against the Corporation, its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten (10) days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth (including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.

* * *

3. That the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance with Section 228 of the General Corporation Law.

4. That this Second Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation’s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation Law.

IN WITNESS WHEREOF, this Second Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on this 7^th day of August, 2023.


By:		/s/ Abraham N. Ceesay
Name: Abraham N. Ceesay
Title: Chief Executive Officer

CERTIFICATE OF AMENDMENT

TO THE

CERTIFICATE OF INCORPORATION

RAPPORT THERAPEUTICS, INC.

Rapport Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”),

DOES HEREBY CERTIFY:

FIRST: That the name of this Corporation is Rapport Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on February 10, 2022.

SECOND: That the Board of Directors of the corporation adopted resolutions setting forth the proposed amendment to the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”), declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendment are substantially as follows:

RESOLVED, that Article FOURTH, Section B, Subsection 5.1, of the Certificate of Incorporation be amended and restated to read in its entirety as follows:

1.1 “5.1 Trigger Events. Upon either (a) the date and time, or the occurrence of an event, specified by vote or written consent of holders representing the Required Vote or (b) the closing of the sale of shares of Common Stock to the public at a price per share of at least $1.67727 (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common Stock) in a firm commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”), provided that such offering results in at least $50 million of gross proceeds, after deducting the underwriting discounts and commissions, to the Corporation and in connection with such offering the Common Stock is listed for trading on the Nasdaq Stock Market’s National Market, the New York Stock Exchange or another exchange or marketplace approved by the Board of Directors, including the approval of a majority of the Preferred Directors (such an event a “QPO”) (the date and time specified or the time of the event specified in such vote or written consent, or the time of such closing, respectively, is referred to herein as the “Mandatory Conversion Time”), (i) all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate thereof, and (ii) such shares of Preferred Stock may not be reissued by the Corporation.”

***

THIRD: That thereafter said amendment was duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware by written consent of the stockholders holding the requisite number of shares required by statute given in accordance with and pursuant to Section 228 of the General Corporation Law of the State of Delaware.

IN WITNESS WHEREOF, the undersigned has duly executed this Certificate of Amendment in the name and on behalf of the Corporation as of this 28th day of February, 2024.


By:		/s/ Abraham Ceesay
Name: Abraham Ceesay
Title: President and Chief Executive Officer

SECOND CERTIFICATE OF AMENDMENT

OF THE

SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION

RAPPORT THERAPEUTICS, INC.

Rapport Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”),

DOES HEREBY CERTIFY:

That the name of the Corporation is Rapport Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the General Corporation Law on February 10, 2022 under the name Precision NeuroScience NewCo, Inc. The Corporation amended its Certificate of Incorporation by certain certificates of amendment dated as of May 10, 2022, August 9, 2022, October 7, 2022, which changed the Corporation’s name to Rapport Therapeutics, Inc., and November 28, 2022. The Corporations’s Certificate of Incorporation was amended and restated by that certain Amended and Restated Certificate of Incorporation dated as of December 9, 2022, and further amended and restated by that certain Second Amended and Restated Certificate of Incorporation dated as of August 7, 2023, as amended by that certain certificate of amendment dated as of February 28, 2024.

That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Second Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendments are as follows:

RESOLVED, that the following is hereby inserted into Article FOURTH immediately before the first sentence therein:

“Effective upon the filing of this Second Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware (the “Effective Time”), every 8.5648 shares of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time shall automatically be combined into one (1) share of Common Stock, without any further action by the holders of such shares (the “Reverse Stock Split”). The Reverse Stock Split will be effected on a certificate-by-certificate basis, and any fractional shares resulting from such combination shall be rounded down to the nearest whole share on a certificate-by-certificate basis. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares to which a holder would otherwise

be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation’s Board of Directors; provided, however, the Corporation shall not be required to pay an amount for any fractional share less than $25. The Reverse Stock Split shall occur automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the Preferred Stock shall be appropriately adjusted to reflect the Reverse Stock Split in accordance with this Second Amended and Restated Certificate of Incorporation.”

That the foregoing amendment was approved by the holders of the requisite number of shares of the Corporation in accordance with Section 228 of the General Corporation Law.

That said amendment has been duly adopted in accordance with Section 242 of the General Corporation Law.

All other provisions of the Second Amended and Restated Certificate of Incorporation shall remain in full force and effect.

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by a duly authorized officer of the Corporation on this 31st day of May, 2024.

/s/ Abraham N. Ceesay

Name: Abraham N. Ceesay

Title: Chief Executive Officer

EX-3.2 4 d803738dex32.htm EX-3.2 EX-3.2

Exhibit 3.2

THIRD AMENDED AND RESTATED

CERTIFICATE OF INCORPORATION

RAPPORT THERAPEUTICS, INC.

Rapport Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

1. The name of the Corporation is Rapport Therapeutics, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was February 10, 2022 (the “Original Certificate”). The name under which the Corporation filed the Original Certificate was Precision Neuroscience NewCo, Inc. The name of the corporation was changed on October 7, 2022 to Rapport Therapeutics, Inc.

2. The Original Certificate was amended by certain certificates of amendment dated as of May 10, 2022, August 9, 2022, October 7, 2022 and November 28, 2022 and further amended by that certain Amended and Restated Certificate of Incorporation dated as of December 9, 2022. This Third Amended and Restated Certificate of Incorporation (this “Certificate”) amends, restates and integrates the provisions of the Second Amended and Restated Certificate of Incorporation that was filed with the Secretary of State of the State of Delaware on August 7, 2023 (the “Amended and Restated Certificate”), and was duly adopted in accordance with the provisions of Sections 228, 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”).

3. The text of the Amended and Restated Certificate is hereby amended, restated and integrated in its entirety to provide as follows.

ARTICLE I

The name of the Corporation is Rapport Therapeutics, Inc.

ARTICLE II

The address of the Corporation’s registered office in the State of Delaware is 1209 Orange Street, in the City of Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company.

ARTICLE III

The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the DGCL.

ARTICLE IV

CAPITAL STOCK

The total number of shares of capital stock which the Corporation shall have authority to issue is five hundred ten million (510,000,000), of which (i) five hundred million (500,000,000) shares shall be a class designated as common stock, par value $0.001 per share (the “Common Stock”), and (ii) ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the “Preferred Stock”).

Except as otherwise provided in any certificate of designation of any series of Preferred Stock, the number of authorized shares of the class of Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares of such class then outstanding) by the affirmative vote of the holders of a majority in voting power of the outstanding shares of capital stock of the Corporation entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the DGCL, and no vote of the holders of any of the Common Stock or the Preferred Stock voting separately as a class shall be required therefor. For the avoidance of doubt, the elimination and reduction of the voting requirements of Section 242 of the DGCL, as permitted by Section 242(d) of the DGCL, shall apply to any amendments to the Amended and Restated Certificate of Incorporation (the “Certificate”).

The powers, preferences and rights of, and the qualifications, limitations and restrictions upon, each class or series of stock shall be determined in accordance with, or as set forth below in, this Article IV.

A. COMMON STOCK

Subject to all the rights, powers and preferences of the Preferred Stock and except as provided by law or in this Certificate (including any certificate of designation of any series of Preferred Stock):

(a) the holders of the Common Stock shall have the exclusive right to vote for the election of directors of the Corporation (the “Directors”) and on all other matters requiring stockholder action, each outstanding share entitling the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock, as such, shall not be entitled to vote on any amendment to this Certificate (including any amendment to a certificate of designation of any series of Preferred Stock) that alters or changes the powers, preferences, rights or other terms of one or more outstanding series of Preferred Stock if the holders of such affected series of Preferred Stock are entitled to vote, either separately or together with the holders of one or more other such series, on such amendment pursuant to this Certificate (including any certificate of designation of any series of Preferred Stock) or pursuant to the DGCL;

(b) dividends may be declared and paid or set apart for payment upon the shares of Common Stock out of any assets or funds of the Corporation legally available for the payment of dividends, but only when, as and if declared by the Board of Directors of the Corporation (the “Board”) or any authorized committee thereof; and

(c) upon the voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the net assets of the Corporation shall be distributed pro rata to the holders of the Common Stock.

B. PREFERRED STOCK

The Board of Directors or any authorized committee thereof is expressly authorized to provide by resolution or resolutions for, out of the unissued shares of Preferred Stock, the issuance of the shares of Preferred Stock in one or more series of such stock, and by filing a certificate of designation pursuant to applicable law of the State of Delaware, to establish or change from time to time the number of shares of each such series, and to fix the designations, powers, including voting powers, full or limited, or no voting powers, preferences and the relative, participating, optional or other special rights of the shares of each series and any qualifications, limitations and restrictions thereof, all to the fullest extent now or hereafter permitted by the DGCL. The powers, preferences and relative, participating, optional and other special rights of each such series of Preferred Stock, and the qualifications, limitations or restrictions thereof, if any, may differ from those of any and all other series at any time outstanding. Without limiting the generality of the foregoing, the resolution or resolutions providing for the issuance of any series of Preferred Stock may provide that such series shall be superior or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.

ARTICLE V

STOCKHOLDER ACTION

1. Action without Meeting. Subject to the rights, if any, of the holders of shares of any series of Preferred Stock, any action required or permitted to be taken by the stockholders of the Corporation at any annual or special meeting of stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders and may not be taken or effected by a consent of stockholders in lieu thereof.

2. Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of shares of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by the Board of Directors, and special meetings of stockholders may not be called by any other person or persons. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation.

ARTICLE VI

DIRECTORS

1. General. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors except as otherwise provided herein or required by law.

2. Number of Directors; Term of Office. Except as otherwise provided for or fixed pursuant to the provisions of Article IV (including any certificate of designation with respect to any series of Preferred Stock) and this Article VII relating to the rights of the holders of any series of Preferred Stock to elect additional Directors, the number of Directors shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors. The Directors, other than those who may be elected by the holders of any series of Preferred Stock, shall be classified, with respect to the term for which they severally hold office, into three classes. The term of office of the initial Class I Directors shall expire at the first regularly-scheduled annual meeting of stockholders following the closing of the Corporation’s sale of a class of its capital stock to the public pursuant to a registration statement on Form S-1 under the Securities Act (the “IPO Time”). The term of office of the initial Class II Directors shall expire at the second annual meeting of stockholders following the IPO Time. The term of office of the initial Class III Directors shall expire at the third annual meeting of stockholders following the IPO Time. The Board of Directors is authorized to assign members of the Board of Directors already in office to such classes at the time the classification of the Board of Directors becomes effective. At each annual meeting of stockholders, Directors elected to succeed those Directors whose terms expire shall be elected for a term of office to expire at the third succeeding annual meeting of stockholders after their election. Notwithstanding the foregoing, the Directors elected to each class shall hold office until their successors are duly elected and qualified or until their earlier resignation, death, disqualification or removal. No decrease in the number of Directors shall shorten the term of any incumbent Director. There shall be no cumulative voting in the election of Directors. Election of Directors need not be by written ballot unless the Bylaws of the Corporation so provide.

Notwithstanding the foregoing, whenever, pursuant to the provisions of Article IV of this Certificate, the holders of any one or more series of Preferred Stock shall have the right, voting separately as a series or together with holders of other such series, to elect additional Directors, the election, term of office, filling of vacancies and other features of such directorships shall be governed by the terms of this Certificate, including any certificate of designation applicable to such series of Preferred Stock. During any period when the holders of any series of Preferred Stock, voting separately as a series or together with one or more series, have the right to elect additional Directors, then upon commencement and for the duration of the period during which such right continues: (i) the then otherwise total authorized number of Directors shall automatically be increased by such specified number of Directors, and the holders of such Preferred Stock shall be entitled to elect the additional Directors so provided for or fixed pursuant to said provisions, and (ii) each such additional Director shall serve until such Director’s successor shall have been duly elected and qualified, or until such Director’s right to hold

such office terminates pursuant to said provisions, whichever occurs earlier, subject to such Director’s earlier death, resignation, retirement, disqualification or removal. Notwithstanding any other provision of this Certificate of Incorporation, except as otherwise provided by the Board in the resolution or resolutions establishing such series, whenever the holders of any series of Preferred Stock having such right to elect additional Directors are divested of such right pursuant to the provisions of such stock, the terms of office of all such additional Directors elected by the holders of such stock, or elected to fill any vacancies resulting from the death, resignation, disqualification or removal of such additional Directors, shall forthwith terminate (in which case each such Director shall thereupon cease to be qualified as, and shall cease to be, a Director) and the total authorized number of Directors shall automatically be reduced accordingly.

3. Vacancies and Newly Created Directorships. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect Directors and to fill vacancies in the Board of Directors relating thereto, any and all vacancies and newly created directorships in the Board of Directors, however occurring, including, without limitation, by reason of an increase in the size of the Board of Directors, or the death, resignation, disqualification or removal of a Director, shall be filled solely and exclusively by the affirmative vote of a majority of the remaining Directors then in office, even if less than a quorum of the Board of Directors, or by a sole remaining Director, and not by the stockholders. Any Director appointed in accordance with the preceding sentence shall hold office for the remainder of the full term of the class of Directors in which the new directorship was created or the vacancy occurred and until such Director’s successor shall have been duly elected and qualified or until such Director’s earlier resignation, disqualification, death or removal. Subject to the rights, if any, of the holders of any series of Preferred Stock to elect Directors, when the number of Directors is increased or decreased, the Board of Directors shall, subject to Article VI.3 hereof, determine the class or classes to which the increased or decreased number of Directors shall be apportioned. In the event of a vacancy in the Board of Directors, the remaining Directors, except as otherwise provided by law, shall exercise the powers of the full Board of Directors until the vacancy is filled.

4. Removal. Subject to the rights, if any, of any series of Preferred Stock to elect Directors and to remove any Director whom the holders of any such series have the right to elect, any Director may be removed from office (i) only for cause and (ii) only by the affirmative vote of the holders not less than two-thirds (2/3)of the voting power of the outstanding shares of capital stock then entitled to vote at an election of Directors.

ARTICLE VII

LIMITATION OF LIABILITY

1. Directors. To the fullest extent permitted by the DGCL, as the same exists or may hereafter be amended from time to time, a Director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of such Director’s fiduciary duty as a Director, except for liability (a) for any breach of the Director’s duty of loyalty to the Corporation or its stockholders, (b) for acts or omissions not in good faith or which

involve intentional misconduct or a knowing violation of law, (c) under Section 174 of the DGCL or (d) for any transaction from which the Director derived an improper personal benefit. If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Directors, then the liability of a Director of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.

2. Officers. To the fullest extent permitted by the DGCL, as the same exists or may thereafter be amended from time to time, an Officer (as defined below) of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of such Officer’s fiduciary duty as an officer of the Corporation, except for liability (a) for any breach of the Officer’s duty of loyalty to the Corporation or its stockholders, (b) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (c) for any transaction from which the Officer derived an improper personal benefit, or (d) arising from any claim brought by or in the right of the Corporation. If the DGCL is amended after the effective date of this Certificate to authorize corporate action further eliminating or limiting the personal liability of Officers, then the liability of an Officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. For purposes of this Article VII, “Officer” shall mean an individual who has been duly appointed as an officer of the Corporation and who, at the time of an act or omission as to which liability is asserted, is deemed to have consented to service by the delivery of process to the registered agent of the Corporation as contemplated by 10 Del. C. § 3114(b).

3. Amendment or Modification. Any amendment, repeal or modification of this Article VII or any amendment to the DGCL, shall not adversely affect any right or protection existing at the time of such amendment, repeal or modification with respect to any acts or omissions occurring before such amendment, repeal or modification of a person serving as a Director or Officer, as applicable, at the time of such amendment, repeal or modification.

ARTICLE VIII

AMENDMENT OF BYLAWS

1. Amendment by Directors. Except as otherwise provided by law, the Bylaws of the Corporation may be adopted, amended or repealed by the Board of Directors.

2. Amendment by Stockholders. Except as otherwise provided therein, the Bylaws of the Corporation may be amended or repealed by the stockholders by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal, such amendment or repeal shall only require the affirmative vote of the holders of a majority of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.

ARTICLE IX

AMENDMENT OF CERTIFICATE OF INCORPORATION

The Corporation reserves the right to amend or repeal this Certificate in the manner now or hereafter prescribed by statute and this Certificate, and all rights conferred upon stockholders herein are granted subject to this reservation.For the avoidance of doubt, the provisions of Sections 242(d)(1) and (d)(2) of the DGCL shall apply to the Corporation.

[End of Text]

THIS THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION is executed as of this day of , 2024.


RAPPORT THERAPEUTICS, INC.

By:
Name:		Abraham N. Ceesay
Title:		Chief Executive Officer

EX-3.4 5 d803738dex34.htm EX-3.4 EX-3.4

Exhibit 3.4

AMENDED AND RESTATED

BYLAWS

RAPPORT THERAPEUTICS, INC.

(the “Corporation”)

ARTICLE I

Stockholders

SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or in the manner determined by the Board of Directors and stated in the notice of the meeting, which time, date and place may subsequently be changed at any time, before or after the notice for such meeting has been sent to the stockholders, by vote of the Board of Directors. The Board of Directors may, in its sole discretion, determine that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized by Section 211(a)(2) of the General Corporation Law of the State of Delaware (the “DGCL”). In the absence of any such designation or determination, stockholders’ meetings shall be held at the Corporation’s principal executive office. If no Annual Meeting has been held for a period of thirteen (13) months after the Corporation’s last Annual Meeting, a special meeting in lieu thereof may be held, and such special meeting shall have, for the purposes of these Bylaws or otherwise, all the force and effect of an Annual Meeting. Any and all references hereafter in these Bylaws to an Annual Meeting or Annual Meetings also shall be deemed to refer to any special meeting(s) in lieu thereof.

SECTION 2. Notice of Stockholder Business and Nominations.

(a) Annual Meetings of Stockholders.

(1) Nominations of persons for election to the Board of Directors of the Corporation (the “Board of Directors”) and the proposal of other business to be considered by the stockholders may be brought before an Annual Meeting (i) by or at the direction of the Board of Directors or (ii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of notice of the Annual Meeting provided for in this Bylaw, who is entitled to vote at the meeting, who is present (in person or by proxy) at the meeting and who complies with the notice procedures set forth in this Bylaw as to such nomination or business. For the avoidance of doubt, the foregoing clause (ii) shall be the exclusive means for a stockholder to bring nominations or business properly before an Annual Meeting (other than matters properly brought under Rule 14a-8 (or any successor rule) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), and such stockholder must comply with the notice and other procedures set forth in Article I, Section 2(a)(2), (3) and (4) of this Bylaw to bring such nominations or business properly before an Annual Meeting. In addition to the other requirements set forth in this Bylaw, for any proposal of business to be considered at an Annual Meeting, it must be a proper subject for action by stockholders of the Corporation under Delaware law.

(2) For nominations or other business to be properly brought before an Annual Meeting by a stockholder pursuant to clause (ii) of Article I, Section 2(a)(1) of this Bylaw, the stockholder must (i) have given Timely Notice (as defined below) thereof in writing to the Secretary of the Corporation, (ii) have provided any updates or supplements to such notice at the times and in the forms required by this Bylaw and (iii) together with the beneficial owner(s), if any, on whose behalf the nomination or business proposal is made, have acted in accordance with the representations set forth in the Solicitation Statement (as defined below) required by this Bylaw. To be timely, a stockholder’s written notice must be received by the Secretary at the principal executive offices of the Corporation not later than 5:00 p.m. Eastern time on the ninetieth (90th) day nor earlier than 5:00 p.m. Eastern time on the one hundred twentieth (120th) day prior to the one-year anniversary of the preceding year’s Annual Meeting; provided, however, that in the event the Annual Meeting is first convened more than thirty (30) days before or more than sixty (60) days after such anniversary date, or if no Annual Meeting was held in the preceding year, notice by the stockholder to be timely must be received by the Secretary of the Corporation not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting is first made (such notice within such time periods shall be referred to as “Timely Notice”). Notwithstanding anything to the contrary provided herein, for the first Annual Meeting following the initial public offering of common stock of the Corporation, a stockholder’s notice shall be timely if received by the Secretary at the principal executive offices of the Corporation not later than 5:00 p.m. Eastern time on the later of the ninetieth (90th) day prior to the scheduled date of such Annual Meeting or the tenth (10th) day following the day on which public announcement of the date of such Annual Meeting is first made or sent by the Corporation. Such stockholder’s Timely Notice shall set forth or include:

(A) as to each person whom the stockholder proposes to nominate for election or reelection as a director, (i) the name, age, business address and residence address of the nominee, (ii) the principal occupation or employment of the nominee, (iii) the class and number of shares of capital stock of the Corporation that are held of record or are beneficially owned by the nominee or its Affiliates or Associates (each as defined below) and any Synthetic Equity Interest (as defined below) held or beneficially owned by the nominee or its Affiliates or Associates, (iv) a description of all agreements, arrangements or understandings between or among the stockholder and each nominee and any other person or persons (naming such person or persons) pursuant to which the nominations are to be made by the stockholder or concerning the nominee’s potential service on the Board of Directors, (v) a questionnaire with respect to the background and qualifications of the nominee completed by the nominee in the form provided by the Corporation (which questionnaire shall be provided by the

Secretary upon written request of any stockholder of record identified by name within five (5) business days of such written request), (vi) a representation and agreement in the form provided by the Corporation (which form shall be provided by the Secretary upon written request of any stockholder of record identified by name within five (5) business days of such written request) that: (a) such proposed nominee is not and will not become party to any agreement, arrangement or understanding with any person or entity as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a “Voting Commitment”) that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein; (b) such proposed nominee is not and will not become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been disclosed to the Corporation in the questionnaire described in clause (v) herein; (c) such proposed nominee would, if elected as a director, comply with all applicable rules and regulations of the exchanges upon which shares of the Corporation’s capital stock trade, each of the Corporation’s corporate governance, ethics, conflict of interest, confidentiality, stock ownership and trading policies and guidelines applicable generally to the Corporation’s directors and, if elected as a director of the Corporation, such person currently would be in compliance with any such policies and guidelines that have been publicly disclosed; (d) such proposed nominee intends to serve as a director for the full term for which he or she is to stand for election; and (e) such proposed nominee will promptly provide to the Corporation such other information as it may reasonably request to determine the eligibility of such proposed nominee to serve on any committee or sub-committee of the Board of Directors under any applicable stock exchange listing requirements or applicable law, or that the Board of Directors reasonably determines could be material to a reasonable stockholder’s understanding of the background, qualifications, experience, independence, or lack thereof, of such proposed nominee; and (vii) any other information relating to such proposed nominee that is required to be disclosed in solicitations of proxies for election of directors in an election contest, or is otherwise required, in each case pursuant to Regulation 14A under the Exchange Act (including, without limitation, such person’s written consent to being named in the proxy statement as a nominee and to serving as a director if elected);

(B) as to any other business that the stockholder proposes to bring before the meeting: a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting, the text, if any, of any resolutions or Bylaw amendment proposed for adoption, and any material interest in such business of each Proposing Person (as defined below);

(C) (i) the name and address of the stockholder giving the notice, as they appear on the Corporation’s books, and the names and addresses of the other Proposing Persons (if any) and (ii) as to each Proposing Person, the following information: (a) the class or series and number of all shares of capital stock of the Corporation that are, directly or indirectly, owned beneficially or of record by such Proposing Person or any of its Affiliates or Associates, including any shares of any class or series of capital stock of the Corporation as to which such Proposing Person or any of its Affiliates or Associates has a right to acquire beneficial ownership at any time in the future (whether or not such right is exercisable immediately or only after the passage of time or upon the satisfaction of any conditions or both) pursuant to any agreement, arrangement or understanding (whether or not in writing), (b) all Synthetic Equity Interests (as defined below) in which such Proposing Person or any of its Affiliates or Associates, directly or indirectly, holds an interest including a description of the material terms of each such Synthetic Equity Interest, including, without limitation, identification of the counterparty to each such Synthetic Equity Interest and disclosure, for each such Synthetic Equity Interest, as to (1) whether or not such Synthetic Equity Interest conveys any voting rights, directly or indirectly, in such shares to such Proposing Person or any of its Affiliates or Associates and (2) whether or not such Synthetic Equity Interest is required to be, or is capable of being, settled through delivery of such shares, (c) any proxy (other than a revocable proxy given in response to a public proxy solicitation made pursuant to, and in accordance with, the Exchange Act), agreement, arrangement, understanding or relationship pursuant to which such Proposing Person or any of its Affiliates or Associates has or shares a right to, directly or indirectly, vote any shares of any class or series of capital stock of the Corporation, (d) any rights to dividends or other distributions on the shares of any class or series of capital stock of the Corporation, directly or indirectly, owned beneficially by such Proposing Person or any of its Affiliates or Associates that are separated or separable from the underlying shares of the Corporation, (e) if such Proposing Person is not a natural person, the identity of the natural person or persons responsible for making voting and investment decisions (including director nominations and any other business that the stockholder proposes to bring before a meeting) on behalf of the Proposing Person (irrespective of whether such person or persons have “beneficial ownership” for purposes of Rule 13d-3 of the Exchange Act of any securities owned of record or beneficially by the Proposing Person) (such person or persons, the “Responsible Person”), (f) any pending or threatened litigation in which such Proposing Person or any of its Affiliates or Associates or any Responsible Person is a party involving the Corporation or any of its officers or directors, or any Affiliate of the Corporation, and (g) any other information relating to such Proposing Person or any of its Affiliates or Associates that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (a) through (g) are referred to, collectively, as “Material Ownership Interests”); provided, however, that the Material Ownership Interests shall not include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company or other nominee who is a Proposing Person solely as a result of being the stockholder of record directed to prepare and submit the notice required by these Bylaws on behalf of a beneficial owner;

(D) (i) a description of all agreements, arrangements or understandings to which any Proposing Person or any of its Affiliates or Associates is a party (whether the counterparty or counterparties are a Proposing Person or any Affiliate or Associate thereof, on the one hand, or one or more other third parties, on the other hand, (including any proposed nominee(s)) (a) pertaining to the nomination(s) or other business proposed to be brought before the meeting of stockholders or (b) entered into for the purpose of acquiring, holding, disposing or voting of any shares of any class or series of capital stock of the Corporation (which description shall identify the name of each other person who is party to such an agreement, arrangement or understanding) and (ii) identification of the names and addresses of other stockholders (including beneficial owners) known by any of the Proposing Persons to be providing financial support or meaningful assistance in furtherance of the nomination(s) or other business proposed to be brought before the meeting of stockholders and, to the extent known, the class and number of all shares of the Corporation’s capital stock owned beneficially or of record by such other stockholder(s) or other beneficial owner(s); and

(E) a statement (i) that the stockholder is a holder of record of capital stock of the Corporation entitled to vote at such meeting, a representation that such stockholder intends to appear in person or by proxy at the meeting to propose such business or nominees and an acknowledgement that, if such stockholder (or a qualified representative of such stockholder) does not appear to present such business or proposed nominees, as applicable, at such meeting, the Corporation need not present such business or proposed nominees for a vote at such meeting, notwithstanding that proxies in respect of such vote may have been received by the Corporation, (ii) whether or not the stockholder giving the notice and/or the other Proposing Person(s), if any, (a) will deliver a proxy statement and form of proxy to holders of, in the case of a business proposal, at least the percentage of voting power of all of the shares of capital stock of the Corporation required under applicable law to approve the proposal or, in the case of a nomination or nominations, at least 67 percent of the voting power of all of the shares of capital stock of the Corporation entitled to vote on the election of directors or (b) otherwise solicit proxies or votes from stockholders in support of such proposal or nomination, as applicable, (iii) providing a representation as to whether or not such Proposing Person intends to solicit proxies in support of director nominees other than the Corporation’s director nominees in accordance with Rule 14a-19 promulgated under the Exchange Act and (iv) that the stockholder will provide any other information relating to such item of business that would be required to be disclosed in a proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to be brought before the meeting pursuant to Section 14(a) of the Exchange Act (such statement, the “Solicitation Statement”).

For purposes of this Article I, the term “Proposing Person” shall mean the following persons: (i) the stockholder of record providing the notice of nominations or business proposed to be brought before a stockholders’ meeting and (ii) the beneficial owner(s), if different, on whose behalf the nominations or business proposed to be brought before a stockholders’ meeting is made. For purposes of this Section 2, each of the terms “Affiliates” and “Associates” shall have the meaning attributed to such term in Rule 12b-2 under the Exchange Act. For purposes of this Section 2, the term “Synthetic Equity Interest” shall mean any transaction, agreement or arrangement (or series of transactions, agreements or arrangements), including, without limitation, any derivative, swap, hedge, repurchase or so-called “stock borrowing” or securities lending agreement or arrangement, the purpose or effect of which is to, directly or indirectly: (a) give a person or entity economic benefit and/or risk similar to ownership of shares of any class or series of capital stock of the Corporation, in whole or in part, including due to the fact that such transaction, agreement or arrangement provides, directly or indirectly, the opportunity to profit, or share in any profit, or avoid a loss from any increase or decrease in the value of any shares of any class or series of capital stock of the Corporation, (b) mitigate loss to, reduce the economic risk of, or manage the risk of share price changes for, any person or entity with respect to any shares of any class or series of capital stock of the Corporation, or (c) increase or decrease the voting power of any person or entity with respect to any shares of any class or series of capital stock of the Corporation.

(3) A stockholder providing Timely Notice of nominations or business proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information (including, without limitation, the Material Ownership Interests information) provided or required to be provided in such notice pursuant to this Bylaw shall be true and correct as of the record date for the meeting and as of the date that is ten (10) business days prior to such Annual Meeting, and such update and supplement shall be received by the Secretary at the principal executive offices of the Corporation not later than 5:00 p.m. Eastern time on the fifth (5th) business day after the record date for the Annual Meeting (in the case of the update and supplement required to be made as of the record date), and not later than 5:00 p.m. Eastern time on the eighth (8th) business day prior to the date of the Annual Meeting (in the case of the update and supplement required to be made as of ten (10) business days prior to the meeting). For the avoidance of doubt, the obligation to update as set forth in this Section 2(a)(3) shall not limit the Corporation’s rights with respect to any deficiencies in any notice provided by a stockholder, extend any applicable deadlines hereunder, or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. Notwithstanding the foregoing, if a Proposing Person no longer plans to solicit proxies in accordance with its representation pursuant to Article I, Section 2(a)(2)(E), such Proposing Person shall inform the Corporation of this change by delivering a written notice to the Secretary at the principal executive offices of the Corporation no later than two (2) business days after making the determination not to proceed with a solicitation of proxies. A Proposing Person shall also update its notice so that the information required by Article I, Section 2(a)(2)(C) is current through the date of the meeting or any adjournment, postponement or rescheduling thereof, and such update shall be delivered in writing to the secretary at the principal executive offices of the Corporation no later than two (2) business days after the occurrence of any material change to the information previously disclosed pursuant to Article I, Section 2(a)(2)(C).

(4) Notwithstanding anything in the second sentence of Article I, Section 2(a)(2) of this Bylaw to the contrary, in the event that the number of directors to be elected to the Board of Directors is increased and there is no public announcement naming all of the nominees for director or specifying the size of the increased Board of Directors made by the Corporation at least ten (10) days before the last day a stockholder may deliver a notice of nomination in accordance with the second sentence of Article I, Section 2(a)(2), a stockholder’s notice required by this Bylaw shall also be considered timely, but only with respect to nominees for any new positions created by such increase, if it shall be received by the Secretary of the Corporation not later than 5:00 p.m. Eastern time on the tenth (10th) day following the day on which such public announcement is first made by the Corporation.

(b) General.

(1) Only such persons who are nominated in accordance with the provisions of this Bylaw shall be eligible for election and to serve as directors, and only such business shall be conducted at an Annual Meeting as shall have been brought before the meeting in accordance with the provisions of this Bylaw or in accordance with Rule 14a-8 under the Exchange Act. The Board of Directors or a designated committee thereof shall have the power to determine whether a nomination or any business proposed to be brought before the meeting was made in accordance with the provisions of this Bylaw. If neither the Board of Directors nor such designated committee makes a determination as to whether any stockholder proposal or nomination was made in accordance with the provisions of this Bylaw, the chair of the meeting (as defined in Section 9 of this Article I) shall have the power and duty to determine whether the stockholder proposal or nomination was made in accordance with the provisions of this Bylaw. If the Board of Directors or a designated committee thereof or the chair of the meeting, as applicable, determines that any stockholder proposal or nomination was not made in accordance with the provisions of this Bylaw, such proposal or nomination shall be disregarded and shall not be presented for action at the Annual Meeting.

(2) Except as otherwise required by law, nothing in this Article I, Section 2 shall obligate the Corporation or the Board of Directors to include in any proxy statement or other stockholder communication distributed on behalf of the Corporation or the Board of Directors information with respect to any nominee for director or any other matter of business submitted by a stockholder.

(3) Notwithstanding the foregoing provisions of this Article I, Section 2, if the nominating or proposing stockholder (or a qualified representative of the stockholder) does not appear at the Annual Meeting to present a nomination or any business, such nomination or business shall be disregarded, notwithstanding that proxies in respect of such vote may have been received by the Corporation. For purposes of this Article I,

Section 2, to be considered a qualified representative of the proposing stockholder, a person must be authorized by a written instrument executed by such stockholder or an electronic transmission delivered by such stockholder to act for such stockholder as proxy at the meeting of stockholders, and such person must produce such written instrument or electronic transmission, or a reliable reproduction of the written instrument or electronic transmission, to the chair of the meeting at the meeting of stockholders.

(4) For purposes of this Bylaw, “public announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act.

(5) Notwithstanding the foregoing provisions of this Bylaw, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder, including, but not limited to, Rule 14a-19 of the Exchange Act, with respect to the matters set forth in this Bylaw. If a stockholder fails to comply with any applicable requirements of the Exchange Act, including, but not limited to, Rule 14a-19 promulgated thereunder, such stockholder’s proposed nomination or proposed business shall be deemed to have not been made in compliance with this Bylaw and shall be disregarded.

(6) Further notwithstanding the foregoing provisions of this Bylaw, unless otherwise required by law, (i) no Proposing Person shall solicit proxies in support of director nominees other than the Corporation’s nominees unless such Proposing Person has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder with timely notice and (ii) if any Proposing Person (A) provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, (B) subsequently fails to comply with the requirements of Rule 14a-19(a)(2) or Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder with timely notice and (C) no other Proposing Person has provided notice pursuant to, and in compliance with, Rule 14a-19 under the Exchange Act that it intends to solicit proxies in support of the election of such proposed nominee in accordance with Rule 14a-19(b) under the Exchange Act, then such proposed nominee shall be disqualified from nomination, the Corporation shall disregard the nomination of such proposed nominee and no vote on the election of such proposed nominee shall occur. Upon request by the Corporation, if any Proposing Person provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act, such Proposing Person shall deliver to the Corporation, no later than five (5) business days prior to the applicable meeting date, reasonable evidence that it has met the requirements of Rule 14a-19(a)(3) promulgated under the Exchange Act.

(7) The number of nominees a stockholder may nominate for election at the Annual Meeting (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the Annual Meeting on behalf of such beneficial owner) shall not exceed the number of

directors to be elected at such Annual Meeting. A stockholder may not designate any substitute nominees unless the stockholder provides timely notice of such substitute nominee(s) in accordance with these By-laws (and such notice contains all of the information, representations, questionnaires and certifications with respect to such substitute nominee(s) that are required by the By-laws with respect to nominees for director).

SECTION 3. Special Meetings. Except as otherwise required by statute and subject to the rights, if any, of the holders of any series of Preferred Stock, special meetings of the stockholders of the Corporation may be called only by or at the direction of the Board of Directors. The Board of Directors may postpone or reschedule any previously scheduled special meeting of stockholders. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of stockholders of the Corporation. Nominations of persons for election to the Board of Directors and stockholder proposals of other business shall not be brought before a special meeting of stockholders to be considered by the stockholders unless such special meeting is held in lieu of an annual meeting of stockholders in accordance with Article I, Section 1 of these Bylaws, in which case such special meeting in lieu thereof shall be deemed an Annual Meeting for purposes of these Bylaws and the provisions of Article I, Section 2 of these Bylaws shall govern such special meeting.

SECTION 4. Notice of Meetings; Adjournments.

(a) A notice of each Annual Meeting stating the hour, date and place, if any, of such Annual Meeting, the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting, if such date is different from the record date for determining stockholders entitled to notice of the meeting, shall be given not less than ten (10) days nor more than sixty (60) days before the Annual Meeting, to each stockholder entitled to vote thereat by delivering such notice to such stockholder or by mailing it, postage prepaid, addressed to such stockholder at the address of such stockholder as it appears on the Corporation’s stock transfer books. Without limiting the manner by which notice may otherwise be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.

(b) Notice of all special meetings of stockholders shall be given in the same manner as provided for Annual Meetings, except that the notice of all special meetings shall also state the purpose or purposes for which the meeting has been called.

(c) Notice of an Annual Meeting or special meeting of stockholders need not be given to a stockholder if a waiver of notice is executed, or waiver of notice by electronic transmission is provided, before or after such meeting by such stockholder or if such stockholder attends such meeting, unless such attendance is for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting was not lawfully called or convened.

(d) The Board of Directors may postpone and reschedule or cancel any previously scheduled Annual Meeting or special meeting of stockholders and any record date with respect thereto, regardless of whether any notice or public disclosure with respect to any such meeting has been sent or made pursuant to Section 2 of this Article I or otherwise. In no event shall the public announcement of an adjournment, postponement or rescheduling of any previously scheduled meeting of stockholders commence a new time period for the giving of a stockholder’s notice under this Article I.

(e) When any meeting is convened, the chair of the meeting or the stockholders present or represented by proxy at such meeting may adjourn the meeting from time to time for any reason, regardless of whether a quorum is present, to reconvene at any other time and at any place at which a meeting of stockholders may be held under these Bylaws. When any Annual Meeting or special meeting of stockholders is adjourned to another hour, date or place (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), notice need not be given of the adjourned meeting if the time, place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with this Section 4; provided, however, that if the adjournment is for more than thirty (30) days from the meeting date, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting and the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such adjourned meeting shall be given to each stockholder of record entitled to vote thereat and each stockholder who, by law or under the Certificate of Incorporation of the Corporation (as the same may hereafter be amended and/or restated, the “Certificate”) or these Bylaws, is entitled to such notice.

SECTION 5. Quorum. Except as otherwise provided by law, the certificate of incorporation or these Bylaws, at each meeting of stockholders, the presence in person or by remote communication, if applicable, or represented by proxy, of the holders of a majority in voting power of the outstanding shares of stock entitled to vote at the meeting shall be necessary and sufficient to constitute a quorum. If less than a quorum is present at a meeting, the chair of the meeting or the holders of voting stock, by the affirmative vote of a majority of the voting power present in person or by proxy and entitled to vote thereon, may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice, except as otherwise provided in Section 4 of this Article I. At such adjourned meeting at which a quorum is present, any business may be transacted which might have been transacted at the meeting as originally noticed. The stockholders present at a duly constituted meeting may continue to transact business until adjournment, notwithstanding the withdrawal of enough stockholders to leave less than a quorum.

SECTION 6. Voting and Proxies.

(a) The stockholders entitled to vote at any meeting of stockholders shall be determined in accordance with the provisions of Article IV, Section 4 of these Bylaws, subject to Section 217 (relating to voting rights of fiduciaries, pledgors and joint owners of stock) and Section 218 (relating to voting trusts and other voting agreements) of the DGCL. Stockholders shall have one vote for each share of stock entitled to vote owned by them of record according to the stock ledger of the Corporation as of the record date, unless otherwise provided by law or by the Certificate. Stockholders may vote either (i) in person, (ii) by written proxy or (iii) by a transmission permitted by Section 212(c) of the DGCL. Any copy, facsimile telecommunication or other reliable reproduction of the writing or transmission permitted by Section 212(c) of the DGCL may be substituted for or used in lieu of the original writing or transmission for any and all purposes for which the original writing or transmission could be used, provided that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or transmission. Proxies shall be filed in accordance with the procedures established for the meeting of stockholders. A proxy with respect to stock held in the name of two or more persons shall be valid if executed by or on behalf of any one of them unless at or prior to the exercise of the proxy the Corporation receives a specific written notice to the contrary from any one of them. In the event the Corporation receives proxies for disqualified or withdrawn nominees for the Board of Directors, such votes for such disqualified or withdrawn nominees in the proxies will be treated as abstentions.

(b) Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for the exclusive use by the Board of Directors.

SECTION 7. Action at Meeting. When a quorum is present at any meeting of stockholders, any matter before any such meeting (other than an election of a director or directors) shall be decided by a majority of the votes properly cast for and against such matter, except where a larger vote is required by law, by the Certificate or by these Bylaws. Any election of directors by stockholders shall be determined by a plurality of the votes properly cast on the election of directors.

SECTION 8. Stockholder Lists. The Corporation shall prepare, no later than the tenth (10^th) day before each Annual Meeting or special meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of each stockholder; provided, however, that if the record date for determining the stockholders entitled to vote is less than ten (10) days before the meeting date, the list shall reflect the stockholders entitled to vote as of the tenth (10th) day before the meeting date. Such list shall be open to the examination of any stockholder for any purpose germane to the meeting for a period of ten (10) days ending on the day before the meeting date in the manner provided by law.

SECTION 9. Conduct of Meeting. The Board of Directors may adopt by resolution such rules, regulations and procedures for the conduct of any meeting of stockholders as it shall deem appropriate. Except to the extent inconsistent with rules, regulations and procedures adopted by the Board of Directors, the chair of the meeting shall have the right to prescribe such rules, regulations and procedures and to do all such acts, as, in the judgment of such chair, are necessary, appropriate or convenient for the proper conduct of the meeting. Such rules, regulations or procedures, whether adopted by the Board of

Directors or the chair of the meeting, may include, without limitation, the following: (a) the establishment of an agenda for the meeting; (b) rules and procedures for maintaining order at the meeting and the safety of those present at the meeting; (c) limitations on attendance at or participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies, or such other persons as the chair of the meeting shall determine; (d) restrictions on entry to the meeting after the time fixed for the commencement thereof; (e) the determination of the circumstances in which any person may make a statement or ask questions and limitations on the time allotted to questions or comments; (f) the determination of when the polls shall open and close for any given matter to be voted on at the meeting; (g) the exclusion or removal of any stockholders or any other individual who refuses to comply with meeting rules, regulations, or procedures; (h) restrictions on the use of audio and video recording devices, cell phones and other electronic devices; (i) rules, regulations and procedures for compliance with any federal, state or local laws or regulations (including those concerning safety, health or security); (j) procedures (if any) requiring attendees to provide the Corporation advance notice of their intent to attend the meeting; and (k) rules, regulations or procedures regarding the participation by means of remote communication of stockholders and proxy holders not physically present at a meeting, whether such meeting is to be held at a designated place or solely by means of remote communication. The chair of the meeting shall be: (i) such person as the Board of Directors shall have designated to preside over all meetings of the stockholders; (ii) if the Board of Directors has not so designated such a chair of the meeting or if the chair of the meeting is unable to so preside or is absent, then the Chairperson of the Board, if one is elected; (iii) if the Board of Directors has not so designated a chair of the meeting and there is no Chairperson of the Board, or if the chair of the meeting or the Chairperson of the Board is unable to so preside or is absent, then the Chief Executive Officer, if one is elected; or (iv) in the absence or inability to serve of any of the aforementioned persons, the President of the Corporation. Unless and to the extent determined by the Board of Directors or the chair of the meeting, the chair of the meeting shall not be obligated to adopt or follow any technical, formal or parliamentary rules or principles of procedure. In the absence of the Secretary of the Corporation, the secretary of the meeting shall be such person as the chair of the meeting appoints.

SECTION 10. Inspectors of Elections. The Corporation shall, in advance of any meeting of stockholders, appoint one or three inspectors to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the chair of the meeting officer shall appoint one or more inspectors to act at the meeting. Any inspector may, but need not, be an officer, employee or agent of the Corporation. Each inspector, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of his or her ability. The inspectors shall perform such duties as are required by the DGCL, including the counting of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors. The chair of the meeting may review all determinations made by the inspectors, and in so doing the chair of the meeting shall be entitled to exercise his or her sole judgment and discretion and he or she shall not be bound by any determinations made by the inspectors. All determinations by the inspectors and, if applicable, the chair of the meeting, shall be subject to further review by any court of competent jurisdiction.

ARTICLE II

Directors

SECTION 1. Powers. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors, except as otherwise provided by the Certificate or required by law.

SECTION 2. Number and Terms. The number of directors of the Corporation shall be fixed solely and exclusively by resolution duly adopted from time to time by the Board of Directors, provided the Board of Directors shall consist of at least one (1) member. The directors shall hold office in the manner provided in the Certificate.

SECTION 3. Qualification. No director need be a stockholder of the Corporation.

SECTION 4. Vacancies. Vacancies in the Board of Directors shall be filled in the manner provided in the Certificate.

SECTION 5. Removal. Directors may be removed from office only in the manner provided in the Certificate or by applicable law.

SECTION 6. Resignation. A director may resign at any time by electronic transmission or by giving written notice to the Chairperson of the Board, if one is elected, the President or the Secretary. A resignation shall be effective upon receipt, unless the resignation otherwise provides.

SECTION 7. Regular Meetings. Regular meetings of the Board of Directors may be held at such hour, date and place (if any) as the Board of Directors may from time to time determine and publicize by means of reasonable notice given to any director who is not present when such determination is made.

SECTION 8. Special Meetings. Special meetings of the Board of Directors may be called, orally or in writing, by or at the request of a majority of the directors, the Chairperson of the Board, if one is elected, or the President. The person calling any such special meeting of the Board of Directors may fix the hour, date and place (if any) thereof. Notice thereof shall be given to each director as provided in Section 9 of this Article II.

SECTION 9. Notice of Meetings. Notice of the hour, date and place (if any) of all special meetings of the Board of Directors shall be given to each director by the Secretary or an Assistant Secretary, or in case of the death, absence, incapacity or refusal of such persons, by the Chairperson of the Board, if one is elected, the President or such other officer designated by the Chairperson of the Board, if one is elected, or any one of the directors calling the meeting. Notice of any special meeting of the Board of Directors shall be given to each director in person, by telephone, or by facsimile, electronic mail or other form of

electronic communication, sent to his or her business or home address, at least twenty-four (24) hours in advance of the meeting, or by written notice mailed to his or her business or home address, at least forty-eight (48) hours in advance of the meeting provided, however, that if the person or persons calling the meeting determine that it is otherwise necessary or advisable to hold the meeting sooner, then such person or persons may prescribe a shorter time period for notice to be given personally or by telephone, facsimile, electronic mail or other similar means of communication. Such notice shall be deemed to be delivered when hand-delivered to such address; read to such director by telephone; deposited in the mail so addressed, with postage thereon prepaid, if mailed; or dispatched or transmitted if sent by facsimile transmission or by electronic mail or other form of electronic communication. A written waiver of notice signed or electronically transmitted before or after a meeting by a director and filed with the records of the meeting shall be deemed to be equivalent to notice of the meeting. The attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because such meeting is not lawfully called or convened. Except as otherwise required by law, by the Certificate or by these Bylaws, neither the business to be transacted at, nor the purpose of, any meeting of the Board of Directors need be specified in the notice or waiver of notice of such meeting.

SECTION 10. Quorum. At any meeting of the Board of Directors, a majority of the total number of directors shall constitute a quorum for the transaction of business, but if less than a quorum is present at a meeting, a majority of the directors present may adjourn the meeting from time to time, and the meeting may be held as adjourned without further notice. Any business that might have been transacted at the meeting as originally noticed may be transacted at such adjourned meeting at which a quorum is present. For purposes of this Article II, the total number of directors includes any unfilled vacancies on the Board of Directors.

SECTION 11. Action at Meeting. At any meeting of the Board of Directors at which a quorum is present, the affirmative vote of a majority of the directors present shall constitute action by the Board of Directors, unless otherwise required by law, by the Certificate or by these Bylaws.

SECTION 12. Action by Consent. Any action required or permitted to be taken at any meeting of the Board of Directors may be taken without a meeting if all members of the Board of Directors consent thereto in writing or by electronic transmission. After such action is taken, the writing or writings or electronic transmission or transmissions shall be filed with the records of the meetings of the Board of Directors. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form. Such consent shall be treated as a resolution of the Board of Directors for all purposes.

SECTION 13. Manner of Participation. Directors may participate in meetings of the Board of Directors by means of video conference, conference telephone or other communications equipment by means of which all directors participating in the meeting can hear each other, and participation in a meeting in accordance herewith shall constitute presence in person at such meeting for purposes of these Bylaws.

SECTION 14. Presiding Director. The Board of Directors shall designate a representative to preside over all meetings of the Board of Directors, provided that if the Board of Directors does not so designate such a presiding director or such designated presiding director is unable to so preside or is absent, then the Chairperson of the Board, if one is elected, shall preside over all meetings of the Board of Directors. If both the designated presiding director, if one is so designated, and the Chairperson of the Board, if one is elected, are unable to preside or are absent, the Board of Directors shall designate an alternate representative to preside over a meeting of the Board of Directors.

SECTION 15. Committees. The Board of Directors may designate one or more committees, including, without limitation, a Compensation Committee, a Nominating & Corporate Governance Committee and an Audit Committee, and may delegate thereto some or all of its powers to such committee(s) except those which by law, by the Certificate or by these Bylaws may not be delegated. Except as the Board of Directors may otherwise determine, any such committee may make rules for the conduct of its business, but unless otherwise provided by the Board of Directors or in such rules, its business shall be conducted so far as possible in the same manner as is provided by these Bylaws for the Board of Directors. All members of such committees shall hold such offices at the pleasure of the Board of Directors. The Board of Directors may abolish any such committee at any time. Any committee to which the Board of Directors delegates any of its powers or duties shall keep records of its meetings.

SECTION 16. Compensation of Directors. Directors shall receive such compensation for their services as shall be determined by the Board of Directors, or a designated committee thereof, provided that directors who are serving the Corporation as employees shall not receive any salary or other compensation for their services as directors of the Corporation.

SECTION 17. Emergency By-laws. In the event of any emergency, disaster, catastrophe or other similar emergency condition of a type described in Section 110(a) of the DGCL (an “Emergency”), notwithstanding any different or conflicting provisions in the DGCL, the Certificate or these By-laws, during such Emergency:

(a) A meeting of the Board of Directors or a committee thereof may be called by any director, the Chairperson of the Board, the Chief Executive Officer, the President or the Secretary by such means as, in the judgment of the person calling the meeting, may be feasible at the time, and notice of any such meeting of the Board of Directors or any committee may be given, in the judgment of the person calling the meeting, only to such directors as it may be feasible to reach at the time and by such means as may be feasible at the time. Such notice shall be given at such time in advance of the meeting as, in the judgment of the person calling the meeting, circumstances permit.

(b) The director or directors in attendance at a meeting called in accordance with Section 17(a) of this Article II shall constitute a quorum.

(c) No officer, director or employee acting in accordance with this Section 17 shall be liable except for willful misconduct. No amendment, repeal or change to this Section 17 shall modify the prior sentence with regard to actions taken prior to the time of such amendment, repeal or change.

ARTICLE III

Officers

SECTION 1. Enumeration. The officers of the Corporation shall consist of a President, a Treasurer, a Secretary and such other officers, including, without limitation, a Chairperson of the Board, a Chief Executive Officer and one or more Vice Presidents (including Executive Vice Presidents or Senior Vice Presidents), Assistant Vice Presidents, Assistant Treasurers and Assistant Secretaries, as the Board of Directors may determine. Any number of offices may be held by the same person. The salaries and other compensation of the officers of the Corporation will be fixed by or in the manner designated by the Board of Directors or a committee thereof to which the Board of Directors has delegated such responsibility.

SECTION 2. Election. The Board of Directors shall elect the President, the Treasurer and the Secretary. Other officers may be elected by the Board of Directors or by such officers delegated such authority by the Board of Directors.

SECTION 3. Qualification. No officer need be a stockholder or a director.

SECTION 4. Tenure. Except as otherwise provided by the Certificate or by these Bylaws, each of the officers of the Corporation shall hold office until his or her successor is elected and qualified or until his or her earlier death, resignation or removal.

SECTION 5. Resignation and Removal. Any officer may resign by delivering his or her written or electronically transmitted resignation to the Corporation addressed to the President or the Secretary, and such resignation shall be effective upon receipt, unless the resignation otherwise provides. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract to which the officer is a party. Except as otherwise provided by law or by resolution of the Board of Directors, the Board of Directors may remove any officer. Except as the Board of Directors may otherwise determine, no officer who resigns or is removed shall have any right to any compensation as an officer for any period following his or her resignation or removal, or any right to damages on account of such removal, whether his or her compensation be by the month or by the year or otherwise, unless such compensation is expressly provided in a duly authorized written agreement with the Corporation.

SECTION 6. Absence or Disability. In the event of the absence or disability of any officer, the Board of Directors may designate another officer to act temporarily in place of such absent or disabled officer.

SECTION 7. Vacancies. Any vacancy in any office may be filled for the unexpired portion of the term by the Board of Directors.

SECTION 8. President. The President shall, subject to the direction of the Board of Directors, have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 9. Chairperson of the Board. The Chairperson of the Board, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 10. Chief Executive Officer. The Chief Executive Officer, if one is elected, shall have such powers and shall perform such duties as the Board of Directors may from time to time designate.

SECTION 11. Vice Presidents and Assistant Vice Presidents. Any Vice President (including any Executive Vice President or Senior Vice President) and any Assistant Vice President shall have such powers and shall perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

SECTION 12. Treasurer and Assistant Treasurers. The Treasurer shall, subject to the direction of the Board of Directors and except as the Board of Directors or the Chief Executive Officer may otherwise provide, have general charge of the financial affairs of the Corporation and shall cause to be kept accurate books of account. The Treasurer shall have custody of all funds, securities and valuable documents of the Corporation. He or she shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. Any Assistant Treasurer shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

SECTION 13. Secretary and Assistant Secretaries. The Secretary shall record all the proceedings of the meetings of the stockholders and the Board of Directors (including committees of the Board of Directors) in books kept for that purpose. In his or her absence from any such meeting, a temporary secretary chosen at the meeting shall record the proceedings thereof. The Secretary shall have charge of the stock ledger (which may, however, be kept by any transfer or other agent of the Corporation). The Secretary shall have custody of the seal of the Corporation, and the Secretary or an Assistant Secretary shall have authority to affix it to any instrument requiring it, and, when so affixed, the seal may be attested by his or her signature or that of an Assistant Secretary. The Secretary shall have such other duties and powers as may be designated from time to time by the Board of Directors or the Chief Executive Officer. In the absence of the Secretary, any Assistant Secretary may perform his or her duties and responsibilities. Any Assistant Secretary shall have such powers and perform such duties as the Board of Directors or the Chief Executive Officer may from time to time designate.

SECTION 14. Other Powers and Duties. Subject to these Bylaws and to such limitations as the Board of Directors may from time to time prescribe, the officers of the Corporation shall each have such powers and duties as generally pertain to their respective offices, as well as such powers and duties as from time to time may be conferred by the Board of Directors or the Chief Executive Officer.

SECTION 15. Representation of Shares of Other Corporations. The Chairperson of the Board, the President, any Vice President, the Treasurer, the Secretary or Assistant Secretary of this Corporation, or any other person authorized by the Board of Directors or the President or a Vice President, is authorized to vote, represent and exercise on behalf of this Corporation all rights incident to any and all securities of any other entity or entities standing in the name of this Corporation. The authority granted herein may be exercised either by such person directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.

SECTION 16. Bonded Officers. The Board of Directors may require any officer to give the Corporation a bond in such sum and with such surety or sureties as shall be satisfactory to the Board of Directors upon such terms and conditions as the Board of Directors may specify, including, without limitation, a bond for the faithful performance of his or her duties and for the restoration to the Corporation of all property in his or her possession or under his or her control belonging to the Corporation.

ARTICLE IV

Capital Stock

SECTION 1. Certificates of Stock. Each stockholder shall be entitled to a certificate of the capital stock of the Corporation in such form as may from time to time be prescribed by the Board of Directors. Such certificate shall be signed by any two authorized officers of the Corporation. The Corporation seal and the signatures by the Corporation’s officers, the transfer agent or the registrar may be facsimiles. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed on such certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if he or she were such officer, transfer agent or registrar at the time of its issue. Every certificate for shares of stock which are subject to any restriction on transfer and every certificate issued when the Corporation is authorized to issue more than one class or series of stock shall contain such legend with respect thereto as is required by law. Notwithstanding anything to the contrary provided in these Bylaws, the Board of Directors may provide by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares (except that the foregoing shall not apply to shares represented by a certificate until such certificate is surrendered to the Corporation), and by the approval and adoption of these Bylaws, the Board of Directors has determined that all classes or series of the Corporation’s stock may be uncertificated, whether upon original issuance, re-issuance or subsequent transfer.

SECTION 2. Transfers. Subject to any restrictions on transfer and unless otherwise provided by the Board of Directors, shares of stock that are represented by a certificate may be transferred on the books of the Corporation by the surrender to the Corporation or its transfer agent of the certificate therefor properly endorsed or accompanied by a written assignment or power of attorney properly executed, with transfer stamps (if necessary) affixed, and with such proof of the authenticity of signature as the Corporation or its transfer agent may reasonably require. Shares of stock that are not represented by a certificate may be transferred on the books of the Corporation by submitting to the Corporation or its transfer agent such evidence of transfer and following such other procedures as the Corporation or its transfer agent may require.

SECTION 3. Stock Transfer Agreements. The Corporation shall have power to enter into and perform any agreement with any number of stockholders of any one or more classes of stock of the Corporation to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not prohibited by the DGCL.

SECTION 4. Record Holders. Except as may otherwise be required by law, by the Certificate or by these Bylaws, the Corporation shall be entitled to treat the record holder of stock as shown on its books as the owner of such stock for all purposes, including the payment of dividends and the right to vote with respect thereto, regardless of any transfer, pledge or other disposition of such stock, until the shares have been transferred on the books of the Corporation in accordance with the requirements of these Bylaws.

SECTION 5. Record Date. In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date: (a) in the case of determination of stockholders entitled to vote at any meeting of stockholders, shall, unless otherwise required by law, not be more than sixty (60) nor less than ten (10) days before the date of such meeting and (b) in the case of any other action, shall not be more than sixty (60) days prior to such other action. If no record date is fixed: (i) the record date for determining stockholders entitled to notice of or to vote at a meeting of stockholders shall be at 5:00 p.m. Eastern time on the day next preceding the day on which notice is given, or, if notice is waived, at 5:00 p.m. Eastern time on the day next preceding the day on which the meeting is held; and (ii) the record date for determining stockholders for any other purpose shall be at 5:00 p.m. Eastern time on the day on which the Board of Directors adopts the resolution relating thereto.

SECTION 6. Replacement of Certificates. In case of the alleged loss, destruction or mutilation of a certificate of stock of the Corporation, a duplicate certificate may be issued in place thereof, upon such terms as the Board of Directors may prescribe.

ARTICLE V

Indemnification

SECTION 1. Definitions. For purposes of this Article V:

(a) “Corporate Status” describes the status of a person who is serving or has served (i) as a Director of the Corporation, (ii) as an Officer of the Corporation, (iii) as a Non-Officer Employee of the Corporation or (iv) as a director, partner, trustee, officer, employee or agent of any other corporation, partnership, limited liability company, joint venture, trust, employee benefit plan, foundation, association, organization or other legal entity which such person is or was serving at the request of the Corporation. For purposes of this Section 1(a), a Director, Officer or Non-Officer Employee of the Corporation who is serving or has served as a director, partner, trustee, officer, employee or agent of a Subsidiary shall be deemed to be serving at the request of the Corporation. Notwithstanding the foregoing, “Corporate Status” shall not include the status of a person who is serving or has served as a director, officer, employee or agent of a constituent corporation absorbed in a merger or consolidation transaction with the Corporation with respect to such person’s activities prior to said transaction, unless specifically authorized by the Board of Directors or the stockholders of the Corporation;

(b) “Director” means any person who serves or has served the Corporation as a director on the Board of Directors of the Corporation;

(c) “Disinterested Director” means, with respect to each Proceeding in respect of which indemnification is sought hereunder, a Director of the Corporation who is not and was not a party to such Proceeding;

(d) “Expenses” means all attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators and professional advisors (including, without limitation, accountants and investment bankers), travel expenses, duplicating costs, printing and binding costs, costs of preparation of demonstrative evidence and other courtroom presentation aids and devices, costs incurred in connection with document review, organization, imaging and computerization, telephone charges, postage, delivery service fees, and all other disbursements, costs or expenses of the type customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, settling or otherwise participating in, a Proceeding;

(e) “Liabilities” means judgments, damages, liabilities, losses, penalties, excise taxes, fines and amounts paid in settlement;

(f) “Non-Officer Employee” means any person who serves or has served as an employee or agent of the Corporation, but who is not or was not a Director or Officer;

(g) “Officer” means any person who serves or has served the Corporation as an officer of the Corporation appointed by the Board of Directors of the Corporation;

(h) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative or investigative; and

(i) “Subsidiary” means any corporation, partnership, limited liability company, joint venture, trust or other entity of which the Corporation owns (either directly or through or together with another Subsidiary of the Corporation) either (i) a general partner, managing member or other similar interest or (ii) (A) fifty percent (50%) or more of the voting power of the voting capital equity interests of such corporation, partnership, limited liability company, joint venture or other entity, or (B) fifty percent (50%) or more of the outstanding voting capital stock or other voting equity interests of such corporation, partnership, limited liability company, joint venture or other entity.

SECTION 2. Indemnification of Directors and Officers.

(a) Subject to the operation of Section 4 of this Article V, each Director and Officer shall be indemnified and held harmless by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), and to the extent authorized in this Section 2.

(1) Actions, Suits and Proceedings Other than By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses and Liabilities that are incurred or paid by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein (other than an action by or in the right of the Corporation), which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful.

(2) Actions, Suits and Proceedings By or In the Right of the Corporation. Each Director and Officer shall be indemnified and held harmless by the Corporation against any and all Expenses that are incurred by such Director or Officer or on such Director’s or Officer’s behalf in connection with any Proceeding or any claim, issue or matter therein by or in the right of the Corporation, which such Director or Officer is, or is threatened to be made, a party to or participant in by reason of such Director’s or Officer’s Corporate Status, if such Director or Officer acted in good faith and in a manner such Director or Officer reasonably believed to be in or not opposed to the best interests of the Corporation; provided, however, that no indemnification shall be made under this Section 2(a)(2) in respect of any claim, issue or matter as to which such Director or Officer shall have been finally adjudged by a court of competent jurisdiction to be liable to the Corporation, unless, and only to the extent that, the Court of Chancery of the State of Delaware or another court in which such Proceeding was brought shall determine upon application that, despite adjudication of liability, but in view of all the circumstances of the case, such Director or Officer is fairly and reasonably entitled to indemnification for such Expenses that such court deems proper.

(3) Survival of Rights. The rights of indemnification provided by this Section 2 shall continue as to a Director or Officer after he or she has ceased to be a Director or Officer and shall inure to the benefit of his or her heirs, executors, administrators and personal representatives.

(4) Actions by Directors or Officers. Notwithstanding the foregoing, the Corporation shall indemnify any Director or Officer seeking indemnification in connection with a Proceeding initiated by such Director or Officer only if such Proceeding (including any parts of such Proceeding not initiated by such Director or Officer) was authorized in advance by the Board of Directors, unless such Proceeding was brought to enforce such Officer’s or Director’s rights to indemnification or, in the case of Directors, advancement of Expenses under these Bylaws in accordance with the provisions set forth herein.

SECTION 3. Indemnification of Non-Officer Employees. Subject to the operation of Section 4 of this Article V, each Non-Officer Employee may, in the discretion of the Board of Directors, be indemnified by the Corporation to the fullest extent authorized by the DGCL, as the same exists or may hereafter be amended, against any or all Expenses and Liabilities that are incurred by such Non-Officer Employee or on such Non-Officer Employee’s behalf in connection with any threatened, pending or completed Proceeding, or any claim, issue or matter therein, which such Non-Officer Employee is, or is threatened to be made, a party to or participant in by reason of such Non-Officer Employee’s Corporate Status, if such Non-Officer Employee acted in good faith and in a manner such Non-Officer Employee reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal proceeding, had no reasonable cause to believe his or her conduct was unlawful. The rights of indemnification provided by this Section 3 shall exist as to a Non-Officer Employee after he or she has ceased to be a Non-Officer Employee and shall inure to the benefit of his or her heirs, personal representatives, executors and administrators. Notwithstanding the foregoing, the Corporation may indemnify any Non-Officer Employee seeking indemnification in connection with a Proceeding initiated by such Non-Officer Employee only if such Proceeding was authorized in advance by the Board of Directors.

SECTION 4. Determination. Unless ordered by a court, no indemnification shall be provided pursuant to this Article V to a Director, to an Officer or to a Non-Officer Employee unless a determination shall have been made that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal Proceeding, such person had no reasonable cause to believe his or her conduct was unlawful. Such determination shall be made by (a) a majority vote of the Disinterested Directors, even though less than a quorum of the Board of Directors, (b) a committee comprised of Disinterested Directors, such committee having been designated by a majority vote of the Disinterested Directors (even though less than a quorum), (c) if there are no such Disinterested Directors, or if a majority of Disinterested Directors so directs, by independent legal counsel in a written opinion or (d) by the stockholders of the Corporation.

SECTION 5. Advancement of Expenses to Directors Prior to Final Disposition.

(a) The Corporation shall advance all Expenses incurred by or on behalf of any Director in connection with any Proceeding in which such Director is involved by reason of such Director’s Corporate Status within thirty (30) days after the receipt by the Corporation of a written statement from such Director requesting such advance or advances from time to time,

whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Director and shall be preceded or accompanied by an undertaking by or on behalf of such Director to repay any Expenses so advanced if it shall ultimately be determined that such Director is not entitled to be indemnified against such Expenses. Notwithstanding the foregoing, the Corporation shall advance all Expenses incurred by or on behalf of any Director seeking advancement of expenses hereunder in connection with a Proceeding initiated by such Director only if such Proceeding (including any parts of such Proceeding not initiated by such Director) was (i) authorized by the Board of Directors or (ii) brought to enforce such Director’s rights to indemnification or advancement of Expenses under these Bylaws.

(b) If a claim for advancement of Expenses hereunder by a Director is not paid in full by the Corporation within thirty (30) days after receipt by the Corporation of documentation of Expenses and the required undertaking, such Director may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim and, if successful in whole or in part, such Director shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of such advancement of Expenses under this Article V shall not be a defense to an action brought by a Director for recovery of the unpaid amount of an advancement claim and shall not create a presumption that such advancement is not permissible. The burden of proving that a Director is not entitled to an advancement of expenses shall be on the Corporation.

(c) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Director has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 6. Advancement of Expenses to Officers and Non-Officer Employees Prior to Final Disposition.

(a) The Corporation may, at the discretion of the Board of Directors, advance any or all Expenses incurred by or on behalf of any Officer or any Non-Officer Employee in connection with any Proceeding in which such person is involved by reason of his or her Corporate Status as an Officer or Non-Officer Employee upon the receipt by the Corporation of a statement or statements from such Officer or Non-Officer Employee requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by such Officer or Non-Officer Employee and shall be preceded or accompanied by an undertaking by or on behalf of such person to repay any Expenses so advanced if it shall ultimately be determined that such Officer or Non-Officer Employee is not entitled to be indemnified against such Expenses.

(b) In any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that the Officer or Non-Officer Employee has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 7. Contractual Nature of Rights.

(a) The provisions of this Article V shall be deemed to be a contract between the Corporation and each Director and Officer entitled to the benefits hereof at any time while this Article V is in effect, in consideration of such person’s past or current and any future performance of services for the Corporation. Neither amendment, repeal or modification of any provision of this Article V nor the adoption of any provision of the Certificate inconsistent with this Article V shall eliminate or reduce any right conferred by this Article V in respect of any act or omission occurring, or any cause of action or claim that accrues or arises or any state of facts existing, at the time of or before such amendment, repeal, modification or adoption of an inconsistent provision (even in the case of a proceeding based on such a state of facts that is commenced after such time), and all rights to indemnification and advancement of Expenses granted herein or arising out of any act or omission shall vest at the time of the act or omission in question, regardless of when or if any proceeding with respect to such act or omission is commenced. The rights to indemnification and to advancement of expenses provided by, or granted pursuant to, this Article V shall continue notwithstanding that the person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators, legatees and distributees of such person.

(b) If a claim for indemnification hereunder by a Director or Officer is not paid in full by the Corporation within sixty (60) days after receipt by the Corporation of a written claim for indemnification, such Director or Officer may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim, and if successful in whole or in part, such Director or Officer shall also be entitled to be paid the expenses of prosecuting such claim. The failure of the Corporation (including its Board of Directors or any committee thereof, independent legal counsel or stockholders) to make a determination concerning the permissibility of such indemnification under this Article V shall not be a defense to an action brought by a Director or Officer for recovery of the unpaid amount of an indemnification claim and shall not create a presumption that such indemnification is not permissible. The burden of proving that a Director or Officer is not entitled to indemnification shall be on the Corporation.

(c) In any suit brought by a Director or Officer to enforce a right to indemnification hereunder, it shall be a defense that such Director or Officer has not met any applicable standard for indemnification set forth in the DGCL.

SECTION 8. Non-Exclusivity of Rights. The rights to indemnification and to advancement of Expenses set forth in this Article V shall not be exclusive of any other right that any Director, Officer or Non-Officer Employee may have or hereafter acquire under any statute, provision of the Certificate or these Bylaws, agreement, vote of stockholders or Disinterested Directors or otherwise.

SECTION 9. Insurance. The Corporation may maintain insurance, at its expense, to protect itself and any Director, Officer or Non-Officer Employee against any liability of any character asserted against or incurred by the Corporation or any such Director, Officer or Non-Officer Employee, or arising out of any such person’s Corporate Status, whether or not the Corporation would have the power to indemnify such person against such liability under the DGCL or the provisions of this Article V.

SECTION 10. Other Indemnification. The Corporation’s obligation, if any, to indemnify or provide advancement of Expenses to any person under this Article V as a result of such person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be reduced by any amount such person may collect as indemnification or advancement of Expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or enterprise (the “Primary Indemnitor”). Any indemnification or advancement of Expenses under this Article V owed by the Corporation as a result of a person serving, at the request of the Corporation, as a director, partner, trustee, officer, employee or agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall only be in excess of, and shall be secondary to, the indemnification or advancement of Expenses available from the applicable Primary Indemnitor(s) and any applicable insurance policies.

SECTION 11. Savings Clause. If this Article V or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Corporation shall nevertheless indemnify each indemnitee as to any expenses (including, without limitation, attorneys’ fees), liabilities, losses, judgments, fines (including, without limitation, excise taxes and penalties arising under the Employee Retirement Income Security Act of 1974, as amended) and amounts paid in settlement in connection with any action, suit, proceeding or investigation, whether civil, criminal or administrative, including, without limitation, an action by or in the right of the Corporation, to the fullest extent permitted by any applicable portion of this Article V that shall not have been invalidated and to the fullest extent permitted by applicable law.

ARTICLE VI

Miscellaneous Provisions

SECTION 1. Fiscal Year. The fiscal year of the Corporation shall be determined by the Board of Directors.

SECTION 2. Seal. The Board of Directors shall have power to adopt and alter the seal of the Corporation.

SECTION 3. Execution of Instruments. All deeds, leases, transfers, contracts, bonds, notes and other obligations to be entered into by the Corporation in the ordinary course of its business without director action may be executed on behalf of the Corporation by the Chairperson of the Board, if one is elected, the President or the Treasurer or any other officer, employee or agent of the Corporation as the Board of Directors or an executive committee of the Board of Directors may authorize or determine.

SECTION 4. Voting of Securities. Unless the Board of Directors otherwise provides, the Chairperson of the Board, if one is elected, the President or the Treasurer may waive notice of, and act on behalf of the Corporation, or appoint another person or persons to act as proxy or attorney in fact for the Corporation with or without discretionary power and/or power of substitution, at any meeting of stockholders or stockholders of any other corporation or organization, any of whose securities are held by the Corporation.

SECTION 5. Resident Agent. The Board of Directors may appoint a resident agent upon whom legal process may be served in any action or proceeding against the Corporation.

SECTION 6. Corporate Records. The original or attested copies of the Certificate, Bylaws and records of all meetings of the incorporators, stockholders and the Board of Directors and the stock transfer books, which shall contain the names of all stockholders, their record addresses and the amount of stock held by each, may be kept outside the State of Delaware and shall be kept at the principal office of the Corporation, at an office of its counsel, at an office of its transfer agent or in such manner as may be permitted by law.

SECTION 7. Certificate. All references in these Bylaws to the Certificate shall be deemed to refer to the Certificate, as amended and/or restated and in effect from time to time.

SECTION 8. Exclusive Jurisdiction of Delaware Courts or the United States Federal District Courts. Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting a claim of, or a claim based on, a breach of a fiduciary duty owed by any current or former director, officer or other employee or stockholder of the Corporation to the Corporation or the Corporation’s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the DGCL or the Certificate or these Bylaws (including the interpretation, validity or enforceability thereof) or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (iv) any action asserting a claim governed by the internal affairs doctrine; provided, however, that this sentence will not apply to any causes of action arising under the Securities Act of 1933, as amended, or the Exchange Act, or to any claim for which the federal courts have exclusive jurisdiction. Unless the Corporation consents in writing to the selection of an alternative forum, the federal district courts of the United States of America shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Exchange Act, or the respective rules and regulations promulgated thereunder. To the fullest extent permitted by law, any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the Corporation shall be deemed to have notice of and consented to the provisions of this Section 8.

SECTION 9. Amendment of Bylaws.

(a) Amendment by Directors. Except as otherwise required by law, these Bylaws may be amended or repealed by the Board of Directors.

(b) Amendment by Stockholders. Except as otherwise provided herein, the Bylaws of the Corporation may be amended or repealed at any annual meeting of stockholders, or at any special meeting of stockholders called for such purpose, by the affirmative vote of the holders of not less than two-thirds (2/3) of the voting power of the outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class; provided, however, that if the Board of Directors recommends that stockholders approve such amendment or repeal at such meeting of stockholders, such amendment or repeal shall only require the affirmative vote of the majority of outstanding shares of capital stock entitled to vote on such amendment or repeal, voting together as a single class.

SECTION 10. Notices. If mailed, notice to stockholders shall be deemed given when deposited in the mail, postage prepaid, directed to the stockholder at such stockholder’s address as it appears on the records of the Corporation. Without limiting the manner by which notice otherwise may be given to stockholders, any notice to stockholders may be given by electronic transmission in the manner provided in Section 232 of the DGCL.

SECTION 11. Waivers. A written waiver of any notice, signed by a stockholder or director, or waiver by electronic transmission by such person, whether given before or after the time of the event for which notice is to be given, shall be deemed equivalent to the notice required to be given to such person. Neither the business to be transacted at, nor the purpose of, any meeting need be specified in such a waiver.

Adopted on May 29, 2024 and effective upon the effectiveness of the S-1 registration statement.

EX-5.1 6 d803738dex51.htm EX-5.1 EX-5.1

Exhibit 5.1

June 3, 2024

Rapport Therapeutics, Inc.

1325 Boylston Street, Suite 401

Boston, Massachusetts 02215

Re:

Securities Registered under Registration Statement on Form S-1

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-1 (File No. 333-279486) (as amended or supplemented, the “Registration Statement”) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to the registration of the offering by Rapport Therapeutics, Inc, a Delaware corporation (the “Company”), of up to 9,200,000 shares (the “Shares”) of the Company’s Common Stock, par value $0.001 per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the “Underwriting Agreement”).

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

Based on the foregoing, we are of the opinion that the Company Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the Underwriting Agreement, will be validly issued, fully paid and non-assessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 Business Lawyer 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the caption “Legal Matters” in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

EX-10.2 7 d803738dex102.htm EX-10.2 EX-10.2

Exhibit 10.2

RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN

SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS

The name of the plan is the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Rapport Therapeutics, Inc. (the “Company”) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and strengthening their desire to remain with the Company or one of its Affiliates.

The following terms shall be defined as set forth below:

“Act” means the U.S. Securities Act of 1933, as amended, and the rules and regulations thereunder.

“Administrator” means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.

“Affiliate” means, at the time of determination, any “parent” or “subsidiary” of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which “parent” or “subsidiary” status is determined within the foregoing definition.

“Award” or “Awards,” except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights.

“Award Agreement” means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Agreement is subject to the terms and conditions of the Plan.

“Board” means the Board of Directors of the Company.

“Cash-Based Award” means an Award entitling the recipient to receive a cash-denominated payment.

“Code” means the U.S. Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.

“Consultant” means a consultant or adviser who provides bona fide services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act.

“Dividend Equivalent Right” means an Award entitling the grantee to receive credits based on ordinary cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.

“Effective Date” means the date on which the Plan becomes effective as set forth in Section 19.

“Exchange Act” means the U.S. Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.

“Fair Market Value” of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is listed on the National Association of Securities Dealers Automated Quotation System (“NASDAQ”), NASDAQ Global Market, The New York Stock Exchange or another national securities exchange or traded on any established market, the determination shall be made by reference to the closing price. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price; provided further, however, that if the date for which Fair Market Value is determined is the Registration Date, the Fair Market Value shall be the “Price to the Public” (or equivalent) set forth on the cover page for the final prospectus relating to the Company’s initial public offering.

“Incentive Stock Option” means any Stock Option designated and qualified as an “incentive stock option” as defined in Section 422 of the Code.

“Non-Employee Director” means a member of the Board who is not also an employee of the Company or any Subsidiary.

“Non-Qualified Stock Option” means any Stock Option that is not an Incentive Stock Option.

“Option” or “Stock Option” means any option to purchase shares of Stock granted pursuant to Section 5.

“Registration Date” means the date upon which the registration statement on Form S-1 that is filed by the Company with respect to its initial public offering is declared effective by the U.S. Securities and Exchange Commission.

“Restricted Shares” means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company’s right of repurchase.

“Restricted Stock Award” means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.

“Restricted Stock Units” means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.

“Sale Event” shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.

“Sale Price” means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.

“Section 409A” means Section 409A of the Code and the regulations and other guidance promulgated thereunder.

“Service Relationship” means any relationship as an employee, Non-Employee Director or Consultant of the Company or any Affiliate. Unless as otherwise set forth in the Award Agreement, a Service Relationship shall be deemed to continue without interruption in the event a grantee’s status changes from full-time employee to part-time employee or a grantee’s status changes from employee to Consultant or Non-Employee Director or vice versa, provided that there is no interruption or other termination of Service Relationship in connection with the grantee’s change in capacity.

“Stock” means the Common Stock, par value $0.001 per share, of the Company, subject to adjustments pursuant to Section 3.

“Stock Appreciation Right” means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.

“Subsidiary” means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.

“Ten Percent Owner” means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation.

“Unrestricted Stock Award” means an Award of shares of Stock free of any restrictions.

SECTION 2. ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS

(a) Administration of Plan. The Plan shall be administered by the Administrator.

(b) Powers of Administrator. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:

(i) to select the individuals to whom Awards may from time to time be granted;

(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;

(iii) to determine the number of shares of Stock to be covered by any Award;

(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Agreements;

(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award;

(vi) subject to the provisions of Section 5(c) or 6(d), to extend at any time the period in which Stock Options or Stock Appreciation Rights, respectively, may be exercised; and

(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.

All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.

(c) Delegation of Authority to Grant Awards. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company including the Chief Executive Officer of the Company all or part of the Administrator’s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator’s delegate or delegates that were consistent with the terms of the Plan.

(d) Award Agreement. Awards under the Plan shall be evidenced by Award Agreements that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event the Service Relationship terminates.

(e) Indemnification. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys’ fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company’s articles or bylaws or any directors’ and officers’ liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.

(f) Non-U.S. Award Recipients. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Affiliates operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Affiliates shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be incorporated into and made part of this Plan); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.

SECTION 3. STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION

(a) Stock Issuable. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 3,814,618 shares (the “Initial Limit”), plus on January 1, 2025 and on each January 1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be automatically cumulatively increased by five (5%) percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as approved by the Administrator, in all cases subject to adjustment as provided in this Section 3(c) (the “Annual Increase”). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased on

January 1, 2025 and on each January 1 thereafter by the lesser of the Annual Increase for such year or 3,814,618 shares of Stock, subject in all cases to adjustment as provided in Section 3(c). For purposes of this limitation, the shares of Stock underlying any awards under the Plan and the shares of Common Stock of the Company underlying the Company’s 2022 Stock Option and Grant Plan, as amended from time to time that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) shall be added back to the shares of Stock available for issuance under the Plan and, to the extent permitted under Section 422 of the Code and the regulations promulgated thereunder, the shares of Stock that may be issued as Incentive Stock Options. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company. Awards that may be settled solely in cash shall not be counted against the share reserve, nor shall they reduce the shares of Stock authorized for grant to a grantee in any calendar year.

(b) Maximum Awards to Non-Employee Directors. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any Non-Employee Director for services as a Non-Employee Director in any calendar year shall not exceed: (i) $1,000,000 in the first calendar year an individual becomes a Non-Employee Director and (ii) $750,000 in any other calendar year. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC Topic 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions.

(c) Changes in Stock. Subject to Section 3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, extraordinary cash dividend, stock split, reverse stock split or other similar change in the Company’s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of

outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.

(d) Mergers and Other Transactions. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent that the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Agreement, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator’s discretion or to the extent specified in the relevant Award Agreement. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.

SECTION 4. ELIGIBILITY

Grantees under the Plan will be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, Non-Employee Directors or Consultants who are providing services only to any “parent” of the Company, as such term is defined in Rule 405 of the Act, unless (i) the stock underlying the Awards is treated as “service recipient stock” under Section 409A or (ii) the Company has determined that such Awards are exempt from or otherwise comply with Section 409A.

SECTION 5. STOCK OPTIONS

(a) Award of Stock Options. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.

Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a “subsidiary corporation” within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.

Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee’s election, subject to such terms and conditions as the Administrator may establish.

(b) Exercise Price. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii) to individuals who are not subject to U.S. income tax on the date of grant or (iii) if the Stock Option is otherwise exempt from or compliant with Section 409A.

(c) Option Term. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant.

(d) Exercisability; Rights of a Stockholder. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the date of grant. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.

(e) Method of Exercise. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Agreement:

(i) In cash, by certified or bank check or other instrument acceptable to the Administrator;

(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;

(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or

(iv) With respect to Stock Options that are not Incentive Stock Options, by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.

Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Agreement or applicable provisions of laws (including the satisfaction of any taxes that the Company or an Affiliate is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.

(f) Annual Limit on Incentive Stock Options. To the extent required for “incentive stock option” treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.

SECTION 6. STOCK APPRECIATION RIGHTS

(a) Award of Stock Appreciation Rights. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Agreement) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.

(b) Exercise Price of Stock Appreciation Rights. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant. Notwithstanding the foregoing, Stock Appreciation Rights may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii) to individuals who are not subject to U.S. income tax on the date of grant or (iii) if the Stock Appreciation Right is otherwise exempt from or compliant with Section 409A.

(c) Grant and Exercise of Stock Appreciation Rights. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.

(d) Terms and Conditions of Stock Appreciation Rights. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.

SECTION 7. RESTRICTED STOCK AWARDS

(a) Nature of Restricted Stock Awards. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.

(b) Rights as a Stockholder. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of vesting conditions, any dividends paid by the Company shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.

(c) Restrictions. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Agreement. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section 16 below, in writing after the Award is issued, if a grantee’s employment (or other Service Relationship) with the Company and its Affiliates terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee’s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.

(d) Vesting of Restricted Shares. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company’s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed “vested.”

SECTION 8. RESTRICTED STOCK UNITS

(a) Nature of Restricted Stock Units. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the Award Agreement) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.

(b) Election to Receive Restricted Stock Units in Lieu of Compensation. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Agreement.

(c) Rights as a Stockholder. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his or her Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.

(d) Termination. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section 16 below, in writing after the Award is issued, a grantee’s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee’s termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason.

SECTION 9. UNRESTRICTED STOCK AWARDS

Grant or Sale of Unrestricted Stock. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.

SECTION 10. CASH-BASED AWARDS

Grant of Cash-Based Awards. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals, including continued employment (or other Service Relationship). The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash.

SECTION 11. DIVIDEND EQUIVALENT RIGHTS

(a) Dividend Equivalent Rights. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Agreement. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the

Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.

(b) Termination. Except as may otherwise be provided by the Administrator either in the Award Agreement or, subject to Section 16 below, in writing after the Award is issued, a grantee’s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee’s termination of employment (or cessation of Service Relationship) with the Company and its Affiliates for any reason.

SECTION 12. TRANSFERABILITY OF AWARDS

(a) Transferability. Except as provided in Section 12(b) below or otherwise determined by the Administrator, during a grantee’s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee’s legal representative or guardian in the event of the grantee’s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.

(b) Administrator Action. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Agreement regarding a given Award or by subsequent written approval that the grantee (who is an employee or Non-Employee Director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award Agreement. In no event may an Award be transferred by a grantee for value.

(c) Family Member. For purposes of Section 12(b), “family member” shall mean a grantee’s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee’s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.

(d) Designation of Beneficiary. To the extent permitted by the Company and valid under applicable law, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee’s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee’s estate or legal heirs.

SECTION 13. TAX WITHHOLDING

(a) Payment by Grantee. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for tax purposes, pay to the Company or any applicable Affiliate, or make arrangements satisfactory to the Administrator regarding payment of, any U.S. and non-U.S. federal, state, or local taxes of any kind required by law to be withheld by the Company or any applicable Affiliate with respect to such income. The Company and its Affiliates shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee or to satisfy any applicable withholding obligations by any other method of withholding that the Company and its Affiliates deem appropriate. The Company’s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.

(b) Payment in Stock. The Administrator may cause any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require any tax withholding obligation of the Company or any applicable Affiliate to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company or any applicable Affiliate in an amount that would satisfy the withholding amount due.

SECTION 14. SECTION 409A AWARDS

Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute “nonqualified deferred compensation” within the meaning of Section 409A (a “409A Award”), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a “separation from service” (within the meaning of Section 409A) to a grantee who is then considered a “specified employee” (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee’s separation from service, or (ii) the grantee’s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any

409A Award may not be accelerated except to the extent permitted by Section 409A. The Company makes no representation that any or all of the payments or benefits described in the Plan will be exempt from or comply with Section 409A of the Code and makes no undertaking to preclude Section 409A of the Code from applying to any such payment. The grantee shall be solely responsible for the payment of any taxes and penalties incurred under Section 409A.

SECTION 15. TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.

(a) Termination of Service Relationship. If the grantee’s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.

(b) For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:

(i) a transfer to the Service Relationship of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or

(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee’s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.

SECTION 16. AMENDMENTS AND TERMINATION

The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder’s consent. The Administrator is specifically authorized to exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights, or effect the repricing of such Awards through cancellation and re-grants or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, or to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by Company stockholders. Nothing in this Section 16 shall limit the Administrator’s authority to take any action permitted pursuant to Section 3(c) or 3(d).

SECTION 17. STATUS OF PLAN

With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company’s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.

SECTION 18. GENERAL PROVISIONS

(a) No Distribution. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.

(b) Issuance of Stock. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee’s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic “book entry” records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.

(c) Stockholder Rights. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.

(d) Other Incentive Arrangements; No Rights to Continued Service Relationship. Nothing contained in this Plan shall prevent the Board from adopting other or additional incentive arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any grantee any right to continued employment or other Service Relationship with the Company or any Affiliate.

(e) Trading Policy Restrictions. Option exercises and other Awards under the Plan shall be subject to the Company’s insider trading policies and procedures, as in effect from time to time.

(f) Clawback Policy. Awards under the Plan shall be subject to the Company’s clawback policy, as in effect from time to time.

(g) Fractional Shares. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Administrator shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares, or whether such fractional Shares or nay rights thereto shall be cancelled, terminated or otherwise eliminated.

SECTION 19. EFFECTIVE DATE OF PLAN

This Plan shall become effective upon the date immediately preceding the Registration Date subject to prior stockholder approval in accordance with applicable state law, the Company’s bylaws and articles of incorporation, and applicable stock exchange rules. No grants of Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board.

SECTION 20. GOVERNING LAW

This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware, applied without regard to conflict of law principles.

DATE APPROVED BY BOARD OF DIRECTORS: May 29, 2024

DATE APPROVED BY STOCKHOLDERS: May 30, 2024

INCENTIVE STOCK OPTION AGREEMENT

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Optionee:

No. of Option Shares:

Option Exercise Price per Share:		$
		[FMV on Grant Date (110% of FMV if a 10% owner)]

Grant Date:

Expiration Date:
		[up to 10 years (5 if a 10% owner)]

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Rapport Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: __________________, so long as the Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates.

Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.

2. Manner of Exercise.

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.

have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection.

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.

(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee’s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.

(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

3. Termination of Service Relationship. If the Optionee’s Service Relationship with the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.

months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Termination Due to Disability. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of 12 months from the date the Optionee’s Service Relationship is terminated by reason of the Optionee’s disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of the termination of the Optionee’s Service Relationship by reason of the Optionee’s disability shall terminate immediately and be of no further force or effect.

(c) Termination for Cause. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, “Cause” shall mean, unless otherwise provided in an employment or service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee’s duties to the Company.

(d) Other Termination. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee’s death, the Optionee’s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3) months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.

The Administrator’s determination of the reason for termination of the Optionee’s Service Relationship with the Company or a Subsidiary shall be conclusive and binding on the Optionee and his or her representatives or legatees.

4. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

5. Transferability. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee’s

lifetime, only by the Optionee, and thereafter, only by the Optionee’s legal representative or legatee.

6. Status of the Stock Option. This Stock Option is intended to qualify as an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements and that this Stock Option must be exercised within three months after termination of employment as an employee (or 12 months in the case of death or disability) to qualify as an “incentive stock option”. To the extent any portion of this Stock Option does not so qualify as an “incentive stock option,” such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition.

7. Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Optionee on account of such transfer.

8. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee’s Service Relationship with the Company or a Subsidiary at any time.

9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

12. [Clawback Acknowledgement. The Optionee acknowledges that the Optionee may become subject to the Rapport Therapeutics, Inc. Compensation Recovery Policy adopted pursuant to Rule 10D-1 promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the “Clawback Policy”). The Optionee understands that if the Optionee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant to such means as the Company and/or the Board may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee’s employment or service with the Company terminates. The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee acknowledges and agrees that the Optionee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether alone or in combination with any other action, event or condition, be deemed (i) an event giving rise to a right to resign for Good Reason (as defined in the Rapport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to the Optionee, or (ii) to constitute a

breach of a contract or other arrangement to which the Optionee is a party. This Section 12 is a material term of this Agreement.]¹


Rapport Therapeutics, Inc.

By:
		Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Optionee (including through an online acceptance process) is acceptable.


Dated:
		Optionee’s Signature

		Optionee’s name and address:

¹	For Section 16 officers only.

NON-QUALIFIED STOCK OPTION AGREEMENT

FOR COMPANY EMPLOYEES AND CONSULTANTS

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Optionee:

No. of Option Shares:

Option Exercise Price per Share:		$
		[FMV on Grant Date]

Grant Date:

Expiration Date:

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Rapport Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: __________________________, so long as Optionee continues to have a Service Relationship with the Company or a Subsidiary on such dates.

Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.

2. Manner of Exercise.

Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a “net exercise” arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.

The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company’s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.

(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

(a) Termination Due to Death. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee’s legal representative or legatee for a period of twelve (12) months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Termination Due to Disability. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates by reason of the Optionee’s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination, may thereafter be exercised by the Optionee for a period of twelve (12) months from the date the Optionee’s Service Relationship is terminated by reason of the Optionee’s disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of the termination of the Optionee’s Service Relationship by reason of disability shall terminate immediately and be of no further force or effect.

(c) Termination for Cause. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, “Cause” shall mean, unless otherwise provided in an employment or other service agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee’s duties to the Company.

(d) Other Termination. If the Optionee’s Service Relationship with the Company or a Subsidiary terminates for any reason other than the Optionee’s death, the Optionee’s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three (3) months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.

6. Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Optionee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Optionee on account of such transfer.

7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee’s Service Relationship with the Company or a Subsidiary at any time.

8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to, Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file

with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

11. [Clawback Acknowledgement. The Optionee acknowledges that the Optionee may become subject to the Rapport Therapeutics, Inc. Compensation Recovery Policy adopted pursuant to Rule 10D-1 promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the “Clawback Policy”). The Optionee understands that if the Optionee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Optionee pursuant to such means as the Company and/or the Board may elect. The Optionee agrees that the Optionee shall take all required action to enable such recovery. The Optionee understands that such recovery may be sought and occur after the Optionee’s employment or service with the Company terminates. The Optionee further agrees that the Optionee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Optionee hereby irrevocably agrees to forego such indemnification. The Optionee acknowledges and agrees that the Optionee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Optionee shall not, whether alone or in combination with any other action, event or condition, be deemed (i) an event giving rise to a right to resign for Good Reason (as defined in the Rapport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to the Optionee, or (ii) to constitute a breach of a contract or other arrangement to which the Optionee is a party. This Section 11 is a material term of this Agreement.]¹

¹	For Section 16 officers only.


Rapport Therapeutics, Inc.

By:
		Title:


Dated:
		Optionee’s Signature

		Optionee’s name and address:

NON-QUALIFIED STOCK OPTION AGREEMENT

FOR COMPANY NON-EMPLOYEE DIRECTORS

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Optionee:

No. of Option Shares:

Option Exercise Price per Share:		$
		[FMV on Grant Date]

Grant Date:

Expiration Date:
		[No more than 10 years]

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Rapport Therapeutics, Inc. (the “Company”) hereby grants to the Optionee named above, who is a Non-Employee Director of the Company but is not an employee of the Company, an option (the “Stock Option”) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.001 per share (the “Stock”), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an “incentive stock option” under Section 422 of the Internal Revenue Code of 1986, as amended.

1. Exercisability Schedule. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable as follows: __________________________, so long as the Optionee remains in service as a member of the Board on such dates.

Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Option Shares shall immediately be deemed vested and exercisable on the date of such Sale Event; provided, that the Optionee remains in service as a member of the Board until the date of such Sale Event. Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.

2. Manner of Exercise.

(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee

may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.

(c) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.

3. Termination as Non-Employee Director. If the Optionee ceases to be a Non-Employee Director of the Company, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.

(a) Termination Due to Death. If the Optionee’s service as a Non-Employee Director terminates by reason of the Optionee’s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee’s legal representative or legatee for a period of twelve (12) months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.

(b) Other Termination. If the Optionee ceases to be a Non-Employee Director for any reason other than the Optionee’s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Non-Employee Director, for a period of twelve (12) months from the date the Optionee ceased to be a Non-Employee Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Non-Employee Director shall terminate immediately and be of no further force or effect.

6. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Optionee’s Service Relationship with the Company or a Subsidiary at any time.

7. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.

8. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or

desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

9. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.


Rapport Therapeutics, Inc.

By:
		Title:


Dated:
		Optionee’s Signature

		Optionee’s name and address:

RESTRICTED STOCK AWARD AGREEMENT

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Grantee:

No. of Shares:

Grant Date:

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan (the “Plan”) as amended through the date hereof, Rapport Therapeutics, Inc. (the “Company”) hereby grants a Restricted Stock Award (an “Award”) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.001 per share (the “Stock”) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.

1. Award. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company’s transfer agent in book entry form, and the Grantee’s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank.

2. Restrictions and Conditions.

(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan.

(b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting.

(c) If the Grantee’s Service Relationship with the Company or a Subsidiary is voluntarily or involuntarily terminated for any reason (including due to death or disability) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company.

3. Vesting of Restricted Stock. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse as follows: (each such date, a “Vesting Date”), so long as the Grantee continues to have a Service Relationship with the Company or a

Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date.

Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3.

4. Dividends. Dividends on shares of Restricted Stock shall be paid currently to the Grantee.

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

6. Transferability. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.

7. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued or released to the Grantee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer.

8. Election Under Section 83(b). The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election.

9. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time.

10. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

11. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to, Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

12. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

13. [Clawback Acknowledgement. The Grantee acknowledges that the Grantee may become subject to the Rapport Therapeutics, Inc. Compensation Recovery Policy adopted pursuant to Rule 10D-1 promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the “Clawback Policy”). The Grantee understands that if the Grantee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Grantee pursuant to such means as the Company and/or the Board may elect. The Grantee agrees that the Grantee shall take all required action to enable such recovery. The Grantee understands that such recovery may be sought and occur after the Grantee’s employment or service with the Company terminates. The Grantee further agrees that the Grantee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Grantee hereby irrevocably agrees to forego such indemnification. The Grantee acknowledges and agrees that the Grantee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Grantee shall not, whether alone or in combination with any other action, event or condition, be deemed (i) an event giving rise to a right to resign for Good Reason (as defined in the Rapport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to the Grantee, or (ii) to constitute a breach of a contract or

other arrangement to which the Grantee is a party. This Section 13 is a material term of this Agreement.]¹


Rapport Therapeutics, Inc.

By:
		Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.


Dated:
		Grantee’s Signature

		Grantee’s name and address:

¹	For Section 16 officers only.

RESTRICTED STOCK UNIT AWARD AGREEMENT

FOR COMPANY EMPLOYEES AND CONSULTANTS

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Grantee:

No. of Restricted Stock Units:

Grant Date:

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Rapport Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the “Stock”) of the Company.

1. Restrictions on Transfer of Award. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.

2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse as follows: __________________________ (each such date, a “Vesting Date”), so long as the Grantee continues to have a Service Relationship with the Company or a Subsidiary on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.

The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.

3. Termination of Service Relationship. If the Grantee’s Service Relationship with the Company or a Subsidiary terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.

4. Issuance of Shares of Stock. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this

Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.

5. Incorporation of Plan. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.

6. Tax Withholding. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer.

7. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.

8. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time.

9. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

10. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to, Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

11. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.

12. [Clawback Acknowledgement. The Grantee acknowledges that the Grantee may become subject to the Rapport Therapeutics, Inc. Compensation Recovery Policy adopted pursuant to Rule 10D-1 promulgated under the Exchange Act and Nasdaq Rule 5608, or any successor rule (the “Clawback Policy”). The Grantee understands that if the Grantee is or becomes subject to the Clawback Policy, the Company and/or the Board shall be entitled to recover all Erroneously Awarded Compensation (as defined in the Clawback Policy) from the Grantee pursuant to such means as the Company and/or the Board may elect. The Grantee agrees that the Grantee shall take all required action to enable such recovery. The Grantee understands that such recovery may be sought and occur after the Grantee’s employment or service with the Company terminates. The Grantee further agrees that the Grantee is not entitled to indemnification for any Erroneously Awarded Compensation or for any claim or losses arising out of or in any way related to Erroneously Awarded Compensation recovered pursuant to the Clawback Policy and, to the extent any agreement or organizational document purports to provide otherwise, the Grantee hereby irrevocably agrees to forego such indemnification. The Grantee acknowledges and agrees that the Grantee has received and has had an opportunity to review the Clawback Policy. Any action by the Company to recover Erroneously Awarded Compensation under the Clawback Policy from the Grantee shall not, whether alone or in combination with any other action, event or condition, be deemed (i) an event giving rise to a right to resign for Good Reason (as defined in the Rapport Therapeutics, Inc. Executive Severance Plan) or serve as a basis for a claim of constructive termination under any benefits or compensation arrangement applicable to the Grantee, or (ii) to constitute a breach of a contract or other arrangement to which the Grantee is a party. This Section 12 is a material term of this Agreement.]¹

¹	For Section 16 officers only.


Rapport Therapeutics, Inc.

By:
		Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.


Dated:
		Grantee’s Signature

		Grantee’s name and address:

RESTRICTED STOCK UNIT AWARD AGREEMENT

FOR NON-EMPLOYEE DIRECTORS

UNDER THE RAPPORT THERAPEUTICS, INC.

2024 STOCK OPTION AND INCENTIVE PLAN


Name of Grantee:

No. of Restricted Stock Units:

Grant Date:

Pursuant to the Rapport Therapeutics, Inc. 2024 Stock Option and Incentive Plan as amended through the date hereof (the “Plan”), Rapport Therapeutics, Inc. (the “Company”) hereby grants an award of the number of Restricted Stock Units listed above (an “Award”) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.001 per share (the “Stock”) of the Company.

2. Vesting of Restricted Stock Units. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse as follows: ________________________ (each such date, a “Vesting Date” ), so long as the Grantee remains in service as a member of the Board on such Vesting Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.

Notwithstanding the foregoing, in the event of a Sale Event, 100% of the then-outstanding and unvested Restricted Stock Units shall immediately be deemed vested on the date of such Sale Event; provided, that the Grantee remains in service as a member of the Board until the date of such Sale Event. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.

3. Termination of Service as a Non-Employee Director. If the Grantee’s service as a Non-Employee Director terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.

6. Section 409A of the Code. This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as “short-term deferrals” as described in Section 409A of the Code.

7. No Obligation to Continue Service Relationship. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in a Service Relationship with the Company or a Subsidiary and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the Grantee’s Service Relationship with the Company or a Subsidiary at any time.

8. Integration. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.

9. Data Privacy Consent. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the “Relevant Companies”) may process any and all personal or professional data, including but not limited to, Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the “Relevant Information”). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.

10. Notices. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file

with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.


Rapport Therapeutics, Inc.

By:
		Title:

The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company’s instructions to the Grantee (including through an online acceptance process) is acceptable.


Dated:
		Grantee’s Signature

		Grantee’s name and address:

EX-10.3 8 d803738dex103.htm EX-10.3 EX-10.3

Exhibit 10.3

RAPPORT THERAPEUTICS, INC.

2024 EMPLOYEE STOCK PURCHASE PLAN

The purpose of the Rapport Therapeutics, Inc. 2024 Employee Stock Purchase Plan (the “Plan”) is to provide eligible employees of Rapport Therapeutics, Inc. (the “Company”) and each Designated Company (as defined in Section 11) with opportunities to purchase shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”). 324,423 shares of Common Stock in the aggregate have been approved and reserved for this purpose, plus on January 1, 2025 and each January 1 thereafter until the Plan terminates pursuant to Section 20, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 648,486 shares of Common Stock, (ii) 1% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, and (iii) such lesser number of shares of Common Stock as determined by the Administrator (as defined in Section 1). The Plan includes two components: a Code Section 423 Component (the “423 Component”) and a non-Code Section 423 Component (the “Non-423 Component”). It is intended for the 423 Component to constitute an “employee stock purchase plan” within the meaning of Section 423(b) of the U.S. Internal Revenue Code of 1986, as amended (the “Code”), and the 423 Component shall be interpreted in accordance with that intent. Under the Non-423 Component, which does not qualify as an “employee stock purchase plan” within the meaning of Section 423(b) of the Code, options will be granted pursuant to rules, procedures or sub-plans adopted by the Administrator designed to comply with appliable laws to achieve tax and other objectives for eligible employees. Except as otherwise provided herein or by the Administrator, the Non-423 Component will operate and be administered in the same manner as the 423 Component. Unless otherwise defined herein, capitalized terms in this Plan shall have the meaning ascribed to them in Section 11.

1. Administration. The Plan will be administered by the person or persons (the “Administrator”) appointed by the Company’s Board of Directors (the “Board”) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan, including to accommodate the specific requirements of applicable laws, regulations and procedures for jurisdictions outside the United States; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder.

2. Offerings. The Company may make one or more offerings to eligible employees to purchase Common Stock under the Plan (“Offerings”) consisting of one or more Purchase Periods. Each Offering will begin and end on the dates to be determined by the Administrator, provided that no Offering shall exceed 27 months in duration. Unless the Administrator, in its sole discretion, chooses otherwise prior to an Offering Date (as defined below), and to the extent an Offering has more than one Purchase Period and to the extent permitted by applicable law, if the Fair Market Value of the Common Stock on any Exercise Date in an Offering is lower than the Fair Market Value of the Common Stock on the Offering Date, then all participants in such Offering automatically will be withdrawn from such Offering immediately after the exercise of their option on such Exercise Date and automatically re-enrolled in the immediately following Offering as of the first day thereof and the preceding Offering will terminate.

3. Eligibility. All individuals classified as employees on the payroll records of the Company and each Designated Company are eligible to participate in any one or more of the Offerings under the Plan, provided that, the Administrator may determine, in advance of any Offering, that employees are eligible only if, as of the first day of the applicable Offering (the “Offering Date”) (a) they are customarily employed by the Company or a Designated Company for more than twenty (20) hours a week (or such lesser number of hours per week consistent with Section 423 of the Code), (b) they are customarily employed by the Company or a Designated Company for more than five months per calendar year, (c) they have completed such minimum period of service prior to the Offering Date (provided such service requirement does not exceed two years of employment) and/or (d) they satisfy such other criteria as the Administrator may determine consistent with Section 423 of the Code. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Company for purposes of the Company’s or applicable Designated Company’s payroll system are not considered to be eligible employees of the Company or any Designated Company and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Company for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Company on the Company’s or Designated Company’s payroll system to become eligible to participate in this Plan is through an amendment or subplan to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein.

4. Participation.

(a) An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to the Company or an agent designated by the Company (in the manner described in Section 4(b)) at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering).

(b) Enrollment. The enrollment form (which may be in an electronic format or such other method as determined by the Company in accordance with the Company’s practices) will (a) state a whole percentage or amount to be deducted from an eligible employee’s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such Participant’s deductions or contributions and purchases will continue at the same percentage or amount of Compensation for future Offerings, provided he or she remains eligible.

(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code.

5. Employee Contributions. Each eligible employee may authorize payroll deductions or contributions at a minimum of 1 percent up to a maximum of 15 percent of such employee’s Compensation for each pay period or such other maximum as may be specified by the Administrator in advance of an Offering. The Company will maintain book accounts showing the amount of payroll deductions or contributions made by each Participant for each Offering Period. No interest will accrue or be paid on payroll deductions or contributions, except as may be required by applicable law. If payroll deductions or contributions for purposes of the Plan are prohibited or otherwise problematic under applicable law (as determined by the Administrator in its discretion), the Administrator may require Participants to contribute to the Plan by such other means as determined by the Administrator. Any reference to “payroll deductions” or contributions in this Section 5 (or in any other section of the Plan ) will similarly cover contributions by other means made pursuant to this Section 5.

6. Deduction Changes. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction or contributions during any Offering, but may increase or decrease his or her payroll deduction or contributions with respect to the next Offering (subject to the limitations of Section 5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction or contributions during an Offering.

7. Withdrawal. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to the Company or an agent designated by the Company (in accordance with such procedures as may be established by the Administrator). The Participant’s withdrawal will be effective as of the next business day (or such other date established by the Administrator). Following a Participant’s withdrawal, the Company will promptly refund such individual’s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4.

8. Grant of Options. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (“Option”) to purchase on the last day of a Purchase Period (the “Exercise Date”) and at the Option Price hereinafter provided for, the lower of (a) a number of shares of Common Stock determined by dividing such Participant’s accumulated payroll deductions or contributions on such Exercise Date by the Option Price (as defined herein), or (b) the number of shares of Common Stock determined by dividing $25,000 by the Fair Market Value of the Common Stock on the Offering Date for such Offering (or such other maximum number of shares as shall have been established by the Administrator in advance of the Offering); provided, however, that such Option shall be subject to the limitations set forth below. Each Participant’s Option shall be exercisable only to the extent of such Participant’s accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option (the “Option Price”) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less.

Notwithstanding the foregoing, no Participant may be granted an Option hereunder if such Participant, immediately after the Option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the

preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the Fair Market Value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted.

9. Exercise of Option and Purchase of Shares. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions or contributions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Unless otherwise determined by the Administrator in advance of an Offering, any amount remaining in a Participant’s account after the purchase of shares at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant’s account at the end of an Offering will be refunded to the Participant promptly.

10. Issuance of Certificates. Certificates or book-entries at the Company’s transfer agent representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship or in the name of a broker authorized by the employee to be his, her or their nominee for such purpose.

11. Definitions.

The term “Affiliate” means any entity that, directly or indirectly through one or more intermediaries, controls, is controlled by or is under the common control with, the Company.

The term “Compensation” means the amount of base pay, prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains related to options or other share-based awards, and similar items. The Administrator shall have the discretion to determine the application of this definition to Participants outside the United States.

The term “Designated Company” means any present or future Subsidiary or Affiliate that has been designated by the Administrator to participate in the Plan. The Administrator may so designate any Subsidiary or Affiliate, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders, and may further designate such companies or Participants as participating in the 423 Component or the Non-423 Component. The Administrator may also determine which Affiliates or eligible employees may be excluded from participation in the Plan, to the extent consistent with Section 423 of the Code or as implemented under the Non-423 Component, and determine which Designated Company or Companies will participate in separate Offerings (to the extent that the Company makes separate Offerings). For purposes of the 423 Component, only the Company and its Subsidiaries may be Designated Companies; provided, however, that at any given time, a Subsidiary that is a Designated Company under the 423 Component will not be a Designated Company under the Non-423 Component.

The term “Fair Market Value of the Common Stock” on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (“Nasdaq”), Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price.

The term “Initial Public Offering” means the first underwritten, firm commitment public offering pursuant to an effective registration statement under the U.S. Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock.

The term “New Exercise Date” means a new Exercise Date if the Administrator shortens any Offering then in progress.

The term “Parent” means a “parent corporation” with respect to the Company, as defined in Section 424(e) of the Code.

The term “Participant” means an individual who is eligible as determined in Section 3 and who has complied with the provisions of Section 4.

The term “Purchase Period” means a period of time within an Offering, as may be specified by the Administrator in accordance with Section 2, generally beginning on the Offering Date or the next day following an Exercise Date within an Offering, and ending on an Exercise Date. An Offering may consist of one or more Purchase Periods.

The term “Registration Date” means the date on which the registration statement on Form S-1 that is filed by the Company with respect to its Initial Public Offering is declared effective by the U.S. Securities and Exchange Commission (the “SEC”).

The term “Sale Event” means (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization, statutory share exchange, consolidation, or similar transaction pursuant to which the holders of the Company’s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Common Stock to an unrelated person, entity or group thereof acting in concert, (iv) any other transaction in which the owners of the Company’s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company, or (v) the approval by the stockholders of the Company of a complete liquidation or dissolution of the Company.

The term “Subsidiary” means a “subsidiary corporation” with respect to the Company, as defined in Section 424(f) of the Code.

12. Rights on Termination or Transfer of Employment. If a Participant’s employment terminates for any reason before the Exercise Date for any Offering, no payroll deduction or contributions will be taken from any pay due and owing to the Participant and the balance in the Participant’s account will be paid to such Participant or, in the case of such Participant’s death, if permitted by the Administrator and valid under applicable law, to his or her designated

beneficiary or to the legal representative of his or her estate as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Company, ceases to be a Subsidiary or Affiliate, or if the employee is transferred to any corporation other than the Company or a Designated Company. Unless otherwise determined by the Administrator, a Participant whose employment transfers between, or whose employment terminates with an immediate rehire (with no break in service) by, Designated Companies or a Designated Company and the Company will not be treated as having terminated employment for purposes of participating in the Plan or an Offering; provided, however, that if a Participant transfers from an Offering under the 423 Component to an Offering under the Non-423 Component, the exercise of the Participant’s Option will be qualified under the 423 Component only to the extent that such exercise complies with Section 423 of the Code. If a Participant transfers from an Offering under the Non-423 Component to an Offering under the 423 Component, the exercise of the Participant’s Option will remain non-qualified under the Non-423 Component. Further, an employee will not be deemed to have terminated employment for purposes of this Section 12 if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee’s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing.

13. Special Rules and Sub-Plans. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules or sub-plans applicable to the employees of a particular Designated Company, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such

Designated Company has employees, regarding, without limitation, eligibility to participate in the Plan, handling and making of payroll deductions or contributions by other means, establishment of bank or trust accounts to hold payroll deductions or contributions, payment of interest, conversion of local currency, obligation to pay payroll tax, withholding procedures and handling of share issuances, any of which may vary according to applicable requirements; provided that if such special rules or sub-plans are inconsistent with the requirements of Section 423(b) of the Code, the employees subject to such special rules or sub-plans will participate in the Non-423 Component.

14. Optionees Not Stockholders. Neither the granting of an Option to a Participant nor the deductions or contributions from his or her pay shall result in such Participant becoming a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her.

15. Rights Not Transferable. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant’s lifetime only by the Participant.

16. Application of Funds. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose, unless otherwise required under applicable law.

17. Adjustment in Case of Changes Affecting Common Stock. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper effect to such event. In the case of and subject to the consummation of a Sale

Event, the Administrator, in its discretion, and on such terms and conditions as it deems appropriate, is hereby authorized to take any one or more of the following actions whenever the Administrator determines that such action is appropriate in order to prevent the dilution or enlargement of the benefits or potential benefits intended to be made available under the Plan or with respect to any right under the Plan or to facilitate such transactions or events:

(a) To provide for either (i) termination of any outstanding Option in exchange for an amount of cash, if any, equal to the amount that would have been obtained upon the exercise of such Option had such Option been currently exercisable or (ii) the replacement of such outstanding Option with other options or property selected by the Administrator in its sole discretion.

(b) To provide that the outstanding Options under the Plan shall be assumed by the successor or survivor corporation, or a parent or subsidiary thereof, or shall be substituted for similar options covering the stock of the successor or survivor corporation, or a parent or subsidiary thereof, with appropriate adjustments as to the number and kind of shares and prices.

(c) To make adjustments in the number and type of shares of Common Stock (or other securities or property) subject to outstanding Options under the Plan and/or in the terms and conditions of outstanding Options and Options that may be granted in the future.

(d) To provide that the Offering with respect to which an Option relates will be shortened by setting a New Exercise Date on which such Offering will end. The New Exercise Date will occur before the date of the Sale Event. The Administrator will notify each Participant in writing or electronically prior to the New Exercise Date, that the Exercise Date for the Participant’s Option has been changed to the New Exercise Date and that the Participant’s Option will be exercised automatically on the New Exercise Date, unless prior to such date the Participant has withdrawn from the Offering as provided in Section 7 hereof.

(e) To provide that all outstanding Options shall terminate without being exercised and all amounts in the accounts of Participants shall be promptly refunded.

18. Amendment of the Plan. The Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the 423 Component of the Plan, as amended, to qualify as an “employee stock purchase plan” under Section 423(b) of the Code.

19. Insufficient Shares. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions or contributions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date.

20. Termination of the Plan. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded. Unless terminated earlier, the Plan shall expire on the ten-year anniversary of the Registration Date.

21. Governmental Regulations. The Company’s obligation to sell and deliver Common Stock under the Plan is subject to applicable laws and the completion of any registration or qualification of the Common Stock under any U.S. or non-U.S. local, state or federal securities or exchange control law, or under rulings or regulations of the SEC or of any other governmental regulatory body, and to obtaining any approval or other clearance from any U.S. and non-U.S. local, state or federal governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable. The Company is under no obligation to register or qualify the Common Stock with the SEC or any other U.S. or non-U.S. securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of such stock.

22. Governing Law. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in accordance with the internal laws of the State of Delaware applied without regard to conflict of law principles.

23. Issuance of Shares. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company or from any other proper source.

24. Tax Withholding. Participation in the Plan is subject to any applicable U.S. and non-U.S. federal, state or local tax withholding requirements on income the Participant realizes in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company or any Subsidiary or Affiliate may, but will not be obligated to, withhold from a Participant’s wages, salary or other compensation at any time the amount necessary for the Company or any Subsidiary or Affiliate to meet applicable withholding obligations, including any withholding required to make available to the Company or any Subsidiary or Affiliate any tax deductions or benefits attributable to the sale or disposition of Common Stock by such Participant. In addition,

the Company or any Subsidiary or Affiliate may, but will not be obligated to, withhold from the proceeds of the sale of Common Stock or use any other method of withholding that the Company or any Subsidiary or Affiliate deems appropriate to the extent permitted by U.S. Treasury Regulation Section 1.423-2(f) with respect to the 423 Component. The Company will not be required to issue any Common Stock under the Plan until such obligations are satisfied.

25. Notification Upon Sale of Shares Under the 423 Component. Each Participant agrees, by entering the 423 Component of the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased.

26. Effective Date and Approval of Stockholders. The Plan shall take effect on the date immediately preceding the Registration Date, subject to approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders.

EX-10.4 9 d803738dex104.htm EX-10.4 EX-10.4

Exhibit 10.4

RAPPORT THERAPEUTICS, INC.

FORM OF EMPLOYEE DIRECTOR / OFFICER

INDEMNIFICATION AGREEMENT

This Indemnification Agreement (“Agreement”) is made as of [•], 2024, by and between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”).

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;

WHEREAS, in order to induce Indemnitee to [continue to] provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

WHEREAS, the Third Amended and Restated Certificate of Incorporation (as amended and in effect from time to time, the “Charter”) and the Amended and Restated Bylaws (as amended and in effect from time to time, the “Bylaws”) of the Company require indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the “DGCL”);

WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;

WHEREAS, the Board of Directors of the Company (the “Board”) has determined that the increased difficulty in attracting and retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company’s stockholders;

WHEREAS, it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the Charter or the Bylaws, so that they will [continue to] serve the Company free from undue concern that they will not be so indemnified; and

WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

Section 1. Services to the Company. Indemnitee agrees to [continue to] serve as [a director and] an officer of the Company. Indemnitee may at any time and for any reason resign from [any] such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.

Section 2. Definitions.

As used in this Agreement:

(a) “Affiliate” and “Associate” shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as in effect on the date of this Agreement; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of the Company solely as a result of his or her position as director or officer of the Company.

(b) A Person shall be deemed the “Beneficial Owner” of, and shall be deemed to “Beneficially Own” and have “Beneficial Ownership” of, any securities:

(i) which such Person or any of such Person’s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant to Rule 13d-3 of the Rules under the Exchange Act, as in effect on the date of this Agreement);

(ii) which such Person or any of such Person’s Affiliates or Associates, directly or indirectly, has: (A) the legal, equitable or contractual right or obligation to acquire (whether directly or indirectly and whether exercisable immediately or only after the passage of time, compliance with regulatory requirements, satisfaction of one or more conditions (whether or not within the control of such Person) or otherwise) upon the exercise of any conversion rights, exchange rights, rights, warrants or options, or otherwise; (B) the right to vote pursuant to any agreement, arrangement or understanding (whether or not in writing); or (C) the right to dispose of pursuant to any agreement, arrangement or understanding (whether or not in writing) (other than customary arrangements with and between underwriters and selling group members with respect to a bona fide public offering of securities);

(iii) which are Beneficially Owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person or any of such Person’s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or

an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or any of such Person’s Affiliates or Associates an opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A) such derivative security conveys any voting rights in such securities to such Person or any of such Person’s Affiliates or Associates; (B) the derivative security is required to be, or capable of being, settled through delivery of such securities; or (C) such Person or any of such Person’s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative security.

Notwithstanding the foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any securities acquired through such Person’s participation as an underwriter in good faith in a firm commitment underwriting.

(c) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

(i) Acquisition of Stock by Third Party. Any Person is or becomes the Beneficial Owner (as defined above), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company’s then outstanding securities unless the change in relative Beneficial Ownership of the Company’s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors, provided that a Change of Control shall be deemed to have occurred if subsequent to such reduction such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power;

(ii) Change in Board of Directors. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a Person who has entered into an agreement with the Company to effect a transaction described in Sections 2(c)(i), 2(c)(iii) or 2(c)(iv)) whose election by the Board or nomination for election by the Company’s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;

(iii) Corporate Transactions. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving or successor entity;

(iv) Liquidation. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or substantially all of the Company’s assets; and

(v) Other Events. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Exchange Act whether or not the Company is then subject to such reporting requirement.

(d) “Corporate Status” describes the status of a person as a current or former [director or] officer of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company.

(e) “Enforcement Expenses” shall include all reasonable attorneys’ fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action. Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee.

(f) “Enterprise” shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee.

(g) “Expenses” shall include all reasonable attorneys’ fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee.

(h) “Independent Counsel” means a law firm, or a partner (or, if applicable, member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company, any subsidiary of the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any Person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.

(i) “Person” shall mean (i) an individual, a corporation, a partnership, a limited liability company, an association, a joint stock company, a trust, a business trust, a government or political subdivision, any unincorporated organization or any other association or entity including any successor (by merger or otherwise) thereof or thereto, and (ii) a “group” as that term is used for purposes of Section 13(d)(3) of the Exchange Act.

(j) The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was [a director or] an officer of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on his or her part while acting as [a director or] an officer of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; provided, however, that the term “Proceeding” shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee’s rights under this Agreement as provided for in Section 12(a) of this Agreement.

Section 3. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee to the extent set forth in this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

Section 4. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee to the extent set forth in this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the “Delaware Court”) shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper.

Section 5. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement and except as provided in Section 7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

Section 6. Reimbursement for Expenses of a Witness or in Response to a Subpoena. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i) is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii) receives a subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

Section 7. Exclusions. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement:

(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; provided that the foregoing shall not apply to any personal or umbrella liability insurance maintained by Indemnitee;

(b) to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Exchange Act or similar provisions of state statutory law or common law, or from the purchase or sale by Indemnitee of such securities in violation of Section 306 of the Sarbanes-Oxley Act of 2002 (“SOX”);

(c) to indemnify for any reimbursement of, or repayment to, the Company by Indemnitee of (i) any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company pursuant to the terms of (A) Section 304 of SOX, (B) Exchange Act Rule 10D-1 or (C) any formal policy of the Company adopted by the Board (or a committee thereof) or (ii) any other remuneration paid to Indemnitee if it shall be determined by a final judgment or other final adjudication that payment of such remuneration was or would have been in violation of law;

(d) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i) the Board has consented to the initiation of such Proceeding or part thereof and (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; provided, however, that this Section 7(d) shall not apply to (A) counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B) any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section 12; or

(e) to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement).

Section 8. Advancement of Expenses. Subject to Section 9(b), the Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s (i) ability to repay the expenses, (ii) ultimate entitlement to indemnification under the other provisions of this Agreement and (iii) entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section 8 shall limit Indemnitee’s right to advancement pursuant to Section 12(e) of this Agreement.

Section 9. Procedure for Notification and Defense of Claim.

(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company.

(b) In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company’s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; provided that (i) Indemnitee shall have the right to employ separate counsel in any such Proceeding at Indemnitee’s expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C) the Company shall not continue to retain such counsel to defend such Proceeding, or (D) a Change in Control shall have occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder.

(c) In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b) above, then the Company will be entitled to participate in the Proceeding at its own expense.

(d) The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). Without limiting the generality of the foregoing, the fact that an insurer under an applicable insurance policy delays or is unwilling to consent to such settlement or is or may be in breach of its obligations under such policy, or the fact that directors’ and officers’ liability insurance is otherwise unavailable or not maintained by the Company, may not be taken into account by the Company in determining whether to provide its consent. The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i) includes an admission of fault of Indemnitee, any non-monetary remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii) with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding.

Section 10. Procedure Upon Application for Indemnification.

(a) Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination, if such determination is required by applicable law, with respect to Indemnitee’s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: (x) if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, by Independent Counsel in a written opinion to the Board; or (y) in any other case, (i) by a majority vote of the disinterested directors, even though less than a quorum; (ii) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though

less than a quorum; or (iii) if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board. For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought. In the case that such determination is made by Independent Counsel, a copy of Independent Counsel’s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30) days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Company and reasonably necessary to such determination. Any out-of-pocket costs or expenses (including reasonable attorneys’ fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

(b) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(a), the Independent Counsel shall be selected by the Board; provided that, if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, the Independent Counsel shall be selected by Indemnitee. Indemnitee or the Company, as the case may be, may, within ten (10) days after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the Person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 9(a), and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a Person selected by the court or by such other Person as the court shall designate. The Person with respect to whom all objections are so resolved or the Person so appointed shall act as Independent Counsel under Section 10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

(c) Notwithstanding anything to the contrary contained in this Agreement, the determination of entitlement to indemnification under this Agreement shall be made without regard to the Indemnitee’s entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)).

Section 11. Presumptions and Effect of Certain Proceedings.

(a) To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 9(a) of this Agreement, and the Company shall have the burden of proof and the burden of persuasion by clear and convincing evidence to overcome that presumption in connection with the making of any determination contrary to that presumption.

(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of guilty, nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.

(c) Indemnitee shall be deemed to have acted in good faith if Indemnitee’s actions were based on the records or books of account of the Company or any other Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, agents or employees of the Company or any other Enterprise in the course of their duties, or on the advice of legal counsel for the Company or any other Enterprise or on information or records given or reports made to the Company or any other Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or any other Enterprise. The provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 11(c) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.

Section 12. Remedies of Indemnitee.

(a) Subject to Section 12(f), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(a) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv) payment of indemnification or reimbursement of expenses is not made pursuant to Section 5 or 6 or the last sentence of Section 10(a) of this Agreement within thirty (30) days after receipt by the Company of a written request therefor (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.

(b) In the event that a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be.

(c) If a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification or (ii) a prohibition of such indemnification under applicable law.

(d) The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.

(e) The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within thirty (30) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice.

(f) Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.

Section 13. Non-exclusivity; Survival of Rights; Insurance; Subrogation.

(a) The rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise. No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Charter, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee: (i) copies of all of the Company’s potentially applicable directors’ and officers’ liability insurance policies, (ii) copies of such notices delivered to the applicable insurers, and (iii) copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding.

(c) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(d) The Company’s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise.

Section 14. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as [both a director and] an officer of the Company or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

Section 15. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

Section 16. Enforcement.

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee [continue to] serve as [a director and] an officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as [a director and] an officer of the Company.

(b) This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; provided, however, that this Agreement is a supplement to and in furtherance of the Charter, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.

Section 17. Modification and Waiver. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment.

Section 18. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, unless, and then only to the extent that, the Company did not otherwise learn of the Proceeding and such delay is materially prejudicial to the Company’s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of Indemnitee in the event the Company is a party to the same Proceeding.

Section 19. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

(a) If to Indemnitee, at such address as Indemnitee shall provide to the Company.

(b) If to the Company to:

Rapport Therapeutics, Inc.

1325 Boylston Street, Suite 401

Boston, MA 02215 USA

Attention: [Chief Financial Officer]

or to any other address as may have been furnished to Indemnitee by the Company.

Section 20. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transactions.

Section 21. Internal Revenue Code Section 409A. The Company intends for this Agreement to comply with the Indemnification exception under Section 1.409A-1(b)(10) of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the “Code”), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section 409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent.

Section 22. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 19 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

Section 23. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

Section 24. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

Section 25. Monetary Damages Insufficient/Specific Enforcement. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertakings in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.


RAPPORT THERAPEUTICS, INC.

By:
		Name:
		Title:


		[Name]

RAPPORT THERAPEUTICS, INC.

FORM OF NON-EMPLOYEE DIRECTOR

INDEMNIFICATION AGREEMENT

RECITALS

WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;

WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;

[WHEREAS, Indemnitee has certain rights to indemnification and/or insurance provided by [Affiliated Entity] (“[Affiliated Entity]”) which Indemnitee and [Affiliated Entity] intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided in this Agreement, with the Company’s acknowledgment and agreement to the foregoing being a material condition to Indemnitee’s willingness to [continue to] serve on the Board.]¹

¹	This recital should be included if the director is affiliated with a fund or other entity that provides indemnification to the director that is intended to backstop the indemnification provided by the Company.

NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:

Section 26. Services to the Company. Indemnitee agrees to [continue to] serve as a director of the Company. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.

Section 27. Definitions.

As used in this Agreement:

(b) A Person shall be deemed the “Beneficial Owner” of, and shall be deemed to “Beneficially Own” and have “Beneficial Ownership” of, any securities:

(iii) which are Beneficially Owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person or any of such Person’s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or

(iv) that are the subject of a derivative transaction entered into by such Person or any of such Person’s Affiliates or Associates, including, for these purposes, any derivative security acquired by such Person or any of such Person’s Affiliates or Associates that gives such Person or any of such Person’s Affiliates or Associates the economic equivalent of ownership of an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or any of such Person’s Affiliates or Associates an opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A) such derivative security conveys any voting rights in such securities to such Person or any of such Person’s Affiliates or Associates; (B) the derivative security is required to be, or capable of being, settled through delivery of such securities; or (C) such Person or any of such Person’s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative security;

(c) A “Change in Control” shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:

(d) “Corporate Status” describes the status of a person as a current or former director of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company.

(g) “Expenses” shall include all reasonable attorneys’ fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding. Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee.

(j) The term “Proceeding” shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on his or her part while acting as a director of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; provided, however, that the term “Proceeding” shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee’s rights under this Agreement as provided for in Section 12(a) of this Agreement.

Section 28. Indemnity in Third-Party Proceedings. The Company shall indemnify Indemnitee to the extent set forth in this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful.

Section 29. Indemnity in Proceedings by or in the Right of the Company. The Company shall indemnify Indemnitee to the extent set forth in this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor. Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the “Delaware Court”) shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper.

Section 30. Indemnification for Expenses of a Party Who is Wholly or Partly Successful. Notwithstanding any other provisions of this Agreement and except as provided in Section 7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.

Section 31. Reimbursement for Expenses of a Witness or in Response to a Subpoena. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i) is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii) receives a subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.

Section 32. Exclusions. Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement:

(a) to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; provided that the foregoing shall not [(i)] apply to any personal or umbrella liability insurance maintained by Indemnitee, [or, (ii) affect the rights of Indemnitee or the Fund Indemnitors as set forth in Section 13(c)];

(c) to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i) the Board has consented to the initiation of such Proceeding or part thereof and (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; provided, however, that this Section 7(c) shall not apply to (A) counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B) any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section 12; or

(d) to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement).

Section 33. Advancement of Expenses. Subject to Section 9(b), the Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee’s (i) ability to repay the expenses, (ii) ultimate entitlement to indemnification under the other provisions of this Agreement, and (iii) entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein. Nothing in this Section 8 shall limit Indemnitee’s right to advancement pursuant to Section 12(e) of this Agreement.

Section 34. Procedure for Notification and Defense of Claim.

(b) In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company’s election to do so. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; provided that (i) Indemnitee shall have the right to employ separate counsel in any such Proceeding at Indemnitee’s expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C) the Company shall not continue to retain such counsel to defend such Proceeding or (D) a Change in Control shall have occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder.

(c) In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b) above, then the Company will be entitled to participate in the Proceeding at its own expense.

Section 35. Procedure Upon Application for Indemnification.

(a) Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination, if such determination is required by applicable law, with respect to Indemnitee’s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: (x) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board; or (y) if a Change in Control shall not have occurred: (i) by a majority vote of the disinterested directors, even though less than a quorum; (ii) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum; or (iii) if there are no disinterested directors or if the

disinterested directors so direct, by Independent Counsel in a written opinion to the Board. For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought. In the case that such determination is made by Independent Counsel, a copy of Independent Counsel’s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30) days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Company and reasonably necessary to such determination. Any out-of-pocket costs or expenses (including reasonable attorneys’ fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.

(b) If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(a), the Independent Counsel shall be selected by the Board if a Change in Control shall not have occurred or, if a Change in Control shall have occurred, by Indemnitee. Indemnitee or the Company, as the case may be, may, within ten (10) days after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of “Independent Counsel” as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion. Absent a proper and timely objection, the Person so selected shall act as Independent Counsel. If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit. If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 9(a), and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a Person selected by the court or by such other Person as the court shall designate. The Person with respect to whom all objections are so resolved or the Person so appointed shall act as Independent Counsel under Section 10(a) hereof. Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).

Section 36. Presumptions and Effect of Certain Proceedings.

Section 37. Remedies of Indemnitee.

Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors’ and officers’ liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought. Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice.

Section 38. Non-exclusivity; Survival of Rights; Insurance; [Primacy of Indemnification;] Subrogation.

(b) To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee: (i) copies of all of the Company’s potentially applicable directors’ and officers’ liability insurance policies, (ii) copies of such notices delivered to the applicable insurers and (iii) copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding.

(c) [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by [Affiliated Entity] and certain of its affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Charter and/or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 13(c).]²

(d) [Except as provided in paragraph (c) above,] in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [(other than against the Fund Indemnitors)], who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.

(e) [Except as provided in paragraph (c) above,] the Company’s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise.

Section 39. Duration of Agreement. This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director of the Company or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators. The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.

²	This provision is intended to be used for directors appointed by investment funds.

Section 40. Severability. If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.

Section 41. Enforcement.

(a) The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to [continue to] serve as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director of the Company.

Section 42. Modification and Waiver. No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment.

Section 43. Notice by Indemnitee. Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder. The failure of Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise, unless, and then only to the extent that, the Company did not otherwise learn of the Proceeding and such delay is materially prejudicial to the Company’s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of Indemnitee in the event the Company is a party to the same Proceeding.

Section 44. Notices. All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:

(a) If to Indemnitee, at such address as Indemnitee shall provide to the Company.

(b) If to the Company to:

Rapport Therapeutics, Inc.

1325 Boylston Street, Suite 401

Boston, MA 02215 USA

Attention: [Chief Financial Officer]

or to any other address as may have been furnished to Indemnitee by the Company.

Section 45. Contribution. To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transactions.

Section 46. Internal Revenue Code Section 409A. The Company intends for this Agreement to comply with the Indemnification exception under Section 1.409A-1(b)(10) of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the “Code”), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section 409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service provider of the Company. The parties intend that this Agreement be interpreted and construed with such intent.

Section 47. Applicable Law and Consent to Jurisdiction. This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 19 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.

Section 48. Headings. The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.

Section 49. Identical Counterparts. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.

Section 50. Monetary Damages Insufficient/Specific Enforcement. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking.

IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.


RAPPORT THERAPEUTICS, INC.

By:
		Name:
		Title:


		[Name]

EX-10.5 10 d803738dex105.htm EX-10.5 EX-10.5

Exhibit 10.5

RAPPORT THERAPEUTICS, INC.

SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN

1. Purpose

This Senior Executive Cash Incentive Bonus Plan (the “Incentive Plan”) is intended to provide an incentive for superior work and to motivate eligible executives of Rapport Therapeutics, Inc. (the “Company”) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those of the Company and its stockholders and to enable the Company to attract and retain highly qualified executives. The Incentive Plan is for the benefit of Covered Executives (as defined below).

2. Covered Executives

From time to time, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) may select certain key executives (the “Covered Executives”) to be eligible to receive bonuses hereunder. Participation in the Incentive Plan does not change the “at will” nature of a Covered Executive’s employment with the Company.

3. Administration

The Compensation Committee shall have the sole discretion and authority to administer and interpret the Incentive Plan.

4. Bonus Determinations

(a) Corporate Performance Goals. A Covered Executive may receive a bonus payment under the Incentive Plan based upon the attainment of one or more performance objectives that are established by the Compensation Committee in its sole discretion and relate to financial and operational metrics with respect to the Company or any of its subsidiaries (the “Corporate Performance Goals”), including but not limited to: developmental, publication, clinical or regulatory milestones; cash flow (including, but not limited to, operating cash flow and free cash flow); revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of our common stock; economic value-added; acquisitions, licenses, collaborations or strategic transactions; financing or other capital raising transactions; operating income (loss); return on capital, assets, equity, or investment; stockholder returns; return on sales; total shareholder return; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; customer satisfaction; working capital; earnings (loss) per share of the company’s common stock; bookings, new bookings or renewals; sales or market shares; number of prescriptions or prescribing physicians; coverage decisions; leadership development, employee retention and recruiting and other human resources matters; operating income and/or net annual recurring revenue, or any other performance goal selected by the Compensation Committee, any of which may be (A) measured in absolute terms or compared to any incremental increase, (B) measured in terms of growth, (C) compared to another company or companies or to results of a peer group, (D) measured against the market as a whole and/or as compared to applicable market

indices and/or (E) measured on a pre-tax or post-tax basis (if applicable). Further, any Corporate Performance Goals may be used to measure the performance of the Company as a whole or a business unit or other segment of the Company, or one or more product lines or specific markets. The Corporate Performance Goals may differ from Covered Executive to Covered Executive and from performance period to performance period.

(b) Calculation of Corporate Performance Goals. At the beginning of each applicable performance period, the Compensation Committee will determine whether any significant element(s) will be included in or excluded from the calculation of any Corporate Performance Goal with respect to any Covered Executive. In all other respects, Corporate Performance Goals will be calculated in accordance with the Company’s financial statements, generally accepted accounting principles or under a methodology established by the Compensation Committee at the beginning of the performance period and which is consistently applied with respect to a Corporate Performance Goal in the relevant performance period.

(c) Target; Minimum; Maximum. Each Corporate Performance Goal shall have a “target” (i.e., 100 percent attainment of the Corporate Performance Goal) and may also have a “minimum” hurdle and/or a “maximum” amount.

(d) Bonus Requirements; Individual Goals. Except as otherwise set forth in this Section 4(d): (i) any bonuses paid to Covered Executives under the Incentive Plan shall be based upon objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals, (ii) bonus formulas for Covered Executives shall be adopted in each performance period by the Compensation Committee and communicated to each Covered Executive at the beginning of each performance period and (iii) no bonuses shall be paid to Covered Executives unless and until the Compensation Committee makes a determination with respect to the attainment of the performance targets relating to the Corporate Performance Goals. Notwithstanding the foregoing, the Compensation Committee may adjust bonuses payable under the Incentive Plan based on achievement of one or more individual performance objectives or pay bonuses (including, without limitation, discretionary bonuses) to Covered Executives under the Incentive Plan based on individual performance goals and/or upon such other terms and conditions as the Compensation Committee may in its discretion determine.

(e) Individual Target Bonuses. The Compensation Committee shall establish a target bonus opportunity for each Covered Executive for each performance period. For each Covered Executive, the Compensation Committee shall have the authority to apportion the target award so that a portion of the target award shall be tied to attainment of Corporate Performance Goals and a portion of the target award shall be tied to attainment of individual performance objectives.

(f) Employment Requirement. Subject to any additional terms contained in a written agreement between the Covered Executive and the Company, the payment of a bonus to a Covered Executive with respect to a performance period shall be conditioned upon the Covered Executive’s employment by the Company on the bonus payment date. If a Covered Executive was not employed for an entire performance period, the Compensation Committee may pro rate the bonus based on the number of days employed during such period.

5. Timing of Payment

(a) With respect to Corporate Performance Goals established and measured on a basis more frequently than annually (e.g., quarterly or semi-annually), the Corporate Performance Goals will be measured at the end of each performance period after the Company’s financial reports with respect to such period(s) have been published, as applicable. If the Corporate Performance Goals and/or individual goals for such period are met, payments will be made as soon as practicable following the end of such period, but not later than two and one-half months after the end of the fiscal year in which such performance period ends.

(b) With respect to Corporate Performance Goals established and measured on an annual or multi-year basis, Corporate Performance Goals will be measured as of the end of each such performance period (e.g., the end of each fiscal year) after the Company’s financial reports with respect to such period(s) have been published, as applicable. If the Corporate Performance Goals and/or individual goals for any such period are met, bonus payments will be made as soon as practicable, but not later than two and one-half months after the end of the relevant fiscal year.

(c) For the avoidance of doubt, bonuses earned at any time in a fiscal year must be paid no later than two and one-half months after the last day of such fiscal year.

6. Amendment and Termination

The Company reserves the right to amend or terminate the Incentive Plan at any time in its sole discretion.

7. Company Recoupment Rights

A Covered Executive’s rights with respect to any award granted pursuant to the Incentive Plan shall in all events be subject to reduction, cancellation, forfeiture or recoupment to the extent necessary to comply with (i) any right that the Company may have under any Company clawback, forfeiture or recoupment policy as in effect from time to time or other agreement or arrangement with a Covered Executive, or (ii) applicable law.

Adopted May 29, 2024, subject to effectiveness of the Company’s Registration Statement on Form S-1.

EX-10.6 11 d803738dex106.htm EX-10.6 EX-10.6

Exhibit 10.6

RAPPORT THERAPEUTICS, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY

The purpose of this Non-Employee Director Compensation Policy (the “Policy”) of Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (“Outside Directors”). This Policy will become effective as of the effective time of the registration statement for the Company’s initial public offering of its equity securities (the “Effective Date”). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below:

Cash Retainers

Annual Retainer for Board Membership: $40,000 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.


Additional Annual Retainers for Committee Membership:
Audit Committee Chairperson:	$	15,000
Audit Committee member (other than Chairperson):	$	7,500
Compensation Committee Chairperson:	$	10,000
Compensation Committee member (other than Chairperson):	$	5,000
Nominating and Corporate Governance Committee Chairperson:	$	8,000
Nominating and Corporate Governance Committee member (other than Chairperson):	$	4,000
Science & Technology Committee Chairperson:	$	8,000
Science & Technology Committee member (other than Chairperson):	$	4,000

Equity Retainers

All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions:

Initial Award: Upon his or her initial election to the Board of Directors, each Outside Director will receive an initial, one-time stock option award (the “Initial Award”) to purchase 29,756 shares, which shall vest over three years, with first vesting to occur on the first anniversary

of the vesting commencement date and monthly vesting thereafter, provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. The Initial Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company’s 2024 Stock Option and Incentive Plan, as amended from time to time) of the Company’s common stock on the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date.

Annual Award: On each date of each Annual Meeting of Stockholders of the Company following the Effective Date (the “Annual Meeting”), each continuing Outside Director, other than a director receiving an Initial Award, will receive an annual stock option award (the “Annual Award”) to purchase 14,878 shares, which shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii) the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting; provided further that, in the case of an Annual Award to an Outside Director appointed to the Board in the 12 months prior to the Annual Meeting of Stockholders, the Annual Award shall be prorated by multiplying the Annual Award by a fraction, the numerator of which is the number of full months that have elapsed between the date the Outside Director was appointed and the date of the Annual Meeting and the denominator of which is 12. Such Annual Award shall expire ten years from the date of grant, and shall have a per share exercise price equal to the Fair Market Value of the Company’s common stock on the date of grant.

Sale Event Acceleration: All outstanding Initial Awards and Annual Awards held by an Outside Director shall become fully vested, exercisable (if applicable) and nonforfeitable upon a Sale Event (as defined in the Company’s 2024 Stock Option and Incentive Plan, as amended from time to time).

Expenses

The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.

Maximum Annual Compensation

The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in a calendar year for services as an Outside Director shall not exceed $750,000; provided, however, that such amount shall be $1,000,000 for the calendar year in which the applicable Outside Director is initially elected or appointed to the Board of Directors; (or such other limits as may be set forth in Section 3(b) of the Company’s 2024 Stock Option and Incentive Plan, as amended from time to time, or any similar provision of a successor plan). For this purpose, the “amount” of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions.

Adopted May 29, 2024, subject to effectiveness of the Company’s Registration Statement on Form S-1.

EX-10.7 12 d803738dex107.htm EX-10.7 EX-10.7

Exhibit 10.7

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Abraham N. Ceesay (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated December 12, 2022 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:

1. Employment.

(a) Term. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”). The Executive’s employment with the Company shall continue to be “at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.

(b) Position and Duties. The Executive shall serve as the Chief Executive Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Board of Directors (the “Board”). The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board, or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.

2. Compensation and Related Matters.

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $628,000 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers.

(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 55 percent of the Executive’s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation.

(c) Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executives.

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

(e) Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.

(f) Equity. The equity awards held by the Executive shall continue to be governed by the terms and conditions of the applicable equity plan and/or award agreement(s) governing the terms of such equity awards (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below).

(g) Sign-On Bonus Repayment. The Executive previously received a one-time signing bonus of $250,000, less applicable tax-related deductions and withholdings (the “Sign-On Bonus”) in connection with the commencement of the Executive’s employment with the Company. In the event the Executive’s employment is terminated by the Company for Cause or the Executive resigns without Good Reason (as such terms are defined below), in either case, prior to the third anniversary of the date the Executive commenced employment with the Company, the Executive will repay within 30 days after the Date of Termination (as defined below) the applicable percentage of the Sign-On Bonus as follows:


Length of Service	Percentage of Sign-On Bonus Repayment
At least 12 months but less than 24 months		50	%
At least 24 months but less than 36 months		25	%

3. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a) Death. The Executive’s employment hereunder shall terminate upon death.

(b) Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.

(c) Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:

(i) the Executive’s statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in harm to the Company;

(ii) the Executive’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

(iii) the Executive’s failure to perform his or her assigned duties and responsibilities to the reasonable satisfaction of the Board which failure continues, in the reasonable judgment of the Board, for thirty (30) days after written notice given to the Executive describing in reasonable detail such failure;

(iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in harm to the Company; or

(v) the Executive’s violation of any (A) material provision of any agreement(s) between the Executive and the Company or any Company policies including, without limitation, agreements relating to noncompetition, nonsolicitation, nondisclosure and/or assignment of inventions or (B) material Company policies related to ethics or workplace conduct.

(d) Termination by the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.

(e) Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive’s consent (each, a “Good Reason Condition”):

(i) a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company

(ii) a material reduction in the Executive’s duties, authority, or responsibilities following a Change in Control;

(iii) a material change in the geographic location at which the Executive provides services to the Company; or

(iv) a material breach of this Agreement by the Company.

The “Good Reason Process” consists of the following steps:

(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;

(iii) the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;

(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

(v) the Executive terminates employment within 60 days after the end of the Cure Period.

If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

4. Matters related to Termination.

(a) Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.

(b) Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.

(c) Accrued Obligations. If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the Date of Termination and, if applicable, any accrued but unused vacation through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Obligations”).

(d) Resignation of All Other Positions. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive’s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.

5. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period. If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates employment for Good Reason as provided in Section 3(e), in each case outside of the Change in Control Period, then, in addition to the Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and, in the Company’s sole discretion, a one-year post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven (7) business day revocation period:

(a) the Company shall pay the Executive an amount equal to twelve (12) months of the Executive’s Base Salary (the “Severance Amount”); and

(b) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the twelve (12) month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over twelve (12) months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).

6. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive’s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within the Change in Control Period. For the avoidance of doubt, (i) in no event will the Executive be entitled to severance pay and benefits under both Section 5 and Section 6 of this Agreement, and (ii) if the Company has commenced providing severance pay and benefits to the Executive under Section 5 prior to the date that the Executive becomes eligible to receive severance pay and benefits under this Section 6, the severance pay and benefits previously provided to the Covered Executive under Section 5 shall reduce the severance pay and benefits to be provided under this Section 6. These provisions shall terminate and be of no further force or effect after the Change in Control Period.

(a) If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs within the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement (the “Release”) by the Executive and the Release becoming fully effective, all within the time frame set forth in the Release but in no event more than 60 days after the Date of Termination:

(i) the Company shall pay the Executive a lump sum in cash in an amount equal to one and one-half (1.5) times the sum of (A) the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s Target Bonus for the then-current year (or the Executive’s Target Bonus in effect immediately prior to the Change in Control, if higher) (the “Change in Control Payment”); and

(ii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the “Time-Based Equity Awards”) shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i) the Date of Termination (or, if later, the Change in Control) or (ii) the effective date of the Release (the “Accelerated Vesting Date”), provided that in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive’s Time-Based Equity Awards that would otherwise terminate or be forfeited on the Date of Termination will be delayed until the earlier of (A) the later of the effective date of the Release or the date of the Change in Control (at which time acceleration will occur), or (B) the earlier of the date that the Release can no longer become fully effective or, to the extent the Date of Termination occurs prior to a Change in Control, the date that is three (3) months following the Date of Termination if a Change in Control has not been consummated on

or prior to such date (at which time the unvested portion of the Executive’s Time-Based Equity Awards will terminate or be forfeited). Notwithstanding the foregoing, no additional vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and

(iii) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the eighteen (18) month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.

(b) Additional Limitation.

(i) Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash payments not subject to Section 409A of the Code; (2) cash payments subject to Section

409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).

(ii) For purposes of this Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.

(iii) The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.

(i) “Change in Control” shall mean a “Sale Event” as defined in the Company’s 2024 Stock Option and Incentive Plan.

(ii) “Change in Control Period” shall mean the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control.

7. Section 409A.

(a) Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.

(b) All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

(c) To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).

(d) The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.

(e) The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.

8. Continuing Obligations.

(a) Restrictive Covenants Agreement. The terms of the Employee Confidentiality, Assignment, and Nonsolicitation Agreement, dated February 23, 2023 (the “Restrictive Covenants Agreement”), between the Company and the Executive, attached hereto as Exhibit A, continue to be in full force and effect. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” For the avoidance of doubt, all restrictive covenants obligations are supplemental to one another, and in the event of any conflict between restrictive covenants obligations, the most restrictive provision that is enforceable shall govern.

(b) Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.

(c) Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(c).

(d) Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.

9. Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the state and federal courts of the Commonwealth of Massachusetts. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts and (b) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction.

10. Waiver of Jury Trial. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.

11. Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect.

12. Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

13. Assignment; Successors and Assigns. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided, further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails to make such designation).

14. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

15. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

16. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

17. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to the Company email address of the Executive or, in the case of Company, the Company email address of the Chair of the Board, with confirmation of receipt.

18. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

19. Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. Notwithstanding anything to the contrary in this Agreement, all severance pay and benefits provided to the Executive pursuant to Section 5 or Section 6 of this Agreement (as applicable) shall be reduced and/or offset by any amounts or benefits paid to the Executive to satisfy the federal Worker Adjustment and Retraining Notification (WARN) Act, 29 U.S.C. § 2101 et seq., as amended, and any applicable state plant or facility closing or mass layoff law (whether as damages, as payment of salary or other wages during an applicable notice period or otherwise). In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.

20. Governing Law. This is a Massachusetts contract and shall be construed under and be governed in all respects by the laws of the Commonwealth of Massachusetts, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.

21. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.


RAPPORT THERAPEUTICS, INC.

By:
Its:

EXECUTIVE


Abraham N. Ceesay

Exhibit A

Restrictive Covenants Agreement

EX-10.8 13 d803738dex108.htm EX-10.8 EX-10.8

Exhibit 10.8

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Troy Ignelzi(the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated October 24, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

1. Employment.

(b) Position and Duties. The Executive shall serve as the Chief Financial Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer (the “CEO”) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.

2. Compensation and Related Matters.

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $500,000 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers.

(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 40percent of the Executive’s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation.

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

(e) Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.

3. Relocation Assistance. In the event the Executive purchases a new residence in the Cambridge/Boston area within three (3) years of the date the Executive commenced employment with the Company, the Company will provide the Executive with a relocation benefit to be mutually agreed upon with the Executive and the Company at such future date.

4. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a) Death. The Executive’s employment hereunder shall terminate upon death.

(c) Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:

(ii) the Executive’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

(iii) the Executive’s failure to perform his or her assigned duties and responsibilities to the reasonable satisfaction of the CEO which failure continues, in the reasonable judgment of the CEO, for thirty (30) days after written notice given to the Executive describing in reasonable detail such failure;

(iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in harm to the Company; or

(ii) a material reduction in the Executive’s duties, authority, or responsibilities following a Change in Control;

(iii) a material change in the geographic location at which the Executive provides services to the Company; or

(iv) a material breach of this Agreement by the Company.

The “Good Reason Process” consists of the following steps:

(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;

(iii) the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;

(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

(v) the Executive terminates employment within 60 days after the end of the Cure Period.

If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

5. Matters related to Termination.

6. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period. If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates employment for Good Reason as provided in Section 3(e), in each case outside of the Change in Control Period, then, in addition to the Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities that shall not release the Executive’s rights under this Agreement, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and, in the Company’s sole discretion, a one-year post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a revocation period of at least seven (7) days:

(a) the Company shall pay the Executive an amount equal to twelve (12) months of the Executive’s Base Salary (the “Severance Amount”); and

7. Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive’s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within the Change in Control Period. For the avoidance of doubt, (i) in no event will the Executive be entitled to severance pay and benefits under both Section 5 and Section 6 of this Agreement, and (ii) if the Company has commenced providing severance pay and benefits to the Executive under Section 5 prior to the date that the Executive becomes eligible to receive severance pay and benefits under this Section 6, the severance pay and benefits previously provided to the Covered Executive under Section 5 shall reduce the severance pay and benefits to be provided under this Section 6. These provisions shall terminate and be of no further force or effect after the Change in Control Period.

(i) the Company shall pay the Executive a lump sum in cash in an amount equal to one (1) times the sum of (A) the Executive’s then-current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s Target Bonus for the then-current year (or the Executive’s Target Bonus in effect immediately prior to the Change in Control, if higher) (the “Change in Control Payment”); and

(iii) subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider or the COBRA provider a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the twelve (12) month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

(b) Additional Limitation.

(i) “Change in Control” shall mean a “Sale Event” as defined in the Company’s 2024 Stock Option and Incentive Plan.

(ii) “Change in Control Period” shall mean the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control.

8. Section 409A.

9. Continuing Obligations.

(a) Restrictive Covenants Agreement. The terms of the Employee Confidentiality, Assignment, and Nonsolicitation Agreement, dated October 28, 2023 (the “Restrictive Covenants Agreement”), between the Company and the Executive, attached hereto as Exhibit A, continue to be in full force and effect. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” For the avoidance of doubt, all restrictive covenants obligations are supplemental to one another, and in the event of any conflict between restrictive covenants obligations, the most restrictive provision that is enforceable shall govern.

10. Consent to Jurisdiction. The parties hereby consent to the jurisdiction of the state and federal courts of the State of Michigan Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts and (b) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction.

11. Waiver of Jury Trial. Each of the Executive and the Company irrevocably and unconditionally WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE EXECUTIVE’S EMPLOYMENT BY THE COMPANY OR ANY AFFILIATE OF THE COMPANY, INCLUDING WITHOUT LIMITATION THE EXECUTIVE’S OR THE COMPANY’S PERFORMANCE UNDER, OR THE ENFORCEMENT OF, THIS AGREEMENT.

12. Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement, provided that the Restrictive Covenants Agreement and the Equity Documents remain in full force and effect.

13. Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.

14. Assignment; Successors and Assigns. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided, further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. In the event of the Executive’s death after the Executive’s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive’s beneficiary designated in writing to the Company prior to the Executive’s death (or to the Executive’s estate, if the Executive fails to make such designation).

15. Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.

16. Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.

17. Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.

18. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the CEO. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to the Company email address of the Executive or, in the case of Company, the Company email address of the CEO, with confirmation of receipt.

19. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

20. Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. Notwithstanding anything to the contrary in this Agreement, all severance pay and benefits provided to the Executive pursuant to Section 5 or Section 6 of this Agreement (as applicable) shall be reduced and/or offset by any amounts or benefits paid to the Executive to satisfy the federal Worker Adjustment and Retraining Notification (WARN) Act, 29 U.S.C. § 2101 et seq., as amended, and any applicable state plant or facility closing or mass layoff law (whether as damages, as payment of salary or other wages during an applicable notice period or otherwise). In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.

21. Governing Law. This is a Michigan contract and shall be construed under and be governed in all respects by the laws of the State of Michigan, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the Sixth Circuit.

22. Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.


RAPPORT THERAPEUTICS, INC.

By:
Its:

EXECUTIVE


Troy Ignelzi

Exhibit A

Restrictive Covenants Agreement

EX-10.9 14 d803738dex109.htm EX-10.9 EX-10.9

Exhibit 10.9

EMPLOYMENT AGREEMENT

This Employment Agreement (“Agreement”) is made between Rapport Therapeutics, Inc., a Delaware corporation (the “Company”), and Cheryl Gault (the “Executive”) and is effective as of the closing of the Company’s first underwritten public offering of its equity securities pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Effective Date”). Except with respect to the Restrictive Covenants Agreement and the Equity Documents (each as defined below), this Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation (i) the Offer Letter between the Executive and the Company dated June 29, 2023 (the “Prior Agreement”), and (ii) any other offer letter, employment agreement or severance agreement.

WHEREAS, the Company desires to continue to employ the Executive and the Executive desires to continue to be employed by the Company on the new terms and conditions contained herein.

1. Employment.

(b) Position and Duties. The Executive shall serve as the Chief Operating Officer of the Company and shall have such powers and duties as may from time to time be prescribed by the Chief Executive Officer (the “CEO”) or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive’s performance of the Executive’s duties to the Company.

2. Compensation and Related Matters.

(a) Base Salary. The Executive’s initial base salary shall be paid at the rate of $455,000 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for its executive officers.

(b) Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 40percent of the Executive’s Base Salary. The target annual incentive compensation in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the date such incentive compensation is paid in order to earn or receive any annual incentive compensation.

(d) Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.

(e) Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.

(g) Sign-On Bonus Repayment. The Executive previously received a one-time signing bonus of $75,000, less applicable tax-related deductions and withholdings (the “Sign-On Bonus”) in connection with the commencement of the Executive’s employment with the Company. In the event the Executive’s employment is terminated by the Company for Cause or the Executive resigns without Good Reason (as such terms are defined below), in either case, prior to the first anniversary of the date the Executive commenced employment with the Company, the Executive will repay the full Sign-On Bonus within ten (10) business days after the Date of Termination (as defined below).

3. Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:

(a) Death. The Executive’s employment hereunder shall terminate upon death.

(c) Termination by the Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:

(ii) the Executive’s commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud;

(iv) the Executive’s gross negligence, willful misconduct or insubordination with respect to the Company that results in or is reasonably anticipated to result in harm to the Company; or

(ii) a material reduction in the Executive’s duties, authority, or responsibilities following a Change in Control;

(iii) a material change in the geographic location at which the Executive provides services to the Company; or

(iv) a material breach of this Agreement by the Company.

The “Good Reason Process” consists of the following steps:

(i) the Executive reasonably determines in good faith that a Good Reason Condition has occurred;

(ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;

(iii) the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;

(iv) notwithstanding such efforts, the Good Reason Condition continues to exist at the end of the Cure Period; and

(v) the Executive terminates employment within 60 days after the end of the Cure Period.

If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.

4. Matters related to Termination.

defined below), and, in the Company’s sole discretion, a one-year post-employment noncompetition agreement, and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation Agreement”), and (ii) the Separation Agreement becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement), which shall include a seven (7) business day revocation period:

(a) the Company shall pay the Executive an amount equal to twelve (12) months of the Executive’s Base Salary (the “Severance Amount”); and

the cessation of the Executive’s health continuation rights under COBRA; provided, however, that if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments to the Executive shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.

(b) Additional Limitation.

(i) “Change in Control” shall mean a “Sale Event” as defined in the Company’s 2024 Stock Option and Incentive Plan.

(ii) “Change in Control Period” shall mean the period beginning on the date that is three months prior to a Change in Control and ending on the 12 month anniversary of such Change in Control.

7. Section 409A.

8. Continuing Obligations.

(a) Restrictive Covenants Agreement. The terms of the Employee Confidentiality, Assignment, and Nonsolicitation Agreement, dated June 29, 2023 (the “Restrictive Covenants Agreement”), between the Company and the Executive, attached hereto as Exhibit A, continue to be in full force and effect. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.” For the avoidance of doubt, all restrictive covenants obligations are supplemental to one another, and in the event of any conflict between restrictive covenants obligations, the most restrictive provision that is enforceable shall govern.

17. Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the CEO. Notices, requests, demands and other communications provided for by this Agreement shall also be sufficient if sent by email to the Company email address of the Executive or, in the case of Company, the Company email address of the CEO, with confirmation of receipt.

18. Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.

IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.


RAPPORT THERAPEUTICS, INC.

By:
Its:

EXECUTIVE


Cheryl Gault

Exhibit A

Restrictive Covenants Agreement

EX-23.1 15 d803738dex231.htm EX-23.1 EX-23.1

Exhibit 23.1

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We hereby consent to the use in this Amendment No. 1 to the Registration Statement on Form S-1 of Rapport Therapeutics, Inc. of our report dated March 27, 2024, except for the effects of the reverse stock split discussed in Note 16 to the consolidated financial statements, as to which the date is June 3, 2024,relating to the financial statements of Rapport Therapeutics, Inc., which appears in this Registration Statement. We also consent to the reference to us under the heading “Experts” in such Registration Statement.

/s/ PricewaterhouseCoopers LLP

Boston, Massachusetts

June 3, 2024

EX-FILING FEES 16 d803738dexfilingfees.htm EX-FILING FEES EX-FILING FEES

Exhibit 107

Calculation of Filing Fee Table

Form S-1

(Form Type)

Rapport Therapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

Security
Type

Security

Class

Title

Fee

Calculation

or Carry

Forward

Rule

Amount

Registered

Proposed
Maximum
Offering Price
Per Unit

Proposed Maximum
Aggregate Offering

Price⁽¹⁾

Fee

Rate

Amount of
Registration Fee

Newly Registered Securities

Fees to be

Paid

Equity

Common Stock,

$0.001 par value

per share

Rule 457(a)

9,200,000⁽¹⁾

$18.00⁽²⁾

$165,600,000

$0.00014760

$24,442.56

Fees

Previously

Paid

Equity

Common Stock,

$0.001 par value

per share

Rule 457(a)

$100,000,000

$0.00014760

$14,760.00

Carry Forward Securities

Carry

Forward

Securities

Total Offering Amounts

$24,442.56

Total Fees Previously Paid

$14,760.00

Total Fees Offsets

—

Net Fee Due

$9,682.56

(1)	Includes 1,200,000 shares that the underwriters have the option to purchase.

(2)	Estimated solely for the purpose of computing the registration fee in accordance with Rule 457(a) under the Securities Act of 1933, as amended.

GRAPHIC 17 g803738g00m02.jpg GRAPHIC begin 644 g803738g00m02.jpg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

&UP34TZ1&5R:79E9$9R;VT@&EF.D-O;&]R4W!A8V4^-C4U,S4\ M+V5X:68Z0V]L;W)3<&%C93X*(" @(" @(" @/&5X:68Z4&EX96Q81&EM96YS M:6]N/C,U-CPO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B @(" @(" @(#QE>&EF M.E!I>&5L641I;65N&UP M;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" */#]X<&%C M:V5T(&5N9#TB=R(_/O_; $, 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! ?_ !$( $, Z0,!$0 "$0$#$0'_Q ? " @(" M P$ "0@* 0<&"P($!0/_Q [$ !@$# P(% @(* 04 ! M @,$!08' @1"1(A$S$*%!4B05%A%H$7(R0R,W&1H;'1)D*2TN'P_\0 '0$ M 00# 0$ (#!@X?J1KQ,V\K&$HZ/D08B9J[N4L4SAH+E)18BQ8=HF*7S; M5;:>T'@E(*WE'_+W;B#M3!W ;02HSB"!'/$< M!]2*Y.+=%U_,3&)=P4N[08%L<4D=@YBEW2A44%73?^L15:BN=,BAR"0Q"'$_ M @00#B]#_'_47=5M=.ZB80NWN7 T+A"X6VM:H28V %')5,$ &!6MH/73UY<- ML7[+:&W/E\9!C:J0$[AM0E0E0GC&1/%.J0< N1%5,_>DL7E,P<<&+]HE-X$? M!P'N*(#Y+P(>!UZX*SXK4$EMQ"B(X!^6#[$$GRJRP0I&Y/H0>Q!DCZ&!GO/M M'N:V*S1R ^P\Z**-%%&BBC111HHHT44:**-%%&BBC111HHHT44:*)',X\Z-% M%&BBC116.0'V$!_GHHK.BBC111HHHT45IVX;@<(X^FE*Y>\OXPIE@210<16UF#]I)M&[]@X0=LG:23AH[;*IKMW39=,JR#ANLD8 MZ:R*J1RG353,8BA1 Y!$H@(A$?SCWIU"PL2.,9[&F43>L< M2>9?C_UTYI%BGIFPD.WS$W*DD#:VZI0"9&96D*401F#GFH!UUK";:R_I3:E! MV[;)7M,%+1.W;(S"H.X")^4'"HI.=)I5CR%9XBGU*-6E9J9>)M635(#>F0RA MN3+N5 Y6[5N3E1=P?@I2%'@#'$A#^2=!T._ZCU&UTW2FRK4KIX)0X2M*0%* M2 2I"5$!)W+)"3B>>]6V#-UJ5U;6-NE1&T-JB202I:E20?NA)Y, $X DN8Q METS:)#0K9]DN;DK)95?3,=E$.W$7"L%A !]- R147K@$3B!A77,!Q'[@(''& MO773'^'_ $C3]/%SK[J[W6@"\CP5*#2%H3(2=Z I?S$2%) C@ &!;=AT%IB- MJKE1=<2E2U;80@* D!)(4HF1@R#/' J%=DWN[F*78)NG)6=".;5J5?P;=FO! M,CJMF\7&GHN1;JLW7& M&VU)"EI;;4I"0H*;A4!(DJ."([5$KWK'6-.O7M.2@!#"EM-*4VWRA10F26U3 M!$9)48!F9CPA>HEN0CG)%GLS SJ!1$3M'\,BB0_ @($]1D9%0H#["8#&XYY[ M##XTS9_'_K:T>2;]U-R@*&Y$)3(DD@!*1!@#O'MFD,=;Z\TH>,&W!W"FT)^A M*$(4/+[W;.9J>V!.HQ2+T_95K)D>G1IQ\HFV;2?K%6K3ERHBJQ,8 MZ@>5R*(@4!,=;<#C3B4J04P4E)R% M CD$>7YU,0I*@"D@@Y!!D$8B",>H,Y&1BO9,8"E$P^P!R/'Z?_7Y_0/(Z=K- M:'W [F\&[6Z!(9-SOD.!Q[3X\#%!_,NTR.9)WV>HG&0D:F8\A-RJX< A'QC= MTY4,( "8<\ZSM,3B/S\OUK3N;^ULT[KAP(' )C/' F3SSP.Y&*KQ7[XI3:[& M69:&QK@O,-XB2O0;(3TNK6Z:1^F9P*7KH1RKZ8>E1[.%2E<"BY,0W"C9%4O8 M#J6Y ,3,9()\OI$\X/E465UA;.7*F&TJ4A#BD[RI(!2# P"J!&>>/K#GMRG4 M8VP[0\/U3+>?;PC4D[G6(N?K%#8&;S-ZL:DC%(R9H^%@DW#=1T#03J-W,HN= MI"M!3%5X^;%$1#'A*),#$_OY>DCR_ 37=N];T^QMFW+A>76PM*$@%:A ) !( M3 )!*B1/ ,FD@/?BKMMZ%@.S8[:LP.:RFN*?U=S-U&/E3HE4$H+C#B\612'L M$RITU),I4_[IU@*!E /"/:9]08^O,8C^'$57\0--0I0#+A2DY(*)B0 <&/O3 M'/:>]3M9?$,=-=SB-GE=YD6XL'3F12B76*STT[K*4>\.4QA66KJ,B9FM%%33 M%\[ M]L3C[TSVK9V4^MSLBPYCC;SE2\.\K,Z=N9K,K;,DY[4]<=4Z5;!GQ2Z$O(" MT_*C[A44I)!<$21(Y_,5&[NPBL=*6_<++OHMA+**8Z;1K"LQJ,D MW(NDTD[).NFJ9)!--5 KMFP9/%V:QCMW!T5T54BGAG)4>V(D]\9\CF/./6M& M\ZSTJT6A+06[O0')2$@9*AM5N5N!&W.(S6I<&_% ;/,@6IC6LKXTRCAEE(+I MMTK%$H*01Y_-(YP8\\=JL4UK)M%N]":9-I-EBKA1Y.# M/8HFQ5E\UF(V6B2-C.AO$XOD^VT@U&8IOG$#=:2YA[!9@ M56.V!G36#-])EL$D1$HR9F(F9F?(>9'O4=:Z MPT5:%J"G$@"84A,JD@0"EP@G.-Q B?*H&V/XJ?;-'6-:/K&W',LY6DW9TTIF M0FJE!OW38#\$=)PQ)"330%4 [R-W,B10"B!3B4_)2A;5YD\28/$#\QWG^_*7 MUYIB'E,H:/L5Y#;L M(.XJ()>B#EU"$0D7["R,FQE"D57B'BRJ(%$[IHU Q><*00,&1.!G.#G\C_," M0Z9U!INIK+;"RAT-[]CFT%0! .TA2@J"H3W]XIG*JR::9SGX A>>1-QP 'D MY@$?[@!R8PB'@I1$=( ),#)-=Q:@E)4KB,QG'?CTS2+]Y'7]V0[2K9*8YAU+ M%GG(L$N=I.QN+2PJ]:@GQ.P%8^3N$A)-X\TBB"@_,M(EM*F;'340>F:JAVZ< M\-9&2?;)]<^7:HGJ?5^D::LH!+RQ_P#6E ,D1NW \ M[1%2R=C3)N&H^:EFD6E;Y->NV6JPZCU8J2+ZR.HYZV?PT8EW N\D"LWB+-$# MK+ "91,&2WB.#/KWG\1ZC)Y [4Q:=96=R6UE"VVW2$I)VF/F*)(D'!$G;,S. M8JR/5;97+Q 15KJ$Y%66KSS!M)PD]"/FLG$RK!VD59N[8OF:JS9R@JFTB$( O9RP/D62)UC"8$63%(Y@7D'[DQ!(V8,4UWJYA $D#<"(92G<>0/ M?\?QP:8N[RVL65/7*TMMI'?N3@ #DDD\ 'U%5U\I_%)[2*I97D-C##&7 +PWB%E".7,>VLM1:S18]=9(B8.%VR:Z:9EB>D!E4A *F(B&0" F,P<^ M1$^7M.)S/F!4.ZLO%KURPNT I0MFV>3DD[7&4J''&%9$@>7 FT?TB>KM4-]% MA2V[5[$5DI$AB3"D)*N[%-6")D64J2LJ05440:LV*!7;C875DW,Y17M+>U!.$)\!EY85D[Y6^L DSD MC %4+UD^X]U*K?!+*DMC& A"U!( X[2H\F!-3?Z7.-XMRWO&2W;'RJ0ANTLWDC F MU6) A9$/Q[AKU>3\TD3MPF!)&[G\AF#B.*L> M2>YS@^L?S\:4_X%V 5,A(W-%20H[MX))"53\^2>.Q,9;-TZ=T$L[??T%W62L72GE M.)81I04 5I4G?XZ%+*B5 H\,I!X,@GL+/Z+ZA^UI&G/K"BE,VY)EP[4DK:4? M)*4E23S)(F( ;W.3#"!@9>>F'B+"+AHI[+2;U<2D09,_V]<+G,/85%NW1 M445,8>"D(81\!KU0H[4J5"E0)"4@%1@< $@$GM)%6"5H1N4LPAOYE*__ "!) M/I@5UZ>8UMT777WJS$G6Y!S6<&Q-M>5/%B,V5^->K%0;G%LJ^8Q*:PE>VB49 MM"6"T.R*)E1<.TV2CSY,&C?46ZFZOTSIO4+'0RO^I:IK"_#M!:Y39822JX28 M!0GQ!N*LXE(5*HI6YN;_ *HUNXLFU3;I4?"2@%"D)W&%*4@\!(E2C$Y5 DT^ M&E_#C]/O">+9FXYGDMI0U<.M.NH2$N+:0$(4M.%*2%2H JR!,P0,YJ M76_16E65L7[@W"W6V=RBA]Q*<"5 J)4?51/U@S5RA*YF[K']0.-ID3-.8]& MUOU8:MK22SU]#8?P=33*&8-4VW\P/::B-LI[7M758%6^V8WM@* "DH"AM&_)4$!,?3RJU[7_ (9K MI^1^.R5F?=YEF+D,>D@XR&2\-(Z2-(F2*#AZS@VM>-7VC<%@$S5DJR? B0Q4 MU%U3D]8<%TB/F!YF!'MS^<_I%31'0^D%AQMQI>]8!"O$*84%A7 3D0F#*C,D M@I,13UZE&P&Z=/#<9*88L$LI:JI+QZ-HQI=BH*,OXHJSL%$@-(-^ 2:S<4[( M[8RJ+0RR .2 X25]!RDFFM"U*()(S,X [G/?W]YSFJXZBTG^DZDS: 6:]O& M"4J ,[HD9QSC;$]S*CJ2I@?8+T>/ B*FW?*:BG(\B< ND. E#N$WN4H=O;VB M8?!C=H\:45$ 09Y[=LQ$X$>7G':M[7=KEKH^Y(E=F_,8Q;JN0R9$\>&@J_\ M8S/)%2VZ-G0TK&]3'@;EMRT]:H7$HW6I5J8G9YE&%<+@9FQL$$UE%WS5(O!9.* M9*F#UG+LYLA(@CM,C,\=NWK/)]2>.=T9J[Z+IS3[E84A .T$ $$23\T@F0DC MMF!F!5?7;Q@"\[H\]T# F-FZ2]PR3:QA(TSHRORC)NF*\A+2KXQ"+K%CX2'9 M/I5[Z93 FS9*&*4"D 0><44\$#N9$CT]A^0\JA&EVSU[>(M60G8X4@ I&)(B M503P3WQ/UJ\EB_X9C817\:M8'(\MEN_9 4CBIR]Z:7!&MHIRPI?VEQ 5]E!J ML6;,K@3F;M)()MD!M]R;C*2/6L-3M,O.8=R@H1RV%S+-_HD4Z3,"Z;&95<@9-9!+0$B23[C MGGS_ ![14JUW7G6NG&GK9:0_DH6GUVIN6T?9,@R$0NX0L$B]GG\;*)Q4!'S F:D^2;*/ M)9_]7 BS%-N"BCKBRCOVQQ)_+ [S_81_ISIAO5VDW6I)*Q)^ZHIW$>42D 8! M)!,B.,AD/4+^'(VW53;[D3+6T^:O5,O6*Z=8[TI4+38?XJK5PBJM#OIR6BT# MKQ7UB,G'3)@J2(-6TNK4)>1SPD\DS;E^69+QL@X33)\VN)U.I4H)5S@)X M,E1B!Y S]*U.B=4NDW5WIUZZE;:$!; B"/#PH3,G<#.1 V\U##>+>MRO6S MWRV.@8ND'C+;SCV\RM QH1^#Y.JHMHUZZCG%N68( X1E;+84$SRRY2!\Q'P9 MFB1E6B*1CN8=KW5=ITYN=,MU@H;<4VPW$#:C[RED3@A*C)&",",AX6 OAE]DE5IL;_3 M3.97RE=E6Y595\A:DJC7FSQ3D3I1$-$1I7:;=+_#(H]E'BI^ .(@ ]@=RPN[ MRXMT./J#:U 2DMH!"I/$CZ=ICB*E]GT-I+32%7;2G;J 5J0XI*-Q' 3&8[$C M.8@1%>;X@FCP&/NH!%X[K:+A<W!&#:?"(.G)W+I&$@:T6'CTUG:H@=PX39 M-TBG<*?>HH G, F,(#U60%A17DB3($9.28'$YX@#V%1'K)M+6J63* A MF@ M")(0EM* .#!"0!.(B?6KA?3:Z8VU/:%$UG.N%ZY:(G(.3,/UF,M3V8M!$?G39^POZ?[C_WI-2.O$5 *(@)3!P C MR/: >.?R)N//'CD0T@*,*)21M) &"51W&8_$CUH,#N/]O>:JT;IRF7W&9=22 M*Z0=.H,^ ]J>J/:BTTK_NML.6=C;H\0V#:2RJJ%FHA6;7).2[/%_Q#]-L#YHA(EK=3BCNT8H5HQFY0-)R,JW ME" \5.R39E^764+>++2D;U$(65F1))B1!!Q&)[ QCL*X_4W5*K-P6=GO3<;P M-_R;8F%9W$B,9VGGMFM7=*?X@[,^6-P%'V\;Q4:O/L,HS#6JTW)];A$JS)Q% MLD"N0B8^T1C%T,._C9MV1O%H.H^.CW+1^\0$Y56AU"IJ=80I"U+*MR4R$HP@ MQDA0! (@#E*IR..=;I_JUY^^3I][N6XXI(2L!.U)4K:,_*HR2/\ QD8XS5R? MR)> #MY >. Y#CC\^W #^-:@DC$(2.( _0R!5D0)[GOR<_B8_&EE=1O"L+9L M9N,I,63=&TT=1L=Z\13 KB2@'2Z39=NZ$B8F5*T5< [0,8>$_35 AN%!*/G[ MX[]&VNH]/7&N6]NA6H6K:G'74( ==;;"2"2GDI"0$@F(]ZAW6NELWVDOW2$I M\>T;4LRD[E-QN* 4@DD* *-Q ^90(J!'3XQC8KAG> NC-BY3K-#,YDI24$AR M-3NUF3EDTBR*@ D4<+"Y.JH@(]Q$TA,H).],#T;\#>EM0N^K+765-J1::0ZA M;H6E:5.J=)"4LRD)5'A2LJ4A.U0C=F(?\/\ 27GKS[>I):;M"L0[N"E^(TM' MR@ IP<*"B"$F0.U.'WJ,)U_M&W(QL$X.WF)3#-[BHQ=N=0BJ#N1@'[(BQ3%# MN*"8.>X1*(F[2FX 1X ?#:,EY"52K:6PLJ*T[8@C:(!5,& M1,5:6M* TN_4@'<+9X\@$_+@3([SW[XI-G1[Q55<CN)I4IDG;]FG'\482RUWQ/D&JL#)G[3_4+!4Y:*9@F< M,+EVD!3#V@ \"/L(:]CH*9DY!&/6>#F(GUX\JM*_;4]:W#:,%2%@ \Y28&)\ MP")_$<]>CT2-PM-V5=1J,3SHJC3HF>C[C@^R34N3Y)O2K.\?,DVZLLJL)?IC M8MEAR0DBX<]I6#5TJJ\%%--4Q,B5$\1Q\WD2TQ3Z3M.<''D/Y_;-7&'4*0'$K0$E(4 MDE7;DF1C \O<&NO^^) W:XNW$[LJ'C[%TO%6EAM]J$G6+-:81PA(1CVV6)XU MEY&"9R3=51%TG7BM(]F^,W.HDD^7DD"J&42,36PCY )S$S&3Z?KP,\@]JJ'K MJ]9N;UL-I*RQM"EC:4J.5&/FS]XC@<&#Q6@^I$<#;!>CN!1$?1V[91*(&XX/ M_P":PR@ASSQRH4P$^X0+W" &$"CSK!((.($DP?+ZQQZ^?O6CK29LM'NMP#=M M9/H<024N*+SCX!0 "DPIP;BI28@^@-I/X>7=WB;+>Q?'^!XVT6TMFPI"[?Q&U[PD!2E.J=W)(424PX$DJ .Y*A$;2IK M>\7=-BC:3@"^YBRK8HV)BH2!D!AHMP\:DD[7/J-5"Q%<@V*BQ%Y)])O3(("B MV*IZ3=15PX%)NDJJ3"$G=D1$DS/;M[S@>OM7?U._MK&T=>?4-I24@""5*6"$ M@ G/[=XJ@WT,:!9,K=1N/R'&1BY(''E&SA?[8Y:%_LL6TG<UP$&5 ?EY'R'\S[54_2+!N==>>@ELKW @&<;B. M1&"4R08Y,P!,9NE%N.I6U3J!X-S'D=PBPHT;8;'6K-,.$@4) 1]V@9BIA/F* M')R(P[F7;OGJQ $R$>B[5,!R)J%%2B%$=A)@XGGZ9C'E SBN9T]?L6FJ-+4" MA)4F2M(P)B<$Y$@B#VX$".T#KEEKUI@(VQUN9C9ZO3+1*1BIJ)>MG\9(,7"9 M5D';1ZU5406063,!R*$4$/NXY 0'C7((,1^_>*O=#S3J ZAQ"T%(.Y)!$ >? MH/Y,U2#^)UW98ORUDW"NWB@3D99Y[#O\6S]^E8ATW?-(*9M)(V+9U-5ZW.J@ M:3:M(L\C)M"'Y9"NQ!RH5(@I((#GAOX,*PD 9(DR2((XC!OIVMY(Q_T:NFE>9N,DF[2'FLGS-C;G17($ M"QS8^3MM*4>MQ AF8O&D6@W)ZPAZ2[Y-L?\ KG*)3J*TP,=S)Q($C\2(D"?7 M%,ZW8/6O3UDEQ)=^9"R4 D)&Y*ANW08C)/>)@][!WPXF[;%F1MC]8VYHS_KW',>@YB7]'WUL[IK;(=;2ZDKPHQ(*B1&)5'JD>W%057\A.2BK5@DS; MD46,55142 BDHH5 29$ P".<>_\ ,U(M1N;>VM'R^^VD%EQ(,_>44*"0 0#. M1V'GV-41.A%CFZW+=!F_(];;.T8[&>UW-[]]((E63;-IJUP7T.LQZBA"E(5T MZU0Z$8NW!O!IC6JWNDA:G?!:9_^ @;%@E"_L]V5$@%)65"?NUM= M#I0[U'?W"FEH61/VX\ M?I^OL);8<1L7B1_X*4(]B(/;_BKCF./S _YKKP/B26Z[?J:R:RZ1TD5<5XK6 M154#M(JBG'N$SJD./ &3*JDLD*AA H*(J%Y^WG6W;PVD#)$0#.<#;F3^9/ZU M3G7)V:U:%6 I;/S9@# )..Q!_"KXVV*R0ECV[8/EX"1:3,6_Q10'#)_'N$7# M5V@:L1A 5053.)3E!0ITQX\@=,X" "&FU)(),8['MV\O>K6TY3:K.T2AUM?^ MF;,I*B,#:>4@X*3.,8F*WUWA^@_[?]Z16Y2>=\>\N\TRZNL3XPE30:\0U:'L MEC13;JO!=NVZ3DL>Q%5!1-L*2*R1G#GM[A.=1%$""3O#RQ\:?BKK>B:RST[T MU#N4XX KPTEU*R GJ.JG=-?-G:07$G_-4!N5) M(2!!@!.V3&XJ, P#,@]G$+C#*N+J[DJ8J] M.UU""8Z[E,[=SZH\''O #"(IAVSSX76O3_4_3=IU _I]NO6W;A]G47GD)7<% M]EXI*E?,H0XDI<2M( (5 (B!W.G56FJV3-^IAERX!4%NK;!=#J5JDDD3NX() MB<',@U/]N"1""FD4J9"& I2AP < 4O' <\ 'XX#QR ^.>=7.WM2/#2$I#<)2 ME) A,"(2/NY)Q4E@9 Q[8_/N:ZXKKO;)X)6Z_&4R5+8F<=\^8$4G$S/O8P8AFP;KJJF%RF MY42(V:N3*)4H!*C((VDQ([@XCU)S/H:N5-N-MMK0X5*0XD?* MM*^2-N-L 8R2?(#L3]TN=VV <7/[>5 CV9=+I1->8&.4A7,L] Q43*"(_P"" MU3*JZ7*7@QRH^F4Q3'*.JW^(75S?2'3]SJ)(\;PE!A.)4LX2 %1.8$#D'RS5 MLZSJ:-)L';M2=ZDC:VC_ -EGCN) [B1/$B:3%B_<1EW.6;*/4 ;U8X[))!,5&Q (F!3*G.L($Y,J8QU##Y0Z;^(/5G6/5UI MIFI7RGM&O[QILV#A8\,,J*0IN$IWJ#D*405$]A.*K73.J+K6=7L[*X"U6EZZ M XR4@)* 2"AP(2 =N03ZP!D6 :A4*O3(M*'JT#%P$:B1,",XMDDU1\%[>\Q M4B !C<%[1$3&-P X-6VU;LVS89MVT--I)A#:0A(SY "2<$D\GVKC^:*]*VW$N1*S!MP=3$Y49N M,C6QCII N\=,E4D$A.N8B1.\Y@ #*F*0!$!$0]]:75MG?ZETSK=EI00K4;K3 M[EFR2X4H0JX6@I;"E.0A*=QRI6!WIB_95<65TPC[[S#C:,Q\RDD)R>(,&EJ; M$-MF9<,Y*LT]?JHC$1JZ3FXD*'H]@B)BB %$1 0$Q1X 0$ M 1#N#P/ ?GQQ[Z]1\1&(B([14_/S;@1R3,<9)XQ!'\-5/NL)T"[!N O]CW-[ M-DX1KD&TJ.);)>(Y%5"'9V^>4*Z4>VJJRKQ8L:SGY0RI?JT5(&9L7RPJO4': M#IPX!=Q)&2<*/GP3^WK^4=H!U#TG<7+WVW2G$LN *4ZB=I4LD'*K^$VF=:JK1ZV#H['6]5A6CE/'C3HB9NIZ4=(HG3,@1:)G%JL6/. #P8KP MK,Z14S$.<@)\KG'(&#WD"8SV]/+FH8O3>L2%VR7GT@D(Y5 "3Y[(@B1WQ@>= M<_5^'NZH*M;K-E2PS!/7UC1D74A6E,BTUG8:T5NY1*U"PE>RZ,>#^7*HLX22 MCY64,B7O%V5NXY0)B!P5#V)]?<1@D?AY5D]%]1.MAUYT*<5."L%0/J(G (P! MF,FMB=8S"V0MO&UOI98;RM$(UW(% P?DR$M$,B^:2;:/DDK5".ET4Y!DHX:. MA%-9H8#H*K$( B($Y 2BHD%,8()Y]QVY'('/>.:V.K;)=KIEE;+4$.)9;04E M4*4KQ220FHY&XGQ3NRVZ4>[6RJY"KP6:O6?"5@5+=:\ M)7;YFO'R<;'KQEC9NTW#!0QU&*,DP5%=$Z:ACF%!$X S!YYSR941/ ,]_:M1 MC1]=%A;7.FJ4EKPCNVGYBXE1W&!*I@) X&",&MH5KIH]8'>O;H:.R/0,Z/6B M2Q40N6XNRSD77ZZB0W8HX!*TO5Y$Z9"E'N+#1CIVL03)$(8IA*.)\X'N<_V] M_:*GETR,<=-_;5?:W'OT+OER MZUF3=Y2R01BJQ4FWC*+D_IT)#-E5EE6=;AC.W!&B)E05>+*N9!\!7"XHH)*I M( [GG^9_0\15GZ'HC.A,[P-[QVE9 )^[/R@9/O.3B8 @=>/M>VO9-WAYM9X+ MP^6#7R!/1=SF81E8'YXR/DOX7AI"=>1H/BHK$;NWC1DLBR.X])J+DQ"+KI$, M)@5$_C@2\>NP#HRC'^'J+.6YQ3'22PB'#5S6)MU7DFIC*&,8S9T"0B)C',' M(@!YYXGG]_3\Z[:]+ZJMP&&';@- " 5*.2),X/GYF0('!%,RZ;/P[V<;SD:O MYBWW1(43'L/*-[$.*Y*42E[]D&1271?ILK.O%O7K>O0*ZYC&DP7>KS;P.]N+ M1H*QW2*%$'!/!X'L1D\?3MZX-=_1>DM0=N$76K.!;:4[PVHRHNRDA0 &)25@ MJ/S9CSJXEGW;3B3<;@2W;=A=U#]G>2W=KVXL+;F2F(.SNJAD?#?SJJ;[I74]'/^ MA<=6V.%,E2MO (4 "03@8!&9D@5I^L].'J_[W+I6Z]DZB[AG<:619L5[CN"F M["RK%3CUE$47%14*W$5E"IZ#QDC&#F,_C/$X MSVR*TQHVNZQX-JM5PA+*@'%N^(E!25%B^3H0T8*W:B"[ATJ8S MITX$O%Z@87=Z/J3%NPA^Y=LKIEE*PD2IUE:=NY0D JVXX)R>*M'3-$&FZ<[: ML%(<=9*7%@@%;@;*$1N!!B3)/,YB8K6&R':YFO$N<6ELO%3^D005^=9*/OJD M6Z*59VFB5LD"#5VJMW*F!01'TN"@'D2\@ >8_@Y\/.LND>KFM0U73F6+&\T6 M\;>>#ULXIO?<,.(;(2HN)=*T-F !\@4"0!%1GI;I[5=/U:\O;L)0P57$#@1FX2=NF"KAJ"J;A!Q)$ $\&1/'\DD^] M1#JGI[^M-(6W >:3\LR"8)C;ZB)8+$ MDH2J0%Y5F5<<-;4>UUX2!6.7CZL@^78_/*]T8L(?+^H8I.P3&-A>"!/;]S_/ M+R KE=(V&I65ZZS>*>\)#9""O?L$P(!,)[$^QD<@BWIR7]_]"_\ 6D58E5U^ MH'BJ>I.;YFXN&JAJ]D R$A&R #WH%D6K!JW?L#J )BIK$.EZJ*8B G(8O8 C MR!?!OQXZ9U33>JG=96RLZ?>%I3+X(*$D(;24F#B%I/([^E4UUOI%RSJ"]20) M;=VK!$2E02D*3B3@@&.Z5)P^P2A:=J MR 2B H@@24@&1)$<&N9H74U[H3Z65-^):NJ274P! 61*@J,*1DD&1$R#()== M3-^&W"TQ3=^XO+>MO3D SJ*L+1RP>M3@4G<0Q@;*(J@4PB4%$5E2&$ANTY@# M7K[2_C#T-J%NFX5J+5HXI02M#Z%(4%!*5%0)1\R0%"#)[CWMNWZFT:Y0DIO6 MFR4@EMPE)"I,B2-I(XQ R.1Y]YYI?4VB:L O3M6M+J4Y::>0I8$S)1 0XG. M8,CN?QI6O5/F6:5)QQ!"L'SCZR.I)-#D.3(,V:J1U..0'@IG2'GV^[CGGD!\ MP?XE+QI&CZ99;AXKKI7M,SM0M*C[XR?0]^*@?Q$N$M:6PU/S//$)'H"V%'@P M/F G$_3"UMH[99[N0P\FW+WG2N3%P?\ 4$FR3@RZ@UR^1UF M5F+K6*J9J[GY:N.(])NE/2+-1V4R$:Z66.W*W?'_' MKQFH%U9H%SK%U;.-(W):2E/WD@':LJ(^8CSG'<'ZMYZ9&#LC[;-C6W["&6XE MK!Y#Q[4EH>S1C&5CIMFV>J2\B^*1M*13ATQ=I^@[2'U$51#N[BB " Z2L@D1 MV$'WDU)]%M7+.Q;8=$*03B0><\@D=_/F9J>>D5UJX_:V+F3K5AC628*O)""F M&+9,QRI@=P\CW#=$ICG$"E**BA0$P^ #R/C115-CI%='+??M&WZXVSKF['-7 M@,+ D7$RCA\L"KQVB"AB(B"1#=YQ+YUL#N9 M!\X,Y '$3Z56'3O3M_IMVVY<-E* V8P0( 62>?2?H!5S8))@1[]-,\:!( MF0^<(R]=('AFG>5$7)6HF]L'9>]NN511-['/2")F[]@Y*<#H.6QQ$Q#"(D,43)'*9,YB&C/5 M/2^E=5Z:K3M5M$7;)(4$J6XVH%)!$+:6VKD<;H/!!!(K6O+.VU!E=O=M)=:7 M$I(*8(X*2@I4DB(E)!B12$,Y[%LP8E?/'T%#O+Y3@55.UE()#YN4:M?N,"6VV5DI0 M4C>Z2VF,DK4=LYJHM6Z,U&T#RK99N+;>XIM*$(4I#9)(1M(4L0, RK DJY*8 M8.H]^Q6%!XQ=,G*9Q*H@[;.6ZR:A>0 ID5BD.0P )!#GN 0]P'BH+JPU*W M<\"XTV_MEA*3X9MKA)4"H_.0M!)*E IW"$G:,3-0D:?>,DA3+X5,DC>/;(!' M;CM'X<[Q;?K1BR]5VYUMTLP?QZ()1(L@X:BHEZ:A3 M!S$,0"F*4==WI/6-8Z;URPU"U7J=L$OMM.[V5+0XRZM <:+;[3C9+B1MW(2' M4B2A0R1V-'O+[2[YFYVOE(/A[5A6V%&8@I[P1 @F8!SBSG;LS4+'E*2MUPL\ M5"MCQ7SZ#-9VV^>=+?*D6!FS:"H+ATX.8P)II)$$QC'#N$HM:E1M 1"@59('%[.ZA:VMJ+BX=0V MG8D_.H DD [4ID%1SV[>7-5TMSFX&8W"Y$\#2"2RV4I0@ $B9/( )()E1]O05++IHX@< M6#(DEE628*?1JHS5BH16^]FV5.GO$K2"X$$*<2$J2%1) W;P-J0 )43)>A='/CKU%]L MDMC8TLD@[U(@@# 4 A2MT@D$@C!P]TA (' '/ (A^>.>/^=>SH$SWB/I5J M')G^8KA63'-N9X\NSN@M8=[=6U7FEZLTL#MW'PCB<28+GCDI1\Q(H\:,CN"D M!=PV(99(G)R!W &E)Y'N*:>W>$YM^]L5'O%5'%,X[QLA]"3)^1*G=Q94OG4VX"*>GH M!@1C)B8^OTGSCT/:!6NH:@[TV[=./J5=MW1;0\4-[MI)$% 0$&,"=I.<2:;Q M2=[N\3%V?=MN)]W&$L5TO'FZ-.9A<867&%ZEK1/TRUP%<_B9.K9&1F8>/8OE MG,,B?,#RJ0,ZA=6[FE-W@24WA M>0O:("=C84WD >L@$$DX,"*C%9^M)EF62RYEK$U=VJ+8'P];KE"$IV3,^L:G MN,RS T2548SECH]4*B:,B?J*:*ZE/BYE%P^GDT2"4.7*1C8V)CUP(DR<<^Q( MGF03'%:B.H'757ZF&TN-VGVM!2DRYO9O4LI7Q 1L*D_,#DIY(D[]L/4TW!Y( MSW@C#>T+"5$R1%9VVL5;Q4.C%/2+,(YQ9%%4I9TFF9(4TSB (B3*1*1YSD><3/GP: M-A5FLPX;.O1]95F@O9G#U)TBP:(R!VZ29T MR"FL(',3B8R.V>#/^WG6FOJ.X2,GF^^[K"[.]5 M:7B-NYC[2R0GE 2K<,2"=R3'?('!Q#MIUPLI-*G#[E)ZI[6B[:YJ?9I*XTB\ M]L7N[" H4M-HQ$=>'U+ I8IT_2(LE(R5.;M0D6;$RBAW0 4#AA24@ _OG$SC M/;SC\.><.I5(97HW!)D5F!S&153%P! MC]IC(*0 H#N_P Q[6L!9SP_P!HN.Y7;5FF8@_I5I/6B+LHHN'(D #!2C(B._/:3]/?'EQ6=/U2_N[+3]0^S_Y5WN"FD@%2 M0H@M+YD#8,F(,@XD5K"W=4S.KZL2DB\,_ATG!Y,)9HW.(N6ICE$ (3!B#'.! M2'-8OOZ@JW0RD-)4D%*L.$$1N3/(!$D & <@@&GPQ3M9\P9.W#=5FLZ:-W"K M)P"?S+119,JBC9P*1CI>LW$WHJ^F82>J17M,0_?Q[_[^-).[MMCUFBOP M40(LF*2Q$E"#_P"DQ!,7R/(\@)N>?W ??SQ^-"D(6(6E*@>R@"/SK!$B#D?A MY]Q^']ZXH_Q[2I4_J2E5@'ZO !ZKJ+:+G'@1'[C*I&,/N/N/'GG@!]^:_HFC MW*PY<:98O+ "0MRU94J 20)*"8!)(\B3YUKKL[5P@K8:69DE:$J)/N03C'?] M:^0XQ+CQR",'/':JZNZ+!N2<67^<2FV M-@FJP]DG;RN6 Q'T@P,P75]5)D*IDU2,G30BH("@<4B&[0%(X@/:'A3XD=%] M7:=J]Q]I&J:G8+<>7;%";IZW:;F4)+: 4I@$24@01 !!Q3_4VG:S97:P ]<6 M)*RPEI,I2@D; 2$F7(*=P) .T\ @'UL ;3\DYVG&:3:)D*]4"N4PE;3*,EFS M5-$JA/52C"+H@,@\,F)P2%,GRZ9^!45X#@=#HKX5=2=57]L'K)^RTY+K?VBY M?8=;"VDJ"EI$A)!4E, B1'WB,QJZ!TK?ZI=(N+A!MVDK"U*>0I,[9B)@*4(X M .8G&:L9XIQA6,24N%IE49)M(V);^D)@ /6>+CSZSQTIP J.G"GWK''GD?M# M[2E /?'3G3NG],:3:Z5IK26VK=O9NY4M1)4I2E&225$G\N *NNTM&K)A%NR M$($"!$GNHGF5',<#@" *V2'@/(\_OKO)$ #^7Z"NC>Z8JZ=TQQ+B4"R<4M:5 DN!3900"(VD3/>?Q M-+.<='K-5 D\BX]PL393)XCO^0+#GCK<%$V&J#CJ@[-6&V9& M:Q)82=>3T?;F=@&PH1$'#L:E%PZZ38P!'QQF9&;A44&4:FT(04TE8((CDX\Q MDG](_;&*ZC&G.-7=O=*6TL,:HZQ.Q;?/M_M M.=*9M+SKA"#V\Y[O5HR)]8MDKD?#%CO@JN;BKCWZ* 0MB0[7+LS7LIQ49(2]?2FIEI9KK#.) M2*DT(MV]9NB*M8RPLS$2%5!Z^!L90I2F,L*!C'WI'U'$XXSG%<:\TV_MK;2+ M1I]@OV]ZJX4\6E;%[[D/$!,[DD YDF,DQQ3+H+8%N,W#YU2S=OYR)B*PL:EA MS(>'\98SP+&6AA6&*&589Q7[I0,4Q:=/J8WI4Y;N-ES M2//GR,8J7%[V6;NL9;K\J;C=FF4<&PL3N!IN/ZME>E9MKUL M>-H"1QC!KURJ6JC&IA4DSK(1"YTUX)^,?'K'$Y 7*B8A4T2),#![']O*,Q6Y M_3[]J]^T6MU;-M;4A32V5*5(X(*2E(Q)&/3L#6@X/I.9XB=B%1_'U\O;O]/6N:=!OCI0T]-Y;!T:BF^\53+A24)"P6]NZ=Q*\JF!C J1\W ML+RMFO.CW+>XVR8U=1^0M@=TVBY4@,=$LB*"EIO%Q^N2,]42SC45 KS>*.L1 MN,B\))?/ @8S4R)#"4W@ _EYY]YSY5TU6-VYJ2KQYZW6P;2XMPR&E!25.N M-$+G<0$A*(4#GR KAV%-H_4KQM"X8P$XW/84A-NV%I&!CFE[I=/L"F?;UC2G M +.O4&RL+&Q=X_B!>0R;2.FY^'!625!OWM!2[SCK.\3P??$UKVFFZI:LV=J+ MRV-M:A>Y(86%KW$;(.X !" 4D$$DD'/?4V[_ *8V[#L8[>8K#NE:@Y>FX^TVOAE0(!8474IX@+WCD3R" &YA:0H?=/8U@H2N M*5"1A0"AR.QD5X,&3-FD M@BT;(-DBD-VIHIE3*7R'@H% *7P'VAP4>/(:S9L,L6[2&6T-IV#Y4"!G/'N M:R4I22$I"1V $ 8& .P]!BOHD_NA_/\ Y'6PDR 3Z_J:*\M*HHT45@2E$>1 M!_S]N??GCVY_?CGP'Z!HHK'84! >/(>PB(C_ ,B/M^ _'(\<X.#<@ ]P![ //N ?OHHK E*("''@>>??GSSSY]^1Y'SSSY MT45GM#@ X\!QP'Z<>W\OV]M%8@<_2LZ*S6. . ./TX#C_3116=%%&BBC11 /1HHHT44:**-%%&BBO__9 end GRAPHIC 18 g803738g00m26.jpg GRAPHIC begin 644 g803738g00m26.jpg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

!%L0%5PO/,SDN03>U\VNESU^Y[]^-'<1"UC1$+5:-KFVV)6H=I]?+?_ /U.(%[C:]O^;?EW MV].^N8>QGU_N+^W;MO\ *^MN#!B0>4.8\0Y7QN@Q[#T1:O#)HIGCD'4BF0?_ M Y4%F>.9,T;I=0RNP+:GAJKIFZZE=84"$+04*TF%"08()-E!5TF/O"1>,*T MH*@'DA:>0JX/)!G<1(/[(L)S7S!28W4U5?'0/TN:,"FK?CZ2E6U L!A*&5SQ$Z=I4T[1I7ZA8-,"@^92C8 I*I,E) !@ "2 MJ +8@9I3MI=9=H=*6PXEPHDI"P04K2.$F/,-Y*1(N<0__"X7PBJ$D-3GZIJ8 M9:ABL<4,3QI+)2?S1U*B0M"E1&48+ EU ^\-@'V5Q"H<5X@61

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�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end GRAPHIC 20 g803738g00m29.jpg GRAPHIC begin 644 g803738g00m29.jpg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à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end GRAPHIC 21 g803738g00m30.jpg GRAPHIC begin 644 g803738g00m30.jpg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�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g803738g00m31.jpg GRAPHIC begin 644 g803738g00m31.jpg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g803738g00m33.jpg GRAPHIC begin 644 g803738g00m33.jpg M_]C_X 02D9)1@ ! 0(!>0%Y #_[18\4&AO=&]S:&]P(#,N, X0DE-! 0 M %B"^5F0X0DE-!"4 ! .$))300Z M #E $ $ MP'1E96Y" M:71B;V]L MP.$))3009 $ 'CA"24T#\P M"0 0 X0DE-)Q H 0 !.$))30/U !( M "]F9@ ! &QF9@ & ! "]F9@ ! *&9F@ & ! #( ! %H M & ! #4 ! "T & !.$))30/X !P #_____ M________________________ ^@ ____________________________ M_P/H /____________________________\#Z #_____________ M________________ ^@ #A"24T$" $ $ ) "0 X M0DE-!!X 0 .$))300: -! !@ &+0 M#L< & &< , P &T ,P S 0 ! M [' &+0 ! M ! ! ;G5L; ( &8F]U;F1S3V)J8P $ M !28W0Q ! !4;W @;&]N9P 3&5F=&QO;F< M $)T;VUL;VYG &+0 !29VAT;&]N9P #L< &7!E M $YO;F4 )=&]P3W5T)E\K.$P]-UX_-&)Y2DA;25 MQ-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$ @(! @0$ P0% M!@<'!@4U 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C M+RLX3#TW7C\T:4I(6TE<34Y/2E MM<75Y?569G:&EJ:VQM;F]B7I[?'_]H # ,! (1 Q$ /P#TVQN0 M+_4;'@/C0@QH/;HAQ"P 0;5PFKI*DDDG(4DDDDI2#8T&^IQK>X MMF$ M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M M #_ MX4!*:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+P \/WAP86-K970@8F5G M:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX M;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X.GAM<'1K/2)!9&]B M92!835 @0V]R92 V+C M8S P,B W.2XQ-C0T.#@L(#(P,C O,#&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT7!E+U)E7!E+U)E&UP.DUE=&%D871A1&%T93XR,#(T+3 T+3(V5#$P.C,S.C,Q*S U.C,P M/"]X;7 Z365T861A=&%$871E/@H@(" @(" @(" \9&,Z9F]R;6%T/FEM86=E M+V5P&UP+FEI9#HQ M,S%B-3DY-"TP9&$R+3-F-&$M8F$Q,2TP,V4W-S&UP+F1I9#HX,S,U8F9E9"TU,S)C+6(V-&,M8F8W M9"UC,S$U-C,S837!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V M=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @ M(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC871I;VXO=FYD M+F%D;V)E+G!H;W1O7!E/2)297-O=7)C92(^"B @(" @(" @(" @ M(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO7!E/2)297-O M=7)C92(^"B @(" @(" @(" @(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z M8C&UP;65T83X*(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" * M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @ M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @ M(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $, 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_ !$( /T" M70,!$0 "$0$#$0'_Q > $ 00# 0$ !P$%!@@" PD$"O_$ M %X0 & @( ! ($!PD(# P' $" P0%!@ '"!$2$Q0A%C$)%2)!%S(U45:5 MU1@C,S=A=X&QMR0T0E)Q=J&V)28G1E=E=9&6M/#Q-D-%57)T@X6SM<'41U1B M#DJ*TQ.$(1V:$ M)V6%H[?#Q?_: P# 0 "$0,1 #\ _?QBE,4IBE,4IBE,4IBE,4IBE,4IBE,4 MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4 MIBE,4IBE,4IBE,4IBE:@JQK8!5[!ZN6.$XR:[-XS8N"#Y3XB:]QYH_"6K7VBZ'9)=118>[ MM-4DU"YT^U;(N-0BLI=*M%G>WC]X?C7$&[VF2&6*&1:YK6[W6[73;J:VLH%= M%ZRQ737$D$?[^80O:0ABBY.=["//,961&K(M#WK?]MUG1IN_:YKC&7DH]J>3 M>OK>[@Y9XR%7P(3J]60ILDA&O)!AY4@>*-+H@*R@_O4414K-KL.!]:XXU7AO M1;W7= L8+RX@C-Q+-J)R(@=B[.YZ-6^KPRY(V M/DU"V[G/1:58-Q#7M[A,-M=6J#D[:*&A'&B>/NL[ULOX0EVCCU5&_#34)YU7 MJ(K4U&!&.U8*7GD!+/2CM=:L;?=SCIW^.2O>K)JL,376R[!$ M,B-+BT-K9P2S\IU.8?:HW,\]JVJIQ3;:^L] 2E^JFQ8BI1LN:Y5'8"6UZ;O^@%V E%1RMM5>:G:- M)=RY9UI,\X'0=,@@GSZ$CN>QZ$?GQW-1=3WH-Y*%NE@DL;RSA=92%$\%HTJ3 M+$KS!6)"5O%QS"N6/8.[*OJNY[-O7&IYK?7C1M8K)LS;- MT;M-L3#_ &4PV#&:PVO>+)*WH01I:6OG=A2J]N-!4^?6BW5:5B;9(V\"4G.! MD ')\@.G3&1]_>MG96>:R,,($CW%Q*!<,9A,L%S+(TW2+DE^7)MB? M:4*R&3&GLA([=U'0 =QU[?+S^-:]& MNK>"80O,?Q.N3L9Y+JY=C9W;16<2/+,S1*8Y,YC(>01J5.06K*=@ MXZ!"3#P:NWCMR-&;&&8'@+_0YK4F]-5TJK**Q]::OYFKQU^K$Y;)>'D+A>Y. M2VU6FS&_U>"KB_@U0 Z=#VZYQ@^Z3TR<''RP/,G-5RWMV\US"I/+"W(4(" MLT3V]U;QQY5%+1K,CR.C23.UP@$T<<,>5,Q\H9:$;;SL33;UXW52J>VT#37_ M !K2TW:+I7+!9-]+WG:*&RFE3B*T\;UK8^U8V':Z%)1J3L)A8H-Q'S=I3&OO MJO)7\ @=O+O@YQZ=._;/7K\.E9%^R"Y<7$MU%&+2-K(6TDJ.]WS9Q.(TC(CG MN%7V7E13*ZD,^$*&;$4VK?'(R[O0J4):#Q\U([8J:%QB(2IO6DCQP>4_Z0+C M_K*C5JP.8E\SD;#$;DTK/WFV6!C9WH,KO U6;L%:69:RL!XYO.!Z>7W@J3G[ M".A^\9JP]W>2L(U?:S3H)46,AK,Q:M9P1(Y0AF6YM7ED99#B54=T(MV(&1H< MFN1#*QLZW*RC)*7KES:5&F0CRAI(RG)TS7FGNGC[>R)"CZZ"/O.1U^7>J_;;P.$+#56U0=NY R'TA];6NNJMVUG7#[7G(RCU( M.KWNG?A*GVC1KBL[2D8J!VU) M3:]HNR*%6G*5'6R(KEFH]:C:Z"4)LN=;STVD9'<'L<]CT[>7Z^6*$DO&U ME#+;74<)AO8HOQMNUMRXI+4I<,J7+/S)27^O$LBI)$BI[EPXV%Y)6+9:FA]L M+Q-=MM,7B;+6(MS+U.9"1N$CIOX^JK?:UVI9J:LO9(2PH:G6NLC76\>5&YQL MLS:.(A(DNFQ'*1C(^1\O/!P._;.._P!HK-O7G-I/M62(B2-2T;9E-MSHQ<2Q M\O+HXMS*4"_C5905PVVHQXXS-+GV^Z-7,[K=;#IBZ[&L#'CQ,JWK9TA+S&OH MK4>IW>SPHNWAFE+F:K0&TIZYM:Y8$[HD[82!I>#I\@2"KL4W92?(],XR>WF> MG3MV(_35BQ:-Q=0++*]M).XLV,LY9H1;VQGY5QNYIC2X>4(XER&W+&VQ%"ZK M2E3.UX]Z(N4QOBZ:5A-O3UNW6N7<&R.8UMCH./NE3CW6KM6O[94MXZ_N,9*0 M-,-$,5*A8MLQ+"S;"-:[)7*K.2Z9H)O/F1@'&!T ZGU.1TZ^@QV&>V< H19V MDCWMI[P2T/ MQQF*3$26J;=?=>R,_3)=:_#U>GZ,UGRSW7LEDT2F"6:(O(CJ\\D M92SDG$9,F&+G)*4=SEX)37J,(T;3ML3IK N=0O84V&15DDZ\A)#46CHK:,:\8VJE'B;%>:&^'*))TR_6YY'_ LQ.Q[J.G8_$G/P'0>OZ,Y'7.,9C74K1-'5I/ M*;NFO4OK;6%&;C8U%VQ](ANO4OU[2VDDA:[79XNB:BC8>SQ\'7$M?5#3M7"F MSE@M=OIMCB:E!SM[]P0/+&,A03GT^?7)Z8\ZP$O[M#"B2F7==-EI5(,T-QJ] MS;[X@1+)(L-N$D5$Y$5M&(W>22)UB79.3V;N?=7"_DG.6)"?H%KBJS9]0-%] M>'GJG9B;'UY'?!.Z+A0K#&2(V-BQ)MU&Z5JAR,(QE,96!B[<#+D7"#TQ M]_7X]@1\NOVUFM-=76FWS.'AD6.6W4PEXY.="G*N9(71N8H%R)4A92& B$BL M=P-:V1^XN5K"_(7J?4OZ+C1G&3D3IZ;@)".L0TK8^W-$W'0XW/D -59BBQGV M%^C9URXUXX72=R4;$Q-L1@G )2\P1Q5TP ,'+ GH,X.>F1V[=<8K"%SJ"S3GW@%D"=&:LRWCOK;MUM4I9]7;&GJM M0JFIM./BKI4XU=6J/Z+![?\ HY57]QDOK(B]5TBC,JK+&ON&);C1RTK;@495 M26Y(DQMY6\@[=S&XS7*?;E:>2<7 7")1D6[O=EKU]4'E:D[/);YG8OE]L'7= M+H4+/2TQ(*,(Z[T-BSF3VV],DD?R^A'< MYH]_<(65)$!!NI(8RC2-=N-1EBBA5W9BJ2Q ;!'C;D21XAC9#QI_(7DM";1J M6NBFCV];=;%DABQV"\?+SNTHRV\Q-X4Z\QT,+J)G+1+)ZKU5 U9]6F-14C6E M&0?PUBV(X'63Z,%D(&#ZX';R(49SUZ$MD'UP<#-(KN]2:.+IL,[[><26G634 M[N.55R&D806RQM&(]JQ!E>8^SE2C6FUIJVU:0C8&I#(S$K*1!(MO),H'8= ML$G.1\!TSWSWQBEZQ%W>!)KE;Q8K0Z?#'-<"-Y3S.AMU?V>2)G"K5?(ENYF$8FWTR+45D-A%V3'3T&TJQ.-YZ=OFM4*AU!2[RT-8ZO$ MV+<.L9&SV>OV/1%0MT$S9SM'R[8/KD>0Z$X/I\,CO26_O M6"R1*2TW/5U">QI6*10N0:OY8\AM@;AU;". M8V*KE5GF6K4OAJY03>LVK95_$O+>O6=G['U:Q MB]::*!=56&0QW$UNH@&D33(K/#)&P1KB17R6]Z3E@[M MB 1 VY,\B*8KK"E0,_83QKB[U-O54]KUQX-XO^C=H\P;WJ:F6-96Q,)W8^Q; M'4-"QM:N-QO1YYWCM!'(VX0&%2DUS)*93&NVM.W7/;( MXQ[BV%OV4LNF*[6$)C7-LF=;HSZ-0G;3Y+C<+*_4:BR M$ Q">-#5N+LE8=I2DLQDT8Q@C'7Y_'MZ>6#]N,5L(KEY[&YFNV>U1 T+O"&6 M17@ BNGB(#2 &Y$T410;RJ*\9W,K#0"UVF0D*'4%J)M=K":OM&U]MVZ%KVV^ M2&[D=9ZPBXG4^O(&H:?V7OO55QF;^3:5@NTM(;CJ-"1N,]KZ*;R&P("!=S$S M2:'+*2._8]NN ,GN,@$=L=#C'Q'>M1)(6ACY5P$@>XN)$2XOKH00*MO"D5M< M7D$C3"X>1C*O#[9,FTV:JN>Z M1>R+M"[4J][;6!-T1N6(G'<;K.E2UCK[9K'(MK+(S,XM&,W]B>BM!^SNW;TZ M?RUN=/DF8A7,I!L-.F83EN:LTJW$L,8&I6NM2<>6.O3IU)&.N2.@_7X:+4UADN8T,5T9RD M96[2"\EBM$65FW0&WC=!=R'((Z#EJIN&Y8CBEKQUKEEC]PQ+Q:M7V%N;6M;I M;\G;)8Z[>(FJ7JZ2.P:HZUE(5^>GR)U:[I%BV]J>4)U2WT^SH.O'"E/DBUV,@CICMGMU^(^(Z9/7RI81NMVK#4))$E6*:9IXC;LKN!'/E M!(8&A+"& \IN7E8QNQ;YN=KRT+(-!B5X9W/UB ?L7+5X$F92R6%C! \9R*3\ MK5$C()%%T+9:,-;0UJXXXX8TBB18XXU"HB*%15'8*H ] *R!P@ MDZ07;+D!1!PBH@LF(F*!TEB&34()BB4P 8AA+V4P&#OL! >AQ51 ((/8C!^1 MJRU>K5VDP$;5JG#L8&OQ")T(Z+CT@1;-RJK*NG"@^YE%G3QVNX>OGC@ZKM^^ M<.7KQ==VX66.)SU-4QQI$BQQJ$11@*HP!DDD_$DDEB]MSNVY],]<>M7?%54Q2F*4Q2K:WAXII)R4RUCF;>5F$8 M]O*R"*":;N12B@=%C2O5B% [GT1'CE-N943'325%(IO+*0I7Z_K]U0%4$D*H M9L;F 9L=!N.,D#R!) R<8R:^MRV1>-G#1R3S6[I!5LNF)C%!1%=,R2I!,0Q M3E\9#&+XB&*8.^RF 0 <4(!!![$8/R-6BKU>NTJ C*M5(=C 5Z&;BVC8J.1! M!JU2,HHNJ8"AV=5=RY56=O'2YU'3UXNX>.UEG2ZRIU4QQI$BQQJ$11A548 \ MS\R3DDGJ2222235^Q5=6UE#Q4<\EY!A'M&CZ?>H2,V[00(FXE'S6-8P[9T^5 M* '<+(148P8(F4$?+:M$4B=%( 8JD*JEF"@%R&<@8+$*%!)\R%4*,^0 JY8J MJF*4Q2H[V;^1(+^<36']H5;Q2I$Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F M*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F M*5P4$Y4U#)D!10I#"FF)P3!0X%$2D$X@8" 8W11.)3 7OOH>NLIV:TXY/[0W MS1]2S,[2:&A$O4W#5"2L;&<:65Y6HA43^IEF\,,0B54P*%1:G>*%<(QJ;D[U M5N)4A7;_ #SXV<;>*7#' >H:IPUPO%8W*2PQWNL6VIV^LW.C6$F>;?Q:<;"- M9,.(X'N'$R6:3&Y>$JAEA];\-^&^"-9XIM++6=<>ZA9)'M]/FLI=.AU&Z4#E MVLEW[4Q0$%I5B4QO<-&(5D!;9)+&JKEM^QT^ER5ZUJR@9>5CH]:?,%E1;K-/ M.$"J/S0)XU1PR66;>!^>$5>BY9*+&CUE2KHG\/><"\0^(&K\/<.7G%'!UMI> MH7UG:2:J1K$<4D',(#W1TMK-Y;>26';=-ILER9K9Y#:2R+)&VWEN)])X4T_5 MM7M]$XAFOK2UGG6Q'T>TB2[,[8!>K<+',B29A%XD(CF5!.BE'7,Y9Z97&5X: M\D;GR<@+?SDHE+M&X0@]V?7#?5UL@Y2UBCQ^<:(X_P"M+_M(*?,M%Q<4/\,% M0L+B(H"M648$9;7AYN?0,6=E'*JE8 .W\_QR2!]Q_37+WLM\DNJ11/<;+G(@ MD1I"+3V6SMYKCEL#F$W,W]7\?Y3859V3"5N-G37:I;$0VG2^0.OU;\6%C!M*WX)FC* M:2.P.@P"<@GSZ9]>Q&".WVBES<7H-Y,@NA#)8WMI"Z291;BVLVG6X6- M6YL4JSQ7L33;%#A;?WNB9W>XY/JY;=A[KK>J=@[*V+QNVIM:]D M8;:F7^RF-_BM:;CN5FE[XHHWI:&OGT\A7+FI%4><6B75:6A[+*68B<'(QD ' MKY#MTQD??WK9V;1RS7*V\TTUER80)&FGE N&,PE$%S([2'$0A+B.4K$Y4KM= MGQJ"RF-VZTU1M%&D6_9KXA:)]*GL&=<;*O6]-LVV7'C=R"L.NN/=&IEFM^S7 M&TBC=YRT*E) H.03VQY8\OT]:KEOKEYKF%'R@%R J*4FA:WN8(X M\A"S()4>1@99"UPBK-%'#'N4S)R@L<'';SL;#;VQMQZ]IZ&@*;(\;$M0VRX5 MB?MF^7-YVBVV4QJ<)77C>O;5VC$Q#30I*5KN^QUH@WC&P61,]8DJW*7<"0.V M1UZ]G;X]_=)/KV^'J,] M:QWO+V5N6DJJ[3H)$6,AK)H]6M+>))"K!G6ZMGED97($JH[1D0/@9&CRDY L MK&RKTQ MJ2+@)#82=WLC)MK5HA#+3@'L/+U[>Z"/O/3)Z=_LK]NO!($9T#)*L4:-%[U_ MC4[JSFVX(*M#:PQ3L8AM1I1+(H@&PY]J+9.])C:'%&>VMM2,C*_N/4&_9^3H M;6FL*E77=Q83.BRZ\I31S*R;^7=V]I69"[V5$@OE).2+$W9>.BVM>36:0T'' M7'D1\>G7K\NWYJOV\UTT]@UQ.JI3+&P:*I\= V:R5F^6NA6W92VE MTZ$\<0E;UO6%HK257:3I\Q@8J MB"1UU$IS^?S)[E'@#7JR6L:H\B2R1R3FW$)*I#'MM8U3$0CH= M&=074? ^H/W9[5J;:\M6TPA[UQLCN.9 M,DC/.J12>\=X#OS!')'C'XS#AD (!&M:EBC+!KV)LD#RO1U=JF7VOL:6JT+= MMV%)EY&YS$NRN%^C]?3>\).-AW&Q5H77T3L%& M@%;&8Z]L]O(#[<$8QY=O+.1GKA"57A22/4%@MWGG9%EN;VX$($,&R"6YMKN, M\YB))A ]TP4S%85F$.*WRV;Q*;>2:(O*DB-,\16SDG$;%RK%A*BQNSX=@6&%<@KJ-N3F1R M,U_7BUI]N0<=?(9'Q .ON=1O(4Y;2HDDCC M9-RX8PN^R695Q<2K"(X[A@KL6DFY1"*CN&E79:T;EN3RI/=S4O9+U7 MHN*VD1W'62C)1,M=*\PWWR-H^_)&/.LV2YD,;7,4XY"O!:K<9#Q!#*@N[W"[8G"MB*-V4 M)$T?^Z-0%LU)8 MRTK8+E8X#7^K8V%L45!0"%0J6HZ\VJKFQV^WUF?CJQ U8'7H>PQCRPH)ZXQU M]>N?2L!-0ND,*+.)"UP >8F#-'<:M(,TDLBQ0*KJB"*.V0(9)94<(NR, MIM/5U3'NM=K3U2N$3?Z*W847=5DI=A8OS3[%.,W*W MV!5J3+,#(JC$TV/L;)R[1F$W!J< $8Z^>/AWQ]W7YG '3KFM<75UIM[(P:"1 M0UNO)+1R"6$+%=/&X;>-MR)HXB.NV-9%+!P:UQBMZ%= M@QF9@'-6%/;S(/3 P#G Z_G'?X5A+=WXF$TAE7V>QN[>2,K)R);FTGLA/=B, M8#"022"%CE@B/L(#L#EFZ^0NW;G.OK5JS981]SK$>X>4N0H]:WU MP :KW64(_7&M3;6-I]PVZX87<>V 4E>T/89\2#>2;]: !Y^GY]K=.W?( \\' MY8JY=7MQ*QDMYRD2&X59(QF-HDN]'!E;<2C!8Y;DB7HO)+LIV$L;E)\LMKU^ M4D(J$NE;(\;R^S[#0JA(04O:)C?,BAS)V5J^N4BM3LM9'Z[)C:-=1+)_ ,ZN M44XM19E9:TBRUM4Y:LN&!WP?0_#W0<]!Y'N?S$U4^HSH[*DL8]^=X8RK2O=D M:C/ D2.SD@/"H*\L *<.FV"-XSPU[R/Y%QNR*/KET^BD(=U=4$XY+8CITYLV MU8FW\I]QU"^!"+O"2%IDPU7K>"KSFN1]3:E9TTHQ\QLATVUU,0[F*G:.OP'E M\ #GITZ]>_?RJ(+V]$T4)8 &8[1.1?0<.Y@[#8=:Q\;49ME-6B6<6VLV.'8 !Z=1GJ#G!ST]/A MY=5P$ERB%7>!1&X>1C)&Z]F_ M[XT/LV')M;:-\UWJN,YL#K>VNJSMO9&H(Z.H,?P(MVPJM%RMCUO::C*-&$[M MBRQM@54^LT0G9E:K1,@H_)!PC1K [=!UQGL#YXSY_+'S/SF[G G7VB>2"W74 MS!(RW$ULJQ#29)D5GBDC.&GD#9W>\YC4Y*(%B>/Y4<@*FZU128JQ2JS9_=Z- M'5MMM.KG3O-_TAMSF+L'4%#NBIIH[O8=]L%6X^1U.O5B74@Z(O2U%(FY;>M% MJ=W9Y5H"<=\C/KCR(&3V&._3]':L9;^ZC:WB61L-) $%Q'B6:VN=2FMHI#OS M/,\=H(Y7.R$Q>[+HST].];".[::QN9[MGM8XMT,CQ!UD#08CNVC(WN ;D30Q%!OVH'C;4/=D9%ZSM&RMUVB A=M\I-SQVN=:L8G6&JX:EZ>V/R0U1=9K M82NWI"XS,KN"FZY+<++2641-[$KU??2;W7.O9I&>@/4=@!T ZDD]@1C'EG'? M&.]:F2\3V> DNL1L._5[9-=O4/8&!2)MJ].C':UI M=@LU98HM&C*V6&>EBLFZ\\X,M##'EYL/L&,5N=/DE9MLC3,#8:=.>?TE6:5) MTF5U[1OB")Y(Q@"1W;&6-;L936TJ/;1M6A4VWZ]H5AGT&=OVE,R$%28%)N[> MOI1[%5JP6U^LN1D@X+%1C>%K$P<9>5,RC%'R3>*2='DWS-HO(!() Z#O^O\ M)\ZL27,,4L$#N!+<,RQ)@EF*H\C$X!VJ%1O>;"EL*"68 XQ2>0.L=@W21H59 MD9Y:=9(6YVR7DZ51674B8I3%*8I3%*8I3%*8I3%*8I3 M%*BVOSMK>;3OU7FF2Z)I&E3A/9VZ-SAR92SNJYFF*4Q2F*4Q2F*4Q2F*4 MQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*500 0$! ! 0 M$! 0[ 0'V$! ?80$/F&" 001D'H0>Q'H:=NU5Q2F*4Q2F*4Q2F*4Q2F*4Q2F M*4Q2F*4Q2F*4Q2F*5'-_U)KK:(PREZK#6;=5XS\821*ZD8J7BTI8C4DNR9S, M*\CI5&,F2,6!9F**\^K9<&##ZR:.O1-?*D$CM5F:WAGVF6,,4W;&RRLH;&X! ME*L%;:NY<[6VC<#@8R&FTRIZ[JE?HM$KD-4*;5(IG!UJL5Z/;14)!Q$>D5!G M'1L>T32;M6K=(H%(FD0H=]F-VI5?BZM58EI!U^&;BVC8QD02(-TS**+K',8YCK.'3IRLL M\?/7*BSQ^]79^))))).2222235_Q5=,4 MJSEK\(2P+6HL4R+9'$.WKZTV"! DE81H]=236*.ZZ\PS)!^]=NTD!'P$7<*J M 'B.(XJG8N\R;1O*A"V/>*@E@I/H"20/(D^IJ\8JJF*4Q2F*5;6T-%,Y.3F6 ML>T;2LRE'HRS]!$B3F23BB.$X[UJA 7!V:3M=%!17Q*$0,5'Q^4DD0BJ0JA MF8 !F"AB!U(7.W/KC)Q]WI7V.6Z+MNNU<%$Z#E%5NN0#G3$Z*Q#)J%!1,Q%" M"8AC !TSE.7OQ%,4P (*D@$$'L1@_(U9JM5J]2:_&5:J1+.#K\,@9O'1C$@D M00(HJHX74.8YCK.7;QTLN]?OG2JSV0?.'+YZNX=N%EE%4QQI$BQQJ$1U>KJM&+U1?7&QGJ5]>VUM(2\LOKS9.MPB6WP]%/ MVZ$<6-V(M+>L5.9SZ^,(T]-Z=R9PG4"!G.>O3IZ??^OQK O(;J62U>W]G MY M3,><9 6;DSP;1L5@%"S%LYSN& !WJ/\ 17%2R:FW38MGR%AJ;M&8C]B-)9_# MLK2%DV&^OUXC+NE-66/FIZ0I]$<0#II))OH_6L1&Q]SE);Z[D21",8QA"BV1 MC\WI@8^9^VL6RTR2UO)+EI(CN6=6*"7?.9YUFWR*[M% 4(.Y;=565FW,%"JE M;$;3A63A*K3:BLH5ZQOVM&Z"2,[-MHHZ:NP($IA=P3:12@Y!8 7.*;A_'.7" M1@1,DJ0S= 4Z:W-2UBE,4IBE,4IBE,4IBE,4IBE,4J)*W_'-M7_-#5'_ %C8 MV>?:+_/)X]_O>X!_SW&-=7J/[CN%_P"Z_%7^;X=^^I;ST&N4IBE,4IBE8I>; M:VHE1G[B]C)688UN.7EI!C"$8*29H]H *OG#=.3D(MFH#%H"SU=,[U)4[=NJ M5L1PY%%NKH>)]?AX6X?U;B*YLK_4+71K.74+NVTQ;1[TV=OA[J:%+V[L;=Q: MVXDNI4:Y21H89! DTYCADVFBZ7)K>JV.D0W-K:3ZA<):P37AG6V%Q+E8(Y&M MH+F53/+L@1A"RB21#*T<0>1+Y%/CR<9'R*K![%*/F;=V>-D?2>O8&<)%5%H] M^KW;]CZE 3>6MZ1Z[;^84WE.%2=''9V%TU[96EX]I7-(F'.%=0K;7,]NL\-TL$TD2W-OS>1.(W* MB6'GQ03\N3&Y.=#%)M(WQHV5'WYEU8IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4 MIBE,4IBE,4IBE,4IBE,4IBE:([^H?-T^M;"PT]N.KV2WSH&A&S7X B* XAHN M32<(R,VRM:UPE%64I&M1\$6JSCU'A)%9L[3\DKV'8 M^T/K!F"[05).<'RCB[2O% Z)>0\-\26-[J-V#:H@TBVTA[ M6"=72:ZBU!]2F:*X@3/L[1PM()FCD7:$+#,]/U3EXZJU-DMN[;J,+9D1;A<: ME&ZRAIE%P1@_.BLDSMC&X-DA--QJ";KUJ<.D>/7?'3]$H+4 4L7DND"69;.T MF>(YY,S7+H1N7()B:$GW&)&TN=P7ZW6MGPW8>(DFGZ;/Q%Q!I]K?J4^DM.AT M2UN5=89BK+'J$.I*I-U BR:BO1*\<;5M&1T[RNN=R4DK MQMI_\4[-D7FNH>Y[FK>R*53:]I2QR<5#R>E9-&SZ5OND9>=JD8I0]E5?\'$H ME>;=5F":MHN3VX1-EK R .O?O@$=?CW!Z9QGL/3MSCSM;ZA+(#-VFM6:)3%/&(6$LD:EGD,BO%,'8+[4CZJT[S+L>Z*+%U7>$_ M;;595MRWV+?66I[3X_7^U12C_9.F;BUDEH-MR)AMGQ=*II;$JC5:_$T*O(,6 MR#2&9(C@DE<'W?3S! ['OT\\#/7NZA6.[:21_:YU9XI[.=UW M3VTH8H+Q9Q'%O(B184"@!0-HKO7[W>OH]7\C;I/=#>[5XUVFMH355M[^U2NE753D+;$6],\BI9'3M_98=O9FJOI(&-P[8Z9 M[8^/?(QG[^PK/D2:32&,C70E3FM"PEG@N3$)Y%MFE,;1RF1K8QF19/>+DF11 M(#BQW79&Y=.0$W,Q;RRR=6H6R]XTK7U?3KEOO,M7JEK;0^T)V L=DD+!?FP^_&>H_BS^N *)9[FVC=QO9(9 M[J*)-DLKI%!:7#I([/,'N&>0+N,LFS:JXVL#)64<7=P;@VAN6&;7B;-/0%1; M\CZLPLE=?JR%2O44E#<*[K4;(^EHBH:^I]KD(YUL&^UVNV:"ID3$N8N/DP@5 M91-25G9<1@?$X/7O^^_^U56-SW0LT8:$J[2ST M]RR=0<3?WB;>$GW!;#4D(Z >2066V5VO&EY%&!W&.OS^7\7ZCRK,O)$6T=[H M30H'4,L$AYL@WC;&)(RI19CA7.^,*I;?(B;F&JK2]%9<0X.JQ^T+-8E9>^1= MVMCFDV[8URL5!XOO^4E<;;)JD;MX"GN,NGJ?55F5I-BMS><2N*%>BYZP5!5D MA%1*\=402>WPZC&3@]<9\R.GEZ^=8/-QIRQ\^1BTJRR&*2:5XK(WZ1,DM5$8EP:",GKWP2<>H MS_(,U[^J23]?7<%"2< GI;G5J#BY4;)$JNG$76'][VKK+8 MECOB"5J6B]<.;7%5Q_'1]:H;.R@_G:,^?D0#\5+?,C\Y'QJQ+>WUM&6F8X;V MM03"J,JV^IVUG#*N[:C2W5M.TZE]L#,(V15A#ELBLUUL&Q>'%%MEDWXT>8=MZ.YJK.Q[#6J^M-XW7C3*UI?548TK7P9'VZ?C&#T'ED=/AY ]^N?7Y=*JDE:;38I)+L>]NU-&V4F-LD5HZFELEHEKCN9TTKCK; M'.6OSEJJ5NV)%P!;5%2]8UCKVQZTV!=*2E:IFFV2D2^SD+BX'3';J3@^OSJBWN+IN4D8DC5ULXM\C2W.(VN-41Y(Y)E02*T=O"\$TL0D: M.2)K@29"U&]NY?;KGK=6M;RVR&.O'R.MZ:\LY6:-$IC6XV.QU3:S5] E6M+I M]L=EL2R72*U8:A5?6L9Z$S*R.XI_8@DY1@>+ #OY=<9SZCTQT [G.,_9FU)J M-T\L<#3"%A#$9<"&(2.\=P"GXPF<323+;F%(%P%%Z,RT-!6R,VX5).MNYYT^L>RW/U(_MEAL[#71F4@ MXI:#8NTH!<)\0,$@^?\ &1T^\?\ @1659W=X]U'!)M5%"JT;G,IA%JKK<8VM M(2\QVM([K#@F+ G0[XG&Z6>#V3L&4U/,[@OG)V(Y3[?]7J9:][:FJ!)Z,B&= MB=IQ=HIDQ,/]54BM+1#>++KZRQ\/!S2MW4K4/7Y)T2=F(N48]>@P.N!GR/3 MZY_1G/8UCF21)I7MVN9[Y;ZY_:QGN&A:U4,=KQ.[6\,>T+RG"(W,V*A.YE;Y M+1S%W] PY9B%V/ 7*CQT- V1U=V='B*Q9;)L.1IB\Y9M#TR)L[)KK^S2M'EV M['S]8/K?1-QV-&ULZ5$7DUMH=VE56T?IQU\LGJ?AVP1TZ9/2HDU*Z1=Z3QRP MA58QEGM(U<"*1HF S;F6&Z<2")9>;#*QV8X_<@-\[%Y(7:GW1E7H* MHQTGNMFKKUVBX;7:G5RE7V*K^G+@Y8MJV+R'3V;3E5+;(%NMG7:6DECC'&N6 M[%I3K2U?P0 H/7R\NF<=1GMT^';S^&;9WEU->RQ2JB(K70,1!$D:0S".VE(" MDH+B+,I$K_C-ZF# BD!]%S?R)!?SB:P_M!K>*5(F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2HDK7\3Q[_>]P#_GN,:ZO4?W'<+_ -U^*O\ -\._=^I\ MZEO/0:Y2F*4Q2F*5%>\_XEMM_P VMW_U;DO\G]><+XH?SM?$#'_ OB?_ *%O M:Z;@O]V'"O\ ?%HO_2-O4ELO[S:?^K(?_")G:6_^MX/[#%_D+7.S?E9?[(_^ M4:^G+U6Z8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I M3%*8I3%*8I3%*8I3%*8I3%*8I3%*Q>Y4JI["KSNJ7>OQ=GKKY>/=.(F7;$=- M1>Q$BUEXA^B!NE&TC$2[%C*Q4BU.B]C9-FT?L5T';=%8BJ)(HYD,P,H$ZZC4U'#B6JJJ2]6F7Z'8, MY.:K"S=LM6YB1;.I.!5:,U(ETT.S:BE.3VSZ_G[_ **L-:V[RB9H8VE!1MY4 M9+1D&-B.S-&0"C$%DP-I&!4J9%7Z8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I M3%*8I3%*8I3%*@G:6S;=1]C9F 4= K%LI"_'SE!8=R;#4823>'A*;:X>_3>MXI MU0-E5RP/(VAW-C6%7*-]GQ/2+Z\6CY!G*VN#AHNJ.Z0_D&L1$NMC,6DY8HFI MEP/4],]>W\8^%8=CJ,EW/AE5(9$F>!3#.CD0RK&2)WS#.<$-(J+$8BP5#. [ MKL)M.:9-TZM"*)2AGKZ_:S<(*HP_P![W /^>XQKJ]1_<=PO_=;BK_-\/=_C_%BI;ST&N4IB ME,4IBE17O/\ B6VWU\_P:W?K_HW)9POBA_.U\0/[R^)_^A;VNFX*_=CPK_?% MHO\ TC;_ #_0:DME_>;3_P!60_\ A$SM+?\ UO!_88O\A:YV;\K+_9'_ ,HU M].7JMTQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2O. M?DGIOZ0BZ:>NM>U/RCU5%7*129#"FKVF+)JJ>,@A+,W+UBPV.;K.-K.RV_9[UWKF$V%MVO;$I=/KND['+1 M<%,\?IAI9=.W/2TK-56-N&%8W=8+1;K0\WK=ZO(6>G;0X_7ZVPPR.S]+WUD M_5KC7D-"[-A:+2@M2R%8KD#0JZG'MD&<.P;R<'JN.WH.A! [=NWGT\S\3CQR M3QB"VU.2Z@$=T9))#=RQEXKBSG==UQ;2J>6+U)UBBYF(T6!-HP@&T%TB;_=_ MH]G\S:)W=T?=Z\:[3.NI^+N^T]4[9D:0SV79X334S>#T>=IULD;+-Z74\274..EBNNT=RZ=@IR:8R-BE*I0]E[PI% MA30=ZOTY!U;6>B-H3\)9;A*V79K":VY(SEL+$F?O+_<&->1C(>-5:N8>:2=6 M@8 !/V#/;U ] !\,=?B>U4RW%S;H[@R,D4UU%"FR69E2"UN'620O.KW!:38# MS91& JX*/^,&4<7=R[AVCN2(87F<";@J>CR/JK6P5F0,]J-[CVD/PMN=1LTA M(PM?J%,M$G%N-C7RMP-C@:Q'Q*\ %@H(ED0 [AL:2>V]^&%R M )7RH5"P8@'KI#4MH3W[C>-J,K82VT]D+19ZW9-FSL@XXHLN84; WBWZ MYVG*D)L>1UM7]03_ -01-_?RS>_%U]'/KE7Y1IBH5ZO ME9T!LZ8U7/2UEJ).3%1IG'>W7-2R;'.A(^1)QTZ@$CU'IG^(UD132QV::VCD?<[6?MQ6+)?7T$;.[A@QO(P>2B,GLNJV]A'("S M+&TMQ!,\P$A2#F*A 2$.3DUBO-EV#P\U];K1OZ/6<2&[K XM=N+931-#>55I M8=BJU;6.YMD\896(_!'&M:\2FL+38JY.S,)&[,CHJHV&1O%8L+Y"P1V)P,=/ M3)^)P<=_LZ>57'E>;3HI)+MXSZ@8/>FWN M;ES''$'C#I:1B21I+DJC7&JH\DX$N0!&]NYA;OG M[A5M;R.R(C7#U+65/DK3Z(->4HEPL=@JNUFTA!LS7.:>[.:7JQW*&UA\!UK5 M]=?-"LK$_B7UO0FY*.^//(#D'9=WU;6]L^HF=9:-8Z D: MK.J.%KXO3&.AX&X1^W@ D>]LCUY9=CNOJ1_9I^0CM=&829ZD@<-GP*Y+((&" M1Z]/(=^WI@>6.O?R[9=G=W;W,<$FT( J-&YS*8A:I(+GL9&+SG8TCL(<-R^D MZ'?$I[]9X/8]^E=66;;^Q.3,-RGW DYTNMLG:UAHLAHN&96)V$98M?3$[*:P MUU6CQ#:+-0+;&5^NR[J\#5X.$DWY+%*0\Q'3SZ# P<#OTZ]._7N,_G%63-(D MTK0/=.\1M5#G:\3N8(4VA3#(%0F7EHK'>RM\EGYD[]@8CZUA]C MT^YTR,A(*U/+Y&TJ%KD[8;S)4M>PV315-A+9(QE!L\Q19-%BJ]UNZO5)W)/Q MULBZ=#6A6VTF[3:L@ ^6/AG/VG';/3!P1\.HJB34;Q5WI/%+$J+(95B5'>5H MB[VL2R,L,C1,%)@,L5RXD$2R_)=I%%G8D;+"+:Z(@SJ5G3EH(&! MCOTS\HSUK-L[N[FO)8I0BQAKLYNX1)+[-;K;Q!F>2>\:.38F=SB**TN$VD#B]7T>Y2E]K5?>,K)*$L"8'5$[M%#S7 >7DHG,8!GW$ U>-F_D2" M_G$UA_:#6\C]?NK*J1,4IBE,4IBE,4IBE,4IBE=#E86S9PX!%=P*""JP-VQ M43#-,(Y9C%%)*(8%#S2\M" M_+A0LH:5\;8U+*&<@%@#D5QIS)(X]Z1\QT3F2$K&FY@N^1@"51<[G(!(4$X/ M:L8HURC[]7&5HBF,PPCI RX-$IMD1@]5305,B+@&Y%W @HH4Y4CBH!C> PB M4H==Z/A;B2SXMT:VUVPM=1M+.[:46Z:G;+:7,B1.8S,(EEF'*=U81MORVT^Z M//9ZWH]QH6HS:9=3VD]Q $,K64QGA5G4.$YA2/WU4@L-N!D=36@FL7W(2^\@ M>0DI3=E5!O7H:1CZSZN;J;J2B7C>*DYMI MX*+;2+!P4L*9I9(]]*C-+MWKX MSE3R7IEDEF/RGP5<^+/%?BQXMWW#?&O#\.E:=>VFBM<:EH$][87$-C>ZG!I, M.EV$5Y:RA=--OK%K M?41%9ZK%;7,4EU;64U_)>W4EO<1DW@ET^>&U%FDD, B7?"$9)]GQJ?)Q3R_% MN/6J'R\SR-22"GSZ\0!YU\^UX??PCTGWW]K[@#VT\/\ C:VS/B/P9%VW\OP^ MNG[XSCF<5=<==OU,^>.F/-AJGANN<<(\1OZ;^*[=>V<9V:%TSY_6QY?&HTCD MFA]@#KY/P9\9V8EO%3AF,$=! M'X:JV#VZ!^+,X/?JQZ^6#@/IGP[ ' ^LL1W+<9$$]^^W0<=/@!VZGOGC\ \ MD!*(#R%JY3=^QB:1CN^O8>OMW
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end GRAPHIC 24 g803738g25c41.jpg GRAPHIC begin 644 g803738g25c41.jpg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end GRAPHIC 25 g803738g35h11.jpg GRAPHIC begin 644 g803738g35h11.jpg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end GRAPHIC 26 g803738g41i38.jpg GRAPHIC begin 644 g803738g41i38.jpg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g803738g56a01.jpg GRAPHIC begin 644 g803738g56a01.jpg M_]C_X 02D9)1@ ! 0(!>0%Y #_X5M3:'1T<#HO+VYS+F%D;V)E+F-O;2]X M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](EG)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO&UL;G,Z>&UP1TEM9STB:'1T<#HO M+VYS+F%D;V)E+F-O;2]X87 O,2XP+V&UP.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R M-"TP,RTR-%0Q,#HQ,CHP,RLP-3HS,#PO>&UP.D-R96%T941A=&4^"B @(" @ M(" @(#QX;7 Z36]D:69Y1&%T93XR,#(T+3 S+3(T5#$P.C$R.C T*S U.C,P M/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^ M,C R-"TP,RTR-%0Q,#HQ,CHP-"LP-3HS,#PO>&UP.DUE=&%D871A1&%T93X* M(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \7!E/2)297-O M=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U-CPO M>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @(#QX M;7!'26UG.F9OF%'.7=)1$UU34%!-%%K;$Y!*S!!04%!04%" M04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=404%! M04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+0W=O M2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C2'@X M9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[2'@X M9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF M2'@X9DAX.&9(>#AF+SA!04519T%C045!07=%4B8C>$$[04%)4D%135)!9B]% M06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W14%! M9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!04-! M44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%54UP M1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-00TY5 M46YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y-"]0 M128C>$$[,4]4,%I85T9L85&18;#E76C)H<&%M='-B5S5V63-2,61N9#1E M6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[<6)N M2C)E;C5+:G!+5VUP-FEP<7%U28C>$$[;V)(=T9-2%(T4TY# M1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H9UI* M:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&195U9P M8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H66%( M:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ2VUQ M<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$T,VMN5$]X5C)+=7A6,DMU>%8R M2R8C>$$[;VI4$9M;5HK M6G9YD)';B8C>$$[:75P M8FU33F]QF]F5)**S4U9D-196AX="8C>$$[:C1-=35&84XK5VUS M,S!9=7)I5T=(5#-T$$[<6LO3SAL$$[7@X.'1B>'I,<%I9>6=.2&),3$%B:W%:=G$Q M9G%W9C$V0V(T1#A'>#8T,FIW6F1Y:&0K479.1G1*9%)T8G=Z4R8C>$$[,EAP M:3=J=&)U,75M:4TP=F])2%=#5U%G*W)24T\Q4E=L4FAT2&A35$AY>BM81C5Q M;7!A-W Q-C%Z1&5A1$58=4Q05#=:9%)U2DI"3R8C>$$[&]K,%-S5DPQ M2D0Y06-&<&AI=378X,%-Y>71P9&IC>5=Q4U!"175O3&(V9F5V3D9# M$$[>#1"=&9";#!23VMF;%!R=7!A='!T M#-:5C99,FM9 M0U-%=E U6BMC;B8C>$$[;'0P=#=%5$,W;&IH=&=*4YU,'-F<6,T M5FU#:V\P9U5.,D].;SA'4TES+W=!<5!/371Z87!,6F$$[2V5944-33TU80T)W2D$$[,4=' M4W)Q,S5A95IR3SDQ4T\R9RMT,FUN6$8S1$A.>6EJ;6YJ$9!=UAU9'-B531P3&)R.'(O4$9T85A&,R8C>$$[3'!Y*VIA:50V>G=U M8E=2-#)I:CEA4DAJ4U9N16E2:FMY535!9%)J86Y$3'533%8Y1S%,4TQZ-FYQ M35!O6%AP>'I'3&MJ14I-9VM4;"8C>$$[=TQ52E)G84AC9#A,6$M*0F]O3$9$ M$$[5&8X04Y/2RM(3'5,=CA*96%V.$%Q>E@S+U-.3B]W M03 T$$[.2\P:E1F.$%.3TLK2$QU3'8X2F5A=CA!<7I8,R]33DXO=T$P-'(T M8W4T=2]W;#5Q+W=#3=I$$[85AK M1C-(;W0V6DQE4DI51%=S>%5S:D)H5VEJ8F)&26A)1S94>4$$[;U=107%6:S5#;EA! M>DA(6DYC,'=U9DUF-6A8:TUK3CDU5E,X:$0K<%EX5#9F8T]L;V9Q>5=G.49# M94Q!47A)04IG*S9H=G1B-'-J3R8C>$$[6C5J-T5B8RME=GI/;7-L$$[,$LW.&TO<%-Y:'5P3'E%,U9V<5-/3!U-W%A M>28C>$$[=797:R]2,W!Y1T%5:UI044TP24EB:4I#3FDS8D9S335B54\U4W1V M4'8U$$[2SEY M-#)C07)S465U2U!%>60S,W)T53@P*V-*8D14,',O3&0T*V]R<#=75W V;&17 M,30Q=R]Q,V-L>$UK8W%Y:VQ*038X;EEE<#EQ:B8C>$$[0W13<$TU9$%J.44X M*V5D63E:5%9T53!#+W=#9&A9>C)T:&%25W0S9$Q.2DMW;&I.>E!F>E1Z8TEP M55(Q;U=O5BM%1&,T<&IK;&1K1B8C>$$[:&UG9C0P,&HY2TQ*-6%M,4](5TEH M0F91,VQT93!:4DMS,5$Q=3A$:'5A02]A>&%O.%%V8FUY3WHX>"M93DXP1WAG M,')Y8DIB87):,R8C>$$[.7IE,GA.<&5Y5SEQ6F])655K='I*3DI),&=-8DU2 M3GE7<$9",&]T9VM13F\W<59N-7HO36TS87A-=FQ96%DP>')36%0Q;G-R,FM- M,28C>$$[;$%TC,K8D%/;$4V M2F-S,FMV03A#;5!5+U)K5S(R:5-3,D5W=&E&04&AJ4W9+="8C>$$[4U9F M17ED,S-O9E)V3F8U;6%22EI08F586&,R1G)(6E$K<%HS6D)J:7929G%7-'-V M>&5Q2T=N-U!V=FI3:DI-9$9/3'I**UI%8U-%928C>$$[6$A..4A#8E)D4TYN M9"]70F%'67IM,BLQ-F9$:U-+.$]F2&)L5$=L-#4Y,S)+38O-E%K3C1,92]7>G5H3F)2828C>$$[:DDX='A&0E9J2'A,5%!X36E/>3$R M3TLX8RLU;45V;DM$.4I7;#%"-6(Q<49$<6(V='%N2%1F:FY:-UEW4$)*>6YD M2E!716II4G=S828C>$$[9V9::3-/0G0T.2M2-3EZ>6I8.4LX-38Q$$[1VTO-7!W&0O M:$QZ5B\Q6G(W+W!';2]W0V%C5CA/6&-89C13.#%F.5=A*R\V4B8C>$$[<'8X M06UN1F9$;#-&,RM%=DY8+U9M=G8K:V%B+T%*<'A8=S5D>&0O:$QZ5B\Q6G(W M+W!';2]W0V%C5CA/6&-89C13.#%F.5=A*R\V4B8C>$$[<'8X06UN1F9$;#-& M.6QF.')B+TQJ+W$K,B\S4V8X,#50=THY>G1016HS=2\U5S,K6$@O5CET+W5K M+S5P>#A#9F-V:5(W,V8X$$[:B]Q*S(O,U-F.# T*T)0=5AX23DW M=CA!;&)F-6-F.$%6.70O=6LO-7!X.$-F8W9I4C$$[9D5J,W4O-5$$[04IP>#A#9F-V:5(W,V8X04LR+WDT+S9V='8X061*+WI4:C1%*S5F M16HS=2\U5S,K6$@O5CET+W5K+S5P>#A#9F-V:5(W,V8X$$[:B]Q M*S(O,U-F.# T*T)0=5AX23DW=CA!;&)F-6-F.$%6.70O=6LO-7!X.$-F8W9I M4C$$[9D5J,W4O-5$$[:B]Q*S(O,U-F.# T*T)0=5AX23DW=CA!;&)F-6-F M.$%6.70O=6LO-7!X.$-F8W9I4C$$[9D5J,W4O-5$$[.6IV M631'0WI.2'DK17-+9TAK0FM*44UE8DE30C5*<%5:1DQQ:GAX5C%2-#1Q-F\X M8U9D565/2W5Q4$A&6%9(:FER<6IX>%8X335V2"8C>$$[5G5X5C)+=7A6,DMU M>%9N4&QY2'DX,F$\K,E54-')O6# O83-W<28C>$$[=FUV.'(R=6A*-5(Q>415;C!X3#!I M4F]P-5AG;75&<&)&-&QJ5W%V.%5H059O2$I$5D5I.&-%>65)5F%W03149$E8 M.'99.4YT=%4Q6B8C>$$[9%-J5=7>4)89C5S8V178E1W-DHU6&)Y+TYQ;7!7,6YB>GHS1V]" M8B8C>$$[9UAC3$]R=T-!,G-5161Q,$YR37!A47))631A04=U,E8X57)O9519 M27AQ>6UC*VTO;%IE,VPR8G5E>6E333-N<&96;FE24D5D4W9F,R8C>$$[:65N M3F)H-45H15!P3#AF=T55:EED23-K2#0X9VUO2&UH9CA!1%@U9C(T,'!D46AT M3&5A83-T2FQ1,VHX-7I.<'I44VTT4G P15$K$$[96YW<3A18FQ4:T)U M<#0U;38O1S8X14)Z4VI7=$0X:U)A1')U<%=#:#)S$$[8VY'57)!3$=563!31E=#-SAL4S94 M;V5J,TM7>EA&-T9A0S5M159T8G)B=#EC67I35%@V8S4K5%%$9U5D3TMG:'-" M17)*+TAY5S0P028C>$$[;7EW*U)R3F)I>G0O,%E96'5T36YN5G Q9%5!9VY3 M8U(X-VDT1'%K=$MR>F5N3W94:5)$,6YF9G%Z2$-/-4)83VPO;&9A861"9'$$[-S(T5WAE5#9R2F-/;G%Y9U$$[1V%( M,$-Z1S1G5C%-4$QI>&M29F@R3$XX3'A*;GHS=EI.435D2&Q7;U(R,%=O6$U6 M4)I1EE%:%-A:C)'6EDU3R8C>$$[365A2'=O9&ERD1C M:%%W<3=&6%EQ-T9867$W1EA9<28C>$$[*TMC,V)Q,UEQ-T9867$W1EA9<3=& M6%EQ-T975BM8+TQ-=7,R9&IB6$8U3DA$23AS%AA44@T928C>$$[:F)5<&Y/:5$$[67$W1EA9<3=&6%EQ-T9867$Y+R]! M3V-:+W=$:FMA-2]Z15$O.%%B3F9R3UEC>E0X:3EE=79T:C5::'51;UE69&ER M>FIY.35D,2]44"8C>$$[3BMU-FQ";S!L:F(V;D@V0FLK='A84$LU3GA)4F1+ M5V1(35A"=S$$[5#5O-VE'3#9X8C$EK<"]P17%(=GDW=%1&<#A/5F59 M97(O;$XU63%0>7HU45A33E)J.4]E1S9U4VYX2R]+2G!363-Q:"8C>$$[4#)L M,SAF2$,S-&\X36%:;&DR3WA6-40O04Y#>5=V.$$Q34PO05!32U K<75:;C5W M.7IJ9FQH,W4O=T-H6DQ8+T%+;48O=T1P1D@O5B8C>$$[6$@X-&4U9GEW-S-F M.4-Y5W8O57=V+S!I:B]Q$$[,4U,+T%04TM0*W%U4#5W.7DO;&@S M=2\V1FMT9BMP:&8O<$9(+U982#@T935F>7$$[3"M72&4W+V]74S$O-FU&+RMK568Y5F-F>F@W;"], M1'9D+S!,2F$O.51#+R]!16EJ+W%R:BMC4&-V-5ED-EI7=C5$6#EM:T%S9DYL M>B8C>$$[6E-7-E!%:SET0S!5:&IK8FUY37E4:7$X=#9:139O2&U'9F3AU36Q48R8C>$$[;%59 M96\Q5$=Q;'5R5DE">4DQ074V4V-E,5=K;6\O:V)Q25%7,"]M-CEN:#%3-4@Q M<4XP67$X=D5V-G-I;5EH,B]D.3DX:E!7:4IJ-B8C>$$[4G5A8359=DTW&982&U&-W5F,28C>$$[4%=K3GAB97 V:C$U2#%#6G545E!8 M9D@X,W162CA!6&1Q5G@O>FI:2&,S171X4#5K;&MN;61P2EI'=%%3>G5A$$[-F-D-FXO,$Q*82\Y5$,O+T%%:6HO<7)J*V-08VHX M$$[4B\Q5G@O3TAU6#AS3SDS+T%%3$IA+SA!57=V+T%.26\O=T-Q=5 U M=SEY+VQH,W4O-D9K=&8K<&AF+W!&2"]66$@X-&4U9GEW-S-F.28C>$$[0WE7 M=B]5=W8O=T));R\V<30O;D0S3"M72&4W+T%+1FMT9CA!<5E8+T%/:U5F.59C M9GIH-VPO3$1V9"\P3$IA+SE40R\O4TM0*W%U4"8C>$$[-72]L:#-S.2], M8CAU679*3G!E,CAD*S$Y.6-K4U%S,%EI-#A!4E-G6C8Y8V]Z6F5-='502'=H M;&,X3'5W27!S37!B1E V=$HW628C>$$[<3$$[4DYX+S%4>"],>C=L.%=093$$[-W8X M06QC,S5:+SA!5C=4+T%*13-(+U902#AV4'58>%DY-W8K5GIF;&XO,64P+S5% M,T@O5E!(.'90=5AX63DW=BM6>F9L;B\Q93 O-28C>$$[13-(+T%&5'@O3'HW M;#A74&4W+VQC,S5:+W=$5C=4+VM48V8Y53AF>3@K-69&:C-U+W=#5GIF;&XO M=T)8=% X06M48V8Y53AF>3@K-28C>$$[9D9J,W!26AW:F)I,V$U-4%32TMB M+SAR;2],4"]Q.28C>$$[<"]Y2G50.$%Q;FU8*UAN,TYN:7@W,V8X7HO04]R,FXO26TT+S9P-"]L M-28C>$$[.7DK3$AV9"]Y=6(X2M,2'9D+WEU8CAS+R8C>$$[*W(R M;B]);30O=T-Q95 U969C=FEX-S-F.')M+TQ0.$$V=F%F.&EB:B]Q;FHK6&XS M3#1S93DS+TLU=GEZ+W=#$$[-3EY*TQ(=F0O=T%R M;2],4"]Q.7 O=T%I8FHO<6YJ*UAN,TPTB\V=F%F.&EB:B]! M2W T+VPU.7DK3$AV9"]Y=6(X$$[+W=$<3EP+WE*=5 K<650-65F8W9I M>#&)Y3S-92DUY<39C5UE602M.5CA-:%!'63@R M55I!.&LR6C!8<28C>$$[44UG>6$Y5U K65EQ-S%9+S5H:7)V5FHO04IH:7)V M5FHO;4=+=3E74"M967$W,5DO-6AIF5/$$[9%4O4D-A3E,;F,R-E-Y8T$$[94@K M5C!W.&-E.65!.7IO9DQE=E124GI,651,0DY$4&-W5%-)630U26)A37EZ4$7IQ.&UL<'%G5R8C>$$[0F)36&XV264U=&MM M:SE.=4QE;D$X:7I0.%E-B;#=6.4UU3&4T4TY: M:D9C;V)D=E1A6DQC34).=W%05B8C>$$[;%9D=C1(2'A).39I0C=L0657+TU* M8496,'DV8S-,=DAA;$E:2$5R>%8Y45)&45$O2&EA.&$T94UD-D]!.7IB95=V M36$O5T]7;%AG*R8C>$$[<4]K9#%7,VQ(<%!*44EK;G$$[2FM&15,S<75H-G)P5'%M;U%',V0R:U)&3$M35$,U:F-J:50X26-% M0G5H;V%D35EY0C5,2TI(3D$$[:&%6 M9E)J84-/;DM14U,X131J:TXV.7AK6EI):G%K635(;W R=FQ45W)R4C(Q94)B M9')&1S1-,S%U,45O8SAU369O1U%48S,Y3G5#."8C>$$[2W1464A#8V="<%)! M:U=Q1'E8-7!&79,-'%F:5!% M65!%:C-R-%I15C5O97(R555S;"8C>$$[-V%35V]H;%$$[<%@Y;T1):DQ%:3!N1U50+T%)5CAW+U9:8FLR36EX M=T9H37)C5FM6;&UJ=#)5>$5I5&M*6FM7;D=U+WIW.%E89TLS+T,O;6)L8W(K M:28C>$$[3#-L6D-T-'8Q95=S24LX+S-V=R]".$ER.%AB2&IJ,V\T1#-+575G M-C5$1W-S,FY836-4=R]756ME1U)63491=G%G:U5+5F12>39B:B8C>$$[1'A$ M=EAH4&-H8FTR=6)7-&MT4YC+S5I268K24YM=B8C>$$[,6Y-3UIP*U)E=EA8 M,G@X$$[5T-),D=R,E)75T)R<4DO5TEQ3F)P M6&Y-=GAB>')X3E$$[$$[6%9"975S-'5F$$[-FY& M44992S=T,#1G:&%54F@S=2]X9'%C,C%59SE/.#9W>&58-U!22FAF>%)7>G57 M83)V=E-T<%!5;#E13E!A*VI*-FY!+S59=WEX-R8C>$$[,W0X;4UC;7=#9&$Q M*UHQ9W5U,S=A8EET4' W5#-,47I35$AN23 K;U%86FQ&66Q:15IB4E%S6D96 M-44Q4%1)4G=M:&8T,EIN3G5Q828C>$$[5BMA;'!,2EE7="]:2F$R,75:2'5B M;4UR>F8P-U7=C-E--,V5G6F9Z4$5U M;5A7;'@V9C9%528C>$$[,%5D=%IZ4%!Z84=/3S-I=&$$[:51.4$Y(54DV.#=I4C-"24)Y5TQ(56%,2$I/>G-P*UHO3W1T6E*,SE.2&1M3&-N6FUO5R8C>$$[,T-G M;&E41$AW;FUS.&Y%3U--=2]Z244Y=E!'=6Y&2'9)<#%U,TTU64=A93%7,$1X M2U4O9&]QB8C>$$[>F9.;V1Q:U5.E=50TUQ0E4X=E$$[5T)T6G U:C9K-&E(4&UB='=/2W)X M*TAR43%R.$4Y-U!X=DI+9DY8;E-06%E':&IS4F%)5W1M5VIO84QA,C5T,4A' M3TM&0E9A2#16028C>$$[2%%#;51H:C1E$$[9VLR:&]V>F%N:79:8GA.35%Y=DM*5413:W%!=#-B,TMH:'="63!T M3TI.4E5N;#=99D$R-7(T+VMJ52].1%10<59X94=Y-%@P3C%:="8C>$$[<&QG M:DI';U$$[,&M73TE%1G9257$P M<%EG.5@T:%)H;&A.1W5Q235T.3-N=#EE5#-T-V-8;'"LX-6M!54MA0V).<4=&1'-6928C>$$[+W=$+T%$:E O=T%C:EA0*UEI2"]! M26$$[15EU;$14<$M);U5%875)1VQJ46U#:DUS,4]*<'&UY=#%$.&YD4W5F3#EN1D4Y<$1R.&)83#-&-EI*,VA62DIP-VU',VIJ M2R8C>$$[0DA15%0P6FY3=DAL$$[+V]8 M5'E&+W8O55 K4C!F+T%&4WI*+TYZ.&UN=TEU+S9&,#AH9C"].>CAL.$-,=CA!;UA4>48O=B]!1D0O04I(4B8C>$$[+W=$5DQ(.#-0>5AW M274O-D8P.&AF-R\Q1"]K9$@O,5-X+TYZ.&PX0TQV.$%O6%1Y1B]V+T%&1"]! M2DA2+W=$5DQ(.#-0>5AW274O-B8C>$$[1C X:&8W+S%$+VMD2"\Q4W@O3GHX M;#A#3'8X06]85'E&+W8O049$+T%*2%(O=T163$@X,U!Y6'=)=2\V1C X:&8W M+S%$+VMD2"\Q4R8C>$$[>"].>CAL.$-,=CA!;UA4>48O=B]!1D0O04I(4B]W M1%9,2#@S4'E8=TEU+S9&,#AH9C"].>CAL.$-,=CA!;UA4 M>28C>$$[1B]V+T%&1"]!2DA2+W=$5DQ(.#-0>5AW26]3*R]W0V-F+TDQ=DI: M<6LQ.%)C5&E*-GI2-TM59'1Q4CEA$$[1$55 M:2]W1&]85'E&+W8X03%$+VMD2"\Q4WDS.#-0>5IE0D8S+U%U;FM,+V8K;V8X M:F\O*W%74#5U9FMV9U)D+S!,<#5#+S,O04MH+R8C>$$[>4]J+T%/<5=0-75F M:W9G4F0O,$QP-4,O,R]Q2"])-E O<6QJ*V)N-4PT15AF.4,V95%V.2]W0V]F M.&IO+W=$<6QJ*V)N-4PT15AF.28C>$$[0S9E478Y+S9H+WE/:B\V<%DO;34K M4RM"1C,O475N:TPO9CA!<4@O2390.$$V<%DO;34K4RM"1C,O475N:TPO9BMO M9CAJ;R\K<5=0-28C>$$[=69K=F=29"\P3' U0R\S+T%+:"]Y3VHO04]Q5U U M=69K=F=29"\P3' U0R\S+W%(+TDV4"]Q;&HK8FXU3#1%6&8Y0S9E478Y+W=# M;R8C>$$[9CAJ;R]W1'%L:BMB;C5,-$575RM39DE/:65428C>$$[=&US M*W%(*V(X359D.550.#,T67$W-F]F-79W>%8S,5$O=T$S-%EQ-S9O9C5V=WA6 M,S%1+WIF:&ER=G%H+VTO1$954FER$$[9&ER7AJ M2T%0.#$$[,G5X5C)+=7A6,DMU>%8R2W5X5C)+ M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5CAD+SAR1C@K+SA!57=A:"]W M0DI%;CEC,B]G=R8C>$$[-V&90=B]!1DU';V8X05-22B]82'=99'=8>%ID-W8K5FDK9F8X M028C>$$[<5E.42]W0VMI5"MU4&=W-V=V:7DW,V8X$$[3$QV M9"]W07)&."LO.51"<4@O4U)*+UA(=UED=UAX6F0W=CA!;%EV;C,O<5E.42\V M4TI0-C0K1$1U0RM,3'9D+WES6'HW+S%-1V]F.28C>$$[2D5N.6-F0F@S0F9& M;#-U+S573#4Y+S9M1%50*VMI5"MU4&=W-V=V:7DW,V8X$$[4"]N85%O6DYC=EI$1V556F5:,DMS M4#)L<61J-VI)>3 R33%C4G-G-4I(<78O=T-6:2MF9BMP9S%$+W!):R]R:W9" M:#-"4&EY-S-F."8C>$$[$$[=UED=UAX6F0W=CA!;%EV;C,O<5E.42\V4TI0-C0K1$1U0RM,3'9D M+WES6'HW+S%-1V]F.4I%;CEC9D)H,T)F1FPS=2\U5TPU.2\V;28C>$$[1%50 M*VMI5"MU4&=W-V=V:7DW,V8X$$[*TQ,=F0O>7-8>C%ID-W8K5FDK9F8K<&$$[$YC4TY)5D)2 M:5%/4DY-=W1604%I9S5/0U)),V5O,T5J<7=#;6=P;4LS<5AR>2]Z67$W,35F M-7-69#8X=C@R2R8C>$$[=3EE6"MB1EAE=DPO0419<3%8R2W959%=U9DI/<2MB.51T26)3=U$$[5S%S-TDYU3FHR3TQ%4T519#-* M4$-3:'!T0R],,35,4TMW;7,U3$HW-'!*9EA6.#A&=U9&,4MO:B8C>$$[84MH M06A."8C>$$[-C1C6FME8D=9:4]8 M97EB5F1/.'9A;G(K<')"<#)L4S9F6E$$[3GIF=5 V5UI!2E!,-T5&8C)8-6$K M<&4R8C-&<4Y-*W-Y4GA80EI$8T-$.4HR9T)2>BLX+W5056\S6&AY4%-U16UF M4'(K=W)515%V;"8C>$$[9CAU>70O8VA,5C='2V$P:'5B;')P;S%T>$QA>E-4 M+U9U3C%-:S!G84Y3<65P2E4Q1RM02% X9C),=U%53%1Y=BM896]Z-E!945!" M1B8C>$$[4&8R$$[*U%1 M;5IY,%5C9#0T+UEO4Y$.6I807@S6D0U9G1F245&<' K<6MA M96PO3F---E$$[17AR5#=83G%N:EA- M>C-'-UI%435O3S,P>CAU-VI1-W%A*VUT;V11:7-9=4-1>4M#$LX07,V M96\W>B]#+W=31VY8:EAN:$UP,R8C>$$[=#-O<49B;VTV:#AG5VPQ<4$P=4Q4 M,45K5W)755-.9'E/:%-&;U1B>D(S;5!&<$5E44M184Y39T)054%Z3EAF4E!P M2$QZ67HK62MN*R8C>$$[53=054Q195A':3E"-&Y--G=Z+U=&<4I70TYY.5-E M;DM0:C%:5#--869:>3-#6D5E<'%Y:4DU35)Y-7%D:7)S5F1I$$[+W=$>'E.8R\U:4EF*TE.;78Q;DU/6G K4F5V6%@R>#AS=S-)54U+ M=7A6:'5L4')/;BMA9DY0,70Y474W2V53>B]24'%*2DI%2&QJ:R8C>$$[3'!$ M=U0P:U)'-'%Z:U5',TTQ,W=-0EE*95-25"]N1&%7;&YD,C8V-V-Z5W1Y='I, M1$UT-%9L-#(X6FQT,U-4:WI$;4=&9C=T;2MW;R8C>$$[-EEU3T]/4Y+>4Q+46I6:W%X56HW4&%N5$,S M-&=E2&1M5TQ9-T98>5@O04UQ-B8C>$$[."LO.5,O<4@O4U!*+U1.=#0P3SA/ M=CA!0VPS3R]W0U9D969F*W!F,40O<$AK+W!J-#!/.$PT574U,R]+=790=B]5 M=C9H+S!J>68P>"8C>$$[.&%(948X2UAC-R]L6%AN,R]Q6#E1+S92-5 V62M. M1'9#*T9,=60O>7)R>C$$[04ML+U50.$%P2&LO<&HT,$\X3#15=34S+TMU=E!V.$$Q3"MO9CE) M.&XY369':#-H9D-L,T\O-58Q-3DO-FPO55 K:V54*VU0:E$W=R8C>$$[=FA3 M-VYF.$%+=790=B]5=C9H+S!J>68P>#AA2&5&.$M88W%1*U$O>D9H16=H,%15 M-&A-:&IM0U%42TA1:T5Q,4)U=%9";V-F1F@S:"8C>$$[4&AY-VQ0.$$U5C$U M.2\V;"]54"MK950K;5!J43=W:G=P9'EO4$EN-6I#,F$Q1VEA;4Q6,U=6-$)$ M3C9::U5&5F-R4VY)0FE!9F,T*R8C>$$[3$1V0V9$;#-,-U1Y5"M:9&XV=C%4 M4CE6="]R16)15"ML1DUN<5)05&Q'+T5$:W)51E9/,DIY45!-:%)J;4]I:"]W M07$V."LO.5,O<28C>$$[2"]34$HO5$AX;V0T4C15=34S+TMU=E!V+U5V-F@O M,&IY9C!X.&%(948X2UAC-R]L6%AN,R]Q6#E1+S92-5 V62M.1'9#*T9,=60O M>28C>$$[68P>#AA2&5&.$M88S$$[;CE- M9D=H,VAF0VPS3R\U5C$U.2\V;"]54"MK950K;5!J43=W=FA3-VYF.$%+=790 M=B]5=C9H+S!J>68P>#AA2&5&.$M88S$$[-3DO-FPO55 K:V54 M*VU0:E$W=W9H4S=N9CAQ-C@K+SE3+W%(+U-02B]42'AO9#18=W!D>C)Z+VY( M-U%.8C!F5$Y9:C%7=VYS6&UN:28C>$$[84IB:4YO>7=#34-2>4%R;49Q<&=K M55A*=U))1S'=Q-S U4#54.7AX5C-P M>69Y;C=J:7)V5"8C>$$[:R]L4#-(1EAE;DHO2V9U3TMU.4]4*U4O8V-69#9C M;CAP*S0T<2\O6CPO>&UP1TEM9SII;6%G93X*(" @(" @(" @(" @(" @/"]R M9&8Z;&D^"B @(" @(" @(" @(#PO7!E+U)E&UL;G,Z&%P+S$N,"]S5'EP92]297-O=7)C M945V96YT(R(^"B @(" @(" @(#QX;7!-33I$;V-U;65N=$E$/GAM<"YD:60Z M,CDW.3&UP34TZ1&5R:79E9$9R;VT@&UP+F1I9#HR-S&UP34TZ1&5R:79E9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y M/@H@(" @(" @(" @(" \7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @ M(#QS=$5V=#IA8W1I;VX^&UP+FEI9#HW-T0P0S(U,SDP M13E%13$Q0CDX-D4X,3,V,$,U-C8R-3PO&UL.FQA;F<](G@M$$[26QL=7-T$$[ M(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[(" @(" @(" @($%R:6%L+4ET M86QI8TU4)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P$$[ M(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @ M(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E&UL;G,Z>&UP5%!G/2)H M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @ M('AM;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C OF4@ M7!E/2)2 M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M93Y! M3Y!3X* M(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0\+W-T1FYT M.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @ M/'-T1FYT.G9E3Y!3X*(" @(" @(" @(" @(" @(" @ M/'-T1FYT.F9O;G1&86-E/DET86QI8SPO7!E/@H@(" @(" @(" @(" @(" @(" \&UP5%!G.E-W871C:$=R;W5P&UP1SIG&UP1SIG&UP1SIG&UP5%!G.E-W871C:$=R;W5P+;_Q < 0$ 04! 0 !0$" P0&!PC_Q !6$0 " M 0," 0<) PD%!00)! ,! @, !!$%$B$&$Q8Q59.4%!4B05%35-'289'3%R,R M<722H=3A-3:!L<$S0E+"\ S:O%J-M/"FD998DU]TEQAAA^4KMB90M1&P3!V&'I((]A,A$.C M:-:\#4NEE4?<#S&HEZ VIS F&*GPA4\,")VO) ZSG@/63@<3_U[?7@UP$&D MW>NWFI74HLM)M[5R;V0@PVEJXRAABC!;+91B5W[1UEP716Q_MIPM,G:[P_#6 M8,4Y/QQMSK]GZ6D8[QGE[!YZY6C69)5*5:-% 'Y@6A&J9I,Z*FYT3M:,EN+**UN;:X@U.SO91!;W-H209R2 MHA=#DJ[%6"@,WI*RMM8;:E>\\!F:LID@Q4?N=JH+.,^W'V MX^SKJ2;D=*I>W.JZ=YTC@\H?33(PD5=@?89CZ DVD8!4)@AMXC(DJ,&KW#4B M&;,-QS->:-W=;M66*?3UPQQCJ*3IP72S(<@D+8L-;52A]B4;4%*8.QF.)!R9 M(YR-01R+G:I)'#!)]?J_Z/7P_5[>$?I^@QW=K'=W6K6.GK/, MT$$4Q,D[NK%#OC0@Q+N! 9SZMQ"J5+;.N'!P_#M8=]N(/J[LS$L697><6Z!9 M1F4=(G.(P1+67RIG>B6EZ.2"470)'5G7"=6\A4V;L"IV",JF6?3C$.'4$@6ORQL =)6\].?EG'9@4[8Y7&F2BO&$]AE M6M>RE9;]-?$",<6;/ZS\J]@U:#5H+QH]*Y,:+=V82,K-+;6HYU=FC7/3S)NNI#4\90Q(W(@0O#<2OC_3-:FH\GGL[!=3M;ZUU.SYT03RVNXK'F+M@L+:AK6]7I0NDHH%AK#I#3AE0&_G^S4]+H M3-B7DA1- FD*/.#UVNFE6 MTDRUV:=B\/:>ZW6R@X M8KA$]RR4\KU&09Z ]8,YFB4;8RRSCVEL"D7$N#N-86%.-J>1)T*I&P/JILO) MXX R<9QD#[R:XZRY/M=VTNHW5]:Z98^4-;Q37(9C-+N;*QQIC*K@AFSPVL0I M5'*WE$."IL._[WJM$'J=XY894LQ*OS?!,HHCG61XWR3C8("Q,6M@1K$R:!)#;-=PW W2 M07$'#8\9 !PYRO$>BRL.( )_N3.#I+(YK?E[/>'-IM==F7G6BQ(MG<68=>79 MS?L3$6\JLZKD;PL2DM\Q:V'S<[GN3LF3M#HGJ M_P _X==)^3$B6-S>6NH65^]A_:%M;,Q>V SO(8@"54VN68!%*HY0ML(J[(MP M8"TT%P*YY^W>USUHREL[CUMR;AG%F2F^<"1N47?D'G)A'+\F)&PJ%0UQ7)!$ MC4MYZAR.1&J"D=KJG&XD5J;CQP"0#@G[?]:RQ\E<0V;7FK6-A<7\*SVMO.LN M&C8;EYR<*(HV(()7TL$@<3PJ+;9PX9V^:I;5;/1S*6-)8/3W+2;&66,=PQRO M+EBEI7/30PM^3X;,6 Y=%91C]R5N2Y0W.Z%3:RIKCSZZ M9&C":;7/$#VC(^ M7Z\Z/)8:=IU_--'NU)7DAM@KW@=1)9)'P*K(D@E*\OR8D9='_W>) );)'Z MEQ74\B[<2V&NR1V-K?WD*6IM(KJ&*56E*W1"9D*[5<@;L2)G R>%6_Q'W+B) MQ_4C(*78_A-:):N8OD[I"8^OS5A_'F.&K(\8=03!FD#.EC+K&,TS)T;S']4P M>8G4X+ J(.8G!T1'&IK*@G@+C/!B>!X'./9[/5GA]M8]<;6TTV<7W)S2-/MY M&B1KJV@@6>-N=1U$;1W4K+O*;&.P@HS XSFL%I.!(X,YFOELL[T:P8;OM'CF M"2S"+7,3)$7*)G,)TC3K28(FC]@$73$LP76-HG"6JEQ38K>9*ULS*C='"YY) M3=U\#PSGJ]7^-:G1 H;(7.L6%J=0@ADM%EWB2664 B$)PP%W(#*2%+2*JJQR M!7ZGZ19_P(_\6_ \ZQ]K,\S77O4F<.D[69BASOD YOC1D*DTA:)UKP^(_-PH M]+7N.*$;_%9(\(B!I;J&CSFVHER-8B)J2,#B<%AU?X]8_K^K/75VFZ3>6;\I M;.:&P:6RTV5I3 MUFO.I[/GYR<&G7**9G<'Y.ZY0/0J!(PNCDL:$*HJ%1=6JZ 1 M\/1#6WNK.:XL\<8)QUXQP^\C)K1MN33RZ?!?W>HV6G+>,RV,=TSAK@@X#,R@ MB*-CCTR'"J0S!0RYV3<53AM2+8;BDX'U3UB@.*\5J1Z38[G.17)N9VB#8YAS M;'YMDYMF>2)?>*- 0J;A- RM G AN6.3NX*6-O$8$D8#TUJMA222>/\ CZO; M4]RBT*2^Y0V>G6$-O;GS3!-.RJL,$2I-<++/)S:C/'8N0I9F* \.(U1[3\,9 M;@_ 8MI\';+89W!U^99^7BO(4XQ!=X0K<;SQ0608A129A> &BNQ.HU:%.TR) M$XGD+#G-H'Y*4C=VQ6KN!XX/ ^SAQ%5ZAM3-IQD18$ F5[2)W55=V7:1X?.7*U*18TJ9:-&7'7^01XQ \!D M")$!.U$J8S*VUI?7ET9+HE5HE>R,=K MNH8,9!A5'.L>'&N6F' =G9"/*D+PUN#K#L)M)@N,K93EC5C'3R\VR U)&<) M']MBJUQ3%ER=\9E:E.W+&Q:U1LU.YJ$C.N&A>U[%5DY M'S8N(K74]/O=0M(S):)OQ 7R!6EC+#V>^292E6LVP"9HB!LC2M]I([HE#BB9BD3(JY2XCF(TXF8R1 C9\L))& MV%RV[*4:M\W$M*EL&E)->2'H^*%BDEF[AG!(]O\ K]_#U??PJHY&3;EM&U33 MDU5H>>73#(W.D;"_-\YC;SFT9P%*X!8,8QOJ)>JO"KR7GB*[#93S/E& :@X2 MU=ERG&N7ML=9K>4N+^TKUS4B=R!+DII:U\8T#20\K MW"R4FI(X#K)ZL?YU&Z=R=N+R.]N+JXATRTT^0P7,]T&]&X! ,*QKQ+JS*&!8 M'+HJ!V; SG)."5+HH=IRK7[7X">8?NSE=[Q;BC(4-#)9+#>GNB=U4 ?%3B%( M@/.(GZE*RLA34!(4ZQJ0/MFEY(L*^$]EZ>[+;C:\RN>Q'%R'2*' MY$G>8,JR5M>U<0M&(*X$A0.#4E1%6H>DJUO:U[,F,?2 MF9='+K%0DIAIB,;<4)0,!!8"[%7 X@9S]A]E=KRLUHSZC;OI>I3&W73X$?R6 MXFCC$RRSEP55D&\*4R<9QM&>'"S.'%LAKMD?2K=WAT;29R#KV[;/R^(Y:Q]L M%+D+M(8RHGT;>HF_N+'D1R3#$J0D.;G H^J$ZNZDI"M2.DH&(Q_T/76/0[ZQGTK5M$U"[%DU_+%WCZS\OEQV[C4 MM/T73=-TNTNX]4F@U6'5+J: $6ZB"02+#&S9#%]JC()QAV;;O5:R%MIC/A&[ M8;,Y?XA64N(2F%A3*<#;)09KCCMK4L^UB7)[1CZ/1%!$D+9(661H$J8:YA M M\O=(Z)E*6JK-A[D5&TPI68&X#&.(]9(QC_KU=?\ E6?4K?DUJ5_W<=I/-CG*I=/\OZ78YT2P%(M?=B]3M2=C MXAD&5/&W4SS[AMKR_LZ\1,J3.:EC08,.>(#*[/"H,6LTD-#9#VAH;%"DT@XY MVBTB1/OG(0P((D52<$M&X?,J'??738SBQ[R9\)V+QVHQ)F#AI+<;0"9%JW&S M<[9$-,QTA+@O1C;@JTTD&.-NJNR-2G) %)8HT1MNE#SJ8.%&.ILG]636^VL: M7TDU:\%] ;:YT(P0R[CM:P;WL %^2U[_-5]>9V[!;B!F(" MK-$S$]0 =22?L &:[;7$/1:9;K[,R#/,#XX4'P)'7F,Q%A(QRTLF2G9$@41I MI VJG$"QFG\10C&ZFANK, !E),+$*X3#E OTE[!N QM_B*])UH:7JM^]Y#RM MBLHWCB00(L[!3&NTME)XAZ1X_H#]9JP.%EB[",+7<;?&B_:HO.6#5&G#43,] MJXG&7PTUPC4OQMD)TR!+D$76O#\_.[I!C'E]0*$(W58K?W*.G]%S?+@)P&SE M#CCGJ)^T #/ZLTB/*R ZCY7:'3$YW48XW):.6"=II1&7=V:'< MX(W%G9#CK J*69L@:IZ2$_+^C6,-J\>;>9EVTS?$!P6+=3GR=05.'S(05VQ[FV1'\0/3 M 7'@Q[LF'8?']\%->DP<>N&3;*G'T;236QDEO>.&G>;O*K.'(K37YEDMR_TP M/TGSWY+0IVD8XD_9]E3IUG2SRO@OO+8/)$TGF&N,GFQ+F3\WG;G=Z0ZAZZC+ MI/NWA_(O#>AVGR/8S5W6?/.!,Y3J6-3CN%B*,9.Q%DK&4YEQ+9A%Y, MQL$Q;5\[4HB1DD%OIB1A+;RR!M4C4N#5<1AB<$Y&.!]>1U\>(_5P]?Z]'2=6 MM9]#CTQ;[3["\L[R:16U2VCGM9X)I9I2R&1'5)5,Q&<;$MQMD+++31C8Y@V M#XYL*20[8U;<8O2-92MB1M;PZ4/Z!X8SQQG)ZQUU(Z3?1WO*V(17HOXK;2YH$N%M MH[5,A@S1Q)& &B0MA7(&22%R@5F@/BV6Z,<./3_B%OF-]TH7M',]W<2.N$,' M8HB,=D+5-XG&)2US1F-?72-#TS6W@U6+4)=6MFM+2VC1UFCCD65-]TKCT M'03;G#;1^;(0N9 %FKI7NOC2-X,UJB#QQ)]5\GZI,,)C#'L'K;OMBH8LUXZ; MV>P2'N"X9!&&L!>0&]M9+B884=*ELD\5?;[5_#$-=6K2+B'Q/-N'6N&-+,I0$,;.DB\BDL9FS.54P3&H'/! 0!$LPR%"<(+\@08H2C;I9T!9=[IQ&$S4Y^8BUI7.$M9F!DN,?1D$E$E M&!]IXG_'^/WU$G6Z@Y4"W!63'JX2EDSZU1<]6*E!P5L MV:[0[5WB58*S9M+%M5))L;$<31+',\?PO)ZU J1->84CO(&A&R*&Y:J,CQK^ MSC.**>&HZXEQ%BE0+W$(-6SZ) S@MPR!U@5((O@F>RI@XU47VBD4;1('5@P9:*9&) M4SIRL[($84B%4_Y-?FQ$K0)5:IU I/:E5PEH32R[ &98P($YXKC[<@UJ:AI] ME'9S2)RKCU!XU#):P@GU M?:>OV9Q6H=?TZZO^55QSZ1176DM9V1D#*UR\=O)&"JD9!D!R1]]:,TFE:YHNC M1SZI#IMQH\3V]Q%.CLTD)6%>M>LL<...ZQNV62&11*R,6SA1DR33-L%.F(QN6#<24)")K;94A W.2 MM0_HECA<3.D<304"G'JX-G&>L?8?5_CBIJ3E'I,?*6.X6Y5[*YT..P>Y"&06 M\WE$DJ\ZNUMP "K(-K*"ZLQVJQJ >_VRS)#-%Y]@!)OOJWGJ6YMR+'37#$.F MVL.*X/C=7C^)/T;EC),<@SN-Q6-KXW,T+K&DE[M"-4Y.!HU"!E))5LZ=Z>2Z M@<OAD^KU^K[JA]:U!(](FLAK&G7DMW/'FVTNP@B@,,;QRK+-,B M(8Y5:,>B"S'*K@H':I*Y5WIU)>_R@S4W:!KSU!UVOT'P,JC,IRF2J7BB["^# MQ%GYD"U+#A(;*@*!/,H8D5@%I1@\I=4_YW((8@TVG9C''_#V_*MVYU?37Y:: M=J"WD+645FTQ3C<<:N%*.RBXDDKCRF]U8DM[@=TM_^D(=@"#Z'#JZ_ MX5$V&H6<=MRS22YC5[\'R,,3FX/.WS?F^''A(AXX_2%9S=.)%KEA5SX .462 M8M>2A:CX9G/2Y]CG'6.78*E"J*2$J'UI;E4E=VQ 0JYJY='A M)+*D]S0FV%2=WVXQ_A6Z^NV-JW(RX259_-MK-%?1QY,D'/6]O;ME3M!=09&4 M X8IC/4:RQB*:\.;0_<'8[BBL._<'V$;\AHLR2K"VMT#89$1F)XF.:7DV2'1 MN?%N0 F1MM8U"M8U =9&ULX5 3$[\YW;%[:%C=:D$C;C'4"<@CAUXQ]O$?9P MX]=;-M+H>D:G?\H$UF&]6<74EK80HXNFENWYPQS XV*A)4,ZJ#D.VUDVM#!! MO1AZ"<*S0MN02V*R;8# W%":]I)9A-&:2HG&GO,DL*5'DFIAHTK,YK'1C M;21V4'C)"\).<5>UAI5PS)3Q&VSC$]8C#FW'Z84?RFYZUJXA)0[$AR-&L:(8 M,D@:2/!&)2/V5+O M)H,NN+RG\]Q+" EPU@T;^6\_';B%80F2=I*J20&7K0-L(D&)L/[+81X@6G7$ MEPUGB0RS4F(9MW6DVU^.-@'3%\SG&'8\Z2)TA;E\%^0Y-$V\;$@DS6UL3,6K M"[/;,-T%+T;HTV6*6],T.(@@@CC@8QU?X\:UK:_M=:TO7;6\>338KK59-1@O M6MY9;5&=HF\GGDC78)%5%W;G4MSH9 2H1K>XFI&.L.\(;A1H=;\JOT_B\"S/ MF!SQ]EM='ET&>)2^1R73-<\3QAC#H>H=V!@-G0ESE"T[D:)R31DV/#< EK## M"PEZVS]G#_#_ *S5FOB6%H.6KFRMJ*/ M)*4G,5O+6B"65"N:G?8S,43FF%8A02.Y1Z6,Y"YQ_B?_ #]N#PJ2Y1:A F@B M_A3FKWE-%9+<#&UN:M8Q)L%["K_?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O M]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_?3(]H M^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L* MO]],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_?3(]H^\4Z-:_V5>=U_6G5(<3' ML2;!>PJ_WTR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HUK_95YW7] M:=4AQ,>Q)L%["K_?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O M]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_?3(]H M^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L* MO]],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_?3(]H^\4Z-:_V5>=U_6G5(<3' ML2;!>PJ_WTR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HUK_95YW7] M:=4AQ,>Q)L%["K_?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O M]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_?3(]H M^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O]E7G=?UJ2^!]2.-%K9"L M^X_Q+J1G%BB^S.-UN)\O(UV(4+X<_0EP;GUK5-R%8[HU:IB4#121V+"XM!J1 M< 1X# G6&04(%#M.,D<.KC_6M^STSE5817L%MIMTD=_ ;:Y#6ZN7B974A2V2 MAQ(WI+@\?L%1HZI#B8]B38+V%7^^JY'M'WBM#HUK_95YW7]:=4AQ,>Q)L%[" MK_?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_WTR/:/O%.C6O]E7G=?UJ2FJ.H MO&ATJRP5FS7S4C.,6R$3'7F+%NKIB)%*4MF9_P#)?.:?S5($;@W7,.\B3\Q1 M=/<+E$J>!(^^M_3M,Y5:5T?>*T.C6 MOG__ !5YW7]:_/5(<3'L2;!>PJ_WTR/:/O%.C6O]E7G=?UJ>^I..>.UI!")_ M"-<]1\I0X.0UAK@X2Q?@1DDLW8U:AK3,ZDV+2)_0KS6<"A(C1B-3= I2>5)2 M%@" J2[&U0[3UD??_6IG3;?E?I,,T-CIL\7/DLTK6DXN"Z&.BM:N7+#AJ%:Q8J/,,/4JE2@P MP]0H.&,TXT8S#!B&*][UR/:/O%0[))ZS M5)U2'$Q[$FP7L*O]],CVC[Q5.C6O]E7G=?UIU2'$Q[$FP7L*O]],CVC[Q3HU MK_95YW7]:DML=J1QHMKK8FMFO4C.,BMA+&#%A['GF_$*&/>:H''.=YI;%7F1 M&B\ZJ2.>+GN;CY0O/Y?TIX^2U 5&<$<3GK]=;]_IO*K4O)O*]-NG\DMTMH=M MNJ;84_14[<;B/^(Y)]M1IZI#B8]B38+V%7^^F1[1]XK0Z-:_V5>=U_6G5(<3 M'L2;!>PJ_P!],CVC[Q3HUK_95YW7]:=4AQ,>Q)L%["K_ 'TR/:/O%.C6O]E7 MG=?UIU2'$Q[$FP7L*O\ ?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_P!],CVC M[Q3HUK_95YW7]:=4AQ,>Q)L%["K_ 'TR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L M*O\ ?3(]H^\4Z-:_V5>=U_6G5(<3'L2;!>PJ_P!],CVC[Q3HUK_95YW7]:=4 MAQ,>Q)L%["K_ 'TR/:/O%.C6O]E7G=?UIU2'$Q[$FP7L*O\ ?3(]H^\4Z-:_ MV5>=U_6IRZ?XFX[.CR"J89&B M561K[)#!(U2EJ4MXW-(!*F=?+B$* ":AVG&2.'5QQ_D?LJ7TRVY7Z0)DL].N M>9GP9H)K9)H9". 8HX.#CT25*[EP&SA<73EV+9L*9KR3JGE9[=-=UEE M6'H$1@-A:\20TLP:,;@A3XZ;F],R.*1Y WH4SN)W"O6+4")"W"6!0H$*=,&T M @$#/7Q_K62YCY97=U:7<^G7#M9'-M"+2-;:,<-R\PH"L& "MNR2H"Y Q7 MN'KIQP-ZYQ'YUL1JMG:0JXXJKK'5:!,@2*%QB!K:TJ,"HZB!_CU_Q_I]YK7U.QY6ZO*DU]I]VYB3FXD2 MW6.*)"PJ_WU7(]H^\5&=&M?[*O.Z_ MK3JD.)CV)-@O85?[Z9'M'WBG1K7^RKSNOZTZI#B8]B38+V%7^^F1[1]XIT:U M_LJ\[K^M.J0XF/8DV"]A5_OID>T?>*=&M?[*O.Z_K3JD.)CV)-@O85?[Z9'M M'WBG1K7^RKSNOZTZI#B8]B38+V%7^^F1[1]XIT:U_LJ\[K^M.J0XF/8DV"]A M5_OID>T?>*=&M?[*O.Z_K3JD.)CV)-@O85?[Z9'M'WBG1K7^RKSNOZTZI#B8 M]B38+V%7^^F1[1]XIT:U_LJ\[K^M.J0XF/8DV"]A5_OID>T?>*=&M?[*O.Z_ MK3JD.)CV)-@O85?[Z9'M'WBG1K7^RKSNOZTZI#B8]B38+V%7^^F1[1]XIT:U M_LJ\[K^M.J0XF/8DV"]A5_OID>T?>*=&M?[*O.Z_K3JD.)CV)-@O85?[Z9'M M'WBG1K7^RKSNOZTZI#B8]B38+V%7^^F1[1]XIT:U_LJ\[K^M.J0XF/8DV"]A M5_OID>T?>*=&M?[*O.Z_K7JB5@KZ$I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I M2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I M2E*4I2E*4K3)U]W#E]?LA]U4L\-79] N47N;;Q4=S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W M52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SP MU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7 M*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W- MMXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ. MG2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1 MO>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S= MQ)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J M=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=P MY?7[(?=5+/#4Z!* MCITKT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[ M(?=5+/#4Z!*CITK MT;WLW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5 M+/#4Z!*CITKT;WL MW<2?*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4 MZ!*CITKT;WLW<2? M*G7W<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W M<.7U^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\J=?=PY?7[(?=5+/#4Z!*CITKT;WLW<2?*G7W<.7U M^R'W52SPU.@7*+W-MXJ.G2O1O>S=Q)\JV,:R[/8EVYQ>1F#"KHZN\(4/CO'2 MECRR+H^MNZ,8B .!=VYQ !38HL2DKHSKAYAO+>X+WYMZYS4]+N](NC9WJHDX MC23".LB['SM.Y>&>!R.L5,6-];ZA!Y1;,S1%V3+*4.Y<9&&X^L<:D'4?6Y2E M*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I7E/U]45X/2E*4I2E*4I2E* M4I2E*4I2E*4I2E*E/I+@F-[-[4X7P/+W=\8HUDJ4'L;N[QL: M\0IBF1U<[& MMPW1$XH GW.0%%WNI0J"^C&9R L+FB#%ZU?2:;I=[?PHCRVT7.(D@8HQWJN& MVLK8PQZF!S6]IEJE[?VUK(S(D\FQF3&\#:S97<&&258H&NPKILYP^3NRKG*E?2QEL*/LQ6O'$F/5N6\JXSQ4VN:!E<,F9 AN M/D#PZBN%L:5DRD;;'$SDXW#<(K(4)SD!4KY@K#Z HRP+\[DKH;NX6TM;FZ96 M=;:WFN&1/TW6&-I"J_\ B8+A?M(J(MX3<3P0!@IGFCA#-^BID=4#-]@+9/V" MMU^9^'GP]L8RK).O;UG79S"V>X+%71RCN5=BHC!(?K%E62-*-(H S0M8G0II M3Y$^'J;%-[D8[*DQ*8M8L1*)")(2D7\797LERD=D8.%L M(RS"9F7]&13DA@O4PX$]?"L4YMQ5IY)5.-83HZLVQGN69Q-T<6]&,V1?'[*B M= .X+(F9%%AQ6Y*A2_K7Y0@1V)6C"DZ \0N<$SFWK;LKK6(EN9]<&DP6D$#2 M\Y8R7+LFS+2-+SPP(UC#'*^ED>RM>Z@TUS#%I;7\UQ+*$V7*1*&W<%$?-X)< MN0,'ABL>S_0_<7%F/'C*^0]==UK*^R9V81%)&=8@=3&-2>Y)RS37! M$S^=BKH$\A4)"V!:>8G"CWUW1[JX2UM]1M9KB1%>.)) 6=602 * M?T6?8=QC!YQ0#N4;6QBFTK4;>%IYK.>.%&*.[)@*0Q4DCK"[A@.1L)QACD9F M_K_P[\/YGV#T@P\ZJ=AX0R[):_/.4YN_2-NA;0-3(6N!.\K+58@4A;78AQ@" MMRDAB90 MI9V7RYR)+5)1F(P!5INEG;S6M+T]XH[Z^M[:690Z1R/AMIX;RH#%$)! =]JD MA@&)4XBK?3;Z[61[6UFGCB8JSHO#(_W021N;&"57+#(X<15N8RU+V6S**6EX MNPGD&:J8%)6>'35 RL*DUSBTG?G%2TMK,^M9W0N+:L$O1K2%EE*4LMKLB6G. M@T2=(H-*R7.K:;9\UY5>V\ GBDFA:20!98HU#N\;<58;64K@DON 0,2!5L&G MWMR9!!:S2F)UCE"H2T;NQ55=3@J<@@Y "[6+8"DBOD^F^TL-S&P:_23!.16[ M,DK( KB\""Q'+G>1H!%JS1NC&:WB5MSJT)2D#@8X.Z%:>V-@6YQ$X*DUF]9T M%L6L:7-9R:A%?6[6<1(EN.<"I&P(&V0-ADD3@J8CWNX!EBLT#T>ZAN)[?4 M()8K1.&QIAI@DYUTX#@%B%;:?4K%$LY&N8@FH/$EDV2?*6F :(1 D M[U((. !D9(S6!;.Z9KA%@D+6BNUR,8YE8R58G/2NRL0R[IRC1G ME)[!4D@Z3G1G*35KG1[".ZM8H99I+N"V"W&_F\3"3B>;=&R"HXYQ@G@:WM%T M^'4;MX)WECC2WEG+1;=^8RG#TU88(8^H<<<16>IMI+IUE'4K.FSFEF8\YO*K M6Y=$#,DP3/D2BS2J7L4P8M76),.BNXXU+)(=H*-'Z.>LX.2=I!"DJ3#]7P_-TD.(Q9U6:WY-3 MXK+CWI<;*#&8%KDQ3R3SA>2GL7E-Y(0P ;?^=#'@YG WEM7*Z#4!06NIM+C7 M]%:[\A&I6INN=)U);?RLV4XM]G.$V^EN*[0OI9V\:D%)>&'E. ZVZM;,2M#,'6-9XF+:GFL:C$>1A M=<:P232F,1W'3E=R7N9J=WD64B7^[C$TEF].WIRCV@M6>>8K4A2:$?*:UGU+ M5=,B:%);"%C#)+(Q6YGBBEDN5V*H*1VICVRMN+,0^T# W;;Z)/%96%[()&CN MY )8T0!H8GDC2%MS-AGG#[HQM *YSDXQ7.]',HRG:K+.OFK6(; M=EG;&R-\_C[2K96E;Y3D(UK.2Q&/FJ5ZXXMMN8O2E+$PDA9/2JQ&@K:M](R,>O-87)U)V6/RQ(\% PI/@Y?B3(XR608].934\ MD01YK3$+5;V%$H$59:U^1JDRM*N0#5)W!,H(/;S%11H!"W3JVFBTCOO+;?R. M5UCCN X,32.=JIN&=K;@596P5((8 @UK>;[WRA[7R:7RB-6=X2I#A% );!ZU MP001D$$$$BL@O_#ZW'ASYB5BG.O^0X6?FR3-40Q^<_,_0%.DA=P7/2LRJQ1Q MIC.]^0EJG#S$]!;GD:1"O-+0BLC4]%KQZ_H\R7D,Y7TC48FMUEM)HS#._$(2"=K8!.QL-@,<<#C, M^R_"VV1PKM)\67',)FN:U[G&&:20N4,,8"VI)JW)XI$UL]?D26[FO(98U$YJ M_K(B8YOCDE)Z=*BLH.+5KBB+Z6F-FV MJ7EF@C6;;&I(!; VJ36S?:'>6M_Y##%+=%D5XI$CVB51'&TK@;F"I'(YC+,P M&0,G) J'V=-:\\:SR%MB^>,72K&3T\H3'-E)D2,L*-Z0$FA(4*69V1'+&AV+ M2'#+*6>;URD2,PTD"H)(CBK#F+'4K#4XVEL+J*Z1&VN8VR48C(#H0'0D<1N4 M9 .,X-1]U97=DZQW<$D#,-RAQP8 X)5@2K8/ X)QPSC-8/K=K5I2E*4I2E*4 MI2E*4I2E*4I2E*4I2E=ZG\G[_5Z-'[7\F_ZAGKPWE_\ W@;]CMO\I*]1Y(_V M0/VF?_DK=O7$UT]8]E QA<@V"(5K>2E?-85[6_Z9O_=>E8W)!X$CA[?M-6YT MAGT@_P!X7OI5F3[3]YITAGT@_P!X7OI3)]I^\TZ0SZ0?[PO?2F3[3]YITAGT M@_WA>^E,GVG[S3I#/I!_O"]]*9/M/WFG2&?2#_>%[Z4R?:?O-.D,^D'^\+WT MID^T_>:=(9](/]X7OI3)]I^\TZ0SZ0?[PO?2F3[3]YITAGT@_P!X7OI3)]I^ M\TZ0SZ0?[PO?2F3[3]YITAGT@_WA>^E,GVG[S3I#/I!_O"]]*9/M/WFG2&?2 M#_>%[Z4R?:?O-.D,^D'^\+WTID^T_>:\P2OJBO#J4I2E*4I2E*4I2E*4I2E* M4I2E*4I4PN']EZ(8%W/UTRU/UHFR%1#(S:?*'4)!RFS.RNJ58PKGDY.F :J/ M3-!+H)R5E)23U0TR4T*9.>?Y6NO G.*!9L&N7MO"7EU*VMTM4$< MDK3,?T&P&79K38^G$/QW)REFPV.8T@4GC= MLCJ8UG#0-B,JO'D61YG!LBY]E+ H: MSA0]BLE8X^UR"09"1FC)2O1BM:^*UAZ=0:Q-[8ZJB ,_F=S;17*VYTK0-6TK ME*)H><:VAGMK"&0.!+)F21HH[9N)CPL:J"!([H#O[:&9X3,M_JVGW^BF*38) MI(IKN1-OYM,(JN\PX!R2[$C*JK$;>JK+\))6/"4.SVW9)QBO;)_.I1%&_$J" M5V7YCAZ-B/12?23:-N#Q.*X.2V"6T=T)X&6662,6XDSCY.SM'8ZJD-Y:V=W(;7R>2YEB MC7*M(7($@<,-F5X(V"PZN!%Y/HMP9)MIP\I-M!NOJQM(WQ_<'%C%#X[@S(&/ M)-*(PLE$G87!X>G1IA&/(4<%A4D1%O0GN+BI7%IG 3<'U#2'OM M3L+]4U&!(TM9H9)(S)(I9F6*&+T"(P"Q)PVT #<:D-D4Y!KGF+BTYXS5M!BF M=XKS5C/-6&X'AY#E F13][R:^N/F6,0=SQ>:9=T8%>+2$;K"35*A%9,@8G(; M\WG7CUU"P$=;;M1L^2=A9:7=6]U97-C>W%X;4QV\=K&F^6=+H>A(+LLD^ V6 MD3FV DPM;E[@>[%I(T^#7 M&E(@M+RXUU);=%MYB\\7ED3:L"[&-YHSV-H!:PG@%\FJV][::SJ\THU 6^IV5M';/9:9#J(N M%2W6&2QVAOR@QRIZB>'U[ MI=Y,C;@)+,GY&W.+:PY97HUC <_.Z=.VGGS,U6M4^9#S%M[;B(:9>))KQ5YOG5S#$SJTEHK+)S:$N!!@#G!MJL+F]@Y3-%/;P&>:R43 MK(T=NS;RC8D< JEPP*%V 4F7).TYKY%9P:\)SKAA8'+V>UK=M@,"8MSNQ99, '8NT,741E$SE7VM'GB .F%<8Z]84F^ M/+P_779F&[&(9K&->,#;6*=AL/$MS.@4/0LU%1%O7&0_&3N=)2D"9GLU-K.X M*DXU*52)[LH5&,6_H"WMUJ%[!<<_J.F3Z:T,NHW^E#3KPN[!/(C,RB:Z01%R MV]G4'!'-X DU-6:V@L[66'F[.^CO!*EG:7_E=L JE_*A&I,4#%PH7:%8@D'? MDE,U<1[)V*X)IO+]@,3F@:9_QQ12'B)IKN=UMG8=0 M"VZEXO6G-+P!S6SK,\$6G27=OZ,W*$VTDB=1CBMXE:8*>L[IF"OQPV]CDU ' M@DY+A>*-L,@RRV9B87)],7PY2VL8CGQ:A1KU3E=(<$ MMI <)2N)+4 **'8([AZ#EK:S7>DP0P0SS,=2M"RV\;R2+&!*&DQ&K%0N1ER, M*2,FHGDS/%;ZA+)+)%&HLK@*965$9\QE4RQ );'!["J65BF[:2%9@,;F MSJ76M7EW ;5^8@MW96DCM8%A5RI!&\*Y76,& M:,*3J%9$TME$!@6RN7MT7+)6?F51=( M<%<1'V]M<"UCBX,J+S^8:C=V]H'LKV">VUJ*XN-,L]%6UL+)%F<&83QP&:YE M=2I#"5AM,K,I55=NOC\CMY;@K9 ES="G[*#0U39$FE.R,>]#^6'K M5X7!U0L[&%-(S33RBTC'% 6>2AA0I3Q$=%S;V_*'E/&]E=5E DO4YK\V6RP5, M/QX)'Z0]$'$VU^;->LFY,XKF$FA_PC.YEF#*&&)K!VV89Z68?@&7%C-+-,4E>RGC?"RJR*9#'E H8'?S8:3:ZLYY]>M5:UFDN)[:6)9 M+LV\-W$D40:-;F)UR8RK-L#@,3@^CO*VO!]E($S<1*$^D>2],G&G$!UFQQ7T*Z MQ%OGLD\ETF2W$L-RTD:N!N2$W$Y'.R1DD!@SEL^D> Y2BC3CK%D>D.-U12V3Q]2?'5<@4' M,\A:Q.QPFQT5VLF*YJU@W\F+"UFT_68;K2]1,DUQ:6I2XM9GN;J2.X$3J)+J M.&*11*L8#QOL&]1QJ;GEVZY=SQWFFRP7UGLCBN)PT,\:PP(\)D4[+=Y'0E"Y M*NN[T6/ :U^*ZU:]M>/]8$N.%B"!Y22HYX5.-98)LLX;-8EPNQ'.:0UH41=\ M&O71^$KY8> 3HIC,7+:4!ZT8VY@U*?3%T MR[O9 K!^=CVK).L(] 2REV!& _I%$A=>6S6&Q$)$5P!*);**]-];VR%@5V/N M*Q&0^D8T"J1UKZ(9M*E=I7-4I2E*4I2E*4I2E*4I2E*4I2E*4I2N]3^3]_J] M&C]K^3?]0SUX;R__ +P-^QVW^4E>H\D?[('[3/\ \E;MZXFNGK'PP7^85K7I3(/4<^K_'V5^C32B"C#SS2R22@",-.-&$LH MHL%KB&,PP=P@ (;7N(0KV"&UKWO>UJ4K\#5)2B+*C%*4%. M*PK\@;A.N.Q=^=?Y@\@OGO\ -;YZ53(QG(Q[?57V+-+.+ :28 THP-A ,+&$ M98PW_H$ 8;W"(-_^%[7O:]*K7[I2E*4I2E*4I2O,'KZHKP^E*4I2E*4I2E*4 MI2E*4I2E*4I2E*4I2E*4I2E*4I2E*5?F+%'(T\OQO+H_-XP>X M(RW!"2_1ET3.[4:L0FW"4L3 6I"1')C+V <7818KVL*]8+JVBO+:XM)@3#
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end GRAPHIC 29 g803738g91o98.jpg GRAPHIC begin 644 g803738g91o98.jpg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end